02403000000000505000450099100020000070000020000270600020000470100020000609100090
00081300026000174210011000431510017000540350010000714800033000810300018001149300
00500132117000600137085000500143935001000148031000300158032000200161036000600163
04200020016920000020017106500090017312200030018204800140018504800140019904800240
02130490032002370490034002690490033003030490030003360490028003660490021003940490
04700415049003000462043007100492043007100563043007100634540038800705540040201093
540039601495541000601891#1#0#i#1#20110330#International braz j urol#int j urol#I
nt. braz j urol#1677-5538#Sociedade Brasileira de Urologia#Int. braz j urol.#IBJ
U#other#decs#1677-5538#37#1#20111#1#0#20110200#32#^les^hSumario#^lpt^hSumário#^l
en^hTable of Contents#^len^cIBJU010^tClinical Urology#^len^cIBJU030^tSurgical Te
chnique#^len^cIBJU050^tUrological Survey#^len^cIBJU110^tReview article#^len^cIBJ
U120^tNeurourology#^len^cIBJU160^tVideo#^len^cIBJU200^tBasic and Translational U
rology#^len^cIBJU210^tRadiology Page#^les^tInt. braz j urol.^vvol.37^nno.1^cRio 
de Janeiro^mene./feb.^a2011#^lpt^tInt. braz j urol.^vvol.37^nno.1^cRio de Janeir
o^mjan./fev.^a2011#^len^tInt. braz j urol.^vvol.37^nno.1^cRio de Janeiro^mJan./F
eb.^a2011#^t<a rel="license" href="http://creativecommons.org/licenses/by-nc/3.0
/"><img alt="Creative Commons License" style="border-width:0" src="http://i.crea
tivecommons.org/l/by-nc/3.0/80x15.png" /></a> Todo el contenido de esta revista,
 excepto dónde está identificado, est&#225; bajo una <a rel="license" href="http
://creativecommons.org/licenses/by-nc/3.0/">Licencia Creative Commons</a>^les#^t
<a rel="license" href="http://creativecommons.org/licenses/by-nc/3.0/"><img alt=
"Creative Commons License" style="border-width:0" src="http://i.creativecommons.
org/l/by-nc/3.0/80x15.png" /></a> Todo o conteúdo deste periódico, exceto onde e
st&#225 identificado, est&#225; licenciado sob uma <a rel="license" href="http:/
/creativecommons.org/licenses/by-nc/3.0/">Licen&#231;a Creative Commons</a>^lpt#
^t<a rel="license" href="http://creativecommons.org/licenses/by-nc/3.0/"><img al
t="Creative Commons License" style="border-width:0" src="http://i.creativecommon
s.org/l/by-nc/3.0/80x15.png" /></a> All the contents of this journal, except whe
re otherwise noted, is licensed under a <a rel="license" href="http://creativeco
mmons.org/licenses/by-nc/3.0/">Creative Commons Attribution License</a>^len#BY-N
C##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a01v37n1.htm#S#o#1#1#text#1#20
110407#120623#a01v37n1.htm#60##
00667000000000385000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000300093158000300096030001800099
03100030011703200020012006500090012201400070013103500100013812300020014801200270
0150010003600177070001000213010002300223010002200246002001300268#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ND#01#nd
#nd#Int. braz j urol.#37#1#20110200#^f1^l4#1677-5538#1#Editor&#8217;s Comment^le
n#^rND^1A01^nFrancisco J. B.^sSampaio#IBJU^iA01#^rND^nFernando J.^sKim#^rND^nMir
iam^sDambros#a01v37n1.htm##
00674000000000385000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000300093158000300096030001800099
03100030011703200020012006500090012201400070013103500100013812300020014801200340
0150010003600184070001000220010002300230010002200253002001300275#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ND#01#nd
#nd#Int. braz j urol.#37#1#20110200#^f1^l4#1677-5538#1#<b>Editor&#8217;s Comment
</b>^len#^rND^1A01^nFrancisco J. B.^sSampaio#IBJU^iA01#^rND^nFernando J.^sKim#^r
ND^nMiriam^sDambros#a01v37n1.htm##
00782000000000397000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000300108158000300111030001700114
03100030013103200020013406500090013601400070014503500100015212300020016201200270
0164010003500191070001200226010002200238010002200260002001300282008008900295#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a01v37n1.htm#S#l#4#1#text#1#^mJan./Feb.^a2
011#oa#en#br1.1#1#4.0#01#nd#nd#Int. braz j urol#37#1#20110200#^f1^l4#1677-5538#1
#Editor&#8217;s Comment^len#^rND^1A01^nFrancisco J. B^sSampaio#^iA01^1IBJU#^rND^
nFernando J^sKim#^rND^nMiriam^sDambros#a01v37n1.htm#Internet^ihttp://www.scielo.
br/scielo.php?script=sci_arttext&pid=S1677-55382011000100001##
00352000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704012300070002001300193#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#5#1#text#56#<p align="right"><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>EDITOR'S    COMMENT</b></
font></p>     ^cY#a01v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#6#2#text#56#<p>&nbsp;</p>     ^cY#a01
v37n1.htm##
00365000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704013600070002001300206#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#7#3#text#56#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>Time to acknowledge    and plan for the
 future</b></font></p>     ^cY#a01v37n1.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704011600070002001300186#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#8#4#text#56#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif">Dear Readers and    Contributors,</font></
p>     ^cY#a01v37n1.htm##
00808000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704057900070002001300649#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#9#5#text#56#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif"> Our International    Braz J Urol began th
e year 2011 with changes in the Editorial Board. We would    like to reserve thi
s space for a message from Prof. Francisco J. B. Sampaio,    who during the past
 10 years as Editor-in-Chief of the Journal has without question    significantl
y raised its national and international scientific standard. Prof.    Fernando K
im, has now assumed the recently created position of International    Editor and
 Prof. Miriam Dambros, is the current Editor-in-Chief.</font></p>     ^cY#a01v37
n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#10#6#text#56#<p>&nbsp;</p>     ^cY#a0
1v37n1.htm##
00274000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704004400071002001300115#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#11#7#text#56#<p>&nbsp;</p> <hr size="
1" noshade>     ^cY#a01v37n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#12#8#text#56#<p>&nbsp;</p>     ^cY#a0
1v37n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#13#9#text#56#<p>&nbsp;</p>     ^cY#a0
1v37n1.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011500072002001300187#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#14#10#text#56#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="3"><b>Past Editor's    comment</b> </font><
/p>     ^cY#a01v37n1.htm##
00387000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704015600072002001300228#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#15#11#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Dear Readers, Authors    and Colleagues 
of the International Braz J Urol,</font></p>     ^cY#a01v37n1.htm##
00639000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704040800072002001300480#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#16#12#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> It is probably    not in the best of in
terests of the Journal to remain as Editor for more than    10 years. Also, the 
position is tiring and consumes a considerable portion of    the Editor's academ
ic time. I was appointed to the position in 2000 and therefore    I consider tha
t it is time to step down as Editor-in-Chief.</font></p>     ^cY#a01v37n1.htm##
00784000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704055300072002001300625#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#17#13#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">During this period,    the International
 Braz J Urol (IBJU) experienced many changes and developments.    The IBJU is no
w recognized as a major publication in urology and is well known    all over the
 world. The IBJU is now a truly international journal and our on-line    version
 receives more than 45,000 visits every month from more than 60 different    cou
ntries. Also, during the last five years, the Journal published contributions   
 from more than 30 countries. </font></p>     ^cY#a01v37n1.htm##
01442000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704121100072002001301283#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#18#14#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">At this moment,    according to SCImago 
Journal and Country Rank (<a href="http://www.scimagojr.com" target="_blank">www
.scimagojr.com</a>),    the IBJU is "Number One" in the ranking of Urological, S
urgical and Surgical    Specialties Journal in Latin America and the Iberian Pen
insula. The IBJU has    also gained a major place in the world urological litera
ture. The Journal has    been covered by Thomson Reuters (ISI) Current Contents 
/ Clinical Medicine since    January 2008 and has been included in the Science C
itation Index Expanded, accessible    through the Web of Science. Our current un
official Impact Factor is 1.2, calculated    in the same way that ISI generates 
its Impact Factors. Our official Impact Factor    will appear in the 2010 Journa
l Citation Report (JCR), which will be released    in mid-2011, with respect to 
articles published in 2008 and 2009. We are confident    that the official Impac
t Factor will be even higher than 1.2. This is thanks    to the enthusiastic eff
orts and dedication of our Readers, Authors, Editorial    Board and Ad-hoc Revie
wers who have devoted their time to our Journal.</font></p>     ^cY#a01v37n1.htm
##
00709000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704047800072002001300550#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#19#15#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">In early December    2010, I asked for m
y replacement and Dr. Miriam Dambros was appointed to my    position. Dr. Dambro
s is Professor of Urology at Federal University of S&atilde;o    Paulo and has a
ll attributes necessary for the position. I have been working    on the transiti
on with Dr. Dambros during several weeks and I have now passed    on the editors
hip of the Journal to my successor.</font></p>     ^cY#a01v37n1.htm##
00500000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704026900072002001300341#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#20#16#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">I am profoundly    grateful to you all f
or your invaluable support and friendship during these    past years, which has 
been of utmost importance for the great success of our    Journal.</font></p>   
  ^cY#a01v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#21#17#text#56#<p>&nbsp;</p>     ^cY#a
01v37n1.htm##
00363000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704013200072002001300204#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#22#18#text#56#<p align="right"><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2"><img src="/img/revistas/ib
ju/v37n1/a01ass.jpg">    ^cY#a01v37n1.htm##
00289000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005800072002001300130#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#23#19#text#56#<br>   <i><b>Francisco 
J. B. Sampaio, M.D.</b></i>    ^cY#a01v37n1.htm##
00290000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005900072002001300131#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#24#20#text#56#<br>   Editor-in-Chief,
 IBJU, 2000-2010</font></p>     ^cY#a01v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#25#21#text#56#<p>&nbsp;</p>     ^cY#a
01v37n1.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004400072002001300116#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#26#22#text#56#<p>&nbsp;</p> <hr size=
"1" noshade>     ^cY#a01v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#27#23#text#56#<p>&nbsp;</p>     ^cY#a
01v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#28#24#text#56#<p>&nbsp;</p>     ^cY#a
01v37n1.htm##
00354000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704012300072002001300195#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#29#25#text#56#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>International    Editor's comment</b>
</font></p>     ^cY#a01v37n1.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010000072002001300172#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#30#26#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Dear Colleagues,</font></p>     ^cY#a01
v37n1.htm##
00407000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704017600072002001300248#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#31#27#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> It is an honor    to write you as the I
nternational Editor of the International Braz J Urol.</font></p>     ^cY#a01v37n
1.htm##
00557000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704032600072002001300398#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#32#28#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Together with    Prof. Miriam Dambros, 
the new Editor-in-chief of the IBJU, we can reassure our    readers as to the co
ntinuation of the Journal's mission to inform, educate and    establish a produc
tive rapport with the urological community.</font></p>     ^cY#a01v37n1.htm##
00648000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704041700072002001300489#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#33#29#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Since the IBJU    was founded in 1975 b
y Dr. Alberto Gentile, the editors, reviewers and authors    have promoted and d
eveloped a pivotal instrument of urological knowledge, in    their native langua
ge, allowing the Brazilian urological community to exchange    their knowledge a
nd experience via articles, comments and case reports.</font></p>     ^cY#a01v37
n1.htm##
00672000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704044100072002001300513#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#34#30#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Undoubtedly, due    to the dynamic edit
orship of Prof. Francisco Sampaio, the IBJU evolved in the    last decade to Int
ernational status with the recruitment of worldwide expert's    contributions. N
ot only the prestige of the journal has risen to a new level,    but also the vo
lume and quality of manuscript submissions has achieved new high    standards.</
font></p>     ^cY#a01v37n1.htm##
00461000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704023000072002001300302#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#35#31#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Therefore, the    Brazilian Society of 
Urology (SBU) and IBJU governing board have created the    position of Internati
onal Editor of the Journal.</font></p>     ^cY#a01v37n1.htm##
00647000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704041600072002001300488#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#36#32#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">As the International    Editor of the IB
JU it is my privilege to serve as the liaison between the IBJU    and the intern
ational urologic community to continue the promotion of the journal    nar&shy;r
owing our relationships, improving communication and encourage scientific    sub
missions from international authors and institutions.</font></p>     ^cY#a01v37n
1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#37#33#text#56#<p>&nbsp;</p>     ^cY#a
01v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#38#34#text#56#<p>&nbsp;</p>     ^cY#a
01v37n1.htm##
00361000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704013000072002001300202#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#39#35#text#56#<p align="right"><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">    <i><b>Fernando J. Kim,
 M.D., FACS</b></i>    ^cY#a01v37n1.htm##
00288000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005700072002001300129#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#40#36#text#56#<br>   International As
sociate Editor</font></p>     ^cY#a01v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#41#37#text#56#<p>&nbsp;</p>     ^cY#a
01v37n1.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004400072002001300116#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#42#38#text#56#<p>&nbsp;</p> <hr size=
"1" noshade>     ^cY#a01v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#43#39#text#56#<p>&nbsp;</p>     ^cY#a
01v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#44#40#text#56#<p>&nbsp;</p>     ^cY#a
01v37n1.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011000072002001300182#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#45#41#text#56#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="3"><b>Editor's    comment</b> </font></p>  
   ^cY#a01v37n1.htm##
00567000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704033600072002001300408#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#46#42#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Firstly may I    say that I feel extrem
ely honored to have been appointed to the post of Editor-in-Chief    of the IBJU
. I am very flattered to assume the coordination and grateful for    the possibi
lity of the challenge to further improve our Journal.</font></p>     ^cY#a01v37n
1.htm##
00369000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704013800072002001300210#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#47#43#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">At this particular    time there are no 
words to thank;</font></p>     ^cY#a01v37n1.htm##
00630000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704039900072002001300471#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#48#44#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">- the commitment    and work of Professo
r Francisco Sampaio who for these past 10 years with dedication    and patience 
has made the IBJU a fundamental and reputable scientific journal.    I thank him
 as Editor-in-Chief and as a member of the Brazilian Society of Urology    in th
e name of all Brazilians urologists.</font></p>     ^cY#a01v37n1.htm##
00819000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704058800072002001300660#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#49#45#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">- the Associate    Technical Editor, Dr.
 Luciano A Favorito, Associate Editors, Dr. Gerard C. Freire,    Miguel Srougi, 
Dr. Wachira Kochakarn, Dr Mark S. Soloway, Dr. Claude Schulman,    Video Section
 Editor, Dr. Philippe E. Spiess, Assistant Medical Editor, Richard    Medeiros, 
Urological Survey Committee, Dr Athanase Billis, Dr. Andreas Bohle,    Dr. Sean 
P Elliott, Dr. Fernando Kim, Dr. Adilson Prando, Dr. M. Chad Wallis,    Dr. Mano
j Monga, Dr. Steven P. Petrou and all Consulting Editor members. </font></p>    
 ^cY#a01v37n1.htm##
00447000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704021600072002001300288#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#50#46#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">The time involved    and personal experi
ence were essential to the growth of the IBJU. I look forward    to closely work
ing with you.</font></p>     ^cY#a01v37n1.htm##
00415000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704018400072002001300256#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#51#47#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">- the efficiency    and good job that Ri
cardo de Morais has done in running the Editorial Office.    </font></p>     ^cY
#a01v37n1.htm##
00390000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704015900072002001300231#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#52#48#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">- Prof. Modesto    Jacobino for his genu
ine interest in the growth of IBJU. </font></p>     ^cY#a01v37n1.htm##
00584000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704035300072002001300425#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#53#49#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">- the readers,    authors and Brazilian 
urological community because they believe and have become    partners in the Jou
rnal. I am anxious to receive your comments and feedback    on how you think the
 journal is progressing and what could be done to improve    the IBJU.</font></p
>     ^cY#a01v37n1.htm##
00991000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704076000072002001300832#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#54#50#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">In the position    of Editor-in-Chief of
 the IBJU some changes were proposed such as the creation    of the position of 
Editor for the Portuguese language, which will be occupied    by Prof. Silvio Tu
cci, University of S&atilde;o Paulo - Ribeir&atilde;o Preto,    aimed at facilit
ating the dissemination of the journal in the Brazilian community.    Along with
 the English edition will be sent via Compact Disc, the Portuguese    version of
 the Journal's content. The newly created position of International    Editor wi
ll be occupied by Prof. Dr. Fernando Kim, who is a faithful friend    and collab
orator and has the task of increasing internationalization of our    journal.</f
ont></p>     ^cY#a01v37n1.htm##
01204000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704097300072002001301045#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#55#51#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Another point that    I would like to co
mment on is that since 2009 we have attempted to install the    Editorial Manage
r system as a work platform for the submission of papers. This    is a mission t
hat is at this moment one of my top priorities, which we can start    using very
 soon. I would also like to offer my total commitment and firm interest    in en
couraging the submission and publication of articles from Brazilian authors.    
The main reason for the existence of IBJU is to provide a vehicle for the disclo
sure    of basic science, clinical scientific articles and reviews of good quali
ty within    our specialty, by Brazilian researchers. To this end, the Brazilian
 Society    of Urology will organize meetings with residents, preceptors and the
 Editor-in-Chief    as well as a blog where interested individuals can resolve t
heir doubts and    suggest changes in the journal.</font></p>     ^cY#a01v37n1.h
tm##
00512000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704028100072002001300353#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#56#52#text#56#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Finally, may I    re-confirm my total co
mmitment to the further growth of the IBJU with the sincere    hope that our Jou
rnal will continue to be the source of pride for all Brazilian    urologists. </
font></p>     ^cY#a01v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#57#53#text#56#<p>&nbsp;</p>     ^cY#a
01v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#58#54#text#56#<p>&nbsp;</p>     ^cY#a
01v37n1.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704012200072002001300194#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#59#55#text#56#<p align="right"><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Miriam    Dambros, M
.D.</b></i>    ^cY#a01v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004200072002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a01v37n1.htm#S#p#60#56#text#56#<br>   Editor-in-Chief<
/font></p>     ^cY#a01v37n1.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#o#1#1#article#1
#20110330#144447#a02v37n1.htm#268##
02396000000000493000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030001800109
03100030012703200020013006500090013201400080014103500100014901200390015901000300
01980100026002280700074002540700060003280831307003880850010016950850029017050850
01801734085002401752085002301776085004501799085003601844117000601880072000301886
002001301889#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#h#2#1#artic
le#1#oa#en#br1.1#1#4.0#ILUS#02#IBJU110#nd#Int. braz j urol.#37#1#20110200#^f5^l1
5#1677-5538#Novel concepts in male infertility^len#^rND^1A01^nSandro C.^sEsteves
#^rND^1A02^nAshok^sAgarwal#ANDROFERT^iA01^1Center for Male Reproduction^cCampina
s^sSao Paulo^pBrazil#Center for Reproductive Medicine^iA02^cCleveland^sOhio^pUSA
#^len^aExtraordinary advances have been achieved in the field of male infertilit
y in the last decades. There are new concepts in sperm physiology and several mo
dern tools for the assessment of spermatogenesis kinetics in vivo. New tests usi
ng molecular biology and DNA damage assays allow the clinician to correctly diag
nose men so far classified as having idiopathic male infertility. In the field o
f treatment, microsurgery has increased success rates either for reconstruction 
of the reproductive tract or the retrieval of spermatozoa for assisted conceptio
n. Emerging evidence suggests that life-style and environmental conditions are o
f utmost importance in male fertility and subfertility. This review discusses se
veral concepts that have changed over the last years, such as the duration of th
e spermatogenic cycle in humans, Y-chromosome infertility, the reproductive pote
ntial of non-mosaic Klinefelter syndrome men, the impact of paternal age and spe
rm DNA in male infertility, the role of antioxidants in the treatment of inferti
le men, the predictive factors and techniques for sperm retrieval in non-obstruc
tive azoospermia, and the microsurgical treatment of clinical varicoceles. Whene
ver possible, levels of evidence are provided as suggested by the Oxford Center 
of Evidence-based Medicine.#^ddecs^i1#^tm^len^kmale infertility^i1#^tm^len^kseme
n^i1#^tm^len^kazoospermia^i1#^tm^len^kvaricocele^i1#^tm^len^kassisted reproducti
ve techniques^i1#^tm^len^kevidence-based medicine^i1#other#60#a02v37n1.htm##
02403000000000493000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030001800109
03100030012703200020013006500090013201400080014103500100014901200460015901000300
02050100026002350700074002610700060003350831307003950850010017020850029017120850
01801741085002401759085002301783085004501806085003601851117000601887072000301893
002001301896#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#f#3#1#artic
le#1#oa#en#br1.1#1#4.0#ILUS#02#IBJU110#nd#Int. braz j urol.#37#1#20110200#^f5^l1
5#1677-5538#<b>Novel concepts in male infertility</b>^len#^rND^1A01^nSandro C.^s
Esteves#^rND^1A02^nAshok^sAgarwal#ANDROFERT^iA01^1Center for Male Reproduction^c
Campinas^sSao Paulo^pBrazil#Center for Reproductive Medicine^iA02^cCleveland^sOh
io^pUSA#^len^aExtraordinary advances have been achieved in the field of male inf
ertility in the last decades. There are new concepts in sperm physiology and sev
eral modern tools for the assessment of spermatogenesis kinetics in vivo. New te
sts using molecular biology and DNA damage assays allow the clinician to correct
ly diagnose men so far classified as having idiopathic male infertility. In the 
field of treatment, microsurgery has increased success rates either for reconstr
uction of the reproductive tract or the retrieval of spermatozoa for assisted co
nception. Emerging evidence suggests that life-style and environmental condition
s are of utmost importance in male fertility and subfertility. This review discu
sses several concepts that have changed over the last years, such as the duratio
n of the spermatogenic cycle in humans, Y-chromosome infertility, the reproducti
ve potential of non-mosaic Klinefelter syndrome men, the impact of paternal age 
and sperm DNA in male infertility, the role of antioxidants in the treatment of 
infertile men, the predictive factors and techniques for sperm retrieval in non-
obstructive azoospermia, and the microsurgical treatment of clinical varicoceles
. Whenever possible, levels of evidence are provided as suggested by the Oxford 
Center of Evidence-based Medicine.#^ddecs^i1#^tm^len^kmale infertility^i1#^tm^le
n^ksemen^i1#^tm^len^kazoospermia^i1#^tm^len^kvaricocele^i1#^tm^len^kassisted rep
roductive techniques^i1#^tm^len^kevidence-based medicine^i1#other#60#a02v37n1.ht
m##
02529000000000517000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108121000300113049000800116158000300124
03000170012703100030014403200020014706500090014901400080015803500100016601200390
01760100029002150100026002440700076002700700062003460831307004080850010017150850
02901725085001801754085002401772085002301796085004501819085003601864117000601900
072000301906002001301909008008901922#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
2v37n1.htm#S#l#4#1#article#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#ilus#02#IBJU110
#nd#Int. braz j urol#37#1#20110200#^f5^l15#1677-5538#Novel concepts in male infe
rtility^len#^rND^1A01^nSandro C^sEsteves#^rND^1A02^nAshok^sAgarwal#^iA01^1ANDROF
ERT^2Center for Male Reproduction^cCampinas^sSao Paulo^pBrazil#^iA02^1Center for
 Reproductive Medicine^cCleveland^sOhio^pUSA#^len^aExtraordinary advances have b
een achieved in the field of male infertility in the last decades. There are new
 concepts in sperm physiology and several modern tools for the assessment of spe
rmatogenesis kinetics in vivo. New tests using molecular biology and DNA damage 
assays allow the clinician to correctly diagnose men so far classified as having
 idiopathic male infertility. In the field of treatment, microsurgery has increa
sed success rates either for reconstruction of the reproductive tract or the ret
rieval of spermatozoa for assisted conception. Emerging evidence suggests that l
ife-style and environmental conditions are of utmost importance in male fertilit
y and subfertility. This review discusses several concepts that have changed ove
r the last years, such as the duration of the spermatogenic cycle in humans, Y-c
hromosome infertility, the reproductive potential of non-mosaic Klinefelter synd
rome men, the impact of paternal age and sperm DNA in male infertility, the role
 of antioxidants in the treatment of infertile men, the predictive factors and t
echniques for sperm retrieval in non-obstructive azoospermia, and the microsurgi
cal treatment of clinical varicoceles. Whenever possible, levels of evidence are
 provided as suggested by the Oxford Center of Evidence-based Medicine.#^ddecs^i
1#^tm^len^kmale infertility^i1#^tm^len^ksemen^i1#^tm^len^kazoospermia^i1#^tm^len
^kvaricocele^i1#^tm^len^kassisted reproductive techniques^i1#^tm^len^kevidence-b
ased medicine^i1#other#60#a02v37n1.htm#Internet^ihttp://www.scielo.br/scielo.php
?script=sci_arttext&pid=S1677-55382011000100002##
00355000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012200074002001300196#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#5#1#article#204#<p align="right"><fon
t face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>REVIEW    ARTICLE </b
></font></p>     ^cY#a02v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#6#2#article#204#<p>&nbsp;</p>     ^cY
#a02v37n1.htm##
00378000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704014500074002001300219#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#7#3#article#204#<p><font face="Verdan
a, Arial, Helvetica, sans-serif" size="4"><a name="top"></a><b>Novel    concepts
 in male infertility</b></font></p>     ^cY#a02v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#8#4#article#204#<p>&nbsp;</p>     ^cY
#a02v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#9#5#article#204#<p>&nbsp;</p>     ^cY
#a02v37n1.htm##
00385000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704015100075002001300226#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#10#6#article#204#<p> <font face="Verd
ana, Arial, Helvetica, sans-serif" size="2"><b>Sandro C. Esteves<sup>I</sup>;   
 Ashok Agarwal<sup>II</sup></b></font></p>     ^cY#a02v37n1.htm##
00388000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704015400075002001300229#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#11#7#article#204#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>ANDROFERT,    Center for 
Male Reproduction, Campinas, Sao Paulo, Brazil    ^cY#a02v37n1.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011500075002001300190#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#12#8#article#204#<br>   <sup>II</sup>
Center    for Reproductive Medicine, Cleveland Clinic, Cleveland, Ohio, USA</fon
t></p>     ^cY#a02v37n1.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011600075002001300191#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#13#9#article#204#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#end">Correspondence</a></fo
nt></p>     ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#14#10#article#204#<p>&nbsp;</p>     ^
cY#a02v37n1.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#15#11#article#204#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a02v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#16#12#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#a
02v37n1.htm##
01666000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704143100076002001301507#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#17#13#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Extraordinary advances    have been 
achieved in the field of male infertility in the last decades. There    are new 
concepts in sperm physiology and several modern tools for the assessment    of s
permatogenesis kinetics in vivo. New tests using molecular biology and DNA    da
mage assays allow the clinician to correctly diagnose men so far classified    a
s having idiopathic male infertility. In the field of treatment, microsurgery   
 has increased success rates either for reconstruction of the reproductive tract
    or the retrieval of spermatozoa for assisted conception. Emerging evidence s
uggests    that life-style and environmental conditions are of utmost importance
 in male    fertility and subfertility. This review discusses several concepts t
hat have    changed over the last years, such as the duration of the spermatogen
ic cycle    in humans, Y-chromosome infertility, the reproductive potential of n
on-mosaic    Klinefelter syndrome men, the impact of paternal age and sperm DNA 
in male infertility,    the role of antioxidants in the treatment of infertile m
en, the predictive factors    and techniques for sperm retrieval in non-obstruct
ive azoospermia, and the microsurgical    treatment of clinical varicoceles. Whe
never possible, levels of evidence are    provided as suggested by the Oxford Ce
nter of Evidence-based Medicine.</font></p>     ^cY#a02v37n1.htm##
00471000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023600076002001300312#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#18#14#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Key words:</b>    male infertilit
y, semen, azoospermia, varicocele, assisted reproductive techniques,    evidence
-based medicine</font></p> <hr size="1" noshade>     ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#19#15#article#204#<p>&nbsp;</p>     ^
cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#20#16#article#204#<p>&nbsp;</p>     ^
cY#a02v37n1.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#21#17#article#204#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODUCTION</b></font></p>     ^
cY#a02v37n1.htm##
00920000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068500076002001300761#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#22#18#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Approximately 8%    of men in reprod
uctive age seek medical assistance for fertility-related problems.    Of these, 
1-10% carries conditions that compromise the reproductive potential;    varicoce
le accounts for 35% of the cases (1). The urologist's role in    this field cann
ot be underestimated. He/she is trained to diagnose, counsel,    provide medical
 or surgical treatment whenever possible and correctly refer    the male patient
 for assisted conception. By integrating the reproductive team,    the urologist
 is responsible for the above-cited tasks and to perform surgical    sperm retri
eval. </font></p>     ^cY#a02v37n1.htm##
00677000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044200076002001300518#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#23#19#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The urologist should    also be awar
e of the recently published evidence that have challenged several    established
 concepts in male infertility. This review discusses the main concepts    that h
ave changed over the previous years and provides the levels of evidence,    when
ever possible, as suggested by the Oxford Center of Evidence-based Medicine    (
2).</font></p>     ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#24#20#article#204#<p>&nbsp;</p>     ^
cY#a02v37n1.htm##
00363000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012800076002001300204#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#25#21#article#204#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>DURATION OF    THE SPERMATOGENIC 
CYCLE</b></font></p>     ^cY#a02v37n1.htm##
01769000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704153400076002001301610#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#26#22#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Misell et al. (2006)    have shown f
or the first time that the time from initiation of spermatogenesis    to appeara
nce in the ejaculate is approximately 64 days, significantly shorter    than the
 previously suspected 70 to 80-day period (3). Men with normal sperm    concentr
ations ingested <sup>2</sup>H<sub>2</sub>O daily and semen samples were    colle
cted every 2 weeks for up to 90 days. <sup>2</sup>H<sub>2</sub>O label incorpora
tion into sperm    DNA was quantified by gas chromatography/mass spectrometry, a
llowing calculation    of the percent of new cells. The overall mean time to det
ection of labeled sperm    in the ejaculate was 64&plusmn;8 days (range 42-76). 
They also observed biological    variability, thus contradicting the current bel
ief that spermatogenesis duration    is fixed among individuals. All subjects ac
hieved greater than 70% new sperm    in the ejaculate by day 90, but plateau lab
eling was not attained in most, suggesting    rapid washout of old sperm in the 
epididymal reservoir (4). Their data also    suggested that in normal men, sperm
 released from the seminiferous epithelium    enter in the epididymis in a coord
inated manner with little mixing of old and    new sperm before subsequent ejacu
lation. This is also a new concept, because    it had been suggested that becaus
e of mixing, in any segment of the epididymal    duct, the population of sperm w
ould be heterogeneous in age and biological status.    </font></p>     ^cY#a02v3
7n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#27#23#article#204#<p>&nbsp;</p>     ^
cY#a02v37n1.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011700076002001300193#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#28#24#article#204#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Y-CHROMOSOME    INFERTILITY</b></
font></p>     ^cY#a02v37n1.htm##
01064000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082900076002001300905#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#29#25#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Y-chromosome infertility    is char
acterized by azoospermia or severe to moderate oligozoospermia, although    rare
 cases of mild oligozoospermia (5-20x10<sup>6</sup> sperm/mL semen) may    occur
. Men with Y-chromosome infertility have no obvious symptoms, but physical    ex
amination may reveal small testes and/or cryptorchidism or varicoceles. One    r
eport suggested that a specific deletion in the AZFc region (gr/gr) might increa
se    the susceptibility to testicular cancer (5). The prevalence of Y-chromosom
e    microdeletions is estimated to be about 1:2000 to 1:3000 males; the frequen
cy    in males with azoospermia or severe oligozoospermia is about 5%-12%, altho
ugh    a marked difference is reported in different world regions (6).</font></p
>     ^cY#a02v37n1.htm##
01249000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704101400076002001301090#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#30#26#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Clinically available    molecular te
sting may reveal microdeletions in the long arm of the Y-chromosome    The diagn
osis of Y-chromosome microdeletions consists of a series of polymerase    chain 
reaction amplifications within relatively broad regions of the Y-chromosome.    
Originally, three regions were defined: AZFa, AZFb and AZFc (azoospermia factor)
,    which map on the long arm (Yq) from the centromere to the telomere (7). A f
ourth    region, named AZFd, located between AZFb and AZFc was also reported. Th
e relative    frequency of individual microdeletions are 60%, 5% and 16% for AZF
c, AZFa and    AZFb regions, but combined deletions occur in about 15% of cases 
(8). Because    deletions tend to occur between large palindromic repeats, Reppi
ng et al. (2002)    proposed a more appropriate nomenclature using the name of t
he flanking repeats    for the types of recurrent deletions (7) (<a href="#fig1"
>Figure-1</a>).</font></p>     ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#31#27#article#204#<p>&nbsp;</p>     ^
cY#a02v37n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010300076002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#32#28#article#204#<p><font face="Verd
ana, Arial, Helvetica, sans-serif"><a name="fig1" id="fig1"></a></font></p>     
^cY#a02v37n1.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#33#29#article#204#<p align="center"><
img src="/img/revistas/ibju/v37n1/a02fig1.jpg"></p>     ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#34#30#article#204#<p>&nbsp;</p>     ^
cY#a02v37n1.htm##
01750000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704151500076002001301591#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#35#31#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Pregnancies can    be achieved by in
 vitro fertilization (IVF) using intracytoplasmic sperm injection    (ICSI) in m
ales with Y-chromosome infertility exhibiting oligozoospermia or    azoospermia 
with retrievable testicular sperm (9,10). The presence of a deletion    has no a
pparent negative effect on fertilization or pregnancy and it does not    increas
e the risk for birth defects in children conceived via assisted reproduction    
technology (ART) (11) (Level C evidence). The presence of sperm in men with    Y
-chromosome microdeletions varies with the type of deletion. Testicular phenotyp
es    associated with microdeletions in the AZFa region are the most severe and 
include    Sertoli cell-only (SCO) pattern on testis histology (10). Testicular 
phenotypes    associated with microdeletions restricted to AZFc ranged from azoo
spermia to    moderate oligozoospermia whereas AZFb microdeletions are often ass
ociated to    azoospermia. Individuals with AZFd microdeletions manifest the bro
adest range    of testicular phenotypes. In partial and complete AZFc deletion a
zoospermic    patients, sperm can be found in the testis in 70% of the cases. In
 contrast,    the chance of finding sperm in azoospermic men with complete AZFa 
or AZFb deletions    is unlikely (11) (Level C evidence). Large deletions involv
ing multiple AZF    regions generally present with testicular phenotypes similar
 to those restricted    to AZFa (6).</font></p>     ^cY#a02v37n1.htm##
00862000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062700076002001300703#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#36#32#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Y-chromosome infertility    is inhe
rited in a Y-linked manner. Deletions are usually de novo and therefore    not p
resent in the father of the proband. Rarely, within a family, the same    deleti
on of the Y chromosome can cause infertility in some males but not in    others;
 hence, some fertile males with deletion of the AZF regions have fathered    son
s who are infertile (12). In pregnancies achieved from males with infertility   
 caused by deletion of the AZF regions using ICSI, male offspring have the same 
   deletion as their father.</font></p>     ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#37#33#article#204#<p>&nbsp;</p>     ^
cY#a02v37n1.htm##
00389000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704015400076002001300230#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#38#34#article#204#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REPRODUCTIVE    POTENTIAL OF NON-
MOSAIC KLINEFELTER SYNDROME MEN</b></font></p>     ^cY#a02v37n1.htm##
00837000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060200076002001300678#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#39#35#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The frequency    of Klinefelter syn
drome (KS), a specific chromosomal abnormality (47,XXY), is    0.2% of male newb
orns and 11% of azoospermic men (13). The sterility of KS is    due to the high 
prevalence of azoospermia present in 92% of KS men; the remainder    have a medi
an of 0.1 million sperm/mL. Nevertheless, sperm are found in 50%    of cases on 
testicular exploration and pregnancy rates by ICSI range from 30%    to 50% (13)
. None of the clinical parameters are predictive of success in sperm    retrieva
l. </font></p>     ^cY#a02v37n1.htm##
00960000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072500076002001300801#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#40#36#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">KS men fathered    more than 60 chil
dren worldwide; ~50 had karyotype analysis all being normal    (13,14). Sciurano
 et al. (2009) have shown that seminiferous tubuli with germ    cells represents
 only a minor fraction of all tubuli in men with non-mosaic    KS. Using fluores
cence in situ hybridization (FISH), they showed that meiotic    spermatocytes ar
e euploid, and thus can form normal, haploid gametes. Sertoli    cells showed tw
o marks for the X chromosome, meaning that they were 47, XXY    (15). These new 
findings may explain the high rate of normal children born after    testicular s
perm extraction plus ICSI when applied to KS. </font></p>     ^cY#a02v37n1.htm##
00998000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076300076002001300839#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#41#37#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Sperm retrieval    rate appeared to 
be lower (20%) in KS men who previously received exogenous    androgens (13). Su
ch treatment may suppress the hypothalamic-pituitary-testis    axis, impairing F
SH secretion and decreasing intratesticular androgen levels    that could impair
 spermatogenesis. Ramasamy et al. (2009) showed that other    medications leadin
g to endogenous testosterone increase seem to benefit KS men.    In their study,
 KS men with either normal or low baseline testosterone but who    respond to me
dical therapy (aromatase inhibitors, clomiphene or human chorionic    gonadotrop
in) had a better chance of sperm retrieval (77% vs. 55%) (16) (Level    C eviden
ce).</font></p>     ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#42#38#article#204#<p>&nbsp;</p>     ^
cY#a02v37n1.htm##
00356000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012100076002001300197#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#43#39#article#204#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>PATERNAL    AGE AND INFERTILITY</
b></font></p>     ^cY#a02v37n1.htm##
01620000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704138500076002001301461#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#44#40#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">There is a general    belief that th
e fertility potential of older man is fairly well preserved. However,    recent 
evidence support the concept that advanced paternal age is associated    with an
 increase in sperm chromosomal aneuploidy (17,18). The risk for a father    over
 40 years-old to have a child with an autosomal dominant mutation equals    the 
risk of Down syndrome for a child whose mother is 35-40 years-old. Also,    fath
ers over the age of 40 had a 20% greater chance of having a baby born with    a 
serious birth defect (18). Moskovtsky et al. (2006) demonstrated that the    rat
e of sperm with fragmented DNA doubled in men 45 years and older compared    to 
those less than 30 years old (19) (Level B evidence). Siddighi et al. (2007)    
showed increased necrosis, DNA damage and apoptosis while rapid progression    a
nd total motility declined with advancing male age beginning as early as age    
35 (20). Plastira et al. (2007) demonstrated that increased age in infertile    
patients was associated with an increase in sperm DNA fragmentation and poor    
chromatin packaging, as well as with a decline in semen volume, sperm morphology
    and motility (21) (Level C evidence). The current findings may help to defin
e    better cut-off age limits for donor sperm banking guidelines.</font></p>   
  ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#45#41#article#204#<p>&nbsp;</p>     ^
cY#a02v37n1.htm##
00361000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012600076002001300202#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#46#42#article#204#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>SPERM DNA INTEGRITY    AND FERTIL
ITY</b></font></p>     ^cY#a02v37n1.htm##
00626000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039100076002001300467#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#47#43#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In clinical practice,    traditional
 semen analysis maintains its central role in the assessment of male    fertilit
y potential. However, in several cases abnormalities in the male genome    chara
cterized by damaged sperm DNA may be indicative of subfertility regardless    of
 routine semen parameters (22). </font></p>     ^cY#a02v37n1.htm##
02241000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704200600076002001302082#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#48#44#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Assays to evaluate    sperm chromati
n/DNA integrity can be divided in three groups (23): a) sperm    chromatin struc
tural probes using nuclear dyes (e.g. microscopic acridine orange    test &#91;A
OT&#93;, sperm chromatin structural assay &#91;SCSA&#93;, aniline blue test &#91
;AB&#93;,    chromomycin- A3 &#91;CMA3&#93; and toluidine blue &#91;TB&#93;, b) 
tests for direct assessment    of sperm DNA fragmentation (e.g. terminal deoxynu
cleotidyl transferase mediated    dUTP nick end labeling assay &#91;TUNEL&#93; a
nd single-cell gel electrophoresis assay    &#91;COMET&#93;, and c) sperm nuclea
r matrix assays (e.g. sperm chromatin dispersion    test). Sperm DNA damage leve
ls are significantly different between fertile and    infertile men. The probabi
lity of fertilization in vivo and by intrauterine    insemination (IUI) seems to
 be close to zero if the proportion of sperm cells    with DNA damage exceeds 30
% (DFI) as detected by SCSA (24) (Level B evidence).    Semen samples containing
 &gt;12% sperm with fragmented DNA (TUNEL) resulted    in no pregnancies in IUI 
(25). Sperm DNA damage is negatively correlated with    embryo quality and blast
ocyst formation in IVF cycles and with fertilization    rates in both IVF and IC
SI (26). However, successful pregnancies in IVF/ICSI    can be obtained using se
men samples with high proportion of DNA damage. Bungum    et al. (2004) demonstr
ated that higher clinical pregnancy rates (52.9 % vs.    22.2 %) and delivery ra
tes (47.1 % vs. 22.2 %) were obtained after ICSI as compared    to IVF when seme
n samples with high levels of sperm DNA damage were used, as    previously sugge
sted (27) (Level B evidence). Despite these data, a recent meta-analysis    fail
ed to support the concept that DNA integrity testing was more predictive    for 
IVF than ICSI, and even that such testing is predictive of pregnancy outcome    
either in IVF or ICSI (28) (Level A evidence). </font></p>     ^cY#a02v37n1.htm#
#
01293000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704105800076002001301134#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#49#45#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The proportion    of sperm with DNA 
damage was shown to be higher in men from couples with recurrent    pregnancy lo
ss compared to the general population or fertile donors (29). It    is suggested
 that 39% of miscarriages could be predicted using a combination    of sperm DNA
 integrity assays (30) (Level C evidence). Aitken and Krausz (2001)    proposed 
that sperm DNA damage is promutagenic; mutations can occur after fertilization  
  as the oocyte attempts to repair DNA damage prior to the initiation of the fir
st    cleavage. Mutations occurring at this point will be fixed in the germline 
and    may be responsible for the induction of infertility, childhood cancer in 
the    offspring and higher risk of imprinting diseases (31). So far, follow-up 
of    children born after ICSI compared with children born after conventional IV
F    have not been conclusive regarding the risks of congenital malformations, i
mprinting    diseases and health problems in general (32). </font></p>     ^cY#a
02v37n1.htm##
01227000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704099200076002001301068#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#50#46#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Existing data justify    the introdu
ction of sperm DNA damage assessment into the male infertility workup,    but cu
rrent evidence are not strong enough to provide a clinical indication    for rou
tine use in infertility evaluation (23,28) (Level A-B evidence). Sperm    DNA da
mage testing may be indicated in unexplained or idiopathic infertility,    when 
a traditional semen analysis is normal and no evident female reproductive    sys
tem pathologies can be revealed, and in selected cases of recurrent miscarriage.
    The ART method of choice can be recommended based on sperm DNA damage result
s    and testicular instead of ejaculated sperm may be used for ICSI attempting 
to    optimize reproductive outcomes in selected cases. Whether sperm DNA damage
 can    be treated, allowing these couples to switch from ICSI to IVF/IUI or eve
n achieve    a pregnancy in a natural way, remains to be elucidated (33).</font>
</p>     ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#51#47#article#204#<p>&nbsp;</p>     ^
cY#a02v37n1.htm##
00360000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012500076002001300201#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#52#48#article#204#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>OXIDATIVE STRESS    AND INFERTILI
TY</b></font></p>     ^cY#a02v37n1.htm##
01247000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704101200076002001301088#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#53#49#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Oxidative stress    (OS) is induced 
by reactive oxygen species (ROS) (33). Normal levels of ROS    are required for 
sperm physiology, but excessive levels of ROS can negatively    affect sperm qua
lity (<a href="/img/revistas/ibju/v37n1/a02fig2.jpg">Figure-2</a>). The OS-induc
ed    sperm damage has been suggested to be a significant contributing factor in
 30&#8211;80%    of all cases of male infertility (34). The generation of ROS ca
n be exacerbated    by environmental, infectious, and lifestyle etiologies (35-3
7). For example,    exposure to cigarette smoke generates high levels of OS, dir
ectly increasing    seminal leukocyte concentrations and seminal ROS generation,
 and decreasing    seminal levels of the antioxidant enzyme superoxide dismutase
 (SOD). Smoking    decreases concentrations of the seminal plasma antioxidants t
hereby reducing    the oxidant scavenging capacity of the spermatozoa and semina
l fluid (38).</font></p>     ^cY#a02v37n1.htm##
01112000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087700076002001300953#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#54#50#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Oxidative stress    can be measured 
using direct and indirect assays. Direct assays measure the    net oxidative sum
 of the balance between ROS production and intra- and extracellular    antioxida
nts that scavenge ROS. The most used direct assay measures malondialdehyde,    o
ne of the final products of sperm cell membrane lipid peroxidation. Quantificati
on    of sperm DNA damage has also been used as a direct assay of intracellular 
ROS-induced    oxidant injury (39). The most common indirect method for seminal 
ROS measurement    is via chemiluminescence. Luminol or lucigen probes can be us
ed for quantification    of redox activities of spermatozoa; they have well esta
blished reported ranges    for fertile and infertile populations thus bringing c
linical relevance to its    use (39). </font></p>     ^cY#a02v37n1.htm##
02429000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704219400076002001302270#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#55#51#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Recent reports    have focused on th
e therapeutic management of OS in male infertility. Varicocele    increase OS le
vels in the testes as well as semen, and varicocelectomy may decrease    seminal
 OS, increase seminal concentrations of antioxidants and also improve    sperm q
uality (40) (Level C evidence). In recent years, interest has increased    in th
e role of antioxidants and B vitamins as modulators of fertility outcome.    The
 antioxidants alpha-tocopherol (Vitamin A), ascorbic acid (Vitamin C) and    the
 retinoids (Vitamin A) are potent scavengers of ROS. Deficient vitamin-B    conc
entrations cause elevated homocysteine concentrations and impair the remethylati
on    cycle of phospholipids, proteins, DNA, and RNA. These processes are essent
ial    in spermatogenesis. Wong et al. (2002) demonstrated that folic acid (5 mg
) and    zinc phosphate (66 mg) caused a 74% increase of total normal sperm coun
t in    subfertile men (41) (Level B evidence). Boxmeer et al. (2009) reported f
or the    first time that a low folate concentration in seminal plasma is associ
ated with    more sperm DNA damage in fertile men (42). Folate shortage increase
s DNA fragility    due to the misincorporation of uracil instead of thymine. Gre
co et al. (2005)    studied a large cohort of infertile men with &gt;15% DNA-fra
gmented spermatozoa    treated with either 1 gram of Vitamin C and E daily or pl
acebo for two months,    and demonstrated that the percentage of DNA-fragmented 
spermatozoa was reduced,    but with no effects on the sperm parameters (43). Th
e authors further went on    to demonstrate that supplementation with vitamins E
 and C significantly increased    rates of clinical pregnancy and implantation f
ollowing ICSI (44) (Level B evidence).    Recently, a case series study suggeste
d that an increased intake of antioxidant-rich    food or antioxidant supplement
s (see <a href="#ap">appendix</a>) by men with    high levels of sperm DNA fragm
entation or lipid peroxidation may result in an    improvement in gestational ou
tcomes for couples with recurrent embryo losses    (45) (Level C evidence).</fon
t></p>     ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#56#52#article#204#<p>&nbsp;</p>     ^
cY#a02v37n1.htm##
00268000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003300076002001300109#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#57#53#article#204#<p><a name="ap"></a
></p>     ^cY#a02v37n1.htm##
00370000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013500076002001300211#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#58#54#article#204#<p align="center"><
font face="Verdana, Arial, Helvetica, sans-serif"><img src="/img/revistas/ibju/v
37n1/a02ap.jpg"></font></p>     ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#59#55#article#204#<p>&nbsp;</p>     ^
cY#a02v37n1.htm##
00412000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017700076002001300253#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#60#56#article#204#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>PREDICTIVE FACTORS    AND TECHNIQ
UES FOR SPERM RETRIEVAL IN NON-OBSTRUCTIVE AZOOSPERMIA</b></font></p>     ^cY#a0
2v37n1.htm##
00865000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063000076002001300706#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#61#57#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">To date, there    are still no absol
ute preoperative predictive factors for successful sperm retrieval    (SR), alth
ough the probability seems to depend on the biopsy technique. Microdissection   
 testicular sperm extraction (micro-TESE) has been shown to be more successful  
  in sperm retrieval than a single biopsy or multiple random biopsies (46,47)   
 (Level C evidence). Moreover, micro-TESE seems to have less effect on testicula
r    function because it spares vessels during dissection and removes less tissu
e    than random biopsies (48).</font></p>     ^cY#a02v37n1.htm##
01162000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704092700076002001301003#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#62#58#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The concept that    elevated FSH lev
els are associated with male sterility has now been challenged.    Serum FSH is 
an indirect reflection of the global spermatogenic function and    testis histol
ogy. In cases of diffuse maturation arrest (MA), adequate control    feedback fr
om germ cells and Sertoli cells exists despite the absence of sperm    productio
n (49). Sperm retrieval techniques can obtain sperm from the testicle    even in
 cases of elevated FSH, but their results depend on the retrieval method.    Bro
mage et al. (2007) reported that the probability for sperm retrieval in non    o
bstructive azoospermia (NOA) men with elevated FSH are lower using random biopsy
    TESE (50), while Ramasamy et al. (2009) demonstrated nearly identical retrie
val    rates by micro-TESE of ~60% regardless of FSH levels (51) (Level B eviden
ce).    </font></p>     ^cY#a02v37n1.htm##
00894000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065900076002001300735#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#63#59#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Testicular histology    is considere
d the best predictor for successful sperm retrieval in NOA. However,    even the
 combination of histology and FSH results provides only a 'fair'    accuracy rat
e of 0.74 (52) (Evidence level B). Nonetheless, Esteves et al. (2006)    have sh
own that SR by micro-TESE were significantly higher in cases of hypospermatogene
sis    or MA (100% and 75%, respectively) as compared to SCO (32%) (53), thus hi
ghlighting    the concept that even the more adverse histological pattern cannot
 determine    if sperm are present elsewhere in the testis. </font></p>     ^cY#
a02v37n1.htm##
00838000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060300076002001300679#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#64#60#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Recently, the importance    of surgi
cal treatment prior to sperm retrieval in NOA men has been highlighted.    Inci 
et al. (2009) reported that treatment of clinical varicoceles prior to    SR inc
reased the chance of obtaining testicular sperm using micro-TESE in a    group o
f NOA individuals with clinical varicoceles (54). Retrieval rates were    53% an
d 30% in the treated and untreated men, respectively (odds-ratio &#91;OR&#93;:  
  2.63; 95% confidence interval &#91;CI&#93; of 1.05&#8211;6.60) (Level C eviden
ce).</font></p>     ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#65#61#article#204#<p>&nbsp;</p>     ^
cY#a02v37n1.htm##
00375000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014000076002001300216#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#66#62#article#204#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>MICROSURGICAL    TREATMENT OF CLI
NICAL VARICOCELES</b></font></p>     ^cY#a02v37n1.htm##
02024000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704178900076002001301865#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#67#63#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Although several    studies demonstr
ated the beneficial effect of the surgical treatment of clinical    varicoceles 
in infertility (40,55), a recent meta-analysis concluded that treatment    of va
ricocele in men from couples with otherwise unexplained subfertility could    no
t be recommended (56) (Level B evidence). This meta-analysis was challenged    b
y Ficcara et al. (2006), who argued that less than half of the studies in the   
 Cochrane review included patients with abnormal semen analysis and palpable    
varicocele and demonstrated that its methodology and statistical power was poor,
    thereby minimizing its significance against varicocele repair (57). The most
    recent meta-analysis on varicocelectomy unequivocally demonstrated that the 
   chances of obtaining a spontaneous conception were 2.8 times higher in the va
ricocelectomy    group as compared to the group of patients who received either 
no treatment    or medication (58) (Level A evidence). Recently, it has been sho
wn that treatment    of clinical varicoceles may also improve the outcomes of as
sisted reproduction    in couples with varicocele-related infertility. Esteves e
t al. (2010) observed    higher pregnancy rates after ICSI in the group of men w
ho underwent microsurgical    varicocele repair before ART (60.3% versus 45.0%),
 and logistic regression showed    that the chance of obtaining a clinical pregn
ancy was increased by 69% if the    varicocele had been treated before ICSI (OR:
 1.69, 95% CI 1.00&#8211;2.84).    Also, the chance of having a miscarriage afte
r ICSI was significantly reduced    by 2.3 times if the varicocele had been trea
ted (OR: 0.433; 95% CI 0.22-0.83;    P=0.01) (59). (Level C evidence).</font></p
>     ^cY#a02v37n1.htm##
00766000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053100076002001300607#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#68#64#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">To date varicoceles    are treated u
sing different techniques. A recent systematic review including    4,473 individ
uals concluded that open microsurgical inguinal or sub-inguinal    varicocelecto
my techniques resulted in higher spontaneous pregnancy rates with    fewer recur
rences and postoperative complications than laparoscopic, radiologic    emboliza
tion and macroscopic inguinal or retroperitoneal varicocelectomy (60)    (Level 
A evidence).</font></p>     ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#69#65#article#204#<p>&nbsp;</p>     ^
cY#a02v37n1.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010100076002001300177#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#70#66#article#204#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUSIONS</b></font></p>     ^c
Y#a02v37n1.htm##
02504000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704226900076002001302345#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#71#67#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The entire duration    of the sperma
togenic cycle is shorter (~60 days) than the previously suspected    70 to 80-da
y period. About 10% of the infertile male population previously misdiagnosed    
as idiopathic have de novo Yq microdeletions, and the presence or absence of    
sperm (ejaculated or retrieved) vary depending on the specific deletion. Althoug
h    no treatment exists, ICSI may be effective but the male offspring will inhe
rit    the same deletion as their father. In ~50% of non-mosaic KS azoospermic m
en    testicular sperm are found by micro-TESE. Children born after ICSI using t
esticular    sperm from KS men have normal karyotype because the minor foci of g
erm cells    into the seminiferous tubuli are euploid. Sperm quality declines wi
th paternal    age beginning as early as age 35, and it may explain certain case
s of male infertility,    recurrent miscarriages and the occurrence of autosomal
 dominant, single gene    disorders in offspring. Abnormalities in the male geno
me characterized by damaged    sperm DNA may be indicative of male subfertility 
regardless of normal routine    semen parameters. DNA integrity testing is now c
linically available and results    may predict reproductive outcomes. Oxidative 
stress is associated with sperm    quality and infertility. Therapeutic measures
 to decrease OS, including lifestyle    modifications, varicocelectomy in select
ed cases and the use of vitamins/antioxidants,    show promising results. In the
 subset of men with NOA, FSH levels are not predictive    of SR or sterility. Mi
cro-TESE yields the best SR rates in NOA; success may    be optimized by surgica
l treatment of clinical varicoceles or by medical therapy    in non-mosaic KS me
n. Microsurgical varicocelectomy is associated with lower    recurrence and comp
lications. Spontaneous and assisted-conception conception    may be increased af
ter repair of clinical varicocele. We hope that our review    will provide a bet
ter understanding of evolving concepts in the field of male    infertility to ur
ologists and male infertility specialists. This increased knowledge    will no d
oubt aid in the better management and treatment of the infertile male.</font></p
>     ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#72#68#article#204#<p>&nbsp;</p>     ^
cY#a02v37n1.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#73#69#article#204#<p> <font size="3" 
face="Verdana, Arial, Helvetica, sans-serif"><b>ACKNOWLEDGEMENTS</b></font></p> 
    ^cY#a02v37n1.htm##
00523000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028800076002001300364#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#74#70#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Extracted from    a Roundtable Sylla
bus "New Concepts in Male Infertility", presented    by the author (SCE) at the 
2009 American Society for Reproductive Medicine Annual    Meeting, Atlanta, Geor
gia, USA.</font></p>     ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#75#71#article#204#<p>&nbsp;</p>     ^
cY#a02v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#76#72#article#204#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>CONFLICT OF    INTEREST</b></font
></p>     ^cY#a02v37n1.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#77#73#article#204#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">None declared.</font></p>     ^cY#a0
2v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#78#74#article#204#<p>&nbsp;</p>     ^
cY#a02v37n1.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#79#75#article#204#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFERENCES</b></font></p>     ^cY
#a02v37n1.htm##
00468000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021900078002001300297#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#80#76#article#204#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Vital and Health   
 Statistics, series 23, no. 26, CDC, 2002. <a href="http://www.cdc.gov" target="
_blank">http://www.cdc.gov</a>    </font></p>     ^cY#a02v37n1.htm##
00562000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704031300078002001300391#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#81#77#article#204#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Centre for evidence
-based    medicine: Oxford Centre for Evidence-based Medicine - Levels of Eviden
ce, March    2009. <a href="http://www.cebm.net/index.aspx?o=1025" target="_blan
k">http://www.cebm.net/index.aspx?o=1025</a>    </font></p>     ^cY#a02v37n1.htm
##
00470000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022100078002001300299#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#82#78#article#204#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Clermont Y:    Kine
tics of spermatogenesis in mammals: seminiferous epithelium cycle and spermatogo
nial    renewal. Physiol Rev. 1972; 52: 198-236.    ^cY#a02v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#83#79#article#204#</font></p>     ^cY
#a02v37n1.htm##
00532000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028300078002001300361#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#84#80#article#204#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Misell LM, Holochwo
st    D, Boban D, Santi N, Shefi N, Hellerstein MK, Turek PJ: A stable isotope-m
ass    spectrometric method for measuring human spermatogenesis kinetics in vivo
. J    Urol. 2006; 175: 242-6.    ^cY#a02v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#85#81#article#204#</font></p>     ^cY
#a02v37n1.htm##
00511000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026200078002001300340#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#86#82#article#204#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Nathanson KL,    Ka
netsky PA, Hawes R, Vaughn DJ, Letrero R, Tucker K et al: The Y deletion gr/gr  
  and susceptibility to testicular germ cell tumor. Am J Hum Genet. 2005; 77:   
 1034-43.    ^cY#a02v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#87#83#article#204#</font></p>     ^cY
#a02v37n1.htm##
00466000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021700078002001300295#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#88#84#article#204#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Simoni M: Clinical 
   consequences of microdeletions of the Y chromosome: the extended M&uuml;nster
    experience. RBM online 2008; 16: 289-30.    ^cY#a02v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#89#85#article#204#</font></p>     ^cY
#a02v37n1.htm##
00574000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704032500078002001300403#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#90#86#article#204#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Repping S, Skaletsk
y    H, Lange J, Silber S, Van Der Veen F, Oates RD, Page DC, Rozen S: Recombina
tion    between palindromes P5 and P1 on the human Y chromosome causes massive d
eletions    and spermatogenic failure. Am J Hum Genet. 2002; 71: 906-22.    ^cY#
a02v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#91#87#article#204#</font></p>     ^cY
#a02v37n1.htm##
00435000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704018600078002001300264#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#92#88#article#204#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Shefi S, Turek    P
J: Definition and current evaluation of subfertile men. Int Braz J Urol. 2006;  
  32: 385-97.    ^cY#a02v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#93#89#article#204#</font></p>     ^cY
#a02v37n1.htm##
00554000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704030500078002001300383#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#94#90#article#204#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Sun C, Skaletsky   
 H, Rozen S, Gromoll J, Nieschlag E, Oates R, Page DC: Deletion of azoospermia  
  factor a (AZFa) region of human Y chromosome caused by recombination between  
  HERV15 proviruses. Hum Mol Genet: 2000; 9: 2291-6.    ^cY#a02v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#95#91#article#204#</font></p>     ^cY
#a02v37n1.htm##
00630000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704038000079002001300459#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#96#92#article#204#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Kamp C, Huellen  
  K, Fernandes S, Sousa M, Schlegel PN, Mielnik A, Kleiman S, Yavetz H, Krause  
  W, K&uuml;pker W, Johannisson R, Schulze W, Weidner W, Barros A, Vogt PH: High
    deletion frequency of the complete AZFa sequence in men with Sertoli-cell-on
ly    syndrome. Mol Hum Reprod. 2001; 7: 987-94.    ^cY#a02v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#97#93#article#204#</font></p>     ^cY
#a02v37n1.htm##
00530000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704028000079002001300359#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#98#94#article#204#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Hopps CV, Mielnik
    A, Goldstein M, Palermo GD, Rosenwaks Z, Schlegel PN: Detection of sperm in 
   men with Y chromosome microdeletions of the AZFa, AZFb and AZFc regions. Hum 
   Reprod. 2003; 18: 1660-5.    ^cY#a02v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#99#95#article#204#</font></p>     ^cY
#a02v37n1.htm##
00506000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704025500080002001300335#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#100#96#article#204#12#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Saut N, Terriou 
   P, Navarro A, Levy N, Mitchell MJ: The human Y chromosome genes BPY2, CDY1 an
d    DAZ are not essential for sustained fertility. Mol Hum Reprod. 2000; 6: 789
-93.    ^cY#a02v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#101#97#article#204#</font></p>     ^c
Y#a02v37n1.htm##
00558000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704030700080002001300387#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#102#98#article#204#13#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Schiff JD,    Pa
lermo GD, Veeck LL, Goldstein M, Rosenwaks Z, Schlegel PN: Success of testicular
    sperm injection and intracytoplasmic sperm injection in men with Klinefelter
    syndrome. J Clin Endocrinol Metab. 2005; 90: 6263-7.    ^cY#a02v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#103#99#article#204#</font></p>     ^c
Y#a02v37n1.htm##
00526000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027400081002001300355#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#104#100#article#204#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Staessen C,    
Tournaye H, Van Assche E, Michiels A, Van Landuyt L, Devroey P, Liebaers I,    V
an Steirteghem A: PGD in 47, XXY Klinefelter's syndrome patients. Hum    Reprod 
Update. 2003; 9: 319-30.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#105#101#article#204#</font></p>     ^
cY#a02v37n1.htm##
00546000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029400081002001300375#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#106#102#article#204#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Sciurano RB,   
 Luna Hisano CV, Rahn MI, Brugo Olmedo S, Rey Valzacchi G, Coco R, Solari AJ:   
 Focal spermatogenesis originates in euploid germ cells in classical Klinefelter
    patients. Hum Reprod. 2009; 24: 2353-60.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#107#103#article#204#</font></p>     ^
cY#a02v37n1.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023800081002001300319#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#108#104#article#204#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Ramasamy R,    
Ricci JA, Palermo GD, Gosden LV, Rosenwaks Z, Schlegel PN: Successful fertility 
   treatment for Klinefelter's syndrome. J Urol. 2009; 182: 1108-13.    ^cY#a02v
37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#109#105#article#204#</font></p>     ^
cY#a02v37n1.htm##
00541000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028900081002001300370#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#110#106#article#204#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Johnson L,    P
etty CS, Porter JC, Neaves WB: Germ cell degeneration during postprophase of    
meiosis and serum concentrations of gonadotropins in young adult and older adult
    men. Biol Reprod. 1984; 31: 779-84.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#111#107#article#204#</font></p>     ^
cY#a02v37n1.htm##
00537000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028500081002001300366#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#112#108#article#204#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Wyrobek AJ,    
Aardema M, Eichenlaub-Ritter U, Ferguson L, Marchetti F: Mechanisms and targets 
   involved in maternal and paternal age effects on numerical aneuploidy. Enviro
n    Mol Mutagen. 1996; 28: 254-64.    ^cY#a02v37n1.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#113#109#article#204# </font></p>     
^cY#a02v37n1.htm##
00508000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025600081002001300337#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#114#110#article#204#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Moskovtsev    S
I, Willis J, Mullen JB: Age-related decline in sperm deoxyribonucleic acid    in
tegrity in patients evaluated for male infertility. Fertil Steril. 2006; 85:    
496-9.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#115#111#article#204#</font></p>     ^
cY#a02v37n1.htm##
00479000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022700081002001300308#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#116#112#article#204#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Siddighi S,    
Chan CA, Patton WC, Jacobson JD, Chan PJ: Male age and sperm necrosis in assiste
d    reproductive technologies. Urol Int. 2007; 9: 231-4.    ^cY#a02v37n1.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#117#113#article#204# </font></p>     
^cY#a02v37n1.htm##
00642000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704039000081002001300471#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#118#114#article#204#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Plastira K,    
Msaouel P, Angelopoulou R, Zanioti K, Plastiras A, Pothos A, Bolaris S, Paparist
eidis    N, Mantas D: The effects of age on DNA fragmentation, chromatin packagi
ng and    conventional semen parameters in spermatozoa of oligoasthenoteratozoos
permic    patients. J Assist Reprod Genet. 2007; 24: 437-43.    ^cY#a02v37n1.htm
##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#119#115#article#204#</font></p>     ^
cY#a02v37n1.htm##
00462000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021000081002001300291#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#120#116#article#204#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Agarwal A,    S
aid TM: Role of sperm chromatin abnormalities and DNA damage in male infertility
.    Hum Reprod Update. 2003; 9: 331-45.    ^cY#a02v37n1.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#121#117#article#204# </font></p>     
^cY#a02v37n1.htm##
00503000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025100081002001300332#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#122#118#article#204#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Erenpreiss    J
, Spano M, Erenpreiss J, Bungum M, Giwercman A: Sperm chromatin structure and   
 male fertility: biological and clinical aspects. Asian J Androl. 2006; 8: 11-29
.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#123#119#article#204#</font></p>     ^
cY#a02v37n1.htm##
00563000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031100081002001300392#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#124#120#article#204#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Bungum M, Humai
dan    P, Spano M, Jepson K, Bungum L, Giwercman A: The predictive value of sper
m chromatin    structure assay (SCSA) parameters for the outcome of intrauterine
 insemination,    IVF and ICSI. Hum Reprod. 2004; 19: 1401-8.    ^cY#a02v37n1.ht
m##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#125#121#article#204#</font></p>     ^
cY#a02v37n1.htm##
00497000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024500081002001300326#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#126#122#article#204#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Duran EH, Morsh
edi    M, Taylor S, Oehninger S: Sperm DNA quality predicts intrauterine insemin
ation    outcome: a prospective cohort study. Hum Reprod. 2002; 17: 3122-8.    ^
cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#127#123#article#204#</font></p>     ^
cY#a02v37n1.htm##
00544000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029200081002001300373#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#128#124#article#204#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Seli E, Gardner
    DK, Schoolcraft WB, Moffatt O, Sakkas D: Extent of nuclear DNA damage in eja
culated    spermatozoa impacts on blastocyst development after in vitro fertiliz
ation.    Fertil Steril. 2004; 82: 378-83.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#129#125#article#204#</font></p>     ^
cY#a02v37n1.htm##
00599000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034700081002001300428#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#130#126#article#204#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Larson-Cook    
KL, Brannian JD, Hansen KA, Kasperson KM, Aamold ET, Evenson DP: Relationship   
 between the outcomes of assisted reproductive techniques and sperm DNA fragment
ation    as measured by the sperm chromatin structure assay. Fertil Steril. 2003
; 80:    895-902.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#131#127#article#204#</font></p>     ^
cY#a02v37n1.htm##
00479000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022700081002001300308#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#132#128#article#204#28#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Collins JA,    
Barnhart KT, Schlegel PN: Do sperm DNA integrity tests predict pregnancy with   
 in vitro fertilization? Fertil Steril. 2008; 89: 823-31.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#133#129#article#204#</font></p>     ^
cY#a02v37n1.htm##
00536000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028400081002001300365#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#134#130#article#204#29#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Carrell DT,    
Liu L, Peterson CM, Jones KP, Hatasaka HH, Erickson L, Campbell B.: Sperm DNA   
 fragmentation is increased in couples with unexplained recurrent pregnancy loss
.    Arch Androl. 2003; 49: 49-55.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#135#131#article#204#</font></p>     ^
cY#a02v37n1.htm##
00571000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031900081002001300400#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#136#132#article#204#30#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Evenson DP,    
Jost LK, Marshall D, Zinaman MJ, Clegg E, Purvis K, de Angelis P, Claussen OP:  
  Utility of the sperm chromatin structure assay as a diagnostic and prognostic 
   tool in the human fertility clinic. Hum Reprod. 1999; 14: 1039-49.    ^cY#a02
v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#137#133#article#204#</font></p>     ^
cY#a02v37n1.htm##
00438000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018600081002001300267#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#138#134#article#204#31#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Aitken RJ,    K
rausz C: Oxidative stress, DNA damage and the Y chromosome. Reproduction. 2001; 
   122: 497-506.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#139#135#article#204#</font></p>     ^
cY#a02v37n1.htm##
00505000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025300081002001300334#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#140#136#article#204#32#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Hansen M, Kurin
czuk    JJ, Bower C, Webb S: The risk of major birth defects after intracytoplas
mic    sperm injection and in vitro fertilization. N Engl J Med. 2002; 346: 725-
30.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#141#137#article#204#</font></p>     ^
cY#a02v37n1.htm##
00464000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021200081002001300293#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#142#138#article#204#33#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Kefer JC, Agarw
al    A, Sabanegh E: Role of antioxidants in the treatment of male infertility. 
International    J Urol. 2009; 16: 449-57.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#143#139#article#204#</font></p>     ^
cY#a02v37n1.htm##
00643000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704039100081002001300472#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#144#140#article#204#34#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Auger J, Eustac
he    F, Andersen AG, Irvine DS, J&oslash;rgensen N, Skakkebaek NE, Suominen J, 
Toppari    J, Vierula M, Jouannet P: Sperm morphological defects related to envi
ronment,    lifestyle and medical history of 1001 male partners of pregnant wome
n from four    European cities. Hum Reprod. 2001; 16: 2710-7.    ^cY#a02v37n1.ht
m##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#145#141#article#204#</font></p>     ^
cY#a02v37n1.htm##
00544000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029200081002001300373#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#146#142#article#204#35#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Kasahara E,    
Sato EF, Miyoshi M, Konaka R, Hiramoto K, Sasaki J, Tokuda M, Nakano Y, Inoue   
 M: Role of oxidative stress in germ cell apoptosis induced by di(2-ethylhexyl)p
hthalate.    Biochem J. 2002; 365: 849-56.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#147#143#article#204#</font></p>     ^
cY#a02v37n1.htm##
00501000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024900081002001300330#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#148#144#article#204#36#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Gennart JP,    
Buchet JP, Roels H, Ghyselen P, Cuelemans E, Lauerys R: Fertility of male worker
s    exposed to cadmium, lead or manganese. Am J Epidemiol. 1992; 135: 1208-19. 
   ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#149#145#article#204#</font></p>     ^
cY#a02v37n1.htm##
00443000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019100081002001300272#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#150#146#article#204#37#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Gonzalez-Flecha
    B: Oxidant mechanisms in response to ambient air particles. Mol Aspects Med.
    2004; 25: 169-82.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#151#147#article#204#</font></p>     ^
cY#a02v37n1.htm##
00409000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704015700081002001300238#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#152#148#article#204#38#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">38. Vine MF: Smokin
g    and male reproduction: A review. Int J Androl.1996; 19: 323-7.    ^cY#a02v3
7n1.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#153#149#article#204# </font></p>     
^cY#a02v37n1.htm##
00478000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022600081002001300307#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#154#150#article#204#39#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">39. Agarwal A,    M
akker K, Sharma R: Clinical relevance of oxidative stress in male factor inferti
lity:    an update. Am J Reprod Immunol. 2008; 59: 2-11.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#155#151#article#204#</font></p>     ^
cY#a02v37n1.htm##
00486000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023400081002001300315#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#156#152#article#204#40#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">40. Zini A, Blumenf
eld    A, Libman J, Willis J: Beneficial effect of microsurgical varicocelectomy
 on    human sperm DNA integrity. Hum Reprod. 2005; 20: 1018-21.    ^cY#a02v37n1
.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#157#153#article#204#</font></p>     ^
cY#a02v37n1.htm##
00569000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031700081002001300398#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#158#154#article#204#41#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">41. Wong WY, Merkus
    HM, Thomas CM, Menkveld R, Zielhuis GA, Steegers-Theunissen RP: Effects of f
olic    acid and zinc sulfate on male factor subfertility: a double-blind, rando
mized,    placebo-controlled trial. Fertil Steril. 2002; 77: 491-8.    ^cY#a02v3
7n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#159#155#article#204#</font></p>     ^
cY#a02v37n1.htm##
00569000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031700081002001300398#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#160#156#article#204#42#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">42. Boxmeer JC,    
Smit M, Utomo E, Romijn JC, Eijkemans MJ, Lindemans J, Laven JS, Macklon NS,    
Steegers EA, Steegers-Theunissen RP: Low folate in seminal plasma is associated 
   with increased sperm DNA damage. Fertil Steril 2009; 92: 548-56.    ^cY#a02v3
7n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#161#157#article#204#</font></p>     ^
cY#a02v37n1.htm##
00510000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025800081002001300339#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#162#158#article#204#43#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">43. Greco E, Iacobe
lli    M, Rienzi L, Ubaldi F, Ferrero S, Tesarik J: Reduction of the incidence o
f sperm    DNA fragmentation by oral antioxidant treatment. J. Androl. 2005; 26:
 349-53.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#163#159#article#204#</font></p>     ^
cY#a02v37n1.htm##
00545000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029300081002001300374#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#164#160#article#204#44#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">44. Greco E, Romano
    S, Iacobelli M, Ferrero S, Baroni E, Minasi MG, Ubaldi F, Rienzi L, Tesarik 
   J: ICSI in cases of sperm DNA damage: Beneficial effect of oral antioxidant  
  treatment. Hum. Reprod. 2005; 20: 2590-4.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#165#161#article#204#</font></p>     ^
cY#a02v37n1.htm##
00515000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026300081002001300344#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#166#162#article#204#45#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">45. Gil-Villa AM,  
  Cardona-Maya W, Agarwal A, Sharma R, Cadavid A: Role of male factor in early  
  recurrent embryo loss: do antioxidants have any effect? Fertil Steril. 2009;  
  92: 565-71.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#167#163#article#204#</font></p>     ^
cY#a02v37n1.htm##
00469000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021700081002001300298#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#168#164#article#204#46#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">46. Schlegel PN:   
 Testicular sperm extraction: Microdissection improves sperm yield with minimal 
   tissue excision. Hum Reprod 1999; 14: 131-5.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#169#165#article#204#</font></p>     ^
cY#a02v37n1.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028100081002001300362#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#170#166#article#204#47#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">47. Okada H, Dobash
i    M, Yamazaki T, Hara I, Fujisawa M, Arakawa S, Kamidono S: Conventional vers
us    microdissection testicular sperm extraction for nonobstructive azoospermia
.    J Urol. 2002; 168: 1063-7.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#171#167#article#204#</font></p>     ^
cY#a02v37n1.htm##
00515000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026300081002001300344#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#172#168#article#204#48#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">48. Ramasamy R,    
Yagan N, Schlegel PN: Structural and functional changes to the testis after    c
onventional versus microdissection testicular sperm extraction. Urology. 2005;  
  65: 1190-4.    ^cY#a02v37n1.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#173#169#article#204# </font></p>     
^cY#a02v37n1.htm##
00483000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023100081002001300312#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#174#170#article#204#49#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">49. Hung AJ, King  
  P, Schlegel PN: Uniform testicular maturation arrest: a unique subset of men  
  with nonobstructive azoospermia. J Urol. 2007; 178: 608-12.    ^cY#a02v37n1.ht
m##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#175#171#article#204#</font></p>     ^
cY#a02v37n1.htm##
00483000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023100081002001300312#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#176#172#article#204#50#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">50. Bromage SJ,    
Falconer DA, Lieberman BA, Sangar V, Payne SR: Sperm retrieval rates in subgroup
s    of primary azoospermic males. Eur Urol. 2007; 51: 534-9.    ^cY#a02v37n1.ht
m##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#177#173#article#204#</font></p>     ^
cY#a02v37n1.htm##
00568000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031600081002001300397#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#178#174#article#204#51#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">51. Ramasamy R,    
Lin K, Gosden LV, Rosenwaks Z, Palermo GD, Schlegel PN: High serum FSH levels   
 in men with nonobstructive azoospermia does not affect success of microdissecti
on    testicular sperm extraction. Fertil Steril. 2009; 92: 590-3.    ^cY#a02v37
n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#179#175#article#204#</font></p>     ^
cY#a02v37n1.htm##
00557000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030500081002001300386#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#180#176#article#204#52#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">52. Tournaye H,    
Verheyen G, Nagy P, Ubaldi F, Goossens A, Silber S, Van Steirteghem AC, Devroey 
   P: Are there any predictive factors for successful testicular sperm recovery 
   in azoospermic patients? Hum Reprod. 1997; 12: 80-6.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#181#177#article#204#</font></p>     ^
cY#a02v37n1.htm##
00550000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029800081002001300379#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#182#178#article#204#53#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">53. Esteves SC,    
Verza Jr S, Gomes AP: Successful retrieval of testicular spermatozoa by microdis
section    (micro-TESE) in nonobstructive azoospermia is related to testicular h
istology.    Fertil Steril 2006;86: Suppl., 354.    ^cY#a02v37n1.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#183#179#article#204# </font></p>     
^cY#a02v37n1.htm##
00556000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030400081002001300385#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#184#180#article#204#54#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">54. Inci K, Hascice
k    M, Kara O, Dikmen AV, G&uuml;rgan T, Ergen A. Sperm retrieval and intracyto
plasmic    sperm injection in men with nonobstructive azoospermia, and treated a
nd untreated    varicocele. J Urol. 2009; 182: 1500-5.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#185#181#article#204#</font></p>     ^
cY#a02v37n1.htm##
00518000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026600081002001300347#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#186#182#article#204#55#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">55. Esteves SC,    
Glina S: Recovery of spermatogenesis after microsurgical subinguinal varicocele 
   repair in azoospermic men based on testicular histology. Int Braz J Urol. 200
5;    31: 541-8.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#187#183#article#204#</font></p>     ^
cY#a02v37n1.htm##
00471000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021900081002001300300#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#188#184#article#204#56#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">56. Evers JLH,    C
ollins JA: Assessment of efficacy of varicocele repair for male subfertility:   
 A systematic review. Lancet. 2003; 361: 1849-52.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#189#185#article#204#</font></p>     ^
cY#a02v37n1.htm##
00531000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027900081002001300360#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#190#186#article#204#57#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">57. Ficcara V,    C
erruto MA, Liguori G, Mazzoni G, Minucci S, Tracia A, Gentile V: Treatment    of
 varicocele in subfertile men: The Cochrane review &#8211; a contrary opinion.  
  Eur Urol. 2006; 49: 258-63.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#191#187#article#204#</font></p>     ^
cY#a02v37n1.htm##
00552000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030000081002001300381#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#192#188#article#204#58#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">58. Marmar JL,    A
garwal A, Prabaskan S, Agarwal R, Short RA, Benoff S, Thomas AJ Jr: Reassessing 
   the value of varicocelectomy as a treatment for male subfertility with a new 
   meta-analysis. Fertil Steril. 2007; 88: 639-48.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#193#189#article#204#</font></p>     ^
cY#a02v37n1.htm##
00520000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026800081002001300349#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#194#190#article#204#59#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">59. Esteves SC,    
Oliveira FV, Bertolla RP: Clinical outcomes of intracytoplasmic sperm injection 
   in infertile men with treated and untreated clinical varicocele. J Urol. 2010
;    184: 1442-46.    ^cY#a02v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#195#191#article#204#</font></p>     ^
cY#a02v37n1.htm##
00499000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024700081002001300328#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#196#192#article#204#60#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">60. Cayan S, Shavak
habov    S, Kadioglu A. Treatment of palpable varicocele review in infertile men
: a meta-analysis    to define the best technique. J Androl. 2009; 30: 33-40.   
 ^cY#a02v37n1.htm##
00303000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006600078002001300144#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#197#193#article#204#</font><font face
="Verdana, Arial, Helvetica, sans-serif">    ^cY#a02v37n1.htm##
00264000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002700078002001300105#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#198#194#article#204#<br>   </font></p
>     ^cY#a02v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#199#195#article#204#<p>&nbsp;</p>    
 ^cY#a02v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#200#196#article#204#<p>&nbsp;</p>    
 ^cY#a02v37n1.htm##
00356000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011900078002001300197#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#201#197#article#204#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><i>Accepted:    February 1, 2010</
i></font></p>     ^cY#a02v37n1.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019300078002001300271#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#202#198#article#204#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><b><a name="end"></a><a href="#top
"><img src="/img/revistas/ibju/v37n1/seta.gif" border="0"></a>    Correspondence
 to</b>:    ^cY#a02v37n1.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003300078002001300111#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#203#199#article#204#<br>   Dr. Sandro
 Esteves    ^cY#a02v37n1.htm##
00292000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005500078002001300133#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#204#200#article#204#<br>   ANDROFERT 
- Center for Male Reproduction    ^cY#a02v37n1.htm##
00281000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004400078002001300122#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#205#201#article#204#<br>   Av. Dr. He
itor Penteado, 1464    ^cY#a02v37n1.htm##
00297000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006000078002001300138#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#206#202#article#204#<br>   13075-460,
 Campinas, S&atilde;o Paulo, BRAZIL    ^cY#a02v37n1.htm##
00274000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003700078002001300115#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#207#203#article#204#<br>   Fax: + 55 
19 3294-6992    ^cY#a02v37n1.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010900078002001300187#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a02v37n1.htm#S#p#208#204#article#204#<br>   E-mail: <a
 href="mailto:s.esteves@androfert.com.br">s.esteves@androfert.com.br</a></font><
/p>     ^cY#a02v37n1.htm##
00443000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750300028000770320003001050650
00900108064000500117037001900122865000900141002001300150035001000163801002800173
#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#209#1#article#60#1#Vi
tal and Health Statistics#26#20020000#2002#http://www.cdc.gov#20110200#a02v37n1.
htm#0083-1972#VITAL AND HEALTH STATISTICS##
00476000000000217000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170078000770180023001550650
00900178064001100187037003800198865000900236002001300245#v37n1#V:\SciELO\serial\
ibju\v37n1\markup\a02v37n1.htm#S#c#210#2#article#60#2#Centre for evidence-based 
medicine: Oxford Centre for Evidence-based Medicine#Levels of Evidence^len#20090
300#March 2009#http://www.cebm.net/index.aspx?o=1025#20110200#a02v37n1.htm##
00543000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770120101000950300
01200196065000900208064000500217031000300222014000800225865000900233002001300242
035001000255801001200265#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S
#c#211#3#article#60#3#^rND^sClermont^nY#Kinetics of spermatogenesis in mammals: 
seminiferous epithelium cycle and spermatogonial renewal^len#Physiol Rev#1972000
0#1972#52#198-236#20110200#a02v37n1.htm#0031-9333#Physiol Rev##
00705000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100020000940100
01500114010001500129010001500144010002200159010001600181012010000197030000700297
06500090030406400050031303100040031801400060032286500090032800200130033703500100
0350801000700360#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#212#4
#article#60#4#^rND^sMisell^nLM#^rND^sHolochwost^nD#^rND^sBoban^nD#^rND^sSanti^nN
#^rND^sShefi^nN#^rND^sHellerstein^nMK#^rND^sTurek^nPJ#A stable isotope-mass spec
trometric method for measuring human spermatogenesis kinetics in vivo^len#J Urol
#20060000#2006#175#242-6#20110200#a02v37n1.htm#0022-5347#J Urol##
00686000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100019000970100
01500116010001700131010001700148010001600165810000600181012007400187030001500261
06500090027606400050028503100030029001400080029386500090030100200130031003500100
0323801001500333#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#213#5
#article#60#5#^rND^sNathanson^nKL#^rND^sKanetsky^nPA#^rND^sHawes^nR#^rND^sVaughn
^nDJ#^rND^sLetrero^nR#^rND^sTucker^nK#et al#The Y deletion gr/gr and susceptibil
ity to testicular germ cell tumor^len#Am J Hum Genet#20050000#2005#77#1034-43#20
110200#a02v37n1.htm#0002-9297#Am J Hum Genet##
00503000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770120097000930300
01100190710000200201065000900203064000500212031000300217014000700220865000900227
002001300236#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#214#6#art
icle#60#6#^rND^sSimoni^nM#Clinical consequences of microdeletions of the Y chrom
osome: the extended Münster experience^len#RBM online#2#20080000#2008#16#289-30#
20110200#a02v37n1.htm##
00773000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100019000940100
01500113010001600128010002200144010001600166010001500182010001500197012012500212
03000150033706500090035206400050036103100030036601400070036986500090037600200130
0385035001000398801001500408#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.h
tm#S#c#215#7#article#60#7#^rND^sRepping^nS#^rND^sSkaletsky^nH#^rND^sLange^nJ#^rN
D^sSilber^nS#^rND^sVan Der Veen^nF#^rND^sOates^nRD#^rND^sPage^nDC#^rND^sRozen^nS
#Recombination between palindromes P5 and P1 on the human Y chromosome causes ma
ssive deletions and spermatogenic failure^len#Am J Hum Genet#20020000#2002#71#90
6-22#20110200#a02v37n1.htm#0002-9297#Am J Hum Genet##
00494000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100016000920120
05600108030001600164710000200180065000900182064000500191031000300196014000700199
865000900206002001300215#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S
#c#216#8#article#60#8#^rND^sShefi^nS#^rND^sTurek^nPJ#Definition and current eval
uation of subfertile men^len#Int Braz J Urol#2#20060000#2006#32#385-97#20110200#
a02v37n1.htm##
00734000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100013000770100019000900100
01500109010001700124010001900141010001500160010001500175012012300190030001400313
06500090032706400050033603100020034101400070034386500090035000200130035903500100
0372801001400382#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#217#9
#article#60#9#^rND^sSun^nC#^rND^sSkaletsky^nH#^rND^sRozen^nS#^rND^sGromoll^nJ#^r
ND^sNieschlag^nE#^rND^sOates^nR#^rND^sPage^nDC#Deletion of azoospermia factor a 
(AZFa) region of human Y chromosome caused by recombination between HERV15 provi
ruses^len#Hum Mol Genet#20000000#2000#9#2291-6#20110200#a02v37n1.htm#0964-6906#H
um Mol Genet##
00947000000000433000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100017000930100
01900110010001500129010001900144010001700163010001700180010001600197010001600213
01000160022901000210024501000170026601000170028301000160030001000150031601200970
03310300015004280650009004430640005004520310002004570140007004598650009004660020
01300475035001000488801001500498#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37
n1.htm#S#c#218#10#article#60#10#^rND^sKamp^nC#^rND^sHuellen^nK#^rND^sFernandes^n
S#^rND^sSousa^nM#^rND^sSchlegel^nPN#^rND^sMielnik^nA#^rND^sKleiman^nS#^rND^sYave
tz^nH#^rND^sKrause^nW#^rND^sKüpker^nW#^rND^sJohannisson^nR#^rND^sSchulze^nW#^rND
^sWeidner^nW#^rND^sBarros^nA#^rND^sVogt^nPH#High deletion frequency of the compl
ete AZFa sequence in men with Sertoli-cell-only syndrome^len#Mol Hum Reprod#2001
0000#2001#7#987-94#20110200#a02v37n1.htm#1360-9947#Mol Hum Reprod##
00689000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01900112010001800131010001900149010001900168012009800187030001100285065000900296
06400050030503100030031001400070031386500090032000200130032903500100034280100110
0352#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#219#11#article#60
#11#^rND^sHopps^nCV#^rND^sMielnik^nA#^rND^sGoldstein^nM#^rND^sPalermo^nGD#^rND^s
Rosenwaks^nZ#^rND^sSchlegel^nPN#Detection of sperm in men with Y chromosome micr
odeletions of the AZFa, AZFb and AZFc regions^len#Hum Reprod#20030000#2003#18#16
60-5#20110200#a02v37n1.htm#0268-1161#Hum Reprod##
00653000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100017000930100
01700110010001400127010001900141012009400160030001500254065000900269064000500278
031000200283014000700285865000900292002001300301035001000314801001500324#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#220#12#article#60#12#^rND^sSa
ut^nN#^rND^sTerriou^nP#^rND^sNavarro^nA#^rND^sLevy^nN#^rND^sMitchell^nMJ#The hum
an Y chromosome genes BPY2, CDY1 and DAZ are not essential for sustained fertili
ty^len#Mol Hum Reprod#20000000#2000#6#789-93#20110200#a02v37n1.htm#1360-9947#Mol
 Hum Reprod##
00729000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
01600114010001900130010001900149010001900168012011200187030002400299065000900323
06400050033203100030033701400070034086500090034700200130035603500100036980100240
0379#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#221#13#article#60
#13#^rND^sSchiff^nJD#^rND^sPalermo^nGD#^rND^sVeeck^nLL#^rND^sGoldstein^nM#^rND^s
Rosenwaks^nZ#^rND^sSchlegel^nPN#Success of testicular sperm injection and intrac
ytoplasmic sperm injection in men with Klinefelter syndrome^len#J Clin Endocrino
l Metab#20050000#2005#90#6263-7#20110200#a02v37n1.htm#0021-972X#J Clin Endocrino
l Metab##
00726000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970100
02000115010001800135010002100153010001700174010001800191010002500209012005100234
03000180028506500090030306400050031203100020031701400070031986500090032600200130
0335035001000348801001800358#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.h
tm#S#c#222#14#article#60#14#^rND^sStaessen^nC#^rND^sTournaye^nH#^rND^sVan Assche
^nE#^rND^sMichiels^nA#^rND^sVan Landuyt^nL#^rND^sDevroey^nP#^rND^sLiebaers^nI#^r
ND^sVan Steirteghem^nA#PGD in 47, XXY Klinefelter's syndrome patients^len#Hum Re
prod Update#20030000#2003#9#319-30#20110200#a02v37n1.htm#1355-4786#Hum Reprod Up
date##
00721000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100022000980100
01500120010002200135010002300157010001400180010001700194012009300211030001100304
06500090031506400050032403100030032901400080033286500090034000200130034903500100
0362801001100372#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#223#1
5#article#60#15#^rND^sSciurano^nRB#^rND^sLuna Hisano^nCV#^rND^sRahn^nMI#^rND^sBr
ugo Olmedo^nS#^rND^sRey Valzacchi^nG#^rND^sCoco^nR#^rND^sSolari^nAJ#Focal sperma
togenesis originates in euploid germ cells in classical Klinefelter patients^len
#Hum Reprod#20090000#2009#24#2353-60#20110200#a02v37n1.htm#0268-1161#Hum Reprod#
#
00646000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01800113010001700131010001900148010001900167012006200186030000700248065000900255
06400050026403100040026901400080027386500090028100200130029003500100030380100070
0313#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#224#16#article#60
#16#^rND^sRamasamy^nR#^rND^sRicci^nJA#^rND^sPalermo^nGD#^rND^sGosden^nLV#^rND^sR
osenwaks^nZ#^rND^sSchlegel^nPN#Successful fertility treatment for Klinefelter's 
syndrome^len#J Urol#20090000#2009#182#1108-13#20110200#a02v37n1.htm#0022-5347#J 
Urol##
00663000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01700112010001700129012013500146030001200281065000900293064000500302031000300307
014000700310865000900317002001300326035001000339801001200349#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a02v37n1.htm#S#c#225#17#article#60#17#^rND^sJohnson^nL#^rN
D^sPetty^nCS#^rND^sPorter^nJC#^rND^sNeaves^nWB#Germ cell degeneration during pos
tprophase of meiosis and serum concentrations of gonadotropins in young adult an
d older adult men^len#Biol Reprod#19840000#1984#31#779-84#20110200#a02v37n1.htm#
0006-3363#Biol Reprod##
00685000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
02700114010001800141010001900159012009700178030002000275065000900295064000500304
031000300309014000700312865000900319002001300328035001000341801002000351#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#226#18#article#60#18#^rND^sWy
robek^nAJ#^rND^sAardema^nM#^rND^sEichenlaub-Ritter^nU#^rND^sFerguson^nL#^rND^sMa
rchetti^nF#Mechanisms and targets involved in maternal and paternal age effects 
on numerical aneuploidy^len#Environ Mol Mutagen#19960000#1996#28#254-64#20110200
#a02v37n1.htm#0893-6692#Environ Mol Mutagen##
00614000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100016001000100
01700116012010800133030001400241065000900255064000500264031000300269014000600272
865000900278002001300287035001000300801001400310#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a02v37n1.htm#S#c#227#19#article#60#19#^rND^sMoskovtsev^nSI#^rND^sWilli
s^nJ#^rND^sMullen^nJB#Age-related decline in sperm deoxyribonucleic acid integri
ty in patients evaluated for male infertility^len#Fertil Steril#20060000#2006#85
#496-9#20110200#a02v37n1.htm#0015-0282#Fertil Steril##
00619000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100015000970100
01700112010001900129010001500148012007000163030000900233065000900242064000500251
031000200256014000600258865000900264002001300273035001000286801000900296#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#228#20#article#60#20#^rND^sSi
ddighi^nS#^rND^sChan^nCA#^rND^sPatton^nWC#^rND^sJacobson^nJD#^rND^sChan^nPJ#Male
 age and sperm necrosis in assisted reproductive technologies^len#Urol Int#20070
000#2007#9#231-4#20110200#a02v37n1.htm#0042-1138#Urol Int##
00861000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
02200114010001700136010001900153010001600172010001700188010002300205010001600228
01201550024403000220039906500090042106400050043003100030043501400070043886500090
0445002001300454035001000467801002200477#v37n1#V:\SciELO\serial\ibju\v37n1\marku
p\a02v37n1.htm#S#c#229#21#article#60#21#^rND^sPlastira^nK#^rND^sMsaouel^nP#^rND^
sAngelopoulou^nR#^rND^sZanioti^nK#^rND^sPlastiras^nA#^rND^sPothos^nA#^rND^sBolar
is^nS#^rND^sPaparisteidis^nN#^rND^sMantas^nD#The effects of age on DNA fragmenta
tion, chromatin packaging and conventional semen parameters in spermatozoa of ol
igoasthenoteratozoospermic patients^len#J Assist Reprod Genet#20070000#2007#24#4
37-43#20110200#a02v37n1.htm#1058-0468#J Assist Reprod Genet##
00557000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960120
07700111030001800188065000900206064000500215031000200220014000700222865000900229
002001300238035001000251801001800261#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
2v37n1.htm#S#c#230#22#article#60#22#^rND^sAgarwal^nA#^rND^sSaid^nTM#Role of sper
m chromatin abnormalities and DNA damage in male infertility^len#Hum Reprod Upda
te#20030000#2003#9#331-45#20110200#a02v37n1.htm#1355-4786#Hum Reprod Update##
00614000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100015000990100
02000114010001600134010001900150012008200169030001500251710000200266065000900268
064000500277031000200282014000600284865000900290002001300299#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a02v37n1.htm#S#c#231#23#article#60#23#^rND^sErenpreiss^nJ#
^rND^sSpano^nM#^rND^sErenpreiss^nJ#^rND^sBungum^nM#^rND^sGiwercman^nA#Sperm chro
matin structure and male fertility: biological and clinical aspects^len#Asian J 
Androl#2#20060000#2006#8#11-29#20110200#a02v37n1.htm##
00720000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01500113010001600128010001600144010001900160012013700179030001100316065000900327
06400050033603100030034101400070034486500090035100200130036003500100037380100110
0383#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#232#24#article#60
#24#^rND^sBungum^nM#^rND^sHumaidan^nP#^rND^sSpano^nM#^rND^sJepson^nK#^rND^sBungu
m^nL#^rND^sGiwercman^nA#The predictive value of sperm chromatin structure assay 
(SCSA) parameters for the outcome of intrauterine insemination, IVF and ICSI^len
#Hum Reprod#20040000#2004#19#1401-8#20110200#a02v37n1.htm#0268-1161#Hum Reprod##
00558000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01600113010001900129012009300148030001700241710000200258031000300260014000700263
865000900270002001300279#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S
#c#233#25#article#60#25#^rND^sDuran^nEH#^rND^sMorshedi^nM#^rND^sTaylor^nS#^rND^s
Oehninger^nS#Sperm DNA quality predicts intrauterine insemination outcome: a pro
spective cohort study^len#Hum Reprod. 2002#2#17#3122-8#20110200#a02v37n1.htm##
00686000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100018000930100
02200111010001700133010001600150012012200166030001400288065000900302064000500311
031000300316014000700319865000900326002001300335035001000348801001400358#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#234#26#article#60#26#^rND^sSe
li^nE#^rND^sGardner^nDK#^rND^sSchoolcraft^nWB#^rND^sMoffatt^nO#^rND^sSakkas^nD#E
xtent of nuclear DNA damage in ejaculated spermatozoa impacts on blastocyst deve
lopment after in vitro fertilization^len#Fertil Steril#20040000#2004#82#378-83#2
0110200#a02v37n1.htm#0015-0282#Fertil Steril##
00756000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100019001010100
01700120010002000137010001700157010001800174012015300192030001400345065000900359
06400050036803100030037301400080037686500090038400200130039303500100040680100140
0416#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#235#27#article#60
#27#^rND^sLarson-Cook^nKL#^rND^sBrannian^nJD#^rND^sHansen^nKA#^rND^sKasperson^nK
M#^rND^sAamold^nET#^rND^sEvenson^nDP#Relationship between the outcomes of assist
ed reproductive techniques and sperm DNA fragmentation as measured by the sperm 
chromatin structure assay^len#Fertil Steril#20030000#2003#80#895-902#20110200#a0
2v37n1.htm#0015-0282#Fertil Steril##
00589000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
01900116012008000135030001400215065000900229064000500238031000300243014000700246
865000900253002001300262035001000275801001400285#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a02v37n1.htm#S#c#236#28#article#60#28#^rND^sCollins^nJA#^rND^sBarnhart
^nKT#^rND^sSchlegel^nPN#Do sperm DNA integrity tests predict pregnancy with in v
itro fertilization?^len#Fertil Steril#20080000#2008#89#823-31#20110200#a02v37n1.
htm#0015-0282#Fertil Steril##
00711000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100013000970100
01900110010001600129010001900145010001800164010001800182012009400200030001200294
06500090030606400050031503100030032001400060032386500090032900200130033803500100
0351801001200361#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#237#2
9#article#60#29#^rND^sCarrell^nDT#^rND^sLiu^nL#^rND^sPeterson^nCM#^rND^sJones^nK
P#^rND^sHatasaka^nHH#^rND^sErickson^nL#^rND^sCampbell^nB#Sperm DNA fragmentation
 is increased in couples with unexplained recurrent pregnancy loss^len#Arch Andr
ol#20030000#2003#49#49-55#20110200#a02v37n1.htm#0148-5016#Arch Androl##
00764000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100015000970100
01800112010001800130010001500148010001600163010002000179010001900199012011700218
03000110033506500090034606400050035503100030036001400080036386500090037100200130
0380035001000393801001100403#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.h
tm#S#c#238#30#article#60#30#^rND^sEvenson^nDP#^rND^sJost^nLK#^rND^sMarshall^nD#^
rND^sZinaman^nMJ#^rND^sClegg^nE#^rND^sPurvis^nK#^rND^sde Angelis^nP#^rND^sClauss
en^nOP#Utility of the sperm chromatin structure assay as a diagnostic and progno
stic tool in the human fertility clinic^len#Hum Reprod#19990000#1999#14#1039-49#
20110200#a02v37n1.htm#0268-1161#Hum Reprod##
00495000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960120
05400112030001300166710000200179065000900181064000500190031000400195014000800199
865000900207002001300216#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S
#c#239#31#article#60#31#^rND^sAitken^nRJ#^rND^sKrausz^nC#Oxidative stress, DNA d
amage and the Y chromosome^len#Reproduction#2#20010000#2001#122#497-506#20110200
#a02v37n1.htm##
00631000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100020000950100
01500115010001400130012010200144030001300246065000900259064000500268031000400273
014000700277865000900284002001300293035001000306801001300316#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a02v37n1.htm#S#c#240#32#article#60#32#^rND^sHansen^nM#^rND
^sKurinczuk^nJJ#^rND^sBower^nC#^rND^sWebb^nS#The risk of major birth defects aft
er intracytoplasmic sperm injection and in vitro fertilization^len#N Engl J Med#
20020000#2002#346#725-30#20110200#a02v37n1.htm#0028-4793#N Engl J Med##
00539000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01800112012006200130030002100192710000200213065000900215064000500224031000300229
014000700232865000900239002001300248#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
2v37n1.htm#S#c#241#33#article#60#33#^rND^sKefer^nJC#^rND^sAgarwal^nA#^rND^sSaban
egh^nE#Role of antioxidants in the treatment of male infertility^len#Internation
al J Urol#2#20090000#2009#16#449-57#20110200#a02v37n1.htm##
00862000000000373000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100018000940100
01900112010001700131010001900148010002100167010001800188010001700206010001700223
01000180024001201520025803000110041006500090042106400050043003100030043501400070
0438865000900445002001300454035001000467801001100477#v37n1#V:\SciELO\serial\ibju
\v37n1\markup\a02v37n1.htm#S#c#242#34#article#60#34#^rND^sAuger^nJ#^rND^sEustach
e^nF#^rND^sAndersen^nAG#^rND^sIrvine^nDS#^rND^sJørgensen^nN#^rND^sSkakkebaek^nNE
#^rND^sSuominen^nJ#^rND^sToppari^nJ#^rND^sVierula^nM#^rND^sJouannet^nP#Sperm mor
phological defects related to environment, lifestyle and medical history of 1001
 male partners of pregnant women from four European cities^len#Hum Reprod#200100
00#2001#16#2710-7#20110200#a02v37n1.htm#0268-1161#Hum Reprod##
00725000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100015000970100
01700112010001600129010001800145010001600163010001600179010001600195010001500211
01200890022603000110031571000020032606500090032806400050033703100040034201400070
0346865000900353002001300362#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.h
tm#S#c#243#35#article#60#35#^rND^sKasahara^nE#^rND^sSato^nEF#^rND^sMiyoshi^nM#^r
ND^sKonaka^nR#^rND^sHiramoto^nK#^rND^sSasaki^nJ#^rND^sTokuda^nM#^rND^sNakano^nY#
^rND^sInoue^nM#Role of oxidative stress in germ cell apoptosis induced by di(2-e
thylhexyl)phthalate^len#Biochem J.#2#20020000#2002#365#849-56#20110200#a02v37n1.
htm##
00665000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
01500114010001800129010001900147010001700166012006800183030001500251065000900266
06400050027503100040028001400080028486500090029200200130030103500100031480100150
0324#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#244#36#article#60
#36#^rND^sGennart^nJP#^rND^sBuchet^nJP#^rND^sRoels^nH#^rND^sGhyselen^nP#^rND^sCu
elemans^nE#^rND^sLauerys^nR#Fertility of male workers exposed to cadmium, lead o
r manganese^len#Am J Epidemiol#19920000#1992#135#1208-19#20110200#a02v37n1.htm#0
002-9262#Am J Epidemiol##
00518000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100025000790120060001040300
01600164065000900180064000500189031000300194014000700197865000900204002001300213
035001000226801001600236#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S
#c#245#37#article#60#37#^rND^sGonzalez-Flecha^nB#Oxidant mechanisms in response 
to ambient air particles^len#Mol Aspects Med#20040000#2004#25#169-82#20110200#a0
2v37n1.htm#0098-2997#Mol Aspects Med##
00485000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790120044000940300
01300138065000900151064000500160031000300165014000600168865000900174002001300183
035001000196801001300206#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S
#c#246#38#article#60#38#^rND^sVine^nMF#Smoking and male reproduction: A review^l
en#Int J Androl#19960000#1996#19#323-7#20110200#a02v37n1.htm#0105-6263#Int J And
rol##
00593000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01600112012008100128030002000209065000900229064000500238031000300243014000500246
865000900251002001300260035001000273801002000283#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a02v37n1.htm#S#c#247#39#article#60#39#^rND^sAgarwal^nA#^rND^sMakker^nK
#^rND^sSharma^nR#Clinical relevance of oxidative stress in male factor infertili
ty: an update^len#Am J Reprod Immunol#20080000#2008#59#2-11#20110200#a02v37n1.ht
m#0271-7352#Am J Reprod Immunol##
00610000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100020000930100
01600113010001600129012008400145030001100229065000900240064000500249031000300254
014000800257865000900265002001300274035001000287801001100297#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a02v37n1.htm#S#c#248#40#article#60#40#^rND^sZini^nA#^rND^s
Blumenfeld^nA#^rND^sLibman^nJ#^rND^sWillis^nJ#Beneficial effect of microsurgical
 varicocelectomy on human sperm DNA integrity^len#Hum Reprod#20050000#2005#20#10
18-21#20110200#a02v37n1.htm#0268-1161#Hum Reprod##
00729000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01700111010001800128010001900146010003000165012012500195030001400320065000900334
06400050034303100030034801400060035186500090035700200130036603500100037980100140
0389#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#249#41#article#60
#41#^rND^sWong^nWY#^rND^sMerkus^nHM#^rND^sThomas^nCM#^rND^sMenkveld^nR#^rND^sZie
lhuis^nGA#^rND^sSteegers-Theunissen^nRP#Effects of folic acid and zinc sulfate o
n male factor subfertility: a double-blind, randomized, placebo-controlled trial
^len#Fertil Steril#20020000#2002#77#491-8#20110200#a02v37n1.htm#0015-0282#Fertil
 Steril##
00802000000000373000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100014000970100
01500111010001700126010002000143010001900163010001600182010001800198010001900216
01000300023501200790026503000140034406500090035806400050036703100030037201400070
0375865000900382002001300391035001000404801001400414#v37n1#V:\SciELO\serial\ibju
\v37n1\markup\a02v37n1.htm#S#c#250#42#article#60#42#^rND^sBoxmeer^nJC#^rND^sSmit
^nM#^rND^sUtomo^nE#^rND^sRomijn^nJC#^rND^sEijkemans^nMJ#^rND^sLindemans^nJ#^rND^
sLaven^nJS#^rND^sMacklon^nNS#^rND^sSteegers^nEA#^rND^sSteegers-Theunissen^nRP#Lo
w folate in seminal plasma is associated with increased sperm DNA damage^len#Fer
til Steril#20090000#2009#92#548-56#20110200#a02v37n1.htm#0015-0282#Fertil Steril
##
00669000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100019000940100
01600113010001600129010001700145010001700162012008800179030001000267065000900277
06400050028603100030029101400070029486500090030100200130031003500100032380100100
0333#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#251#43#article#60
#43#^rND^sGreco^nE#^rND^sIacobelli^nM#^rND^sRienzi^nL#^rND^sUbaldi^nF#^rND^sFerr
ero^nS#^rND^sTesarik^nJ#Reduction of the incidence of sperm DNA fragmentation by
 oral antioxidant treatment^len#J. Androl#20050000#2005#26#349-53#20110200#a02v3
7n1.htm#0196-3635#J. androl##
00757000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100016000940100
01900110010001700129010001600146010001700162010001600179010001600195010001700211
01200870022803000120031506500090032706400050033603100030034101400070034486500090
0351002001300360035001000373801001200383#v37n1#V:\SciELO\serial\ibju\v37n1\marku
p\a02v37n1.htm#S#c#252#44#article#60#44#^rND^sGreco^nE#^rND^sRomano^nS#^rND^sIac
obelli^nM#^rND^sFerrero^nS#^rND^sBaroni^nE#^rND^sMinasi^nMG#^rND^sUbaldi^nF#^rND
^sRienzi^nL#^rND^sTesarik^nJ#ICSI in cases of sperm DNA damage: Beneficial effec
t of oral antioxidant treatment^len#Hum. Reprod#20050000#2005#20#2590-4#20110200
#a02v37n1.htm#0268-1161#Hum. reprod##
00658000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100022000990100
01700121010001600138010001700154012008900171030001400260065000900274064000500283
031000300288014000700291865000900298002001300307035001000320801001400330#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#253#45#article#60#45#^rND^sGi
l-Villa^nAM#^rND^sCardona-Maya^nW#^rND^sAgarwal^nA#^rND^sSharma^nR#^rND^sCadavid
^nA#Role of male factor in early recurrent embryo loss: do antioxidants have any
 effect?^len#Fertil Steril#20090000#2009#92#565-71#20110200#a02v37n1.htm#0015-02
82#Fertil Steril##
00540000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790120099000980300
01100197065000900208064000500217031000300222014000600225865000900231002001300240
035001000253801001100263#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S
#c#254#46#article#60#46#^rND^sSchlegel^nPN#Testicular sperm extraction: Microdis
section improves sperm yield with minimal tissue excision^len#Hum Reprod#1999000
0#1999#14#131-5#20110200#a02v37n1.htm#0268-1161#Hum Reprod##
00704000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01800111010001400129010001800143010001700161010001800178012009900196030000700295
06500090030206400050031103100040031601400070032086500090032700200130033603500100
0349801000700359#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#255#4
7#article#60#47#^rND^sOkada^nH#^rND^sDobashi^nM#^rND^sYamazaki^nT#^rND^sHara^nI#
^rND^sFujisawa^nM#^rND^sArakawa^nS#^rND^sKamidono^nS#Conventional versus microdi
ssection testicular sperm extraction for nonobstructive azoospermia^len#J Urol#2
0020000#2002#168#1063-7#20110200#a02v37n1.htm#0022-5347#J Urol##
00615000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100015000970100
01900112012012200131030000800253065000900261064000500270031000300275014000700278
865000900285002001300294035001000307801000800317#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a02v37n1.htm#S#c#256#48#article#60#48#^rND^sRamasamy^nR#^rND^sYagan^nN
#^rND^sSchlegel^nPN#Structural and functional changes to the testis after conven
tional versus microdissection testicular sperm extraction^len#Urology#20050000#2
005#65#1190-4#20110200#a02v37n1.htm#0090-4295#Urology##
00585000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100014000940100
01900108012009700127030000700224065000900231064000500240031000400245014000700249
865000900256002001300265035001000278801000700288#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a02v37n1.htm#S#c#257#49#article#60#49#^rND^sHung^nAJ#^rND^sKing^nP#^rN
D^sSchlegel^nPN#Uniform testicular maturation arrest: a unique subset of men wit
h nonobstructive azoospermia^len#J Urol#20070000#2007#178#608-12#20110200#a02v37
n1.htm#0022-5347#J Urol##
00623000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
02000116010001600136010001600152012006800168030000900236065000900245064000500254
031000300259014000600262865000900268002001300277035001000290801000900300#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#258#50#article#60#50#^rND^sBr
omage^nSJ#^rND^sFalconer^nDA#^rND^sLieberman^nBA#^rND^sSangar^nV#^rND^sPayne^nSR
#Sperm retrieval rates in subgroups of primary azoospermic males^len#Eur Urol#20
070000#2007#51#534-9#20110200#a02v37n1.htm#0302-2838#Eur Urol##
00728000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100013000970100
01700110010001900127010001800146010001900164012013600183030001400319065000900333
06400050034203100030034701400060035086500090035600200130036503500100037880100140
0388#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#259#51#article#60
#51#^rND^sRamasamy^nR#^rND^sLin^nK#^rND^sGosden^nLV#^rND^sRosenwaks^nZ#^rND^sPal
ermo^nGD#^rND^sSchlegel^nPN#High serum FSH levels in men with nonobstructive azo
ospermia does not affect success of microdissection testicular sperm extraction^
len#Fertil Steril#20090000#2009#92#590-3#20110200#a02v37n1.htm#0015-0282#Fertil 
Steril##
00751000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970100
01400115010001600129010001800145010001600163010002600179010001700205012010300222
03000110032506500090033606400050034503100030035001400050035386500090035800200130
0367035001000380801001100390#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.h
tm#S#c#260#52#article#60#52#^rND^sTournaye^nH#^rND^sVerheyen^nG#^rND^sNagy^nP#^r
ND^sUbaldi^nF#^rND^sGoossens^nA#^rND^sSilber^nS#^rND^sVan Steirteghem^nAC#^rND^s
Devroey^nP#Are there any predictive factors for successful testicular sperm reco
very in azoospermic patients?^len#Hum Reprod#19970000#1997#12#80-6#20110200#a02v
37n1.htm#0268-1161#Hum Reprod##
00652000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970100
01600115012014800131030001400279065000900293064000500302031000300307032000600310
865000900316002001300325035001000338801001400348#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a02v37n1.htm#S#c#261#53#article#60#53#^rND^sEsteves^nSC#^rND^sVerza^nJ
r S#^rND^sGomes^nAP#Successful retrieval of testicular spermatozoa by microdisse
ction (micro-TESE) in nonobstructive azoospermia is related to testicular histol
ogy^len#Fertil Steril#20060000#2006#86#^s354#20110200#a02v37n1.htm#0015-0282#Fer
til Steril##
00704000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100018000930100
01400111010001700125010001600142010001500158012013400173030000700307065000900314
06400050032303100040032801400070033286500090033900200130034803500100036180100070
0371#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#262#54#article#60
#54#^rND^sInci^nK#^rND^sHascicek^nM#^rND^sKara^nO#^rND^sDikmen^nAV#^rND^sGürgan^
nT#^rND^sErgen^nA#Sperm retrieval and intracytoplasmic sperm injection in men wi
th nonobstructive azoospermia, and treated and untreated varicocele^len#J Urol#2
0090000#2009#182#1500-5#20110200#a02v37n1.htm#0022-5347#J Urol##
00572000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100015000970120
13100112030001600243710000200259065000900261064000500270031000300275014000600278
865000900284002001300293#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S
#c#263#55#article#60#55#^rND^sEsteves^nSC#^rND^sGlina^nS#Recovery of spermatogen
esis after microsurgical subinguinal varicocele repair in azoospermic men based 
on testicular histology^len#Int Braz J Urol#2#20050000#2005#31#541-8#20110200#a0
2v37n1.htm##
00555000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960120
09100114030000700205065000900212064000500221031000400226014000800230865000900238
002001300247035001000260801000700270#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
2v37n1.htm#S#c#264#56#article#60#56#^rND^sEvers^nJLH#^rND^sCollins^nJA#Assessmen
t of efficacy of varicocele repair for male subfertility: A systematic review^le
n#Lancet#20030000#2003#361#1849-52#20110200#a02v37n1.htm#0099-5355#Lancet##
00698000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
01700114010001700131010001700148010001600165010001700181012008800198030000900286
06500090029506400050030403100030030901400070031286500090031900200130032803500100
0341801000900351#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#265#5
7#article#60#57#^rND^sFiccara^nV#^rND^sCerruto^nMA#^rND^sLiguori^nG#^rND^sMazzon
i^nG#^rND^sMinucci^nS#^rND^sTracia^nA#^rND^sGentile^nV#Treatment of varicocele i
n subfertile men: The Cochrane review - a contrary opinion^len#Eur Urol#20060000
#2006#49#258-63#20110200#a02v37n1.htm#0302-2838#Eur Urol##
00730000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01900113010001700132010001600149010001600165010002000181012010700201030001400308
06500090032206400050033103100030033601400070033986500090034600200130035503500100
0368801001400378#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a02v37n1.htm#S#c#266#5
8#article#60#58#^rND^sMarmar^nJL#^rND^sAgarwal^nA#^rND^sPrabaskan^nS#^rND^sAgarw
al^nR#^rND^sShort^nRA#^rND^sBenoff^nS#^rND^sThomas^nAJ Jr#Reassessing the value 
of varicocelectomy as a treatment for male subfertility with a new meta-analysis
^len#Fertil Steril#20070000#2007#88#639-48#20110200#a02v37n1.htm#0015-0282#Ferti
l Steril##
00619000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
01900116012012200135030000700257065000900264064000500273031000400278014000800282
865000900290002001300299035001000312801000700322#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a02v37n1.htm#S#c#267#59#article#60#59#^rND^sEsteves^nSC#^rND^sOliveira
^nFV#^rND^sBertolla^nRP#Clinical outcomes of intracytoplasmic sperm injection in
 infertile men with treated and untreated clinical varicocele^len#J Urol#2010000
0#2010#184#1442-46#20110200#a02v37n1.htm#0022-5347#J Urol##
00603000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100021000940100
01800115012010700133030000900240065000900249064000500258031000300263014000600266
865000900272002001300281035001000294801000900304#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a02v37n1.htm#S#c#268#60#article#60#60#^rND^sCayan^nS#^rND^sShavakhabov
^nS#^rND^sKadioglu^nA#Treatment of palpable varicocele review in infertile men: 
a meta-analysis to define the best technique^len#J Androl#20090000#2009#30#33-40
#20110200#a02v37n1.htm#0196-3635#J Androl##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#o#1#1#article#1
#20110330#144452#a03v37n1.htm#198##
03623000000000493000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000180011303100030013103200020013406500090013601400090014503500100015401200580
01640100031002220100032002530700078002850700079003630832513004420850010029550850
02502965085002302990085002603013085003503039085003303074117000603107072000303113
002001303116#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#h#2#1#artic
le#1#oa#en#br1.1#1#4.0#ILUS#TAB#03#IBJU110#nd#Int. braz j urol.#37#1#20110200#^f
16^l28#1677-5538#Constipation and LUTS: how do they affect each other?^len#^rND^
1A01^nMarcio A.^sAverbeck#^rND^1A02^nHelmut^sMadersbacher#Mae de Deus Center Hos
pital^iA01^1Department of Urology^sPorto Alegre^pBrazil#Medical University Innsb
ruck^iA02^1Department of Neurology^sInnsbruck^pAustria#^len^aCONTEXT: Urinary bl
adder and rectum share a common embryological origin. Their autonomic and somati
c innervations have close similarities. Moreover, the close proximity of these t
wo organ systems could suggest that dysfunction in one may influence, also mecha
nically, the function of the other. Therefore, it is not surprising that defecat
ion problems and lower urinary tract symptoms (LUTS) occur together, as reported
 in the literature. OBJECTIVE: To study the relationship between constipation an
d LUTS focusing on what is evidence-based. EVIDENCE ACQUISITION: We searched the
 Medical Literature Analysis and Retrieval System Online (MEDLINE) database in F
ebruary 2010 to retrieve English language studies (from 1997 to 2009) and the 20
05, 2006 and 2007 abstract volumes of the European Association of Urology (EAU),
 American Urological Association (AUA) and International Continence Society (ICS
). EVIDENCE SYNTHESIS: We present the findings according to the studied populati
on in four groups: (a) children, (b) middle-aged women, (c) elderly and (d) neur
opathic patients. Most published studies that correlated rectal and bladder dysf
unction were carried out in children or in young women. On the other hand, there
 are few studies regarding the association between constipation and LUTS in the 
elderly and in neuropathic patients. CONCLUSIONS: Several studies in children do
cumented that constipation is linked to urinary tract problems, including infect
ions, enuresis, vesicoureteral reflux and upper renal tract dilatation. The unde
rlying pathophysiology of these findings has not yet been clearly defined. Studi
es in middle-aged women also support a high prevalence of constipation among pat
ients suffering from urinary tract dysfunction. Furthermore, an association betw
een constipation and urinary incontinence, as well as between constipation and p
elvic organ prolapse, has been suggested. The only prospective study in constipa
ted elderly with concomitant LUTS demonstrates that the medical relief of consti
pation also significantly improves LUTS. Finally, the available data on neuropat
hic patients suggest that stool impaction in the rectum may mechanically impede 
bladder emptying. However, most of the studies only include a small number of pa
tients, are not prospective and are uncontrolled. Therefore, there is a need for
 large-scale, controlled studies to further improve evidence and to provide a va
lid recommendation for all groups, especially for the elderly and neuropathic pa
tients.#^ddecs^i1#^tm^len^kconstipation^i1#^tm^len^kdefecation^i1#^tm^len^kurina
ry tract^i1#^tm^len^kurinary tract diseases^i1#^tm^len^kurinary incontinence^i1#
other#35#a03v37n1.htm##
03665000000000493000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000180011303100030013103200020013406500090013601400090014503500100015401200720
01640100031002360100032002670700078002990700079003770832541004560850010029970850
02503007085002303032085002603055085003503081085003303116117000603149072000303155
002001303158#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#f#3#1#artic
le#1#oa#en#br1.1#1#4.0#ILUS#TAB#03#IBJU110#nd#Int. braz j urol.#37#1#20110200#^f
16^l28#1677-5538#<b>Constipation and LUTS</b>: <b>how do they affect each other?
</b>^len#^rND^1A01^nMarcio A.^sAverbeck#^rND^1A02^nHelmut^sMadersbacher#Mae de D
eus Center Hospital^iA01^1Department of Urology^sPorto Alegre^pBrazil#Medical Un
iversity Innsbruck^iA02^1Department of Neurology^sInnsbruck^pAustria#^len^a<b>CO
NTEXT:</b> Urinary bladder and rectum share a common embryological origin. Their
 autonomic and somatic innervations have close similarities. Moreover, the close
 proximity of these two organ systems could suggest that dysfunction in one may 
influence, also mechanically, the function of the other. Therefore, it is not su
rprising that defecation problems and lower urinary tract symptoms (LUTS) occur 
together, as reported in the literature. <b>OBJECTIVE:</b> To study the relation
ship between constipation and LUTS focusing on what is evidence-based. EVIDENCE 
ACQUISITION: We searched the Medical Literature Analysis and Retrieval System On
line (MEDLINE) database in February 2010 to retrieve English language studies (f
rom 1997 to 2009) and the 2005, 2006 and 2007 abstract volumes of the European A
ssociation of Urology (EAU), American Urological Association (AUA) and Internati
onal Continence Society (ICS). <b>EVIDENCE SYNTHESIS:</b> We present the finding
s according to the studied population in four groups: (a) children, (b) middle-a
ged women, (c) elderly and (d) neuropathic patients. Most published studies that
 correlated rectal and bladder dysfunction were carried out in children or in yo
ung women. On the other hand, there are few studies regarding the association be
tween constipation and LUTS in the elderly and in neuropathic patients. <b>CONCL
USIONS:</b> Several studies in children documented that constipation is linked t
o urinary tract problems, including infections, enuresis, vesicoureteral reflux 
and upper renal tract dilatation. The underlying pathophysiology of these findin
gs has not yet been clearly defined. Studies in middle-aged women also support a
 high prevalence of constipation among patients suffering from urinary tract dys
function. Furthermore, an association between constipation and urinary incontine
nce, as well as between constipation and pelvic organ prolapse, has been suggest
ed. The only prospective study in constipated elderly with concomitant LUTS demo
nstrates that the medical relief of constipation also significantly improves LUT
S. Finally, the available data on neuropathic patients suggest that stool impact
ion in the rectum may mechanically impede bladder emptying. However, most of the
 studies only include a small number of patients, are not prospective and are un
controlled. Therefore, there is a need for large-scale, controlled studies to fu
rther improve evidence and to provide a valid recommendation for all groups, esp
ecially for the elderly and neuropathic patients.#^ddecs^i1#^tm^len^kconstipatio
n^i1#^tm^len^kdefecation^i1#^tm^len^kurinary tract^i1#^tm^len^kurinary tract dis
eases^i1#^tm^len^kurinary incontinence^i1#other#35#a03v37n1.htm##
03756000000000517000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000300117049000800120
15800030012803000170013103100030014803200020015106500090015301400090016203500100
01710120058001810100030002390100032002690700080003010700081003810832513004620850
01002975085002502985085002303010085002603033085003503059085003303094117000603127
072000303133002001303136008008903149#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
3v37n1.htm#S#l#4#1#article#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#ilus#tab#03#IBJ
U110#nd#Int. braz j urol#37#1#20110200#^f16^l28#1677-5538#Constipation and LUTS:
 how do they affect each other?^len#^rND^1A01^nMarcio A^sAverbeck#^rND^1A02^nHel
mut^sMadersbacher#^iA01^1Mae de Deus Center Hospital^2Department of Urology^sPor
to Alegre^pBrazil#^iA02^1Medical University Innsbruck^2Department of Neurology^s
Innsbruck^pAustria#^len^aCONTEXT: Urinary bladder and rectum share a common embr
yological origin. Their autonomic and somatic innervations have close similariti
es. Moreover, the close proximity of these two organ systems could suggest that 
dysfunction in one may influence, also mechanically, the function of the other. 
Therefore, it is not surprising that defecation problems and lower urinary tract
 symptoms (LUTS) occur together, as reported in the literature. OBJECTIVE: To st
udy the relationship between constipation and LUTS focusing on what is evidence-
based. EVIDENCE ACQUISITION: We searched the Medical Literature Analysis and Ret
rieval System Online (MEDLINE) database in February 2010 to retrieve English lan
guage studies (from 1997 to 2009) and the 2005, 2006 and 2007 abstract volumes o
f the European Association of Urology (EAU), American Urological Association (AU
A) and International Continence Society (ICS). EVIDENCE SYNTHESIS: We present th
e findings according to the studied population in four groups: (a) children, (b)
 middle-aged women, (c) elderly and (d) neuropathic patients. Most published stu
dies that correlated rectal and bladder dysfunction were carried out in children
 or in young women. On the other hand, there are few studies regarding the assoc
iation between constipation and LUTS in the elderly and in neuropathic patients.
 CONCLUSIONS: Several studies in children documented that constipation is linked
 to urinary tract problems, including infections, enuresis, vesicoureteral reflu
x and upper renal tract dilatation. The underlying pathophysiology of these find
ings has not yet been clearly defined. Studies in middle-aged women also support
 a high prevalence of constipation among patients suffering from urinary tract d
ysfunction. Furthermore, an association between constipation and urinary inconti
nence, as well as between constipation and pelvic organ prolapse, has been sugge
sted. The only prospective study in constipated elderly with concomitant LUTS de
monstrates that the medical relief of constipation also significantly improves L
UTS. Finally, the available data on neuropathic patients suggest that stool impa
ction in the rectum may mechanically impede bladder emptying. However, most of t
he studies only include a small number of patients, are not prospective and are 
uncontrolled. Therefore, there is a need for large-scale, controlled studies to 
further improve evidence and to provide a valid recommendation for all groups, e
specially for the elderly and neuropathic patients.#^ddecs^i1#^tm^len^kconstipat
ion^i1#^tm^len^kdefecation^i1#^tm^len^kurinary tract^i1#^tm^len^kurinary tract d
iseases^i1#^tm^len^kurinary incontinence^i1#other#35#a03v37n1.htm#Internet^ihttp
://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382011000100003##
00355000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012200074002001300196#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#5#1#article#159#<p align="right"><fon
t face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>REVIEW    ARTICLE </b
></font></p>     ^cY#a03v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#6#2#article#159#<p>&nbsp;</p>     ^cY
#a03v37n1.htm##
00398000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704016500074002001300239#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#7#3#article#159#<p><font face="Verdan
a, Arial, Helvetica, sans-serif" size="4"><a name="top"></a><b>Constipation    a
nd LUTS - how do they affect each other?</b></font></p>     ^cY#a03v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#8#4#article#159#<p>&nbsp;</p>     ^cY
#a03v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#9#5#article#159#<p>&nbsp;</p>     ^cY
#a03v37n1.htm##
00390000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704015600075002001300231#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#10#6#article#159#<p><font face="Verda
na, Arial, Helvetica, sans-serif"size="2"><b>Marcio A. Averbeck<sup>I</sup>;    
Helmut Madersbacher<sup>II</sup></b></font></p>     ^cY#a03v37n1.htm##
00392000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704015800075002001300233#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#11#7#article#159#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Department    of Urology,
 Mae de Deus Center Hospital, Porto Alegre, Brazil    ^cY#a03v37n1.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704018300075002001300258#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#12#8#article#159#<br>   </font><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>II</sup>Department   
 of Neurology, Medical University Innsbruck, Innsbruck, Austria</font></p>     ^
cY#a03v37n1.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011600075002001300191#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#13#9#article#159#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#end">Correspondence</a></fo
nt></p>     ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#14#10#article#159#<p>&nbsp;</p>     ^
cY#a03v37n1.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#15#11#article#159#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a03v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#16#12#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#a
03v37n1.htm##
00769000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053400076002001300610#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#17#13#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONTEXT:</b>    Urinary bladder a
nd rectum share a common embryological origin. Their autonomic    and somatic in
nervations have close similarities. Moreover, the close proximity    of these tw
o organ systems could suggest that dysfunction in one may influence,    also mec
hanically, the function of the other. Therefore, it is not surprising    that de
fecation problems and lower urinary tract symptoms (LUTS) occur together,    as 
reported in the literature.    ^cY#a03v37n1.htm##
00362000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012700076002001300203#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#18#14#article#159#<br>   <b>OBJECTIVE
:</b> To study the relationship between constipation and LUTS focusing    on wha
t is evidence-based.    ^cY#a03v37n1.htm##
00621000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038600076002001300462#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#19#15#article#159#<br>   EVIDENCE ACQ
UISITION: We searched the Medical Literature Analysis and Retrieval    System On
line (MEDLINE) database in February 2010 to retrieve English language    studies
 (from 1997 to 2009) and the 2005, 2006 and 2007 abstract volumes of    the Euro
pean Association of Urology (EAU), American Urological Association (AUA)    and 
International Continence Society (ICS).    ^cY#a03v37n1.htm##
00705000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047000076002001300546#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#20#16#article#159#<br>   <b>EVIDENCE 
SYNTHESIS:</b> We present the findings according to the studied    population in
 four groups: (a) children, (b) middle-aged women, (c) elderly    and (d) neurop
athic patients. Most published studies that correlated rectal    and bladder dys
function were carried out in children or in young women. On the    other hand, t
here are few studies regarding the association between constipation    and LUTS 
in the elderly and in neuropathic patients.    ^cY#a03v37n1.htm##
01481000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704124600076002001301322#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#21#17#article#159#<br>   <b>CONCLUSIO
NS:</b> Several studies in children documented that constipation    is linked to
 urinary tract problems, including infections, enuresis, vesicoureteral    reflu
x and upper renal tract dilatation. The underlying pathophysiology of these    f
indings has not yet been clearly defined. Studies in middle-aged women also    s
upport a high prevalence of constipation among patients suffering from urinary  
  tract dysfunction. Furthermore, an association between constipation and urinar
y    incontinence, as well as between constipation and pelvic organ prolapse, ha
s    been suggested. The only prospective study in constipated elderly with conc
omitant    LUTS demonstrates that the medical relief of constipation also signif
icantly    improves LUTS. Finally, the available data on neuropathic patients su
ggest that    stool impaction in the rectum may mechanically impede bladder empt
ying. However,    most of the studies only include a small number of patients, a
re not prospective    and are uncontrolled. Therefore, there is a need for large
-scale, controlled    studies to further improve evidence and to provide a valid
 recommendation for    all groups, especially for the elderly and neuropathic pa
tients.</font></p>     ^cY#a03v37n1.htm##
00446000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021100076002001300287#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#22#18#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Key words:</b>    constipation; d
efecation; urinary tract; urinary tract diseases; urinary incontinence</font></p
> <HR size="1" noshade>     ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#23#19#article#159#<p>&nbsp;</p>     ^
cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#24#20#article#159#<p>&nbsp;</p>     ^
cY#a03v37n1.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#25#21#article#159#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODUCTION</b></font></p>     ^
cY#a03v37n1.htm##
00937000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070200076002001300778#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#26#22#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The urinary bladder    and the rect
um have a common embryological origin in the cloaca. The motor nerve    supply o
f each is provided by the parasympathetic outflow arising from S2-S4.    The sam
e is true for the external (striated) anal and for the external (striated)    ur
ethral sphincter; both are innervated by the pudendal nerve, arising from    the
 Onuf's nucleous in S2-S4. In healthy individuals bladder and rectum    function
 are "in harmony" (1). However, constipation and lower urinary    tract symptoms
 (LUTS) can occur concomitantly in children, women, the elderly,    as well as i
n neuropathic patients.</font></p>     ^cY#a03v37n1.htm##
00851000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061600076002001300692#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#27#23#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Autonomic reflex    interaction betw
een the urinary bladder and the distal part of the gastrointestinal    tract has
 been investigated in animal models and humans (2). It has been demonstrated    
that anal stimulation abolishes a prevailing detrusor contraction. On the other 
   hand, distension of the urinary bladder in man produces an increase in intern
al    anal sphincter pressure. This response is abolished by blockade of the tho
racolumbar    sympathetic outflow by epidural anaesthesia, indicating a spinal r
eflex arc    (2).</font></p>     ^cY#a03v37n1.htm##
00860000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062500076002001300701#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#28#24#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The coincidence    of defecation pro
blems and LUTS reported in the literature may have several    different aetiolog
ies: (a) it may be that rectum and bladder are affected by    the same neuropath
ology; (b) that dysfunction in one system may impede the neighbouring    organs 
and structures mechanically, e.g. stool impaction from severe constipation    ma
y impede voiding; or (c) severe straining due to constipation may induce changes
    in the pelvic floor musculature, resulting in pelvic organ prolapse (POP) an
d    urinary incontinence.</font></p>     ^cY#a03v37n1.htm##
00920000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068500076002001300761#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#29#25#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Most studies that    correlated rect
al and bladder dysfunction were carried out in children or in    middle-aged wom
en, but there is only one prospective cohort study, to our knowledge,    regardi
ng constipation and LUTS in the elderly (1). One of the difficulties    to condu
ct clinical studies, including bowel dysfunction is the subjective aspect    ass
ociated with the definition of constipation (3). Some studies used self-applied 
   questionnaires where the patients could define themselves as constipated or  
  not. Only recently, has chronic functional constipation been clearly defined  
  (4).</font></p>     ^cY#a03v37n1.htm##
00531000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029600076002001300372#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#30#26#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The aim of this    review was to stu
dy the relationship between constipation and LUTS, focusing    on what is eviden
ce-based and what can be recommended so far from the diagnostic    and therapeut
ic point of view.</font></p>     ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#31#27#article#159#<p>&nbsp;</p>     ^
cY#a03v37n1.htm##
00366000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013100076002001300207#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#32#28#article#159#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>EVIDENCE    ACQUISITION - SEARCH 
STRATEGY</b></font></p>     ^cY#a03v37n1.htm##
00567000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033200076002001300408#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#33#29#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> A literature search    was performe
d in the Medical Literature Analysis and Retrieval System Online    (MEDLINE) da
tabase in February 2010 to retrieve English language studies (from    1997 to 20
09) on the association between constipation and LUTS.</font></p>     ^cY#a03v37n
1.htm##
00853000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061800076002001300694#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#34#30#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">For retrieving    the references in 
MEDLINE we used the following medical subject heading terms:    "constipation" (
major subject descriptor) and "defecation",    "urinary tract", "urinary tract d
iseases", "urinary    tract infections", "urinary incontinence" or "urinary    r
etention" (subject descriptors). Furthermore, we searched the abstract    volume
s of the annual meetings of 2007, 2008 and 2009 of the European Association    o
f Urology the American Urological Association and the International Continence  
  Society meetings.</font></p>     ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#35#31#article#159#<p>&nbsp;</p>     ^
cY#a03v37n1.htm##
00354000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011900076002001300195#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#36#32#article#159#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>DEFINITION    OF CONSTIPATION</b>
</font></p>     ^cY#a03v37n1.htm##
01450000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704121500076002001301291#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#37#33#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Constipation is    an end-point def
ined by a constellation of symptoms, including infrequent passage    of stool, f
aeces that are either large, hard or in small pieces, abdominal pain,    palpabl
e stool in the abdomen, stool in the rectal vault or faecal soiling.    Function
al constipation (FC) is considered a symptom-based disorder that is    character
ized by both decreased frequency and hard consistency of stools, as    well as s
ymptoms relating to difficult evacuation (5). <a href="/img/revistas/ibju/v37n1/
a03tab1.jpg">Table-1</a>    presents the Rome III criteria for chronic functiona
l constipation in adults    and in children (4). Other terms and definitions hav
e been used by some authors.    Obstructive defecation was defined as difficulty
 in passing stool, hard stool,    straining for more than 15 min., or incomplete
 evacuation, occurring at least    weekly (6). Anal incontinence was defined as 
involuntary leakage of solid or    liquid faeces or gas (7). Finally, dysfunctio
nal elimination syndrome (DES)    has been defined as any pattern of voiding or 
stooling that varies from the    developmental norm (8).</font></p>     ^cY#a03v
37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#38#34#article#159#<p>&nbsp;</p>     ^
cY#a03v37n1.htm##
00382000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014700076002001300223#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#39#35#article#159#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>EVIDENCE SYNTHESIS    ACCORDING T
O THE STUDIED POPULATION</b></font></p>     ^cY#a03v37n1.htm##
01229000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704099400076002001301070#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#40#36#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The studies on    Constipation and 
LUTS will be presented and discussed, as well as the levels    of evidence (LoE)
 and grades of recommendation (GR). The publications were organized    according
 to the studied population in four groups: Children, Middle-Aged Women,    Elder
ly, Neuropathic Patients. We were able to retrieve altogether 8 case-reports,   
 5 review studies, 3 case-control studies, 3 case-series, 6 cross-sectional stud
ies,    5 cohort studies and 1 non-controlled clinical study. <a href="/img/revi
stas/ibju/v37n1/a03tab2.jpg">Table-2</a>    lists the review articles on constip
ation and LUTS published so far. <a href="/img/revistas/ibju/v37n1/a03tab3.jpg">
Table-3</a>    and <a href="/img/revistas/ibju/v37n1/a03tab4.jpg">Table-4</a> li
sts the published studies on    children and middle-aged women, respectively, an
d Table-5 shows the studies,    only case-reports, in neuropathic patients.</fon
t></p>     ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#41#37#article#159#<p>&nbsp;</p>     ^
cY#a03v37n1.htm##
00361000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012600076002001300202#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#42#38#article#159#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>CONSTIPATION    AND LUTS IN CHILD
REN</b></font></p>     ^cY#a03v37n1.htm##
01444000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704120900076002001301285#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#43#39#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Constipation is    responsible for 
3% of visits to a paediatrician and 25% of consultations with    a gastroenterol
ogist. Children diagnosed with constipation frequently have a    poor appetite a
nd have been shown to have a lower calorie and fibre intake,    lower body mass 
index and more frequent anorexia than non-constipated children    (9). Some chil
dren voluntarily suppress the urge to defecate and they refuse    toileting, alt
hough a strong need to defecate is present. Withholding behaviour    over time c
an cause DES (8). This behaviour may be due to an impairment of learning    subs
equent to distress, trauma, disruption of routine, inattention or cognition    d
ifficulties and is often associated with the memory or expectation of pain    at
 defecation. Also the presence of an anal fissure or an anal streptococcal    in
fection may induce this behaviour (9). Environmental factors regarding toilets, 
   lack of privacy, risk of bullying, limited access, lack of essential products
    for good hygiene and dirty bathrooms can all contribute in encouraging a chi
ld    to withhold urine and stool while at school.</font></p>     ^cY#a03v37n1.h
tm##
00656000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042100076002001300497#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#44#40#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">There are 12 studies    addressing t
he relationship between constipation and LUTS on children (10-21).    <a href="/
img/revistas/ibju/v37n1/a03tab3.jpg">Table-3</a> summarizes these studies, as we
ll as,    the LoE and GR, number of patients included in each study and their me
an age.    The important findings will be discussed in detail.</font></p>     ^c
Y#a03v37n1.htm##
01232000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704099700076002001301073#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#45#41#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Loening-Baucke    (10) published a 
cohort study evaluating the frequency of urinary incontinence    and urinary tra
ct infection in constipated children and the effect of successful    treatment o
f constipation on urologic symptoms: 234 chronic constipated and    encopretic c
hildren were evaluated before and at least 12 months after the treatment    for 
constipation (mean follow-up = 15 months), which was successful in 52% of    the
 children. In this group, relief of constipation resulted in disappearance    of
 daytime urinary incontinence in 89% and night-time urinary incontinence in    6
3% of patients, and disappearance of recurrent urinary tract infections in    al
l patients who had no anatomic abnormality of the urinary tract. This study    s
howed that with treatment of the constipation, most children became clean and   
 dry and recurrence of urinary tract infections was prevented (LoE 1B / GR B).</
font></p>     ^cY#a03v37n1.htm##
00952000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071700076002001300793#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#46#42#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">McGrath et al.    (11) performed a p
rospective cross-sectional study of children with enuresis    at presentation to
 a continence service. Data relating to the child's    bowel habits, pattern of 
enuresis and other history items were obtained from    parental questionnaires a
nd paediatrician's assessments. Of the 277 participants    aged 4.8-17.5 years (
median 8.6 years), 100 (36.1%) were identified as constipated    by the clinicia
n, compared with only 39 (14.1%) from parental reporting (Kappa    = 0.155; P = 
0.003). Constipation was high among children with enuresis, but    was often not
 recognized by parents (LoE 2 / GR B).</font></p>     ^cY#a03v37n1.htm##
00851000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061600076002001300692#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#47#43#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Kajiwara et al.    (15) retrospectiv
ely studied the differences between monosymptomatic and non-monosymptomatic    e
nuresis on the basis of LUTS and constipation. Eighty-eight patients (9.8 &plusm
n;    3.1 years old) were enrolled, 67 with monosymptomatic and 21 with non-mono
symptomatic    enuresis. Besides a history of urinary tract infections, mechanic
al obstructions    and vesicoureteral reflux, constipation was also strongly ass
ociated with non-monosymptomatic    enuresis compared to monosymptomatic enuresi
s (LoE 2 / GR C).</font></p>     ^cY#a03v37n1.htm##
00748000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051300076002001300589#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#48#44#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Bael et al. (12)    studied the eff
icacy of treating urinary incontinence (UI) in children with    concomitant func
tional fecal incontinence (FFI) or FC. After treatment of UI,    FFI dropped fro
m 32% to 21% (P = 0.035); for FC, the number of evaluated children    was too sm
all. Although the studied population was rather small, the outcome    supports a
 mutual relationship between LUTS and bowel dysfunction (LoE 2 / GR    B).</font
></p>     ^cY#a03v37n1.htm##
01232000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704099700076002001301073#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#49#45#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Koff et al. (13)    performed a pros
pective cohort study to evaluate the prevalence of DES in children    with vesic
oureteral reflux and to determine whether functional bladder and/or    bowel dis
orders influence the natural history or treatment of children with    primary ve
sicoureteral reflux. One hundred and forty-three children with primary    vesico
ureteral reflux, that stopped spontaneously or was surgically corrected,    were
 included. Unsuccessful surgical outcomes involving persistent, recurrent    and
 contralateral reflux occurred only in children with DES. The authors concluded 
   that dysfunctional elimination syndromes are common and are often unrecognize
d    in children with primary reflux. These syndromes are associated with delaye
d    reflux resolution and an increased rate of breakthrough urinary tract infec
tion,    which leads more frequently to reimplantation surgery (LoE 2 / GR B).</
font></p>     ^cY#a03v37n1.htm##
01283000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704104800076002001301124#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#50#46#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Loening-Baucke    (14) evaluated the
 prevalence rates for constipation, as well as of faecal and    urinary incontin
ence in children attending primary care clinics in the United    States. 482 chi
ldren (7-17 years of age) were included in the study. The prevalence    rate for
 constipation was 22.6% and was similar in boys and girls. The prevalence    rat
e for faecal incontinence (&gt; or = 1/week) was 4.4%. Faecal incontinence    wa
s associated with constipation in 95% of the patients. The prevalence rate    fo
r urinary incontinence was 10.5%; 3.3% for daytime only, 1.8% for day- and    ni
ght-time and 5.4% for night-time urinary incontinence. Faecal and urinary    inc
ontinence were significantly more commonly observed in children with constipatio
n    than in children without constipation. Children with constipation had highe
r    prevalence rates not only for faecal but also for urinary incontinence than
    children without constipation (LoE 2 / GR C).</font></p>     ^cY#a03v37n1.ht
m##
00997000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076200076002001300838#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#51#47#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">De Paepe et al.    (16) analysed the
 results after treating young children with LUTS and constipation,    using a no
ninvasive training programme. Therapy consisted of keeping a voiding    and drin
king chart, instructions on proper toilet posture, daily rules for application  
  at home, and if possible relaxation biofeedback of the pelvic-floor muscles.  
  Twenty children were treated and 13 had a good result (became dry during the  
  day and night, and encopresis resolved). This study shows that pelvic-floor   
 muscle- and toilet training can improve both LUTS and constipation, but the    
studied population was very small and there was no control group (LoE 2 / GR    
C).</font></p>     ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#52#48#article#159#<p>&nbsp;</p>     ^
cY#a03v37n1.htm##
00370000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013500076002001300211#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#53#49#article#159#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>CONSTIPATION    AND LUTS IN MIDDL
E-AGED WOMEN</b></font></p>     ^cY#a03v37n1.htm##
00735000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050000076002001300576#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#54#50#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Constipation may    affect 12 to 32
% of middle-aged women (6,7). Women with constipation are more    likely than me
n to seek medical attention or use medication for this condition.    There are 5
 studies examining the prevalence of constipation and its association    with LU
TS and/or POP in middle-age women (6,7,22-24). These studies are summarized    i
n <a href="/img/revistas/ibju/v37n1/a03tab4.jpg">Table-4</a>.</font></p>     ^cY
#a03v37n1.htm##
01217000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704098200076002001301058#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#55#51#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Varma et al. (6)    analysed data f
rom a randomly selected cohort of 2,109 women, 40-69 years old,    to describe t
he prevalence of obstructive defecation and identify associated    risk factors.
 Obstructive defecation that occurred at least weekly was reported    by 12.3% o
f women. Significant independent risk factors included vaginal or    laparoscopi
c hysterectomy &#91;odds ratio (OR) = 2.01; 95% confidence interval (CI)    = 1.
15-3.54&#93;, using three or more medications &#91;1.81 (1.36-2.42)&#93;, sympto
matic    pelvic organ prolapse &#91;2.34 (1.47-3.71)&#93;, urinary incontinence 
surgery &#91;2.52    (1.29-4.90)&#93;, and other pelvic surgery &#91;1.35 (1.03-
1.78)&#93;. Women who had undergone    laparoscopic/vaginal hysterectomies or su
rgery for pelvic organ prolapse or    for urinary incontinence had a nearly two 
times higher risk for obstructive    defecation (LoE 2 / GR B).</font></p>     ^
cY#a03v37n1.htm##
00866000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063100076002001300707#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#56#52#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Ewings et al.    (22) performed a c
ohort study assessing risk factors for developing urinary    incontinence follow
ing childbirth. A total of 723 women were recruited from    the study. At 6 mont
hs post-partum, 45% of women reported some incontinence    problems. Chronic con
stipation was the second strongest predictor for post-partum    incontinence (OR
 = 1.86; 95% CI = 1.03-3.34), along with a pre-existing incontinence    problem 
&#91;4.49 (3.09-6.53)&#93; and episiotomy in at least one delivery &#91;1.96 (1.
25-3.07)&#93;    (LoE 2 / GR C).</font></p>     ^cY#a03v37n1.htm##
01111000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087600076002001300952#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#57#53#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Soligo et al.    (7) analysed the p
revalence and patterns of constipation in women with urinary    symptoms and/or 
genital prolapse. Seven hundred and eighty-six consecutive urogynaecological    
patients participated in a questionnaire and structured clinical assessment.    
Thirty-two percent of women were constipated. A genital prolapse of grade 2    o
r more occurred in 44% of women. A posterior colpocele was more frequent in    c
onstipated women (35% vs. 19%; p &lt; 0.0001), resulting in a risk factor for   
 constipation (OR = 2.31; 95% CI = 1.63-3.27). By contrast, higher degrees of   
 anterior colpocele appeared to protect against constipation &#91;0.80 (0.66-0.9
6)&#93;.    Constipation correlated exclusively with posterior aspects of the pe
lvic floor    support (LoE 2 / GR C).</font></p>     ^cY#a03v37n1.htm##
01402000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704116700076002001301243#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#58#54#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Spence-Jones et    al. (24) perform
ed a case-control study to investigate the aetiological importance    of constip
ation in patients with uterovaginal prolapse and urinary stress incontinence.   
 Twenty-three women with uterovaginal prolapse (mean age 57 years), 23 women    
with urinary stress incontinence (mean age 52 years) and 27 control women (mean 
   age 52 years) were included. All three groups were comparable in terms of par
ity,    age and birth weight of children. However, constipation as a young adult
 prior    to the development of urogynaecological symptoms was significantly mor
e common    in women with uterovaginal prolapse (61% vs. 4%; P &lt; 0.001) and w
omen with    urinary stress incontinence (30% vs. 4%; P &lt; 0.05), compared to 
controls.    At the time of consultation, 95% of the women with uterovaginal pro
lapse were    constipated, compared with only 11% of control women. Constipation
, in addition    to obstetric history, appears to be an important factor in the 
pathogenesis    of uterovaginal prolapse and stress urinary incontinence (LoE 3 
/ GR C).</font></p>     ^cY#a03v37n1.htm##
00979000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074400076002001300820#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#59#55#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Ng et al. (23)    evaluated the pre
valence of anorectal dysfunction among women with LUTS. All    320 women who att
ended the urogynaecological outpatient clinic for urodynamic    evaluation were 
requested to complete a structured questionnaire. Forty-nine    (15.9%) women re
ported having anal incontinence. Constipation was reported by    100 (31.5%) of 
the women. A multiple logistic regression analysis revealed that    the main ris
k factor associated with anal incontinence and constipation was    the presence 
of uterovaginal prolapse (OR = 5.02; 95% CI = 2.19-11.5 for anal    incontinence
; OR = 1.78; 95% CI = 1.03-3.09 for constipation) (LoE 3 / GR C).</font></p>    
 ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#60#56#article#159#<p>&nbsp;</p>     ^
cY#a03v37n1.htm##
00364000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012900076002001300205#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#61#57#article#159#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>CONSTIPATION    AND LUTS IN THE E
LDERLY</b></font></p>     ^cY#a03v37n1.htm##
01996000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704176100076002001301837#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#62#58#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> There is only    one prospective co
hort study, to our knowledge, evaluating the effect of alleviating    constipati
on on LUTS in the elderly (1). Charach et al. studied fifty-two patients,    age
d 65-89 (mean 72 &plusmn; 13) years, with chronic constipation and LUTS,    recr
uited from gastroenterology and urology clinics.(1) All patients were generally 
   mobile, sensitive and continent. Before treatment of constipation was initiat
ed,    patients completed a questionnaire regarding their constipation pattern, 
LUTS,    sexual function and mood. The follow-up was 4 months. Successful treatm
ent of    constipation increased the number of weekly defecations from 1.5 &plus
mn; 0.9    to 4.7 &plusmn; 1.2 (P &lt; 0.001); patients spent less time on the t
oilet (25    &plusmn; 2.1 versus 63 &plusmn; 1.9 min; P &lt; 0.0001); fewer pati
ents reported    urgency (16 vs. 34; P &lt; 0.001), frequency (25 vs. 47; P &lt;
 0.001) and burning    sensation during urination (6 vs. 17; P &lt; 0.05). At th
e same time, there    was also an improvement in the scoring of urgency, frequen
cy and burning sensation    (from a baseline of 52 to 126, 131 and 95, respectiv
ely; P &lt; 0.001). Urinary    stream disturbances improved in 32 of the 52 pati
ents (P &lt; 0.001). Residual    urine volume decreased from 85 &plusmn; 39.5 to
 30 &plusmn; 22.56 mL (P &lt;    0.001). There was also a significant decrease i
n the number of patients with    bacteriuria events (5 vs. 17; P &lt; 0.001), an
d an improvement in sexual activity    and mood (P &lt; 0.05). Treatment of cons
tipation significantly improved LUTS,    as well as, patient's mood, sexual acti
vity and quality of life (LoE 2,    GR B).</font></p>     ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#63#59#article#159#<p>&nbsp;</p>     ^
cY#a03v37n1.htm##
00377000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014200076002001300218#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#64#60#article#159#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>CONSTIPATION    AND LUTS IN THE N
EUROPATHIC PATIENTS</b></font></p>     ^cY#a03v37n1.htm##
00858000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062300076002001300699#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#65#61#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Neuropathic lower    urinary tract 
dysfunction and neuropathic colorectal dysfunction, as in patients    with spina
l cord lesions, share several similarities. The affected nerves causing    the d
ysfunction are similar and the pattern of bowel and bladder dysfunction    may c
hange over the years (25). However, there are only case-reports and review    st
udies (26-30) addressing constipation and LUTS in neuropathic patients. <a href=
"/img/revistas/ibju/v37n1/a03tab5.jpg">Table-5</a>    provides the case-report s
tudies published so far.</font></p>     ^cY#a03v37n1.htm##
02212000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704197700076002001302053#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#66#62#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Only recently,    Pannek et al. (26
) published an interesting article reporting two cases with    mechanical compre
ssion of the urinary bladder by an over distended bowel. The    first patient (6
3 year-old male), who had post-traumatic paraplegia sub Th 7    since 17 years, 
was performing intermittent catheterization and was referred    because of recur
rent urinary tract infections and urinary incontinence. He showed    a distended
 abdomen and palpable masses in the left lower quadrant. Digital    rectal exami
nation revealed massive stool masses. Computed tomography showed    dilatation o
f the colon, completely filled with stool, compressing the bladder    and the le
ft ureter, resulting in upper urinary tract dilatation. The second    patient (6
2 year-old male), with post-traumatic quadriplegia sub C 7 since 42    years, ha
d undergone sacral deafferentation and implantation of a Brindley anterior    ro
ot stimulator. He presented with urinary retention since 3 days, due to malfunct
ion    of the Brindley device. Physical examination revealed a minimally distend
ed    abdomen, but with palpable masses in the left lower quadrant. On digital r
ectal    examination, lumps of hard stool were detected. Video-urodynamics demon
strated    compression of the urinary bladder against the symphysis, making void
ing impossible    despite sufficient detrusor contractions. The patients were pr
operly treated    with evacuation by colonic hydrotherapy. After successful trea
tment of constipation,    upper urinary tract dilatation resolved in the first p
atient, and in the second    patient, after re-establishing the function of the 
Brindley device, with electrically    driven defecation, stool impaction disappe
ared and electromicturition was possible.    This case report shows that massive
 stool impaction due to neuropathic bowel    dysfunction can mechanically impede
 bladder emptying.</font></p>     ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#67#63#article#159#<p>&nbsp;</p>     ^
cY#a03v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#68#64#article#159#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>COMMENTS</b></font></p>     ^cY#a
03v37n1.htm##
02228000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704199300076002001302069#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#69#65#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Much attention    has been focused 
on the evaluation of colon, rectum and anus in children with    chronic constipa
tion with or without encopresis, but little thought has been    given to a possi
ble association to urinary tract symptoms, such as day- and    night-time urinar
y incontinence, urinary tract infection, and urinary retention    in these child
ren (10), despite the well-known fact that the lower urinary tract    and the lo
wer bowel tract are interrelated structures (31). Anatomically bladder    and re
ctum lay in close communication and share muscular structures of the pelvic    f
loor. Nevertheless, it has been suggested that the distension of the rectum    b
y stool impaction in constipated children presses on the bladder wall causing   
 bladder outflow obstruction, as well as inducing detrusor overactivity (32).   
 Urodynamic studies have reported detrusor overactivity in patients with functio
nal    constipation. Additionally, both, bladder overactivity and bowel dysfunct
ion    may lead to overactivity of the pelvic floor musculature, resulting in a 
high    muscle tone, which again causes dysfunctional elimination of urine and f
aeces    (<a href="/img/revistas/ibju/v37n1/a03fig1.jpg">Figure-1</a>) (16). A c
omprehensive medical history    along with physical examination must be done for
 every child either with LUTS    and/or with chronic constipation and encopresis
, bearing in mind the neighbouring    organ systems. It has been shown that it i
s not enough only asking the parents    about the bowel habits of the child, as 
constipation is frequently not recognized    and reported by parents (11). Moreo
ver, it is important to pay attention during    the physical examination to find
ings suggesting stool impaction, such as abdominal    masses and/or abdominal di
stension. Complementary ultrasound may provide additional    information on fill
ing condition of colon and rectum.</font></p>     ^cY#a03v37n1.htm##
01441000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704120600076002001301282#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#70#66#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">When a child presents    with enures
is, it is for various reasons important to differentiate between    monosymptoma
tic and non-monosymptomatic enuresis: it has been shown by Kajiwara    et al. th
at constipation is more often found in association with non-monosymptomatic    e
nuresis (15). Also in the setting of vesicoureteral reflux, it makes sense    to
 search for constipation, because this condition can cause delayed reflux    res
olution and urinary tract infections. In this situation, successful treatment   
 of constipation could avoid breakthrough urinary tract infections, which are   
 often an indication for reimplantation surgery (13). In children with constipat
ion    and concomitant LUTS, adequate treatment of constipation also improves or
 abolishes    LUTS. Loening-Baucke et al. performed a prospective study in this 
context: disappearance    of day- and night-time urinary incontinence, only by t
reating constipation,    occurred in 89% and 63% of patients, respectively. Addi
tionally, urinary tract    infections disappeared in all patients who had no ana
tomic abnormality of the    urinary tract (10).</font></p>     ^cY#a03v37n1.htm#
#
01278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704104300076002001301119#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#71#67#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Constipation in    women may signif
icantly impact overall quality of life (33). Bowel habits must    be investigate
d, especially in women with previous hysterectomy, pelvic organ    prolapse and 
urinary incontinence surgery, as it was shown that these conditions    are indep
endent risk factors for constipation, probably due to an iatrogenic    lesion of
 the innervation (6,7,23). In contrast, constipation in young women    is a risk
 factor for future uterovaginal prolapse and urinary stress incontinence    (24)
. Constipation has frequently been described to increase the risk for pelvic    
organ prolapse (34). Pregnant women should have their bowel habits investigated,
    because there is good evidence that chronic constipation is a risk factor fo
r    postpartum urinary incontinence (22). When a pregnant woman presents with c
hronic    constipation, one should treat this condition in time as an attempt to
 prevent    postpartum urinary incontinence.</font></p>     ^cY#a03v37n1.htm##
01379000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704114400076002001301220#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#72#68#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> In community-based    surveys, faec
al incontinence (FI) is strongly associated with urinary incontinence    and ove
ractive bladder in both men and woman. Among nursing home patients, the    assoc
iation between urinary incontinence and FI is even stronger (35). It has    also
 been shown that constipation and urinary symptoms are very common and disturbin
g    in the elderly population (1). In the only prospective study addressing thi
s    problem in the elderly, Charach et al. (1) have shown that the treatment of
    constipation, at the same time, also improves or abolishes the urologic symp
toms    as urgency, frequency and burning sensation can be significantly improve
d after    treatment of constipation. Besides, improvements in sexual activity a
nd mood    have been reported. Thus, it is important to take into consideration 
that treatment    of chronic constipation in elderly patients, by appropriate us
e of stool softeners,    adequate fluid intake, exercise and disimpaction if nec
essary, may also improve    or even cure the urological symptoms.</font></p>    
 ^cY#a03v37n1.htm##
01155000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704092000076002001300996#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#73#69#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Indeed, there    are only a few cas
e-reports addressing the relationship between neuropathic    bowel dysfunction a
nd neuropathic urinary tract dysfunction (26-30). It has    been documented that
 overdistended bowel can mechanically impede bladder emptying    and can cause u
pper urinary tract dilatation (26). This has to be considered,    especially at 
long term follow-up, when upper and/or lower urinary tract unexpectedly    deter
iorates; in this situation it is mandatory to exclude stool impaction by    abdo
minal palpation and digital rectal examination, as well as by a plain abdominal 
   X-ray, ultrasound and/or computed tomography. Colonic hydrotherapy is widely 
   used for the treatment of this type of constipation. In these patients, with 
   successful management of constipation, the urinary tract function can recover
.</font></p>     ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#74#70#article#159#<p>&nbsp;</p>     ^
cY#a03v37n1.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010100076002001300177#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#75#71#article#159#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUSIONS</b></font></p>     ^c
Y#a03v37n1.htm##
02106000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704187100076002001301947#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#76#72#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Studies in children    have linked 
constipation to urinary tract problems, including infections, enuresis,    vesic
oureteral reflux and upper renal tract dilatation. As a consequence of    this i
nteraction between bladder and bowel dysfunction, also overactivity of    pelvic
 floor muscles is likely to occur. It is important in children with LUTS    also
 to assess their bowel habits by taking a targeted history and proper clinical  
  examination, as constipation may not be recognized and, thus, may not be repor
ted    by the parents. Studies in middle-aged women support a high prevalence of
 constipation    among patients suffering from lower urinary tract dysfunction. 
There is some    evidence for an association between constipation and urinary in
continence, as    well as between constipation and POP and vice-versa. The only 
prospective study    regarding the elderly population clearly shows that the med
ical relief of constipation    significantly improves concomitant LUTS, which, i
n turn, improves the patient's    mood, sexual activity and quality of life. Fin
ally, the available data on neuropathic    patients suggest that neuropathic bow
el dysfunction with chronic constipation    may mechanically cause urinary tract
 dysfunction. Chronic constipation and stool    impaction may develop over many 
years, e.g. in spinal cord injured patients,    and they are often subjectively 
unaware, of their condition which may be the    reason for unexpected and otherw
ise unexplainable upper urinary tract deterioration    and/or lower urinary trac
t dysfunction. In conclusion, despite the apparent    relationship between const
ipation and LUTS, large scale, prospective, controlled    studies are still need
ed, especially as regards the elderly and the neuropathic    population.</font><
/p>     ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#77#73#article#159#<p>&nbsp;</p>     ^
cY#a03v37n1.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010600076002001300182#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#78#74#article#159#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ACKNOWLEDGEMENTS</b></font></p>  
   ^cY#a03v37n1.htm##
00617000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038200076002001300458#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#79#75#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> We would like    to thank Prof. Gis
ele Alsina Nader, from Federal University of Health Sciences    of Porto Alegre 
&#8211; UFCSPA (Brazil), for her help in classifying the available    studies on
 constipation and LUTS, according to the levels of evidence (LoE)    and grades 
of recommendation (GR).</font></p>     ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#80#76#article#159#<p>&nbsp;</p>     ^
cY#a03v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#81#77#article#159#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONFLICT    OF INTEREST</b></font
></p>     ^cY#a03v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#82#78#article#159#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> None declared.</font></p>     ^cY#a
03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#83#79#article#159#<p>&nbsp;</p>     ^
cY#a03v37n1.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#84#80#article#159#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>     ^cY
#a03v37n1.htm##
00500000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025100078002001300329#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#85#81#article#159#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Charach G, Greenste
in    A, Rabinovich P, Groskopf I, Weintraub M: Alleviating constipation in the 
elderly    improves lower urinary tract symptoms. Gerontology. 2001; 47: 72-6.  
  ^cY#a03v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#86#82#article#159# </font></p>     ^c
Y#a03v37n1.htm##
00498000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024900078002001300327#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#87#83#article#159#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Buntzen S, Nordgren
    S, Delbro D, Hult&eacute;n L: Anal and rectal motility responses to distensi
on    of the urinary bladder in man. Int J Colorectal Dis. 1995; 10: 148-51.    
^cY#a03v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#88#84#article#159#</font></p>     ^cY
#a03v37n1.htm##
00440000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019100078002001300269#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#89#85#article#159#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Drossman DA:    The
 functional gastrointestinal disorders and the Rome II process. Gut. 1999;    (4
5 Suppl 2): II1-5.    ^cY#a03v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#90#86#article#159#</font></p>     ^cY
#a03v37n1.htm##
00433000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704018400078002001300262#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#91#87#article#159#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Bharucha AE,    Wal
d A, Enck P, Rao S: Functional anorectal disorders. Gastroenterology. 2006;    1
30: 1510-8.    ^cY#a03v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#92#88#article#159#</font></p>     ^cY
#a03v37n1.htm##
00541000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029200078002001300370#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#93#89#article#159#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. American College   
 of Gastroenterology Chronic Constipation Task Force (2005) An evidence-based   
 approach to the management of chronic constipation in North America. Am J Gastr
oenterol.    2005; 100(Suppl 1): S1-S4.    ^cY#a03v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#94#90#article#159#</font></p>     ^cY
#a03v37n1.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022400078002001300302#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#95#91#article#159#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Varma MG, Hart    S
L, Brown JS, Creasman JM, Van Den Eeden SK, Thom DH: Obstructive defecation    i
n middle-aged women. Dig Dis Sci. 2008; 53: 2702-9.    ^cY#a03v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#96#92#article#159#</font></p>     ^cY
#a03v37n1.htm##
00544000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029500078002001300373#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#97#93#article#159#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Soligo M, Salvatore
    S, Emmanuel AV, De Ponti E, Zoccatelli M, Cortese M, et al.: Patterns of con
stipation    in urogynecology: clinical importance and pathophysiologic insights
. Am J Obstet    Gynecol. 2006; 195: 50-5.    ^cY#a03v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#98#94#article#159#</font></p>     ^cY
#a03v37n1.htm##
00458000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020900078002001300287#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#99#95#article#159#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Kistner M: Dysfunct
ional    elimination behaviors and associated complications in school-age childr
en. J    Sch Nurs. 2009; 25: 108-16.    ^cY#a03v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#100#96#article#159#</font></p>     ^c
Y#a03v37n1.htm##
00441000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704019100079002001300270#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#101#97#article#159#9#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Chase JW, Homsy   
 Y, Siggaard C, Sit F, Bower WF: Functional constipation in children. J Urol.   
 2004; 171: 2641-3.    ^cY#a03v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#102#98#article#159#</font></p>     ^c
Y#a03v37n1.htm##
00503000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704025200080002001300332#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#103#99#article#159#10#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Loening-Baucke  
  V: Urinary incontinence and urinary tract infection and their resolution with 
   treatment of chronic constipation of childhood. Pediatrics. 1997; 100: 228-32
.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#104#100#article#159#</font></p>     ^
cY#a03v37n1.htm##
00517000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026500081002001300346#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#105#101#article#159#11#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. McGrath KH,    
Caldwell PH, Jones MP: The frequency of constipation in children with nocturnal 
   enuresis: a comparison with parental reporting. J Paediatr Child Health. 2008
;    44: 19-27.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#106#102#article#159#</font></p>     ^
cY#a03v37n1.htm##
00562000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031000081002001300391#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#107#103#article#159#12#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Bael AM, Bennin
ga    MA, Lax H, Bachmann H, Janhsen E, De Jong TP, et al.: Functional urinary a
nd    fecal incontinence in neurologically normal children: symptoms of one 'fun
ctional    elimination disorder'? BJU Int. 2007; 99: 407-12.    ^cY#a03v37n1.htm
##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#108#104#article#159#</font></p>     ^
cY#a03v37n1.htm##
00528000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027600081002001300357#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#109#105#article#159#13#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Koff SA, Wagner
    TT, Jayanthi VR: The relationship among dysfunctional elimination syndromes,
    primary vesicoureteral reflux and urinary tract infections in children. J Ur
ol.    1998; 160: 1019-22.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#110#106#article#159#</font></p>     ^
cY#a03v37n1.htm##
00454000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020200081002001300283#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#111#107#article#159#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Loening-Baucke 
   V: Prevalence rates for constipation and faecal and urinary incontinence. Arc
h    Dis Child. 2007; 92: 486-9.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#112#108#article#159#</font></p>     ^
cY#a03v37n1.htm##
00509000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025700081002001300338#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#113#109#article#159#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Kajiwara M,    
Kato M, Mutaguchi K, Usui T: Overactive bladder in children should be strictly  
  differentiated from monosymptomatic nocturnal enuresis. Urol Int. 2008; 80:   
 57-61.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#114#110#article#159#</font></p>     ^
cY#a03v37n1.htm##
00535000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028300081002001300364#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#115#111#article#159#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. De Paepe H,    
Renson C, Van Laecke E, Raes A, Vande Walle J, Hoebeke P: Pelvic-floor therapy  
  and toilet training in young children with dysfunctional voiding and obstipati
on.    BJU Int. 2000; 85: 889-93.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#116#112#article#159#</font></p>     ^
cY#a03v37n1.htm##
00467000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021500081002001300296#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#117#113#article#159#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Robson WL,    L
eung AK, Van Howe R: Primary and secondary nocturnal enuresis: similarities    i
n presentation. Pediatrics. 2005; 115: 956-9.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#118#114#article#159#</font></p>     ^
cY#a03v37n1.htm##
00516000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026400081002001300345#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#119#115#article#159#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Kasirga E,    A
kil I, Yilmaz O, Polat M, G&ouml;zmen S, Egemen A: Evaluation of voiding dysfunc
tions    in children with chronic functional constipation. Turk J Pediatr. 2006;
 48:    340-3.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#120#116#article#159#</font></p>     ^
cY#a03v37n1.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023800081002001300319#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#121#117#article#159#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Erickson BA,   
 Austin JC, Cooper CS, Boyt MA: Polyethylene glycol 3350 for constipation in    
children with dysfunctional elimination. J Urol. 2003; 170: 1518-20.    ^cY#a03v
37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#122#118#article#159#</font></p>     ^
cY#a03v37n1.htm##
00503000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025100081002001300332#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#123#119#article#159#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Lucanto C,    B
auer SB, Hyman PE, Flores AF, Di Lorenzo C: Function of hollow viscera in childr
en    with constipation and voiding difficulties. Dig Dis Sci. 2000; 45: 1274-80
.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#124#120#article#159#</font></p>     ^
cY#a03v37n1.htm##
00554000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030200081002001300383#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#125#121#article#159#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Chrzan R, Klijn
    AJ, Vijverberg MA, Sikkel F, de Jong TP: Colonic washout enemas for persiste
nt    constipation in children with recurrent urinary tract infections based on 
dysfunctional    voiding. Urology. 2008; 71: 607-10.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#126#122#article#159#</font></p>     ^
cY#a03v37n1.htm##
00609000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704035700081002001300438#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#127#123#article#159#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Ewings P, Spenc
er    S, Marsh H, O'Sullivan M: Obstetric risk factors for urinary incontinence 
   and preventative pelvic floor exercises: cohort study and nested randomized  
  controlled trial. J Obstet Gynaecol. 2005; 25: 558-64. Erratum in: J Obstet   
 Gynaecol. 2005; 25: 834-5.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#128#124#article#159#</font></p>     ^
cY#a03v37n1.htm##
00496000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024400081002001300325#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#129#125#article#159#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Ng SC, Chen    
YC, Lin LY, Chen GD: Anorectal dysfunction in women with urinary incontinence   
 or lower urinary tract symptoms. Int J Gynaecol Obstet. 2002; 77: 139-45.    ^c
Y#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#130#126#article#159#</font></p>     ^
cY#a03v37n1.htm##
00516000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026400081002001300345#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#131#127#article#159#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Spence-Jones   
 C, Kamm MA, Henry MM, Hudson CN: Bowel dysfunction: a pathogenic factor in uter
ovaginal    prolapse and urinary stress incontinence. Br J Obstet Gynaecol. 1994
; 101: 147-52.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#132#128#article#159#</font></p>     ^
cY#a03v37n1.htm##
00504000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025200081002001300333#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#133#129#article#159#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Faaborg PM,    
Christensen P, Finnerup N, Laurberg S, Krogh K: The pattern of colorectal dysfun
ction    changes with time since spinal cord injury. Spinal Cord. 2008; 46: 234-
8.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#134#130#article#159#</font></p>     ^
cY#a03v37n1.htm##
00464000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021200081002001300293#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#135#131#article#159#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Pannek J, G&oum
l;cking    K, Bersch U: 'Neurogenic' urinary tract dysfunction: don't    overloo
k the bowel!. Spinal Cord. 2009; 47: 93-4.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#136#132#article#159#</font></p>     ^
cY#a03v37n1.htm##
00650000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704039800081002001300479#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#137#133#article#159#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Karatzoglou    
P, Karagiannidis A, Kountouras J, Christofiridis CV, Karavalaki M, Zavos C,    e
t al.: Von Recklinghausen's disease associated with malignant peripheral    nerv
e sheath thmor presenting with constipation and urinary retention: a case    rep
ort and review of the literature. Anticancer Res. 2008; 28: 3107-13.    ^cY#a03v
37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#138#134#article#159#</font></p>     ^
cY#a03v37n1.htm##
00464000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021200081002001300293#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#139#135#article#159#28#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Gividen J,    V
an Savage JG: Improvement in neurogenic bladder after the antegrade continence  
  enema procedure. Urology. 2002; 59: 137.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#140#136#article#159#</font></p>     ^
cY#a03v37n1.htm##
00450000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019800081002001300279#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#141#137#article#159#29#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Milne HJ: An   
 unusual cause of constipation presenting to the emergency department. Eur J    
Emerg Med. 2006; 13: 119-21.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#142#138#article#159#</font></p>     ^
cY#a03v37n1.htm##
00472000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022000081002001300301#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#143#139#article#159#30#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Merenda L,    B
rown JP: Bladder and bowel management for the child with spinal cord dysfunction
.    J Spinal Cord Med. 2004; 27(Suppl 1): S16-23.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#144#140#article#159#</font></p>     ^
cY#a03v37n1.htm##
00551000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029900081002001300380#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#145#141#article#159#31#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Wyndaele JJ,   
 Kovindha A, Madersbacher H, et al.: Neurologic Urinary and Faecal Incontinence.
    In: Abrams P, Cardozo L, Khoury S, Wein A (ed.), Incontinence. Paris, Health
    Publication Ltd. 2009; Committee 10, pp. 797.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#146#142#article#159#</font></p>     ^
cY#a03v37n1.htm##
00467000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021500081002001300296#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#147#143#article#159#32#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. O'Regan    S, Y
azbeck S, Hamberger B, Schick E: Constipation a commonly unrecognized cause    o
f enuresis. Am J Dis Child. 1986; 140: 260-1.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#148#144#article#159#</font></p>     ^
cY#a03v37n1.htm##
00534000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028200081002001300363#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#149#145#article#159#33#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Irvine EJ,    F
errazzi S, Pare P, Thompson WG, Rance L: Health-related quality of life in    fu
nctional GI disorders: focus on constipation and resource utilization. Am    J G
astroenterol. 2002; 97: 1986-93.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#150#146#article#159#</font></p>     ^
cY#a03v37n1.htm##
00584000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033200081002001300413#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#151#147#article#159#34#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Koelbl H, Nitti
    V, Baessler K, et al.: Pathophysiology of Urinary Incontinence, Faecal Incon
tinence    and Pelvic Organ Prolapse. In: Abrams P, Cardozo L, Khoury S, Wein A 
(ed.),    Incontinence. Paris, Health Publication Ltd. 2009; Committee 4, pp. 28
3.    ^cY#a03v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#152#148#article#159#</font></p>     ^
cY#a03v37n1.htm##
00578000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032600081002001300407#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#153#149#article#159#35#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Norton C, White
head    W, Bliss DZ, et al.: Conservative and Pharmacological Management of Faec
al Incontinence    in Adults. In: Abrams P, Cardozo L, Khoury S, Wein A (ed.), I
ncontinence. Paris,    Health Publication Ltd. 2009; Committee 16, pp. 1333.    
^cY#a03v37n1.htm##
00265000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002800078002001300106#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#154#150#article#159#<br>   </font> </
p>     ^cY#a03v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#155#151#article#159#<p>&nbsp;</p>    
 ^cY#a03v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#156#152#article#159#<p>&nbsp;</p>    
 ^cY#a03v37n1.htm##
00367000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704013000078002001300208#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#157#153#article#159#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><i>Accepted after    revision: Jun
e 7, 2010</i></font></p>     ^cY#a03v37n1.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019300078002001300271#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#158#154#article#159#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><b><a name="end"></a><a href="#top
"><img src="/img/revistas/ibju/v37n1/seta.gif" border="0"></a>    Correspondence
 to</b>:    ^cY#a03v37n1.htm##
00286000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004900078002001300127#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#159#155#article#159#<br>   Dr. M&aacu
te;rcio Augusto Averbeck    ^cY#a03v37n1.htm##
00297000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006000078002001300138#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#160#156#article#159#<br>   Rua Soleda
de, 569 Bairro Tr&ecirc;s Figueiras    ^cY#a03v37n1.htm##
00287000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005000078002001300128#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#161#157#article#159#<br>   Porto Aleg
re, RS, 90470-340, Brazil    ^cY#a03v37n1.htm##
00274000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003700078002001300115#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#162#158#article#159#<br>   Fax: + 55 
51 3378-9996    ^cY#a03v37n1.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010500078002001300183#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a03v37n1.htm#S#p#163#159#article#159#<br>   E-mail: <a
 href="mailto:marcioaverbeck@gmail.com">marcioaverbeck@gmail.com</a></font></p> 
    ^cY#a03v37n1.htm##
00645000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100020000940100
02000114010001800134010001900152012008200171030001200253065000900265064000500274
031000300279014000500282865000900287002001300296035001000309801001200319#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#c#164#1#article#35#1#^rND^sChar
ach^nG#^rND^sGreenstein^nA#^rND^sRabinovich^nP#^rND^sGroskopf^nI#^rND^sWeintraub
^nM#Alleviating constipation in the elderly improves lower urinary tract symptom
s^len#Gerontology#20010000#2001#47#72-6#20110200#a03v37n1.htm#0304-324X#Gerontol
ogy##
00627000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100018000940100
01600112010001600128012008300144030002100227065000900248064000500257031000300262
014000700265865000900272002001300281035001000294801002100304#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a03v37n1.htm#S#c#165#2#article#35#2#^rND^sBuntzen^nS#^rND^
sNordgren^nS#^rND^sDelbro^nD#^rND^sHultén^nL#Anal and rectal motility responses 
to distension of the urinary bladder in man^len#Int J Colorectal Dis#19950000#19
95#10#148-51#20110200#a03v37n1.htm#0179-1958#Int J Colorectal Dis##
00511000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770120070000960300
00400166065000900170064000500179031000300184032000400187014000600191865000900197
002001300206035001000219801000400229#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
3v37n1.htm#S#c#166#3#article#35#3#^rND^sDrossman^nDA#The functional gastrointest
inal disorders and the Rome II process^len#Gut#19990000#1999#45#^s2#II1-5#201102
00#a03v37n1.htm#0017-5749#Gut##
00565000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100014000960100
01400110010001300124012003500137030001700172065000900189064000500198031000400203
014000700207865000900214002001300223035001000236801001700246#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a03v37n1.htm#S#c#167#4#article#35#4#^rND^sBharucha^nAE#^rN
D^sWald^nA#^rND^sEnck^nP#^rND^sRao^nS#Functional anorectal disorders^len#Gastroe
nterology#20060000#2006#130#1510-8#20110200#a03v37n1.htm#0016-5085#Gastroenterol
ogy##
00650000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750110069000770650009001460640
00500155012009000160030001900250065000900269064000500278031000400283032000400287
014000600291865000900297002001300306035001000319801001900329#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a03v37n1.htm#S#c#168#5#article#35#5#American College of Ga
stroenterology Chronic Constipation Task Force#20050000#2005#An evidence-based a
pproach to the management of chronic constipation in North America^len#Am J Gast
roenterol#20050000#2005#100#^s1#S1-S4#20110200#a03v37n1.htm#0002-9270#Am J Gastr
oenterol##
00636000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100015000930100
01600108010001900124010002400143010001500167012004800182030001200230065000900242
06400050025103100030025603100070025986500090026600200130027503500100028880100120
0298#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#c#169#6#article#35#
6#^rND^sVarma^nMG#^rND^sHart^nSL#^rND^sBrown^nJS#^rND^sCreasman^nJM#^rND^sVan De
n Eeden^nSK#^rND^sThom^nDH#Obstructive defecation in middle-aged women^len#Dig D
is Sci#20080000#2008#53#2702-9#20110200#a03v37n1.htm#0163-2116#Dig Dis Sci##
00722000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100019000930100
01900112010001800131010002000149010001700169810000600186012009700192030002000289
06500090030906400050031803100040032301400050032786500090033200200130034103500100
0354801002000364#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#c#170#7
#article#35#7#^rND^sSoligo^nM#^rND^sSalvatore^nS#^rND^sEmmanuel^nAV#^rND^sDe Pon
ti^nE#^rND^sZoccatelli^nM#^rND^sCortese^nM#et al#Patterns of constipation in uro
gynecology: clinical importance and pathophysiologic insights^len#Am J Obstet Gy
necol#20060000#2006#195#50-5#20110200#a03v37n1.htm#0002-9378#Am J Obstet Gynecol
##
00530000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770120092000940300
01100186065000900197064000500206031000300211014000700214865000900221002001300230
035001000243801001100253#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S
#c#171#8#article#35#8#^rND^sKistner^nM#Dysfunctional elimination behaviors and a
ssociated complications in school-age children^len#J Sch Nurs#20090000#2009#25#1
08-16#20110200#a03v37n1.htm#1059-8405#J Sch Nurs##
00580000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100015000930100
01800108010001300126010001600139012004000155030000700195065000900202064000500211
031000400216014000700220865000900227002001300236035001000249801000700259#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#c#172#9#article#35#9#^rND^sChas
e^nJW#^rND^sHomsy^nY#^rND^sSiggaard^nC#^rND^sSit^nF#^rND^sBower^nWF#Functional c
onstipation in children^len#J Urol#20040000#2004#171#2641-3#20110200#a03v37n1.ht
m#0022-5347#J Urol##
00574000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100024000790120126001030300
01100229065000900240064000500249031000400254014000700258865000900265002001300274
035001000287801001100297#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S
#c#173#10#article#35#10#^rND^sLoening-Baucke^nV#Urinary incontinence and urinary
 tract infection and their resolution with treatment of chronic constipation of 
childhood^len#Pediatrics#19970000#1997#100#228-32#20110200#a03v37n1.htm#0031-400
5#Pediatrics##
00633000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
01600116012010800132030002400240065000900264064000500273031000300278014000600281
865000900287002001300296035001000309801002400319#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a03v37n1.htm#S#c#174#11#article#35#11#^rND^sMcGrath^nKH#^rND^sCaldwell
^nPH#^rND^sJones^nMP#The frequency of constipation in children with nocturnal en
uresis: a comparison with parental reporting^len#J Paediatr Child Health#2008000
0#2008#44#19-27#20110200#a03v37n1.htm#1034-4810#J Paediatr Child Health##
00699000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100019000940100
01300113010001800126010001700144010001800161810000600179012013200185030000800317
71000020032506500090032706400050033603100030034101400070034486500090035100200130
0360#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#c#175#12#article#35
#12#^rND^sBael^nAM#^rND^sBenninga^nMA#^rND^sLax^nH#^rND^sBachmann^nH#^rND^sJanhs
en^nE#^rND^sDe Jong^nTP#et al#Functional urinary and fecal incontinence in neuro
logically normal children: symptoms of one 'functional elimination disorder'?^le
n#BJU Int#2#20070000#2007#99#407-12#20110200#a03v37n1.htm##
00627000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01900111012013500130030000700265065000900272064000500281031000400286014000800290
865000900298002001300307035001000320801000700330#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a03v37n1.htm#S#c#176#13#article#35#13#^rND^sKoff^nSA#^rND^sWagner^nTT#
^rND^sJayanthi^nVR#The relationship among dysfunctional elimination syndromes, p
rimary vesicoureteral reflux and urinary tract infections in children^len#J Urol
#19980000#1998#160#1019-22#20110200#a03v37n1.htm#0022-5347#J Urol##
00528000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100024000790120074001030300
01500177065000900192064000500201031000300206014000600209865000900215002001300224
035001000237801001500247#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S
#c#177#14#article#35#14#^rND^sLoening-Baucke^nV#Prevalence rates for constipatio
n and faecal and urinary incontinence^len#Arch Dis Child#20070000#2007#92#486-9#
20110200#a03v37n1.htm#0003-9888#Arch Dis Child##
00628000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100014000970100
01900111010001400130012010900144030000900253065000900262064000500271031000300276
014000600279865000900285002001300294035001000307801000900317#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a03v37n1.htm#S#c#178#15#article#35#15#^rND^sKajiwara^nM#^r
ND^sKato^nM#^rND^sMutaguchi^nK#^rND^sUsui^nT#Overactive bladder in children shou
ld be strictly differentiated from monosymptomatic nocturnal enuresis^len#Urol I
nt#20080000#2008#80#57-61#20110200#a03v37n1.htm#0042-1138#Urol Int##
00661000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
02000113010001400133010002100147010001700168012010600185030000800291710000200299
065000900301064000500310031000300315014000700318865000900325002001300334#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#c#179#16#article#35#16#^rND^sDe
 Paepe^nH#^rND^sRenson^nC#^rND^sVan Laecke^nE#^rND^sRaes^nA#^rND^sVande Walle^nJ
#^rND^sHoebeke^nP#Pelvic-floor therapy and toilet training in young children wit
h dysfunctional voiding and obstipation^len#BJU Int#2#20000000#2000#85#889-93#20
110200#a03v37n1.htm##
00573000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01800112012007500130030001100205065000900216064000500225031000400230014000600234
865000900240002001300249035001000262801001100272#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a03v37n1.htm#S#c#180#17#article#35#17#^rND^sRobson^nWL#^rND^sLeung^nAK
#^rND^sVan Howe^nR#Primary and secondary nocturnal enuresis: similarities in pre
sentation^len#Pediatrics#20050000#2005#115#956-9#20110200#a03v37n1.htm#0031-4005
#Pediatrics##
00672000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100014000960100
01600110010001500126010001600141010001600157012008800173030001500261065000900276
06400050028503100030029001400060029386500090029900200130030803500100032180100150
0331#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#c#181#18#article#35
#18#^rND^sKasirga^nE#^rND^sAkil^nI#^rND^sYilmaz^nO#^rND^sPolat^nM#^rND^sGözmen^n
S#^rND^sEgemen^nA#Evaluation of voiding dysfunctions in children with chronic fu
nctional constipation^len#Turk J Pediatr#20060000#2006#48#340-3#20110200#a03v37n
1.htm#0041-4301#Turk J Pediatr##
00610000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
01700115010001500132012008900147030000700236065000900243064000500252031000400257
014000800261865000900269002001300278035001000291801000700301#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a03v37n1.htm#S#c#182#19#article#35#19#^rND^sErickson^nBA#^
rND^sAustin^nJC#^rND^sCooper^nCS#^rND^sBoyt^nMA#Polyethylene glycol 3350 for con
stipation in children with dysfunctional elimination^len#J Urol#20030000#2003#17
0#1518-20#20110200#a03v37n1.htm#0022-5347#J Urol##
00646000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01600112010001700128010002000145012008600165030001200251065000900263064000500272
031000300277014000800280865000900288002001300297035001000310801001200320#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#c#183#20#article#35#20#^rND^sLu
canto^nC#^rND^sBauer^nSB#^rND^sHyman^nPE#^rND^sFlores^nAF#^rND^sDi Lorenzo^nC#Fu
nction of hollow viscera in children with constipation and voiding difficulties^
len#Dig Dis Sci#20000000#2000#45#1274-80#20110200#a03v37n1.htm#0163-2116#Dig Dis
 Sci##
00690000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
02100111010001600132010001800148012013800166030000800304065000900312064000500321
031000300326014000700329865000900336002001300345035001000358801000800368#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#c#184#21#article#35#21#^rND^sCh
rzan^nR#^rND^sKlijn^nAJ#^rND^sVijverberg^nMA#^rND^sSikkel^nF#^rND^sde Jong^nTP#C
olonic washout enemas for persistent constipation in children with recurrent uri
nary tract infections based on dysfunctional voiding^len#Urology#20080000#2008#7
1#607-10#20110200#a03v37n1.htm#0090-4295#Urology##
00686000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01500112010002000127012014500147030001800292065000900310064000500319031000300324
014000700327865000900334002001300343035001000356801001800366#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a03v37n1.htm#S#c#185#22#article#35#22#^rND^sEwings^nP#^rND
^sSpencer^nS#^rND^sMarsh^nH#^rND^sO'Sullivan^nM#Obstetric risk factors for urina
ry incontinence and preventative pelvic floor exercises: cohort study and nested
 randomized controlled trial^len#J Obstet Gynaecol#20050000#2005#25#558-64#20110
200#a03v37n1.htm#0144-3615#J Obstet Gynaecol##
00631000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100013000790100015000920100
01400107010001500121012009300136030002200229065000900251064000500260031000300265
014000700268865000900275002001300284035001000297801002200307#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a03v37n1.htm#S#c#186#23#article#35#23#^rND^sNg^nSC#^rND^sC
hen^nYC#^rND^sLin^nLY#^rND^sChen^nGD#Anorectal dysfunction in women with urinary
 incontinence or lower urinary tract symptoms^len#Int J Gynaecol Obstet#20020000
#2002#77#139-45#20110200#a03v37n1.htm#0020-7292#Int J Gynaecol Obstet##
00650000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100015001010100
01600116010001700132012010000149030002100249065000900270064000500279031000400284
014000700288865000900295002001300304035001000317801002100327#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a03v37n1.htm#S#c#187#24#article#35#24#^rND^sSpence-Jones^n
C#^rND^sKamm^nMA#^rND^sHenry^nMM#^rND^sHudson^nCN#Bowel dysfunction: a pathogeni
c factor in uterovaginal prolapse and urinary stress incontinence^len#Br J Obste
t Gynaecol#19940000#1994#101#147-52#20110200#a03v37n1.htm#0306-5456#Br J Obstet 
Gynaecol##
00647000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100021000970100
01800118010001800136010001500154012008500169030001200254065000900266064000500275
031000300280014000600283865000900289002001300298035001000311801001200321#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#c#188#25#article#35#25#^rND^sFa
aborg^nPM#^rND^sChristensen^nP#^rND^sFinnerup^nN#^rND^sLaurberg^nS#^rND^sKrogh^n
K#The pattern of colorectal dysfunction changes with time since spinal cord inju
ry^len#Spinal Cord#20080000#2008#46#234-8#20110200#a03v37n1.htm#1362-4393#SPINAL
 CORD##
00566000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01600112012007000128030001200198065000900210064000500219031000300224014000500227
865000900232002001300241035001000254801001200264#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a03v37n1.htm#S#c#189#26#article#35#26#^rND^sPannek^nJ#^rND^sGöcking^nK
#^rND^sBersch^nU#'Neurogenic' urinary tract dysfunction: don't overlook the bowe
l!^len#Spinal Cord#20090000#2009#47#93-4#20110200#a03v37n1.htm#1362-4393#SPINAL 
CORD##
00818000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100023001000100
02000123010002500143010002000168010001500188810000600203012018400209030001500393
06500090040806400050041703100030042201400080042586500090043300200130044203500100
0455801001500465#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#c#190#2
7#article#35#27#^rND^sKaratzoglou^nP#^rND^sKaragiannidis^nA#^rND^sKountouras^nJ#
^rND^sChristofiridis^nCV#^rND^sKaravalaki^nM#^rND^sZavos^nC#et al#Von Recklingha
usen's disease associated with malignant peripheral nerve sheath thmor presentin
g with constipation and urinary retention: a case report and review of the liter
ature^len#Anticancer Res#20080000#2008#28#3107-13#20110200#a03v37n1.htm#0250-700
5#Anticancer Res##
00549000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100021000960120
08500117030000800202065000900210064000500219031000300224014000400227865000900231
002001300240035001000253801000800263#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
3v37n1.htm#S#c#191#28#article#35#28#^rND^sGividen^nJ#^rND^sVan Savage^nJG#Improv
ement in neurogenic bladder after the antegrade continence enema procedure^len#U
rology#20020000#2002#59#137#20110200#a03v37n1.htm#0090-4295#Urology##
00525000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120076000950300
01600171065000900187064000500196031000300201014000700204865000900211002001300220
035001000233801001600243#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S
#c#192#29#article#35#29#^rND^sMilne^nHJ#An unusual cause of constipation present
ing to the emergency department^len#Eur J Emerg Med#20060000#2006#13#119-21#2011
0200#a03v37n1.htm#0969-9546#Eur J Emerg Med##
00574000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960120
07600112030001800188065000900206064000500215031000300220032000400223014000700227
865000900234002001300243035001000256801001800266#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a03v37n1.htm#S#c#193#30#article#35#30#^rND^sMerenda^nL#^rND^sBrown^nJP
#Bladder and bowel management for the child with spinal cord dysfunction^len#J S
pinal Cord Med#20040000#2004#27#^s1#S16-23#20110200#a03v37n1.htm#1079-0268#J Spi
nal Cord Med##
00662000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
02200116810000600138012004700144016001600191016001700207016001600224016001400240
01800170025406600060027106200230027706500090030006400050030986500090031400200130
0323#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#c#194#31#article#35
#31#^rND^sWyndaele^nJJ#^rND^sKovindha^nA#^rND^sMadersbacher^nH#et al#Neurologic 
Urinary and Faecal Incontinence^len#^rND^sAbrams^nP#^rND^sCardozo^nL#^rND^sKhour
y^nS#^rND^sWein^nA#Incontinence^len#Paris#Health Publication Ltd#20090000#2009#2
0110200#a03v37n1.htm##
00595000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01900113010001600132012005900148030001500207065000900222064000500231031000400236
014000600240865000900246002001300255035001000268801001500278#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a03v37n1.htm#S#c#195#32#article#35#32#^rND^sO'Regan^nS#^rN
D^sYazbeck^nS#^rND^sHamberger^nB#^rND^sSchick^nE#Constipation a commonly unrecog
nized cause of enuresis^len#Am J Dis Child#19860000#1986#140#260-1#20110200#a03v
37n1.htm#0002-922X#Am J Dis Child##
00681000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
01400114010001900128010001500147012011000162030001900272065000900291064000500300
031000300305014000800308865000900316002001300325035001000338801001900348#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#c#196#33#article#35#33#^rND^sIr
vine^nEJ#^rND^sFerrazzi^nS#^rND^sPare^nP#^rND^sThompson^nWG#^rND^sRance^nL#Healt
h-related quality of life in functional GI disorders: focus on constipation and 
resource utilization^len#Am J Gastroenterol#20020000#2002#97#1986-93#20110200#a0
3v37n1.htm#0002-9270#Am J Gastroenterol##
00712000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
01800110810000600128012009100134016001600225016001700241016001600258016001400274
01800170028806600060030506200230031106500090033406400050034301400040034886500090
0352002001300361#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#c#197#3
4#article#35#34#^rND^sKoelbl^nH#^rND^sNitti^nV#^rND^sBaessler^nK#et al#Pathophys
iology of Urinary Incontinence, Faecal Incontinence and Pelvic Organ Prolapse^le
n#^rND^sAbrams^nP#^rND^sCardozo^nL#^rND^sKhoury^nS#^rND^sWein^nA#Incontinence^le
n#Paris#Health Publication Ltd#20090000#2009#283#20110200#a03v37n1.htm##
00705000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100019000950100
01600114810000600130012008100136016001600217016001700233016001600250016001400266
01800170028006600060029706200230030306500090032606400050033501400050034086500090
0345002001300354#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a03v37n1.htm#S#c#198#3
5#article#35#35#^rND^sNorton^nC#^rND^sWhitehead^nW#^rND^sBliss^nDZ#et al#Conserv
ative and Pharmacological Management of Faecal Incontinence in Adults^len#^rND^s
Abrams^nP#^rND^sCardozo^nL#^rND^sKhoury^nS#^rND^sWein^nA#Incontinence^len#Paris#
Health Publication Ltd#20090000#2009#1333#20110200#a03v37n1.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#o#1#1#article#1
#20110330#144455#a04v37n1.htm#141##
02645000000000481000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030001800108
03100030012603200020012906500090013101400090014003500100014901200610015901000290
02200100024002490100025002730100031002980100033003290700074003620831622004360850
01002058085002802068085002302096085002202119117000602141072000302147002001302150
#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#h#2#1#article#1#oa#en#b
r1.1#1#4.0#TAB#04#IBJU010#nd#Int. braz j urol.#37#1#20110200#^f29^l34#1677-5538#
Rate of renal cell carcinoma subtypes in different races^len#^rND^1A01^nAlexande
r^sSankin#^rND^1A01^nJacob^sCohen#^rND^1A01^nHongbei^sWang#^rND^1A01^nRichard J.
^sMacchia#^rND^1A01^nNicholas^sKaranikolas#State University of New York Downstat
e Medical School^iA01^sNew York^pUSA#^len^aPURPOSE: We sought to identify racial
 differences among histological subtypes of renal cell carcinoma (RCC) between b
lack and non-black patients in an equal-access health care system. MATERIALS AND
 METHODS: We established a multi-institutional, prospective database of patients
 undergoing partial or radical nephrectomy between January 1, 2000 and Sept 31, 
2009. For the purposes of this study, data captured included age at diagnosis, r
ace, tumor size, presence of lymphovascular invasion, presence of capsular invas
ion, margin status, and tumor histology. RESULTS: 204 kidney tumors were identif
ied (Table-1). Of these, 117 (57.4%) were in black patients and 87 (42.6%) were 
in non-black patients. Age at surgery ranged from 37 to 87 with a median of 62. 
Tumor size ranged from 1.0 to 22.0 cm with a median of 5.0 cm. Overall, tumors w
ere composed of clear cell RCC in 97 cases (47.5%), papillary RCC in 65 cases (3
1.9%), chromophobe RCC in 13 cases (6.4%), collecting duct/medullary RCC in 2 ca
ses (1.0%), RCC with multiple histological subtypes in 8 cases (3.9%), malignant
 tumors of other origin in 6 cases (2.9%), and benign histology in 13 cases (6.4
%). Among black patients, papillary RCC was seen in 56 cases (47.9%), compared t
o 9 cases (10.3%) among non-black patients (p < 0.001) (Table-2). Clear cell RCC
 was present in 38 (32.5%) of black patients and in 59 (67.8%) of non-blacks (p 
< 0.001). CONCLUSIONS: In our study, papillary RCC had a much higher occurrence 
among black patients compared to non-black patients. This is the first study to 
document such a great racial disparity among RCC subtypes.#^ddecs^i1#^tm^len^kki
dney neoplasm^i1#^tm^len^krenal cell^i1#^tm^len^kcarcinoma^i1#other#19#a04v37n1.
htm##
02737000000000481000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030001800108
03100030012603200020012906500090013101400090014003500100014901200680015901000290
02270100024002560100025002800100031003050100033003360700074003690831707004430850
01002150085002802160085002302188085002202211117000602233072000302239002001302242
#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#f#3#1#article#1#oa#en#b
r1.1#1#4.0#TAB#04#IBJU010#nd#Int. braz j urol.#37#1#20110200#^f29^l34#1677-5538#
<b>Rate of renal cell carcinoma subtypes in different races</b>^len#^rND^1A01^nA
lexander^sSankin#^rND^1A01^nJacob^sCohen#^rND^1A01^nHongbei^sWang#^rND^1A01^nRic
hard J.^sMacchia#^rND^1A01^nNicholas^sKaranikolas#State University of New York D
ownstate Medical School^iA01^sNew York^pUSA#^len^a<b>PURPOSE:</b> We sought to i
dentify racial differences among histological subtypes of renal cell carcinoma (
RCC) between black and non-black patients in an equal-access health care system.
 <b>MATERIALS AND METHODS:</b> We established a multi-institutional, prospective
 database of patients undergoing partial or radical nephrectomy between January 
1, 2000 and Sept 31, 2009. For the purposes of this study, data captured include
d age at diagnosis, race, tumor size, presence of lymphovascular invasion, prese
nce of capsular invasion, margin status, and tumor histology. <b>RESULTS:</b> 20
4 kidney tumors were identified (<a href="/img/revistas/ibju/v37n1/a04tab1.jpg">
Table-1</a>). Of these, 117 (57.4%) were in black patients and 87 (42.6%) were i
n non-black patients. Age at surgery ranged from 37 to 87 with a median of 62. T
umor size ranged from 1.0 to 22.0 cm with a median of 5.0 cm. Overall, tumors we
re composed of clear cell RCC in 97 cases (47.5%), papillary RCC in 65 cases (31
.9%), chromophobe RCC in 13 cases (6.4%), collecting duct/medullary RCC in 2 cas
es (1.0%), RCC with multiple histological subtypes in 8 cases (3.9%), malignant 
tumors of other origin in 6 cases (2.9%), and benign histology in 13 cases (6.4%
). Among black patients, papillary RCC was seen in 56 cases (47.9%), compared to
 9 cases (10.3%) among non-black patients (p &lt; 0.001) (Table-2). Clear cell R
CC was present in 38 (32.5%) of black patients and in 59 (67.8%) of non-blacks (
p &lt; 0.001). <b>CONCLUSIONS:</b> In our study, papillary RCC had a much higher
 occurrence among black patients compared to non-black patients. This is the fir
st study to document such a great racial disparity among RCC subtypes.#^ddecs^i1
#^tm^len^kkidney neoplasm^i1#^tm^len^krenal cell^i1#^tm^len^kcarcinoma^i1#other#
19#a04v37n1.htm##
02867000000000505000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000400108121000300112049000800115158000300123
03000170012603100030014303200020014606500090014801400090015703500100016601200610
01760100029002370100024002660100025002900100030003150100033003450700076003780831
71300454085001002167085002802177085002302205085002202228117000602250072000302256
002001302259008008902272#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S
#l#4#1#article#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#tab#04#IBJU010#nd#Int. braz
 j urol#37#1#20110200#^f29^l34#1677-5538#Rate of renal cell carcinoma subtypes i
n different races^len#^rND^1A01^nAlexander^sSankin#^rND^1A01^nJacob^sCohen#^rND^
1A01^nHongbei^sWang#^rND^1A01^nRichard J^sMacchia#^rND^1A01^nNicholas^sKaranikol
as#^iA01^1State University of New York Downstate Medical School^sNew York^pUSA#^
len^aPURPOSE: We sought to identify racial differences among histological subtyp
es of renal cell carcinoma (RCC) between black and non-black patients in an equa
l-access health care system. MATERIALS AND METHODS: We established a multi-insti
tutional, prospective database of patients undergoing partial or radical nephrec
tomy between January 1, 2000 and Sept 31, 2009. For the purposes of this study, 
data captured included age at diagnosis, race, tumor size, presence of lymphovas
cular invasion, presence of capsular invasion, margin status, and tumor histolog
y. RESULTS: 204 kidney tumors were identified (Table-1). Of these, 117 (57.4 per
cent) were in black patients and 87 (42.6 percent) were in non-black patients. A
ge at surgery ranged from 37 to 87 with a median of 62. Tumor size ranged from 1
.0 to 22.0 cm with a median of 5.0 cm. Overall, tumors were composed of clear ce
ll RCC in 97 cases (47.5 percent), papillary RCC in 65 cases (31.9 percent), chr
omophobe RCC in 13 cases (6.4 percent), collecting duct/medullary RCC in 2 cases
 (1.0 percent), RCC with multiple histological subtypes in 8 cases (3.9 percent)
, malignant tumors of other origin in 6 cases (2.9 percent), and benign histolog
y in 13 cases (6.4 percent). Among black patients, papillary RCC was seen in 56 
cases (47.9 percent), compared to 9 cases (10.3 percent) among non-black patient
s (p < 0.001) (Table-2). Clear cell RCC was present in 38 (32.5 percent) of blac
k patients and in 59 (67.8 percent) of non-blacks (p < 0.001). CONCLUSIONS: In o
ur study, papillary RCC had a much higher occurrence among black patients compar
ed to non-black patients. This is the first study to document such a great racia
l disparity among RCC subtypes.#^ddecs^i1#^tm^len^kkidney neoplasm^i1#^tm^len^kr
enal cell^i1#^tm^len^kcarcinoma^i1#other#19#a04v37n1.htm#Internet^ihttp://www.sc
ielo.br/scielo.php?script=sci_arttext&pid=S1677-55382011000100004##
00356000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012300074002001300197#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#5#1#article#118#<p align="right"><fon
t face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>CLINICAL    UROLOGY</
b></font></p>     ^cY#a04v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#6#2#article#118#<p>&nbsp;</p>     ^cY
#a04v37n1.htm##
00474000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704024100074002001300315#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#7#3#article#118#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><b><a name="top"></a></b></font><font 
size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Rate    of renal cell c
arcinoma subtypes in different races</b></font></p>     ^cY#a04v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#8#4#article#118#<p>&nbsp;</p>     ^cY
#a04v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#9#5#article#118#<p>&nbsp;</p>     ^cY
#a04v37n1.htm##
00412000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704017800075002001300253#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#10#6#article#118#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Alexander    Sankin; Jacob Cohen; 
Hongbei Wang; Richard J. Macchia; Nicholas Karanikolas</b></font></p>     ^cY#a0
4v37n1.htm##
00398000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704016400075002001300239#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#11#7#article#118#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">State University    of New York Downs
tate Medical School, Brooklyn, New York, USA</font></p>     ^cY#a04v37n1.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011600075002001300191#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#12#8#article#118#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#end">Correspondence</a></fo
nt></p>     ^cY#a04v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#13#9#article#118#<p>&nbsp;</p>     ^c
Y#a04v37n1.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#14#10#article#118#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a04v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#15#11#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#a
04v37n1.htm##
00505000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027000076002001300346#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#16#12#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>PURPOSE:</b>    We sought to iden
tify racial differences among histological subtypes of renal    cell carcinoma (
RCC) between black and non-black patients in an equal-access    health care syst
em.    ^cY#a04v37n1.htm##
00642000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040700076002001300483#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#17#13#article#118#<br>   <b>MATERIALS
 AND METHODS:</b> We established a multi-institutional, prospective    database 
of patients undergoing partial or radical nephrectomy between January    1, 2000
 and Sept 31, 2009. For the purposes of this study, data captured included    ag
e at diagnosis, race, tumor size, presence of lymphovascular invasion, presence 
   of capsular invasion, margin status, and tumor histology.    ^cY#a04v37n1.htm
##
01192000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704095700076002001301033#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#18#14#article#118#<br>   <b>RESULTS:<
/b> 204 kidney tumors were identified (<a href="/img/revistas/ibju/v37n1/a04tab1
.jpg">Table-1</a>).    Of these, 117 (57.4%) were in black patients and 87 (42.6
%) were in non-black    patients. Age at surgery ranged from 37 to 87 with a med
ian of 62. Tumor size    ranged from 1.0 to 22.0 cm with a median of 5.0 cm. Ove
rall, tumors were composed    of clear cell RCC in 97 cases (47.5%), papillary R
CC in 65 cases (31.9%), chromophobe    RCC in 13 cases (6.4%), collecting duct/m
edullary RCC in 2 cases (1.0%), RCC    with multiple histological subtypes in 8 
cases (3.9%), malignant tumors of other    origin in 6 cases (2.9%), and benign 
histology in 13 cases (6.4%). Among black    patients, papillary RCC was seen in
 56 cases (47.9%), compared to 9 cases (10.3%)    among non-black patients (p &l
t; 0.001) (Table-2). Clear cell RCC was present    in 38 (32.5%) of black patien
ts and in 59 (67.8%) of non-blacks (p &lt; 0.001).    ^cY#a04v37n1.htm##
00483000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024800076002001300324#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#19#15#article#118#<br>   <b>CONCLUSIO
NS:</b> In our study, papillary RCC had a much higher occurrence    among black 
patients compared to non-black patients. This is the first study    to document 
such a great racial disparity among RCC subtypes.</font></p>     ^cY#a04v37n1.ht
m##
00399000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016400076002001300240#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#20#16#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Key words:</b>    kidney neoplasm
; renal cell; carcinoma</font></p> <HR size="1" noshade>     ^cY#a04v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#21#17#article#118#<p>&nbsp;</p>     ^
cY#a04v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#22#18#article#118#<p>&nbsp;</p>     ^
cY#a04v37n1.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#23#19#article#118#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODUCTION</b></font></p>     ^
cY#a04v37n1.htm##
01237000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704100200076002001301078#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#24#20#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Renal cell carcinoma    (RCC) is the
 seventh most common human malignancy, having accounted for approximately    59,
702 new cancer cases in the United States in 2009 (1). The histological classifi
cation    of RCC has undergone several major revisions, with the current 2004 Wo
rld Health    Organization (WHO) guidelines incorporating new cytogenetic findin
gs and molecular    markers that help guide diagnosis, prognosis, and therapy (2
). RCC is now recognized    to be a complex neoplasm consisting of several diffe
rent tumor subtypes, each    with distinct genetic and clinical features. Previo
us population-based studies    on racial differences in incidence patterns and o
utcomes of RCC have failed    to account for the different histological subtypes
 of RCC (3). We sought to    identify racial differences in the patterns of hist
ological subtypes of RCC    in a racially diverse, equal-access health care syst
em.</font></p>     ^cY#a04v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#25#21#article#118#<p>&nbsp;</p>     ^
cY#a04v37n1.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011400076002001300190#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#26#22#article#118#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>MATERIALS    AND METHODS</b></fon
t></p>     ^cY#a04v37n1.htm##
01210000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704097500076002001301051#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#27#23#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> We performed a    multi-institution
al, retrospective review of patients undergoing partial or    radical nephrectom
y between January 1<sup>st</sup>, 2000 and Sept 31<sup>st</sup>,    2009. Our ho
spitals included a tertiary care academic center, a veteran's administration    
hospital, and an inner-city county hospital, ensuring a mixed ethnic population.
    All slides underwent centralized pathology review using the WHO 2004 Classif
ication    of renal cell histology to classify tumors into clear cell, papillary
, chromophobe,    or medullary/collecting duct varieties. We did not differentia
te between papillary    RCC type 1 and papillary RCC type 2. Data was collected 
by reviewing patient    charts and capturing the following parameters: age at di
agnosis, race, tumor    size, presence of lymphovascular invasion, presence of c
apsular invasion, margin    status, and tumor histology.</font></p>     ^cY#a04v
37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#28#24#article#118#<p>&nbsp;</p>     ^
cY#a04v37n1.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010100076002001300177#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#29#25#article#118#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" suze="3"><b>RESULTS</b>    </font></p>     ^c
Y#a04v37n1.htm##
00740000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050500076002001300581#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#30#26#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Two hundred and    four kidney tumo
rs were identified (<a href="/img/revistas/ibju/v37n1/a04tab1.jpg">Table-1</a>).
    Of these, 117 (57.4%) were in black patients and 87 (42.6%) were in non-blac
k    patients. Age at surgery ranged from 37 to 87 with a median age of 62. Amon
g    black patients the age range was 37 to 82 with a median of 63 and among non
-black    patients the age range was 40 to 87 with a median of 60.</font></p>   
  ^cY#a04v37n1.htm##
00717000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048200076002001300558#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#31#27#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Tumor size ranged    from 1.0 to 22.
0 cm with a median of 5.0 cm. The size of tumors among blacks    ranged from 1.4
 to 20.0 cm and from 1.0 to 22.0 cm in non-blacks. There was    no statistically
 significant difference in tumor size between blacks and non-blacks    when subd
ivided into groups of 4 cm or less, greater than 4 cm and less than    or equal 
to 7 cm, and greater than 7 cm ( p = 0.25).</font></p>     ^cY#a04v37n1.htm##
00558000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032300076002001300399#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#32#28#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The majority of    tumors in blacks 
and non-blacks had absence of lymphovascular invasion (4.3%    and 11.9%, p = 0.
05), absence of capsular invasion (91.3% and 86.9%, p = 0.32),    and negative s
urgical margins (94.8% and 94.0%, p = 0.82).</font></p>     ^cY#a04v37n1.htm##
00985000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704075000076002001300826#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#33#29#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Overall, tumors    were composed of 
clear cell RCC in 97 cases (47.5%), papillary RCC in 65 cases    (31.9%), chromo
phobe RCC in 13 cases (6.4%), collecting duct/medullary RCC in    2 cases (1.0%)
, RCC with multiple histological subtypes in 8 cases (3.9%), malignant    tumors
 of other origin in 6 cases (2.9%), and benign histology in 13 cases (6.4%).    
Among black patients, papillary RCC was seen in 56 cases (47.9%), compared to   
 9 cases (10.3%) among non-black patients (p &lt; 0.001) (<a href="/img/revistas
/ibju/v37n1/a04tab2.jpg">Table-2</a>).    Clear cell RCC was present in 38 (32.5
%) of black patients and in 59 (67.8%)    of non-blacks (p &lt; 0.001).</font></
p>     ^cY#a04v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#34#30#article#118#<p>&nbsp;</p>     ^
cY#a04v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#35#31#article#118#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>COMMENTS</b></font></p>     ^cY#a
04v37n1.htm##
00533000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029800076002001300374#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#36#32#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Our study found    a greater than f
our-fold increase in occurrence of papillary RCC in blacks when    compared to n
on-blacks. This is the first study to document such a large ethnic    disparity 
among RCC subtypes.</font></p>     ^cY#a04v37n1.htm##
00787000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055200076002001300628#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#37#33#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This phenomenon    of neoplastic var
iability among different races has been observed in other urologic    cancers. P
rostate cancer is a well-studied malignancy that tends to behave differently    
among different races. Compared with whites, blacks are more likely to be diagno
sed    with prostate cancer at a younger age (4). Black patients with prostate c
ancer    are also less likely to be treated with surgical intervention and have 
an overall    lower survival (5).</font></p>     ^cY#a04v37n1.htm##
01261000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704102600076002001301102#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#38#34#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">There are many    previously reporte
d, large, population-based studies elucidating the racial    disparities among p
atients with RCC. These reports, however, have focused on    topics such as over
all survival and access to health care. A recent paper by    Stafford et al. fou
nd that blacks had an overall increase in incidence of renal    cell carcinoma a
nd decrease in survival rate when compared to other ethnicities    (6). Zini et 
al. concluded that black patients with RCC were 50% less likely    to undergo ne
phrectomy compared to white patients (7). A study by Brendt et    al. also addre
sses the lower survival rate among blacks with renal cell carcinoma    and propo
ses that this may be explained by both a higher number of comorbidities    and l
ower rate of surgical treatment (8). While these studies have unearthed    many 
interesting data trends among RCC cases, none have included information    on hi
stological subtypes of RCC.</font></p>     ^cY#a04v37n1.htm##
01069000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704083400076002001300910#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#39#35#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Beyond the well-described    associa
tion or renal medullary carcinoma with sickle-cell disease and trait    in black
 patients, there has been very little reported regarding racial differences    f
or the other RCC histologies (9). Historically, clear cell tumors have accounted
    for 70-80% of RCC, followed by 10-15% for papillary, 3-5% for chromophobe, a
nd    1-2% for medullary/collecting duct (10). Our reported 47.9% incidence of p
apillary    tumors among black patients is the first of its kind and is more tha
n four-fold    the incidence of papillary tumors among non-black patients in our
 study. One    explanation for this observation may be a genomic predisposition 
for blacks    to express genes unique for the development of papillary RCC.</fon
t></p>     ^cY#a04v37n1.htm##
01401000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704116600076002001301242#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#40#36#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Papillary RCC is    commonly found i
n two classic genetic syndromes, hereditary papillary RCC and    hereditary leio
myomatosis and renal cell cancer syndrome. Papillary tumors have    also previou
sly been reported to be associated with acquired renal cystic disease.    The ch
romosomal abnormalities for papillary tumors are distinct from the chromosome   
 3 and Von-Hippel Lindau gene abnormalities of clear cell tumors. Papillary tumo
rs    typically demonstrate trisomy of chromosomes 7 and 17 and loss of the Y ch
romosome.    Mutations in the met-oncogene, which encodes hepatocyte growth fact
or, is the    usual mutation for papillary tumors, which usually display multice
ntricity and    hypovascularity. As expected with the new era of targeted therap
ies for RCC,    unique molecular agents separate from tyrosine kinase inhibitors
 are being developed    for papillary tumors. If black patients with RCC truly h
ave a predisposition    for expression of papillary type tumors, they may benefi
t from early counseling    and treatment with novel agents targeting this unique
 tumor.</font></p>     ^cY#a04v37n1.htm##
00895000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704066000076002001300736#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#41#37#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">More recently,    papillary RCC has 
been subdivided into type 1 and type 2, with type 2 tumors    exhibiting more ag
gressive clinicopathological features and worse prognosis    (11). Our retrospec
tive analysis does not allow statements regarding the influence    of tumor subt
ype on clinical course and prognosis following treatment. As such,    we do not 
present any outcomes data and do not differentiate between subtypes    of papill
ary RCC. Of note, there have been studies demonstrating no differences    in dis
ease-free survival between papillary and clear cell RCC (12).</font></p>     ^cY
#a04v37n1.htm##
00742000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050700076002001300583#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#42#38#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">One must also consider    the possib
le influence of confounding factors on the variable expression of    RCC subtype
s. Previous studies have shown that there is a predisposition among    males and
 patients with end stage renal disease to develop papillary RCC (13,14).    This
 potential bias should be taken into consideration when designing future    stud
ies aimed to capture racial differences observed among RCC subtypes.</font></p> 
    ^cY#a04v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#43#39#article#118#<p>&nbsp;</p>     ^
cY#a04v37n1.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#44#40#article#118#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>CONCLUSION</b></font></p>     ^cY
#a04v37n1.htm##
00895000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704066000076002001300736#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#45#41#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> We report for    the first time, to
 our knowledge, that black patients seem to have an increased    risk of develop
ing papillary RCC than the general population. This result needs    to be confir
med by large, population-based studies that examine different RCC    histologies
 against a wide range of demographic, geographic, and environmental    factors. 
Given the complex genetic and molecular basis for RCC and its role    in respons
e to adjuvant treatments, race and ethnicity may be important factors    when co
unseling patients regarding prognosis and treatment outcomes.</font></p>     ^cY
#a04v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#46#42#article#118#<p>&nbsp;</p>     ^
cY#a04v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#47#43#article#118#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONFLICT    OF INTEREST</b></font
></p>     ^cY#a04v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#48#44#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> None declared.</font></p>     ^cY#a
04v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#49#45#article#118#<p>&nbsp;</p>     ^
cY#a04v37n1.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#50#46#article#118#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFERENCES</b></font></p>     ^cY
#a04v37n1.htm##
00613000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704036400078002001300442#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#51#47#article#118#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. American Cancer    
Society: Cancer Facts &amp; Figures 2009. Atlanta: American Cancer Society 2009.
    Available at. <a href="http://oralcancerfoundation.org/facts/pdf/Us_Cancer_F
acts.pdf%20" target="_blank">http://oralcancerfoundation.org/facts/pdf/Us_Cancer
_Facts.pdf    </a> </font></p>     ^cY#a04v37n1.htm##
00470000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022100078002001300299#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#52#48#article#118#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Lopez-Beltran    A,
 Scarpelli M, Montironi R, Kirkali Z: 2004 WHO classification of the renal    tu
mors of the adults. Eur Urol. 2006; 49: 798-805.    ^cY#a04v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#53#49#article#118#</font></p>     ^cY
#a04v37n1.htm##
00470000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022100078002001300299#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#54#50#article#118#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Vaishampayan    UN,
 Do H, Hussain M, Schwartz K: Racial disparity in incidence patterns and    outc
ome of kidney cancer. Urology. 2003; 62: 1012-7.    ^cY#a04v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#55#51#article#118#</font></p>     ^cY
#a04v37n1.htm##
00503000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025400078002001300332#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#56#52#article#118#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Shao YH, Demissie  
  K, Shih W, Mehta AR, Stein MN, Roberts CB, et al.: Contemporary risk profile  
  of prostate cancer in the United States. J Natl Cancer Inst. 2009; 101: 1280-3
.    ^cY#a04v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#57#53#article#118#</font></p>     ^cY
#a04v37n1.htm##
00530000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028100078002001300359#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#58#54#article#118#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Schwartz K,    Powe
ll IJ, Underwood W 3rd, George J, Yee C, Banerjee M: Interplay of race,    socio
economic status, and treatment on survival of patients with prostate cancer.    
Urology. 2009; 74: 1296-302.    ^cY#a04v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#59#55#article#118#</font></p>     ^cY
#a04v37n1.htm##
00516000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026700078002001300345#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#60#56#article#118#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Stafford HS,    Sal
tzstein SL, Shimasaki S, Sanders C, Downs TM, Sadler GR: Racial/ethnic and    ge
nder disparities in renal cell carcinoma incidence and survival. J Urol. 2008;  
  179: 1704-8.    ^cY#a04v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#61#57#article#118#</font></p>     ^cY
#a04v37n1.htm##
00505000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025600078002001300334#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#62#58#article#118#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Zini L, Perrotte   
 P, Capitanio U, Jeldres C, Duclos A, Arjane P, et al.: Race affects access to  
  nephrectomy but not survival in renal cell carcinoma. BJU Int. 2009; 103: 889-
93.    ^cY#a04v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#63#59#article#118#</font></p>     ^cY
#a04v37n1.htm##
00514000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026500078002001300343#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#64#60#article#118#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Berndt SI, Carter  
  HB, Schoenberg MP, Newschaffer CJ: Disparities in treatment and outcome for   
 renal cell cancer among older black and white patients. J Clin Oncol. 2007;    
25: 3589-95.    ^cY#a04v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#65#61#article#118#</font></p>     ^cY
#a04v37n1.htm##
00474000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022500078002001300303#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#66#62#article#118#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Assad L, Resetkova 
   E, Oliveira VL, Sun W, Stewart JM, Katz RL, et al.: Cytologic features of ren
al    medullary carcinoma. Cancer. 2005; 105: 28-34.    ^cY#a04v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#67#63#article#118#</font></p>     ^cY
#a04v37n1.htm##
00458000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704020800079002001300287#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#68#64#article#118#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Reuter VE,    Pre
sti JC Jr: Contemporary approach to the classification of renal epithelial    tu
mors. Semin Oncol. 2000; 27: 124-37.    ^cY#a04v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#69#65#article#118#</font></p>     ^cY
#a04v37n1.htm##
00535000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704028500079002001300364#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#70#66#article#118#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Yamashita S,    I
oritani N, Oikawa K, Aizawa M, Endoh M, Arai Y: Morphological subtyping of    pa
pillary renal cell carcinoma: clinicopathological characteristics and prognosis.
    Int J Urol. 2007; 14: 679-83.    ^cY#a04v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#71#67#article#118#</font></p>     ^cY
#a04v37n1.htm##
00508000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704025800079002001300337#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#72#68#article#118#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Dall'Oglio    MF,
 Antunes AA, Pompeo AC, Mosconi A, Leite KR, Srougi M: Prognostic relevance    o
f the histological subtype of renal cell carcinoma. Int Braz J Urol. 2008;    34
: 3-8.    ^cY#a04v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#73#69#article#118#</font></p>     ^cY
#a04v37n1.htm##
00499000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704024900079002001300328#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#74#70#article#118#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Schrader AJ,    S
evinc S, Olbert PJ, Hegele A, Varga Z, Hofmann R: Gender-specific characteristic
s    and survival of renal cell carcinoma. Urologe A. 2008; 47: 1182, 1184-6.   
 ^cY#a04v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#75#71#article#118#</font></p>     ^cY
#a04v37n1.htm##
00470000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704022000079002001300299#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#76#72#article#118#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Ishikawa I,    Ko
vacs G: High incidence of papillary renal cell tumours in patients on chronic   
 haemodialysis. Histopathology. 1993; 22: 135-9.    ^cY#a04v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#77#73#article#118#</font></p>     ^cY
#a04v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#78#74#article#118#<p>&nbsp;</p>     ^
cY#a04v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#79#75#article#118#<p>&nbsp;</p>     ^
cY#a04v37n1.htm##
00366000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013100076002001300207#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#80#76#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>Accepted after    revision: July 
30, 2010</i></font></p>     ^cY#a04v37n1.htm##
00428000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019300076002001300269#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#81#77#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b><a name="end"></a><a href="#top">
<img src="/img/revistas/ibju/v37n1/seta.gif" border="0"></a>    Correspondence t
o</b>:    ^cY#a04v37n1.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#82#78#article#118#<br>   Dr. Alexande
r Sankin    ^cY#a04v37n1.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003400076002001300110#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#83#79#article#118#<br>   Division of 
Urology    ^cY#a04v37n1.htm##
00298000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006300076002001300139#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#84#80#article#118#<br>   State Univ. 
of New York Downstate Medical School    ^cY#a04v37n1.htm##
00267000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003200076002001300108#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#85#81#article#118#<br>   450 Clarkson
 Ave,    ^cY#a04v37n1.htm##
00274000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003900076002001300115#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#86#82#article#118#<br>   Brooklyn, NY
, 11203, USA    ^cY#a04v37n1.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#87#83#article#118#<br>   Fax: + 1 718
 270-3848    ^cY#a04v37n1.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#88#84#article#118#<br>   E-mail: <a h
ref="mailto:alexsankin@gmail.com">alexsankin@gmail.com</a></font></p>     ^cY#a0
4v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#89#85#article#118#<p>&nbsp;</p>     ^
cY#a04v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#90#86#article#118#<p>&nbsp;</p>     ^
cY#a04v37n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704001700076002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#91#87#article#118#<p> </p>     ^cY#a0
4v37n1.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011000076002001300186#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#92#88#article#118#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL    COMMENT</b></font></
p>     ^cY#a04v37n1.htm##
00774000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053900076002001300615#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#93#89#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> We have known    for a while that r
enal cell carcinomas (RCC) are more common in blacks compared    to non-Blacks a
nd Asians. Not only more common, RCC tend to be more aggressive    in blacks, wi
th a higher disease-specific mortality even when tumor size and    stage are ind
ependent variables. Black patients have a significantly higher    incidence rate
 and lower survival rate than all other races/ethnicities even    when having mo
re localized cancer.</font></p>     ^cY#a04v37n1.htm##
01086000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704085100076002001300927#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#94#90#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This study lists    the rates of dif
ferent types of renal cell carcinoma in a population composed    of many ethnici
ties. In blacks, almost half of all tumors were papillary RCC,    compared to on
ly 10% in non-blacks. This disparity is not commonly addressed.    In addition, 
it found a much lower rate of clear cell RCC in blacks, which is    not a common
 finding in the literature. The readers could have benefited by    data on survi
val or progression, which unfortunately the study lacks. Nonetheless,    given s
uch racial disparities in renal cell carcinoma incidence in this one    study, o
ne should consider expanding and confirming these findings that may    help eluc
idate biological, behavioral and environmental factors that can potentially    b
e addressed.</font></p>     ^cY#a04v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#95#91#article#118#<p>&nbsp;</p>     ^
cY#a04v37n1.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011400076002001300190#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#96#92#article#118#<p align="right"><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Dr.    Fabio Tav
ora</b>    ^cY#a04v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003800076002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#97#93#article#118#<br>   Department o
f Pathology    ^cY#a04v37n1.htm##
00298000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006300076002001300139#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#98#94#article#118#<br>   Hospital de 
Messejana Dr. Carlos Alberto Studart    ^cY#a04v37n1.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#99#95#article#118#<br>   Fortaleza, C
E, Brazil    ^cY#a04v37n1.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704009500077002001300172#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#100#96#article#118#<br>   E-mail: <a 
href="mailto:ftavora@gmail.com">ftavora@gmail.com</a></i></font></p>     ^cY#a04
v37n1.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002200077002001300099#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#101#97#article#118#<p>&nbsp;</p>     
^cY#a04v37n1.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704011000077002001300187#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#102#98#article#118#<p><font size="3" 
face="Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL    COMMENT</b></font><
/p>     ^cY#a04v37n1.htm##
01447000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704121100077002001301288#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#103#99#article#118#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"> Renal cell carcinoma    (RCC) tend
s to manifest variable prognoses and outcomes. Previous articles have    already
 pointed toward prognostic parameters including pathological subtypes    and eth
nic origin. Yet the issue of race was not fully addressed. Epidemiologic    lite
rature showed shorter survival in Black Americans with RCC. Tripathi et    al. c
oncluded that the overall survival for metastatic RCC was significantly    short
er for Black Americans. Vaishampayan et al. had a similar conclusion for    loca
l RCC, emphasizing a higher incidence, poorer outcome in Black patients    with 
a similar age and stage. However, the histology subtypes disparities were    not
 mentioned, demonstrating the advantage of the recent manuscript based on    dat
a that was retrieved from an equal-access health care system. Stafford published
    a major study comparing ethnic groups (White, Black, Hispanic and Asian -Pac
ific)    concluding that Black patients tend to have a higher incidence and a sh
orter    survival while Asian patients demonstrate the opposite. Yet even this a
rticle    did not point to the histology subdivision.</font></p>     ^cY#a04v37n
1.htm##
00678000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704044100078002001300519#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#104#100#article#118#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Herein we can appreciate    an imp
ortant study advancing our knowledge regarding the correlation between    race a
nd RCC histology subtypes. Further studies should investigate the papillary    p
redominance of the RCC in the black population while paradoxically demonstrating
    a poorer prognosis than what was known previously for that histological subt
ype.</font></p>     ^cY#a04v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#105#101#article#118#<p>&nbsp;</p>    
 ^cY#a04v37n1.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010000078002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#106#102#article#118#<p><font size="3"
 face="Verdana, Arial, Helvetica, sans-serif"><b>REFERENCES</b></font></p>     ^
cY#a04v37n1.htm##
00509000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025700081002001300338#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#107#103#article#118#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 1. Tripathi RT,   
 Heilbrun LK, Jain V, Vaishampayan UN: Racial disparity in outcomes of a clinica
l    trial population with metastatic renal cell carcinoma. Urology. 2006; 68: 2
96-301.    ^cY#a04v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#108#104#article#118#</font></p>     ^
cY#a04v37n1.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022100081002001300302#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#109#105#article#118#16#<p
><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Vaishampayan    
UN, Do H, Hussain M, Schwartz K: Racial disparity in incidence patterns and    o
utcome of kidney cancer. Urology. 2003; 62: 1012-7.    ^cY#a04v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#110#106#article#118#</font></p>     ^
cY#a04v37n1.htm##
00517000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026500081002001300346#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#111#107#article#118#17#<p
><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Berndt SI, Carte
r    HB, Schoenberg MP, Newschaffer CJ: Disparities in treatment and outcome for
    renal cell cancer among older black and white patients. J Clin Oncol. 2007; 
   25: 3589-95.    ^cY#a04v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#112#108#article#118#</font></p>     ^
cY#a04v37n1.htm##
00508000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025600081002001300337#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#113#109#article#118#18#<p
><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Zini L, Perrotte
    P, Capitanio U, Jeldres C, Duclos A, Arjane P, et al.: Race affects access t
o    nephrectomy but not survival in renal cell carcinoma. BJU Int. 2009; 103: 8
89-93.    ^cY#a04v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#114#110#article#118#</font></p>     ^
cY#a04v37n1.htm##
00520000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026800081002001300349#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#115#111#article#118#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 5. Stafford HS,   
 Saltzstein SL, Shimasaki S, Sanders C, Downs TM, Sadler GR: Racial/ethnic and  
  gender disparities in renal cell carcinoma incidence and survival. J Urol. 200
8;    179: 1704-8.    ^cY#a04v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#116#112#article#118#</font></p>     ^
cY#a04v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#117#113#article#118#<p>&nbsp;</p>    
 ^cY#a04v37n1.htm##
00356000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011900078002001300197#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#118#114#article#118#<p align="right">
<font size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Dr.    Avraham
 Shtricker</b>    ^cY#a04v37n1.htm##
00282000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004500078002001300123#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#119#115#article#118#<br>   Department
 of Urologic Surgery    ^cY#a04v37n1.htm##
00281000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004400078002001300122#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#120#116#article#118#<br>   The E. Wol
fson Medical Center    ^cY#a04v37n1.htm##
00265000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002800078002001300106#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#121#117#article#118#<br>   Holon, Isr
ael    ^cY#a04v37n1.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011500078002001300193#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a04v37n1.htm#S#p#122#118#article#118#<br>   E-mail: <a
 href="mailto:shtrickeravi@hotmail.com">shtrickeravi@hotmail.com</a></i></font><
/p>           ^cY#a04v37n1.htm##
00505000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170024000770180032001010660
00800133062002400141065000900165064000500174037006200179865000900241002001300250
#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#c#123#1#article#19#1#Am
erican Cancer Society#Cancer Facts & Figures 2009^len#Atlanta#American Cancer So
ciety#20090000#2009#http://oralcancerfoundation.org/facts/pdf/Us_Cancer_Facts.pd
f#20110200#a04v37n1.htm##
00594000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100023000770100019001000100
01900119010001700138012006200155030000900217065000900226064000500235031000300240
014000800243865000900251002001300260035001000273801000900283#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a04v37n1.htm#S#c#124#2#article#19#2#^rND^sLopez-Beltran^nA
#^rND^sScarpelli^nM#^rND^sMontironi^nR#^rND^sKirkali^nZ#2004 WHO classification 
of the renal tumors of the adults^len#Eur Urol#20060000#2006#49#798-805#20110200
#a04v37n1.htm#0302-2838#Eur Urol##
00593000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100023000770100012001000100
01700112010001800129012007200147030000800219065000900227064000500236031000300241
014000700244865000900251002001300260035001000273801000800283#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a04v37n1.htm#S#c#125#3#article#19#3#^rND^sVaishampayan^nUN
#^rND^sDo^nH#^rND^sHussain^nM#^rND^sSchwartz^nK#Racial disparity in incidence pa
tterns and outcome of kidney cancer^len#Urology#20030000#2003#62#1012-7#20110200
#a04v37n1.htm#0090-4295#Urology##
00642000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100018000920100
01400110010001600124010001600140010001800156810000600174012007000180030001700250
71000020026706500090026906400050027803100040028301400070028786500090029400200130
0303#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#c#126#4#article#19#
4#^rND^sShao^nYH#^rND^sDemissie^nK#^rND^sShih^nW#^rND^sMehta^nAR#^rND^sStein^nMN
#^rND^sRoberts^nCB#et al#Contemporary risk profile of prostate cancer in the Uni
ted States^len#Natl Cancer Inst#2#20090000#2009#101#1280-3#20110200#a04v37n1.htm
##
00686000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100017000950100
02300112010001600135010001300151010001800164012010400182030000800286065000900294
06400050030303100030030801400090031186500090032000200130032903500100034280100080
0352#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#c#127#5#article#19#
5#^rND^sSchwartz^nK#^rND^sPowell^nIJ#^rND^sUnderwood^nW 3rd#^rND^sGeorge^nJ#^rND
^sYee^nC#^rND^sBanerjee^nM#Interplay of race, socioeconomic status, and treatmen
t on survival of patients with prostate cancer^len#Urology#20090000#2009#74#1296
-302#20110200#a04v37n1.htm#0090-4295#Urology##
00671000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100021000960100
01900117010001700136010001600153010001700169012008800186030000700274065000900281
06400050029003100040029501400070029986500090030600200130031503500100032880100070
0338#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#c#128#6#article#19#
6#^rND^sStafford^nHS#^rND^sSaltzstein^nSL#^rND^sShimasaki^nS#^rND^sSanders^nC#^r
ND^sDowns^nTM#^rND^sSadler^nGR#Racial/ethnic and gender disparities in renal cel
l carcinoma incidence and survival^len#J Urol#20080000#2008#179#1704-8#20110200#
a04v37n1.htm#0022-5347#J Urol##
00646000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100018000910100
01900109010001700128010001600145010001600161810000600177012008000183030000800263
71000020027106500090027306400050028203100040028701400070029186500090029800200130
0307#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#c#129#7#article#19#
7#^rND^sZini^nL#^rND^sPerrotte^nP#^rND^sCapitanio^nU#^rND^sJeldres^nC#^rND^sDucl
os^nA#^rND^sArjane^nP#et al#Race affects access to nephrectomy but not survival 
in renal cell carcinoma^len#BJU Int#2#20090000#2009#103#889-93#20110200#a04v37n1
.htm##
00639000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100017000940100
02100111010002200132012010000154030001300254065000900267064000500276031000300281
014000800284865000900292002001300301035001000314801001300324#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a04v37n1.htm#S#c#130#8#article#19#8#^rND^sBerndt^nSI#^rND^
sCarter^nHB#^rND^sSchoenberg^nMP#^rND^sNewschaffer^nCJ#Disparities in treatment 
and outcome for renal cell cancer among older black and white patients^len#J Cli
n Oncol#20070000#2007#25#3589-95#20110200#a04v37n1.htm#0732-183X#J Clin Oncol##
00642000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100019000920100
01900111010001300130010001800143010001500161810000600176012005200182030000700234
06500090024106400050025003100040025501400060025986500090026500200130027403500100
0287801000700297#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#c#131#9
#article#19#9#^rND^sAssad^nL#^rND^sResetkova^nE#^rND^sOliveira^nVL#^rND^sSun^nW#
^rND^sStewart^nJM#^rND^sKatz^nRL#et al#Cytologic features of renal medullary car
cinoma^len#Cancer#20050000#2005#105#28-34#20110200#a04v37n1.htm#0008-543X#Cancer
##
00549000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100020000960120
07500116030001200191065000900203064000500212031000300217014000700220865000900227
002001300236035001000249801001200259#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
4v37n1.htm#S#c#132#10#article#19#10#^rND^sReuter^nVE#^rND^sPresti^nJC Jr#Contemp
orary approach to the classification of renal epithelial tumors^len#Semin Oncol#
20000000#2000#27#124-37#20110200#a04v37n1.htm#0093-7754#Semin Oncol##
00694000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
01600116010001600132010001500148010001400163012011300177030001100290065000900301
06400050031003100030031501400070031886500090032500200130033403500100034780100110
0357#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#c#133#11#article#19
#11#^rND^sYamashita^nS#^rND^sIoritani^nN#^rND^sOikawa^nK#^rND^sAizawa^nM#^rND^sE
ndoh^nM#^rND^sArai^nY#Morphological subtyping of papillary renal cell carcinoma:
 clinicopathological characteristics and prognosis^len#Int J Urol#20070000#2007#
14#679-83#20110200#a04v37n1.htm#0919-8172#Int J Urol##
00636000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100018001000100
01700118010001700135010001600152010001600168012007700184030001600261710000200277
065000900279064000500288031000300293014000400296865000900300002001300309#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#c#134#12#article#19#12#^rND^sDa
ll'Oglio^nMF#^rND^sAntunes^nAA#^rND^sPompeo^nAC#^rND^sMosconi^nA#^rND^sLeite^nKR
#^rND^sSrougi^nM#Prognostic relevance of the histological subtype of renal cell 
carcinoma^len#Int Braz J Urol#2#20080000#2008#34#3-8#20110200#a04v37n1.htm##
00659000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01700114010001600131010001500147010001700162012007300179030001000252065000900262
06400050027103100030027601400120027986500090029100200130030003500100031380100100
0323#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#c#135#13#article#19
#13#^rND^sSchrader^nAJ#^rND^sSevinc^nS#^rND^sOlbert^nPJ#^rND^sHegele^nA#^rND^sVa
rga^nZ#^rND^sHofmann^nR#Gender-specific characteristics and survival of renal ce
ll carcinoma^len#Urologe A#20080000#2008#47#182, 1184-6#20110200#a04v37n1.htm#03
40-2592#Urologe A##
00564000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970120
08800113030001500201065000900216064000500225031000300230014000600233865000900239
002001300248035001000261801001500271#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
4v37n1.htm#S#c#136#14#article#19#14#^rND^sIshikawa^nI#^rND^sKovacs^nG#High incid
ence of papillary renal cell tumours in patients on chronic haemodialysis^len#Hi
stopathology#19930000#1993#22#135-9#20110200#a04v37n1.htm#0309-0167#Histopatholo
gy##
00629000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100019000780100019000970100
01400116010002300130012010100153030000800254065000900262064000500271031000300276
014000800279865000900287002001300296035001000309801000800319#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a04v37n1.htm#S#c#137#15#article#19#1#^rND^sTripathi^nRT#^r
ND^sHeilbrun^nLK#^rND^sJain^nV#^rND^sVaishampayan^nUN#Racial disparity in outcom
es of a clinical trial population with metastatic renal cell carcinoma^len#Urolo
gy#20060000#2006#68#296-301#20110200#a04v37n1.htm#0090-4295#Urology##
00594000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100023000780100012001010100
01700113010001800130012007200148030000800220065000900228064000500237031000300242
014000700245865000900252002001300261035001000274801000800284#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a04v37n1.htm#S#c#138#16#article#19#2#^rND^sVaishampayan^nU
N#^rND^sDo^nH#^rND^sHussain^nM#^rND^sSchwartz^nK#Racial disparity in incidence p
atterns and outcome of kidney cancer^len#Urology#20030000#2003#62#1012-7#2011020
0#a04v37n1.htm#0090-4295#Urology##
00640000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100017000780100017000950100
02100112010002200133012010000155030001300255065000900268064000500277031000300282
014000800285865000900293002001300302035001000315801001300325#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a04v37n1.htm#S#c#139#17#article#19#3#^rND^sBerndt^nSI#^rND
^sCarter^nHB#^rND^sSchoenberg^nMP#^rND^sNewschaffer^nCJ#Disparities in treatment
 and outcome for renal cell cancer among older black and white patients^len#J Cl
in Oncol#20070000#2007#25#3589-95#20110200#a04v37n1.htm#0732-183X#J Clin Oncol##
00647000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100014000780100018000920100
01900110010001700129010001600146010001600162810000600178012008000184030000800264
71000020027206500090027406400050028303100040028801400070029286500090029900200130
0308#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#c#140#18#article#19
#4#^rND^sZini^nL#^rND^sPerrotte^nP#^rND^sCapitanio^nU#^rND^sJeldres^nC#^rND^sDuc
los^nA#^rND^sArjane^nP#et al#Race affects access to nephrectomy but not survival
 in renal cell carcinoma^len#BJU Int#2#20090000#2009#103#889-93#20110200#a04v37n
1.htm##
00672000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100019000780100021000970100
01900118010001700137010001600154010001700170012008800187030000700275065000900282
06400050029103100040029601400070030086500090030700200130031603500100032980100070
0339#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a04v37n1.htm#S#c#141#19#article#19
#5#^rND^sStafford^nHS#^rND^sSaltzstein^nSL#^rND^sShimasaki^nS#^rND^sSanders^nC#^
rND^sDowns^nTM#^rND^sSadler^nGR#Racial/ethnic and gender disparities in renal ce
ll carcinoma incidence and survival^len#J Urol#20080000#2008#179#1704-8#20110200
#a04v37n1.htm#0022-5347#J Urol##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#o#1#1#article#1
#20110330#144459#a05v37n1.htm#128##
02407000000000541000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000180011303100030013103200020013406500090013601400090014503500100015401200980
01640100022002620100026002840100028003100100028003380100034003660100030004000700
10200430070005300532083111600585085001001701085003601711085002001747085002001767
085002901787085002701816117000601843072000301849002001301852#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a05v37n1.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#
05#IBJU010#nd#Int. braz j urol.#37#1#20110200#^f35^l41#1677-5538#Risk of catecho
lamine crisis in patients undergoing resection of unsuspected pheochromocytoma^l
en#^rND^1A01^nGina^sSong#^rND^1A01^nBonnie N.^sJoe#^rND^1A01^nBenjamin M.^sYeh#^
rND^1A02^nMaxwell V.^sMeng#^rND^1A01^nAntonio C.^sWestphalen#^rND^1A01^nFergus V
.^sCoakley#University of California San Francisco^iA01^1Departments of Radiology
^cSan Francisco^sCalifornia^pUSA#University of California San Francisco^iA02^1Ur
ology#^len^aPURPOSE: To report the risk of catecholamine crisis in patients unde
rgoing resection of unsuspected pheochromocytoma. MATERIALS AND METHODS: Over a 
four-year period, we retrospectively identified four patients who underwent rese
ction of adrenal pheochromocytoma in whom the diagnosis was unsuspected based on
 preoperative clinical, biochemical, and imaging evaluation. RESULTS: None of th
e patients exhibited preoperative clinical features of catecholamine excess. Pre
operative biochemical screening in two patients was normal. CT scan performed in
 all patients demonstrated a nonspecific enhancing adrenal mass. During surgical
 resection of the adrenal mass, hemodynamic instability was observed in two of f
our patients, and one of these two patients also suffered a myocardial infarct. 
CONCLUSION: Both surgeons and radiologists should maintain a high index of suspi
cion for pheochromocytoma, as the tumor can be asymptomatic, biochemically negat
ive, and have nonspecific imaging features. Resection of such unsuspected pheoch
romocytomas carries a substantial risk of intraoperative hemodynamic instability
.#^ddecs^i1#^tm^len^kadrenal gland neoplasms^i1#^tm^len^kimaging^i1#^tm^len^ksur
gery^i1#^tm^len^kpheochromocytoma^i1#^tm^len^kcatecholamines^i1#other#20#a05v37n
1.htm##
02442000000000541000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000180011303100030013103200020013406500090013601400090014503500100015401201050
01640100022002690100026002910100028003170100028003450100034003730100030004070700
10200437070005300539083114400592085001001736085003601746085002001782085002001802
085002901822085002701851117000601878072000301884002001301887#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a05v37n1.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#
05#IBJU010#nd#Int. braz j urol.#37#1#20110200#^f35^l41#1677-5538#<b>Risk of cate
cholamine crisis in patients undergoing resection of unsuspected pheochromocytom
a</b>^len#^rND^1A01^nGina^sSong#^rND^1A01^nBonnie N.^sJoe#^rND^1A01^nBenjamin M.
^sYeh#^rND^1A02^nMaxwell V.^sMeng#^rND^1A01^nAntonio C.^sWestphalen#^rND^1A01^nF
ergus V.^sCoakley#University of California San Francisco^iA01^1Departments of Ra
diology^cSan Francisco^sCalifornia^pUSA#University of California San Francisco^i
A02^1Urology#^len^a<b>PURPOSE:</b> To report the risk of catecholamine crisis in
 patients undergoing resection of unsuspected pheochromocytoma. <b>MATERIALS AND
 METHODS:</b> Over a four-year period, we retrospectively identified four patien
ts who underwent resection of adrenal pheochromocytoma in whom the diagnosis was
 unsuspected based on preoperative clinical, biochemical, and imaging evaluation
. <b>RESULTS:</b> None of the patients exhibited preoperative clinical features 
of catecholamine excess. Preoperative biochemical screening in two patients was 
normal. CT scan performed in all patients demonstrated a nonspecific enhancing a
drenal mass. During surgical resection of the adrenal mass, hemodynamic instabil
ity was observed in two of four patients, and one of these two patients also suf
fered a myocardial infarct. <b>CONCLUSION:</b> Both surgeons and radiologists sh
ould maintain a high index of suspicion for pheochromocytoma, as the tumor can b
e asymptomatic, biochemically negative, and have nonspecific imaging features. R
esection of such unsuspected pheochromocytomas carries a substantial risk of int
raoperative hemodynamic instability.#^ddecs^i1#^tm^len^kadrenal gland neoplasms^
i1#^tm^len^kimaging^i1#^tm^len^ksurgery^i1#^tm^len^kpheochromocytoma^i1#^tm^len^
kcatecholamines^i1#other#20#a05v37n1.htm##
02568000000000565000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000300117049000800120
15800030012803000170013103100030014803200020015106500090015301400090016203500100
01710120098001810100022002790100025003010100027003260100027003530100033003800100
02900413070010400442070008700546083111600633085001001749085003601759085002001795
08500200181508500290183508500270186411700060189107200030189700200130190000800890
1913#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#l#4#1#article#1#^mJ
an./Feb.^a2011#oa#en#br1.1#1#4.0#ilus#tab#05#IBJU010#nd#Int. braz j urol#37#1#20
110200#^f35^l41#1677-5538#Risk of catecholamine crisis in patients undergoing re
section of unsuspected pheochromocytoma^len#^rND^1A01^nGina^sSong#^rND^1A01^nBon
nie N^sJoe#^rND^1A01^nBenjamin M^sYeh#^rND^1A02^nMaxwell V^sMeng#^rND^1A01^nAnto
nio C^sWestphalen#^rND^1A01^nFergus V^sCoakley#^iA01^1University of California S
an Francisco^2Departments of Radiology^cSan Francisco^sCalifornia^pUSA#^iA02^1Un
iversity of California San Francisco^2Urology^cSan Francisco^sCalifornia^pUSA#^l
en^aPURPOSE: To report the risk of catecholamine crisis in patients undergoing r
esection of unsuspected pheochromocytoma. MATERIALS AND METHODS: Over a four-yea
r period, we retrospectively identified four patients who underwent resection of
 adrenal pheochromocytoma in whom the diagnosis was unsuspected based on preoper
ative clinical, biochemical, and imaging evaluation. RESULTS: None of the patien
ts exhibited preoperative clinical features of catecholamine excess. Preoperativ
e biochemical screening in two patients was normal. CT scan performed in all pat
ients demonstrated a nonspecific enhancing adrenal mass. During surgical resecti
on of the adrenal mass, hemodynamic instability was observed in two of four pati
ents, and one of these two patients also suffered a myocardial infarct. CONCLUSI
ON: Both surgeons and radiologists should maintain a high index of suspicion for
 pheochromocytoma, as the tumor can be asymptomatic, biochemically negative, and
 have nonspecific imaging features. Resection of such unsuspected pheochromocyto
mas carries a substantial risk of intraoperative hemodynamic instability.#^ddecs
^i1#^tm^len^kadrenal gland neoplasms^i1#^tm^len^kimaging^i1#^tm^len^ksurgery^i1#
^tm^len^kpheochromocytoma^i1#^tm^len^kcatecholamines^i1#other#20#a05v37n1.htm#In
ternet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382011000
100005##
00356000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012300074002001300197#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#5#1#article#104#<p align="right"><fon
t face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>CLINICAL    UROLOGY</
b></font></p>     ^cY#a05v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#6#2#article#104#<p>&nbsp;</p>     ^cY
#a05v37n1.htm##
00437000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704020400074002001300278#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#7#3#article#104#<p><font face="Verdan
a, Arial, Helvetica, sans-serif" size="4"><a name="top"></a><b>Risk    of catech
olamine crisis in patients undergoing resection of unsuspected pheochromocytoma<
/b></font></p>     ^cY#a05v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#8#4#article#104#<p>&nbsp;</p>     ^cY
#a05v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#9#5#article#104#<p>&nbsp;</p>     ^cY
#a05v37n1.htm##
00503000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704026900075002001300344#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#10#6#article#104#<p><b><font face="Ve
rdana, Arial, Helvetica, sans-serif" size="2">Gina Song<sup>I</sup>;    Bonnie N
. Joe<sup>I</sup>; Benjamin M. Yeh<sup>I</sup>; Maxwell V. Meng<sup>II</sup>;   
 Antonio C. Westphalen<sup>I</sup>; Fergus V. Coakley<sup>I</sup></font></b></p>
     ^cY#a05v37n1.htm##
00419000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704018500075002001300260#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#11#7#article#104#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Departments    of Radiolo
gy, University of California San Francisco, San Francisco, California,    USA   
 ^cY#a05v37n1.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704018900075002001300264#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#12#8#article#104#<br>   </font><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>II</sup>Urology,    U
niversity of California San Francisco, San Francisco, California, USA</font></p>
     ^cY#a05v37n1.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011600075002001300191#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#13#9#article#104#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#end">Correspondence</a></fo
nt></p>     ^cY#a05v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#14#10#article#104#<p>&nbsp;</p>     ^
cY#a05v37n1.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#15#11#article#104#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a05v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#16#12#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#a
05v37n1.htm##
00436000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020100076002001300277#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#17#13#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>PURPOSE:</b>    To report the ris
k of catecholamine crisis in patients undergoing resection    of unsuspected phe
ochromocytoma.    ^cY#a05v37n1.htm##
00516000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028100076002001300357#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#18#14#article#104#<br>   <b>MATERIALS
 AND METHODS:</b> Over a four-year period, we retrospectively identified    four
 patients who underwent resection of adrenal pheochromocytoma in whom the    dia
gnosis was unsuspected based on preoperative clinical, biochemical, and imaging 
   evaluation.    ^cY#a05v37n1.htm##
00690000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045500076002001300531#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#19#15#article#104#<br>   <b>RESULTS:<
/b> None of the patients exhibited preoperative clinical features    of catechol
amine excess. Preoperative biochemical screening in two patients    was normal. 
CT scan performed in all patients demonstrated a nonspecific enhancing    adrena
l mass. During surgical resection of the adrenal mass, hemodynamic instability  
  was observed in two of four patients, and one of these two patients also suffe
red    a myocardial infarct.    ^cY#a05v37n1.htm##
00599000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036400076002001300440#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#20#16#article#104#<br>   <b>CONCLUSIO
N:</b> Both surgeons and radiologists should maintain a high index    of suspici
on for pheochromocytoma, as the tumor can be asymptomatic, biochemically    nega
tive, and have nonspecific imaging features. Resection of such unsuspected    ph
eochromocytomas carries a substantial risk of intraoperative hemodynamic instabi
lity.</font></p>     ^cY#a05v37n1.htm##
00436000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020100076002001300277#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#21#17#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Key words: </b>adrenal    gland n
eoplasms; imaging; surgery; pheochromocytoma; catecholamines</font></p> <HR size
="1" noshade>     ^cY#a05v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#22#18#article#104#<p>&nbsp;</p>     ^
cY#a05v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#23#19#article#104#<p>&nbsp;</p>     ^
cY#a05v37n1.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#24#20#article#104#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODUCTION</b></font></p>     ^
cY#a05v37n1.htm##
01483000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704124800076002001301324#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#25#21#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">While there is    widespread awarene
ss of the classical clinical and radiological features of    pheochromocytoma, i
t is perhaps less well known that 10% of pheochromocytomas    are not associated
 with symptoms of excess catecholamine production, and up    to 35% of pheochrom
ocytomas have atypical imaging findings (1-5). Accordingly,    the diagnosis may
 be unsuspected, and an indeterminate adrenal or retroperitoneal    mass that is
 actually a pheochromocytoma could undergo resection without preoperative    com
mencement of biochemical blockade. Such a patient is then at risk for a potentia
lly    a life-threatening intraoperative catecholamine crisis. However, while th
e risks    of iodinated contrast administration and percutaneous biopsy have bee
n reported    in these unsuspected pheochromocytomas (6-8), to our knowledge, th
e risk of    surgery in this population has not been well described. We recently
 encountered    several patients who underwent surgical resection of unsuspected
 pheochromocytomas.    Therefore, we undertook this study to report the risk of 
catecholamine crisis    in patients undergoing resection of unsuspected pheochro
mocytoma.</font></p>     ^cY#a05v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#26#22#article#104#<p>&nbsp;</p>     ^
cY#a05v37n1.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011400076002001300190#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#27#23#article#104#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>MATERIALS    AND METHODS</b></fon
t></p>     ^cY#a05v37n1.htm##
01405000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704117000076002001301246#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#28#24#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> This was a retrospective    study a
pproved by our Committee on Human Research with waiver of the requirement    for
 informed consent. Four cases of pathologically proven pheochromocytoma that    
underwent attempted surgical resection were identified by the study authors    b
etween 2004 and 2007. All available imaging studies and medical records of    th
ese patients were reviewed by the principal investigator. Preoperative imaging  
  consisted of CT scan examination obtained with multiple contiguous axial image
s    performed in the venous phase following intravenous contrast agent in all f
our    patients with additional delayed phases obtained in two patients. One of 
the    patients also underwent whole body PET scan after the administration of 1
6.4    milliCurie intravenous fluoro-2-deoxy-D-glucose (FDG) and utilizing atten
uation-corrected    regional emission images. None of the patients underwent ima
ging with iodine-131-meta-iodobenzylguanidine.    The diagnosis of pheochromocyt
oma was confirmed by pathology of the surgically    resected specimen in all fou
r patients.</font></p>     ^cY#a05v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#29#25#article#104#<p>&nbsp;</p>     ^
cY#a05v37n1.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#30#26#article#104#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>RESULTS</b></font></p>     ^cY#a0
5v37n1.htm##
01961000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704172600076002001301802#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#31#27#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The clinical and    radiologic char
acteristics and intraoperative and postoperative course of the    four patients 
in this study are summarized in <a href="/img/revistas/ibju/v37n1/a05tab1.jpg">T
able-1</a>.    Three of the patients underwent imaging for purposes of staging a
 malignancy,    and one patient underwent imaging for abdominal pain. None of th
e four patients    exhibited preoperative clinical features of catecholamine exc
ess. One patient    underwent serologic analysis, which demonstrated normal leve
ls of plasma metanephrine    and normetanephrine. Another patient underwent urin
ary analysis, which demonstrated    normal levels of urinary vanillyl-mandelic a
cid and normetanephrine. All patients    demonstrated an adrenal mass (mean diam
eter 2.7 cm, range 1.7 to 4.5 cm) with    associated heterogeneous (n = 2) or ho
mogeneous (n = 2) enhancement on CT scan.    Delayed images obtained in two case
s demonstrated less than fifty percent washout.    One patient had additional im
aging with PET, which demonstrated increased FDG    uptake within the lesion. Th
e radiological findings of the four patients are    highlighted in <a href="/img
/revistas/ibju/v37n1/html/a05fig1-4.htm">Figures-1 to 4</a>. All 4    patients p
roceeded to adrenalectomy, either open (n = 2) or laparoscopic (n    = 2). The i
ntraoperative course of two patients was notable for blood pressure    lability 
peaking at 200/100 to 220/110 mmHg systolic/diastolic. The postoperative    cour
se of one of these two patients was complicated by an elevated troponin    level
 to 9.7 and an electrocardiogram consistent with a non Q-wave myocardial    infa
rction.</font></p>     ^cY#a05v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#32#28#article#104#<p>&nbsp;</p>     ^
cY#a05v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#33#29#article#104#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>COMMENTS</b></font></p>     ^cY#a
05v37n1.htm##
01118000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704088300076002001300959#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#34#30#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Our study illustrates    the import
ance of keeping a high index of suspicion for the possibility of pheochromocytom
a    for any retroperitoneal mass. While hemodynamic instability associated with
    surgical and laparoscopic resection of known or suspected pheochromocytoma h
as    been reported (9,10), the risk of resection in the population of unsuspect
ed    pheochromocytoma has not been well described to our knowledge. Two out of 
four    of our patients demonstrated intraoperative hemodynamic instability that
 may    have been prevented by appropriate preoperative alpha-blockade. The post
operative    morbidity in our population might also have been averted, as the my
ocardial    infarction of one of our patients was presumably related to the sudd
en intraoperative    hypertensive challenge.</font></p>     ^cY#a05v37n1.htm##
02519000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704228400076002001302360#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#35#31#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Defining typical    characteristics 
of a pheochromocytoma by CT is difficult as heterogeneous enhancement    and poo
r washout as well as FDG uptake on PET may also be seen in a metastasis    or ad
enoma (1,4,11). Further imaging by magnetic resonance (MR) is also problematic, 
   as up to 35% of pheochromocytomas do not exhibit the "lightbulb bright"    hi
gh T2 signal classically associated with pheochromocytomas (1). Current guidelin
es    on preoperative diagnosis thus include additional studies after diagnosis 
of    an adrenal mass with nonspecific characteristics on cross-sectional imagin
g.    Metaiodobenzylguanidine (MIBG) reportedly has an excellent specificity of 
up    to 100% and may increase the sensitivity of pheochromocytoma detection to 
around    80% (10,12). Given the suboptimal sensitivity of biochemical markers a
lone,    a combination of MIBG imaging supplemented with biochemical testing is 
currently    recommended (12,13). Such an imaging approach may result in better 
preoperative    identification of pheochromocytomas, and facilitate commencement
 of pre-operative    alpha blockade. Both appropriate pretreatment with alpha bl
ockade and readily    available intraoperative antihypertensive agents have been
 shown to decrease    intraoperative lability (14). While pretreatment does not 
exclude the possibility    of intraoperative fluctuations in blood pressure (9,1
0), more favorable blood    pressure control may be achieved with a combination 
of pretreatment and intraoperative    medications (15). In a recent series of 24
 patients who underwent laparoscopic    adrenalectomy for adrenal pheochromocyto
ma (most were treated pre-operatively    with prazosin), no cases of intra-opera
tive hemodynamic instability were reported    (16). While such pharmacological b
lockade may prevent clinically significant    hemodynamic changes, it may not pr
event biochemical changes. For example, analysis    of serial catecholamine leve
ls in 11 patients undergoing 12 laparoscopic adrenalectomies    while being main
tained on an intravenous alpha 1 blocker showed significant    elevations relate
d to the induction of pneumoperitoneum and manipulation of    the adrenal gland 
(17).</font></p>     ^cY#a05v37n1.htm##
01058000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082300076002001300899#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#36#32#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Our report has    several limitation
s. The study is a small retrospective case series, and cases    were not identif
ied systematically. Patients with enhancing adrenal masses with    poor washout 
or increased FDG uptake at PET imaging undergoing resection were    not studied 
prospectively, and as such, the frequency of pheochromocytoma in    adrenal mass
es with nonspecific imaging characteristics is unknown. Only two    out of four 
patients received screening for catecholamines, and systematic evaluation    of 
the rate of false negatives either by urinary or plasma analysis was therefore  
  not made. Further imaging with MIBG was not obtained in any of our patients,  
  and the rate of false negatives by MIBG was thus not obtained.</font></p>     
^cY#a05v37n1.htm##
01035000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080000076002001300876#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#37#33#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In conclusion,    we report that two
 of four patients who underwent resection of unsuspected pheochromocytoma    sus
tained intraoperative hemodynamic instability. This study emphasizes the    asym
ptomatic presentation, nonspecific imaging characteristics, potential for    fal
se negative preoperative laboratory analysis, and resultant risk of catecholamin
e    crisis in patients with adrenal masses. Accordingly, both surgeons and radi
ologists    should maintain a high index of suspicion for pheochromocytoma befor
e resection    of nonspecific adrenal masses even in asymptomatic patients. Furt
her studies    to better delineate the imaging and biochemical preoperative eval
uation of these    patients are required.</font></p>     ^cY#a05v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#38#34#article#104#<p>&nbsp;</p>     ^
cY#a05v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#39#35#article#104#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONFLICT    OF INTEREST</b></font
></p>     ^cY#a05v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#40#36#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> None declared.</font></p>     ^cY#a
05v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#41#37#article#104#<p>&nbsp;</p>     ^
cY#a05v37n1.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#42#38#article#104#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFERENCES</b></font></p>     ^cY
#a05v37n1.htm##
00485000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023600078002001300314#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#43#39#article#104#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 1. Blake MA, Kalra   
 MK, Maher MM, Sahani DV, Sweeney AT, Mueller PR, et al.: Pheochromocytoma: an  
  imaging chameleon. Radiographics. 2004; 24 (Suppl 1): S87-99.    ^cY#a05v37n1.
htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#44#40#article#104#</font> </p>     ^c
Y#a05v37n1.htm##
00440000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019100078002001300269#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#45#41#article#104#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Mayo-Smith WW,    B
oland GW, Noto RB, Lee MJ: State-of-the-art adrenal imaging. Radiographics.    2
001; 21: 995-1012.    ^cY#a05v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#46#42#article#104#</font></p>     ^cY
#a05v37n1.htm##
00482000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023300078002001300311#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#47#43#article#104#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Sutton MG, Sheps   
 SG, Lie JT: Prevalence of clinically unsuspected pheochromocytoma. Review of   
 a 50-year autopsy series. Mayo Clin Proc. 1981; 56: 354-60.    ^cY#a05v37n1.htm
##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#48#44#article#104#</font></p>     ^cY
#a05v37n1.htm##
00443000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019400078002001300272#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#49#45#article#104#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Dunnick NR,    Koro
bkin M: Imaging of adrenal incidentalomas: current status. AJR Am J Roentgenol. 
   2002; 179: 559-68.    ^cY#a05v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#50#46#article#104#</font></p>     ^cY
#a05v37n1.htm##
00498000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024900078002001300327#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#51#47#article#104#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Mansmann G,    Lau 
J, Balk E, Rothberg M, Miyachi Y, Bornstein SR: The clinically inapparent    adr
enal mass: update in diagnosis and management. Endocr Rev. 2004; 25: 309-40.    
^cY#a05v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#52#48#article#104#</font></p>     ^cY
#a05v37n1.htm##
00535000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028600078002001300364#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#53#49#article#104#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Mukherjee JJ,    Pe
ppercorn PD, Reznek RH, Patel V, Kaltsas G, Besser M, et al.: Pheochromocytoma: 
   effect of nonionic contrast medium in CT on circulating catecholamine levels.
    Radiology. 1997; 202: 227-31.    ^cY#a05v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#54#50#article#104#</font></p>     ^cY
#a05v37n1.htm##
00522000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027300078002001300351#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#55#51#article#104#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Bessell-Browne    R
, O'Malley ME: CT of pheochromocytoma and paraganglioma: risk of adverse    even
ts with i.v. administration of nonionic contrast material. AJR Am J Roentgenol. 
   2007; 188: 970-4.    ^cY#a05v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#56#52#article#104#</font></p>     ^cY
#a05v37n1.htm##
00542000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029300078002001300371#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#57#53#article#104#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Casola G, Nicolet  
  V, vanSonnenberg E, Withers C, Bretagnolle M, Saba RM, et al.: Unsuspected phe
ochromocytoma:    risk of blood-pressure alterations during percutaneous adrenal
 biopsy. Radiology.    1986; 159: 733-5.    ^cY#a05v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#58#54#article#104#</font></p>     ^cY
#a05v37n1.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028400078002001300362#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#59#55#article#104#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Kinney MA, Warner  
  ME, vanHeerden JA, Horlocker TT, Young WF Jr, Schroeder DR, et al.: Perianesth
etic    risks and outcomes of pheochromocytoma and paraganglioma resection. Anes
th Analg.    2000; 91: 1118-23.    ^cY#a05v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#60#56#article#104#</font></p>     ^cY
#a05v37n1.htm##
00436000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704018600079002001300265#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#61#57#article#104#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Bravo EL, Tagle  
  R: Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev. 2003; 
   24: 539-53.    ^cY#a05v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#62#58#article#104#</font></p>     ^cY
#a05v37n1.htm##
00498000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704024800079002001300327#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#63#59#article#104#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Yoon JK, Remer   
 EM, Herts BR: Incidental pheochromocytoma mimicking adrenal adenoma because    
of rapid contrast enhancement loss. AJR Am J Roentgenol. 2006; 187: 1309-11.    
^cY#a05v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#64#60#article#104#</font></p>     ^cY
#a05v37n1.htm##
00483000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704023300079002001300312#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#65#61#article#104#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Guller U, Turek  
  J, Eubanks S, Delong ER, Oertli D, Feldman JM: Detecting pheochromocytoma: def
ining    the most sensitive test. Ann Surg. 2006; 243: 102-7.    ^cY#a05v37n1.ht
m##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#66#62#article#104#</font></p>     ^cY
#a05v37n1.htm##
00509000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704025900079002001300338#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#67#63#article#104#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Kudva YC, Sawka  
  AM, Young WF Jr: Clinical review 164: The laboratory diagnosis of adrenal pheo
chromocytoma:    the Mayo Clinic experience. J Clin Endocrinol Metab. 2003; 88: 
4533-9.    ^cY#a05v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#68#64#article#104#</font></p>     ^cY
#a05v37n1.htm##
00520000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704027000079002001300349#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#69#65#article#104#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Weismann D,    Fa
ssnacht M, Schubert B, Bonfig R, Tschammler A, Timm S, et al.: A dangerous    li
aison--pheochromocytoma in patients with malignant disease. Ann Surg Oncol.    2
006; 13: 1696-701.    ^cY#a05v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#70#66#article#104#</font></p>     ^cY
#a05v37n1.htm##
00520000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704027000079002001300349#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#71#67#article#104#15#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Chung PC, Ng    Y
T, Hsieh JR, Yang MW, Li AH: Labetalol pretreatment reduces blood pressure    in
stability during surgical resection of pheochromocytoma. J Formos Med Assoc.    
2006; 105: 189-93.    ^cY#a05v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#72#68#article#104#</font></p>     ^cY
#a05v37n1.htm##
00549000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704029900079002001300378#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#73#69#article#104#16#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Castilho LN,    S
imoes FA, Santos AM, Rodrigues TM, dos Santos Junior CA: Pheochromocytoma:    a 
long-term follow-up of 24 patients undergoing laparoscopic adrenalectomy.    Int
 Braz J Urol. 2009; 35: 24-31; discussion 32-5.    ^cY#a05v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#74#70#article#104#</font></p>     ^cY
#a05v37n1.htm##
00567000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704031700079002001300396#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#75#71#article#104#17#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Rocha MF, Tauzin-
Fin    P, Vasconcelos PL, Ballanger P: Assessment of serum catecholamine concent
rations    in patients with pheochromocytoma undergoing videolaparoscopic adrena
lectomy.    Int Braz J Urol. 2005; 31: 299-307; discussion 307-8.    ^cY#a05v37n
1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#76#72#article#104#</font></p>     ^cY
#a05v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#77#73#article#104#<p>&nbsp;</p>     ^
cY#a05v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#78#74#article#104#<p>&nbsp;</p>     ^
cY#a05v37n1.htm##
00367000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013200076002001300208#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#79#75#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>Accepted after    revision: Augus
t 3, 2010</i></font></p>     ^cY#a05v37n1.htm##
00428000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019300076002001300269#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#80#76#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b><a name="end"></a><a href="#top">
<img src="/img/revistas/ibju/v37n1/seta.gif" border="0"></a>    Correspondence t
o</b>:    ^cY#a05v37n1.htm##
00268000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003300076002001300109#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#81#77#article#104#<br>   Dr. Fergus C
oakley    ^cY#a05v37n1.htm##
00274000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003900076002001300115#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#82#78#article#104#<br>   Chief, Abdom
inal Imaging    ^cY#a05v37n1.htm##
00288000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704005300076002001300129#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#83#79#article#104#<br>   University o
f California San Francisco    ^cY#a05v37n1.htm##
00287000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704005200076002001300128#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#84#80#article#104#<br>   Box 0628, M-
372, 505 Parnassus Avenue    ^cY#a05v37n1.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004800076002001300124#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#85#81#article#104#<br>   San Francisc
o, CA 94143-0628, USA    ^cY#a05v37n1.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012300076002001300199#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#86#82#article#104#<br>   E-mail: <a h
ref="mailto:fergus.coakley@radiology.ucsf.edu">fergus.coakley@radiology.ucsf.edu
</a></font></p>     ^cY#a05v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#87#83#article#104#<p>&nbsp;</p>     ^
cY#a05v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#88#84#article#104#<p>&nbsp;</p>     ^
cY#a05v37n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704001700076002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#89#85#article#104#<p> </p>     ^cY#a0
5v37n1.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#90#86#article#104#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>EDITORIAL COMMENT</b></font></p> 
    ^cY#a05v37n1.htm##
00543000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030800076002001300384#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#91#87#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The authors of    this paper deserv
e to be complimented because, despite the modest data, that    was analyzed retr
ospectively, they raise some issues that are very relevant    for those who stud
y and treat adrenal diseases.</font></p>     ^cY#a05v37n1.htm##
01009000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077400076002001300850#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#92#88#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">First of all, they    point out that
 adrenal masses, and I would add retroperitoneal masses in general,    can be ph
eochromocytomas or paragangliomas without clinical signs or with very    subtle 
symptoms, which do not lead the physician to consider lesions that produce    ad
renergic substances. In my personal experience (1-3), I had the opportunity    t
o find some pheochromocytomas that had not been diagnosed preoperatively, much  
  like the authors of this paper. Even worse, I found pheochromocytomas that had
    been diagnosed by endocrinologists as non-functioning, which produced adrene
rgic    discharges in the operating room, causing all of the risks described by 
the    authors.</font></p>     ^cY#a05v37n1.htm##
01044000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080900076002001300885#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#93#89#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Secondly, the authors    show that a
ny surgeon is likely to encounter a patient that has not been properly    diagno
sed and reacts to what he believes to be a pheochromocytoma in the beginning    
of the procedure, causing hemodynamic instability. This creates a dilemma to    
the surgical team: move forward or abort the procedure? In my personal opinion, 
   the safest measure is to stop the procedure and adequately prepare the patien
t    for another surgery 30 or 45 days later. However, I acknowledge that if the
    team is very experienced (both surgeons and anesthesiologists), in a hospita
l    with all the necessary resources (medications and support), the procedure c
an    be carried out with good chances of success.</font></p>     ^cY#a05v37n1.h
tm##
00911000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067600076002001300752#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#94#90#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Finally, and this    is the main poi
nt of my analysis before the facts that were presented by the    authors, each c
ase of adrenal mass or retroperitoneal mass suspected of being    a pheochromocy
toma or a paraganglioma, regardless of the existence of symptoms,    must be exh
austively analyzed by an endocrinologist with expertise in adrenal    diseases. 
Personally, I do not consider myself capable of making such evaluation    and I 
believe that most adrenal surgeons are not. From my own personal experience,    
I believe that most endocrinologists are not capable of performing this task.</f
ont></p>     ^cY#a05v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#95#91#article#104#<p>&nbsp;</p>     ^
cY#a05v37n1.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#96#92#article#104#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>     ^cY
#a05v37n1.htm##
00442000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704019200079002001300271#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#97#93#article#104#18#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 1. Castilho LN:    L
aparoscopic adrenalectomy--experience of 10 years. Arq Bras Endocrinol Metabol. 
   2004; 48: 776-83.    ^cY#a05v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#98#94#article#104#</font></p>     ^cY
#a05v37n1.htm##
00549000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704029900079002001300378#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#99#95#article#104#19#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 2. Castilho LN,    S
imoes FA, Santos AM, Rodrigues TM, dos Santos Junior CA: Pheochromocytoma:    a 
long-term follow-up of 24 patients undergoing laparoscopic adrenalectomy.    Int
 Braz J Urol. 2009; 35: 24-31; discussion 32-5.    ^cY#a05v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#100#96#article#104#</font></p>     ^c
Y#a05v37n1.htm##
00460000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704020900080002001300289#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#101#97#article#104#20#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 3. Castilho LN,    
Castillo OA, D&eacute;nes FT, Mitre AI, Arap S: Laparoscopic adrenal surgery    
in children. J Urol. 2002; 168: 221-4.    ^cY#a05v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#102#98#article#104#</font></p>     ^c
Y#a05v37n1.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002200077002001300099#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#103#99#article#104#<p>&nbsp;</p>     
^cY#a05v37n1.htm##
00370000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704013300078002001300211#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#104#100#article#104#<p align="right">
<font size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Dr.    L&iacut
e;sias Nogueira Castilho</b>    ^cY#a05v37n1.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003300078002001300111#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#105#101#article#104#<br>   Section of
 Urology    ^cY#a05v37n1.htm##
00280000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004300078002001300121#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#106#102#article#104#<br>   Catholic U
niversity Campinas    ^cY#a05v37n1.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003500078002001300113#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#107#103#article#104#<br>   Campinas, 
SP, Brazil    ^cY#a05v37n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010100078002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a05v37n1.htm#S#p#108#104#article#104#<br>   E-mail: <a
 href="mailto:lisias@dglnet.com.br">lisias@dglnet.com.br</a></i></font></p>     
^cY#a05v37n1.htm##
00663000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100016000930100
01600109010001700125010001800142010001800160810000600178012004300184030001400227
06500090024106400050025003100030025503200020025801400070026086500090026700200130
0276035001000289801001400299#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.h
tm#S#c#109#1#article#20#1#^rND^sBlake^nMA#^rND^sKalra^nMK#^rND^sMaher^nMM#^rND^s
Sahani^nDV#^rND^sSweeney^nAT#^rND^sMueller^nPR#et al#Pheochromocytoma: an imagin
g chameleon^len#Radiographics#20040000#2004#24#1#S87-99#20110200#a05v37n1.htm#02
71-5333#Radiographics##
00569000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100021000770100017000980100
01500115010001400130012003700144030001400181065000900195064000500204031000300209
014000900212865000900221002001300230035001000243801001400253#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a05v37n1.htm#S#c#110#2#article#20#2#^rND^sMayo-Smith^nWW#^
rND^sBoland^nGW#^rND^sNoto^nRB#^rND^sLee^nMJ#State-of-the-art adrenal imaging^le
n#Radiographics#20010000#2001#21#995-1012#20110200#a05v37n1.htm#0271-5333#Radiog
raphics##
00594000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100016000940100
01400110012009400124030001500218065000900233064000500242031000300247014000700250
865000900257002001300266035001000279801001500289#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a05v37n1.htm#S#c#111#3#article#20#3#^rND^sSutton^nMG#^rND^sSheps^nSG#^
rND^sLie^nJT#Prevalence of clinically unsuspected pheochromocytoma: Review of a 
50-year autopsy series^len#Mayo Clin Proc#19810000#1981#56#354-60#20110200#a05v3
7n1.htm#0025-6196#Mayo Clin Proc##
00542000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100018000950120
05400113030002000167065000900187064000500196031000400201014000700205865000900212
002001300221035001000234801002000244#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
5v37n1.htm#S#c#112#4#article#20#4#^rND^sDunnick^nNR#^rND^sKorobkin^nM#Imaging of
 adrenal incidentalomas: current status^len#AJR Am J Roentgenol#20020000#2002#17
9#559-68#20110200#a05v37n1.htm#0361-803X#AJR Am J Roentgenol##
00660000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100013000950100
01400108010001800122010001700140010002000157012007900177030001100256065000900267
06400050027603100030028101400070028486500090029100200130030003500100031380100110
0323#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#c#113#5#article#20#
5#^rND^sMansmann^nG#^rND^sLau^nJ#^rND^sBalk^nE#^rND^sRothberg^nM#^rND^sMiyachi^n
Y#^rND^sBornstein^nSR#The clinically inapparent adrenal mass: update in diagnosi
s and management^len#Endocr Rev#20040000#2004#25#309-40#20110200#a05v37n1.htm#01
63-769X#Endocr Rev##
00703000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100021000970100
01700118010001500135010001700150010001600167810000600183012009900189030001000288
06500090029806400050030703100040031201400070031686500090032300200130033203500100
0345801001000355#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#c#114#6
#article#20#6#^rND^sMukherjee^nJJ#^rND^sPeppercorn^nPD#^rND^sReznek^nRH#^rND^sPa
tel^nV#^rND^sKaltsas^nG#^rND^sBesser^nM#et al#Pheochromocytoma: effect of nonion
ic contrast medium in CT on circulating catecholamine levels^len#Radiology#19970
000#1997#202#227-31#20110200#a05v37n1.htm#0033-8419#Radiology##
00618000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100024000770100019001010120
12400120030002000244065000900264064000500273031000400278014000600282865000900288
002001300297035001000310801002000320#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
5v37n1.htm#S#c#115#7#article#20#7#^rND^sBessell-Browne^nR#^rND^sO'Malley^nME#CT 
of pheochromocytoma and paraganglioma: risk of adverse events with i.v. administ
ration of nonionic contrast material^len#AJR Am J Roentgenol#20070000#2007#188#9
70-4#20110200#a05v37n1.htm#0361-803X#AJR Am J Roentgenol##
00710000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100017000930100
02300110010001700133010002100150010001500171810000600186012010400192030001000296
06500090030606400050031503100040032001400060032486500090033000200130033903500100
0352801001000362#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#c#116#8
#article#20#8#^rND^sCasola^nG#^rND^sNicolet^nV#^rND^svanSonnenberg^nE#^rND^sWith
ers^nC#^rND^sBretagnolle^nM#^rND^sSaba^nRM#et al#Unsuspected pheochromocytoma: r
isk of blood-pressure alterations during percutaneous adrenal biopsy^len#Radiolo
gy#19860000#1986#159#733-5#20110200#a05v37n1.htm#0033-8419#Radiology##
00704000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100017000940100
02100111010002000132010001900152010002000171810000600191012008600197030001300283
06500090029606400050030503100030031001400080031386500090032100200130033003500100
0343801001300353#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#c#117#9
#article#20#9#^rND^sKinney^nMA#^rND^sWarner^nME#^rND^svanHeerden^nJA#^rND^sHorlo
cker^nTT#^rND^sYoung^nWF Jr#^rND^sSchroeder^nDR#et al#Perianesthetic risks and o
utcomes of pheochromocytoma and paraganglioma resection^len#Anesth Analg#2000000
0#2000#91#1118-23#20110200#a05v37n1.htm#0003-2999#Anesth Analg##
00526000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950120
06000110030001100170065000900181064000500190031000300195014000700198865000900205
002001300214035001000227801001100237#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
5v37n1.htm#S#c#118#10#article#20#10#^rND^sBravo^nEL#^rND^sTagle^nR#Pheochromocyt
oma: state-of-the-art and future prospects^len#Endocr Rev#20030000#2003#24#539-5
3#20110200#a05v37n1.htm#0163-769X#Endocr Rev##
00615000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100016000940100
01600110012010100126030002000227065000900247064000500256031000400261014000800265
865000900273002001300282035001000295801002000305#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a05v37n1.htm#S#c#119#11#article#20#11#^rND^sYoon^nJK#^rND^sRemer^nEM#^
rND^sHerts^nBR#Incidental pheochromocytoma mimicking adrenal adenoma because of 
rapid contrast enhancement loss^len#AJR Am J Roentgenol#20060000#2006#187#1309-1
1#20110200#a05v37n1.htm#0361-803X#AJR Am J Roentgenol##
00643000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
01700110010001700127010001600144010001800160012006500178030000900243065000900252
06400050026103100040026601400060027086500090027600200130028503500100029880100090
0308#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#c#120#12#article#20
#12#^rND^sGuller^nU#^rND^sTurek^nJ#^rND^sEubanks^nS#^rND^sDelong^nER#^rND^sOertl
i^nD#^rND^sFeldman^nJM#Detecting pheochromocytoma: defining the most sensitive t
est^len#Ann Surg#20060000#2006#243#102-7#20110200#a05v37n1.htm#0003-4932#Ann Sur
g##
00630000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01900111012010600130030002400236065000900260064000500269031000300274014000700277
865000900284002001300293035001000306801002400316#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a05v37n1.htm#S#c#121#13#article#20#13#^rND^sKudva^nYC#^rND^sSawka^nAM#
^rND^sYoung^nWF Jr#Clinical review 164: The laboratory diagnosis of adrenal pheo
chromocytoma: the Mayo Clinic experience^len#J Clin Endocrinol Metab#20030000#20
03#88#4533-9#20110200#a05v37n1.htm#0021-972X#J Clin Endocrinol Metab##
00693000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
01800116010001600134010002000150010001400170810000600184012007700190030001500267
06500090028206400050029103100030029601400090029986500090030800200130031703500100
0330801001500340#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#c#122#1
4#article#20#14#^rND^sWeismann^nD#^rND^sFassnacht^nM#^rND^sSchubert^nB#^rND^sBon
fig^nR#^rND^sTschammler^nA#^rND^sTimm^nS#et al#A dangerous liaison--pheochromocy
toma in patients with malignant disease^len#Ann Surg Oncol#20060000#2006#13#1696
-701#20110200#a05v37n1.htm#1068-9265#Ann Surg Oncol##
00669000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100013000950100
01600108010001500124010001300139012010800152030001900260065000900279064000500288
031000400293014000700297865000900304002001300313035001000326801001900336#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#c#123#15#article#20#15#^rND^sCh
ung^nPC#^rND^sNg^nYT#^rND^sHsieh^nJR#^rND^sYang^nMW#^rND^sLi^nAH#Labetalol pretr
eatment reduces blood pressure instability during surgical resection of pheochro
mocytoma^len#J Formos Med Assoc#20060000#2006#105#189-93#20110200#a05v37n1.htm#0
929-6646#J Formos Med Assoc##
00642000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
01700115010002000132010002800152012009700180030001600277710000200293065000900295
064000500304031000300309014000600312865000900318002001300327#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a05v37n1.htm#S#c#124#16#article#20#16#^rND^sCastilho^nLN#^
rND^sSimoes^nFA#^rND^sSantos^nAM#^rND^sRodrigues^nTM#^rND^sdos Santos Junior^nCA
#Pheochromocytoma: a long-term follow-up of 24 patients undergoing laparoscopic 
adrenalectomy^len#Int Braz J Urol#2#20090000#2009#35#24-31#20110200#a05v37n1.htm
##
00641000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100020000950100
02200115010001900137012013000156030001600286710000200302065000900304064000500313
031000300318014000800321865000900329002001300338#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a05v37n1.htm#S#c#125#17#article#20#17#^rND^sRocha^nMF#^rND^sTauzin-Fin
^nP#^rND^sVasconcelos^nPL#^rND^sBallanger^nP#Assessment of serum catecholamine c
oncentrations in patients with pheochromocytoma undergoing videolaparoscopic adr
enalectomy^len#Int Braz J Urol#2#20050000#2005#31#299-307#20110200#a05v37n1.htm#
#
00530000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100019000780120055000970300
02800152065000900180064000500189031000300194014000700197865000900204002001300213
035001000226801002800236#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S
#c#126#18#article#20#1#^rND^sCastilho^nLN#Laparoscopic adrenalectomy--experience
 of 10 years^len#Arq Bras Endocrinol Metabol#20040000#2004#48#776-83#20110200#a0
5v37n1.htm#0004-2730#Arq Bras Endocrinol Metabol##
00641000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100019000780100017000970100
01700114010002000131010002800151012009700179030001600276710000200292065000900294
064000500303031000300308014000600311865000900317002001300326#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a05v37n1.htm#S#c#127#19#article#20#2#^rND^sCastilho^nLN#^r
ND^sSimoes^nFA#^rND^sSantos^nAM#^rND^sRodrigues^nTM#^rND^sdos Santos Junior^nCA#
Pheochromocytoma: a long-term follow-up of 24 patients undergoing laparoscopic a
drenalectomy^len#Int Braz J Urol#2#20090000#2009#35#24-31#20110200#a05v37n1.htm#
#
00591000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100019000780100019000970100
01600116010001600132010001400148012004500162030000700207065000900214064000500223
031000400228014000600232865000900238002001300247035001000260801000700270#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a05v37n1.htm#S#c#128#20#article#20#3#^rND^sCas
tilho^nLN#^rND^sCastillo^nOA#^rND^sDénes^nFT#^rND^sMitre^nAI#^rND^sArap^nS#Lapar
oscopic adrenal surgery in children^len#J Urol#20020000#2002#168#221-4#20110200#
a05v37n1.htm#0022-5347#J Urol##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#o#1#1#article#1
#20110330#144502#a06v37n1.htm#149##
02708000000000517000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030001800108
03100030012603200020012906500090013101400090014003500100014901201180015901000290
02770100032003060100031003380100028003690100040003970100034004370100043004710700
06500514083147000579085001002049085002702059085002302086085003002109085002902139
117000602168072000302174002001302177#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
6v37n1.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#TAB#06#IBJU010#nd#Int. braz j uro
l.#37#1#20110200#^f42^l48#1677-5538#Early removal of nasogastric tube is benefic
ial for patients undergoing radical cystectomy with urinary diversion^len#^rND^1
A01^nIoannis^sAdamakis#^rND^1A01^nStavros I.^sTyritzis#^rND^1A01^nGeorge^sKoutal
ellis#^rND^1A01^nTheodoros^sTokas#^rND^1A01^nKonstantinos G.^sStravodimos#^rND^1
A01^nDionysios^sMitropoulos#^rND^1A01^nConstantinos A.^sConstantinides#Athens Un
iversity Medical School^iA01^11st Department of Urology#^len^aPURPOSE: Examine t
he beneficial effect of early nasogastric tube (NGT) removal in patients undergo
ing radical cystectomy with urinary diversion. PATIENTS AND METHODS: 43 consecut
ive patients underwent radical cystectomy with urinary diversion and were random
ized into 2 groups. In the intervention group (n = 22), the NGT was removed 12 h
ours after the operation. Comparatively, in the control group (n = 21), the NGT 
remained in place until the appearance of the first flatus. The appearance of il
eus, patient ambulation, time to regular diet, and hospital discharge of the two
 patient groups were assessed. Patient discomfort due to the NGT was also record
ed. RESULTS: The 2 groups showed statistical homogeneity of their baseline chara
cteristics. Two patients (9.09%) from the intervention and 3 patients (14.3%) fr
om the control group developed postoperative ileus and were treated conservative
ly. No significant differences in intraoperative, postoperative, bowel outcomes 
or other complications were found between the two groups. All patients preferred
 the NGT to be removed first in comparison to their other co-existing drains. CO
NCLUSIONS: This is the first randomized, prospective study, to our knowledge, to
 assess early NGT removal after radical cystectomy. We advocate early removal, i
ndependently of the selected type of urinary diversion, since it is not correlat
ed with ileus and is advantageous in terms of patient comfort and earlier ambula
tion.#^ddecs^i1#^tm^len^kbladder cancer^i1#^tm^len^kcystectomy^i1#^tm^len^kurina
ry diversion^i1#^tm^len^knasogastric tube^i1#other#28#a06v37n1.htm##
02743000000000517000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030001800108
03100030012603200020012906500090013101400090014003500100014901201250015901000290
02840100032003130100031003450100028003760100040004040100034004440100043004780700
06500521083149800586085001002084085002702094085002302121085003002144085002902174
117000602203072000302209002001302212#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
6v37n1.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#TAB#06#IBJU010#nd#Int. braz j uro
l.#37#1#20110200#^f42^l48#1677-5538#<b>Early removal of nasogastric tube is bene
ficial for patients undergoing radical cystectomy with urinary diversion</b>^len
#^rND^1A01^nIoannis^sAdamakis#^rND^1A01^nStavros I.^sTyritzis#^rND^1A01^nGeorge^
sKoutalellis#^rND^1A01^nTheodoros^sTokas#^rND^1A01^nKonstantinos G.^sStravodimos
#^rND^1A01^nDionysios^sMitropoulos#^rND^1A01^nConstantinos A.^sConstantinides#At
hens University Medical School^iA01^11st Department of Urology#^len^a<b>PURPOSE:
</b> Examine the beneficial effect of early nasogastric tube (NGT) removal in pa
tients undergoing radical cystectomy with urinary diversion. <b>PATIENTS AND MET
HODS:</b> 43 consecutive patients underwent radical cystectomy with urinary dive
rsion and were randomized into 2 groups. In the intervention group (n = 22), the
 NGT was removed 12 hours after the operation. Comparatively, in the control gro
up (n = 21), the NGT remained in place until the appearance of the first flatus.
 The appearance of ileus, patient ambulation, time to regular diet, and hospital
 discharge of the two patient groups were assessed. Patient discomfort due to th
e NGT was also recorded. <b>RESULTS:</b> The 2 groups showed statistical homogen
eity of their baseline characteristics. Two patients (9.09%) from the interventi
on and 3 patients (14.3%) from the control group developed postoperative ileus a
nd were treated conservatively. No significant differences in intraoperative, po
stoperative, bowel outcomes or other complications were found between the two gr
oups. All patients preferred the NGT to be removed first in comparison to their 
other co-existing drains. <b>CONCLUSIONS:</b> This is the first randomized, pros
pective study, to our knowledge, to assess early NGT removal after radical cyste
ctomy. We advocate early removal, independently of the selected type of urinary 
diversion, since it is not correlated with ileus and is advantageous in terms of
 patient comfort and earlier ambulation.#^ddecs^i1#^tm^len^kbladder cancer^i1#^t
m^len^kcystectomy^i1#^tm^len^kurinary diversion^i1#^tm^len^knasogastric tube^i1#
other#28#a06v37n1.htm##
02851000000000541000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000400108121000300112049000800115158000300123
03000170012603100030014303200020014606500090014801400090015703500100016601201180
01760100029002940100031003230100031003540100028003850100039004130100034004520100
04200486070006700528083148400595085001002079085002702089085002302116085003002139
085002902169117000602198072000302204002001302207008008902220#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a06v37n1.htm#S#l#4#1#article#1#^mJan./Feb.^a2011#oa#en#br1
.1#1#4.0#tab#06#IBJU010#nd#Int. braz j urol#37#1#20110200#^f42^l48#1677-5538#Ear
ly removal of nasogastric tube is beneficial for patients undergoing radical cys
tectomy with urinary diversion^len#^rND^1A01^nIoannis^sAdamakis#^rND^1A01^nStavr
os I^sTyritzis#^rND^1A01^nGeorge^sKoutalellis#^rND^1A01^nTheodoros^sTokas#^rND^1
A01^nKonstantinos G^sStravodimos#^rND^1A01^nDionysios^sMitropoulos#^rND^1A01^nCo
nstantinos A^sConstantinides#^iA01^1Athens University Medical School^21st Depart
ment of Urology#^len^aPURPOSE: Examine the beneficial effect of early nasogastri
c tube (NGT) removal in patients undergoing radical cystectomy with urinary dive
rsion. PATIENTS AND METHODS: 43 consecutive patients underwent radical cystectom
y with urinary diversion and were randomized into 2 groups. In the intervention 
group (n = 22), the NGT was removed 12 hours after the operation. Comparatively,
 in the control group (n = 21), the NGT remained in place until the appearance o
f the first flatus. The appearance of ileus, patient ambulation, time to regular
 diet, and hospital discharge of the two patient groups were assessed. Patient d
iscomfort due to the NGT was also recorded. RESULTS: The 2 groups showed statist
ical homogeneity of their baseline characteristics. Two patients (9.09 percent) 
from the intervention and 3 patients (14.3 percent) from the control group devel
oped postoperative ileus and were treated conservatively. No significant differe
nces in intraoperative, postoperative, bowel outcomes or other complications wer
e found between the two groups. All patients preferred the NGT to be removed fir
st in comparison to their other co-existing drains. CONCLUSIONS: This is the fir
st randomized, prospective study, to our knowledge, to assess early NGT removal 
after radical cystectomy. We advocate early removal, independently of the select
ed type of urinary diversion, since it is not correlated with ileus and is advan
tageous in terms of patient comfort and earlier ambulation.#^ddecs^i1#^tm^len^kb
ladder cancer^i1#^tm^len^kcystectomy^i1#^tm^len^kurinary diversion^i1#^tm^len^kn
asogastric tube^i1#other#28#a06v37n1.htm#Internet^ihttp://www.scielo.br/scielo.p
hp?script=sci_arttext&pid=S1677-55382011000100006##
00356000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012300074002001300197#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#5#1#article#117#<p align="right"><fon
t face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>CLINICAL    UROLOGY</
b></font></p>     ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#6#2#article#117#<p>&nbsp;</p>     ^cY
#a06v37n1.htm##
00460000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704022700074002001300301#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#7#3#article#117#<p><a name="top"></a>
<font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Early    removal 
of nasogastric tube is beneficial for patients undergoing radical cystectomy    
with urinary diversion</b></font></p>     ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#8#4#article#117#<p>&nbsp;</p>     ^cY
#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#9#5#article#117#<p>&nbsp;</p>     ^cY
#a06v37n1.htm##
00488000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704025400075002001300329#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#10#6#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Ioannis    Adamakis; Stavros I. Ty
ritzis; George Koutalellis; Theodoros Tokas; Konstantinos    G. Stravodimos; Dio
nysios Mitropoulos; Constantinos A. Constantinides</b></font></p>     ^cY#a06v37
n1.htm##
00411000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704017700075002001300252#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#11#7#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">1st Department    of Urology, Athens 
University Medical School, LAIKO Hospital, Athens, Greece</font></p>     ^cY#a06
v37n1.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011600075002001300191#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#12#8#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#end">Correspondence</a></fo
nt></p>     ^cY#a06v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#13#9#article#117#<p>&nbsp;</p>     ^c
Y#a06v37n1.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#14#10#article#117#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a06v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#15#11#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#a
06v37n1.htm##
00463000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022800076002001300304#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#16#12#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>PURPOSE:</b>    Examine the benef
icial effect of early nasogastric tube (NGT) removal in patients    undergoing r
adical cystectomy with urinary diversion.    ^cY#a06v37n1.htm##
00791000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055600076002001300632#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#17#13#article#117#<br>   <b>PATIENTS 
AND METHODS:</b> 43 consecutive patients underwent radical cystectomy    with ur
inary diversion and were randomized into 2 groups. In the intervention    group 
(n = 22), the NGT was removed 12 hours after the operation. Comparatively,    in
 the control group (n = 21), the NGT remained in place until the appearance    o
f the first flatus. The appearance of ileus, patient ambulation, time to regular
    diet, and hospital discharge of the two patient groups were assessed. Patien
t    discomfort due to the NGT was also recorded.    ^cY#a06v37n1.htm##
00745000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051000076002001300586#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#18#14#article#117#<br>   <b>RESULTS:<
/b> The 2 groups showed statistical homogeneity of their baseline    characteris
tics. Two patients (9.09%) from the intervention and 3 patients (14.3%)    from 
the control group developed postoperative ileus and were treated conservatively.
    No significant differences in intraoperative, postoperative, bowel outcomes 
   or other complications were found between the two groups. All patients prefer
red    the NGT to be removed first in comparison to their other co-existing drai
ns.    ^cY#a06v37n1.htm##
00608000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037300076002001300449#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#19#15#article#117#<br>   <b>CONCLUSIO
NS:</b> This is the first randomized, prospective study, to our    knowledge, to
 assess early NGT removal after radical cystectomy. We advocate    early removal
, independently of the selected type of urinary diversion, since    it is not co
rrelated with ileus and is advantageous in terms of patient comfort    and earli
er ambulation.</font></p>     ^cY#a06v37n1.htm##
00424000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018900076002001300265#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#20#16#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Key words: </b>bladder    cancer;
 cystectomy; urinary diversion; nasogastric tube</font></p> <HR size="1" noshade
>     ^cY#a06v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#21#17#article#117#<p>&nbsp;</p>     ^
cY#a06v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#22#18#article#117#<p>&nbsp;</p>     ^
cY#a06v37n1.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#23#19#article#117#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODUCTION</b></font></p>     ^
cY#a06v37n1.htm##
00842000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060700076002001300683#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#24#20#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Radical cystectomy    with urinary d
iversion for the management of muscle-invasive bladder cancer,    even nowadays,
 is considered to be an operation that conceals a variety of intraoperative    a
nd postoperative hazards. During the last decades, there has nevertheless been  
  an evolution of the surgical experience concerning various techniques. Thus,  
  the risk of complications is much lower, with postoperative ileus being the   
 most common, resulting in prolonged fasting and hospitalization of the patients
    (1).</font></p>     ^cY#a06v37n1.htm##
01428000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704119300076002001301269#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#25#21#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A common way to    avoid this compli
cation is the use of a nasogastric tube (NGT) which is considered    a useful to
ol that decompresses the intestine and the stomach, increases bowel    motility,
 offering safety to the postoperative care plan. In previous decades,    the app
lication of NGTs had become a tradition due to the sense of security    it provi
des to the postoperative outcome. Recently, there have been several    prospecti
ve randomized trials in the field of general surgery and gynecology    supportin
g the opinion that the benefits outnumber the risks for early NGT removal    (2-
9). In the last decade there has also been a trend of early NGT removal after   
 major urologic operations, including radical cystectomy with urinary diversion 
   (10-14). However, a recently published Cochrane Meta-Analysis of 33 studies  
  concluded that NGT decompression should be abandoned in favor of selective use
,    since it does not accomplish any of its intended goals (15). The purpose of
    our study was to support this opinion, proving that NGTs can be safely remov
ed    shortly after the operation.</font></p>     ^cY#a06v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#26#22#article#117#<p>&nbsp;</p>     ^
cY#a06v37n1.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011400076002001300190#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#27#23#article#117#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>MATERIALS AND    METHODS</b></fon
t></p>     ^cY#a06v37n1.htm##
01113000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087800076002001300954#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#28#24#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Under institutional    approval we p
rospectively evaluated 56 patients from March 2004 to April 2008.    Thirteen pa
tients were excluded from the study, 7 due to refusal to participate    and 6 pa
tients due to intensive care unit stay, previous history of major abdominal    s
urgery and/or neoadjuvant radiotherapy or chemotherapy. The remaining 43 patient
s,    after providing inform consent, were randomly divided into 2 groups. The i
ntervention    and control groups consisted of 22 and 21 patients, respectively.
 Their demographic    characteristics are listed in <a href="/img/revistas/ibju/
v37n1/a06tab1.jpg">Table-1</a>. They    underwent radical cystectomy with curati
ve intent for invasive bladder cancer,    (30 men and 13 women). The operations 
were performed by 4 different surgeons.</font></p>     ^cY#a06v37n1.htm##
03529000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704329400076002001303370#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#29#25#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The perioperative    care plan of th
e two groups is presented in <a href="/img/revistas/ibju/v37n1/a06tab2.jpg">Tabl
e-2</a>.    The patients of the intervention group followed a common preoperativ
e strategy    including admission 2 days before the operation, and counseling re
garding the    importance of early ambulation and pulmonary physiotherapy compar
ed with the    use of NGTs. Bowel preparation was administered the day before th
e operation,    usually with sodium phosphate solution. The night before the ope
ration, a clear    liquid diet was administered, and patients received nothing b
y mouth after midnight.    The day of the operation, patients received prophylax
is for deep vein thrombosis    including low molecular weight heparin and elasti
c stockings, as well as chemoprophylaxis    usually with intravenous administrat
ion of ampicillin and metronidazole. After    anesthesia induction a NGT was ins
erted for bowel and stomach decompression    and its correct placement was inspe
cted by the surgeon intraoperatively. We    performed an infraumbilical incision
 starting just below the umbilical level    and extending to the pubic symphysis
 reaching a maximum length of 12 cm. The    operation was performed through an i
ntraperitoneal approach. Removal of the    urinary bladder, the prostate, the se
minal vesicles and the distal ureters was    performed in men, and the bladder w
ith the uterus was performed in women. Bilateral    pelvic lymphadenectomy was r
outinely a part of the operation plan. The urinary    diversion was executed wit
h a Bricker ileal conduit (13 patients), or orthotopic    bladder substitution (
9 patients). The bowel segment that was routinely used    was 15-20 cm long, app
roximately 20 cm away from the ileocecal valve. A longer,    ileal loop of 36 cm
, formatted accordingly to our personal modification of the    S-pouch, was used
 for the neobladder formation (16). For bowel segment isolation,    as well as f
or restoration of bowel continuity, special staplers were used in    most cases.
 One or two drains were usually applied for postoperative fluid drainage.    The
 simultaneous use of an epidural is not common in postoperative analgesia.    Po
stoperative pain was managed with systemic use of opioids and nonsteroidal    an
ti-inflammatory drugs. Metoclopramide was routinely used in all cases for    48 
hours postoperatively. The NGT was removed within 12 hrs postoperatively.    Amb
ulation with respiratory physiotherapy if needed was usually begun on the    fir
st postoperative day along with a clear liquid diet, whereas the patients    had
 their first regular meal after 3 to 4 days. This postoperative care plan    was
 applied irrespectively of the presence of flatus or bowel sounds. Postoperative
    ileus was defined as the absence of normal flatus or stool for 5 days with a
ccompanying    symptoms like nausea, vomiting, gas distention, and confirmation 
with imaging    parameters. The criteria for safe discharge included adequate or
al intake, pain    control with oral medication and defecation accomplishment. A
ll of the patients    that suffered from ileus were treated conservatively with 
reinsertion of the    NGT and modification of the diet.</font></p>     ^cY#a06v3
7n1.htm##
00790000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055500076002001300631#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#30#26#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The 21 patients    of the control gr
oup were operated on during the same period of time by the    same group of surg
eons and with identical surgical techniques. Urinary diversion    was executed w
ith a Bricker ileal conduit(9 patients) and orthotopic bladder    substitution (
12 patients). The preoperative plan was identical to those of    the interventio
n group. Postoperatively, the only difference was that the NGT    remained until
 the appearance of the first flatus.</font></p>     ^cY#a06v37n1.htm##
00493000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025800076002001300334#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#31#27#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The patients were    asked a simple 
question 12 hours postoperatively about which "tube" (catheter,    drain, NGT) t
hey would prefer to be removed first due to its discomfort.</font></p>     ^cY#a
06v37n1.htm##
00907000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067200076002001300748#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#32#28#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Statistical "homogeneity"    of the 
two patient groups was explored using the Kolmogorov-Smirnov and Shapiro-Wilk   
 tests. Pearson's chi-square test was used to examine the "relationship"    betw
een the time of NGT removal and the operative techniques (type of operation,    
use of staplers). The use of epidural anesthesia was examined using the Fisher's
    exact test. We also performed the parametric test (independent samples t-tes
t)    to compare the (mean) operation time with a 95% confidence interval. Final
ly,    the Mann-Whitney U test was used to examine the surgical outcomes.</font>
</p>     ^cY#a06v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#33#29#article#117#<p>&nbsp;</p>     ^
cY#a06v37n1.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#34#30#article#117#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>RESULTS</b></font></p>     ^cY#a0
6v37n1.htm##
00808000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057300076002001300649#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#35#31#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> No statistical    difference was fo
und in any demographic or clinical parameter between the 2    groups. No patient
s were lost to follow-up during the intervention, nor discontinued    the interv
ention. Likewise, no difference was recorded in the postoperative    course, esp
ecially concerning bowel movement, ambulation or patient diet. The    main resul
ts are listed in <a href="/img/revistas/ibju/v37n1/a06tab2.jpg">Tables 2</a> and
 <a href="/img/revistas/ibju/v37n1/a06tab3.jpg">3</a>.</font></p>     ^cY#a06v37
n1.htm##
00573000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033800076002001300414#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#36#32#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The only parameter    which showed a
 statistically significant difference was the mean operative time    (p = 0.026)
. Complications (<a href="/img/revistas/ibju/v37n1/a06tab3.jpg">Table-3</a>) wer
e rare    and comparable between the two groups (p = 0.69).</font></p>     ^cY#a
06v37n1.htm##
00442000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020700076002001300283#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#37#33#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Concerning the    tube removal quest
ion, all patients (100%) answered that they would prefer the    NGT to be remove
d first.</font></p>     ^cY#a06v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#38#34#article#117#<p>&nbsp;</p>     ^
cY#a06v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#39#35#article#117#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>COMMENTS</b></font></p>     ^cY#a
06v37n1.htm##
01227000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704099200076002001301068#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#40#36#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The 90-day morbidity    and mortali
ty rates for radical cystectomy have been reported to reach the non-negligible  
  rates of 64% (17) and 5.6% (18). This is the main reason why many urologists  
  prefer being more conservative in their postoperative treatment plan. A major 
   postoperative concern is related to postoperative ileus. In many cases, to av
oid    this complication, a NGT remains in place for several days after the oper
ation.    The preservation of the NGT for more than one day though, is associate
d with    patient discomfort, increased pulmonary complications like atelectasis
 and respiratory    tract infections, gastroesophageal reflux and electrolyte im
balances (10). Early    patient ambulation has been traditionally encouraged to 
stimulate the bowel    and prevent respiratory events, but despite the strong cl
inical bias, it seems    to have little or no effect on NGT removal (11).</font>
</p>     ^cY#a06v37n1.htm##
01262000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704102700076002001301103#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#41#37#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">There have been    alternative metho
ds used for gastrointestinal (GI) tract decompression. Some    centers have test
ed the use of tube gastrostomy with positive results &#91;19-22&#93;.    In 1976
, the first trial comparing tube gastrostomies and NGTs was published    conclud
ing that gastrostomies have a definite place in surgical urology (19).    Fiftee
n years later, Van Poppel et al. reported that tube gastrostomies can    be an e
asy procedure for gastric decompression after urinary diversion procedures    bu
t can be used only as an alternative to NGTs (20). Finally in 2000, Buscarini   
 et al. presented a clinical trial with 709 patients, suggesting the tube gastro
stomy    with the Stamm technique as an effective method with a low complication
 rate    (0.05%) (22). Currently, this technique is not so popular among urologi
sts due    to its high level of invasiveness and the reduced need for long lasti
ng gastric    decompression.</font></p>     ^cY#a06v37n1.htm##
01735000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704150000076002001301576#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#42#38#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Early NGT removal    has been a matt
er of controversy. In 1999, Donat et al. presented the first    prospective stud
y comparing 27 patients receiving intravenous metoclopramide    combined with NG
T removal before 24 hours, with 54 control patients. Their results    focused on
 the importance of metoclopramide with early NGT removal in the reduction    of 
postoperative atelectasis, early return of bowel function, and safety to    the 
small bowel anastomosis (10). In 2003, Pruthi et al. with a relatively small    
sample of patients, was the first to focus on a specific preoperative plan with 
   bowel preparation and patient education, combined with a limited incision len
gth,    preperitoneal approach, use of staplers, and early NGT removal, in the e
arly    hospital discharge of their patients (12). Inman et al. during the same 
year,    with a large sample of 430 patients, retrospectively compared patients 
who received    postoperative NGTs with those who did not, suggesting that NGTs 
may prolong    GI recovery and increase duration of hospitalization (13). Finall
y, in 2005,    Park et al. pointed out the importance of sodium phosphate for bo
wel preparation    in the reduction of the incidence of postoperative ileus and 
supported the opinion    that early NGT removal after cystectomy is not related 
with ileus (14). Other    authors propose the use of chewing gum for bowel motil
ity stimulation (23).</font></p>     ^cY#a06v37n1.htm##
00804000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056900076002001300645#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#43#39#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Postoperative ileus    is associated
 with pre-, intra- and postoperative factors, such as prolonged    fasting, the 
surgical stress along with the sympathetic hyperactivity, uncontrolled    pain, 
hypotension, hypovolemia, surgical dissection and excessive saline administratio
n.    We tried to avoid all of the above factors, in cooperation with our anesth
esiologists,    by creating a careful prospective, preoperative and postoperativ
e care plan,    incorporating respective measures.</font></p>     ^cY#a06v37n1.h
tm##
01566000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704133100076002001301407#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#44#40#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Preoperatively,    we carried-out a 
meticulous counseling effort to stress the importance of bowel    preparation, e
arly ambulation and pulmonary exercise. Sodium phosphate solutions    fulfill th
e criteria regarding tolerability, adequate preparation of the ileum    and redu
ced morbidity. Even though patients do not benefit from bowel preparation,    as
 a recent meta-analysis in major abdominal surgery suggests (24), we proceeded  
  to use a one-day bowel preparation. Nevertheless, we do not consider bowel pre
paration    as an important factor in the preoperative preparation of the patien
t. Furthermore,    we do not advocate prolonged fasting, because it leads to ins
ulin resistance    and it is not recommended by international anesthesiology gui
delines (25). Moreover,    gastric emptying of water and other clear fluids has 
an extremely fast exponential    curve (50% of intake clearance within 20 minute
s) (26). The preoperative care    plan rarely included chemoprophylaxis from the
 previous day because of the small    bowel segment used in most of the cases. I
n this instance, possible postoperative    complications like ileus or superinfe
ction by Clostridium difficile resulting    in pseudomembranous colitis can be a
voided (27).</font></p>     ^cY#a06v37n1.htm##
00997000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076200076002001300838#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#45#41#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Intraoperatively,    performing radi
cal cystectomy through a limited infraumbilical incision not    exceeding 12 cm 
provided us with several benefits. The bowel loops do not block    the surgical 
field and are better protected inside the abdomen due to the smaller    incision
 of the peritoneum. Finally, the postoperative pain is limited with    this type
 of incision. The use of staplers during all of the stages of the operation    o
ffers less operating time, reduced intraoperative blood loss, and improved    bo
wel manipulation (28). In this case, the risk of postoperative bowel edema    an
d ileus is greatly reduced and the early induction of a normal diet is facilitat
ed.</font></p>     ^cY#a06v37n1.htm##
00590000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035500076002001300431#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#46#42#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Of the 43 patients,    only 5 had GI
 tract complications. These complications occurred with no significant    differ
ence between the two groups, they were not related with increased estimated    b
lood loss, transfusion requirement, or other major complications like fever.</fo
nt></p>     ^cY#a06v37n1.htm##
01108000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087300076002001300949#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#47#43#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This study is not    without limitat
ions. Firstly, our patient sample is rather small, but it is    homogeneous. Sec
ond, our patients were operated on by 4 different surgeons creating    a possibl
e bias. However, the technique used by all surgeons in our department    was exa
ctly the same, although it might have created a difference in operative    time.
 Additionally, the tube removal question is rather simple, not subjective,    bu
t it does reflect the patient's discomfort accurately. Finally, it is    obvious
 that this study did not follow the multimodal approach of the fast track    pro
gram (no mechanical bowel preparation, no drainages, epidural analgesia,    etc.
), but it was done in order to focus entirely on the effects of NGT in the    po
stoperative course of the patient.</font></p>     ^cY#a06v37n1.htm##
00730000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049500076002001300571#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#48#44#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">To our knowledge,    this is the fir
st randomized, prospective trial evaluating the value of early    NGT removal in
 a radical cystectomy with urinary diversion. We believe that    NGT does not af
fect bowel movement and does not prevent prolonged postoperative    ileus. Our r
esults are in accordance to the current literature that reducing    time to NGT 
removal can be advantageous in terms of patient comfort.</font></p>     ^cY#a06v
37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#49#45#article#117#<p>&nbsp;</p>     ^
cY#a06v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#50#46#article#117#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONFLICT OF    INTEREST</b></font
></p>     ^cY#a06v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#51#47#article#117#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> None declared.</font></p>     ^cY#a
06v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#52#48#article#117#<p>&nbsp;</p>     ^
cY#a06v37n1.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#53#49#article#117#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFERENCES</b></font></p>     ^cY
#a06v37n1.htm##
00518000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026900078002001300347#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#54#50#article#117#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 1. Chang SS, Cookson 
   MS, Baumgartner RG, Wells N, Smith JA Jr: Analysis of early complications aft
er    radical cystectomy: results of a collaborative care pathway. J Urol. 2002;
 167:    2012-6.    ^cY#a06v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#55#51#article#117#</font> </p>     ^c
Y#a06v37n1.htm##
00520000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027100078002001300349#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#56#52#article#117#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Cheatham ML,    Cha
pman WC, Key SP, Sawyers JL: A meta-analysis of selective versus routine    naso
gastric decompression after elective laparotomy. Ann Surg. 1995; 221: 469-76;   
 discussion 476-8.    ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#57#53#article#117#</font></p>     ^cY
#a06v37n1.htm##
00529000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028000078002001300358#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#58#54#article#117#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Cunningham J,    Te
mple WJ, Langevin JM, Kortbeek J: A prospective randomized trial of routine    p
ostoperative nasogastric decompression in patients with bowel anastomosis.    Ca
n J Surg. 1992; 35: 629-32.    ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#59#55#article#117#</font></p>     ^cY
#a06v37n1.htm##
00489000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024000078002001300318#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#60#56#article#117#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Wu CC, Hwang    CR,
 Liu TJ: There is no need for nasogastric decompression after partial gastrectom
y    with extensive lymphadenectomy. Eur J Surg. 1994; 160: 369-73.    ^cY#a06v3
7n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#61#57#article#117#</font></p>     ^cY
#a06v37n1.htm##
00448000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019900078002001300277#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#62#58#article#117#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Seenu V, Goel    AK
: Early oral feeding after elective colorectal surgery: is it safe. Trop Gastroe
nterol.    1995; 16: 72-3.    ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#63#59#article#117#</font></p>     ^cY
#a06v37n1.htm##
00542000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029300078002001300371#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#64#60#article#117#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Carr&egrave;re    N
, Seulin P, Julio CH, Bloom E, Gouzi JL, Prad&egrave;re B: Is nasogastric or    
nasojejunal decompression necessary after gastrectomy? A prospective randomized 
   trial. World J Surg. 2007; 31: 122-7.    ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#65#61#article#117#</font></p>     ^cY
#a06v37n1.htm##
00457000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020800078002001300286#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#66#62#article#117#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Akbaba S, Kayaalp  
  C, Savkilioglu M: Nasogastric decompression after total gastrectomy. Hepatogas
troenterology.    2004; 51: 1881-5.    ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#67#63#article#117#</font></p>     ^cY
#a06v37n1.htm##
00479000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023000078002001300308#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#68#64#article#117#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Chung HY, Yu    W: 
Reevaluation of routine gastrointestinal decompression after gastrectomy    for 
gastric cancer. Hepatogastroenterology. 2003; 50: 1190-2.    ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#69#65#article#117#</font></p>     ^cY
#a06v37n1.htm##
00557000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704030800078002001300386#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#70#66#article#117#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Cutillo G, Maneschi
    F, Franchi M, Giannice R, Scambia G, Benedetti-Panici P: Early feeding compa
red    with nasogastric decompression after major oncologic gynecologic surgery:
 a    randomized study. Obstet Gynecol. 1999; 93: 41-5.    ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#71#67#article#117#</font></p>     ^cY
#a06v37n1.htm##
00512000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026200079002001300341#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#72#68#article#117#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Donat SM, Slaton 
   JW, Pisters LL, Swanson DA: Early nasogastric tube removal combined with meto
clopramide    after radical cystectomy and urinary diversion. J Urol. 1999; 162:
 1599-602.    ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#73#69#article#117#</font></p>     ^cY
#a06v37n1.htm##
00423000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704017300079002001300252#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#74#70#article#117#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Schuster TG,    M
ontie JE: Postoperative ileus after abdominal surgery. Urology. 2002; 59: 465-71
.    ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#75#71#article#117#</font></p>     ^cY
#a06v37n1.htm##
00532000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704028200079002001300361#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#76#72#article#117#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Pruthi RS,    Chu
n J, Richman M: Reducing time to oral diet and hospital discharge in patients   
 undergoing radical cystectomy using a perioperative care plan. Urology. 2003;  
  62: 661-5; discussion 665-6.    ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#77#73#article#117#</font></p>     ^cY
#a06v37n1.htm##
00540000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704029000079002001300369#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#78#74#article#117#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Inman BA, Harel  
  F, Tiguert R, Lacombe L, Fradet Y: Routine nasogastric tubes are not required 
   following cystectomy with urinary diversion: a comparative analysis of 430 pa
tients.    J Urol. 2003; 170: 1888-91.    ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#79#75#article#117#</font></p>     ^cY
#a06v37n1.htm##
00515000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026500079002001300344#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#80#76#article#117#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Park HK, Kwak    
C, Byun SS, Lee E, Lee SE: Early removal of nasogastric tube after cystectomy   
 with urinary diversion: does postoperative ileus risk increase? Urology. 2005; 
   65: 905-8.    ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#81#77#article#117#</font></p>     ^cY
#a06v37n1.htm##
00469000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704021900079002001300298#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#82#78#article#117#15#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Nelson R, Edwards
    S, Tse B: Prophylactic nasogastric decompression after abdominal surgery. Co
chrane    Database Syst Rev. 2007; 3: CD004929.    ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#83#79#article#117#</font></p>     ^cY
#a06v37n1.htm##
00557000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704030700079002001300386#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#84#80#article#117#16#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Constantinides   
 C, Manousakas T, Chrisofos M, Giannopoulos A: Orthotopic bladder substitution  
  after radical cystectomy: 5 years of experience with a novel personal modifica
tion    of the ileal s pouch. J Urol. 2001; 166: 532-7.    ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#85#81#article#117#</font></p>     ^cY
#a06v37n1.htm##
00556000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704030600079002001300385#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#86#82#article#117#17#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Shabsigh A,    Ko
rets R, Vora KC, Brooks CM, Cronin AM, Savage C, et al.: Defining early morbidit
y    of radical cystectomy for patients with bladder cancer using a standardized
    reporting methodology. Eur Urol. 2009; 55: 164-74.    ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#87#83#article#117#</font></p>     ^cY
#a06v37n1.htm##
00535000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704028500079002001300364#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#88#84#article#117#18#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Isbarn H, Jeldres
    C, Zini L, Perrotte P, Baillargeon-Gagne S, Capitanio U, et al.: A populatio
n    based assessment of perioperative mortality after cystectomy for bladder ca
ncer.    J Urol. 2009; 182: 70-7.    ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#89#85#article#117#</font></p>     ^cY
#a06v37n1.htm##
00426000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704017600079002001300255#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#90#86#article#117#19#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Fromang DL,    Dr
ylie DM: Urinary diversion: adjunctive tube gastrostomy. J Urol. 1976; 115:    2
7-8.    ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#91#87#article#117#</font></p>     ^cY
#a06v37n1.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704022300079002001300302#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#92#88#article#117#20#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Van Poppel    H, 
Baert L: The percutaneous operative gastrostomy for gastric decompression    in 
major urological surgery. J Urol. 1991; 145: 100-2.    ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#93#89#article#117#</font></p>     ^cY
#a06v37n1.htm##
00516000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026600079002001300345#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#94#90#article#117#21#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. van Adrichem    N
P, van Leewaarden B, Vos P, Wagenaar J: Gastrostomy instead of gastric intubatio
n    for stomach decompression after large urologic operations. Urologe A. 1993;
    32: 480-1.    ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#95#91#article#117#</font></p>     ^cY
#a06v37n1.htm##
00537000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704028700079002001300366#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#96#92#article#117#22#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Buscarini M,    S
tein JP, Lawrence MA, Lieskovsky G, Skinner DG: Tube gastrostomy after radical  
  cystectomy and urinary diversion: surgical technique and experience in 709 pat
ients.    Urology. 2000; 56: 150-2.    ^cY#a06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#97#93#article#117#</font></p>     ^cY
#a06v37n1.htm##
00493000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704024300079002001300322#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#98#94#article#117#23#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Kouba EJ, Wallen 
   EM, Pruthi RS: Gum chewing stimulates bowel motility in patients undergoing  
  radical cystectomy with urinary diversion. Urology. 2007; 70: 1053-6.    ^cY#a
06v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#99#95#article#117#</font></p>     ^cY
#a06v37n1.htm##
00487000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704023600080002001300316#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#100#96#article#117#24#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Guenaga KK,    M
atos D, Wille-J&oslash;rgensen P: Mechanical bowel preparation for elective    c
olorectal surgery. Cochrane Database Syst Rev. 2009; 1: CD001544.    ^cY#a06v37n
1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#101#97#article#117#</font></p>     ^c
Y#a06v37n1.htm##
00607000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704035600080002001300436#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#102#98#article#117#25#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Maffezzini    M,
 Campodonico F, Canepa G, Gerbi G, Parodi D: Current perioperative management   
 of radical cystectomy with intestinal urinary reconstruction for muscle-invasiv
e    bladder cancer and reduction of the incidence of postoperative ileus. Surg 
Oncol.    2008; 17: 41-8.    ^cY#a06v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#103#99#article#117#</font></p>     ^c
Y#a06v37n1.htm##
00411000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704015900081002001300240#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#104#100#article#117#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Ljungqvist    O
, S&oslash;reide E: Preoperative fasting. Br J Surg. 2003; 90: 400-6.    ^cY#a06
v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#105#101#article#117#</font></p>     ^
cY#a06v37n1.htm##
00431000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017900081002001300260#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#106#102#article#117#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Physicians'    
Desk Reference: Montvale NJ. (56th ed.), Medical Economics Company Inc. 2002;   
 pp. 446.    ^cY#a06v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#107#103#article#117#</font></p>     ^
cY#a06v37n1.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027100081002001300352#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#108#104#article#117#28#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Chang SS, Smith
    JA Jr, Cookson MS: Decreasing blood loss in patients treated with radical cy
stectomy:    a prospective randomizes trial using a new stapling device. J Urol.
 2003; 169:    951-4.    ^cY#a06v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#109#105#article#117#</font></p>     ^
cY#a06v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#110#106#article#117#<p>&nbsp;</p>    
 ^cY#a06v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#111#107#article#117#<p>&nbsp;</p>    
 ^cY#a06v37n1.htm##
00370000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704013300078002001300211#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#112#108#article#117#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><i>Accepted after    revision:    
June 6, 2010</i></font></p>     ^cY#a06v37n1.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019300078002001300271#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#113#109#article#117#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><b><a name="end"></a><a href="#top
"><img src="/img/revistas/ibju/v37n1/seta.gif" border="0"></a>    Correspondence
 to:</b>    ^cY#a06v37n1.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003500078002001300113#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#114#110#article#117#<br>   Dr. Stavro
s Tyritzis    ^cY#a06v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003600078002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#115#111#article#117#<br>   Department
 of Urology    ^cY#a06v37n1.htm##
00284000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004700078002001300125#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#116#112#article#117#<br>   Athens Uni
versity Medical School    ^cY#a06v37n1.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002900078002001300107#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#117#113#article#117#<br>   LAIKO Hosp
ital    ^cY#a06v37n1.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#118#114#article#117#<br>   17 Agiou T
homa str.    ^cY#a06v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003600078002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#119#115#article#117#<br>   11527, Ath
ens, Greece    ^cY#a06v37n1.htm##
00277000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004000078002001300118#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#120#116#article#117#<br>   Fax: + 00 
30 210 932-7744    ^cY#a06v37n1.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009700078002001300175#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a06v37n1.htm#S#p#121#117#article#117#<br>   E-mail: <a
 href="mailto:statyr@freemail.gr%20">statyr@freemail.gr </a></font></p>     ^cY#
a06v37n1.htm##
00654000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100018000930100
02200111010001500133010001900148012010200167030000700269065000900276064000500285
031000400290014000700294865000900301002001300310035001000323801000700333#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#c#122#1#article#28#1#^rND^sChan
g^nSS#^rND^sCookson^nMS#^rND^sBaumgartner^nRG#^rND^sWells^nN#^rND^sSmith^nJA Jr#
Analysis of early complications after radical cystectomy: results of a collabora
tive care pathway^len#J Urol#20020000#2002#167#2012-6#20110200#a06v37n1.htm#0022
-5347#J Urol##
00623000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100018000960100
01400114010001800128012010000146030000900246065000900255064000500264031000400269
014000700273865000900280002001300289035001000302801000900312#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a06v37n1.htm#S#c#123#2#article#28#2#^rND^sCheatham^nML#^rN
D^sChapman^nWC#^rND^sKey^nSP#^rND^sSawyers^nJL#A meta-analysis of selective vers
us routine nasogastric decompression after elective laparotomy^len#Ann Surg#1995
0000#1995#221#469-76#20110200#a06v37n1.htm#0003-4932#Ann Surg##
00652000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100017000970100
01900114010001800133012012100151030001100272065000900283064000500292031000300297
014000700300865000900307002001300316035001000329801001100339#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a06v37n1.htm#S#c#124#3#article#28#3#^rND^sCunningham^nJ#^r
ND^sTemple^nWJ#^rND^sLangevin^nJM#^rND^sKortbeek^nJ#A prospective randomized tri
al of routine postoperative nasogastric decompression in patients with bowel ana
stomosis^len#Can J Surg#19920000#1992#35#629-32#20110200#a06v37n1.htm#0008-428X#
Can J Surg##
00597000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100013000770100016000900100
01400106012010800120030001100228065000900239064000500248031000400253014000700257
865000900264002001300273035001000286801001100296#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a06v37n1.htm#S#c#125#4#article#28#4#^rND^sWu^nCC#^rND^sHwang^nCR#^rND^
sLiu^nTJ#There is no need for nasogastric decompression after partial gastrectom
y with extensive lymphadenectomy^len#Eur J Surg#19940000#1994#160#369-73#2011020
0#a06v37n1.htm#1102-4151#Eur J Surg##
00546000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100015000920120
06900107030001900176065000900195064000500204031000300209014000500212865000900217
002001300226035001000239801001900249#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
6v37n1.htm#S#c#126#5#article#28#5#^rND^sSeenu^nV#^rND^sGoel^nAK#Early oral feedi
ng after elective colorectal surgery: is it safe^len#Trop Gastroenterol#19950000
#1995#16#72-3#20110200#a06v37n1.htm#0250-636X#Trop Gastroenterol##
00690000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100016000940100
01600110010001500126010001600141010001700157012010900174030001300283065000900296
06400050030503100030031001400060031386500090031900200130032803500100034180100130
0351#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#c#127#6#article#28#
6#^rND^sCarrère^nN#^rND^sSeulin^nP#^rND^sJulio^nCH#^rND^sBloom^nE#^rND^sGouzi^nJ
L#^rND^sPradère^nB#Is nasogastric or nasojejunal decompression necessary after g
astrectomy?: A prospective randomized trial^len#World J Surg#20070000#2007#31#12
2-7#20110200#a06v37n1.htm#0364-2313#World J Surg##
00577000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100017000930100
02100110012005400131030002300185065000900208064000500217031000300222014000700225
865000900232002001300241035001000254801002300264#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a06v37n1.htm#S#c#128#7#article#28#7#^rND^sAkbaba^nS#^rND^sKayaalp^nC#^
rND^sSavkilioglu^nM#Nasogastric decompression after total gastrectomy^len#Hepato
gastroenterology#20040000#2004#51#1881-5#20110200#a06v37n1.htm#0172-6390#Hepatog
astroenterology##
00581000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100012000930120
09600105030002300201065000900224064000500233031000300238014000700241865000900248
002001300257035001000270801002300280#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
6v37n1.htm#S#c#129#8#article#28#8#^rND^sChung^nHY#^rND^sYu^nW#Reevaluation of ro
utine gastrointestinal decompression after gastrectomy for gastric cancer^len#He
patogastroenterology#20030000#2003#50#1190-2#20110200#a06v37n1.htm#0172-6390#Hep
atogastroenterology##
00720000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100018000940100
01700112010001800129010001700147010002600164012012000190030001500310065000900325
06400050033403100030033901400050034286500090034700200130035603500100036980100150
0379#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#c#130#9#article#28#
9#^rND^sCutillo^nG#^rND^sManeschi^nF#^rND^sFranchi^nM#^rND^sGiannice^nR#^rND^sSc
ambia^nG#^rND^sBenedetti-Panici^nP#Early feeding compared with nasogastric decom
pression after major oncologic gynecologic surgery: a randomized study^len#Obste
t Gynecol#19990000#1999#93#41-5#20110200#a06v37n1.htm#0029-7844#Obstet Gynecol##
00634000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01800112010001800130012011100148030000700259065000900266064000500275031000400280
014000900284865000900293002001300302035001000315801000700325#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a06v37n1.htm#S#c#131#10#article#28#10#^rND^sDonat^nSM#^rND
^sSlaton^nJW#^rND^sPisters^nLL#^rND^sSwanson^nDA#Early nasogastric tube removal 
combined with metoclopramide after radical cystectomy and urinary diversion^len#
J Urol#19990000#1999#162#1599-602#20110200#a06v37n1.htm#0022-5347#J Urol##
00513000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980120
04800115030000800163065000900171064000500180031000300185014000700188865000900195
002001300204035001000217801000800227#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
6v37n1.htm#S#c#132#11#article#28#11#^rND^sSchuster^nTG#^rND^sMontie^nJE#Postoper
ative ileus after abdominal surgery^len#Urology#20020000#2002#59#465-71#20110200
#a06v37n1.htm#0090-4295#Urology##
00616000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100014000960100
01700110012012800127030000800255065000900263064000500272031000300277014000600280
865000900286002001300295035001000308801000800318#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a06v37n1.htm#S#c#133#12#article#28#12#^rND^sPruthi^nRS#^rND^sChun^nJ#^
rND^sRichman^nM#Reducing time to oral diet and hospital discharge in patients un
dergoing radical cystectomy using a perioperative care plan^len#Urology#20030000
#2003#62#661-5#20110200#a06v37n1.htm#0090-4295#Urology##
00657000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
01700110010001700127010001600144012013100160030000700291065000900298064000500307
031000400312865000900316002001300325035001000338801000700348#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a06v37n1.htm#S#c#134#13#article#28#13#^rND^sInman^nBA#^rND
^sHarel^nF#^rND^sTiguert^nR#^rND^sLacombe^nL#^rND^sFradet^nY#Routine nasogastric
 tubes are not required following cystectomy with urinary diversion: a comparati
ve analysis of 430 patients^len#J Urol#20030000#2003#170#20110200#a06v37n1.htm#0
022-5347#J Urol##
00654000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100014000940100
01500108010001300123010001400136012011900150030000800269065000900277064000500286
031000300291014000600294865000900300002001300309035001000322801000800332#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#c#135#14#article#28#14#^rND^sPa
rk^nHK#^rND^sKwak^nC#^rND^sByun^nSS#^rND^sLee^nE#^rND^sLee^nSE#Early removal of 
nasogastric tube after cystectomy with urinary diversion: does postoperative ile
us risk increase?^len#Urology#20050000#2005#65#905-8#20110200#a06v37n1.htm#0090-
4295#Urology##
00525000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01300112012006700125030002700192710000200219065000900221064000500230032000200235
865000900237002001300246#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S
#c#136#15#article#28#15#^rND^sNelson^nR#^rND^sEdwards^nS#^rND^sTse^nB#Prophylact
ic nasogastric decompression after abdominal surgery^len#Cochrane Database Syst 
Rev#2#20070000#2007#3#20110200#a06v37n1.htm##
00676000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100024000790100020001030100
01900123010002200142012014000164030000700304065000900311064000500320031000400325
014000600329865000900335002001300344035001000357801000700367#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a06v37n1.htm#S#c#137#16#article#28#16#^rND^sConstantinides
^nC#^rND^sManousakas^nT#^rND^sChrisofos^nM#^rND^sGiannopoulos^nA#Orthotopic blad
der substitution after radical cystectomy: 5 years of experience with a novel pe
rsonal modification of the ileal s pouch^len#J Urol#20010000#2001#166#532-7#2011
0200#a06v37n1.htm#0022-5347#J Urol##
00723000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01500113010001700128010001700145010001600162810000600178012012700184030000900311
06500090032006400050032903100030033401400070033786500090034400200130035303500100
0366801000900376#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#c#138#1
7#article#28#17#^rND^sShabsigh^nA#^rND^sKorets^nR#^rND^sVora^nKC#^rND^sBrooks^nC
M#^rND^sCronin^nAM#^rND^sSavage^nC#et al#Defining early morbidity of radical cys
tectomy for patients with bladder cancer using a standardized reporting methodol
ogy^len#Eur Urol#20090000#2009#55#164-74#20110200#a06v37n1.htm#0302-2838#Eur Uro
l##
00700000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01400112010001800126010002700144010001900171810000600190012009700196030000700293
06500090030006400050030903100040031401400050031886500090032300200130033203500100
0345801000700355#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#c#139#1
8#article#28#18#^rND^sIsbarn^nH#^rND^sJeldres^nC#^rND^sZini^nL#^rND^sPerrotte^nP
#^rND^sBaillargeon-Gagne^nS#^rND^sCapitanio^nU#et al#A population based assessme
nt of perioperative mortality after cystectomy for bladder cancer^len#J Urol#200
90000#2009#182#70-7#20110200#a06v37n1.htm#0022-5347#J Urol##
00512000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970120
05100114030000700165065000900172064000500181031000400186014000500190865000900195
002001300204035001000217801000700227#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
6v37n1.htm#S#c#140#19#article#28#19#^rND^sFromang^nDL#^rND^sDrylie^nDM#Urinary d
iversion: adjunctive tube gastrostomy^len#J Urol#19760000#1976#115#27-8#20110200
#a06v37n1.htm#0022-5347#J Urol##
00559000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100015000990120
09700114030000700211065000900218064000500227031000400232014000600236865000900242
002001300251035001000264801000700274#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
6v37n1.htm#S#c#141#20#article#28#20#^rND^sVan Poppel^nH#^rND^sBaert^nL#The percu
taneous operative gastrostomy for gastric decompression in major urological surg
ery^len#J Urol#19910000#1991#145#100-2#20110200#a06v37n1.htm#0022-5347#J Urol##
00638000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100023000790100024001020100
01300126010001800139012010400157030001000261065000900271064000500280031000300285
014000600288865000900294002001300303035001000316801001000326#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a06v37n1.htm#S#c#142#21#article#28#21#^rND^svan Adrichem^n
NP#^rND^svan Leewaarden^nB#^rND^sVos^nP#^rND^sWagenaar^nJ#Gastrostomy instead of
 gastric intubation for stomach decompression after large urologic operations^le
n#Urologe A#19930000#1993#32#480-1#20110200#a06v37n1.htm#0340-2592#Urologe A##
00675000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01900114010002000133010001800153012011900171030000800290065000900298064000500307
031000300312014000600315865000900321002001300330035001000343801000800353#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#c#143#22#article#28#22#^rND^sBu
scarini^nM#^rND^sStein^nJP#^rND^sLawrence^nMA#^rND^sLieskovsky^nG#^rND^sSkinner^
nDG#Tube gastrostomy after radical cystectomy and urinary diversion: surgical te
chnique and experience in 709 patients^len#Urology#20000000#2000#56#150-2#201102
00#a06v37n1.htm#0090-4295#Urology##
00598000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01700112012010700129030000800236065000900244064000500253031000300258014000700261
865000900268002001300277035001000290801000800300#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a06v37n1.htm#S#c#144#23#article#28#23#^rND^sKouba^nEJ#^rND^sWallen^nEM
#^rND^sPruthi^nRS#Gum chewing stimulates bowel motility in patients undergoing r
adical cystectomy with urinary diversion^len#Urology#20070000#2007#70#1053-6#201
10200#a06v37n1.htm#0090-4295#Urology##
00535000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100015000970100
02500112012006500137030002700202710000200229065000900231064000500240032000200245
865000900247002001300256#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S
#c#145#24#article#28#24#^rND^sGuenaga^nKK#^rND^sMatos^nD#^rND^sWille-Jørgensen^n
P#Mechanical bowel preparation for elective colorectal surgery^len#Cochrane Data
base Syst Rev#2#20090000#2009#1#20110200#a06v37n1.htm##
00744000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100021000990100
01600120010001500136010001600151012018700167030001100354065000900365064000500374
031000300379014000500382865000900387002001300396035001000409801001100419#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#c#146#25#article#28#25#^rND^sMa
ffezzini^nM#^rND^sCampodonico^nF#^rND^sCanepa^nG#^rND^sGerbi^nG#^rND^sParodi^nD#
Current perioperative management of radical cystectomy with intestinal urinary r
econstruction for muscle-invasive bladder cancer and reduction of the incidence 
of postoperative ileus^len#Surg Oncol#20080000#2008#17#41-8#20110200#a06v37n1.ht
m#0960-7404#Surg Oncol##
00494000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100017000990120
02500116030001000141065000900151064000500160031000300165014000600168865000900174
002001300183035001000196801001000206#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
6v37n1.htm#S#c#147#26#article#28#26#^rND^sLjungqvist^nO#^rND^sSøreide^nE#Preoper
ative fasting^len#Br J Surg#20030000#2003#90#400-6#20110200#a06v37n1.htm#0007-13
23#Br J Surg##
00444000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760180031000790160019001100630
00300129062003000132065000900162064000500171014000400176865000900180002001300189
#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a06v37n1.htm#S#c#148#27#article#28#27#
Physicians' Desk Reference^len#^rND^sMontvale^nNJ#56#Medical Economics Company I
nc#20020000#2002#446#20110200#a06v37n1.htm##
00622000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100019000950100
01800114012013000132030000700262065000900269064000500278031000400283014000600287
865000900293002001300302035001000315801000700325#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a06v37n1.htm#S#c#149#28#article#28#28#^rND^sChang^nSS#^rND^sSmith^nJA 
Jr#^rND^sCookson^nMS#Decreasing blood loss in patients treated with radical cyst
ectomy: a prospective randomizes trial using a new stapling device^len#J Urol#20
030000#2003#169#951-4#20110200#a06v37n1.htm#0022-5347#J Urol##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#o#1#1#article#1
#20110330#144506#a07v37n1.htm#157##
02674000000000505000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090038000400094121000300098049000800101158000300109
03000180011203100030013003200020013306500090013501400090014403500100015301200840
01630100033002470100023002800100031003030100023003340100035003570700099003920831
54500491085001002036085003802046085002302084085002202107085001702129117000602146
072000302152002001302155#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S
#h#2#1#article#1#oa#en#br1.1#1#4.0#GRA#TAB#07#IBJU010#nd#Int. braz j urol.#37#1#
20110200#^f49^l56#1677-5538#Invasive bladder cancer in the eighties: transurethr
al resection or cystectomy?^len#^rND^1A01^nOscar Rodriguez^sFaba#^rND^1A01^nJoan
^sPalou#^rND^1A01^nGuillermo^sUrdaneta#^rND^1A01^nLuis^sGausa#^rND^1A01^nHumbert
o^sVillavicencio#Universitat Autonoma de Barcelona^iA01^1Fundacio Puigvert^2Depa
rtment of Urology^cBarcelona^pSpain#^len^aPURPOSE: Describe morbidity and surviv
al in patients older than 80 years with muscle invasive bladder cancer (MIBC) tr
eated with radical cystectomy (RC) or transurethral resection (TUR) in our insti
tution. MATERIALS AND METHODS: We reviewed our database of all patients older th
an 80 years treated with RC and TUR for MIBC between 1993 and 2005 in our instit
ution. Twenty-seven patients were submitted to RC, with mean age of 82 years and
 mean follow-up of 16.4 months. RC was carried out following diagnosis of previo
us MIBC in 14 cases (51.9%). The American Society of Anesthesiology (ASA) score 
was III or IV in 23 patients (85.1%). Seventy-two patients with a mean age of 84
 years and mean follow-up of 33 months, diagnosed with MIBC, were managed by mea
ns of TUR. The ASA score was III-IV in 64 (88.8%) patients. RESULTS: Pathologica
l stage of the RC specimen was pT3 in 18 cases (66.7%). Mean hospital stay was 1
6 days. Early complications were assessed in 8 patients (29.6%), with an overall
 survival (OS) of 42.94%, and cancer-specific survival (CSS) of 60.54%. In patie
nts submitted to TUR, clinical stage was T2 in 36 cases (50%). The mean hospital
 stay was 7 days, with a readmission rate (RR) of 87.5%. OS and CSS was less tha
n 20%. CONCLUSIONS: RC in octogenarian patients is a safe procedure, with compli
cation and survival rates comparable to RC series in general population. Transur
ethral resection (TUR) for patients with MIBC within this age range is a much le
ss morbid procedure, but disease specific survival is lower.#^ddecs^i1#^tm^len^k
urinary bladder neoplasms^i1#^tm^len^kcystectomy^i1#^tm^len^kendoscopy^i1#^tm^le
n^kaged^i1#other#22#a07v37n1.htm##
02709000000000505000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090038000400094121000300098049000800101158000300109
03000180011203100030013003200020013306500090013501400090014403500100015301200910
01630100033002540100023002870100031003100100023003410100035003640700099003990831
57300498085001002071085003802081085002302119085002202142085001702164117000602181
072000302187002001302190#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S
#f#3#1#article#1#oa#en#br1.1#1#4.0#GRA#TAB#07#IBJU010#nd#Int. braz j urol.#37#1#
20110200#^f49^l56#1677-5538#<b>Invasive bladder cancer in the eighties: transure
thral resection or cystectomy?</b>^len#^rND^1A01^nOscar Rodriguez^sFaba#^rND^1A0
1^nJoan^sPalou#^rND^1A01^nGuillermo^sUrdaneta#^rND^1A01^nLuis^sGausa#^rND^1A01^n
Humberto^sVillavicencio#Universitat Autonoma de Barcelona^iA01^1Fundacio Puigver
t^2Department of Urology^cBarcelona^pSpain#^len^a<b>PURPOSE:</b> Describe morbid
ity and survival in patients older than 80 years with muscle invasive bladder ca
ncer (MIBC) treated with radical cystectomy (RC) or transurethral resection (TUR
) in our institution. <b>MATERIALS AND METHODS:</b> We reviewed our database of 
all patients older than 80 years treated with RC and TUR for MIBC between 1993 a
nd 2005 in our institution. Twenty-seven patients were submitted to RC, with mea
n age of 82 years and mean follow-up of 16.4 months. RC was carried out followin
g diagnosis of previous MIBC in 14 cases (51.9%). The American Society of Anesth
esiology (ASA) score was III or IV in 23 patients (85.1%). Seventy-two patients 
with a mean age of 84 years and mean follow-up of 33 months, diagnosed with MIBC
, were managed by means of TUR. The ASA score was III-IV in 64 (88.8%) patients.
 <b>RESULTS:</b> Pathological stage of the RC specimen was pT3 in 18 cases (66.7
%). Mean hospital stay was 16 days. Early complications were assessed in 8 patie
nts (29.6%), with an overall survival (OS) of 42.94%, and cancer-specific surviv
al (CSS) of 60.54%. In patients submitted to TUR, clinical stage was T2 in 36 ca
ses (50%). The mean hospital stay was 7 days, with a readmission rate (RR) of 87
.5%. OS and CSS was less than 20%. <b>CONCLUSIONS:</b> RC in octogenarian patien
ts is a safe procedure, with complication and survival rates comparable to RC se
ries in general population. Transurethral resection (TUR) for patients with MIBC
 within this age range is a much less morbid procedure, but disease specific sur
vival is lower.#^ddecs^i1#^tm^len^kurinary bladder neoplasms^i1#^tm^len^kcystect
omy^i1#^tm^len^kendoscopy^i1#^tm^len^kaged^i1#other#22#a07v37n1.htm##
02876000000000529000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000400108038000400112121000300116049000800119
15800030012703000170013003100030014703200020015006500090015201400090016103500100
01700120084001800100033002640100023002970100031003200100023003510100035003740700
10100409083161500510085001002125085003802135085002302173085002202196085001702218
117000602235072000302241002001302244008008902257#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a07v37n1.htm#S#l#4#1#article#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#gra
#tab#07#IBJU010#nd#Int. braz j urol#37#1#20110200#^f49^l56#1677-5538#Invasive bl
adder cancer in the eighties: transurethral resection or cystectomy?^len#^rND^1A
01^nOscar Rodriguez^sFaba#^rND^1A01^nJoan^sPalou#^rND^1A01^nGuillermo^sUrdaneta#
^rND^1A01^nLuis^sGausa#^rND^1A01^nHumberto^sVillavicencio#^iA01^1Universitat Aut
onoma de Barcelona^2Fundacio Puigvert^3Department of Urology^cBarcelona^pSpain#^
len^aPURPOSE: Describe morbidity and survival in patients older than 80 years wi
th muscle invasive bladder cancer (MIBC) treated with radical cystectomy (RC) or
 transurethral resection (TUR) in our institution. MATERIALS AND METHODS: We rev
iewed our database of all patients older than 80 years treated with RC and TUR f
or MIBC between 1993 and 2005 in our institution. Twenty-seven patients were sub
mitted to RC, with mean age of 82 years and mean follow-up of 16.4 months. RC wa
s carried out following diagnosis of previous MIBC in 14 cases (51.9 percent). T
he American Society of Anesthesiology (ASA) score was III or IV in 23 patients (
85.1 percent). Seventy-two patients with a mean age of 84 years and mean follow-
up of 33 months, diagnosed with MIBC, were managed by means of TUR. The ASA scor
e was III-IV in 64 (88.8 percent) patients. RESULTS: Pathological stage of the R
C specimen was pT3 in 18 cases (66.7 percent). Mean hospital stay was 16 days. E
arly complications were assessed in 8 patients (29.6 percent), with an overall s
urvival (OS) of 42.94 percent, and cancer-specific survival (CSS) of 60.54 perce
nt. In patients submitted to TUR, clinical stage was T2 in 36 cases (50 percent)
. The mean hospital stay was 7 days, with a readmission rate (RR) of 87.5 percen
t. OS and CSS was less than 20 percent. CONCLUSIONS: RC in octogenarian patients
 is a safe procedure, with complication and survival rates comparable to RC seri
es in general population. Transurethral resection (TUR) for patients with MIBC w
ithin this age range is a much less morbid procedure, but disease specific survi
val is lower.#^ddecs^i1#^tm^len^kurinary bladder neoplasms^i1#^tm^len^kcystectom
y^i1#^tm^len^kendoscopy^i1#^tm^len^kaged^i1#other#22#a07v37n1.htm#Internet^ihttp
://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382011000100007##
00356000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012300074002001300197#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#5#1#article#131#<p align="right"><fon
t face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>CLINICAL    UROLOGY</
b></font></p>     ^cY#a07v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#6#2#article#131#<p>&nbsp;</p>     ^cY
#a07v37n1.htm##
00422000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704018900074002001300263#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#7#3#article#131#<p><a name="top"></a>
<font face="Verdana, Arial, Helvetica, sans-serif"size="4"><b>Invasive    bladde
r cancer in the eighties: transurethral resection or cystectomy?</b></font></p> 
    ^cY#a07v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#8#4#article#131#<p>&nbsp;</p>     ^cY
#a07v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#9#5#article#131#<p>&nbsp;</p>     ^cY
#a07v37n1.htm##
00415000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704018100075002001300256#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#10#6#article#131#<p><font face="Verda
na, Arial, Helvetica, sans-serif" size="2"><b>Oscar Rodriguez    Faba; Joan Palo
u; Guillermo Urdaneta; Luis Gausa; Humberto Villavicencio</b></font></p>     ^cY
#a07v37n1.htm##
00413000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704017900075002001300254#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#11#7#article#131#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Department of Urology,    Fundacio Pu
igvert, Universitat Autonoma de Barcelona, Barcelona, Spain</font></p>     ^cY#a
07v37n1.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011600075002001300191#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#12#8#article#131#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#end">Correspondence</a></fo
nt></p>     ^cY#a07v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#13#9#article#131#<p>&nbsp;</p>     ^c
Y#a07v37n1.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#14#10#article#131#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a07v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#15#11#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#a
07v37n1.htm##
00527000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029200076002001300368#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#16#12#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>PURPOSE:</b>    Describe morbidit
y and survival in patients older than 80 years with muscle    invasive bladder c
ancer (MIBC) treated with radical cystectomy (RC) or transurethral    resection 
(TUR) in our institution.    ^cY#a07v37n1.htm##
00889000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065400076002001300730#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#17#13#article#131#<br>   <b>MATERIALS
 AND METHODS:</b> We reviewed our database of all patients older    than 80 year
s treated with RC and TUR for MIBC between 1993 and 2005 in our    institution. 
Twenty-seven patients were submitted to RC, with mean age of 82    years and mea
n follow-up of 16.4 months. RC was carried out following diagnosis    of previou
s MIBC in 14 cases (51.9%). The American Society of Anesthesiology    (ASA) scor
e was III or IV in 23 patients (85.1%). Seventy-two patients with    a mean age 
of 84 years and mean follow-up of 33 months, diagnosed with MIBC,    were manage
d by means of TUR. The ASA score was III-IV in 64 (88.8%) patients.    ^cY#a07v3
7n1.htm##
00698000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046300076002001300539#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#18#14#article#131#<br>   <b>RESULTS:<
/b> Pathological stage of the RC specimen was pT3 in 18 cases (66.7%).    Mean h
ospital stay was 16 days. Early complications were assessed in 8 patients    (29
.6%), with an overall survival (OS) of 42.94%, and cancer-specific survival    (
CSS) of 60.54%. In patients submitted to TUR, clinical stage was T2 in 36 cases 
   (50%). The mean hospital stay was 7 days, with a readmission rate (RR) of 87.
5%.    OS and CSS was less than 20%.    ^cY#a07v37n1.htm##
00571000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033600076002001300412#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#19#15#article#131#<br>   <b>CONCLUSIO
NS:</b> RC in octogenarian patients is a safe procedure, with complication    an
d survival rates comparable to RC series in general population. Transurethral   
 resection (TUR) for patients with MIBC within this age range is a much less    
morbid procedure, but disease specific survival is lower.</font></p>     ^cY#a07
v37n1.htm##
00415000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018000076002001300256#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#20#16#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Key words:</b>    urinary bladder
 neoplasms; cystectomy; endoscopy; aged</font></p> <HR size="1" noshade>     ^cY
#a07v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#21#17#article#131#<p>&nbsp;</p>     ^
cY#a07v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#22#18#article#131#<p>&nbsp;</p>     ^
cY#a07v37n1.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#23#19#article#131#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODUCTION</b></font></p>     ^
cY#a07v37n1.htm##
00727000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049200076002001300568#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#24#20#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The increased incidence    and preva
lence of genitourinary neoplasias over the last few decades can be    attributed
 to demographic evolution and increased life expectancy. </font><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The    National Cancer Institute has
 estimated that 89% of the bladder tumors are found    in patients older than 55
, and that the mean age at diagnosis, is 73 years(1).</font></p>     ^cY#a07v37n
1.htm##
00522000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028700076002001300363#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#25#21#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Standard treatment    for muscle inv
asive bladder cancer (MIBC) is radical cystectomy with bilateral    pelvic lymph
adenectomy, and is justified in patients with life expectancy greater    than tw
o years.</font></p>     ^cY#a07v37n1.htm##
00960000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072500076002001300801#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#26#22#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In patients more    than 80 years ol
d radical surgery tends to be avoided, since is believed to    be associated wit
h increased morbidity and mortality rates. Historically those    patients have b
een treated with TUR that is a less aggressive procedure. It    is now accepted 
that the American Society of Anesthesiology (ASA) score for    patients undergoi
ng a major procedure is a predictive factor for morbidity and    mortality which
 is more significant than age alone (2). For the last seven years    we have act
ively performed radical cystectomy (RC) in patients of advanced age    with an A
SA score compatible with this type of surgery.</font></p>     ^cY#a07v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#27#23#article#131#<p>&nbsp;</p>     ^
cY#a07v37n1.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011400076002001300190#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#28#24#article#131#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>MATERIALS AND    METHODS</b></fon
t></p>     ^cY#a07v37n1.htm##
00528000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029300076002001300369#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#29#25#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> We reviewed our    database of all 
patients that were treated with either RC or TUR between 1993    and 2005 for in
vasive bladder cancer and age over 80 that did not receive neoadjuvant    or adj
uvant therapy.</font></p>     ^cY#a07v37n1.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010500076002001300181#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#30#26#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Radical Surgery</b></font></p>   
  ^cY#a07v37n1.htm##
00987000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704075200076002001300828#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#31#27#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Twenty-seven patients    over 80 ye
ars with MIBC were submitted to RC and urinary diversion at our institution    b
etween 1993 and 2005. Twenty-two (81.5%) were males and 5 (18.5%) females with  
  mean age 82 &plusmn; 3 years (range 80 - 91 years). Inclusion criteria for the
    patients were detailed medical history, a physical examination, cardiovascul
ar    and pulmonary parameters including their metabolic and nutritional status.
 Indications    of RC were based on finding MIBC in TUR, or recurrent high-grade
 superficial    tumors unresponsive to Bacillus Calmette-Guerin (BCG) therapy. B
efore surgery    all patients were staged according to the ASA score (3).</font>
</p>     ^cY#a07v37n1.htm##
00478000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024300076002001300319#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#32#28#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Following surgery    patients were m
onitored at the post-operative care unit during 24 hours. Ureteral    catheters 
were removed 7-10 days following cystectomy.</font></p>     ^cY#a07v37n1.htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011600076002001300192#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#33#29#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Transurethral    Resection</b></f
ont></p>     ^cY#a07v37n1.htm##
00862000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062700076002001300703#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#34#30#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> A total of 72    patients (59 males
 and 13 females) over 80 years old were staged for MIBC and    suitable for TUR.
 All cases were staged with bimanual examination under anesthesia    and underwe
nt TUR (complete or palliative). Multiple random biopsies were taken    to docum
ent presence of carcinoma in situ. Follow-up consisted of cystoscopy    and TUR 
if recurrence and/or progression occurred. During follow-up, the numbers    of r
e-admittance and health state of the patients were considered to evaluate    the
 progression of the disease.</font></p>     ^cY#a07v37n1.htm##
00685000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045000076002001300526#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#35#31#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Peri-operative    mortality was defi
ned as all-cause death up to 30 days after surgery. The overall    mortality rat
e included cancer-related or cancer-unrelated deaths. The morbidity    rate incl
uded early complications considered adverse effects in the course of    hospital
ization or 30 days post-surgery and late complications longer than 30    days po
st-surgery.</font></p>     ^cY#a07v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#36#32#article#131#<p>&nbsp;</p>     ^
cY#a07v37n1.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#37#33#article#131#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESULTS</b></font></p>     ^cY#a0
7v37n1.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#38#34#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Cystectomy</b></font></p>     ^cY
#a07v37n1.htm##
00592000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035700076002001300433#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#39#35#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Pathology of radical    cystectomy 
(RC) revealed urothelial carcinoma in 26 of the 27 patients (96.3%).    Stage wa
s pT3 in 18 cases (66.7%) and association with prostate carcinoma was    found i
n 10 cases (37%) (<a href="/img/revistas/ibju/v37n1/a07tab1.jpg">Table-1</a>).</
font></p>     ^cY#a07v37n1.htm##
00486000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025100076002001300327#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#40#36#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Urinary diversion    was ileal condu
it in 24 (88.8%) patients, cutaneous diversion in two patients    (7.40%) and St
uder orthotopic substitution in one patient (3.80%).</font></p>     ^cY#a07v37n1
.htm##
00689000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045400076002001300530#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#41#37#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Concomitant cardiovascular    diseas
e was the most frequent co-morbidity, with hypertension in 10 patients    (37%),
 previous acute myocardial infarction in 3 patients (11.1%) and arrhythmia    in
 2 patients (7.4%). Other concomitant pathologies were diabetes mellitus in    4
 patients (14.8%), bronchial asthma in 1 patient (3.7%) and emphysema in 3    pa
tients (11.1%).</font></p>     ^cY#a07v37n1.htm##
00809000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057400076002001300650#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#42#38#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Intra- or post-operative    blood tr
ansfusion was necessary in 10 patients (37%); furthermore there were    two case
s (7.4%) of intraoperative mortality. Early complications occurred in    8 patie
nts (29.6%) and were paralytic ileus in 4 patients, wound infection in    3, int
ra-abdominal abscess in 1 patient and entero-cutaneous fistula in another    one
. The major complications were: acute myocardial infarction in one patient    an
d another patient require re-operation due to bleeding.</font></p>     ^cY#a07v3
7n1.htm##
00441000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020600076002001300282#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#43#39#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The mean hospital    stay was 16 day
s (8-28) and the mean follow-up of these patients was 16.4 months    (1.4-84.2 m
onths).</font></p>     ^cY#a07v37n1.htm##
00446000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021100076002001300287#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#44#40#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Distant disease    was found in 8 pa
tients during follow-up: four of those diseases involved lymph    nodes and 4 we
re multiple.</font></p>     ^cY#a07v37n1.htm##
00522000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028700076002001300363#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#45#41#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Overall survival    (OS) was 42.94% 
and cancer specific survival (CSS) 60.54 % (<a href="/img/revistas/ibju/v37n1/a0
7tab2.jpg">Table-2</a>,    <a href="/img/revistas/ibju/v37n1/a07fig1.jpg">Figure
-1</a>).</font></p>     ^cY#a07v37n1.htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011600076002001300192#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#46#42#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Transurethral    Resection</b></f
ont></p>     ^cY#a07v37n1.htm##
00657000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042200076002001300498#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#47#43#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> In patients submitted    to TUR, th
e stage was cT2 in 36 cases (50%), cT3 in 10 cases (13.9%), cT2-T3    in 24 case
s (33.3%), and cT4 in 2 cases (2.8%). Grade was G3 in 49 cases (68%).    Forty-n
ine patients (68%) had a complete TUR, whereas in 32% resection was incomplete  
  (<a href="/img/revistas/ibju/v37n1/a07tab1.jpg">Table-1</a>).</font></p>     ^
cY#a07v37n1.htm##
01026000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704079100076002001300867#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#48#44#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Intra- or post-operative    blood tr
ansfusion was necessary in 10 patients (13.8%), and there was no case    of intr
a-operative death. Regarding early complications, hemostatic intervention    was
 required in 6 patients (8.3%), and 2 patients showed manifestations of hemodyna
mic    angina that required intensive care. The mean hospital stay was 7 days; w
ith    a readmission rate of 87.5% (thirty patients had 1 readmission, 11 patien
ts    had 2 readmissions and 11 patients had 3 or more readmissions). The mean f
ollow-up    was 19 months with an overall and CSS of less than 20% (<a href="/im
g/revistas/ibju/v37n1/a07tab2.jpg">Table-2</a>,    <a href="/img/revistas/ibju/v
37n1/a07fig2.jpg">Figure-2</a>).</font></p>     ^cY#a07v37n1.htm##
00490000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025500076002001300331#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#49#45#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">At the end of the    follow-up, 8 pa
tients (11%) were alive, 47 (65%) had died due to cancer, 7 (9.7%)    had died d
ue to other causes, and 7 (9.7%) were lost to follow-up.</font></p>     ^cY#a07v
37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#50#46#article#131#<p>&nbsp;</p>     ^
cY#a07v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#51#47#article#131#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>COMMENTS</b></font></p>     ^cY#a
07v37n1.htm##
01202000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704096700076002001301043#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#52#48#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> In the past, advanced    age was a 
contraindication for cystectomy; some studies reported peri-operative    mortali
ty rates of 5.5% in patients younger than 60, versus 11% in patients    between 
60 and 70 years old (4). Improvements in the surgical technique, anesthetic    m
anagement and post-operative care have brought a reduction of major complication
s    from an initial 51% down to the current 10-30%, and the mortality rate subs
equent    to surgery has decreased to 2% (5), with transfusion, hospital stay, e
arly and    late complications and survival rates comparable to those of patient
s younger    than 65 years. Moreover, patients presenting with an ASA score comp
atible with    a major intervention are eligible for cystectomy because when it 
is compatible    with major procedures, it reflects the functional status of a p
atient more accurately    than age itself (2,3).</font></p>     ^cY#a07v37n1.htm
##
00555000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032000076002001300396#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#53#49#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Fifteen years ago,    at our institu
tion we only performed TUR. Later we started doing RC throughout    the eighties
, with two main objectives: improve local control disease with better    oncolog
ical outcomes and minimize complications.</font></p>     ^cY#a07v37n1.htm##
01328000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704109300076002001301169#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#54#50#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Regarding local    control disease, 
the proportion of patients with advanced pathological stage    in our series was
 the highest one of all the series reviewed (81.48%) (6-8);    supporting the RC
 indication, since application of conservative alternatives    (TUR) would yield
 a much poorer tumor control. Moreover, our 42.94% OS rate    is similar to pT3 
series published in younger population (9,10) and the difference    in elderly p
atient data, is because of a shorter follow-up. As to the CSS rate    we obtaine
d 60.54% and observed important differences at each stage. If we compare    pati
ents with pathologic stage pT2 to the rest of grouped stages, at our follow-up  
  period, all of the pT2 patients continue to be alive, whereas survival of the 
   rest of groups was 55.48%. Most series reviewed report CSS rates between 62% 
   and 84% (11-14) and no significant differences regarding OS or CSS were found
    in the series reviewed between patients younger and older than 70 years for 
   RC (15,16).</font></p>     ^cY#a07v37n1.htm##
00997000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076200076002001300838#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#55#51#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Comparing these    results with tran
surethral resection of bladder tumor (TURBT) for MIBC, good    results are shown
 in case of small T2 tumors (17,18). Our survival rate is below    20%, but we a
re dealing with not-selected patients with large tumor volumes    (32% of them r
eceived only palliative TUR). At the end of the follow-up, only    8 patients (1
1%) were alive and the OS rate was lower than 20% independently    of the TUR be
ing complete or partial (Figure-2). Therefore, compared to RC for    this age gr
oup and with a similar follow-up, even if it is not a prospective    and randomi
zed study; overall and cancer-specific survivals are much more favorable    for 
RC.</font></p>     ^cY#a07v37n1.htm##
01372000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704113700076002001301213#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#56#52#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Regarding complications,    intra-op
erative mortality in our series show two cases (7.40%), whereas most    studies 
reviewed, show rates between 0% and 7.40%. The published series comparing    int
ra operative mortality among patients younger and older than 70 shown no    sign
ificant differences between both groups (15). Therefore, peri-operative    morta
lity in the published RC series, some of them with 30 years of follow-up    and 
with 1,359 patients with a mean 67 years of age, was only 2% (19); in this    pe
riod the primary causes of mortality were those due to cardiovascular decompensa
tion,    sepsis frequently related to urinary or bowel fistula, pulmonary emboli
sm and    massive postoperative hemorrhage. In case of TUR we do not have any ca
ses of    intraoperative or perioperative mortality. The most frequent intraoper
ative    complications were hemorrhage that was responsible for re-intervention 
in 84%    of cases, perforation in 1.3% with incidence that is variable in the v
arious    series consulted (2.5-5%) (20) and TUR syndrome.</font></p>     ^cY#a0
7v37n1.htm##
01006000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077100076002001300847#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#57#53#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Ten patients (37%)    required eithe
r intra- or post-operative blood transfusion, and the mean of    transfused unit
s was two (1-3). If differences between the mean units transfused    and bleedin
g in patients younger and older than 70 are compared, significant    differences
 between both groups regarding the mean bleeding in mL and in the    number of t
ransfused patients are found, even though transfused patients are    larger in n
umber in the older-than-70 group (9). In case of our TUR series,    transfusion 
was necessary in 10 patients (13.8%) that is lower compared with    the RC group
, but higher if it is compared with our global transfusion rate    in TUR that i
s 3.4% (21).</font></p>     ^cY#a07v37n1.htm##
00885000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065000076002001300726#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#58#54#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The mean hospitalization    stay of 
our patients in the group of RC was 16 days (range 8-28). Hospital stay    varie
s between 7-34 days, and in our experience prolongation of hospital stay    in p
atients older than 80 is related with the more difficult solution of their    ma
jor complications. Moreover, patients with a poor ASA score will potentially    
be at greater risk of urinary derivation-related post-operative fistulae (2).   
 In our series, the only patient that developed an entero-cutaneous fistula in  
  the postoperative period had an ASA score of III.</font></p>     ^cY#a07v37n1.
htm##
00637000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040200076002001300478#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#59#55#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">TUR group reflect    a mean hospital
ization stay of seven days that is much better than the RC group,    related to 
the lower impact of the endoscopic surgery for the patient. The problem    with 
this group is a readmission rate that was 87%, related in most cases with    hem
aturia in the context of tumor persistence.</font></p>     ^cY#a07v37n1.htm##
00968000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704073300076002001300809#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#60#56#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The evaluation    of the risk-benefi
t ratio of the radio-chemotheraphy protocols in this cohort    of patients over 
80 with co-morbidities avoided their use. Available meta-analysis    of randomiz
ed trials on cisplatin-containing combination neoadjuvant chemotherapy    reveal
ed a 5% difference in favor of neoadjuvant chemotherapy, and no randomized    tr
ials have yet compared survival with TURBT alone versus cystectomy for the    ma
nagement of patients with muscle-invasive disease, moreover collaborative    int
ernational adjuvant chemotherapy trials are needed to assist researchers    in a
ssessing the true value of adjuvant chemotherapy (22).</font></p>     ^cY#a07v37
n1.htm##
00530000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029500076002001300371#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#61#57#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Limitation of this    study is that 
it was a descriptive, and not a comparative analysis of two independent    serie
s of patients. Further prospective randomized trials are necessary to confirm   
 these findings.</font></p>     ^cY#a07v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#62#58#article#131#<p>&nbsp;</p>     ^
cY#a07v37n1.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010100076002001300177#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#63#59#article#131#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUSIONS</b></font></p>     ^c
Y#a07v37n1.htm##
00605000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037000076002001300446#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#64#60#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> RC in octogenarian    patients is a
 safe procedure, with complication and survival rates comparable    to those of 
the series of patients younger than 80, and therefore we consider    that age is
 not a contraindication of surgery if it is not accompanied by an    unfavorable
 ASA score.</font></p>     ^cY#a07v37n1.htm##
00445000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021000076002001300286#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#65#61#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">TUR for patients    with MIBC within
 this age range is a much less morbid procedure, but disease    specific surviva
l is lower.</font></p>     ^cY#a07v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#66#62#article#131#<p>&nbsp;</p>     ^
cY#a07v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#67#63#article#131#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONFLICT OF    INTEREST</b></font
></p>     ^cY#a07v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#68#64#article#131#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> None declared.</font></p>     ^cY#a
07v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#69#65#article#131#<p>&nbsp;</p>     ^
cY#a07v37n1.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#70#66#article#131#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFERENCES</b></font></p>     ^cY
#a07v37n1.htm##
00785000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704053600078002001300614#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#71#67#article#131#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 1. Ries LAG, Melbert 
   D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Fe
uer    EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK (E
d.),    SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bet
hesda,    MD, <a href="http://seer.cancer.gov/csr/1975_2005/" target="_blank">ht
tp://seer.cancer.gov/csr/1975_2005/</a>,    based on November 2007 SEER data sub
mission, posted to the SEER web site, 2008.    ^cY#a07v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#72#68#article#131#</font>  </p>     ^
cY#a07v37n1.htm##
00525000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027600078002001300354#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#73#69#article#131#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Malavaud B,    Vaes
sen C, Mouzin M, Rischmann P, Sarramon J, Schulman C: Complications for    radic
al cystectomy. Impact of the American Society of Anesthesiologists score.    Eur
 Urol. 2001; 39: 79-84.    ^cY#a07v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#74#70#article#131#</font></p>     ^cY
#a07v37n1.htm##
00499000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025000078002001300328#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#75#71#article#131#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Wolters U, Wolf    
T, St&uuml;tzer H, Schr&ouml;der T: ASA classification and perioperative variabl
es    as predictors of postoperative outcome. Br J Anaesth. 1996; 77: 217-22.   
 ^cY#a07v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#76#72#article#131#</font></p>     ^cY
#a07v37n1.htm##
00437000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704018800078002001300266#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#77#73#article#131#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Zincke H: Cystectom
y    and urinary diversion in patients eighty years old or older. Urology. 1982;
    19: 139-42.    ^cY#a07v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#78#74#article#131#</font></p>     ^cY
#a07v37n1.htm##
00545000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029600078002001300374#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#79#75#article#131#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. George L, Bladou   
 F, Bardou VJ, Gravis G, Tallet A, Alzieu C, et al.: Clinical outcome in patient
s    with locally advanced bladder carcinoma treated with conservative multimoda
lity    therapy. Urology. 2004; 64: 488-93.    ^cY#a07v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#80#76#article#131#</font></p>     ^cY
#a07v37n1.htm##
00551000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704030200078002001300380#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#81#77#article#131#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Souli&eacute;    M,
 Straub M, Gam&eacute; X, Seguin P, De Petriconi R, Plante P, et al.: A multicen
ter    study of the morbidity of radical cystectomy in select elderly patients w
ith    bladder cancer. J Urol. 2002; 167: 1325-8.    ^cY#a07v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#82#78#article#131#</font></p>     ^cY
#a07v37n1.htm##
00462000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021300078002001300291#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#83#79#article#131#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Chang SS, Alberts  
  G, Cookson MS, Smith JA Jr: Radical cystectomy is safe in elderly patients at 
   high risk. J Urol. 2001; 166: 938-41.    ^cY#a07v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#84#80#article#131#</font></p>     ^cY
#a07v37n1.htm##
00531000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028200078002001300360#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#85#81#article#131#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Clark PE, Stein    
JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, et al.: Radical cystectomy in   
 the elderly: comparison of clincal outcomes between younger and older patients.
    Cancer. 2005; 104: 36-43.    ^cY#a07v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#86#82#article#131#</font></p>     ^cY
#a07v37n1.htm##
00459000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021000078002001300288#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#87#83#article#131#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Kulovac B, Aganovic
    D, Prcic A: Radical cystectomy early postoperative complications and mortali
ty    rate. Med Arh. 2005; 59: 358-9.    ^cY#a07v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#88#84#article#131#</font></p>     ^cY
#a07v37n1.htm##
00503000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704025300079002001300332#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#89#85#article#131#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Soloway MS,    Lo
pez AE, Patel J, Lu Y: Results of radical cystectomy for transitional cell    ca
rcinoma of the bladder and the effect of chemotherapy. Cancer. 1994; 73: 1926-31
.    ^cY#a07v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#90#86#article#131#</font></p>     ^cY
#a07v37n1.htm##
00537000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704028700079002001300366#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#91#87#article#131#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Gam&eacute;    X,
 Souli&eacute; M, Seguin P, Vazzoler N, Tollon C, Pontonnier F, et al.: Radical 
   cystectomy in patients older than 75 years: assessment of morbidity and morta
lity.    Eur Urol. 2001; 39: 525-9.    ^cY#a07v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#92#88#article#131#</font></p>     ^cY
#a07v37n1.htm##
00442000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704019200079002001300271#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#93#89#article#131#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Stroumbakis    N,
 Herr HW, Cookson MS, Fair WR: Radical cystectomy in the octogenarian. J Urol.  
  1997; 158: 2113-7.    ^cY#a07v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#94#90#article#131#</font></p>     ^cY
#a07v37n1.htm##
00494000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704024400079002001300323#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#95#91#article#131#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Ogawa A, Yanagisa
wa    Y, Nakamoto T, Wajiki M, Hirabayashi N, Nakama M: Treatment of bladder car
cinoma    in patients more than 80 years old. J Urol. 1985; 134: 889-91.    ^cY#
a07v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#96#92#article#131#</font></p>     ^cY
#a07v37n1.htm##
00542000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704029200079002001300371#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#97#93#article#131#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Lodde M, Palermo 
   S, Comploj E, Signorello D, Mian C, Lusuardi L, et al.: Four years experience
    in bladder preserving management for muscle invasive bladder cancer. Eur Uro
l.    2005; 47: 773-8; discussion 778-9.    ^cY#a07v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#98#94#article#131#</font></p>     ^cY
#a07v37n1.htm##
00540000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704029000079002001300369#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#99#95#article#131#15#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Deliveliotis    C
, Papatsoris A, Chrisofos M, Dellis A, Liakouras C, Skolarikos A: Urinary divers
ion    in high-risk elderly patients: modified cutaneous ureterostomy or ileal c
onduit?    Urology. 2005; 66: 299-304.    ^cY#a07v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#100#96#article#131#</font></p>     ^c
Y#a07v37n1.htm##
00553000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704030200080002001300382#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#101#97#article#131#16#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. May M, Fuhrer   
 S, Braun KP, Brookman-Amissah S, Richter W, Hoschke B, et al.: Results from    
three municipal hospitals regarding radical cystectomy on elderly patients.    I
nt Braz J Urol. 2007; 33: 764-73; discussion 774-6.    ^cY#a07v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#102#98#article#131#</font></p>     ^c
Y#a07v37n1.htm##
00535000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704028400080002001300364#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#103#99#article#131#17#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Solsona E,    Ib
orra I, Ric&oacute;s JV, Monr&oacute;s JL, Dumont R: Feasibility of transurethra
l    resection for muscle-infiltrating carcinoma of the bladder: prospective stu
dy.    J Urol. 1992; 147: 1513-5.    ^cY#a07v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#104#100#article#131#</font></p>     ^
cY#a07v37n1.htm##
00448000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019600081002001300277#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#105#101#article#131#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Herr HW: Transu
rethral    resection of muscle-invasive bladder cancer: 10-year outcome. J Clin 
Oncol.    2001; 19: 89-93.    ^cY#a07v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#106#102#article#131#</font></p>     ^
cY#a07v37n1.htm##
00530000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027800081002001300359#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#107#103#article#131#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Quek ML, Stein 
   JP, Daneshmand S, Miranda G, Thangathurai D, Roffey P, et al.: A critical ana
lysis    of perioperative mortality from radical cystectomy. J Urol. 2006; 175: 
886-9;    discussion 889-90.    ^cY#a07v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#108#104#article#131#</font></p>     ^
cY#a07v37n1.htm##
00589000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033700081002001300418#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#109#105#article#131#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Mydlo JH, Weins
tein    R, Shah S, Solliday M, Macchia RJ: Long-term consequences from bladder p
erforation    and/or violation in the presence of transitional cell carcinoma: r
esults of    a small series and a review of the literature. J Urol. 1999; 161: 1
128-32.    ^cY#a07v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#110#106#article#131#</font></p>     ^
cY#a07v37n1.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023800081002001300319#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#111#107#article#131#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Collado A,    C
h&eacute;chile GE, Salvador J, Vicente J: Early complications of endoscopic    t
reatment for superficial bladder tumors. J Urol. 2000; 164: 1529-32.    ^cY#a07v
37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#112#108#article#131#</font></p>     ^
cY#a07v37n1.htm##
00465000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021300081002001300294#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#113#109#article#131#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Calabr&ograve; 
   F, Sternberg CN: Neoadjuvant and adjuvant chemotherapy in muscle-invasive bla
dder    cancer. Eur Urol. 2009; 55: 348-58.    ^cY#a07v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#114#110#article#131#</font></p>     ^
cY#a07v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#115#111#article#131#<p>&nbsp;</p>    
 ^cY#a07v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#116#112#article#131#<p>&nbsp;</p>    
 ^cY#a07v37n1.htm##
00367000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704013000078002001300208#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#117#113#article#131#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><i>Accepted after    revision: Jul
y 7, 2010</i></font></p>     ^cY#a07v37n1.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019300078002001300271#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#118#114#article#131#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><b><a name="end"></a><a href="#top
"><img src="/img/revistas/ibju/v37n1/seta.gif" border="0"></a>    Correspondence
 to</b>:    ^cY#a07v37n1.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004600078002001300124#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#119#115#article#131#<br>   Dr. Oscar 
Rodr&iacute;guez Faba    ^cY#a07v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003600078002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#120#116#article#131#<br>   C/ Cartage
na, 340-350    ^cY#a07v37n1.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003800078002001300116#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#121#117#article#131#<br>   Barcelona,
 08025, Spain    ^cY#a07v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003600078002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#122#118#article#131#<br>   Fax: + 34 
9 3416-9730    ^cY#a07v37n1.htm##
00363000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012600078002001300204#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#123#119#article#131#<br>   E-mail: <a
 href="mailto:orodriguez@fundacio-puigvert.es%20">orodriguez@fundacio-puigvert.e
s    </a></font></p>     ^cY#a07v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#124#120#article#131#<p>&nbsp;</p>    
 ^cY#a07v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#125#121#article#131#<p>&nbsp;</p>    
 ^cY#a07v37n1.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010700078002001300185#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#126#122#article#131#<p><font size="3"
 face="Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL COMMENT</b></font></p
>     ^cY#a07v37n1.htm##
02020000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704178300078002001301861#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#127#123#article#131#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> In the present    manuscript, the
 authors compare the cancer specific outcomes of transurethral    resection (TUR
) versus radical cystectomy in octogenarians with muscle invasive    bladder can
cer. The authors address an interesting clinical question in a cohort    we have
 traditionally associated to be at increased risk of perioperative complications
    with aggressive surgical intervention. The authors conclude appropriately th
at    patients underlying (pre-treatment) co-morbidities (measured using ASA sco
re)    is more of a determinant of surgical risk than age alone. Similarly, the 
authors    conclude that radical cystectomy offers an improved cancer specific s
urvival    (versus TUR) at the cost of increased perioperative morbidity. I woul
d argue    that TUR alone (without consideration of a bladder sparing type appro
ach using    chemo-radiotherapy or at the very least of adjuvant radiotherapy to
 the bladder    and pelvic lymph nodes for local/regional cancer control) is not
 an oncologic    efficacious treatment alternative except in the very rare case 
of a patient    with a focally muscle invasive bladder tumor. Hence, the importa
nce of repeat    TUR (to ensure complete resection), random bladder biopsies (to
 rule out multifocal    disease), and exam under anesthesia (to adequately asses
s clinical stage) should    be considered essential in these select patients tre
ated by TUR alone. Similarly,    careful pathologic review of the TUR specimen b
y an experienced genitourinary    pathologist is essential to confirm tumor inva
sion into the muscularis propria    and rule out the presence of adverse patholo
gical features such as lymphovascular    invasion or micropapillary histology.  
  ^cY#a07v37n1.htm##
00640000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704040300078002001300481#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#128#124#article#131#<br>   In summary
, there clearly remains a subset of patients with muscle invasive    bladder can
cer for whom cystectomy is not a feasible choice because of pre-operative    co-
morbidities or by their refusal to proceed with aggressive surgical intervention
.    In these patients, clinicians must tailor their treatment options based on 
patient    and tumor specific characteristics.</font></p>     ^cY#a07v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#129#125#article#131#<p>&nbsp;</p>    
 ^cY#a07v37n1.htm##
00361000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012400078002001300202#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#130#126#article#131#<p align="right">
<font size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Dr.    Philipp
e E. Spiess</b></i>    ^cY#a07v37n1.htm##
00295000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005800078002001300136#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#131#127#article#131#<br>   <i>Departm
ent of Interdisciplinary Oncology    ^cY#a07v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003600078002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#132#128#article#131#<br>   Moffitt Ca
ncer Center    ^cY#a07v37n1.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004200078002001300120#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#133#129#article#131#<br>   University
 of South Florida    ^cY#a07v37n1.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#134#130#article#131#<br>   Tampa, Flo
rida, USA    ^cY#a07v37n1.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011500078002001300193#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#p#135#131#article#131#<br>   E-mail: <a
 href="mailto:philippe.spiess@moffitt.org">philippe.spiess@moffitt.org</a></i></
font></p>     ^cY#a07v37n1.htm##
00864000000000385000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160016000770160017000930160
01700110016002100127016001800148016001700166016001800183016001700201016001600218
01600200023401600160025401600150027001600170028501600180030201600180032001800450
0338062002600383066000900409037003800418865000900456002001300465#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a07v37n1.htm#S#c#136#1#article#22#1#^rND^sRies^nLAG#^r
ND^sMelbert^nD#^rND^sKrapcho^nM#^rND^sStinchcomb^nDG#^rND^sHowlader^nN#^rND^sHor
ner^nMJ#^rND^sMariotto^nA#^rND^sMiller^nBA#^rND^sFeuer^nEJ#^rND^sAltekruse^nSF#^
rND^sLewis^nDR#^rND^sClegg^nL#^rND^sEisner^nMP#^rND^sReichman^nM#^rND^sEdwards^n
BK#SEER Cancer Statistics Review, 1975-2005^len#National Cancer Institute#Bethes
da#http://seer.cancer.gov/csr/1975_2005/#20110200#a07v37n1.htm##
00682000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100017000950100
01600112010001900128010001800147010001800165012010000183030000900283065000900292
06400050030103100030030601400060030986500090031500200130032403500100033780100090
0347#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#c#137#2#article#22#
2#^rND^sMalavaud^nB#^rND^sVaessen^nC#^rND^sMouzin^nM#^rND^sRischmann^nP#^rND^sSa
rramon^nJ#^rND^sSchulman^nC#Complications for radical cystectomy: Impact of the 
American Society of Anesthesiologists score^len#Eur Urol#20110000#2001#39#79-84#
20110200#a07v37n1.htm#0302-2838#Eur Urol##
00617000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100014000940100
01700108010001800125012009000143030001300233065000900246064000500255031000300260
014000700263865000900270002001300279035001000292801001300302#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a07v37n1.htm#S#c#138#3#article#22#3#^rND^sWolters^nU#^rND^
sWolf^nT#^rND^sStützer^nH#^rND^sSchröder^nT#ASA classification and perioperative
 variables as predictors of postoperative outcome^len#Br J Anaesth#19960000#1996
#77#217-22#20110200#a07v37n1.htm#0007-0912#Br J Anaesth##
00506000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770120075000930300
00800168065000900176064000500185031000300190014000700193865000900200002001300209
035001000222801000800232#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S
#c#139#4#article#22#4#^rND^sZincke^nH#Cystectomy and urinary diversion in patien
ts eighty years old or older^len#Urology#19820000#1982#19#139-42#20110200#a07v37
n1.htm#0090-4295#Urology##
00711000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100016000930100
01700109010001600126010001600142010001600158810000600174012012100180030000800301
06500090030906400050031803100030032301400070032686500090033300200130034203500100
0355801000800365#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#c#140#5
#article#22#5#^rND^sGeorge^nL#^rND^sBladou^nF#^rND^sBardou^nVJ#^rND^sGravis^nG#^
rND^sTallet^nA#^rND^sAlzieu^nC#et al#Clinical outcome in patients with locally a
dvanced bladder carcinoma treated with conservative multimodality therapy^len#Ur
ology#20040000#2004#64#488-93#20110200#a07v37n1.htm#0090-4295#Urology##
00702000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100016000930100
01400109010001600123010002200139010001600161810000600177012011000183030000700293
06500090030006400050030903100040031401400070031886500090032500200130033403500100
0347801000700357#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#c#141#6
#article#22#6#^rND^sSoulié^nM#^rND^sStraub^nM#^rND^sGamé^nX#^rND^sSeguin^nP#^rND
^sDe Petriconi^nR#^rND^sPlante^nP#et al#A multicenter study of the morbidity of 
radical cystectomy in select elderly patients with bladder cancer^len#J Urol#200
20000#2002#167#1325-8#20110200#a07v37n1.htm#0022-5347#J Urol##
00584000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100017000930100
01800110010001900128012006400147030000700211065000900218064000500227031000400232
014000700236865000900243002001300252035001000265801000700275#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a07v37n1.htm#S#c#142#7#article#22#7#^rND^sChang^nSS#^rND^s
Alberts^nG#^rND^sCookson^nMS#^rND^sSmith^nJA Jr#Radical cystectomy is safe in el
derly patients at high risk^len#J Urol#20010000#2001#166#938-41#20110200#a07v37n
1.htm#0022-5347#J Urol##
00696000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100016000930100
01800109010001300127010001700140010002000157810000600177012010500183030000700288
06500090029506400050030403100040030901400060031386500090031900200130032803500100
0341801000700351#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#c#143#8
#article#22#8#^rND^sClark^nPE#^rND^sStein^nJP#^rND^sGroshen^nSG#^rND^sCai^nJ#^rN
D^sMiranda^nG#^rND^sLieskovsky^nG#et al#Radical cystectomy in the elderly: compa
rison of clincal outcomes between younger and older patients^len#Cancer#20050000
#2005#104#36-43#20110200#a07v37n1.htm#0008-543X#Cancer##
00564000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100018000940100
01500112012007600127030000800203065000900211064000500220031000300225014000600228
865000900234002001300243035001000256801000800266#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a07v37n1.htm#S#c#144#9#article#22#9#^rND^sKulovac^nB#^rND^sAganovic^nD
#^rND^sPrcic^nA#Radical cystectomy early postoperative complications and mortali
ty rate^len#Med Arh#20050000#2005#59#358-9#20110200#a07v37n1.htm#0025-8083#Med A
rh##
00625000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01500113010001200128012011200140030000700252065000900259064000500268031000300273
014000800276865000900284002001300293035001000306801000700316#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a07v37n1.htm#S#c#145#10#article#22#10#^rND^sSoloway^nMS#^r
ND^sLopez^nAE#^rND^sPatel^nJ#^rND^sLu^nY#Results of radical cystectomy for trans
itional cell carcinoma of the bladder and the effect of chemotherapy^len#Cancer#
19940000#1994#73#1926-31#20110200#a07v37n1.htm#0008-543X#Cancer##
00690000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100016000930100
01600109010001800125010001600143010002000159810000600179012009400185030000900279
06500090028806400050029703100030030201400060030586500090031100200130032003500100
0333801000900343#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#c#146#1
1#article#22#11#^rND^sGamé^nX#^rND^sSoulié^nM#^rND^sSeguin^nP#^rND^sVazzoler^nN#
^rND^sTollon^nC#^rND^sPontonnier^nF#et al#Radical cystectomy in patients older t
han 75 years: assessment of morbidity and mortality^len#Eur Urol#20010000#2001#3
9#525-9#20110200#a07v37n1.htm#0302-2838#Eur Urol##
00564000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100015001000100
01800115010001500133012004300148030000700191065000900198064000500207031000400212
014000700216865000900223002001300232035001000245801000700255#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a07v37n1.htm#S#c#147#12#article#22#12#^rND^sStroumbakis^nN
#^rND^sHerr^nHW#^rND^sCookson^nMS#^rND^sFair^nWR#Radical cystectomy in the octog
enarian^len#J Urol#19970000#1997#158#2113-7#20110200#a07v37n1.htm#0022-5347#J Ur
ol##
00649000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01800111010001600129010002100145010001600166012007000182030000700252065000900259
06400050026803100040027301400070027786500090028400200130029303500100030680100070
0316#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#c#148#13#article#22
#13#^rND^sOgawa^nA#^rND^sYanagisawa#^rND^sNakamoto^nT#^rND^sWajiki^nM#^rND^sHira
bayashi^nN#^rND^sNakama^nM#Treatment of bladder carcinoma in patients more than 
80 years old^len#J Urol#19850000#1985#134#889-91#20110200#a07v37n1.htm#0022-5347
#J Urol##
00691000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01700111010002000128010001400148010001800162810000600180012009400186030000900280
06500090028906400050029803100030030301400060030686500090031200200130032103500100
0334801000900344#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#c#149#1
4#article#22#14#^rND^sLodde^nM#^rND^sPalermo^nS#^rND^sComploj^nE#^rND^sSignorell
o^nD#^rND^sMian^nC#^rND^sLusuardi^nL#et al#Four years experience in bladder pres
erving management for muscle invasive bladder cancer^len#Eur Urol#20050000#2005#
47#773-8#20110200#a07v37n1.htm#0302-2838#Eur Urol##
00697000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100020001010100
01900121010001600140010001900156010002000175012010300195030000800298065000900306
06400050031503100030032001400080032386500090033100200130034003500100035380100080
0363#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#c#150#15#article#22
#15#^rND^sDeliveliotis^nC#^rND^sPapatsoris^nA#^rND^sChrisofos^nM#^rND^sDellis^nA
#^rND^sLiakouras^nC#^rND^sSkolarikos^nA#Urinary diversion in high-risk elderly p
atients: modified cutaneous ureterostomy or ileal conduit?^len#Urology#20050000#
2005#66#299-304#20110200#a07v37n1.htm#0090-4295#Urology##
00672000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100013000790100016000920100
01600108010002600124010001700150010001700167810000600184012009200190030001600282
71000020029806500090030006400050030903100030031401400070031786500090032400200130
0333#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#c#151#16#article#22
#16#^rND^sMay^nM#^rND^sFuhrer^nS#^rND^sBraun^nKP#^rND^sBrookman-Amissah^nS#^rND^
sRichter^nW#^rND^sHoschke^nB#et al#Results from three municipal hospitals regard
ing radical cystectomy on elderly patients^len#Int Braz J Urol#2#20070000#2007#3
3#764-73#20110200#a07v37n1.htm##
00657000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01600112010001700128010001600145012011100161030000700272065000900279064000500288
031000400293014000700297865000900304002001300313035001000326801000700336#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#c#152#17#article#22#17#^rND^sSo
lsona^nE#^rND^sIborra^nI#^rND^sRicós^nJV#^rND^sMonrós^nJL#^rND^sDumont^nR#Feasib
ility of transurethral resection for muscle-infiltrating carcinoma of the bladde
r: prospective study^len#J Urol#19920000#1992#147#1513-5#20110200#a07v37n1.htm#0
022-5347#J Urol##
00520000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790120079000940300
01300173065000900186064000500195031000300200014000600203865000900209002001300218
035001000231801001300241#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S
#c#153#18#article#22#18#^rND^sHerr^nHW#Transurethral resection of muscle-invasiv
e bladder cancer: 10-year outcome^len#J Clin Oncol#20010000#2001#19#89-93#201102
00#a07v37n1.htm#0732-183X#J Clin Oncol##
00674000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100016000940100
02000110010001700130010002200147010001600169810000600185012007500191030000700266
06500090027306400050028203100040028701400060029186500090029700200130030603500100
0319801000700329#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#c#154#1
9#article#22#19#^rND^sQuek^nML#^rND^sStein^nJP#^rND^sDaneshmand^nS#^rND^sMiranda
^nG#^rND^sThangathurai^nD#^rND^sRoffey^nP#et al#A critical analysis of periopera
tive mortality from radical cystectomy^len#J Urol#20060000#2006#175#886-9#201102
00#a07v37n1.htm#0022-5347#J Urol##
00724000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100019000950100
01400114010001800128010001800146012017400164030000700338065000900345064000500354
031000400359014000800363865000900371002001300380035001000393801000700403#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a07v37n1.htm#S#c#155#20#article#22#20#^rND^sMy
dlo^nJH#^rND^sWeinstein^nR#^rND^sShah^nS#^rND^sSolliday^nM#^rND^sMacchia^nRJ#Lon
g-term consequences from bladder perforation and/or violation in the presence of
 transitional cell carcinoma: results of a small series and a review of the lite
rature^len#J Urol#19990000#1999#161#1128-32#20110200#a07v37n1.htm#0022-5347#J Ur
ol##
00603000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100019000960100
01800115010001700133012007900150030000700229065000900236064000500245031000400250
014000800254865000900262002001300271035001000284801000700294#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a07v37n1.htm#S#c#156#21#article#22#21#^rND^sCollado^nA#^rN
D^sChéchile^nGE#^rND^sSalvador^nJ#^rND^sVicente^nJ#Early complications of endosc
opic treatment for superficial bladder tumors^len#J Urol#20000000#2000#164#1529-
32#20110200#a07v37n1.htm#0022-5347#J Urol##
00544000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100020000960120
07600116030000900192065000900201064000500210031000300215014000700218865000900225
002001300234035001000247801000900257#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
7v37n1.htm#S#c#157#22#article#22#22#^rND^sCalabrò^nF#^rND^sSternberg^nCN#Neoadju
vant and adjuvant chemotherapy in muscle-invasive bladder cancer^len#Eur Urol#20
090000#2009#55#348-58#20110200#a07v37n1.htm#0302-2838#Eur Urol##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#o#1#1#article#1
#20110330#144510#a08v37n1.htm#176##
03694000000000709000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095038000400099121000300103049000800106
15800030011403000180011703100030013503200020013806500090014001400090014903500100
01580120132001680100023003000100023003230100022003460100024003680100023003920100
02100415010002200436010002300458010002100481010002200502010002700524010002500551
07000730057607000930064907000770074207000800081907000690089907000640096807000960
10320831625011280850010027530850032027630850033027950850028028280850026028560850
02702882085002202909085003102931117000602962072000302968002001302971#v37n1#V:\Sc
iELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#I
LUS#GRA#TAB#08#IBJU010#nd#Int. braz j urol.#37#1#20110200#^f57^l66#1677-5538#Par
allel determination of NeuroD1, Chromogranin-A, KI67 and androgen receptor expre
ssion in surgically treated prostate cancers^len#^rND^1A01^nL.^sCindolo#^rND^1A0
2^nM.^sCantile#^rND^1A03^nR.^sFranco#^rND^1A04^nP.^sChiodini#^rND^1A05^nG.^sSchi
avo#^rND^1A03^nI.^sForte#^rND^1A05^nI.^sZlobec#^rND^1A06^nL.^sSalzano#^rND^1A03^
nG.^sBotti#^rND^1A07^nS.^sGidaro#^rND^1A05^nL.^sTerracciano#^rND^1A02 A05^nC.^sC
illo#S. Pio da Pietrelcina Hospital^iA01^1Department of Urology^cVasto^pItaly#Fe
derico II University^iA02^1Department of Clinical and Experimental Medicine^cNap
les^pItaly#G. Pascale National Cancer Institute^iA03^1Surgical Pathology^cNaples
^pItaly#Second University^iA04^1Department of Medicine and Public Health^cNaples
^pItaly#University of Basel^iA05^1Institute of Pathology^cBasel^pSwitzerland#G. 
Rummo Hospital^iA06^1Department of Urology^cBenevento^pItaly#Chieti-Pescara Univ
ersity^iA07^1Department of Surgical and Experimental Sciences^cChieti^pItaly#^le
n^aPURPOSE: Neuroendocrine differentiation is a hallmark of prostate cancer. The
 aim of our study was the detection of the parallel expression of neuroendocrine
 related markers using a prostate tissue microarray (TMA). MATERIALS AND METHODS
: Our study was aimed at detecting the parallel expression of NeuroD1, Chromogra
nin-A (ChrA), Androgen Receptor (AR) and Ki-67 by immunohistochemistry on prosta
te cancer tissue microarray. The data was analyzed using SAS version 8.2 (SAS In
c, Cary, NC). The relationships between NeuroD1, ChrA and AR expressions and pat
ients' characteristics were investigated by multivariate logistic regression ana
lysis. Progression and Overall Survival (OS) distributions were calculated using
 Kaplan-Meier method. RESULTS: Tissue reactivity for NeuroD1, ChrA and AR concer
ned 73%, 49% and 77% of the available cases, respectively. Regarding overall sur
vival, there were 87 deaths and 295 patients alive/censored (6 years of median f
ollow-up). Seventy-seven disease progressions occurred at the median follow-up 5
.4y. A significant correlation between NeuroD1, ChrA and AR expression was obser
ved (p < 0.001 and p < 0.03, respectively). Additionally, ChrA was strongly asso
ciated in multivariate analysis to Gleason score and Ki67 expression (p < 0.009 
and p < 0.0052, respectively). Survival analysis showed no association between m
arkers neither for overall nor for cancer-specific survival. CONCLUSIONS: The re
sults highlight that NeuroD1, Chromogranin-A and Androgen Receptor are strongly 
associated, however their expression does not correlate with overall survival or
 disease progression.#^ddecs^i1#^tm^len^kprostatic neoplasms^i1#^tm^len^kneuroen
docrine cells^i1#^tm^len^kneuroD1 protein^i1#^tm^len^kki-67 antigen^i1#^tm^len^k
chromogranin A^i1#^tm^len^kreceptors^i1#^tm^len^kandrogen prognosis^i1#other#30#
a08v37n1.htm##
03741000000000709000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095038000400099121000300103049000800106
15800030011403000180011703100030013503200020013806500090014001400090014903500100
01580120139001680100023003070100023003300100022003530100024003750100023003990100
02100422010002200443010002300465010002100488010002200509010002700531010002500558
07000730058307000930065607000770074907000800082607000690090607000640097507000960
10390831665011350850010028000850032028100850033028420850028028750850026029030850
02702929085002202956085003102978117000603009072000303015002001303018#v37n1#V:\Sc
iELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#I
LUS#GRA#TAB#08#IBJU010#nd#Int. braz j urol.#37#1#20110200#^f57^l66#1677-5538#<b>
Parallel determination of NeuroD1, Chromogranin-A, KI67 and androgen receptor ex
pression in surgically treated prostate cancers</b>^len#^rND^1A01^nL.^sCindolo#^
rND^1A02^nM.^sCantile#^rND^1A03^nR.^sFranco#^rND^1A04^nP.^sChiodini#^rND^1A05^nG
.^sSchiavo#^rND^1A03^nI.^sForte#^rND^1A05^nI.^sZlobec#^rND^1A06^nL.^sSalzano#^rN
D^1A03^nG.^sBotti#^rND^1A07^nS.^sGidaro#^rND^1A05^nL.^sTerracciano#^rND^1A02 A05
^nC.^sCillo#S. Pio da Pietrelcina Hospital^iA01^1Department of Urology^cVasto^pI
taly#Federico II University^iA02^1Department of Clinical and Experimental Medici
ne^cNaples^pItaly#G. Pascale National Cancer Institute^iA03^1Surgical Pathology^
cNaples^pItaly#Second University^iA04^1Department of Medicine and Public Health^
cNaples^pItaly#University of Basel^iA05^1Institute of Pathology^cBasel^pSwitzerl
and#G. Rummo Hospital^iA06^1Department of Urology^cBenevento^pItaly#Chieti-Pesca
ra University^iA07^1Department of Surgical and Experimental Sciences^cChieti^pIt
aly#^len^a<b>PURPOSE:</b> Neuroendocrine differentiation is a hallmark of prosta
te cancer. The aim of our study was the detection of the parallel expression of 
neuroendocrine related markers using a prostate tissue microarray (TMA). <b>MATE
RIALS AND METHODS:</b> Our study was aimed at detecting the parallel expression 
of NeuroD1, Chromogranin-A (ChrA), Androgen Receptor (AR) and Ki-67 by immunohis
tochemistry on prostate cancer tissue microarray. The data was analyzed using SA
S version 8.2 (SAS Inc, Cary, NC). The relationships between NeuroD1, ChrA and A
R expressions and patients' characteristics were investigated by multivariate lo
gistic regression analysis. Progression and Overall Survival (OS) distributions 
were calculated using Kaplan-Meier method. <b>RESULTS:</b> Tissue reactivity for
 NeuroD1, ChrA and AR concerned 73%, 49% and 77% of the available cases, respect
ively. Regarding overall survival, there were 87 deaths and 295 patients alive/c
ensored (6 years of median follow-up). Seventy-seven disease progressions occurr
ed at the median follow-up 5.4y. A significant correlation between NeuroD1, ChrA
 and AR expression was observed (p &lt; 0.001 and p &lt; 0.03, respectively). Ad
ditionally, ChrA was strongly associated in multivariate analysis to Gleason sco
re and Ki67 expression (p &lt; 0.009 and p &lt; 0.0052, respectively). Survival 
analysis showed no association between markers neither for overall nor for cance
r-specific survival. <b>CONCLUSIONS:</b> The results highlight that NeuroD1, Chr
omogranin-A and Androgen Receptor are strongly associated, however their express
ion does not correlate with overall survival or disease progression.#^ddecs^i1#^
tm^len^kprostatic neoplasms^i1#^tm^len^kneuroendocrine cells^i1#^tm^len^kneuroD1
 protein^i1#^tm^len^kki-67 antigen^i1#^tm^len^kchromogranin A^i1#^tm^len^krecept
ors^i1#^tm^len^kandrogen prognosis^i1#other#30#a08v37n1.htm##
03847000000000733000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113038000400117121000300121
04900080012415800030013203000170013503100030015203200020015506500090015701400090
01660350010001750120132001850100022003170100022003390100021003610100023003820100
02200405010002000427010002100447010002200468010002000490010002100510010002600531
01000240055707000750058107000950065607000790075107000820083007000710091207000660
09830700098010490831646011470850010027930850032028030850033028350850028028680850
02602896085002702922085002202949085003102971117000603002072000303008002001303011
008008903024#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#l#4#1#artic
le#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#ilus#gra#tab#08#IBJU010#nd#Int. braz j 
urol#37#1#20110200#^f57^l66#1677-5538#Parallel determination of NeuroD1, Chromog
ranin-A, KI67 and androgen receptor expression in surgically treated prostate ca
ncers^len#^rND^1A01^nL^sCindolo#^rND^1A02^nM^sCantile#^rND^1A03^nR^sFranco#^rND^
1A04^nP^sChiodini#^rND^1A05^nG^sSchiavo#^rND^1A03^nI^sForte#^rND^1A05^nI^sZlobec
#^rND^1A06^nL^sSalzano#^rND^1A03^nG^sBotti#^rND^1A07^nS^sGidaro#^rND^1A05^nL^sTe
rracciano#^rND^1A02 A05^nC^sCillo#^iA01^1S. Pio da Pietrelcina Hospital^2Departm
ent of Urology^cVasto^pItaly#^iA02^1Federico II University^2Department of Clinic
al and Experimental Medicine^cNaples^pItaly#^iA03^1G. Pascale National Cancer In
stitute^2Surgical Pathology^cNaples^pItaly#^iA04^1Second University^2Department 
of Medicine and Public Health^cNaples^pItaly#^iA05^1University of Basel^2Institu
te of Pathology^cBasel^pSwitzerland#^iA06^1G. Rummo Hospital^2Department of Urol
ogy^cBenevento^pItaly#^iA07^1Chieti-Pescara University^2Department of Surgical a
nd Experimental Sciences^cChieti^pItaly#^len^aPURPOSE: Neuroendocrine differenti
ation is a hallmark of prostate cancer. The aim of our study was the detection o
f the parallel expression of neuroendocrine related markers using a prostate tis
sue microarray (TMA). MATERIALS AND METHODS: Our study was aimed at detecting th
e parallel expression of NeuroD1, Chromogranin-A (ChrA), Androgen Receptor (AR) 
and Ki-67 by immunohistochemistry on prostate cancer tissue microarray. The data
 was analyzed using SAS version 8.2 (SAS Inc, Cary, NC). The relationships betwe
en NeuroD1, ChrA and AR expressions and patients' characteristics were investiga
ted by multivariate logistic regression analysis. Progression and Overall Surviv
al (OS) distributions were calculated using Kaplan-Meier method. RESULTS: Tissue
 reactivity for NeuroD1, ChrA and AR concerned 73 percent, 49 percent and 77 per
cent of the available cases, respectively. Regarding overall survival, there wer
e 87 deaths and 295 patients alive/censored (6 years of median follow-up). Seven
ty-seven disease progressions occurred at the median follow-up 5.4y. A significa
nt correlation between NeuroD1, ChrA and AR expression was observed (p < 0.001 a
nd p < 0.03, respectively). Additionally, ChrA was strongly associated in multiv
ariate analysis to Gleason score and Ki67 expression (p < 0.009 and p < 0.0052, 
respectively). Survival analysis showed no association between markers neither f
or overall nor for cancer-specific survival. CONCLUSIONS: The results highlight 
that NeuroD1, Chromogranin-A and Androgen Receptor are strongly associated, howe
ver their expression does not correlate with overall survival or disease progres
sion.#^ddecs^i1#^tm^len^kprostatic neoplasms^i1#^tm^len^kneuroendocrine cells^i1
#^tm^len^kneuroD1 protein^i1#^tm^len^kki-67 antigen^i1#^tm^len^kchromogranin A^i
1#^tm^len^kreceptors^i1#^tm^len^kandrogen prognosis^i1#other#30#a08v37n1.htm#Int
ernet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-553820110001
00008##
00356000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012300074002001300197#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#5#1#article#142#<p align="right"><fon
t face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>CLINICAL    UROLOGY</
b></font></p>     ^cY#a08v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#6#2#article#142#<p>&nbsp;</p>     ^cY
#a08v37n1.htm##
00474000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704024100074002001300315#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#7#3#article#142#<p><font face="Verdan
a, Arial, Helvetica, sans-serif" size="4"><a name="top"></a><b>Parallel    deter
mination of NeuroD1, Chromogranin-A, KI67 and androgen receptor expression    in
 surgically treated prostate cancers</b></font></p>     ^cY#a08v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#8#4#article#142#<p>&nbsp;</p>     ^cY
#a08v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#9#5#article#142#<p>&nbsp;</p>     ^cY
#a08v37n1.htm##
00632000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704039800075002001300473#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#10#6#article#142#<p><font face="Verda
na, Arial, Helvetica, sans-serif" size="2"><b>L. Cindolo<sup>I</sup>;    M. Cant
ile<sup>II</sup>; R. Franco<sup>III</sup>; P. Chiodini<sup>IV</sup>;    G. Schia
vo<sup>V</sup>; I. Forte<sup>III</sup>; I. Zlobec<sup>V</sup>; L. Salzano<sup>VI
</sup>;    G. Botti<sup>III</sup>; S. Gidaro<sup>VII</sup>; L. Terracciano<sup>V
</sup>;    C. Cillo<sup>II,V</sup></b></font></p>     ^cY#a08v37n1.htm##
00387000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704015300075002001300228#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#11#7#article#142#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Department    of Urology,
 S. Pio da Pietrelcina Hospital, Vasto, Italy    ^cY#a08v37n1.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011900075002001300194#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#12#8#article#142#<br>   <sup>II</sup>
Department of Clinical and Experimental Medicine, Federico II University,    Nap
les, Italy     ^cY#a08v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011400075002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#13#9#article#142#<br>   <sup>III</sup
><sup></sup>Surgical Pathology, G. Pascale National Cancer Institute,    Naples,
 Italy    ^cY#a08v37n1.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010500076002001300181#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#14#10#article#142#<br>   <sup>IV</sup
>Department of Medicine and Public Health, Second University, Naples,    Italy  
  ^cY#a08v37n1.htm##
00325000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009000076002001300166#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#15#11#article#142#<br>   <sup>V</sup>
Institute of Pathology, University of Basel, Basel, Switzerland    ^cY#a08v37n1.
htm##
00321000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008600076002001300162#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#16#12#article#142#<br>   <sup>VI</sup
>Department of Urology, G. Rummo Hospital, Benevento, Italy    ^cY#a08v37n1.htm#
#
00369000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013400076002001300210#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#17#13#article#142#<br>   <sup>VII</su
p>Department of Surgical and Experimental Sciences, Chieti-Pescara    University
, Chieti, Italy</font></p>     ^cY#a08v37n1.htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011600076002001300192#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#18#14#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="#end">Correspondence</a></f
ont></p>     ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#19#15#article#142#<p>&nbsp;</p>     ^
cY#a08v37n1.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#20#16#article#142#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a08v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#21#17#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#a
08v37n1.htm##
00537000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030200076002001300378#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#22#18#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>PURPOSE:</b>    Neuroendocrine di
fferentiation is a hallmark of prostate cancer. The aim of    our study was the 
detection of the parallel expression of neuroendocrine related    markers using 
a prostate tissue microarray (TMA).    ^cY#a08v37n1.htm##
00797000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056200076002001300638#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#23#19#article#142#<br>   <b>MATERIALS
 AND METHODS:</b> Our study was aimed at detecting the parallel    expression of
 NeuroD1, Chromogranin-A (ChrA), Androgen Receptor (AR) and Ki-67    by immunohi
stochemistry on prostate cancer tissue microarray. The data was analyzed    usin
g SAS version 8.2 (SAS Inc, Cary, NC). The relationships between NeuroD1,    Chr
A and AR expressions and patients' characteristics were investigated    by multi
variate logistic regression analysis. Progression and Overall Survival    (OS) d
istributions were calculated using Kaplan-Meier method.    ^cY#a08v37n1.htm##
00971000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704073600076002001300812#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#24#20#article#142#<br>   <b>RESULTS:<
/b> Tissue reactivity for NeuroD1, ChrA and AR concerned 73%, 49%    and 77% of 
the available cases, respectively. Regarding overall survival, there    were 87 
deaths and 295 patients alive/censored (6 years of median follow-up).    Seventy
-seven disease progressions occurred at the median follow-up 5.4y. A    signific
ant correlation between NeuroD1, ChrA and AR expression was observed    (p &lt; 
0.001 and p &lt; 0.03, respectively). Additionally, ChrA was strongly    associa
ted in multivariate analysis to Gleason score and Ki67 expression (p    &lt; 0.0
09 and p &lt; 0.0052, respectively). Survival analysis showed no association    
between markers neither for overall nor for cancer-specific survival.    ^cY#a08
v37n1.htm##
00475000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024000076002001300316#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#25#21#article#142#<br>   <b>CONCLUSIO
NS:</b> The results highlight that NeuroD1, Chromogranin-A and Androgen    Recep
tor are strongly associated, however their expression does not correlate    with
 overall survival or disease progression.</font></p>     ^cY#a08v37n1.htm##
00484000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024900076002001300325#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#26#22#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Key words:</b>    prostatic neopl
asms; neuroendocrine cells; neuroD1 protein; ki-67 antigen; chromogranin    A, r
eceptors, androgen prognosis</font></p> <HR size="1" noshade>     ^cY#a08v37n1.h
tm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#27#23#article#142#<p>&nbsp;</p>     ^
cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#28#24#article#142#<p>&nbsp;</p>     ^
cY#a08v37n1.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#29#25#article#142#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODUCTION</b></font></p>     ^
cY#a08v37n1.htm##
01046000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704081100076002001300887#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#30#26#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Prostate cancer    (PCa) is the most
 frequent cancer in Western countries and the second leading    cause of cancer 
related deaths in men (1,2). The clinical course of this cancer    is often unfa
vorable due to the shift from androgen dependent status to hormone    refractori
ness. The change in clinical course correlates with a strong increase    in biol
ogical aggressiveness and a significant decrease in survival (3). Only    a few 
studies on docetaxel-based chemotherapy have reported results in terms    of sur
vival, pain control, quality of life and progression in patients with    metasta
tic castration-resistant prostate cancer (CRPC) (4,5), albeit the risk    of cyt
otoxic chemotherapy should be individually weighted.</font></p>     ^cY#a08v37n1
.htm##
00869000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063400076002001300710#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#31#27#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In recent years,    the presence of 
neuroendocrine differentiation (NED) features has been reported    as a variable
 associated with the development of the CRPC (6,7) during the natural    history
 of this PCa. In general, pure neuroendocrine (NE) tumor cells do not    express
 androgen receptors (AR), are resistant to androgen deprivation therapy    and d
o not proliferate in response to androgens (8). Autocrine-paracrine epithelial  
  interactions and/or transdifferentiation are the mechanisms through which NE  
  cells act in PCa homeostasis (9).</font></p>     ^cY#a08v37n1.htm##
01522000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704128700076002001301363#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#32#28#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The early detection    of NE activi
ty in prostate adenocarcinoma could suggest or anticipate an early    diagnosis 
of hormones refractoriness behavior and thus justify changes in therapeutic    a
pproaches. Unfortunately, the diagnosis and the quantification of prostatic    N
E cell activity remains a problem. Chromogranin A (ChrA), consistently expressed
    during NE cell differentiation (8), is the most frequently used marker to de
tect    NE differentiation in PCa patients, both at tissue and at serum level (1
0,11).    Nevertheless, differences between assays for serum ChrA provided a sig
nificant    discordance rate, suggesting that the commercial kits for serum dete
ction might    elicit different information (12). Moreover, tissue ChrA lack pro
gnostic significance    in patients with bone metastatic PCa (13). Other NE mark
ers (such as tissue    CD56, synaptophysin) add only little information on the a
cquisition of NE phenotype    in human prostate (14). Neuron-specific enolase (N
SE) could become a valuable    tumor progression marker and could serve as predi
ctor of survival together with    clinical parameters but only in advanced and h
ormone refractory prostate neoplasms    (15,16).</font></p>     ^cY#a08v37n1.htm
##
01335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704110000076002001301176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#33#29#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">These evidences    highlight that th
e identification of new diagnostic and prognostic markers is    relevant for the
 clinical management of PCa patients, especially related to    neuroendocrine di
fferentiation. Following the identification of the neurogenic    characteristic 
of the 2q31-33 genome region (HOX D locus) which houses genes    involved with e
pithelial-neuronal cell conversion (17), we investigated the    role of NeuroD1 
in normal and neoplastic human prostates. We have previously    reported that Ne
uroD1 tissue reactivity correlates with the indicators of malignancy    in moder
ately to poorly differentiated PCa and it could be involved in the pathophysiolo
gy    of PCa neuroendocrine differentiation (14). Here we report on an immunohis
tochemical    analysis using a tissue micro array (TMA) containing a high number
 of different    naive prostate cancer specimens, in order to verify the prognos
tic relevance    of NeuroD1 together with ChrA, AR and Ki67 tissue reactivity an
d their correlations.</font></p>     ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#34#30#article#142#<p>&nbsp;</p>     ^
cY#a08v37n1.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011500076002001300191#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#35#31#article#142#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"> <b>MATERIALS AND    METHODS</b></fo
nt></p>     ^cY#a08v37n1.htm##
01129000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704089400076002001300970#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#36#32#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> A total of 732    patients (members
 of the Kaiser Foundation Health Plan) treated for clinically    localized PCa b
y radical prostatectomy or transurethral resection (TURP) (incidental    diagnos
is) at one of two Kaiser Hospitals in Portland (OR, USA) between 1971    and 199
6, were retrospectively evaluated. The full study protocol, including    access 
to the slides and blocks, was reviewed and approved by the Committee    for the 
Protection of Human Subjects of Kaiser Permanente, Portland, OR. All    patient 
identifiers were removed and replaced by unique study numbers, linked    to the 
original identifiers by a single file kept under high security. Medical    recor
ds for the entire cohort were abstracted at one time, 1999-2001, to assure    un
iform criteria for diagnosis, progression, and staging.</font></p>     ^cY#a08v3
7n1.htm##
00905000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067000076002001300746#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#37#33#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Selection of the    specimens, class
ification, as well as patient management and follow-up have    extensively been 
described elsewhere (18). Before 1992 (pre-PSA era), progression    was defined 
clinically based on the results of bone scans, chest x-rays, and/or    digital r
ectal examination. After 1992, progression was defined by increasing    PSA seru
m concentrations in serial determinations following a postoperative    PSA nadir
 value (18). Patients with N+ or M+ disease at the diagnosis or treated    by ne
oadjuvant or postoperative hormonal or chemotherapy have been excluded.</font></
p>     ^cY#a08v37n1.htm##
00438000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020300076002001300279#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#38#34#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Benign prostatic    hyperplasia (BPH
), as control, was also evaluated in 89 specimens (not included    in the analys
is).</font></p>     ^cY#a08v37n1.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011700076002001300193#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#39#35#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Tissue Microarray    Design</b></
font></p>     ^cY#a08v37n1.htm##
01496000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704126100076002001301337#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#40#36#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The prostate TMA    was constructed
 as previously described (18,19). Briefly, one core tissue-biopsy    (diameter 0
.6 mm) was taken from the least differentiated region of individual    paraffin-
embedded prostate tumors (donor blocks) and precisely arrayed into    a new reci
pient paraffin block (35-20 mm) with a custom-built precision instrument    (Bee
cher Instruments, Silver Spring, MD). The core-tissue biopsies were put    into 
one of the two recipient blocks that defined one replicate TMA. Six replicate   
 TMAs containing the identical set of tumors were constructed. After the block  
  construction, 5 mm sections were cut using a microtome. Originally, 732 donor 
   tissue blocks were available for the construction of this TMA. Specimens from
    74 tumors could not be included in the study because of incomplete follow-up
    data, lack of tumor in the arrayed sample (sampling error), damaged tissue (
heat    or crush artifacts), or a total lack of tissue at some array positions (
'empty    spots'). The number of patients varies between the individual marker a
nalyses    because of variability in the number of interpretable specimens on co
nsecutive    sections.</font></p>     ^cY#a08v37n1.htm##
00502000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026700076002001300343#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#41#37#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The presence of    tumor tissue on 
the arrayed samples was verified on a hematoxylin-eosin-stained    section. All 
data in this study are based upon the analysis of 658 PCa specimens.</font></p> 
    ^cY#a08v37n1.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011000076002001300186#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#42#38#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Immunohistochemistry</b></font></
p>     ^cY#a08v37n1.htm##
00914000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067900076002001300755#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#43#39#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Sections (4 &micro;m)    of TMA blo
cks were transferred to an adhesive-coated slide system (Instrumedics    Inc, Ha
ckensack, NJ, USA). After incubation, immunodetection was performed following   
 a standard avidin-biotin complex method (LSAB-DAKO; Glostrup, Denmark, and DAB;
    Vector Laboratories, Burlingame, CA,). The slides were immunoassayed for neu
roD1    (sc-20805, 1:150; Santa Cruz Biotechnology, Santa Cruz, CA.), Ki-67 (MIB
1, 1:800;    Dako, Glostrup, Denmark), chromogranin A (DAK-A3, 1:100; Dako, Mila
n, Italy)    and androgen receptor (clone AR 441 1:300 DAKO, Glostrup, Denmark).
</font></p>     ^cY#a08v37n1.htm##
00596000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036100076002001300437#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#44#40#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Stained TMA sections    were evaluat
ed by pathologists using uniform criteria. In particular, single    markers expr
ession was recorded as negative/positive, considering expression    in normal ve
rsus neoplastic, being the discrepancies resolved in a reviewed    joint analysi
s.</font></p>     ^cY#a08v37n1.htm##
00844000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060900076002001300685#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#45#41#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The fraction of    immunohistochemic
ally positive cells per punch was evaluated. NeuroD1 was classified    as 0%, 1-
50%, &gt; 50%. Chromogranin A was classified as 0-4%, 5-9%, = 10%.    For Ki67 a
nd androgen receptor, only nuclear staining was considered. AR was    classified
 as 0-10%, 11-50%, &gt; 50%; whereas Ki67 was visually scored and    stratified 
into two groups (low = 10%; high &gt; 10%) (18). The cut-off values    used in t
he analyses have been selected on the bases of the best possible discriminatory 
   effect.</font></p>     ^cY#a08v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#46#42#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Statistical    Analysis</b></font
></p>     ^cY#a08v37n1.htm##
00918000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068300076002001300759#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#47#43#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The data was analyzed    using SAS 
version 8.2 (SAS Inc, Cary, NC). A two-tailed P value &lt; 0.05 was    considere
d significant. Continuous variables were expressed as mean and Standard    Devia
tion and compared with ANOVA. Categorical variables were expressed as a    numbe
r or a percentage and compared by using Fisher's exact test. The    relationship
s between NeuroD1, ChrA and AR expressions and patients' characteristics    were
 investigated by multivariate logistic regression analysis. Progression    and O
verall Survival (OS) distributions were calculated using the Kaplan-Meier    met
hod.</font></p>     ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#48#44#article#142#<p>&nbsp;</p>     ^
cY#a08v37n1.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#49#45#article#142#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESULTS</b></font></p>     ^cY#a0
8v37n1.htm##
00947000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071200076002001300788#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#50#46#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The main clinical-pathological    c
haracteristics of the biopsies are listed in <a href="#tab1">Table-1</a>. Follow
-up    data for progression (median 5.4, range 0.5-20 years) were available in 6
31    cases. For the overall survival were useful data from 623 patients (median
 6,    range 2-20 years). Gleason score was assessed for all the PCa specimens o
n TMA    (658 punches) and classified as well, moderately, or poorly differentia
ted (Gleason    score &lt; 7, 7, &gt; 7, respectively). The Gleason score and pa
thologic stage    were highly predictive for progression (p &lt; 0.0001) and ove
rall survival    (p &lt; 0.0001).</font></p>     ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#51#47#article#142#<p>&nbsp;</p>     ^
cY#a08v37n1.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011200076002001300188#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#52#48#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a name="tab1" id="tab1"></a></font>
</p>     ^cY#a08v37n1.htm##
00381000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014600076002001300222#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#53#49#article#142#<p align="center"><
font size="2" face="Verdana, Arial, Helvetica, sans-serif"><img src="/img/revist
as/ibju/v37n1/a08tab1.jpg"></font></p>     ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#54#50#article#142#<p>&nbsp;</p>     ^
cY#a08v37n1.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011000076002001300186#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#55#51#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Immunohistochemistry</b></font></
p>     ^cY#a08v37n1.htm##
00963000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072800076002001300804#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#56#52#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> A total of 409    PCa punches were 
available to detect for NeuroD1 protein expression. Among these,    302 (73%) sh
owed a NeuroD1 positive cytoplasmic staining (<a href="#tab1">Table-1</a>).    O
nly few cases showed a faint nuclear stain. Results according to Gleason score  
  were reported in Table-2. NeuroD1 expression has shown significant association
    with ChrA (p &lt; 0.001) and AR expression (p &lt; 0.004) (<a href="/img/rev
istas/ibju/v37n1/a08tab3.jpg">Table-3</a>).    Only 3/89 (3%) cases of BPH showe
d a weak positivity. Failure of analysis occurred    in 249 cases mostly for unr
eliability of staining or missing/damaged tissue.</font></p>     ^cY#a08v37n1.ht
m##
01037000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080200076002001300878#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#57#53#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Of 628 PCa punches    valuable for C
hrA expression, 270 (43%) showed a moderately-to-high positive    staining (<a h
ref="#tab1">Table-1</a>). For ChrA, 30 cases are invaluable or    missing tissue
, due to technical problems. The immunohistochemical analysis    revealed a cyto
plasmic positivity, whereas 206 cases were completely negative.    Twenty cases 
of BPH were focally positive. Results according to Gleason score    are reported
 in Table-3. ChrA expression is associated with Gleason score, NeuroD1,    AR an
d Ki67 index (p = 0.002, p &lt; 0.001, p = 0.004 and p &lt; 0.001, respectively)
    (<a href="/img/revistas/ibju/v37n1/a08tab2.jpg">Tables 2</a> and <a href="/i
mg/revistas/ibju/v37n1/a08tab3.jpg">3</a>).</font></p>     ^cY#a08v37n1.htm##
00638000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040300076002001300479#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#58#54#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The staining for    the AR was avail
able for 373 punches of PCa (Table-1), displaying predominantly    a nuclear loc
alization. We detected a low, intermediate and high AR tissue reactivity    in 3
8%, 35% and 27%, respectively. AR expression is associated with NeuroD1    and C
hrA (p = 0.004 and p = 0.004, respectively).</font></p>     ^cY#a08v37n1.htm##
01070000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704083500076002001300911#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#59#55#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A high Ki67 Labelling    Index (miss
ing 121 cases) was found in 14.5% of the 537 evaluated punches and    it was sig
nificantly associated with a high ChrA expression (p &lt; 0.001) (<a href="/img/
revistas/ibju/v37n1/a08tab3.jpg">Table-3</a>).    The univariate analysis associ
ates ChrA and Ki67 with Gleason score (p = 0.002    and p &lt; 0.001) (<a href="
/img/revistas/ibju/v37n1/a08tab2.jpg">Table-2</a>). The multivariate    analysis
 (<a href="/img/revistas/ibju/v37n1/a08tab4.jpg">Table-4</a>) further shows all 
markers    but AR in significant test trend association with the Gleason score. 
Neither    ChrA, nor AR and NeuroD1 positive staining were found to be associate
d with    the presence of seminal vesicles, urethral or perineural invasion.</fo
nt></p>     ^cY#a08v37n1.htm##
00706000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047100076002001300547#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#60#56#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The Kaplan-Meier    model curves sho
wed that Gleason score (data not shown) and Ki67 level had a    significant infl
uence on survival parameters (p &lt; 0.001), whereas ChrA (p    = 0.7), AR (p = 
0.8) and NeuroD1 (p = 0.7) did not show any significant influence    on progress
ion-free (<a href="/img/revistas/ibju/v37n1/a08fig1.jpg">Figure-1</a>) and overa
ll    survival (data not shown).</font></p>     ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#61#57#article#142#<p>&nbsp;</p>     ^
cY#a08v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#62#58#article#142#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>COMMENTS</b></font></p>     ^cY#a
08v37n1.htm##
02759000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704252400076002001302600#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#63#59#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Although several    immunohistochem
ical studies revealed the presence of NE cells in almost all    PCa (20), their 
prognostic relevance remain controversial (21). The NED (mainly    identified by
 tissue ChrA positive staining) seems to be useful as predictor    for biochemic
al failure after radical prostatectomy in clinically localized    PCa (21-23) an
d in low Gleason score PCa (23). As far as NE activity is concerned    it will b
e difficult to detect as the knowledge of NED pathophysiology remains    obscure
, prompting the search for new biomarkers (14). Therefore, we previously    inve
stigated the effects of cAMP on epithelial prostate cancer cell lines detecting 
   a significant variation of HOX-D gene expression and identifying the upstream
    area of the HOX-D locus on chromosome 2q31-33 as potentially involved in a n
eurogenic    program connected to NED (17). Among the genes located in this geno
mic area,    NeuroD1 expression has been related to PCa (14). New evidences have
 further    stressed the use of pro-neural transcription factors, including Neur
oD1, as    cancer biomarkers (24), suggesting that the aberrant initiation of di
fferentiation    programs may confer a selective advantage. The observation that
 in different    PCa models (human derived neoplastic cell-lines, transgenic mou
se tumors and    patient samples) the hallmarks of neural transdifferentiation a
long the progression    to metastatic disease were associated with changes in th
e expression of activator-type    beta-Helix-Loop-Helix transcription factors in
cluding Hes6 and Ascl1 (24) strongly    corroborates our findings. The activatio
n of pro-neural transcription factors    may well be a crucial step in PCa progr
ession even in a na&iuml;ve prostate    cancer. Through the use of TMA methodolo
gy, we have compared different NE markers    in patients who underwent radical p
rostatectomy for surgically treated na&iuml;ve    PCa. This immunohistochemical 
assay (IHC) showed a very low expression of NE    markers in BPH (data not shown
), as previously reported (14). On the other hand,    in PCa we found a higher p
revalence of NeuroD1 (73% of the cases), Ki-67 (85%)    and AR (62%) over ChrA e
xpression (42%), respectively. Herein, we showed that    all the markers in our 
study are mutually and strongly associated (<a href="/img/revistas/ibju/v37n1/a0
8tab2.jpg">Tables    2</a> and <a href="/img/revistas/ibju/v37n1/a08tab3.jpg">3<
/a>).</font></p>     ^cY#a08v37n1.htm##
00880000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064500076002001300721#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#64#60#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The well-documented    correlations 
(18,23,25,26) between the Ki-67 expression and the aggressive features    of PCa
 were confirmed here by the demonstration of its significant association    with
 Gleason score, ChrA expression and survival. On the other hand, the absence    
of correlation with the NeuroD1 and AR (<a href="/img/revistas/ibju/v37n1/a08fig
2.jpg">Figure-2</a>)    could be explained by the fact that Ki-67 is only a mark
er of proliferation,    whereas NeuroD1 and AR are implicated into the neuroendo
crine differentiation    pathway (9,14,27,28).</font></p>     ^cY#a08v37n1.htm##
01015000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704078000076002001300856#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#65#61#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The evidence of    significant assoc
iations between ChrA, NeuroD1 and AR probably suggests that    their expression 
is not only correlated, but also that the biological significance    remains rat
her obscure. We can speculate about the functional relationships    in induction
 or sustain of a neuroendocrine activity or NED in PCa. In the low-grade    (Gle
ason score &lt; 7) group NeuroD1 and ChrA were detected in 71.1 and 40.5%    of 
the cases, respectively. In our opinion this finding is interesting and suggests
    that NeuroD1 could be activated in prostate tumorigenesis and that it probab
ly    is a more accurate marker of transdifferentiated cells or cells predispose
d    to an early NED.</font></p>     ^cY#a08v37n1.htm##
00540000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030500076002001300381#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#66#62#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Further experiments    are needed to
 demonstrate that for the early detection of NE activity an integrated    diagno
stic panel (e.g. Dopa-Decarboxylase, a-methylacyl-CoA racemase, IL-8 receptors) 
   should be proposed (9).</font></p>     ^cY#a08v37n1.htm##
02022000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704178700076002001301863#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#67#63#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A limitation of    our study concern
s the cut-off values used in the analyses, selected on the    bases of the best 
possible discriminatory effect. This approach may predispose    to detect false 
positive results. However, as <a href="/img/revistas/ibju/v37n1/a08fig1.jpg">Fig
ure-1</a>    indicates, only Ki67 robustly emerged as prognostic variable betwee
n the markers    tested for prognostic implication. A clear finding of the study
 is the easy    identification of high- and low-progression risk PCa patients, w
ith the majority    of patients belonging to the intermediate group by all the m
arkers. The intermediate    group includes a significant fraction of patients wh
o experience progression    of disease, urging for additional markers. Furthermo
re, we have used an historical    (1971-1996) series of surgically treated patie
nts (members of the Kaiser Foundation    Health Plan) for the evaluation of the 
prognostic significance and the internal    relationships of the markers. Thus, 
the likelihood of biases due to patient    selection, surgical management, follo
w-up data and tissue quality is not negligible.    On the other hand, the long m
edian follow-up time (almost 6 years with the longest    follow-up time being ov
er 12 years) is an interesting argument suggesting that    PCa cells may remain 
dormant for long periods of time (PCa progression can also    take place 10 year
s after prostatectomy). Moreover, data concerning the kind    of progression det
ection (by the use of the preoperative and during the follow-up    PSA values or
 traditional imaging test) are lacking, hindering any possible    inference rela
tionship between kind of progression, PSA, NE markers and prognosis.</font></p> 
    ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#68#64#article#142#<p>&nbsp;</p>     ^
cY#a08v37n1.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010100076002001300177#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#69#65#article#142#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUSIONS</b></font></p>     ^c
Y#a08v37n1.htm##
00960000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072500076002001300801#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#70#66#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Our study highlights    the utility
 of TMAs to efficiently evaluate candidate prognostic markers in    PCa. While s
ome results confirm previous findings, for the first time, to our    knowledge, 
ChrA, AR and NeuroD1 were evaluated together on a prostate TMA. The    lack of a
ssociation between the ChrA, AR and NeuroD1 tissue reactivity and survival    su
ggest that these markers cannot be considered prognostic marker in patients    s
urgically treated for PCa. Nevertheless, a better identification of such neuroen
docrine    differentiation could advise about a better response rate after carbo
platin-etoposide    regimen chemotherapy (29).</font></p>     ^cY#a08v37n1.htm##
00468000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023300076002001300309#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#71#67#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Also, the highest    reactivity of N
euroD1 over ChrA suggests its possible use, for example, as a    target for anti
sense oligonucletide therapy (30).</font></p>     ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#72#68#article#142#<p>&nbsp;</p>     ^
cY#a08v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#73#69#article#142#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONFLICT OF    INTEREST</b></font
></p>     ^cY#a08v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#74#70#article#142#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> None declared.</font></p>     ^cY#a
08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#75#71#article#142#<p>&nbsp;</p>     ^
cY#a08v37n1.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#76#72#article#142#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFERENCES</b></font></p>     ^cY
#a08v37n1.htm##
00584000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704033500078002001300413#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#77#73#article#142#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 1. Prostate Cancer   
 Incidence and Mortality Worldwide in 2008: Globocan 2002. Available at <a href=
"http://globocan.iarc.fr/factsheets/cancers/prostate.asp" target="_blank">http:/
/globocan.iarc.fr/factsheets/cancers/prostate.asp</a>    Last access 11 Nov. 201
0.    ^cY#a08v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#78#74#article#142#</font> </p>     ^c
Y#a08v37n1.htm##
00710000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704046100078002001300539#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#79#75#article#142#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Altekruse SF,    Ko
sary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al.: Edwards BK (eds).    
SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda,  
  MD. Available at <a href="http://seer.cancer.gov/csr/1975_2007/" target="_blan
k">http://seer.cancer.gov/csr/1975_2007/</a>,    based on November 2009 SEER dat
a submission, posted to the SEER web site, 2010.    ^cY#a08v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#80#76#article#142#</font></p>     ^cY
#a08v37n1.htm##
00499000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025000078002001300328#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#81#77#article#142#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Schr&ouml;der    FH
: Progress in understanding androgen-independent prostate cancer (AIPC): a    re
view of potential endocrine-mediated mechanisms. Eur Urol. 2008; 53: 1129-37.   
 ^cY#a08v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#82#78#article#142#</font></p>     ^cY
#a08v37n1.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027400078002001300352#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#83#79#article#142#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Tannock IF,    de W
it R, Berry WR, Horti J, Pluzanska A, Chi KN, et al.: Docetaxel plus prednisone 
   or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med.  
  2004; 351: 1502-12.    ^cY#a08v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#84#80#article#142#</font></p>     ^cY
#a08v37n1.htm##
00552000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704030300078002001300381#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#85#81#article#142#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Petrylak DP,    Tan
gen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al.: Docetaxel and    es
tramustine compared with mitoxantrone and prednisone for advanced refractory    
prostate cancer. N Engl J Med. 2004; 351: 1513-20.    ^cY#a08v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#86#82#article#142#</font></p>     ^cY
#a08v37n1.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022400078002001300302#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#87#83#article#142#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Jiborn T, Bjartell 
   A, Abrahamsson PA: Neuroendocrine differentiation in prostatic carcinoma duri
ng    hormonal treatment. Urology. 1998; 51: 585-9.    ^cY#a08v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#88#84#article#142#</font></p>     ^cY
#a08v37n1.htm##
00534000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028500078002001300363#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#89#85#article#142#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Hirano D, Okada    
Y, Minei S, Takimoto Y, Nemoto N: Neuroendocrine differentiation in hormone    r
efractory prostate cancer following androgen deprivation therapy. Eur Urol.    2
004; 45: 586-92; discussion 592.    ^cY#a08v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#90#86#article#142#</font></p>     ^cY
#a08v37n1.htm##
00498000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024900078002001300327#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#91#87#article#142#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Kokubo H, Yamada   
 Y, Nishio Y, Fukatsu H, Honda N, Nakagawa A, et al.: Immunohistochemical study 
   of chromogranin A in Stage D2 prostate cancer. Urology. 2005; 66: 135-40.    
^cY#a08v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#92#88#article#142#</font></p>     ^cY
#a08v37n1.htm##
00487000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023800078002001300316#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#93#89#article#142#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Cindolo L, Cantile 
   M, Vacherot F, Terry S, de la Taille A: Neuroendocrine differentiation in pro
state    cancer: from lab to bedside. Urol Int. 2007; 79: 287-96.    ^cY#a08v37n
1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#94#90#article#142#</font></p>     ^cY
#a08v37n1.htm##
00482000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704023200079002001300311#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#95#91#article#142#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Vashchenko    N, 
Abrahamsson PA: Neuroendocrine differentiation in prostate cancer: implications 
   for new treatment modalities. Eur Urol. 2005; 47: 147-55.    ^cY#a08v37n1.htm
##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#96#92#article#142#</font></p>     ^cY
#a08v37n1.htm##
00600000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704035000079002001300429#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#97#93#article#142#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Sciarra A,    Gen
tile V, Monti S, Dattilo C, Gomez AA, Salciccia S, et al.: Comparison of    chro
mogranin A, insulin-like growth factor 1 and prostate-specific antigen serum    
markers in prostate adenocarcinoma and benign prostatic hyperplasia. Urol Int.  
  2008; 80: 68-73.    ^cY#a08v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#98#94#article#142#</font></p>     ^cY
#a08v37n1.htm##
00609000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704035900079002001300438#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#99#95#article#142#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Zitella A,    Ber
ruti A, Destefanis P, Mengozzi G, Torta M, Ceruti C, et al.: Comparison between 
   two commercially available chromogranin A assays in detecting neuroendocrine 
   differentiation in prostate cancer and benign prostate hyperplasia. Clin Chim
    Acta. 2007; 377: 103-7.    ^cY#a08v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#100#96#article#142#</font></p>     ^c
Y#a08v37n1.htm##
00583000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704033200080002001300412#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#101#97#article#142#13#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Yamada Y, Nakamu
ra    K, Aoki S, Taki T, Matsubara H, Sai S, et al.: Is neuroendocrine cell diff
erentiation    detected using chromogranin A from patients with bone metastatic 
prostate cancer    a prognostic factor for outcome? Oncol Rep. 2006; 15: 1309-13
.    ^cY#a08v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#102#98#article#142#</font></p>     ^c
Y#a08v37n1.htm##
00549000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704029800080002001300378#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#103#99#article#142#14#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Cindolo L,    Fr
anco R, Cantile M, Schiavo G, Liguori G, Chiodini P, et al.: NeuroD1 expression 
   in human prostate cancer: can it contribute to neuroendocrine differentiation
    comprehension? Eur Urol. 2007; 52: 1365-73.    ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#104#100#article#142#</font></p>     ^
cY#a08v37n1.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023800081002001300319#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#105#101#article#142#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Hvamstad T,    
Jordal A, Hekmat N, Paus E, Foss&aring; SD: Neuroendocrine serum tumour markers 
   in hormone-resistant prostate cancer. Eur Urol. 2003; 44: 215-21.    ^cY#a08v
37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#106#102#article#142#</font></p>     ^
cY#a08v37n1.htm##
00499000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024700081002001300328#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#107#103#article#142#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Berruti A,    D
ogliotti L, Mosca A, Bellina M, Mari M, Torta M, et al.: Circulating neuroendocr
ine    markers in patients with prostate carcinoma. Cancer. 2000; 88: 2590-7.   
 ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#108#104#article#142#</font></p>     ^
cY#a08v37n1.htm##
00664000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704041200081002001300493#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#109#105#article#142#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Cantile M,    K
isslinger A, Cindolo L, Schiavo G, D'Ant&ograve; V, Franco R, et al.:    cAMP in
duced modifications of HOX D gene expression in prostate cells allow    the iden
tification of a chromosomal area involved in vivo with neuroendocrine    differe
ntiation of human advanced prostate cancers. J Cell Physiol. 2005; 205:    202-1
0.    ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#110#106#article#142#</font></p>     ^
cY#a08v37n1.htm##
00541000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028900081002001300370#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#111#107#article#142#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Zellweger T,   
 Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, et al.: Tissue microarra
y    analysis reveals prognostic significance of syndecan-1 expression in prosta
te    cancer. Prostate. 2003; 55: 20-9.    ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#112#108#article#142#</font></p>     ^
cY#a08v37n1.htm##
00525000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027300081002001300354#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#113#109#article#142#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Kononen J,    B
ubendorf L, Kallioniemi A, B&auml;rlund M, Schraml P, Leighton S, et al.: Tissue
    microarrays for high-throughput molecular profiling of tumor specimens. Nat 
   Med. 1998; 4: 844-7.    ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#114#110#article#142#</font></p>     ^
cY#a08v37n1.htm##
00537000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028500081002001300366#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#115#111#article#142#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Abrahamsson    
PA, Wadstr&ouml;m LB, Alumets J, Falkmer S, Grimelius L: Peptide-hormone- and   
 serotonin-immunoreactive cells in normal and hyperplastic prostate glands. Path
ol    Res Pract. 1986; 181: 675-83.    ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#116#112#article#142#</font></p>     ^
cY#a08v37n1.htm##
00497000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024500081002001300326#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#117#113#article#142#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Komiya A, Suzuk
i    H, Imamoto T, Kamiya N, Nihei N, Naya Y, et al.: Neuroendocrine differentia
tion    in the progression of prostate cancer. Int J Urol. 2009; 16: 37-44.    ^
cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#118#114#article#142#</font></p>     ^
cY#a08v37n1.htm##
00652000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704040000081002001300481#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#119#115#article#142#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Revelos K,    P
etraki C, Scorilas A, Stefanakis S, Malovrouvas D, Alevizopoulos N, et al.:    C
orrelation of androgen receptor status, neuroendocrine differentiation and    an
giogenesis with time-to-biochemical failure after radical prostatectomy in    cl
inically localized prostate cancer. Anticancer Res. 2007; 27: 3651-60.    ^cY#a0
8v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#120#116#article#142#</font></p>     ^
cY#a08v37n1.htm##
00568000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031600081002001300397#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#121#117#article#142#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. May M, Siegsmun
d    M, Hammermann F, Loy V, Gunia S: Prognostic significance of proliferation a
ctivity    and neuroendocrine differentiation to predict treatment failure after
 radical    prostatectomy. Scand J Urol Nephrol. 2007; 41: 375-81.    ^cY#a08v37
n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#122#118#article#142#</font></p>     ^
cY#a08v37n1.htm##
00477000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022500081002001300306#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#123#119#article#142#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Vias M, Massie 
   CE, East P, Scott H, Warren A, Zhou Z, et al.: Pro-neural transcription facto
rs    as cancer markers. BMC Med Genomics. 2008; 1: 17.    ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#124#120#article#142#</font></p>     ^
cY#a08v37n1.htm##
00521000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026900081002001300350#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#125#121#article#142#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Laitinen S,    
Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T: EZH2, Ki-67 and    
MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer.    
2008; 122: 595-602.    ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#126#122#article#142#</font></p>     ^
cY#a08v37n1.htm##
00602000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704035000081002001300431#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#127#123#article#142#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Rubio J, Ramos 
   D, L&oacute;pez-Guerrero JA, Iborra I, Collado A, Solsona E, et al.: Immunohi
stochemical    expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate canc
er; prognostic    value in biopsies and radical prostatectomy specimens. Eur Uro
l. 2005; 48: 745-51.    ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#128#124#article#142#</font></p>     ^
cY#a08v37n1.htm##
00546000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029400081002001300375#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#129#125#article#142#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Zelivianski    
S, Verni M, Moore C, Kondrikov D, Taylor R, Lin MF: Multipathways for transdiffe
rentiation    of human prostate cancer cells into neuroendocrine-like phenotype.
 Biochim Biophys    Acta. 2001; 1539: 28-43.    ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#130#126#article#142#</font></p>     ^
cY#a08v37n1.htm##
00514000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026200081002001300343#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#131#127#article#142#28#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Yuan TC, Veeram
ani    S, Lin MF: Neuroendocrine-like prostate cancer cells: neuroendocrine tran
sdifferentiation    of prostate adenocarcinoma cells. Endocr Relat Cancer. 2007;
 14: 531-47.    ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#132#128#article#142#</font></p>     ^
cY#a08v37n1.htm##
00617000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704036500081002001300446#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#133#129#article#142#29#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Loriot Y, Massa
rd    C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, et al.: Combining carb
oplatin    and etoposide in docetaxel-pretreated patients with castration-resist
ant prostate    cancer: a prospective study evaluating also neuroendocrine featu
res. Ann Oncol.    2009; 20: 703-8.    ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#134#130#article#142#</font></p>     ^
cY#a08v37n1.htm##
00459000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020700081002001300288#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#135#131#article#142#30#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Hadaschik BA,  
  Sowery RD, Gleave ME: Novel targets and approaches in advanced prostate cancer
.    Curr Opin Urol. 2007; 17: 182-7.    ^cY#a08v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#136#132#article#142#</font></p>     ^
cY#a08v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#137#133#article#142#<p>&nbsp;</p>    
 ^cY#a08v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#138#134#article#142#<p>&nbsp;</p>    
 ^cY#a08v37n1.htm##
00370000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704013300078002001300211#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#139#135#article#142#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><i>Accepted after    revision: Aug
ust 28, 2010</i></font></p>     ^cY#a08v37n1.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019300078002001300271#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#140#136#article#142#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><b><a name="end"></a><a href="#top
"><img src="/img/revistas/ibju/v37n1/seta.gif" border="0"></a>    Correspondence
 to</b>:    ^cY#a08v37n1.htm##
00268000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003100078002001300109#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#141#137#article#142#<br>   Dr. Luca C
indolo    ^cY#a08v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003600078002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#142#138#article#142#<br>   Department
 of Urology    ^cY#a08v37n1.htm##
00284000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004700078002001300125#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#143#139#article#142#<br>   "S. Pio da
 Pietrelcina" Hospital    ^cY#a08v37n1.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#144#140#article#142#<br>   Via C. De 
Lellis, 1    ^cY#a08v37n1.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#145#141#article#142#<br>   Vasto, 660
54, Italy    ^cY#a08v37n1.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010300078002001300181#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a08v37n1.htm#S#p#146#142#article#142#<br>   E-mail: <a
 href="mailto:lucacindolo@virgilio.it">lucacindolo@virgilio.it</a></font></p>   
  ^cY#a08v37n1.htm##
00504000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750180062000770620009001390650
00900148064000500157037005600162110000900218109001300227865000900240002001300249
#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#147#1#article#30#1#Pr
ostate Cancer Incidence and Mortality Worldwide in 2008^len#Globocan#20020000#20
02#http://globocan.iarc.fr/factsheets/cancers/prostate.asp#20101111#11 Nov. 2010
#20110200#a08v37n1.htm##
00646000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160020000770160017000970160
01700114016001600131016001600147016001700163810000600180016001800186018004500204
062002600249066000900275037003800284865000900322002001300331#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a08v37n1.htm#S#c#148#2#article#30#2#^rND^sAltekruse^nSF#^r
ND^sKosary^nCL#^rND^sKrapcho^nM#^rND^sNeyman^nN#^rND^sAminou^nR#^rND^sWaldron^nW
#et al#^rED^sEdwards^nBK#SEER Cancer Statistics Review, 1975-2007^len#National C
ancer Institute#Bethesda#http://seer.cancer.gov/csr/1975_2007/#20110200#a08v37n1
.htm##
00564000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770120127000960300
00900223065000900232064000500241031000300246014000800249865000900257002001300266
035001000279801000900289#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S
#c#149#3#article#30#3#^rND^sSchröder^nFH#Progress in understanding androgen-inde
pendent prostate cancer (AIPC): a review of potential endocrine-mediated mechani
sms^len#Eur Urol#20080000#2008#53#1129-37#20110200#a08v37n1.htm#0302-2838#Eur Ur
ol##
00694000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100016000950100
01600111010001500127010001900142010001400161810000600175012009100181030001300272
06500090028506400050029403100040029901400080030386500090031100200130032003500100
0333801001300343#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#150#4
#article#30#4#^rND^sTannock^nIF#^rND^sde Wit^nR#^rND^sBerry^nWR#^rND^sHorti^nJ#^
rND^sPluzanska^nA#^rND^sChi^nKN#et al#Docetaxel plus prednisone or mitoxantrone 
plus prednisone for advanced prostate cancer^len#N Engl J Med#20040000#2004#351#
1502-12#20110200#a08v37n1.htm#0028-4793#N Engl J Med##
00723000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100017000960100
01800113010001800131010001600149010001700165810000600182012011300188030001300301
06500090031406400050032303100040032801400080033286500090034000200130034903500100
0362801001300372#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#151#5
#article#30#5#^rND^sPetrylak^nDP#^rND^sTangen^nCM#^rND^sHussain^nMH#^rND^sLara^n
PN Jr#^rND^sJones^nJA#^rND^sTaplin^nME#et al#Docetaxel and estramustine compared
 with mitoxantrone and prednisone for advanced refractory prostate cancer^len#N 
Engl J Med#20040000#2004#351#1513-20#20110200#a08v37n1.htm#0028-4793#N Engl J Me
d##
00578000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100018000930100
02200111012008400133030000800217065000900225064000500234031000300239014000600242
865000900248002001300257035001000270801000800280#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a08v37n1.htm#S#c#152#6#article#30#6#^rND^sJiborn^nT#^rND^sBjartell^nA#
^rND^sAbrahamsson^nPA#Neuroendocrine differentiation in prostatic carcinoma duri
ng hormonal treatment^len#Urology#19980000#1998#51#585-9#20110200#a08v37n1.htm#0
090-4295#Urology##
00657000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100015000930100
01500108010001800123010001600141012011200157030000900269065000900278064000500287
031000300292014000700295865000900302002001300311035001000324801000900334#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#153#7#article#30#7#^rND^sHira
no^nD#^rND^sOkada^nY#^rND^sMinei^nS#^rND^sTakimoto^nY#^rND^sNemoto^nN#Neuroendoc
rine differentiation in hormone refractory prostate cancer following androgen de
privation therapy^len#Eur Urol#20040000#2004#45#586-92#20110200#a08v37n1.htm#030
2-2838#Eur Urol##
00667000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100016000930100
01600109010001700125010001500142010001800157810000600175012007600181030000800257
06500090026506400050027403100030027901400070028286500090028900200130029803500100
0311801000800321#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#154#8
#article#30#8#^rND^sKokubo^nH#^rND^sYamada^nY#^rND^sNishio^nY#^rND^sFukatsu^nH#^
rND^sHonda^nN#^rND^sNakagawa^nA#et al#Immunohistochemical study of chromogranin 
A in Stage D2 prostate cancer^len#Urology#20050000#2005#66#135-40#20110200#a08v3
7n1.htm#0090-4295#Urology##
00629000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100017000940100
01800111010001500129010002200144012007500166030000900241065000900250064000500259
031000300264014000700267865000900274002001300283035001000296801000900306#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#155#9#article#30#9#^rND^sCind
olo^nL#^rND^sCantile^nM#^rND^sVacherot^nF#^rND^sTerry^nS#^rND^sde la Taille^nA#N
euroendocrine differentiation in prostate cancer: from lab to bedside^len#Urol I
nt#20070000#2007#79#287-96#20110200#a08v37n1.htm#0042-1138#Urol Int##
00570000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100022000990120
09700121030000900218065000900227064000500236031000300241014000700244865000900251
002001300260035001000273801000900283#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
8v37n1.htm#S#c#156#10#article#30#10#^rND^sVashchenko^nN#^rND^sAbrahamsson^nPA#Ne
uroendocrine differentiation in prostate cancer: implications for new treatment 
modalities^len#Eur Urol#20050000#2005#47#147-55#20110200#a08v37n1.htm#0302-2838#
Eur Urol##
00764000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01500113010001700128010001600145010001900161810000600180012016700186030000900353
06500090036206400050037103100030037601400060037986500090038500200130039403500100
0407801000900417#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#157#1
1#article#30#11#^rND^sSciarra^nA#^rND^sGentile^nV#^rND^sMonti^nS#^rND^sDattilo^n
C#^rND^sGomez^nAA#^rND^sSalciccia^nS#et al#Comparison of chromogranin A, insulin
-like growth factor 1 and prostate-specific antigen serum markers in prostate ad
enocarcinoma and benign prostatic hyperplasia^len#Urol Int#20080000#2008#80#68-7
3#20110200#a08v37n1.htm#0042-1138#Urol Int##
00779000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
02000113010001800133010001500151010001600166810000600182012016700188030001500355
06500090037006400050037903100040038401400060038886500090039400200130040303500100
0416801001500426#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#158#1
2#article#30#12#^rND^sZitella^nA#^rND^sBerruti^nA#^rND^sDestefanis^nP#^rND^sMeng
ozzi^nG#^rND^sTorta^nM#^rND^sCeruti^nC#et al#Comparison between two commercially
 available chromogranin A assays in detecting neuroendocrine differentiation in 
prostate cancer and benign prostate hyperplasia^len#Clin Chim Acta#20070000#2007
#377#103-7#20110200#a08v37n1.htm#0009-8981#Clin Chim Acta##
00751000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01400113010001400127010001900141010001300160810000600173012015700179030001000336
06500090034606400050035503100030036001400080036386500090037100200130038003500100
0393801001000403#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#159#1
3#article#30#13#^rND^sYamada^nY#^rND^sNakamura^nK#^rND^sAoki^nS#^rND^sTaki^nT#^r
ND^sMatsubara^nH#^rND^sSai^nS#et al#Is neuroendocrine cell differentiation detec
ted using chromogranin A from patients with bone metastatic prostate cancer a pr
ognostic factor for outcome?^len#Oncol Rep#20060000#2006#15#1309-13#20110200#a08
v37n1.htm#1021-335X#Oncol Rep##
00716000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01700112010001700129010001700146010001800163810000600181012011600187030000900303
06500090031206400050032103100030032601400080032986500090033700200130034603500100
0359801000900369#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#160#1
4#article#30#14#^rND^sCindolo^nL#^rND^sFranco^nR#^rND^sCantile^nM#^rND^sSchiavo^
nG#^rND^sLiguori^nG#^rND^sChiodini^nP#et al#NeuroD1 expression in human prostate
 cancer: can it contribute to neuroendocrine differentiation comprehension?^len#
Eur Urol#20070000#2007#52#1365-73#20110200#a08v37n1.htm#0302-2838#Eur Urol##
00624000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01600113010001400129010001600143012007700159030000900236065000900245064000500254
031000300259014000700262865000900269002001300278035001000291801000900301#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#161#15#article#30#15#^rND^sHv
amstad^nT#^rND^sJordal^nA#^rND^sHekmat^nN#^rND^sPaus^nE#^rND^sFosså^nSD#Neuroend
ocrine serum tumour markers in hormone-resistant prostate cancer^len#Eur Urol#20
030000#2003#44#215-21#20110200#a08v37n1.htm#0302-2838#Eur Urol##
00665000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100019000960100
01500115010001700130010001400147010001500161810000600176012007500182030000700257
06500090026406400050027303100030027801400070028186500090028800200130029703500100
0310801000700320#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#162#1
6#article#30#16#^rND^sBerruti^nA#^rND^sDogliotti^nL#^rND^sMosca^nA#^rND^sBellina
^nM#^rND^sMari^nM#^rND^sTorta^nM#et al#Circulating neuroendocrine markers in pat
ients with prostate carcinoma^len#Cancer#20000000#2000#88#2590-7#20110200#a08v37
n1.htm#0008-543X#Cancer##
00822000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100020000960100
01700116010001700133010001600150010001600166810000600182012020900188030001500397
06500090041206400050042103100040042601400070043086500090043700200130044603500100
0459801001500469#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#163#1
7#article#30#17#^rND^sCantile^nM#^rND^sKisslinger^nA#^rND^sCindolo^nL#^rND^sSchi
avo^nG#^rND^sD'Antò^nV#^rND^sFranco^nR#et al#cAMP induced modifications of HOX D
 gene expression in prostate cells allow the identification of a chromosomal are
a involved in vivo with neuroendocrine differentiation of human advanced prostat
e cancers^len#J Cell Physiol#20050000#2005#205#202-10#20110200#a08v37n1.htm#0021
-9541#J Cell Physiol##
00706000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100015000980100
01900113010001800132010001600150010001700166810000600183012010700189030000900296
06500090030506400050031403100030031901400050032286500090032700200130033603500100
0349801000900359#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#164#1
8#article#30#18#^rND^sZellweger^nT#^rND^sNinck^nC#^rND^sMirlacher^nM#^rND^sAnnef
eld^nM#^rND^sGlass^nAG#^rND^sGasser^nTC#et al#Tissue microarray analysis reveals
 prognostic significance of syndecan-1 expression in prostate cancer^len#Prostat
e#20030000#2003#55#20-9#20110200#a08v37n1.htm#0270-4137#Prostate##
00684000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100019000960100
02100115010001700136010001700153010001800170810000600188012008200194030000800276
06500090028406400050029303100020029801400060030086500090030600200130031503500100
0328801000800338#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#165#1
9#article#30#19#^rND^sKononen^nJ#^rND^sBubendorf^nL#^rND^sKallioniemi^nA#^rND^sB
ärlund^nM#^rND^sSchraml^nP#^rND^sLeighton^nS#et al#Tissue microarrays for high-t
hroughput molecular profiling of tumor specimens^len#Nat Med#19980000#1998#4#844
-7#20110200#a08v37n1.htm#1078-8956#Nat Med##
00677000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100019001010100
01700120010001700137010001900154012009900173030001700272065000900289064000500298
031000400303014000700307865000900314002001300323035001000336801001700346#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#166#20#article#30#20#^rND^sAb
rahamsson^nPA#^rND^sWadström^nLB#^rND^sAlumets^nJ#^rND^sFalkmer^nS#^rND^sGrimeli
us^nL#Peptide-hormone- and serotonin-immunoreactive cells in normal and hyperpla
stic prostate glands^len#Pathol Res Pract#19860000#1986#181#675-83#20110200#a08v
37n1.htm#0344-0338#Pathol Res Pract##
00667000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01700111010001600128010001500144010001400159810000600173012007300179030001100252
06500090026306400050027203100030027701400060028086500090028600200130029503500100
0308801001100318#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#167#2
1#article#30#21#^rND^sKomiya^nA#^rND^sSuzuki^nH#^rND^sImamoto^nT#^rND^sKamiya^nN
#^rND^sNihei^nN#^rND^sNaya^nY#et al#Neuroendocrine differentiation in the progre
ssion of prostate cancer^len#Int J Urol#20090000#2009#16#37-44#20110200#a08v37n1
.htm#0919-8172#Int J Urol##
00820000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01800113010002000131010002100151010002300172810000600195012019400201030001500395
06500090041006400050041903200030042401400080042786500090043500200130044403500100
0457801001500467#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#168#2
2#article#30#22#^rND^sRevelos^nK#^rND^sPetraki^nC#^rND^sScorilas^nA#^rND^sStefan
akis^nS#^rND^sMalovrouvas^nD#^rND^sAlevizopoulos^nN#et al#Correlation of androge
n receptor status, neuroendocrine differentiation and angiogenesis with time-to-
biochemical failure after radical prostatectomy in clinically localized prostate
 cancer^len#Anticancer Res#20070000#2007#27#3651-60#20110200#a08v37n1.htm#0250-7
005#Anticancer Res##
00717000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100013000790100019000920100
02000111010001300131010001500144012014600159030002100305065000900326064000500335
031000300340014000700343865000900350002001300359035001000372801002100382#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#169#23#article#30#23#^rND^sMa
y^nM#^rND^sSiegsmund^nM#^rND^sHammermann^nF#^rND^sLoy^nV#^rND^sGunia^nS#Prognost
ic significance of proliferation activity and neuroendocrine differentiation to 
predict treatment failure after radical prostatectomy^len#Scand J Urol Nephrol#2
0070000#2007#41#375-81#20110200#a08v37n1.htm#0036-5599#Scand J Urol Nephrol##
00616000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100017000930100
01400110010001500124010001600139010001400155810000600169012005500175030001700230
71000020024706500090024906400050025803100020026301400030026586500090026800200130
0277#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#170#24#article#30
#24#^rND^sVias^nM#^rND^sMassie^nCE#^rND^sEast^nP#^rND^sScott^nH#^rND^sWarren^nA#
^rND^sZhou^nZ#et al#Pro-neural transcription factors as cancer markers^len#BMC M
ed Genomics#2#20080000#2008#1#17#20110200#a08v37n1.htm##
00680000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100022000970100
01700119010001500136010001800151010001900169012008200188030001300270065000900283
06400050029203100040029701400080030186500090030900200130031803500100033180100130
0341#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#171#25#article#30
#25#^rND^sLaitinen^nS#^rND^sMartikainen^nPM#^rND^sTolonen^nT#^rND^sIsola^nJ#^rND
^sTammela^nTL#^rND^sVisakorpi^nT#EZH2, Ki-67 and MCM7 are prognostic markers in 
prostatectomy treated patients^len#Int J Cancer#20080000#2008#122#595-602#201102
00#a08v37n1.htm#0020-7136#Int J Cancer##
00760000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100015000940100
02500109010001600134010001700150010001700167810000600184012015800190030000900348
06500090035706400050036603100030037101400070037486500090038100200130039003500100
0403801000900413#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#172#2
6#article#30#26#^rND^sRubio^nJ#^rND^sRamos^nD#^rND^sLópez-Guerrero^nJA#^rND^sIbo
rra^nI#^rND^sCollado^nA#^rND^sSolsona^nE#et al#Immunohistochemical expression of
 Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biop
sies and radical prostatectomy specimens^len#Eur Urol#20050000#2005#48#745-51#20
110200#a08v37n1.htm#0302-2838#Eur Urol##
00713000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100015001000100
01500115010001900130010001600149010001400165012010900179030002100288065000900309
06400050031803200050032301400060032886500090033400200130034303500100035680100210
0366#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#173#27#article#30
#27#^rND^sZelivianski^nS#^rND^sVerni^nM#^rND^sMoore^nC#^rND^nKondrikov^sD#^rND^s
Taylor^nR#^rND^sLin^nMF#Multipathways for transdifferentiation of human prostate
 cancer cells into neuroendocrine-like phenotype^len#Biochim Biophys Acta#200100
00#2001#1539#28-43#20110200#a08v37n1.htm#0006-3002#Biochim Biophys Acta##
00589000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100019000940100
01400113012011600127030002000243710000200263065000900265064000500274031000300279
014000700282865000900289002001300298#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
8v37n1.htm#S#c#174#28#article#30#28#^rND^sYuan^nTC#^rND^sVeeramani^nS#^rND^sLin^
nMF#Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiati
on of prostate adenocarcinoma cells^len#Endocr Relat Cancer#2#20070000#2007#14#5
31-47#20110200#a08v37n1.htm##
00780000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
02200112010001800134010001800152010001500170810000600185012017600191030001000367
06500090037706400050038603100030039101400060039486500090040000200130040903500100
0422801001000432#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a08v37n1.htm#S#c#175#2
9#article#30#29#^rND^sLoriot^nY#^rND^sMassard^nC#^rND^sGross-Goupil^nM#^rND^sDi 
Palma^nM#^rND^sEscudier^nB#^rND^sBossi^nA#et al#Combining carboplatin and etopos
ide in docetaxel-pretreated patients with castration-resistant prostate cancer: 
a prospective study evaluating also neuroendocrine features^len#Ann Oncol#200900
00#2009#20#703-8#20110200#a08v37n1.htm#0923-7534#Ann Oncol##
00534000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100017000990100
01700116012006100133030001500194710000200209065000900211064000500220031000300225
014000600228865000900234002001300243#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
8v37n1.htm#S#c#176#30#article#30#30#^rND^sHadaschik^nBA#^rND^sSowery^nRD#^rND^sG
leave^nME#Novel targets and approaches in advanced prostate cancer^len#Curr Opin
 Urol#2#20070000#2007#17#182-7#20110200#a08v37n1.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#o#1#1#article#1
#20110330#144514#a09v37n1.htm#219##
02467000000000517000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000180011303100030013103200020013406500090013601400090014503500100015401200560
01640100028002200100028002480100024002760100024003000100022003240100021003460831
39400367085001001761085003201771085002601803085002101829085003701850085004001887
117000601927072000301933002001301936#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
9v37n1.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#09#IBJU010#nd#Int. braz 
j urol.#37#1#20110200#^f67^l78#1677-5538#Learning curve for radical retropubic p
rostatectomy^len#^rND^nFernando J. A.^sSaito#^rND^nMarcos F.^sDall'Oglio#^rND^nG
ustavo X.^sEbaid#^rND^nHomero^sBruschini#^rND^nDaher C.^sChade#^rND^nMiguel^sSro
ugi#^len^aPURPOSE: The learning curve is a period in which the surgical procedur
e is performed with difficulty and slowness, leading to a higher risk of complic
ations and reduced effectiveness due the surgeon's inexperience. We sought to an
alyze the residents' learning curve for open radical prostatectomy (RP) in a tra
ining program. MATERIALS AND METHODS: We conducted a prospective study from June
 2006 to January 2008 in the academic environment of the University of São Paulo
. Five residents operated on 184 patients during a four-month rotation in the ur
ologic oncology division, mentored by the same physician assistants. We performe
d sequential analyses according to the number of surgeries, as follows: = 10, 11
 to 19, 20 to 28, and = 29. RESULTS: The residents performed an average of 37 RP
 each. The average psa was 9.3 ng/mL and clinical stage T1c in 71% of the patien
ts. The pathological stage was pT2 (73%), pT3 (23%), pT4 (4%), and 46% of the pa
tients had a Gleason score 7 or higher. In all surgeries, the average operative 
time and estimated blood loss was 140 minutes and 488 mL. Overall, 7.2% of patie
nts required blood transfusion, and 23% had positive surgical margins. CONCLUSIO
N: During the initial RP learning curve, we found a significant reduction in the
 operative time; blood transfusion during the procedures and positive surgical m
argin rate were stable in our series.#^ddecs^i1#^tm^len^kprostatic neoplasms^i1#
^tm^len^kprostatectomy^i1#^tm^len^klearning^i1#^tm^len^kinternship and residency
^i1#^tm^len^kpostoperative complications^i1#other#28#a09v37n1.htm##
02502000000000517000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000180011303100030013103200020013406500090013601400090014503500100015401200630
01640100028002270100028002550100024002830100024003070100022003310100021003530831
42200374085001001796085003201806085002601838085002101864085003701885085004001922
117000601962072000301968002001301971#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
9v37n1.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#09#IBJU010#nd#Int. braz 
j urol.#37#1#20110200#^f67^l78#1677-5538#<b>Learning curve for radical retropubi
c prostatectomy</b>^len#^rND^nFernando J. A.^sSaito#^rND^nMarcos F.^sDall'Oglio#
^rND^nGustavo X.^sEbaid#^rND^nHomero^sBruschini#^rND^nDaher C.^sChade#^rND^nMigu
el^sSrougi#^len^a<b>PURPOSE:</b> The learning curve is a period in which the sur
gical procedure is performed with difficulty and slowness, leading to a higher r
isk of complications and reduced effectiveness due the surgeon's inexperience. W
e sought to analyze the residents' learning curve for open radical prostatectomy
 (RP) in a training program. <b>MATERIALS AND METHODS:</b> We conducted a prospe
ctive study from June 2006 to January 2008 in the academic environment of the Un
iversity of São Paulo. Five residents operated on 184 patients during a four-mon
th rotation in the urologic oncology division, mentored by the same physician as
sistants. We performed sequential analyses according to the number of surgeries,
 as follows: = 10, 11 to 19, 20 to 28, and = 29. <b>RESULTS:</b> The residents p
erformed an average of 37 RP each. The average psa was 9.3 ng/mL and clinical st
age T1c in 71% of the patients. The pathological stage was pT2 (73%), pT3 (23%),
 pT4 (4%), and 46% of the patients had a Gleason score 7 or higher. In all surge
ries, the average operative time and estimated blood loss was 140 minutes and 48
8 mL. Overall, 7.2% of patients required blood transfusion, and 23% had positive
 surgical margins. <b>CONCLUSION:</b> During the initial RP learning curve, we f
ound a significant reduction in the operative time; blood transfusion during the
 procedures and positive surgical margin rate were stable in our series.#^ddecs^
i1#^tm^len^kprostatic neoplasms^i1#^tm^len^kprostatectomy^i1#^tm^len^klearning^i
1#^tm^len^kinternship and residency^i1#^tm^len^kpostoperative complications^i1#o
ther#28#a09v37n1.htm##
02642000000000541000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000300117049000800120
15800030012803000170013103100030014803200020015106500090015301400090016203500100
01710120056001810100027002370100027002640100023002910100024003140100021003380100
02100359083144300380085001001823085003201833085002601865085002101891085003701912
085004001949117000601989072000301995002001301998008008902011#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a09v37n1.htm#S#l#4#1#article#1#^mJan./Feb.^a2011#oa#en#br1
.1#1#4.0#ilus#tab#09#IBJU010#nd#Int. braz j urol#37#1#20110200#^f67^l78#1677-553
8#Learning curve for radical retropubic prostatectomy^len#^rND^nFernando J. A^sS
aito#^rND^nMarcos F^sDall'Oglio#^rND^nGustavo X^sEbaid#^rND^nHomero^sBruschini#^
rND^nDaher C^sChade#^rND^nMiguel^sSrougi#^len^aPURPOSE: The learning curve is a 
period in which the surgical procedure is performed with difficulty and slowness
, leading to a higher risk of complications and reduced effectiveness due the su
rgeon's inexperience. We sought to analyze the residents' learning curve for ope
n radical prostatectomy (RP) in a training program. MATERIALS AND METHODS: We co
nducted a prospective study from June 2006 to January 2008 in the academic envir
onment of the University of São Paulo. Five residents operated on 184 patients d
uring a four-month rotation in the urologic oncology division, mentored by the s
ame physician assistants. We performed sequential analyses according to the numb
er of surgeries, as follows: = 10, 11 to 19, 20 to 28, and = 29. RESULTS: The re
sidents performed an average of 37 RP each. The average psa was 9.3 ng/mL and cl
inical stage T1c in 71 percent of the patients. The pathological stage was pT2 (
73 percent), pT3 (23 percent), pT4 (4 percent), and 46 percent of the patients h
ad a Gleason score 7 or higher. In all surgeries, the average operative time and
 estimated blood loss was 140 minutes and 488 mL. Overall, 7.2 percent of patien
ts required blood transfusion, and 23 percent had positive surgical margins. CON
CLUSION: During the initial RP learning curve, we found a significant reduction 
in the operative time; blood transfusion during the procedures and positive surg
ical margin rate were stable in our series.#^ddecs^i1#^tm^len^kprostatic neoplas
ms^i1#^tm^len^kprostatectomy^i1#^tm^len^klearning^i1#^tm^len^kinternship and res
idency^i1#^tm^len^kpostoperative complications^i1#other#28#a09v37n1.htm#Internet
^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382011000100009
##
00356000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012300074002001300197#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#5#1#article#187#<p align="right"><fon
t face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>CLINICAL    UROLOGY</
b></font></p>     ^cY#a09v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#6#2#article#187#<p>&nbsp;</p>     ^cY
#a09v37n1.htm##
00395000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704016200074002001300236#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#7#3#article#187#<p><a name="top"></a>
<font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Learning    curve
 for radical retropubic prostatectomy</b></font></p>     ^cY#a09v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#8#4#article#187#<p>&nbsp;</p>     ^cY
#a09v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#9#5#article#187#<p>&nbsp;</p>     ^cY
#a09v37n1.htm##
00439000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704020500075002001300280#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#10#6#article#187#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Fernando J.    A. Saito; Marcos F.
 Dall'Oglio; Gustavo X. Ebaid; Homero Bruschini; Daher C.    Chade; Miguel Sroug
i</b></font></p>     ^cY#a09v37n1.htm##
00442000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704020800075002001300283#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#11#7#article#187#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Division of Urology,    University of
 Sao Paulo Medical School and Cancer Institute, State of Sao Paulo,    Sao Paulo
, Brazil</font></p>     ^cY#a09v37n1.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011600075002001300191#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#12#8#article#187#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#end">Correspondence</a></fo
nt></p>     ^cY#a09v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#13#9#article#187#<p>&nbsp;</p>     ^c
Y#a09v37n1.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#14#10#article#187#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a09v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#15#11#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#a
09v37n1.htm##
00653000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041800076002001300494#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#16#12#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>PURPOSE:</b>    The learning curv
e is a period in which the surgical procedure is performed    with difficulty an
d slowness, leading to a higher risk of complications and    reduced effectivene
ss due the surgeon's inexperience. We sought to analyze the    residents' learni
ng curve for open radical prostatectomy (RP) in a training    program.     ^cY#a
09v37n1.htm##
00692000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045700076002001300533#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#17#13#article#187#<br>   <b>MATERIALS
 AND METHODS:</b> We conducted a prospective study from June 2006    to January 
2008 in the academic environment of the University of S&atilde;o    Paulo. Five 
residents operated on 184 patients during a four-month rotation    in the urolog
ic oncology division, mentored by the same physician assistants.    We performed
 sequential analyses according to the number of surgeries, as follows:    = 10, 
11 to 19, 20 to 28, and = 29.     ^cY#a09v37n1.htm##
00714000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047900076002001300555#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#18#14#article#187#<br>   <b>RESULTS:<
/b> The residents performed an average of 37 RP each. The average    psa was 9.3
 ng/mL and clinical stage T1c in 71% of the patients. The pathological    stage 
was pT2 (73%), pT3 (23%), pT4 (4%), and 46% of the patients had a Gleason    sco
re 7 or higher. In all surgeries, the average operative time and estimated    bl
ood loss was 140 minutes and 488 mL. Overall, 7.2% of patients required blood   
 transfusion, and 23% had positive surgical margins.    ^cY#a09v37n1.htm##
00481000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024600076002001300322#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#19#15#article#187#<br>   <b>CONCLUSIO
N:</b> During the initial RP learning curve, we found a significant    reduction
 in the operative time; blood transfusion during the procedures and    positive 
surgical margin rate were stable in our series.</font></p>     ^cY#a09v37n1.htm#
#
00463000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022800076002001300304#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#20#16#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Key words:</b>    prostatic neopl
asms; prostatectomy; learning; internship and residency; postoperative    compli
cations</font></p> <HR size="1" noshade>     ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#21#17#article#187#<p>&nbsp;</p>     ^
cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#22#18#article#187#<p>&nbsp;</p>     ^
cY#a09v37n1.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#23#19#article#187#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODUCTION</b></font></p>     ^
cY#a09v37n1.htm##
00799000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056400076002001300640#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#24#20#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Prostate cancer    (PCa) is currentl
y the most common malignant tumor among men in Europe and the    United States (
US), except for malignant non-melanoma skin tumors. In the US,    it is estimate
d that about 192,280 new cases are diagnosed per year, with 27,360    deaths a y
ear due to PCa, which represents 9% of all cancer deaths in the country    per y
ear (1). In Europe, each year there are an estimated 190,000 new cases,    with 
more than 50,000 deaths from the disease (2).</font></p>     ^cY#a09v37n1.htm##
01090000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704085500076002001300931#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#25#21#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Radical prostatectomy    (RP) was th
e first widely used standard treatment for localized PCa. The classic    approac
h is the retropubic technique. RP was introduced in 1905 by Young and    reviewe
d by Millin in 1946. However, it only became routinely and safely performed    i
n 1982, when Walsh et al. published new technical aspects of the surgery, defini
tely    setting the surgical standards for the treatment of PCa (3). Since then,
 new    techniques and approaches have been developed, such as perineal (4), lap
aroscopic    (5,6) and robotic-assisted RP (7). Throughout the first decade of t
he 21st century,    the use of robotic-assisted surgery has rapidly increased in
 the U.S. (1), spanning    the last three years to Europe (2) and finally to Bra
zil in 2008 (8).</font></p>     ^cY#a09v37n1.htm##
00736000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050100076002001300577#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#26#22#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Subsequently new    technological el
ements have been incorporated into the surgical technique of    RP, and increasi
ngly high additional direct and indirect expenses have significantly    added to
 the total cost of the procedure. &nbsp;Notwithstanding the problem    of signif
icantly elevated costs, technological complexity incorporated into    new techni
ques may result in a longer or yet unclear learning curve (9).</font></p>     ^c
Y#a09v37n1.htm##
00867000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063200076002001300708#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#27#23#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">High costs and    a possibly longer 
learning curve prompted us to question the applicability of    these new surgica
l modalities into clinical practice of our hospitals, especially    those relate
d to the public health system of our country. Furthermore, there    still lacks 
a thorough discussion of their unclear benefits to oncologic outcomes    and qua
lity of life of patients who undergo minimally invasive procedures (10).    To w
hat extent have perineal, laparoscopic or robotic-assisted RP proved superior   
 to the open retropubic approach?</font></p>     ^cY#a09v37n1.htm##
01029000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704079400076002001300870#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#28#24#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The learning curve    in surgery can
 be defined as the number of cases required to perform the procedure    with rea
sonable operating time and an acceptable rate of complications, resulting    in 
an adequate postoperative clinical outcome associated with a shorter hospital   
 stay. Obviously, several key factors may impact the learning curve, not only   
 such as those related to the surgeon, as attitude, confidence, experience with 
   other surgical procedures, but also those related to the team members involve
d    in the procedures. Undoubtedly, the number of cases performed by the surgeo
n    and the volume of surgeries in a given center may certainly delineate the c
ourse    of surgical outcomes (11).</font></p>     ^cY#a09v37n1.htm##
00671000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043600076002001300512#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#29#25#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">RP is a particularly    complex surg
ical procedure and it is assumed to be closely related to the surgical    techni
que employed, depending in part on the surgeon's experience. Currently    each R
P technique, either open (retropubic and perineal), or minimally invasive    (la
paroscopic and robotic), present distinctive learning curves for the surgeon.</f
ont></p>     ^cY#a09v37n1.htm##
01096000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704086100076002001300937#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#30#26#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Due to the wide    variation in trai
ning formats offered in the various surgical programs in urology,    we sought t
o evaluate the learning curve for open RP among third-year urology    residents 
(fifth year of residency in surgery overall) in a high volume tertiary    referr
al center. We aimed at both defining a minimum number of procedures necessary   
 to properly train the resident surgeon in urology for this procedure, as well  
  as on determining the most sensitive key points of the learning process. As   
 a result, we may be able to continuously improve the teaching process of the   
 surgical technique and make it widely available to mentors and teaching centers
,    especially considering the social environment of growing ethical concerns w
ith    patient safety.</font></p>     ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#31#27#article#187#<p>&nbsp;</p>     ^
cY#a09v37n1.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011400076002001300190#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#32#28#article#187#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>MATERIALS AND    METHODS</b></fon
t></p>     ^cY#a09v37n1.htm##
01030000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704079500076002001300871#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#33#29#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> We conducted a    prospective study
 from June 2006 to January 2008 in the urologic oncology division    of the Univ
ersity of S&atilde;o Paulo. Patients with clinically localized prostate    adeno
carcinoma (cT1-2 Nx M0) with medical conditions for surgical treatment    were s
elected. Five residents operated on 184 patients during a four-month rotation   
 in the urologic oncology division, mentored by the same physician assistants.  
  Patients who had undergone other treatments such as chemotherapy, radiation   
 therapy or biological agents prior or concomitant to surgery and patients with 
   significant neurological, psychiatric disorders, including dementia or seizur
es,    were excluded from the study.</font></p>     ^cY#a09v37n1.htm##
00787000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055200076002001300628#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#34#30#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Surgeries were    performed followin
g the same surgical technique for radical retropubic prostatectomy,    as previo
usly described (11,12). In all surgeries, the residents were assisted    by 5 at
tending surgeons. Fifteen days after hospital discharge, the indwelling    cathe
ter and stitches were removed. The first functional evaluation (urinary    incon
tinence) was 60 days after surgery, as well as laboratory tests (PSA value,    b
lood count and serum creatinine).</font></p>     ^cY#a09v37n1.htm##
00604000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036900076002001300445#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#35#31#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The length of operative    time was 
measured from skin incision until the completion of the wound dressing.    The e
stimated blood loss was calculated by measuring the volume of the vacuum    bott
le minus the amount of saline used during surgery. No sponges were used    durin
g surgery.</font></p>     ^cY#a09v37n1.htm##
00714000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047900076002001300555#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#36#32#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">We also assessed    the surgical pat
hology stage and Gleason score, in all cases, as well as positive    surgical ma
rgin for extracapsular extension. Statistical analysis was performed    by using
 analysis of variance (ANOVA) and the number of surgeries in quartiles:    up to
 10, from 11 to 19, from 20 to 28 and more than 29 surgeries. Fisher's    exact 
test was applied to evaluate the groups.</font></p>     ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#37#33#article#187#<p>&nbsp;</p>     ^
cY#a09v37n1.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#38#34#article#187#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESULTS</b></font></p>     ^cY#a0
9v37n1.htm##
00523000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028800076002001300364#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#39#35#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Each resident    participated in th
e study during four consecutive months and, on average, each    one of them perf
ormed 9 surgeries per month (<a href="/img/revistas/ibju/v37n1/a09tab1.jpg">Tabl
e-1</a>).</font></p>     ^cY#a09v37n1.htm##
00413000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017800076002001300254#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#40#36#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The demographics    of patients who 
underwent RP are summarized in <a href="#tab2">Table-2</a>.</font></p>     ^cY#a
09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#41#37#article#187#<p>&nbsp;</p>     ^
cY#a09v37n1.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011200076002001300188#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#42#38#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a name="tab2" id="tab2"></a></font>
</p>     ^cY#a09v37n1.htm##
00372000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013700076002001300213#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#43#39#article#187#<p align="center"><
font face="Verdana, Arial, Helvetica, sans-serif"><img src="/img/revistas/ibju/v
37n1/a09tab2.jpg"></font></p>     ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#44#40#article#187#<p>&nbsp;</p>     ^
cY#a09v37n1.htm##
00447000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021200076002001300288#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#45#41#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The surgical pathology    stage, pro
state size, Gleason score and surgical margins are summarized in <a href="#tab3"
>Table-3</a>.</font></p>     ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#46#42#article#187#<p>&nbsp;</p>     ^
cY#a09v37n1.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011200076002001300188#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#47#43#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a name="tab3" id="tab3"></a></font>
</p>     ^cY#a09v37n1.htm##
00372000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013700076002001300213#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#48#44#article#187#<p align="center"><
font face="Verdana, Arial, Helvetica, sans-serif"><img src="/img/revistas/ibju/v
37n1/a09tab3.jpg"></font></p>     ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#49#45#article#187#<p>&nbsp;</p>     ^
cY#a09v37n1.htm##
00471000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023600076002001300312#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#50#46#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="#tab4">Table-4</a>    prese
nts surgical data. The median operative time was 140 minutes, and most    patien
ts did not require blood transfusion.</font></p>     ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#51#47#article#187#<p>&nbsp;</p>     ^
cY#a09v37n1.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011200076002001300188#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#52#48#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a name="tab4" id="tab4"></a></font>
</p>     ^cY#a09v37n1.htm##
00372000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013700076002001300213#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#53#49#article#187#<p align="center"><
font face="Verdana, Arial, Helvetica, sans-serif"><img src="/img/revistas/ibju/v
37n1/a09tab4.jpg"></font></p>     ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#54#50#article#187#<p>&nbsp;</p>     ^
cY#a09v37n1.htm##
00668000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043300076002001300509#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#55#51#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A curve of decreasing    operative t
ime (p = 0.03) is shown in <a href="/img/revistas/ibju/v37n1/a09fig1.jpg">Figure
-1</a>,    comparing the 19 initial RP to the following 9 RP performed (p = 0.01
) and the    remaining surgeries from 29 and more (p &lt; 0.001). From the twent
ieth RP onwards,    we found a significant decrease in the operative time.</font
></p>     ^cY#a09v37n1.htm##
00506000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027100076002001300347#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#56#52#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">There was a progressive    decrease 
in estimated blood loss as the residents gained surgical experience    with RP, 
as shown in <a href="/img/revistas/ibju/v37n1/a09fig2.jpg">Figure-2</a>.</font><
/p>     ^cY#a09v37n1.htm##
00544000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030900076002001300385#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#57#53#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="/img/revistas/ibju/v37n1/a0
9fig3.jpg">Figure-3</a>    shows the association between the number of surgeries
 performed and need for    blood transfusion, where a 3% transfusion rate was ob
served after the 29th surgery.</font></p>     ^cY#a09v37n1.htm##
00655000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042000076002001300496#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#58#54#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">When the resident    operated on sma
ller prostates, blood transfusion was rarely required, as highlighted    in <a h
ref="/img/revistas/ibju/v37n1/a09tab5.jpg">Tables-5</a> and <a href="/img/revist
as/ibju/v37n1/a09tab6.jpg">6</a>,    where prostates &lt; 40g and &gt; 40g requi
red a blood transfusion in 3% and    13% of RP, respectively.</font></p>     ^cY
#a09v37n1.htm##
00513000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027800076002001300354#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#59#55#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In reviewing the    occurrence of po
sitive surgical margins, we observed that it remained stable    during the four 
phases, as shown in <a href="/img/revistas/ibju/v37n1/a09tab7.jpg">Table-7</a>.<
/font></p>     ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#60#56#article#187#<p>&nbsp;</p>     ^
cY#a09v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#61#57#article#187#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>COMMENTS</b></font></p>     ^cY#a
09v37n1.htm##
00668000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043300076002001300509#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#62#58#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The RP learning    curve for reside
nts showed that after twenty surgeries, there was a significant    reduction in 
operative time from 150 to 120 minutes and, after the 29th surgery,    the need 
for blood transfusion also decreased from 9% to 3%. Moreover, the percentage    
of compromised surgical margins remained stable during the learning curve.</font
></p>     ^cY#a09v37n1.htm##
00808000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057300076002001300649#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#63#59#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The discussion    regarding the lear
ning curve in RP has not been frequently addressed in clinical    studies and fe
w series have reported clinical and pathologic data exclusively    of residents 
in training instead of only experienced surgeons (13,14). Published    evidence 
has demonstrated that the number of RP previously performed by the    surgeon af
fects patient outcomes. It is believed that a learning curve of 200    cases wou
ld be necessary to achieve an "expert" status (13,15).</font></p>     ^cY#a09v37
n1.htm##
00697000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046200076002001300538#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#64#60#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A recent prospective    study evalua
ted surgeons after a urologic oncology fellowship program, after    they had alr
eady completed an initial learning curve of an average of 47 cases    during res
idency and another 87 RP performed during the fellowship (15). The    mean opera
tive time was 201 minutes, the estimated blood loss was 734 mL, with    a 6% rat
e of blood transfusion.</font></p>     ^cY#a09v37n1.htm##
00773000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053800076002001300614#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#65#61#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The learning curve    is a major pr
oblem in surgery, during which the surgical procedure is usually    performed wi
th more difficulty and slowness, associated with a higher risk of    complicatio
ns and low efficacy due to inexperience of the surgeon. If an initial    assessm
ent is made, the learning curve is primarily a theoretical concept, because    t
his is a theme or line of research rarely present in residency programs and    u
rologic literature.</font></p>     ^cY#a09v37n1.htm##
01523000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704128800076002001301364#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#66#62#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The surgeons gain    much of the kno
wledge necessary for surgical procedures during medical residency    programs. I
n the learning process, the urology resident trains in the areas    of endourolo
gy, incontinence and reconstruction, erectile dysfunction and infertility,    pe
diatric urology and kidney transplantation, laparoscopy and cryotherapy. Within 
   the urologic oncology division, several surgeries are performed, such as tran
surethral    resection of the prostate and bladder, cystectomy and urinary recon
struction,    retroperitoneal lymphadenectomy and open and laparoscopic nephrect
omy, fostering    a growing field of surgical procedures and greater confidence 
to perform them.    The American Urological Association reported that the number
 of RP performed    by residents has declined in recent years, and overall 84% o
f surgeons have    performed less than ten RP annually (8). Based on these data,
 we can infer that    much of the surgical experience needed to acquire proficie
ncy in complex procedures    can only be acquired during residency. Eventually, 
according to local community    demand or the volume of surgeries performed at t
he hospital, this development    may never occur.</font></p>     ^cY#a09v37n1.ht
m##
00722000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048700076002001300563#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#67#63#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The percentage    of compromised sur
gical margins varies with the surgeon's experience in this    procedure. Accordi
ng to a landmark study by Vickers et al., the rate of positive    margins was 36
% before 50 RP performed, 29% with 50 to 99 RP, 23% with 100 to    249 RP, 22% w
ith 250 to 999 RP, and 11% with 1000 RP or more (16). Overall,    the surgical m
argin status was positive in 22.9% of surgeries.</font></p>     ^cY#a09v37n1.htm
##
01170000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704093500076002001301011#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#68#64#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Regarding minimally    invasive RP t
echniques, usually performed by surgeons in large centers with    extensive surg
ical experience, data on robotic and laparoscopic was as follows,    respectivel
y: blood transfusion 3% and 9.8%, positive surgical margin of 15.8%    and 19.5%
, mean operative time was 166 and 160 minutes, and average hospital    stay of 5
.4 and 4.9 days (17). A study describing the learning curve of robotic    RP sho
wed that the robotic surgeon with up to 12 surgeries had an average operative   
 time of 242 &plusmn; 64 minutes and 58% of cases with positive margins; with   
 13 to 188 robotic RP, the operative time was reduced to 165 &plusmn; 45 minutes
    and positive margins to 23%. Surgeons who performed more than 189 robotic RP
    had an average operative time of 134 &plusmn; 45 minutes and positive margin
s    in 9% (18).</font></p>     ^cY#a09v37n1.htm##
00807000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057200076002001300648#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#69#65#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The following strengths    can be hi
ghlighted in the present study: a homogeneous group of residents in    training 
who had never performed a RP was included; the prospective design of    the stud
y allowed us to perform the same surgical technique and mentored by    the same 
group of physician assistants; and the sample size accrued was reasonable.    Th
erefore, we believe that these results may generate important information    on 
surgical training and education in urologic oncology.</font></p>     ^cY#a09v37n
1.htm##
00761000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052600076002001300602#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#70#66#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The fact that the    surgeon is inex
perienced, starting the learning curve with this procedure, may    be of benefit
 by rapidly improving the performance in the short term, considering    that a h
omogenous and standardized teaching methodology is applied. As our data    sugge
sts, it renders the possibility to generate less intraoperative morbidity    and
 lower rate of positive surgical margins, improving the clinical course of    pa
tients.</font></p>     ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#71#67#article#187#<p>&nbsp;</p>     ^
cY#a09v37n1.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010100076002001300177#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#72#68#article#187#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUSIONS</b></font></p>     ^c
Y#a09v37n1.htm##
00713000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047800076002001300554#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#73#69#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Open radical prostatectomy    is a 
safe and effective procedure that can be done on a large scale in teaching    in
stitutions, as long as a structured training program provides adequate teaching 
   methods. During the initial training experience of a surgeon, a steep reducti
on    in blood transfusions and a quick stabilization of the learning curve afte
r    twenty procedures can be expected.</font></p>     ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#74#70#article#187#<p>&nbsp;</p>     ^
cY#a09v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#75#71#article#187#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONFLICT OF    INTEREST</b></font
></p>     ^cY#a09v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#76#72#article#187#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> None declared.</font></p>     ^cY#a
09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#77#73#article#187#<p>&nbsp;</p>     ^
cY#a09v37n1.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#78#74#article#187#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFERENCES</b></font></p>     ^cY
#a09v37n1.htm##
00436000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020100076002001300277#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#79#75#article#187#<p> <font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">1. Jemal A, Siegel    R, Ward E, Ha
o Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin.    2009;59:225-49
. </font></p>     ^cY#a09v37n1.htm##
00420000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704017100078002001300249#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#80#76#article#187#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Boyle P, Ferlay    
J: Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005; 16: 481-8.  
  ^cY#a09v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#81#77#article#187#</font></p>     ^cY
#a09v37n1.htm##
00492000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024300078002001300321#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#82#78#article#187#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Walsh PC, Lepor    
H, Eggleston JC: Radical prostatectomy with preservation of sexual function:    
anatomical and pathological considerations. Prostate. 1983; 4: 473-85.    ^cY#a0
9v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#83#79#article#187#</font></p>     ^cY
#a09v37n1.htm##
00465000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021600078002001300294#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#84#80#article#187#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Elder JS, Jewett   
 HJ, Walsh PC: Radical perineal prostatectomy for clinical stage B2 carcinoma   
 of the prostate. J Urol. 1982; 127: 704-6.    ^cY#a09v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#85#81#article#187#</font></p>     ^cY
#a09v37n1.htm##
00518000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026900078002001300347#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#86#82#article#187#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Guillonneau    B, C
athelineau X, Barret E, Rozet F, Vallancien G: Laparoscopic radical prostatectom
y:    technical and early oncological assessment of 40 operations. Eur Urol. 199
9;    36: 14-20.    ^cY#a09v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#87#83#article#187#</font></p>     ^cY
#a09v37n1.htm##
00480000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023100078002001300309#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#88#84#article#187#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Abbou CC, Salomon  
  L, Hoznek A, Antiphon P, Cicco A, Saint F, et al.: Laparoscopic radical prosta
tectomy:    preliminary results. Urology. 2000; 55: 630-4.    ^cY#a09v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#89#85#article#187#</font></p>     ^cY
#a09v37n1.htm##
00502000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025300078002001300331#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#90#86#article#187#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Tewari A, Peabody  
  J, Sarle R, Balakrishnan G, Hemal A, Shrivastava A, et al.: Technique of da   
 Vinci robot-assisted anatomic radical prostatectomy. Urology. 2002; 60: 569-72.
    ^cY#a09v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#91#87#article#187#</font></p>     ^cY
#a09v37n1.htm##
00495000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024600078002001300324#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#92#88#article#187#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Brasil. Minist&eacu
te;rio    da Sa&uacute;de: Estimativa 2008: incid&ecirc;ncia do c&acirc;ncer no 
Brasil.    Instituto Nacional do C&acirc;ncer. Bras&iacute;lia, DF; 2007.    ^cY
#a09v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#93#89#article#187#</font></p>     ^cY
#a09v37n1.htm##
00543000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029400078002001300372#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#94#90#article#187#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Shah A, Okotie    O
T, Zhao L, Pins MR, Bhalani V, Dalton DP: Pathologic outcomes during the learnin
g    curve for robotic-assisted laparoscopic radical prostatectomy. Int Braz J U
rol.    2008; 34: 159-62; discussion 163.    ^cY#a09v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#95#91#article#187#</font></p>     ^cY
#a09v37n1.htm##
00512000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026200079002001300341#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#96#92#article#187#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Frota R, Turna   
 B, Barros R, Gill IS: Comparison of radical prostatectomy techniques: open,    
laparoscopic and robotic assisted. Int Braz J Urol. 2008; 34: 259-68; discussion
    268-9.    ^cY#a09v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#97#93#article#187#</font></p>     ^cY
#a09v37n1.htm##
00569000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704031900079002001300398#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#98#94#article#187#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Srougi M, Nesrall
ah    LJ, Kauffmann JR, Nesrallah A, Leite KR: Urinary continence and pathologic
al    outcome after bladder neck preservation during radical retropubic prostate
ctomy:    a randomized prospective trial. J Urol. 2001; 165: 815-8.    ^cY#a09v3
7n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#99#95#article#187#</font></p>     ^cY
#a09v37n1.htm##
00590000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704033900080002001300419#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#100#96#article#187#12#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Srougi M, Paranh
os    M, Leite KM, Dall'Oglio M, Nesrallah L: The influence of bladder neck muco
sal    eversion and early urinary extravasation on patient outcome after radical
 retropubic    prostatectomy: a prospective controlled trial. BJU Int. 2005; 95:
 757-60.    ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002100077002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#101#97#article#187# </font></p>     ^
cY#a09v37n1.htm##
00547000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704029600080002001300376#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#102#98#article#187#13#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Eastham JA,    K
attan MW, Riedel E, Begg CB, Wheeler TM, Gerigk C, et al.: Variations among    i
ndividual surgeons in the rate of positive surgical margins in radical prostatec
tomy    specimens. J Urol. 2003; 170: 2292-5.    ^cY#a09v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#103#99#article#187#</font></p>     ^c
Y#a09v37n1.htm##
00497000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024500081002001300326#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#104#100#article#187#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Andriole GL,   
 Smith DS, Rao G, Goodnough L, Catalona WJ: Early complications of contemporary 
   anatomical radical retropubic prostatectomy. J Urol. 1994; 152: 1858-60.    ^
cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#105#101#article#187#</font></p>     ^
cY#a09v37n1.htm##
00541000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028900081002001300370#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#106#102#article#187#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Rosser CJ,    K
amat AM, Pendleton J, Robinson TL, Pisters LL, Swanson DA, et al.: Impact of    
fellowship training on pathologic outcomes and complication rates of radical    
prostatectomy. Cancer. 2006; 107: 54-9.    ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#107#103#article#187#</font></p>     ^
cY#a09v37n1.htm##
00531000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027900081002001300360#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#108#104#article#187#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Vickers AJ,    
Bianco FJ, Serio AM, Eastham JA, Schrag D, Klein EA, et al.: The surgical learni
ng    curve for prostate cancer control after radical prostatectomy. J Natl Canc
er    Inst. 2007; 99: 1171-7.    ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#109#105#article#187#</font></p>     ^
cY#a09v37n1.htm##
00553000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030100081002001300382#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#110#106#article#187#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Rozet F, Jaffe 
   J, Braud G, Harmon J, Cathelineau X, Barret E, et al.: A direct comparison of
    robotic assisted versus pure laparoscopic radical prostatectomy: a single in
stitution    experience. J Urol. 2007; 178: 478-82.    ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#111#107#article#187#</font></p>     ^
cY#a09v37n1.htm##
00516000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026400081002001300345#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#112#108#article#187#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Jaffe J, Castel
lucci    S, Cathelineau X, Harmon J, Rozet F, Barret E, et al.: Robot-assisted l
aparoscopic    prostatectomy: a single-institutions learning curve. Urology. 200
9; 73: 127-33.    ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#113#109#article#187#</font></p>     ^
cY#a09v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#114#110#article#187#<p>&nbsp;</p>    
 ^cY#a09v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#115#111#article#187#<p>&nbsp;</p>    
 ^cY#a09v37n1.htm##
00367000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704013000078002001300208#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#116#112#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><i>Accepted after    revision: May
 25, 2010</i></font></p>     ^cY#a09v37n1.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019300078002001300271#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#117#113#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><b><a name="end"></a><a href="#top
"><img src="/img/revistas/ibju/v37n1/seta.gif" border="0"></a>    Correspondence
 to</b>:    ^cY#a09v37n1.htm##
00276000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003900078002001300117#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#118#114#article#187#<br>   Dr. Marcos
 F. Dall'Oglio    ^cY#a09v37n1.htm##
00290000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005300078002001300131#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#119#115#article#187#<br>   Rua Barata
 Ribeiro, 398, 5&ordm; Andar    ^cY#a09v37n1.htm##
00291000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005400078002001300132#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#120#116#article#187#<br>   01308-000,
 S&atilde;o Paulo, SP, Brazil    ^cY#a09v37n1.htm##
00274000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003700078002001300115#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#121#117#article#187#<br>   Fax: + 55 
11 3159-3618    ^cY#a09v37n1.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010700078002001300185#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#122#118#article#187#<br>   E-mail: <a
 href="mailto:marcosdallogliouro@terra.com.br">marcosdallogliouro@terra.com.br</
a>    ^cY#a09v37n1.htm##
00264000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002700078002001300105#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#123#119#article#187#<br>   </font></p
>     ^cY#a09v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#124#120#article#187#<p>&nbsp;</p>    
 ^cY#a09v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#125#121#article#187#<p>&nbsp;</p>    
 ^cY#a09v37n1.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010700078002001300185#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#126#122#article#187#<p><font size="3"
 face="Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL COMMENT</b></font></p
>     ^cY#a09v37n1.htm##
00446000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704020900078002001300287#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#127#123#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> Open radical prostatectomy    is 
the gold standard and most widespread treatment for clinically localized    pros
tate cancer.</font></p>     ^cY#a09v37n1.htm##
00697000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704046000078002001300538#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#128#124#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> About thirty years    ago the fir
st purposeful nerve sparing radical prostatectomies were performed    by Dr. Pat
rick Walsh. Since then, a better understanding of the periprostatic    anatomica
l results with continued improvement in functional outcomes and oncological    c
ontrol for patients undergoing radical prostatectomy, whether by open or minimal
ly-invasive    surgery.</font></p>     ^cY#a09v37n1.htm##
00739000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704050200078002001300580#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#129#125#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> The oncologic    results of autho
r's paper in an important center of high volume treatment of    prostate cancer 
are in line with those reported with the use of the retropubic    approach. With
 a "homogenous and standardized teaching methodology", the residents    can achi
eve good data as regards less intraoperative morbidity and lower rate    of posi
tive surgical margins, improving the clinical course of patients.</font></p>    
 ^cY#a09v37n1.htm##
00607000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704037000078002001300448#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#130#126#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> The learning curve    in surgery 
can be defined as the number of cases required to perform the procedure    with 
reasonable operating time and an acceptable rate of complications, resulting    
in an adequate postoperative clinical outcome associated with a shorter hospital
    stay (1).</font></p>     ^cY#a09v37n1.htm##
00924000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704068700078002001300765#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#131#127#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> A paper was published    about th
e learning curve for surgery for prostate cancer recurrence after radical    pro
statectomy. The study cohort included 7765 prostate cancer patients who were    
treated with radical prostatectomy by one of 72 surgeons at four major US academ
ic    medical centers between 1987 and 2003. The learning curve for prostate can
cer    recurrence after radical prostatectomy was steep and did not start to pla
teau    until a surgeon had completed approximately 250 prior operations (2). As
 a surgeon's    experience increases, cancer control after radical prostatectomy
 improves.</font></p>     ^cY#a09v37n1.htm##
00753000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704051600078002001300594#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#132#128#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> These results    may generate imp
ortant information on surgical training, improve the teaching    process of the 
surgical technique and make it widely available to mentors and    teaching cente
rs, especially considering the social environment of growing ethical    concerns
 with patient safety. Further research is needed to examine the specific    tech
niques used by experienced surgeons that are associated with improved outcomes.<
/font></p>     ^cY#a09v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#133#129#article#187#<p>&nbsp;</p>    
 ^cY#a09v37n1.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010000078002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#134#130#article#187#<p><font size="3"
 face="Verdana, Arial, Helvetica, sans-serif"><b>REFERENCES</b></font></p>     ^
cY#a09v37n1.htm##
00531000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027900081002001300360#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#135#131#article#187#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 1. Vickers AJ,    
Bianco FJ, Serio AM, Eastham JA, Schrag D, Klein EA, et al.: The surgical learni
ng    curve for prostate cancer control after radical prostatectomy. J Natl Canc
er    Inst. 2007; 99: 1171-7.    ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#136#132#article#187#</font></p>     ^
cY#a09v37n1.htm##
00565000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031300081002001300394#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#137#133#article#187#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 2. Vickers A,    B
ianco F, Cronin A, Eastham J, Klein E, Kattan M, et al.: The learning curve    f
or surgical margins after open radical prostatectomy: implications for margin   
 status as an oncological end point. J Urol. 2010; 183: 1360-5.    ^cY#a09v37n1.
htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#138#134#article#187#</font></p>     ^
cY#a09v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#139#135#article#187#<p>&nbsp;</p>    
 ^cY#a09v37n1.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012100078002001300199#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#140#136#article#187#<p align="right">
<font size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Dr.    Maurici
o Rubinstein</b>    ^cY#a09v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003600078002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#141#137#article#187#<br>   Department
 of Urology    ^cY#a09v37n1.htm##
00294000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005700078002001300135#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#142#138#article#187#<br>   Federal Un
iversity of Rio de Janeiro State    ^cY#a09v37n1.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004100078002001300119#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#143#139#article#187#<br>   Rio de Jan
eiro, RJ, Brazil    ^cY#a09v37n1.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010300078002001300181#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#144#140#article#187#<br>   E-mail: <a
 href="mailto:mrubins74@hotmail.com">mrubins74@hotmail.com</a></i></font></p>   
  ^cY#a09v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#145#141#article#187#<p>&nbsp;</p>    
 ^cY#a09v37n1.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010700078002001300185#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#146#142#article#187#<p><font size="3"
 face="Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL COMMENT</b></font></p
>     ^cY#a09v37n1.htm##
00516000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704027900078002001300357#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#147#143#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> The learning curve    plateau com
es with training and experience. Surgeons have always recognized    a structured
 way to introduce new procedures: learning a new technique requires    dedicatio
n.</font></p>     ^cY#a09v37n1.htm##
01047000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704081000078002001300888#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#148#144#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> If we try to define    a learning
 curve, we should look back at the work of Dr. Donald Ross - a pioneer    in car
diac surgery in the United Kingdom - who proposed the Ross procedure in    1962 
(1). The Ross procedure, first performed in 1967, is a challenging operation    
for patients with aortic valve disease. The principle is to remove the patient's
    normal pulmonary valve and used it to replace the patient's diseased aortic 
   valve. In Dr. Ross's own series, 23% of the patients died during the first ye
ar    of the operation and 18% in the second year. The following 10 years, surgi
cal    mortality in a series of 188 patients dropped to 9%. This is a learning c
urve.    The message: it requires time and hard work.</font></p>     ^cY#a09v37n
1.htm##
00799000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704056200078002001300640#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#149#145#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> How many cases    do we need to b
ecome expert surgeons in the technique we perform on an everyday    basis? The l
atter remain a controversial question for the field of radical prostatectomy.   
 The arrival of both, laparoscopy and later robotic surgery has put on stage    
the term learning curve. In fact, laparoscopic series brought with them a tremen
dous    enthusiasm in terms of validation of the technique and therefore extensi
ve work    in the procedure's learning curve.</font></p>     ^cY#a09v37n1.htm##
00607000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704037000078002001300448#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#150#146#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> In our experience    at the Insti
tut Montsouris in Paris, it was hard to keep in mind Dr. Walsh's    concepts on 
radical prostatectomy and simultaneously comply with the demanding    endoscopic
 surgical environment, but a step-by-step structured training brought    us thro
ugh the task.</font></p>     ^cY#a09v37n1.htm##
00772000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704053500078002001300613#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#151#147#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> The paper on the    learning curv
e of retropubic radical prostatectomy presented by Dall'Oglio et    al. in this 
issue of IBJU, represents a comprehensive analysis of the initial    experience 
of a group of residents with retropubic prostatectomy, perhaps missing    in the
 literature. The paper offers real information gained by surgical experience    
and presents a sincere vision of a proctored prostatic surgical approach in    t
he everyday world.</font></p>     ^cY#a09v37n1.htm##
01770000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704153300078002001301611#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#152#148#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> Dall'Oglio et    al. found in the
ir interesting analysis, that improvement of clinical outcomes    can be seen af
ter 20 to 30 cases. We could say that these findings are far from    those prese
nted by Vickers et al in their timely publication assessing surgical    learning
 curve for prostate cancer control (2). Vickers et al. found statistical    sign
ificance related to surgeon's experience and cancer control after radical    pro
statectomy in an analysis of highly dedicated surgeons. This study brought    ba
ck to reality the definition of learning curve in radical prostatectomy, reflect
ing    a real link between surgical technique and cancer control, and establishi
ng    the concept of a dramatic improvement in cancer control with increasing su
rgeon    experience up to 250 previous treated cases. That said, we must agree w
ith Dr.    Stuart Howards in the fact that it is somewhat arbitrary to assert th
at it is    necessary to perform 250 procedures to become competent and provide 
good cancer    control (3). Therefore, establishing solid bases for radical pros
tatectomy performed    in a Urology program, is an important challenge to any in
stitution and it requires    hard dedication and a focused operating room team; 
but as presented in the Dall'Oglio    et al. study this is a feasible task and i
t might get the future urologists    ready to finish their training and be able 
to offer a surgical procedure of    the highest quality.</font></p>     ^cY#a09v
37n1.htm##
01157000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704092000078002001300998#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#153#149#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> The future seems    difficult for
 the young urologist, because as presented by Ficarra et al., positive    surgic
al margin rates decreased with the surgeon's experience and technique    improve
ment, reaching similar percentages for retropubic, laparoscopic and robotic    s
eries (4); but perhaps the positive surgical margins are not so secure as oncolo
gical    endpoint (5) and even our current definitions for biochemical recurrenc
es do    not substantially impact prognostic factor estimates. This situation im
plies    that the training period should provide solid concepts to build a profe
ssional    career, and because knowledge and concepts might and will change; an 
academic    way to learn, and eventually teach, is the way that it ought to be i
n order    to assure the adequate surgical treatment of patients, in years to co
me.</font></p>     ^cY#a09v37n1.htm##
00706000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704046900078002001300547#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#154#150#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> With a structured    methodical s
ystem, it is possible to implement radical prostatectomy safely    and effective
ly without compromising morbidity, oncological and functional outcomes.    A tea
m-based approach helps to reduce the learning curve of the procedure for    indi
vidual surgeons. This was our initial approach for laparoscopic and robotic    p
rostatectomy at our institution.</font></p>     ^cY#a09v37n1.htm##
00673000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704043600078002001300514#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#155#151#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> The fruit you    harvest from the
 three in this interesting publication is that we must be sure    to teach the p
hilosophy of how to adequately treat localized prostate cancer    and then, we m
ust get in the operating room with the urologists-in-training    to provide them
 with the basic tools that will hopefully sustain future reliable    operators.<
/font></p>     ^cY#a09v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#156#152#article#187#<p>&nbsp;</p>    
 ^cY#a09v37n1.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010000078002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#157#153#article#187#<p><font size="3"
 face="Verdana, Arial, Helvetica, sans-serif"><b>REFERENCES</b></font></p>     ^
cY#a09v37n1.htm##
00403000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704015100081002001300232#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#158#154#article#187#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 1. Ross DN: Homogr
aft    replacement of the aortic valve. Lancet. 1962; 2: 487.    ^cY#a09v37n1.ht
m##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#159#155#article#187#</font></p>     ^
cY#a09v37n1.htm##
00531000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027900081002001300360#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#160#156#article#187#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 2. Vickers AJ,    
Bianco FJ, Serio AM, Eastham JA, Schrag D, Klein EA, et al.: The surgical learni
ng    curve for prostate cancer control after radical prostatectomy. J Natl Canc
er    Inst. 2007; 99: 1171-7.    ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#161#157#article#187#</font></p>     ^
cY#a09v37n1.htm##
00539000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028700081002001300368#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#162#158#article#187#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 3. Howards S:    E
ditorial comment. (Savage et Vickers. Low annual caseloads of United States    s
urgeons conducting radical prostatectomy. J Urol. 2009; 182: 2677-9). J Urol.   
 2009; 182: 2679-80; discussion 2681.    ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#163#159#article#187#</font></p>     ^
cY#a09v37n1.htm##
00520000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026800081002001300349#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#164#160#article#187#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 4. Ficarra V,    C
avalleri S, Novara G, Aragona M, Artibani W: Evidence from robot-assisted laparo
scopic    radical prostatectomy: a systematic review. Eur Urol. 2007; 51: 45-55;
 discussion    56.    ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#165#161#article#187#</font></p>     ^
cY#a09v37n1.htm##
00565000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031300081002001300394#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#166#162#article#187#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 5. Vickers A,    B
ianco F, Cronin A, Eastham J, Klein E, Kattan M, et al.: The learning curve    f
or surgical margins after open radical prostatectomy: implications for margin   
 status as an oncological end point. J Urol. 2010; 183: 1360-5.    ^cY#a09v37n1.
htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#167#163#article#187#</font></p>     ^
cY#a09v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#168#164#article#187#<p>&nbsp;</p>    
 ^cY#a09v37n1.htm##
00382000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704014500078002001300223#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#169#165#article#187#<p align="right">
<font face="Verdana, Arial, Helvetica, sans-serif" size="2"><i><b>Dr.    Rafael 
Sanchez-Salas and Dr. Francois Rozet</b>    ^cY#a09v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003600078002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#170#166#article#187#<br>   Department
 of Urology    ^cY#a09v37n1.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#171#167#article#187#<br>   Institut M
ontsouris    ^cY#a09v37n1.htm##
00285000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004800078002001300126#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#172#168#article#187#<br>   Universit&
eacute; Paris Descartes    ^cY#a09v37n1.htm##
00265000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002800078002001300106#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#173#169#article#187#<br>   Paris, Fra
nce    ^cY#a09v37n1.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010300078002001300181#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#174#170#article#187#<br>   E-mail: <a
 href="mailto:francois.rozet@imm.fr">francois.rozet@imm.fr</a></i></font></p>   
  ^cY#a09v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#175#171#article#187#<p>&nbsp;</p>    
 ^cY#a09v37n1.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011300078002001300191#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#176#172#article#187#<p><font size="3"
 face="Verdana, Arial, Helvetica, sans-serif"><b>REPLY BY THE    AUTHORS</b></fo
nt></p>     ^cY#a09v37n1.htm##
00917000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704068000078002001300758#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#177#173#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> Both editorial    comments reassu
red the importance of a structured learning methodology in the    surgical field
 and pointed out the feasibility of safely teaching complex procedures,    such 
as radical prostatectomy. In our study, we sought to demonstrate a real    learn
ing curve of inexperienced surgeons, on which we could evaluate both an    incre
asing growth in surgical skills from an early starting point, combined    with t
he radical prostatectomy training itself. This was possible due to a homogeneous
    group of mentors, all of them with more than 200 prostatectomies performed. 
   </font></p>     ^cY#a09v37n1.htm##
00723000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704048600078002001300564#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#178#174#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> As mentioned in    the editorial,
 the landmark paper by Dr. Vickers demonstrated a long learning    curve, on whi
ch improvements were observed to 250 cases performed (1). This    study differed
 significantly from ours, since not only no standardized surgical    methodology
 was applied by all 72 surgeons, but also several very experienced    surgeons a
fter urology training were included in the study.</font></p>     ^cY#a09v37n1.ht
m##
00657000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704042000078002001300498#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#179#175#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> Although our learning    curve de
monstrated an initial experience with radical prostatectomy, the standardized   
 technique had been extensively improved and validated by Prof. Miguel Srougi,  
  throughout his 4,000 cases (2,3). Currently, two participating residents in   
 the study are now mentors of the residents at our institution.</font></p>     ^
cY#a09v37n1.htm##
00750000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704051300078002001300591#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#180#176#article#187#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> A further study    is now being f
inalized and will focus on the initial 100 consecutive cases operated    with th
is same standardized technique, with a larger number of surgeons, due    to the 
expansion of our program. Therefore, we expect to generate a stronger    evidenc
e to support the use of our teaching methodology, which may help to create    a 
gold standard approach for urology training programs throughout the country.</fo
nt></p>     ^cY#a09v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#181#177#article#187#<p>&nbsp;</p>    
 ^cY#a09v37n1.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010000078002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#182#178#article#187#<p><font face="Ve
rdana, Arial, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>     ^
cY#a09v37n1.htm##
00530000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027800081002001300359#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#183#179#article#187#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 1. Vickers AJ,    
Bianco FJ, Serio AM, Eastham JA, Schrag D, Klein EA, et al: The surgical learnin
g    curve for prostate cancer control after radical prostatectomy. J Natl Cance
r    Inst. 2007; 99: 1171-7.    ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#184#180#article#187#</font></p>     ^
cY#a09v37n1.htm##
00571000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031900081002001300400#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#185#181#article#187#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 2. Srougi M, Nesra
llah    LJ, Kauffmann JR, Nesrallah A, Leite KR: Urinary continence and patholog
ical    outcome after bladder neck preservation during radical retropubic prosta
tectomy:    a randomized prospective trial. J Urol. 2001; 165: 815-8.    ^cY#a09
v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#186#182#article#187#</font></p>     ^
cY#a09v37n1.htm##
00593000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034100081002001300422#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#187#183#article#187#28#<p
><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Srougi    M, Par
anhos M, Leite KM, Dall'Oglio M, Nesrallah L: The influence of bladder    neck m
ucosal eversion and early urinary extravasation on patient outcome after    radi
cal retropubic prostatectomy: a prospective controlled trial. BJU Int. 2005;    
95: 757-60.    ^cY#a09v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#188#184#article#187#</font></p>     ^
cY#a09v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#189#185#article#187#<p>&nbsp;</p>    
 ^cY#a09v37n1.htm##
00362000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012500078002001300203#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#190#186#article#187#<p align="right">
<font face="Verdana, Arial, Helvetica, sans-serif" size="2"><i><b>The    Authors
</b></i></font></p>     ^cY#a09v37n1.htm##
00267000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003000078002001300108#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a09v37n1.htm#S#p#191#187#article#187#<p align="right">
</p>     ^cY#a09v37n1.htm##
00603000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100012000770100016000890100
01400105010001300119010001200132010001500144012002800159030001700187065000900204
06400050021303100030021801400070022186500090022800200130023703500100025080100170
0260#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#c#192#1#article#28#
1#^rND^sJemal#^rND^sSiegel^nR#^rND^sWard^nE#^rND^sHao^nY#^rND^sXu^nJ#^rND^sThun^
nMJ#Cancer statistics, 2009^len#CA Cancer J Clin#20090000#2009#59#225-49#2011020
0#a09v37n1.htm#0007-9235#CA Cancer J Clin##
00512000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100016000920120
05100108030001000159065000900169064000500178031000300183014000600186865000900192
002001300201035001000214801001000224#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a0
9v37n1.htm#S#c#193#2#article#28#2#^rND^sBoyle^nP#^rND^sFerlay^nJ#Cancer incidenc
e and mortality in Europe, 2004^len#Ann Oncol#20050000#2005#16#481-8#20110200#a0
9v37n1.htm#0923-7534#Ann Oncol##
00598000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100015000930100
02000108012010700128030000900235065000900244064000500253031000200258014000700260
865000900267002001300276035001000289801000900299#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a09v37n1.htm#S#c#194#3#article#28#3#^rND^sWalsh^nPC#^rND^sLepor^nH#^rN
D^sEggleston^nJC#Radical prostatectomy with preservation of sexual function: ana
tomical and pathological considerations^len#Prostate#19830000#1983#4#473-85#2011
0200#a09v37n1.htm#0270-4137#Prostate##
00569000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100017000930100
01600110012008300126030000700209065000900216064000500225031000400230014000600234
865000900240002001300249035001000262801000700272#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a09v37n1.htm#S#c#195#4#article#28#4#^rND^sElder^nJS#^rND^sJewett^nHJ#^
rND^sWalsh^nPC#Radical perineal prostatectomy for clinical stage B2 carcinoma of
 the prostate^len#J Urol#19820000#1982#127#704-6#20110200#a09v37n1.htm#0022-5347
#J Urol##
00657000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100021000770100021000980100
01600119010001500135010002000150012010000170030000900270065000900279064000500288
031000300293014000600296865000900302002001300311035001000324801000900334#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#c#196#5#article#28#5#^rND^sGuil
lonneau^nB#^rND^sCathelineau^nX#^rND^sBarret^nE#^rND^sRozet^nF#^rND^sVallancien^
nG#Laparoscopic radical prostatectomy: technical and early oncological assessmen
t of 40 operations^len#Eur Urol#19990000#1999#36#14-20#20110200#a09v37n1.htm#030
2-2838#Eur Urol##
00649000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100017000930100
01600110010001800126010001500144010001500159810000600174012006000180030000800240
06500090024806400050025703100030026201400060026586500090027100200130028003500100
0293801000800303#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#c#197#6
#article#28#6#^rND^sAbbou^nCC#^rND^sSalomon^nL#^rND^sHoznek^nA#^rND^sAntiphon^nP
#^rND^sCicco^nA#^rND^sSaint^nF#et al#Laparoscopic radical prostatectomy: prelimi
nary results^len#Urology#20000000#2000#55#630-4#20110200#a09v37n1.htm#0090-4295#
Urology##
00671000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100017000930100
01500110010002200125010001500147010002100162810000600183012007200189030000800261
06500090026906400050027803100030028301400070028686500090029300200130030203500100
0315801000800325#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#c#198#7
#article#28#7#^rND^sTewari^nA#^rND^sPeabody^nJ#^rND^sSarle^nR#^rND^sBalakrishnan
^nG#^rND^sHemal^nA#^rND^sShrivastava^nA#et al#Technique of da Vinci robot-assist
ed anatomic radical prostatectomy^len#Urology#20020000#2002#60#569-72#20110200#a
09v37n1.htm#0090-4295#Urology##
00465000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170028000770180052001050620
02900157066001300186065000900199064000500208865000900213002001300222#v37n1#V:\Sc
iELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#c#199#8#article#28#8#Brasil^dMinist
ério da Saúde#Estimativa 2008: incidência do câncer no Brasil^lpt#Instituto Naci
onal do Câncer#Brasília^eDF#20070000#2007#20110200#a09v37n1.htm##
00655000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100017000910100
01400108010001500122010001700137010001700154012010600171030001600277710000200293
065000900295064000500304031000300309014000700312865000900319002001300328#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#c#200#9#article#28#9#^rND^sShah
^nA#^rND^sOkotie^nOT#^rND^sZhao^nL#^rND^sPins^nMR#^rND^sBhalani^nV#^rND^sDalton^
nDP#Pathologic outcomes during the learning curve for robotic-assisted laparosco
pic radical prostatectomy^len#Int Braz J Urol#2#20080000#2008#34#159-62#20110200
#a09v37n1.htm##
00586000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100015000940100
01600109010001500125012009200140030001600232710000200248065000900250064000500259
031000300264014000700267865000900274002001300283#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a09v37n1.htm#S#c#201#10#article#28#10#^rND^sFrota^nR#^rND^sTurna^nB#^r
ND^sBarros^nR#^rND^sGill^nIS#Comparison of radical prostatectomy techniques: ope
n, laparoscopic and robotic assisted^len#Int Braz J Urol#2#20080000#2008#34#259-
68#20110200#a09v37n1.htm##
00706000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100020000950100
02000115010001900135010001600154012015200170030000700322065000900329064000500338
031000400343014000600347865000900353002001300362035001000375801000700385#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#c#202#11#article#28#11#^rND^sSr
ougi^nM#^rND^sNesrallah^nLJ#^rND^sKauffmann^nJR#^rND^sNesrallah^nA#^rND^sLeite^n
KR#Urinary continence and pathological outcome after bladder neck preservation d
uring radical retropubic prostatectomy: a randomized prospective trial^len#J Uro
l#20010000#2001#165#815-8#20110200#a09v37n1.htm#0022-5347#J Urol##
00699000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01600113010002000129010001900149012017300168030000800341710000200349065000900351
064000500360031000300365014000700368865000900375002001300384#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a09v37n1.htm#S#c#203#12#article#28#12#^rND^sSrougi^nM#^rND
^sParanhos^nM#^rND^sLeite^nKM#^rND^sDall'Oglio^nM#^rND^sNesrallah^nL#The influen
ce of bladder neck mucosal eversion and early urinary extravasation on patient o
utcome after radical retropubic prostatectomy: a prospective controlled trial^le
n#BJU Int#2#20050000#2005#95#757-60#20110200#a09v37n1.htm##
00711000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
01600114010001500130010001800145010001600163810000600179012011700185030000700302
06500090030906400050031803100040032301400070032786500090033400200130034303500100
0356801000700366#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#c#204#1
3#article#28#13#^rND^sEastham^nJA#^rND^sKattan^nMW#^rND^sRiedel^nE#^rND^sBegg^nC
B#^rND^sWheeler^nTM#^rND^sGerigk^nC#et al#Variations among individual surgeons i
n the rate of positive surgical margins in radical prostatectomy specimens^len#J
 Urol#20030000#2003#170#2292-5#20110200#a09v37n1.htm#0022-5347#J Urol##
00635000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01300114010001900127010001900146012008400165030000700249065000900256064000500265
031000400270014000800274865000900282002001300291035001000304801000700314#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#c#205#14#article#28#14#^rND^sAn
driole^nGL#^rND^sSmith^nDS#^rND^sRao^nG#^rND^sGoodnough^nL#^rND^sCatalona^nWJ#Ea
rly complications of contemporary anatomical radical retropubic prostatectomy^le
n#J Urol#19940000#1994#152#1858-60#20110200#a09v37n1.htm#0022-5347#J Urol##
00704000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01900112010001900131010001800150010001800168810000600186012010500192030000700297
06500090030406400050031303100040031801400050032286500090032700200130033603500100
0349801000700359#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#c#206#1
5#article#28#15#^rND^sRosser^nCJ#^rND^sKamat^nAM#^rND^sPendleton^nJ#^rND^sRobins
on^nTL#^rND^sPisters^nLL#^rND^sSwanson^nDA#et al#Impact of fellowship training o
n pathologic outcomes and complication rates of radical prostatectomy^len#Cancer
#20060000#2006#107#54-9#20110200#a09v37n1.htm#0008-543X#Cancer##
00706000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
01600114010001800130010001600148010001600164810000600180012008800186030001900274
06500090029306400050030203100030030701400070031086500090031700200130032603500100
0339801001900349#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#c#207#1
6#article#28#16#^rND^sVickers^nAJ#^rND^sBianco^nFJ#^rND^sSerio^nAM#^rND^sEastham
^nJA#^rND^sSchrag^nD#^rND^sKlein^nEA#et al#The surgical learning curve for prost
ate cancer control after radical prostatectomy^len#J Natl Cancer Inst#20070000#2
007#99#1171-7#20110200#a09v37n1.htm#0027-8874#J Natl Cancer Inst##
00716000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100015000940100
01500109010001600124010002100140010001600161810000600177012012400183030000700307
06500090031406400050032303100040032801400070033286500090033900200130034803500100
0361801000700371#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#c#208#1
7#article#28#17#^rND^sRozet^nF#^rND^sJaffe^nJ#^rND^sBraud^nG#^rND^sHarmon^nJ#^rN
D^sCathelineau^nX#^rND^sBarret^nE#et al#A direct comparison of robotic assisted 
versus pure laparoscopic radical prostatectomy: a single institution experience^
len#J Urol#20070000#2007#178#478-82#20110200#a09v37n1.htm#0022-5347#J Urol##
00683000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100021000940100
02100115010001600136010001500152010001600167810000600183012008400189030000800273
06500090028106400050029003100030029501400070029886500090030500200130031403500100
0327801000800337#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#c#209#1
8#article#28#18#^rND^sJaffe^nJ#^rND^sCastellucci^nS#^rND^sCathelineau^nX#^rND^sH
armon^nJ#^rND^sRozet^nF#^rND^sBarret^nE#et al#Robot-assisted laparoscopic prosta
tectomy: a single-institutions learning curve^len#Urology#20090000#2009#73#127-3
3#20110200#a09v37n1.htm#0090-4295#Urology##
00705000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100018000780100017000960100
01600113010001800129010001600147010001600163810000600179012008800185030001900273
06500090029206400050030103100030030601400070030986500090031600200130032503500100
0338801001900348#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#c#210#1
9#article#28#1#^rND^sVickers^nAJ#^rND^sBianco^nFJ#^rND^sSerio^nAM#^rND^sEastham^
nJA#^rND^sSchrag^nD#^rND^sKlein^nEA#et al#The surgical learning curve for prosta
te cancer control after radical prostatectomy^len#J Natl Cancer Inst#20070000#20
07#99#1171-7#20110200#a09v37n1.htm#0027-8874#J Natl Cancer Inst##
00727000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100017000780100016000950100
01600111010001700127010001500144010001600159810000600175012013700181030000700318
06500090032506400050033403100040033901400070034386500090035000200130035903500100
0372801000700382#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#c#211#2
0#article#28#2#^rND^sVickers^nA#^rND^sBianco^nF#^rND^sCronin^nA#^rND^sEastham^nJ
#^rND^sKlein^nE#^rND^sKattan^nM#et al#The learning curve for surgical margins af
ter open radical prostatectomy: implications for margin status as an oncological
 end point^len#J Urol#20100000#2010#183#1360-5#20110200#a09v37n1.htm#0022-5347#J
 Urol##
00471000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100015000780120046000930300
00700139065000900146064000500155031000200160014000400162865000900166002001300175
035001000188801000700198#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S
#c#212#21#article#28#1#^rND^sRoss^nDN#Homograft replacement of the aortic valve^
len#Lancet#19620000#1962#2#487#20110200#a09v37n1.htm#0099-5355#Lancet##
00705000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100018000780100017000960100
01600113010001800129010001600147010001600163810000600179012008800185030001900273
06500090029206400050030103100030030601400070030986500090031600200130032503500100
0338801001900348#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#c#213#2
2#article#28#2#^rND^sVickers^nAJ#^rND^sBianco^nFJ#^rND^sSerio^nAM#^rND^sEastham^
nJA#^rND^sSchrag^nD#^rND^sKlein^nEA#et al#The surgical learning curve for prosta
te cancer control after radical prostatectomy^len#J Natl Cancer Inst#20070000#20
07#99#1171-7#20110200#a09v37n1.htm#0027-8874#J Natl Cancer Inst##
00455000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100017000780120022000950300
00700117065000900124064000500133031000400138014000800142865000900150002001300159
035001000172801000700182#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S
#c#214#23#article#28#3#^rND^sHowards^nS#Editorial comment^len#J Urol#20090000#20
09#182#2679-80#20110200#a09v37n1.htm#0022-5347#J Urol##
00641000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100017000780100019000950100
01600114010001700130010001800147012008900165030000900254065000900263064000500272
031000300277014000600280865000900286002001300295035001000308801000900318#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#c#215#24#article#28#4#^rND^sFic
arra^nV#^rND^sCavalleri^nS#^rND^sNovara^nG#^rND^sAragona^nM#^rND^sArtibani^nW#Ev
idence from robot-assisted laparoscopic radical prostatectomy: a systematic revi
ew^len#Eur Urol#20070000#2007#51#45-55#20110200#a09v37n1.htm#0302-2838#Eur Urol#
#
00727000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100017000780100016000950100
01600111010001700127010001500144010001600159810000600175012013700181030000700318
06500090032506400050033403100040033901400070034386500090035000200130035903500100
0372801000700382#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#c#216#2
5#article#28#5#^rND^sVickers^nA#^rND^sBianco^nF#^rND^sCronin^nA#^rND^sEastham^nJ
#^rND^sKlein^nE#^rND^sKattan^nM#et al#The learning curve for surgical margins af
ter open radical prostatectomy: implications for margin status as an oncological
 end point^len#J Urol#20100000#2010#183#1360-5#20110200#a09v37n1.htm#0022-5347#J
 Urol##
00705000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100018000780100017000960100
01600113010001800129010001600147010001600163810000600179012008800185030001900273
06500090029206400050030103100030030601400070030986500090031600200130032503500100
0338801001900348#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#c#217#2
6#article#28#1#^rND^sVickers^nAJ#^rND^sBianco^nFJ#^rND^sSerio^nAM#^rND^sEastham^
nJA#^rND^sSchrag^nD#^rND^sKlein^nEA#et al#The surgical learning curve for prosta
te cancer control after radical prostatectomy^len#J Natl Cancer Inst#20070000#20
07#99#1171-7#20110200#a09v37n1.htm#0027-8874#J Natl Cancer Inst##
00705000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100016000780100020000940100
02000114010001900134010001600153012015200169030000700321065000900328064000500337
031000400342014000600346865000900352002001300361035001000374801000700384#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a09v37n1.htm#S#c#218#27#article#28#2#^rND^sSro
ugi^nM#^rND^sNesrallah^nLJ#^rND^sKauffmann^nJR#^rND^sNesrallah^nA#^rND^sLeite^nK
R#Urinary continence and pathological outcome after bladder neck preservation du
ring radical retropubic prostatectomy: a randomized prospective trial^len#J Urol
#20010000#2001#165#815-8#20110200#a09v37n1.htm#0022-5347#J Urol##
00698000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100016000780100018000940100
01600112010002000128010001900148012017300167030000800340710000200348065000900350
064000500359031000300364014000700367865000900374002001300383#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a09v37n1.htm#S#c#219#28#article#28#3#^rND^sSrougi^nM#^rND^
sParanhos^nM#^rND^sLeite^nKM#^rND^sDall'Oglio^nM#^rND^sNesrallah^nL#The influenc
e of bladder neck mucosal eversion and early urinary extravasation on patient ou
tcome after radical retropubic prostatectomy: a prospective controlled trial^len
#BJU Int#2#20050000#2005#95#757-60#20110200#a09v37n1.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#o#1#1#article#1
#20110330#144517#a10v37n1.htm#185##
02647000000000481000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030001800109
03100030012703200020013006500090013201400090014103500100015001201280016001000240
02880100024003120100024003360100028003600700085003880831579004730850010020520850
02102062085001902083085001902102085002202121117000602143072000302149002001302152
#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#h#2#1#article#1#oa#en#b
r1.1#1#4.0#ILUS#10#IBJU010#nd#Int. braz j urol.#37#1#20110200#^f79^l86#1677-5538
#Reducing infectious complications after transrectal prostate needle biopsy usin
g a disposable needle guide: is it possible?^len#^rND^1A01^nCenk^sGurbuz#^rND^1A
01^nLutfi^sCanat#^rND^1A01^nGokhan^sAtis#^rND^1A01^nTurhan^sCaskurlu#Istanbul Go
ztepe Training Hospital^iA01^1Department of 2nd Urology^cIstanbul^pTurkey#^len^a
PURPOSE: To investigate whether the use of a disposable needle guide results in 
a decreased incidence of infectious complication after transrectal prostate need
le biopsy (TPNB). MATERIALS AND METHODS: Fifty five patients who underwent 10-co
re TPNB were randomized into two groups. A pre-biopsy blood and urine examinatio
n was performed in both groups. Group 1 (25 patients) underwent biopsy with disp
osable biopsy needle guide and Group 2 (30 patients) underwent biopsy with reusa
ble biopsy needle guide. All patients had a blood and negative urine culture bef
ore the procedure. The patients received ciprofloxacin 500 mg twice a day beginn
ing the day before the biopsy and continued for 3 days after. Serum C-reactive p
rotein levels and urine and blood specimens were obtained 48h after the biopsy. 
Primary endpoint of the study was to determine the effect of needle guide on the
 bacteriologic urinary tract infection (UTI) rate and secondary end point was to
 determine symptomatic UTI. RESULTS: The mean age of the patients was 63.46 (ran
ge 55 to 68) years. There were no significant differences regarding the prostate
-specific antigen level, prostate size, existence of comorbidity in two groups b
efore the procedure. Bacteriologic and symptomatic UTI was detected in 4% vs. 6.
6% and 4% vs. 3.9% in Group 1 and 2 relatively (P > 0.05). CONCLUSION: The use o
f a disposable needle guide does not appear to minimize infection risk after TPN
B. Large scale and randomized studies are necessary to determine the effect of d
isposable needle guide on infection rate after TPNB.#^ddecs^i1#^tm^len^kprostate
^i1#^tm^len^kbiopsy^i1#^tm^len^kneedle^i1#^tm^len^kinfection^i1#other#25#a10v37n
1.htm##
02692000000000481000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030001800109
03100030012703200020013006500090013201400090014103500100015001201420016001000240
03020100024003260100024003500100028003740700085004020831610004870850010020970850
02102107085001902128085001902147085002202166117000602188072000302194002001302197
#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#f#3#1#article#1#oa#en#b
r1.1#1#4.0#ILUS#10#IBJU010#nd#Int. braz j urol.#37#1#20110200#^f79^l86#1677-5538
#<b>Reducing infectious complications after transrectal prostate needle biopsy u
sing a disposable needle guide</b>: <b>is it possible?</b>^len#^rND^1A01^nCenk^s
Gurbuz#^rND^1A01^nLutfi^sCanat#^rND^1A01^nGokhan^sAtis#^rND^1A01^nTurhan^sCaskur
lu#Istanbul Goztepe Training Hospital^iA01^1Department of 2nd Urology^cIstanbul^
pTurkey#^len^a<b>PURPOSE:</b> To investigate whether the use of a disposable nee
dle guide results in a decreased incidence of infectious complication after tran
srectal prostate needle biopsy (TPNB). <b>MATERIALS AND METHODS:</b> Fifty five 
patients who underwent 10-core TPNB were randomized into two groups. A pre-biops
y blood and urine examination was performed in both groups. Group 1 (25 patients
) underwent biopsy with disposable biopsy needle guide and Group 2 (30 patients)
 underwent biopsy with reusable biopsy needle guide. All patients had a blood an
d negative urine culture before the procedure. The patients received ciprofloxac
in 500 mg twice a day beginning the day before the biopsy and continued for 3 da
ys after. Serum C-reactive protein levels and urine and blood specimens were obt
ained 48h after the biopsy. Primary endpoint of the study was to determine the e
ffect of needle guide on the bacteriologic urinary tract infection (UTI) rate an
d secondary end point was to determine symptomatic UTI. <b>RESULTS:</b> The mean
 age of the patients was 63.46 (range 55 to 68) years. There were no significant
 differences regarding the prostate-specific antigen level, prostate size, exist
ence of comorbidity in two groups before the procedure. Bacteriologic and sympto
matic UTI was detected in 4% vs. 6.6% and 4% vs. 3.9% in Group 1 and 2 relativel
y (P &gt; 0.05). <b>CONCLUSION:</b> The use of a disposable needle guide does no
t appear to minimize infection risk after TPNB. Large scale and randomized studi
es are necessary to determine the effect of disposable needle guide on infection
 rate after TPNB.#^ddecs^i1#^tm^len^kprostate^i1#^tm^len^kbiopsy^i1#^tm^len^knee
dle^i1#^tm^len^kinfection^i1#other#25#a10v37n1.htm##
02807000000000505000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108121000300113049000800116158000300124
03000170012703100030014403200020014706500090014901400090015803500100016701201280
01770100024003050100024003290100024003530100028003770700087004050831607004920850
01002099085002102109085001902130085001902149085002202168117000602190072000302196
002001302199008008902212#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S
#l#4#1#article#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#ilus#10#IBJU010#nd#Int. bra
z j urol#37#1#20110200#^f79^l86#1677-5538#Reducing infectious complications afte
r transrectal prostate needle biopsy using a disposable needle guide: is it poss
ible?^len#^rND^1A01^nCenk^sGurbuz#^rND^1A01^nLutfi^sCanat#^rND^1A01^nGokhan^sAti
s#^rND^1A01^nTurhan^sCaskurlu#^iA01^1Istanbul Goztepe Training Hospital^2Departm
ent of 2nd Urology^cIstanbul^pTurkey#^len^aPURPOSE: To investigate whether the u
se of a disposable needle guide results in a decreased incidence of infectious c
omplication after transrectal prostate needle biopsy (TPNB). MATERIALS AND METHO
DS: Fifty five patients who underwent 10-core TPNB were randomized into two grou
ps. A pre-biopsy blood and urine examination was performed in both groups. Group
 1 (25 patients) underwent biopsy with disposable biopsy needle guide and Group 
2 (30 patients) underwent biopsy with reusable biopsy needle guide. All patients
 had a blood and negative urine culture before the procedure. The patients recei
ved ciprofloxacin 500 mg twice a day beginning the day before the biopsy and con
tinued for 3 days after. Serum C-reactive protein levels and urine and blood spe
cimens were obtained 48h after the biopsy. Primary endpoint of the study was to 
determine the effect of needle guide on the bacteriologic urinary tract infectio
n (UTI) rate and secondary end point was to determine symptomatic UTI. RESULTS: 
The mean age of the patients was 63.46 (range 55 to 68) years. There were no sig
nificant differences regarding the prostate-specific antigen level, prostate siz
e, existence of comorbidity in two groups before the procedure. Bacteriologic an
d symptomatic UTI was detected in 4 percent vs. 6.6 percent and 4 percent vs. 3.
9 percent in Group 1 and 2 relatively (P > 0.05). CONCLUSION: The use of a dispo
sable needle guide does not appear to minimize infection risk after TPNB. Large 
scale and randomized studies are necessary to determine the effect of disposable
 needle guide on infection rate after TPNB.#^ddecs^i1#^tm^len^kprostate^i1#^tm^l
en^kbiopsy^i1#^tm^len^kneedle^i1#^tm^len^kinfection^i1#other#25#a10v37n1.htm#Int
ernet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-553820110001
00010##
00356000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012300074002001300197#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#5#1#article#156#<p align="right"><fon
t face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>CLINICAL    UROLOGY</
b></font></p>     ^cY#a10v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#6#2#article#156#<p>&nbsp;</p>     ^cY
#a10v37n1.htm##
00470000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704023700074002001300311#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#7#3#article#156#<p><a name="top"></a>
<font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Reducing    infec
tious complications after transrectal prostate needle biopsy using a disposable 
   needle guide: is it possible?</b></font></p>     ^cY#a10v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#8#4#article#156#<p>&nbsp;</p>     ^cY
#a10v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#9#5#article#156#<p>&nbsp;</p>     ^cY
#a10v37n1.htm##
00381000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704014700075002001300222#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#10#6#article#156#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Cenk Gurbuz;    Lutfi Canat; Gokha
n Atis; Turhan Caskurlu</b></font></p>     ^cY#a10v37n1.htm##
00399000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704016500075002001300240#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#11#7#article#156#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Istanbul Goztepe    Training Hospital
, Department of 2nd Urology, Istanbul, Turkey</font></p>     ^cY#a10v37n1.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011600075002001300191#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#12#8#article#156#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#end">Correspondence</a></fo
nt></p>     ^cY#a10v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#13#9#article#156#<p>&nbsp;</p>     ^c
Y#a10v37n1.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#14#10#article#156#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a10v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#15#11#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#a
10v37n1.htm##
00499000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026400076002001300340#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#16#12#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>PURPOSE:</b>    To investigate wh
ether the use of a disposable needle guide results in a decreased    incidence o
f infectious complication after transrectal prostate needle biopsy    (TPNB).   
 ^cY#a10v37n1.htm##
01096000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704086100076002001300937#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#17#13#article#156#<br>   <b>MATERIALS
 AND METHODS:</b> Fifty five patients who underwent 10-core TPNB    were randomi
zed into two groups. A pre-biopsy blood and urine examination was    performed i
n both groups. Group 1 (25 patients) underwent biopsy with disposable    biopsy 
needle guide and Group 2 (30 patients) underwent biopsy with reusable    biopsy 
needle guide. All patients had a blood and negative urine culture before    the 
procedure. The patients received ciprofloxacin 500 mg twice a day beginning    t
he day before the biopsy and continued for 3 days after. Serum C-reactive protei
n    levels and urine and blood specimens were obtained 48h after the biopsy. Pr
imary    endpoint of the study was to determine the effect of needle guide on th
e bacteriologic    urinary tract infection (UTI) rate and secondary end point wa
s to determine    symptomatic UTI.    ^cY#a10v37n1.htm##
00622000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038700076002001300463#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#18#14#article#156#<br>   <b>RESULTS:<
/b> The mean age of the patients was 63.46 (range 55 to 68) years.    There were
 no significant differences regarding the prostate-specific antigen    level, pr
ostate size, existence of comorbidity in two groups before the procedure.    Bac
teriologic and symptomatic UTI was detected in 4% vs. 6.6% and 4% vs. 3.9%    in
 Group 1 and 2 relatively (P &gt; 0.05).    ^cY#a10v37n1.htm##
00554000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031900076002001300395#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#19#15#article#156#<br>   <b>CONCLUSIO
N:</b> The use of a disposable needle guide does not appear to minimize    infec
tion risk after TPNB. Large scale and randomized studies are necessary    to det
ermine the effect of disposable needle guide on infection rate after TPNB.</font
><font face="Verdana, Arial, Helvetica, sans-serif">    ^cY#a10v37n1.htm##
00262000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002700076002001300103#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#20#16#article#156#<br>   </font></p> 
    ^cY#a10v37n1.htm##
00396000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016100076002001300237#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#21#17#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Key words: </b>prostate;    biops
y; needle; infection</font></p> <HR size="1" noshade>     ^cY#a10v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#22#18#article#156#<p>&nbsp;</p>     ^
cY#a10v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#23#19#article#156#<p>&nbsp;</p>     ^
cY#a10v37n1.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#24#20#article#156#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODUCTION</b></font></p>     ^
cY#a10v37n1.htm##
01236000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704100100076002001301077#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#25#21#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Transrectal ultrasound    (TRUS) gui
ded needle biopsy of the prostate is the most common modality used    to diagnos
e prostate cancer. Since male individuals in a screening population    are asymp
tomatic, biopsy procedure should be safe and morbidity should be kept    to a mi
nimum. Transrectal prostate needle biopsy (TPNB) is safe for diagnosing    prost
ate cancer with few major, but frequent minor complications, such as hematuria  
  and hematospermia (1,2). Infectious complications after TPNB are an important 
   issue of concern. Currently, many urologists use prophylactic antibiotic ther
apy    and/or enemas to minimize infection-related complications; however, such 
therapy    does not completely eliminate the risk of infection (3). The infectio
us complications    associated with this procedure include: asymptomatic bacteri
uria, fever, symptomatic    urinary tract infections (UTIs), and bacteremia (4,5
).</font></p>     ^cY#a10v37n1.htm##
01039000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080400076002001300880#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#26#22#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Although many biopsy    protocols ha
ve been described to reduce infectious complications after a TPNB,    such as mo
dified bowel preparation, different type and duration of antibiotic    prophylac
tic schemes, and number of biopsy cores (6,7). The role of a disposable    needl
e guide to reduce the infection rate has not been adequately assessed.    The no
tion that biopsy equipment, such as reusable guides, may be important    as a co
ntamination site for bacteremia, was first evaluated by Tuncel et al.    (8). A 
disposable TRUS-probe needle guide (Matek; Geotek, Inc., Ankara, Turkey)    has 
been developed to reduce the possible source of infectious complications    and 
has been on the market in Turkey for 3 years.</font></p>     ^cY#a10v37n1.htm##
00456000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022100076002001300297#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#27#23#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">We prospectively    investigated whe
ther the novel disposable TRUS-probe needle guide may decrease    infectious com
plications after TPNB.</font></p>     ^cY#a10v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#28#24#article#156#<p>&nbsp;</p>     ^
cY#a10v37n1.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011400076002001300190#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#29#25#article#156#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"> <b>MATERIAL AND    METHODS</b></fon
t></p>     ^cY#a10v37n1.htm##
01030000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704079500076002001300871#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#30#26#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Between January    and June 2009, 5
5 patients were included in this study. All participants gave    written informe
d consent. The local ethics committee approved the study. The    mean age of the
 patients was 63.46 years (range 58-66 years) in the present    study. The patie
nts in whom TRUS-prostate biopsy was planned because of elevated    prostate-spe
cific antigen (PSA) levels were included in the study. Exclusion    criteria inc
luded the following: patients who had an indwelling Foley catheter,    symptomat
ic or asymptomatic UTIs, bleeding disorders, acute prostatitis before    prostat
e biopsy, a previous prostatic biopsy or prostatic surgery, or any antibiotic   
 treatment or anticoagulant therapy.</font></p>     ^cY#a10v37n1.htm##
00656000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042100076002001300497#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#31#27#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A midstream urine    culture, serum 
C-reactive protein (CRP) level, and WBC count of all patients    were obtained t
wo days before the procedure. The biopsy procedure was performed    with the pat
ients in the left lateral decubitus position using a Toshiba Fabio    scanner wi
th a 7.5 MHz bi-planar probe attached (Toshiba, Tokyo, Japan).</font></p>     ^c
Y#a10v37n1.htm##
00912000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067700076002001300753#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#32#28#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Patients were randomized    into 2 g
roups by using sealed, opaque envelopes; in Group 1 (25 patients) the    biopsy 
was performed with disposable TRUS-probe needle guide; and in Group 2    (30 pat
ients) the biopsies were performed with a reusable needle guide. A completely   
 disposable apparatus of single unit construction designed for operative use    
in conjunction with a transrectal ultrasound probe when performing TPNB are    p
resented in <a href="#fig1">Figure-1</a>. The separable and detachable features 
   of the reusable needle guide are presented in <a href="#fig2">Figure-2</a>.</
font></p>     ^cY#a10v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#33#29#article#156#<p>&nbsp;</p>     ^
cY#a10v37n1.htm##
00280000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004500076002001300121#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#34#30#article#156#<p><a name="fig1" i
d="fig1"></a></p>     ^cY#a10v37n1.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#35#31#article#156#<p align="center"><
img src="/img/revistas/ibju/v37n1/a10fig1.jpg"></p>     ^cY#a10v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#36#32#article#156#<p>&nbsp;</p>     ^
cY#a10v37n1.htm##
00280000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004500076002001300121#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#37#33#article#156#<p><a name="fig2" i
d="fig2"></a></p>     ^cY#a10v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#38#34#article#156#<p>&nbsp;</p>     ^
cY#a10v37n1.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#39#35#article#156#<p align="center"><
img src="/img/revistas/ibju/v37n1/a10fig2.jpg"></p>     ^cY#a10v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#40#36#article#156#<p>&nbsp;</p>     ^
cY#a10v37n1.htm##
00602000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036700076002001300443#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#41#37#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Peri-operative    prophylaxis includ
ed administration of 500 mg of ciprofloxacin orally the night    before the proc
edure, and an enema per rectum 1 hour before the procedure. Patients    were ins
tructed to continue to take ciprofloxacin 500 mg p.o. bid 3 days after    the pr
ocedure.</font></p>     ^cY#a10v37n1.htm##
01458000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704122300076002001301299#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#42#38#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Before the biopsy,    a standard con
dom was fitted over the distal tip of the TRUS-probe and filled    with lubrican
t gel. Depending upon randomization, either a reusable or a disposable    needle
 guide was then fitted over the probe and the first condom. A second condom    w
as fitted over these items and filled with lubricant gel. All patients received 
   local anesthesia, consisting of 10 mL 1% lidocaine. Injection was performed  
  around the neurovascular bundle at the prostatic base and apical location with
    an 18 gauge 20 cm needle by inserting the needle through the needle guide un
der    TRUS guidance and entering Denonvilliers' fascia. Infiltration was done o
n each    side of the prostate for a total of 2 punctures. The 10 core prostate 
biopsies    were taken with a spring-loaded biopsy gun (C.R. Bard, Inc., Covingt
on, GA,    USA) and an 18 gauge Tru-cut biopsy needle. The core sampling notch w
as approximately    17 mm long by 1.2 mm in diameter. Repeated biopsy specimen c
ollections were    performed using the same needle. The procedure including ultr
asound examination    and biopsy required 10 minutes on average.</font></p>     
^cY#a10v37n1.htm##
00692000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045700076002001300533#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#43#39#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Upon completion    of the procedure
, the ultrasound probe was disinfected by wiping it with a 3.2%    glutaraldehyd
e solution. The reusable needle guide has two separate pieces which    form a lu
men after being attached together. The reusable needle guide was soaked    in a 
glutaraldehyde solution for at least 30 minutes, then rinsed with sterile    sal
ine and wiped off.</font></p>     ^cY#a10v37n1.htm##
00726000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049100076002001300567#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#44#40#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">UTI was defined    as bacteriologic 
UTI (bUTI): A patient with a blood or urine culture positive    for a known urop
athogen and symptomatic UTI (sUTI): A patient with an acute    onset of one or m
ore symptoms of dysuria, hematuria, frequency, urgency, urinary    retention, su
prapubic pain, flank pain, or rigors that have positive urine culture    (a grow
th of = 10<sup>5</sup> colony forming units per mL).</font></p>     ^cY#a10v37n1
.htm##
00724000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048900076002001300565#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#45#41#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A midstream urine    culture and blo
od cultures were obtained from each patient on day 2 after the    biopsy and rep
eated on day 14 after the biopsy. Patients recorded oral body    temperature twi
ce daily for 2 weeks. Patients were asked to return for a follow-up    visit 14 
days after the biopsy. They were also advised to return immediately    if they h
ad any complication, such as a high fever, chills.</font></p>     ^cY#a10v37n1.h
tm##
00533000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029800076002001300374#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#46#42#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Primary end-point    of the study wa
s to determine the effect of needle guide on the bUTI rate. Secondary    end poi
nt was sUTI. Clinical symptoms and signs of infection were monitored    weekly b
y office interview.</font></p>     ^cY#a10v37n1.htm##
00932000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069700076002001300773#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#47#43#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Complications necessitating    hospi
talization during the 2 week post-biopsy period were defined as serious.    Stat
istical analysis was performed using the Statistical Package for Social    Scien
ces (SPSS) for Windows Version 13.0 software (SPSS, Inc, Chicago, IL, USA).    M
ean ages, serum total PSA levels, total prostate volume, comorbidities, CRP    a
nd WBC in the groups were compared using univariate analysis of variance test.  
  Chi-squared test was used to compare infectious complication rates between the
    groups. A p value less than 0.05 was considered significant with a 95% confi
dence    interval.</font></p>     ^cY#a10v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#48#44#article#156#<p>&nbsp;</p>     ^
cY#a10v37n1.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#49#45#article#156#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESULTS</b></font></p>     ^cY#a1
0v37n1.htm##
01682000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704144700076002001301523#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#50#46#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> There were no    significant differ
ences between the two groups before the TPNB with respect    to PSA levels, co-m
orbidities, CRP levels, and WBC counts. The data for each    group is summarized
 in Table-1. The infectious complications are presented in    Table-2. Bacteriol
ogic UTI was observed in 3 patients (1 in Group 1 and 2 in    Group 2). A total 
of 2 patients had Escherichia Coli (E. Coli) in blood culture    (1 in each Grou
p) and CRP levels were four times higher than before the TPNB    in both groups.
 Two patients (1 in each Group) with high fever were admitted    to the hospital
 and received intravenous antibiotic therapy. After receiving    intravenous ant
ibiotic therapy, the high fever and elevated CRP levels were    controlled withi
n 48 hours. E. Coli was harvested in urine culture in 1 patient    in Group 2. T
his patient required hospitalization due to extended-spectrum beta-lactamase    
(ESBL) producing E. Coli harvested in urine culture in Group 2. No elevated    C
RP level or any signs of infection were recorded in this patient. Symptomatic   
 UTI was diagnosed in 2 patients (1 patient in each group) caused by E. coli    
and received oral antibiotic therapy. All isolates were cipro?oxacin resistant. 
   Bacteriologic and symptomatic UTI was detected in 4% vs. 6.6% and 4% vs. 3.9%
    in Group 1 and 2 respectively (p &gt; 0.05).</font></p>     ^cY#a10v37n1.htm
##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#51#47#article#156#<p>&nbsp;</p>     ^
cY#a10v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#52#48#article#156#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>COMMENTS</b></font></p>     ^cY#a
10v37n1.htm##
00690000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045500076002001300531#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#53#49#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The use of needle    guide for TPNB
 reduces technique variability; leading to a shorter learning    curve for biops
y procedure; reduction in procedure time; and a consistent replicable    procedu
re (9). However, the risk of cross-contamination is questionable. The    disposa
ble needle guide was introduced into the market in an effort to reduce    the ri
sk of infection.</font></p>     ^cY#a10v37n1.htm##
01369000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704113400076002001301210#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#54#50#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The clinical infection    rates afte
r TRNP vary between 0.25 and 5% in past series, though other authors    have rep
orted rates of up to 7.5% (10,11). After biopsy incidence of bacteremia    and b
acteriuria were reported as 15% to 73% and 30% to 53% respectively (12,13).    L
indert et al. reported that bacteremia and bacteriuria after TPNB are common    
but usually asymptomatic (4). Urine cultures alone may not be useful for diagnos
ing    infection (14). There is no unifying definition of infectious complicatio
ns    after TPNB. However, bacteriologic investigation (bacteriuria &#91;more th
an    10<sup>5</sup> CFU/mL&#93; versus no bacteriuria and bacteremia) and clini
cal    diagnosis (no clinical symptoms of UTI versus clinical signs of UTI) at f
ollow-up    are determinant factors to evaluate the complications after TPNB. Th
e clinical    importance of positive urine culture in asymptomatic patients is u
nclear but    one asymptomatic patient in group 2 required hospitalization due t
o ESBL producing    E. Coli harvested in urine culture.</font></p>     ^cY#a10v3
7n1.htm##
00412000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017700076002001300253#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#55#51#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Bacteriologic UTI    rate was found 
to be statistically similar in both groups. (4% vs. 6.6%).</font></p>     ^cY#a1
0v37n1.htm##
00893000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065800076002001300734#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#56#52#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Hospitalization    was required in 4
%, 6.6% in Group 1 and Group 2 relatively. The failures of    quinolone prophyla
xis might be the reason. Worldwide, quinolone-resistance rates    among gram-neg
ative bacilli are rising rapidly. Turkish Urinary Tract Infection    Study Group
 recommended that fluoroquinolone-sparing agents should be evaluated    as alter
native therapies by further clinical efficacy and safety studies (15).    Ozden 
et al. reported the high incidence of &nbsp;ESBL producing E Coli after    TRNP 
(16). New preventive protocols might be necessary for TPNB.</font></p>     ^cY#a
10v37n1.htm##
00792000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055700076002001300633#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#57#53#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Obek et al. reported    periprostati
c lidocaine infiltration may be associated with a higher risk for    infection d
ue to the extra 2 punctures of lidocaine injection into the periprostatic    are
a through the rectum, which is known to be highly colonized by bacteria (17).   
 Intracapsular punctures during anesthesia can also contribute to the increased 
   rate of infection after biopsy but both groups received the same type of peri
prostatic    anesthesia in this study.</font></p>     ^cY#a10v37n1.htm##
02034000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704179900076002001301875#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#58#54#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> There are many    factors that are 
related to the risk of infectious complications in prostate    biopsies, such as
 lack of standardization among urologists in pre-biopsy antimicrobial    prophyl
axis, high incidence of resistant organisms, and the different methods    of dis
infection for reusable guides. Contamination of the tools used in biopsies    ha
s been reported to be the possible cause of infections occurring after TRUS-guid
ed    prostate biopsies (18). These devices have a needle guide that directs bio
psy    needle insertion. The biopsy needle repeatedly traverses the guide, affor
ding    the opportunity for fecal and blood materials to accumulate. Bioburdens 
can    also accumulate in other parts of the transducer assembly. Brushes are re
quired    to clean the transducer assemblies to reduce the bioburden and remove 
proteins.    Transducer assembly kits have not always been supplied with brushes
. Not using    brushes for cleaning has resulted in improperly reprocessed trans
ducer assemblies,    which could lead to pathogen transmission between patients.
 Gillespie et al.    (5) detected an outbreak of Pseudomonas aeruginosa after pr
ostate biopsy due    to the insufficient manual cleaning of reusable needle guid
es. They concluded    that clinicians performing TRUS-guided prostate biopsy pro
cedures should follow    the manufacturer's needle guide reprocessing recommenda
tions or use disposable    needle guides. In this study we used the Toshiba Fabi
o reusable needle guide.    According to our results, all types of infectious co
mplications such as asymptomatic    bacteriuria, acute urinary infection, high f
ever, and bacteremia occurred at    a statistically similar rate in both groups.
</font></p>     ^cY#a10v37n1.htm##
00744000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050900076002001300585#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#59#55#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The permanent reusable    needle gui
de, which has a long, narrow lumen may not have allowed adequate sterilization, 
   as mentioned in previous studies, and may be the basis for the increased risk
    of infectious complications. It is essential to review the manufacturer's re
processing    recommendations and to establish appropriate procedures to avoid p
otential transmission    of pathogens and subsequent patient concerns.</font></p
>     ^cY#a10v37n1.htm##
02164000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704192900076002001302005#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#60#56#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Potential sterilization    problems 
with prostate biopsy equipment encourage the use of disposable equipment.    Tun
cel et al. (8) first reported that the use of a disposable needle guide reduces 
   infectious complications. These authors determined that asymptomatic bacteriu
ria,    high fever, and acute UTIs were statistically lower in the disposable gr
oup    compared to the reusable group a 4.5% vs. 9%; 5% vs. 10%; and 2% vs. 9%, 
respectively).    Inadequate flushing of the lumen with disinfectant to eradicat
e microorganisms    and the lack of availability of a device to clean the long, 
narrow lumen was    suggested as the major problem with the use of a reusable ne
edle guide for infectious    complications. They concluded that the novel device
 which has been used as a    disposable needle guide is a good alternative to re
duce infectious complications.    Our results are inconsistent with the results 
of the initial study but our study    population was smaller than previous study
 populations, possibly affecting the    power of our study. However, if the infe
ctious complications occur due to the    contamination of the needle guide, it m
ay also occur due to the multiple reintroduction    of the needle during the sam
e biopsy. Using a reusable needle guide, even if    the needle guide is changed 
after each pass of the needle, would provide little    difference versus a dispo
sable guide. The other explanation is that the physical    features of the reusa
ble needle guide in this study may have allowed proper    sterilization. The sep
arable and detachable features of the needle guide may    be an important factor
 to prevent the possible infections. The permanent type    of reusable needle gu
ide which has been used in Tuncel et al. study (personal    info from the author
) might not have allowed the appropriate cleaning.</font></p>     ^cY#a10v37n1.h
tm##
00714000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047900076002001300555#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#61#57#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The core sampling    notch was appro
ximately 17 mm long by 1.2 mm in diameter. The procedure time    including anest
hesia application was 15 minutes for each case. There were no    major technical
 problems during the procedure. &nbsp;However, the core length    and the proced
ure time or some minor technical problems may individually affect    the infecti
on rate. We did not focus on this issue.</font></p>     ^cY#a10v37n1.htm##
00750000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051500076002001300591#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#62#58#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In our study, there    were no stati
stically significant differences between the two groups regarding    co-morbidit
y. Therefore, it is difficult to conclude that the risk of infection    is less 
when using a disposable needle guide in patients with additional co-morbidities.
    Although the number of patients was limited in our study; a reusable needle 
   guide was found to be safe in patients who had additional co-morbidities.</fo
nt></p>     ^cY#a10v37n1.htm##
01483000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704124800076002001301324#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#63#59#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Reprocessing instructions    for tra
nsrectal biopsy equipment, such as a transducer, biopsy channel bracket,    and 
needle guide, is well-defined in the Food and Drug Administration recommendation
s    (19). The risks of transmission of hepatitis B virus, hepatitis C virus, hu
man    immunodeficiency virus, during prostate biopsies were evaluated by Lessa 
et    al. (20). Although, on aggregate, their findings do not provide evidence o
f    disease transmission, although they do not rule out transmission in some ca
ses.    We did not focus on viral transmission in this study. The needle guide c
an be    effectively disinfected with glutaraldehyde, but it must be disassemble
d from    the transducer assembly before disinfection. We suggest that following
 the manufacturer's    guidelines for the sterilization may be sufficient for us
ing reusable instruments.    The advantages of using a disposable needle guide a
re that it does not need    to be reprocessed and it saves time, however, its co
st is US$ 5.00 per patient.    Since the rate of infection appears to be same, w
hatever needle guide used,    the issue of cost bene?t ratio must always be kept
 in mind.</font></p>     ^cY#a10v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#64#60#article#156#<p>&nbsp;</p>     ^
cY#a10v37n1.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#65#61#article#156#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUSION</b></font></p>     ^cY
#a10v37n1.htm##
00575000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034000076002001300416#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#66#62#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> It seems to be    ineffective to re
duce the infection rate after the prostate biopsy by using    a disposable needl
e guide. Large scale and randomized studies are necessary    to determine the ef
fect of disposable needle guide on infection rate after TPNB.</font></p>     ^cY
#a10v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#67#63#article#156#<p>&nbsp;</p>     ^
cY#a10v37n1.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010600076002001300182#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#68#64#article#156#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ACKNOWLEDGEMENTS</b></font></p>  
   ^cY#a10v37n1.htm##
00362000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012700076002001300203#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#69#65#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Mr. Rusen Celikoglu    helped in thi
s study.</font></p>     ^cY#a10v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#70#66#article#156#<p>&nbsp;</p>     ^
cY#a10v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#71#67#article#156#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONFLICT OF    INTEREST</b></font
></p>     ^cY#a10v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#72#68#article#156#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> None declared.</font></p>     ^cY#a
10v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#73#69#article#156#<p>&nbsp;</p>     ^
cY#a10v37n1.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#74#70#article#156#<p><font face="Verd
ana, Arial, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>     ^cY
#a10v37n1.htm##
00619000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704037000078002001300448#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#75#71#article#156#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Isen K, K&uuml;peli
    B, Sinik Z, S&ouml;zen S, Bozkirli I: Antibiotic prophylaxis for transrectal
    biopsy of the prostate: a prospective randomized study of the prophylactic u
se    of single dose oral fluoroquinolone versus trimethoprim-sulfamethoxazole. 
Int    Urol Nephrol. 1999; 31: 491-5.    ^cY#a10v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#76#72#article#156# </font></p>     ^c
Y#a10v37n1.htm##
00574000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704032500078002001300403#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#77#73#article#156#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Raaijmakers    R, K
irkels WJ, Roobol MJ, Wildhagen MF, Schrder FH: Complication rates and risk    f
actors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate   
 within a population-based screening program. Urology. 2002; 60: 826-30.    ^cY#
a10v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#78#74#article#156#</font></p>     ^cY
#a10v37n1.htm##
00484000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023500078002001300313#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#79#75#article#156#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Aron M, Rajeev    T
P, Gupta NP: Antibiotic prophylaxis for transrectal needle biopsy of the prostat
e:    a randomized controlled study. BJU Int. 2000; 85: 682-5.    ^cY#a10v37n1.h
tm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#80#76#article#156#</font></p>     ^cY
#a10v37n1.htm##
00469000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022000078002001300298#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#81#77#article#156#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Lindert KA,    Kaba
lin JN, Terris MK: Bacteremia and bacteriuria after transrectal ultrasound    gu
ided prostate biopsy. J Urol. 2000; 164: 76-80.    ^cY#a10v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#82#78#article#156#</font></p>     ^cY
#a10v37n1.htm##
00535000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028600078002001300364#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#83#79#article#156#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Gillespie JL,    Ar
nold KE, Noble-Wang J, Jensen B, Arduino M, Hageman J, et al.: Outbreak of    Ps
eudomonas aeruginosa infections after transrectal ultrasound-guided prostate    
biopsy. Urology. 2007; 69: 912-4.    ^cY#a10v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#84#80#article#156#</font></p>     ^cY
#a10v37n1.htm##
00485000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023600078002001300314#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#85#81#article#156#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Huang YC, Ho    DR,
 Wu CF, Shee JJ, Lin WY, Chen CS: Modified bowel preparation to reduce infection
    after prostate biopsy. Chang Gung Med J. 2006; 29: 395-400.    ^cY#a10v37n1.
htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#86#82#article#156#</font></p>     ^cY
#a10v37n1.htm##
00580000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704033100078002001300409#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#87#83#article#156#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Berger AP, Gozzi   
 C, Steiner H, Frauscher F, Varkarakis J, Rogatsch H, et al.: Complication rate 
   of transrectal ultrasound guided prostate biopsy: a comparison among 3 protoc
ols    with 6, 10 and 15 cores. J Urol. 2004; 171: 1478-80; discussion 1480-1.  
  ^cY#a10v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#88#84#article#156#</font></p>     ^cY
#a10v37n1.htm##
00540000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029100078002001300369#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#89#85#article#156#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Tuncel A, Aslan    
Y, Sezgin T, Aydin O, Tekdogan U, Atan A: Does disposable needle guide minimize 
   infectious complications after transrectal prostate needle biopsy? Urology.  
  2008; 71: 1024-7; discussion 1027-8.    ^cY#a10v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#90#86#article#156#</font></p>     ^cY
#a10v37n1.htm##
00518000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026900078002001300347#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#91#87#article#156#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Phal PM, Brooks    
DM, Wolfe R: Sonographically guided biopsy of focal lesions: a comparison of    
freehand and probe-guided techniques using a phantom. AJR Am J Roentgenol. 2005;
    184: 1652-6.    ^cY#a10v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#92#88#article#156#</font></p>     ^cY
#a10v37n1.htm##
00517000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026700079002001300346#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#93#89#article#156#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Griffith BC,    M
orey AF, Ali-Khan MM, Canby-Hagino E, Foley JP, Rozanski TA: Single dose levoflo
xacin    prophylaxis for prostate biopsy in patients at low risk. J Urol. 2002; 
168:    1021-3.    ^cY#a10v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#94#90#article#156#</font></p>     ^cY
#a10v37n1.htm##
00539000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704028900079002001300368#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#95#91#article#156#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Peyromaure    M, 
Ravery V, Messas A, Toublanc M, Boccon-Gibod L, Boccon-Gibod L: Pain and    morb
idity of an extensive prostate 10-biopsy protocol: a prospective study in    289
 patients. J Urol. 2002; 167: 218-21.    ^cY#a10v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#96#92#article#156#</font></p>     ^cY
#a10v37n1.htm##
00531000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704028100079002001300360#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#97#93#article#156#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Petteffi L,    To
niazzo GP, Sander GB, Stein AC, Koff WJ: Efficiency of short and long term    an
timicrobial therapy in transrectal ultrasound-guided prostate biopsies. Int    B
raz J Urol. 2002; 28: 526-32.    ^cY#a10v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#98#94#article#156#</font></p>     ^cY
#a10v37n1.htm##
00528000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704027800079002001300357#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#99#95#article#156#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Ruebush TK    2nd
, McConville JH, Calia FM: A double-blind study of trimethoprim-sulfamethoxazole
    prophylaxis in patients having transrectal needle biopsy of the prostate. J 
   Urol. 1979; 122: 492-4.    ^cY#a10v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#100#96#article#156#</font></p>     ^c
Y#a10v37n1.htm##
00529000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704027800080002001300358#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#101#97#article#156#14#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Zegarra Montes  
  LZ, Sanchez Mejia AA, Loza Munarriz CA, Gutierrez EC: Semen and urine culture 
   in the diagnosis of chronic bacterial prostatitis. Int Braz J Urol. 2008; 34:
    30-7, discussion 38-40.    ^cY#a10v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#102#98#article#156#</font></p>     ^c
Y#a10v37n1.htm##
00566000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704031500080002001300395#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#103#99#article#156#15#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Yagci D, Yoruk  
  F, Azap A, Memikoglu O: Prevalence and risk factors for selection of quinolone
-resistant    Escherichia coli strains in fecal flora of patients receiving quin
olone therapy.    Antimicrob Agents Chemother. 2009; 53: 1287-9.    ^cY#a10v37n1
.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#104#100#article#156#</font></p>     ^
cY#a10v37n1.htm##
00572000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032000081002001300401#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#105#101#article#156#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Ozden E, Bostan
ci    Y, Yakupoglu KY, Akdeniz E, Yilmaz AF, Tulek N, et al.: Incidence of acute
 prostatitis    caused by extended-spectrum beta-lactamase-producing Escherichia
 coli after    transrectal prostate biopsy. Urology. 2009; 74: 119-23.    ^cY#a1
0v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#106#102#article#156#</font></p>     ^
cY#a10v37n1.htm##
00609000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704035700081002001300438#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#107#103#article#156#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Obek C, Onal   
 B, Ozkan B, Onder AU, Yal&ccedil;in V, Solok V: Is periprostatic local anesthes
ia    for transrectal ultrasound guided prostate biopsy associated with increase
d    infectious or hemorrhagic complications? A prospective randomized trial. J 
Urol.    2002; 168: 558-61.    ^cY#a10v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#108#104#article#156#</font></p>     ^
cY#a10v37n1.htm##
00601000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034900081002001300430#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#109#105#article#156#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Centers for    
Disease Control and Prevention (CDC): Pseudomonas aeruginosa infections associat
ed    with transrectal ultrasound-guided prostate biopsies--Georgia, 2005. MMWR 
Morb    Mortal Wkly Rep. 2006; 55: 776-7. Erratum in: MMWR Morb Mortal Wkly Rep.
 2006;    55: 1177.    ^cY#a10v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#110#106#article#156#</font></p>     ^
cY#a10v37n1.htm##
00735000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704048300081002001300564#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#111#107#article#156#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. US Food and    
Drug Administration. FDA public health notification; Reprocessing of Reusable   
 Ultrasound Transducer Assemblies Used for Biopsy Procedures. 2006. Available   
 at <a href="http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHea
lthNotifications/UCM062086" target="_blank">http://www.fda.gov/MedicalDevices/Sa
fety/AlertsandNotices/PublicHealthNotifications/UCM062086</a></font></p>     ^cY
#a10v37n1.htm##
00570000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031800081002001300399#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#112#108#article#156#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Lessa F, Tak   
 S, Devader SR, Goswami R, Anderson M, Williams I, et al.: Risk of infections   
 associated with improperly reprocessed transrectal ultrasound-guided prostate  
  biopsy equipment. Infect Control Hosp Epidemiol. 2008; 29: 289-93.    ^cY#a10v
37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#113#109#article#156#</font></p>     ^
cY#a10v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#114#110#article#156#<p>&nbsp;</p>    
 ^cY#a10v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#115#111#article#156#<p>&nbsp;</p>    
 ^cY#a10v37n1.htm##
00356000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011900078002001300197#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#116#112#article#156#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><i>Accepted after    revision: Jul
y 30, 2010</i>    ^cY#a10v37n1.htm##
00264000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002700078002001300105#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#117#113#article#156#<br>   </font></p
>     ^cY#a10v37n1.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019300078002001300271#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#118#114#article#156#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><b><a name="end"></a><a href="#top
"><img src="/img/revistas/ibju/v37n1/seta.gif" border="0"></a>    Correspondence
 to</b>:    ^cY#a10v37n1.htm##
00267000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003000078002001300108#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#119#115#article#156#<br>   Dr. Cenk G
urbuz    ^cY#a10v37n1.htm##
00282000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004500078002001300123#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#120#116#article#156#<br>   2222 Medic
al District Dr. 4339    ^cY#a10v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003600078002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#121#117#article#156#<br>   Dallas, TX
 75235, USA    ^cY#a10v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003600078002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#122#118#article#156#<br>   Fax: + 1 4
6 9422-9910    ^cY#a10v37n1.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009700078002001300175#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#123#119#article#156#<br>   E-mail: <a
 href="mailto:gurbuzcenk@yahoo.com">gurbuzcenk@yahoo.com</a></font></p>     ^cY#
a10v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#124#120#article#156#<p>&nbsp;</p>    
 ^cY#a10v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#125#121#article#156#<p>&nbsp;</p>    
 ^cY#a10v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704001600078002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#126#122#article#156#<p></p>     ^cY#a
10v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704001600078002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#127#123#article#156#<p></p>     ^cY#a
10v37n1.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010700078002001300185#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#128#124#article#156#<p><font face="Ve
rdana, Arial, Helvetica, sans-serif" size="3"><b>EDITORIAL COMMENT</b></font></p
>     ^cY#a10v37n1.htm##
01110000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704087300078002001300951#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#129#125#article#156#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> Transrectal guided    prostate ne
edle biopsy (TPNB) is one of the most common outpatient diagnostic    procedures
 in urology clinics and in this study the authors analyzed whether    the use of
 disposable needle guide decrease the infectious complication after    TPNB. Fev
er after prostate biopsy was developed in 3.5% patients (1). Urosepsis    and ba
cteremia were rare but bothersome complications. Antibiotic prophylaxis    inclu
ding ciprofloxacin therapy has been administrated in most of the urology    clin
ics to prevent infectious complications. Recently, Tuncel et al. suggested    th
at the use of disposable needle guide could reduce the infection risk after    p
rostate biopsy (2). However, in the current study the authors showed that it    
is ineffective to prevent infection.</font></p>     ^cY#a10v37n1.htm##
00734000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704049700078002001300575#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#130#126#article#156#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> Rutala et al.    demonstrated tha
t probe disinfection with glutaraldehyde greater than 2% concentration    could 
be achieved when prostate needle guide was removed (3). Therefore, adequate    c
leaning and disinfection could explain the similar infection risks of use dispos
able    and reusable needle guide. However, the small number of patients include
d in    the study group prevents definite clinical judgment.</font></p>     ^cY#
a10v37n1.htm##
00768000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704053100078002001300609#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#131#127#article#156#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> In spite of these    controversia
lly results, the disposable needle guide with a price of $5.00 should    be used
 for biopsy to overcome the difficulty in standardization of proper disinfection
    procedures in urology clinics. Whenever disposable needle is not available, 
   mechanical cleaning to remove biologic material followed by 20 minutes of dis
infection    with glutaraldehyde should be performed after removing the reusable
 needle guide.</font></p>     ^cY#a10v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#132#128#article#156#<p>&nbsp;</p>    
 ^cY#a10v37n1.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010000078002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#133#129#article#156#<p><font face="Ve
rdana, Arial, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>     ^
cY#a10v37n1.htm##
00577000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032500081002001300406#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#134#130#article#156#21#<p
><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Raaijmakers    R
, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH: Complication rates and risk  
  factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate
    within a population-based screening program. Urology. 2002; 60: 826-30.    ^
cY#a10v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#135#131#article#156#</font></p>     ^
cY#a10v37n1.htm##
00543000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029100081002001300372#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#136#132#article#156#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Tuncel A, Aslan 
   Y, Sezgin T, Aydin O, Tekdogan U, Atan A: Does disposable needle guide minimi
ze    infectious complications after transrectal prostate needle biopsy? Urology
.    2008; 71: 1024-7; discussion 1027-8.    ^cY#a10v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#137#133#article#156#</font></p>     ^
cY#a10v37n1.htm##
00478000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022600081002001300307#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#138#134#article#156#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Rutala WA,    Ge
rgen MF, Weber DJ: Disinfection of a probe used in ultrasound-guided prostate   
 biopsy. Infect Control Hosp Epidemiol. 2007; 28: 916-9.    ^cY#a10v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#139#135#article#156#</font></p>     ^
cY#a10v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#140#136#article#156#<p>&nbsp;</p>    
 ^cY#a10v37n1.htm##
00366000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012900078002001300207#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#141#137#article#156#<p align="right">
<font size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Dr.    Onur Ka
yg&yacute;s&yacute;z</b>    ^cY#a10v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003600078002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#142#138#article#156#<br>   Yalova Sta
te Hospital    ^cY#a10v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003600078002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#143#139#article#156#<br>   Department
 of Urology    ^cY#a10v37n1.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002900078002001300107#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#144#140#article#156#<br>   Yalova, TU
RKEY    ^cY#a10v37n1.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009900078002001300177#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#145#141#article#156#<br>   E-mail: <a
 href="mailto:onurkygsz@yahoo.com">onurkygsz@yahoo.com</a></i></font></p>     ^c
Y#a10v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#146#142#article#156#<p>&nbsp;</p>    
 ^cY#a10v37n1.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010700078002001300185#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#147#143#article#156#<p><font size="3"
 face="Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL COMMENT</b></font></p
>     ^cY#a10v37n1.htm##
00883000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704064600078002001300724#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#148#144#article#156#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> The authors should    be commende
d on such a novel concept to potentially reduce infection after transrectal    p
rostate needle biopsy. The methodology used to detect presence of infection    w
as comprehensive and well designed. The randomized cohorts did not demonstrate  
  a significant difference with regard to infection rates as a function of dispo
sable    versus reusable needle guide. The bacteriologic infection rate was 4% i
n both    groups while surprisingly, the symptomatic urinary tract infection rat
e was    greater for the disposable needle guide.</font></p>     ^cY#a10v37n1.ht
m##
01002000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704076500078002001300843#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#149#145#article#156#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> Infection rates    after transrec
tal biopsy are not negligible and certainly, any effort to reduce    them should
 be explored. Our group has offered stereotactic transperineal prostate    biops
y (STPB) for patients that have had prior negative transrectal prostate    biops
y despite continued elevation of PSA (1,2). While 40% of these patients    are i
dentified as having occult malignancy after STPB, an additional benefit    has b
een a true null of post procedure infection. I acknowledge that STPB is    not w
idely accepted as a first line biopsy technique, but given the high diagnostic  
  yield and negligible risk of infection, STPB may be more commonplace in the   
 future.</font></p>     ^cY#a10v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#150#146#article#156#<p>&nbsp;</p>    
 ^cY#a10v37n1.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010000078002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#151#147#article#156#<p><font size="3"
 face="Verdana, Arial, Helvetica, sans-serif"><b>REFERENCES</b></font></p>     ^
cY#a10v37n1.htm##
00425000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017300081002001300254#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#152#148#article#156#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Moran BJ, Bracci
oforte    MH: Stereotactic transperineal prostate biopsy. Urology. 2009; 73: 386
-8.    ^cY#a10v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#153#149#article#156#</font></p>     ^
cY#a10v37n1.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023800081002001300319#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#154#150#article#156#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 2. Moran BJ, Bracc
ioforte    MH, Conterato DJ: Re-biopsy of the prostate using a stereotactic tran
sperineal    technique. J Urol. 2006; 176: 1376-81; discussion 1381.    ^cY#a10v
37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#155#151#article#156#</font></p>     ^
cY#a10v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#156#152#article#156#<p>&nbsp;</p>    
 ^cY#a10v37n1.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011600078002001300194#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#157#153#article#156#<p align="right">
<font size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Dr.    Brian J
. Moran</b>    ^cY#a10v37n1.htm##
00282000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004500078002001300123#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#158#154#article#156#<br>   Chicago Pr
ostate Cancer Center    ^cY#a10v37n1.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003800078002001300116#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#159#155#article#156#<br>   Westmont, 
Illinois, USA    ^cY#a10v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011100078002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a10v37n1.htm#S#p#160#156#article#156#<br>   E-mail: <a
 href="mailto:seeds@prostateimplant.com">seeds@prostateimplant.com</a></i></font
></p>     ^cY#a10v37n1.htm##
00753000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100016000910100
01500107010001500122010001800137012019500155030001700350065000900367064000500376
031000300381014000600384865000900390002001300399035001000412801001700422#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#c#161#1#article#25#1#^rND^sIsen
^nK#^rND^sKüpeli^nB#^rND^sSinik^nZ#^rND^sSözen^nS#^rND^sBozkirli^nI#Antibiotic p
rophylaxis for transrectal biopsy of the prostate: a prospective randomized stud
y of the prophylactic use of single dose oral fluoroquinolone versus trimethopri
m-sulfamethoxazole^len#Int Urol Nephrol#19990000#1999#31#491-5#20110200#a10v37n1
.htm#0301-1623#Int Urol Nephrol##
00712000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100021000770100018000980100
01700116010002000133010001800153012015500171030000800326065000900334064000500343
031000300348014000700351865000900358002001300367035001000380801000800390#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#c#162#2#article#25#2#^rND^sRaai
jmakers^nR#^rND^sKirkels^nWJ#^rND^sRoobol^nMJ#^rND^sWildhagen^nMF#^rND^sSchrder^
nFH#Complication rates and risk factors of 5802 transrectal ultrasound-guided se
xtant biopsies of the prostate within a population-based screening program^len#U
rology#20020000#2002#60#826-30#20110200#a10v37n1.htm#0090-4295#Urology##
00561000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100017000910100
01600108012010400124030000800228710000200236065000900238064000500247031000300252
014000600255865000900261002001300270#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a1
0v37n1.htm#S#c#163#3#article#25#3#^rND^sAron^nM#^rND^sRajeev^nTP#^rND^sGupta^nNP
#Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomi
zed controlled study^len#BJU Int#2#20000000#2000#85#682-5#20110200#a10v37n1.htm#
#
00573000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100018000950100
01700113012008300130030000700213065000900220064000500229031000400234014000600238
865000900244002001300253035001000266801000700276#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a10v37n1.htm#S#c#164#4#article#25#4#^rND^sLindert^nKA#^rND^sKabalin^nJ
N#^rND^sTerris^nMK#Bacteremia and bacteriuria after transrectal ultrasound guide
d prostate biopsy^len#J Urol#20000000#2000#164#76-80#20110200#a10v37n1.htm#0022-
5347#J Urol##
00701000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100017000970100
02000114010001600134010001700150010001700167810000600184012010200190030000800292
06500090030006400050030903100030031401400060031786500090032300200130033203500100
0345801000800355#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#c#165#5
#article#25#5#^rND^sGillespie^nJL#^rND^sArnold^nKE#^rND^sNoble-Wang^nJ#^rND^sJen
sen^nB#^rND^sArduino^nM#^rND^sHageman^nJ#et al#Outbreak of Pseudomonas aeruginos
a infections after transrectal ultrasound-guided prostate biopsy^len#Urology#200
70000#2007#69#912-4#20110200#a10v37n1.htm#0090-4295#Urology##
00616000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100013000930100
01300106010001500119010001400134010001500148012007300163030001700236710000200253
065000900255064000500264031000300269014000800272865000900280002001300289#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#c#166#6#article#25#6#^rND^sHuan
g^nYC#^rND^sHo^nDR#^rND^sWu^nCF#^rND^sShee^nJJ#^rND^sLin^nWY#^rND^sChen^nCS#Modi
fied bowel preparation to reduce infection after prostate biopsy^len#Chang Gung 
Med J#2#20060000#2006#29#395-400#20110200#a10v37n1.htm##
00726000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100015000940100
01700109010001900126010002000145010001800165810000600183012012700189030000700316
06500090032306400050033203100040033701400080034186500090034900200130035803500100
0371801000700381#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#c#167#7
#article#25#7#^rND^sBerger^nAP#^rND^sGozzi^nC#^rND^sSteiner^nH#^rND^sFrauscher^n
F#^rND^sVarkarakis^nJ#^rND^sRogatsch^nH#et al#Complication rate of transrectal u
ltrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 
15 cores^len#J Urol#20040000#2004#171#1478-80#20110200#a10v37n1.htm#0022-5347#J 
Urol##
00678000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100015000930100
01600108010001500124010001800139010001400157012010900171030000800280065000900288
06400050029703100030030201400070030586500090031200200130032103500100033480100080
0344#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#c#168#8#article#25#
8#^rND^sTuncel^nA#^rND^sAslan^nY#^rND^sSezgin^nT#^rND^sAydin^nO#^rND^sTekdogan^n
U#^rND^sAtan^nA#Does disposable needle guide minimize infectious complications a
fter transrectal prostate needle biopsy?^len#Urology#20080000#2008#71#1024-7#201
10200#a10v37n1.htm#0090-4295#Urology##
00632000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100017000920100
01500109012012100124030002000245065000900265064000500274014000400279014000700283
865000900290002001300299035001000312801002000322#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a10v37n1.htm#S#c#169#9#article#25#9#^rND^sPhal^nPM#^rND^sBrooks^nDM#^r
ND^sWolfe^nR#Sonographically guided biopsy of focal lesions: a comparison of fre
ehand and probe-guided techniques using a phantom^len#AJR Am J Roentgenol#200500
00#2005#184#1652-6#20110200#a10v37n1.htm#0361-803X#AJR Am J Roentgenol##
00672000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01900114010002200133010001600155010001900171012008500190030000700275065000900282
06400050029103100040029601400070030086500090030700200130031603500100032980100070
0339#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#c#170#10#article#25
#10#^rND^sGriffith^nBC#^rND^sMorey^nAF#^rND^sAli-Khan^nMM#^rND^sCanby-Hagino^nE#
^rND^sFoley^nJP#^rND^sRozanski^nTA#Single dose levofloxacin prophylaxis for pros
tate biopsy in patients at low risk^len#J Urol#20020000#2002#168#1021-3#20110200
#a10v37n1.htm#0022-5347#J Urol##
00694000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100016000990100
01600115010001800131010002200149010002200171012010400193030000700297065000900304
06400050031303100040031801400070032286500090032900200130033803500100035180100070
0361#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#c#171#11#article#25
#11#^rND^sPeyromaure^nM#^rND^sRavery^nV#^rND^sMessas^nA#^rND^sToublanc^nM#^rND^s
Boccon-Gibod^nL#^rND^sBoccon-Gibod^nL#Pain and morbidity of an extensive prostat
e 10-biopsy protocol: a prospective study in 289 patients^len#J Urol#20020000#20
02#167#218-21#20110200#a10v37n1.htm#0022-5347#J Urol##
00641000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
01700116010001600133010001500149012011100164030001600275710000200291065000900293
064000500302031000300307014000700310865000900317002001300326#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a10v37n1.htm#S#c#172#12#article#25#12#^rND^sPetteffi^nL#^r
ND^sToniazzo^nGP#^rND^sSander^nGB#^rND^sStein^nAC#^rND^sKoff^nWJ#Efficiency of s
hort and long term antimicrobial therapy in transrectal ultrasound-guided prosta
te biopsies^len#Int Braz J Urol#2#20020000#2002#28#526-32#20110200#a10v37n1.htm#
#
00629000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100021001010100
01600122012013100138030000700269065000900276064000500285031000400290014000600294
865000900300002001300309035001000322801000700332#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a10v37n1.htm#S#c#173#13#article#25#13#^rND^sRuebush^nTK 2nd#^rND^sMcCo
nville^nJH#^rND^sCalia^nFM#A double-blind study of trimethoprim-sulfamethoxazole
 prophylaxis in patients having transrectal needle biopsy of the prostate^len#J 
Urol#19790000#1979#122#492-4#20110200#a10v37n1.htm#0022-5347#J Urol##
00602000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100025000790100024001040100
02400128010002000152012007800172030001600250710000200266065000900268064000500277
031000300282014000500285865000900290002001300299#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a10v37n1.htm#S#c#174#14#article#25#14#^rND^sZegarra Montes^nLZ#^rND^sS
anchez Mejia^nAA#^rND^sLoza Munarriz^nCA#^rND^sGutierrez^nEC#Semen and urine cul
ture in the diagnosis of chronic bacterial prostatitis^len#Int Braz J Urol#2#200
80000#2008#34#30-7#20110200#a10v37n1.htm##
00705000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100015000940100
01400109010001900123012014900142030002800291065000900319064000500328031000300333
014000700336865000900343002001300352035001000365801002800375#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a10v37n1.htm#S#c#175#15#article#25#15#^rND^sYagci^nD#^rND^
sYoruk^nF#^rND^sAzap^nA#^rND^sMemikoglu^nO#Prevalence and risk factors for selec
tion of quinolone-resistant Escherichia coli strains in fecal flora of patients 
receiving quinolone therapy^len#Antimicrob Agents Chemother#20090000#2009#53#128
7-9#20110200#a10v37n1.htm#0066-4804#Antimicrob Agents Chemother##
00736000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100018000940100
02000112010001700132010001700149010001500166810000600181012013900187030000800326
06500090033406400050034303100030034801400070035186500090035800200130036703500100
0380801000800390#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#c#176#1
6#article#25#16#^rND^sOzden^nE#^rND^sBostanci^nY#^rND^sYakupoglu^nKY#^rND^sAkden
iz^nE#^rND^sYilmaz^nAF#^rND^sTulek^nN#et al#Incidence of acute prostatitis cause
d by extended-spectrum beta-lactamase-producing Escherichia coli after transrect
al prostate biopsy^len#Urology#20090000#2009#74#119-23#20110200#a10v37n1.htm#009
0-4295#Urology##
00752000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100014000930100
01500107010001600122010001600138010001500154012018600169030000700355065000900362
06400050037103100040037601400070038086500090038700200130039603500100040980100070
0419#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#c#177#17#article#25
#17#^rND^sObek^nC#^rND^sOnal^nB#^rND^sOzkan^nB#^rND^sOnder^nAU#^rND^nYalçin^sV#^
rND^sSolok^nV#Is periprostatic local anesthesia for transrectal ultrasound guide
d prostate biopsy associated with increased infectious or hemorrhagic complicati
ons? A prospective randomized trial^len#J Urol#20020000#2002#168#558-61#20110200
#a10v37n1.htm#0022-5347#J Urol##
00618000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760110049000790120117001280300
02600245065000900271064000500280031000300285014000600288865000900294002001300303
035001000316801002600326#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S
#c#178#18#article#25#18#Centers for Disease Control and Prevention (CDC)#Pseudom
onas aeruginosa infections associated with transrectal ultrasound-guided prostat
e biopsies--Georgia, 2005^len#MMWR Morb Mortal Wkly Rep#20060000#2006#55#776-7#2
0110200#a10v37n1.htm#0149-2195#MMWR Morb Mortal Wkly Rep##
00580000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170032000790180121001110650
00900232064000500241037009400246865000900340002001300349#v37n1#V:\SciELO\serial\
ibju\v37n1\markup\a10v37n1.htm#S#c#179#19#article#25#19#US Food and Drug Adminis
tration#FDA public health notification; Reprocessing of Reusable Ultrasound Tran
sducer Assemblies Used for Biopsy Procedures^len#20060000#2006#http://www.fda.go
v/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/UCM062086#201
10200#a10v37n1.htm##
00756000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100013000940100
01800107010001700125010001800142010001800160810000600178012011800184030003000302
06500090033206400050034103100030034601400070034986500090035600200130036503500100
0378801003000388#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#c#180#2
0#article#25#20#^rND^sLessa^nF#^rND^sTak^nS#^rND^sDevader^nSR#^rND^sGoswami^nR#^
rND^sAnderson^nM#^rND^sWilliams^nI#et al#Risk of infections associated with impr
operly reprocessed transrectal ultrasound-guided prostate biopsy equipment^len#I
nfect Control Hosp Epidemiol#20080000#2008#29#289-93#20110200#a10v37n1.htm#0899-
823X#Infect Control Hosp Epidemiol##
00713000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100021000780100018000990100
01700117010002000134010001800154012015500172030000800327065000900335064000500344
031000300349014000700352865000900359002001300368035001000381801000800391#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#c#181#21#article#25#1#^rND^sRaa
ijmakers^nR#^rND^sKirkels^nWJ#^rND^sRoobol^nMJ#^rND^sWildhagen^nMF#^rND^sSchrder
^nFH#Complication rates and risk factors of 5802 transrectal ultrasound-guided s
extant biopsies of the prostate within a population-based screening program^len#
Urology#20020000#2002#60#826-30#20110200#a10v37n1.htm#0090-4295#Urology##
00679000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100016000780100015000940100
01600109010001500125010001800140010001400158012010900172030000800281065000900289
06400050029803100030030301400070030686500090031300200130032203500100033580100080
0345#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a10v37n1.htm#S#c#182#22#article#25
#2#^rND^sTuncel^nA#^rND^sAslan^nY#^rND^sSezgin^nT#^rND^sAydin^nO#^rND^sTekdogan^
nU#^rND^sAtan^nA#Does disposable needle guide minimize infectious complications 
after transrectal prostate needle biopsy?^len#Urology#20080000#2008#71#1024-7#20
110200#a10v37n1.htm#0090-4295#Urology##
00603000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100017000780100017000950100
01600112012007000128030003000198065000900228064000500237031000300242014000600245
865000900251002001300260035001000273801003000283#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a10v37n1.htm#S#c#183#23#article#25#3#^rND^sRutala^nWA#^rND^sGergen^nMF
#^rND^sWeber^nDJ#Disinfection of a probe used in ultrasound-guided prostate biop
sy^len#Infect Control Hosp Epidemiol#20070000#2007#28#916-9#20110200#a10v37n1.ht
m#0899-823X#Infect Control Hosp Epidemiol##
00513000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100016000780100023000940120
04700117030000800164065000900172064000500181031000300186014000600189865000900195
002001300204035001000217801000800227#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a1
0v37n1.htm#S#c#184#24#article#25#1#^rND^sMoran^nBJ#^rND^sBraccioforte^nMH#Stereo
tactic transperineal prostate biopsy^len#Urology#20090000#2009#73#386-8#20110200
#a10v37n1.htm#0090-4295#Urology##
00574000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100016000780100023000940100
02000117012007500137030000700212065000900219064000500228031000400233014000800237
865000900245002001300254035001000267801000700277#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a10v37n1.htm#S#c#185#25#article#25#2#^rND^sMoran^nBJ#^rND^sBracciofort
e^nMH#^rND^sConterato^nDJ#Re-biopsy of the prostate using a stereotactic transpe
rineal technique^len#J Urol#20060000#2006#176#1376-81#20110200#a10v37n1.htm#0022
-5347#J Urol##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#o#1#1#article#1
#20110330#144521#a11v37n1.htm#152##
03028000000000505000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000180011303100030013103200020013406500090013601400090014503500100015401201750
01640100028003390100029003670100032003960100038004280100030004660700066004960831
80400562085001002366085003102376085001902407085002602426085004802452117000602500
072000302506002001302509#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S
#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#11#IBJU010#nd#Int. braz j urol.#37#1
#20110200#^f87^l93#1677-5538#The implication of initial 24-core transrectal pros
tate biopsy protocol on the detection of significant prostate cancer and high gr
ade prostatic intraepithelial neoplasia^len#^rND^1A01^nMichael^sNomikos#^rND^1A0
1^nIoannis^sKaryotis#^rND^1A01^nProdromos^sPhillipou#^rND^1A01^nCharalambos^sCon
stadinides#^rND^1A01^nDimitrios^sDelakas#Asklepion Voula Hospital^iA01^1Vasilleo
s Paulou 1^cAthens^pGreece#^len^aPURPOSE: To assess the diagnostic value of an i
nitial 24-sample transrectal ultrasound guided (TRUS) prostate biopsy protocol c
ompared to the 10-core technique. MATERIALS AND METHODS: We retrospectively revi
ewed the prostate biopsy database of consecutive men undergoing prostate biopsie
s under local anesthesia by using the 10 (Group A) and 24 (Group B) protocols. M
en were stratified according to biopsy protocol and PSA levels. Exclusion criter
ia were age = 75 years and PSA &gt; 20 ng/mL. The Mann-Whitney U and Fisher's ex
act test were used for statistical analysis. RESULTS: Between April 2007 and Aug
ust 2009, 869 men underwent TRUS prostate biopsies of which 379 were eligible fo
r the study. Group A (10-cores) consisted of 243 (64.11%) men and group B (24-co
res) included 139 (35.89%) men. The overall prostate cancer detection rate was 3
9.09% and 34.55% in Group A and B, respectively (p = 0.43). An overall 9.8% incr
ease in Gleason 7 detection rate was found in Group B (p = 0.24). The high-grade
 prostatic intraepithelial neoplasia (HGPIN) detection rate in men with negative
 initial biopsies was 15.54% and 35.55% in Group A and B, respectively (p < 0.00
1). In patients with PSA < 10 ng/mL, the 24-core technique increased Gleason 7 d
etection rate by 13.4 % (p = 0.16) and HGPIN by 23.4% (p = 0.0008), compared to 
the 10 core technique. The 24-core technique increased the concordance between n
eedle biopsy and prostatectomy specimen compared to 10-core technique (p < 0.002
). CONCLUSIONS: The initial 24-core prostate biopsy protocol did not show any be
nefit in the detection of prostate cancer compared to the 10-core technique. How
ever, it improved the HGPIN detection and the correlation between biopsy results
 and radical prostatectomy Gleason score in men with lower PSA levels.#^ddecs^i1
#^tm^len^kprostatic neoplasm^i1#^tm^len^kbiopsy^i1#^tm^len^kGleason score^i1#^tm
^len^kprostatic intraepithelial neoplasia^i1#other#23#a11v37n1.htm##
03072000000000505000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000180011303100030013103200020013406500090013601400090014503500100015401201820
01640100028003460100029003740100032004030100038004350100030004730700066005030831
84100569085001002410085003102420085001902451085002602470085004802496117000602544
072000302550002001302553#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S
#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#11#IBJU010#nd#Int. braz j urol.#37#1
#20110200#^f87^l93#1677-5538#<b>The implication of initial 24-core transrectal p
rostate biopsy protocol on the detection of significant prostate cancer and high
 grade prostatic intraepithelial neoplasia</b>^len#^rND^1A01^nMichael^sNomikos#^
rND^1A01^nIoannis^sKaryotis#^rND^1A01^nProdromos^sPhillipou#^rND^1A01^nCharalamb
os^sConstadinides#^rND^1A01^nDimitrios^sDelakas#Asklepion Voula Hospital^iA01^1V
asilleos Paulou 1^cAthens^pGreece#^len^a<b>PURPOSE:</b> To assess the diagnostic
 value of an initial 24-sample transrectal ultrasound guided (TRUS) prostate bio
psy protocol compared to the 10-core technique. <b>MATERIALS AND METHODS:</b> We
 retrospectively reviewed the prostate biopsy database of consecutive men underg
oing prostate biopsies under local anesthesia by using the 10 (Group A) and 24 (
Group B) protocols. Men were stratified according to biopsy protocol and PSA lev
els. Exclusion criteria were age = 75 years and PSA &gt; 20 ng/mL. The Mann-Whit
ney U and Fisher's exact test were used for statistical analysis. <b>RESULTS:</b
> Between April 2007 and August 2009, 869 men underwent TRUS prostate biopsies o
f which 379 were eligible for the study. Group A (10-cores) consisted of 243 (64
.11%) men and group B (24-cores) included 139 (35.89%) men. The overall prostate
 cancer detection rate was 39.09% and 34.55% in Group A and B, respectively (p =
 0.43). An overall 9.8% increase in Gleason 7 detection rate was found in Group 
B (p = 0.24). The high-grade prostatic intraepithelial neoplasia (HGPIN) detecti
on rate in men with negative initial biopsies was 15.54% and 35.55% in Group A a
nd B, respectively (p &lt; 0.001). In patients with PSA &lt; 10 ng/mL, the 24-co
re technique increased Gleason 7 detection rate by 13.4 % (p = 0.16) and HGPIN b
y 23.4% (p = 0.0008), compared to the 10 core technique. The 24-core technique i
ncreased the concordance between needle biopsy and prostatectomy specimen compar
ed to 10-core technique (p &lt; 0.002). <b>CONCLUSIONS:</b> The initial 24-core 
prostate biopsy protocol did not show any benefit in the detection of prostate c
ancer compared to the 10-core technique. However, it improved the HGPIN detectio
n and the correlation between biopsy results and radical prostatectomy Gleason s
core in men with lower PSA levels.#^ddecs^i1#^tm^len^kprostatic neoplasm^i1#^tm^
len^kbiopsy^i1#^tm^len^kGleason score^i1#^tm^len^kprostatic intraepithelial neop
lasia^i1#other#23#a11v37n1.htm##
03223000000000529000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000300117049000800120
15800030012803000170013103100030014803200020015106500090015301400090016203500100
01710120175001810100028003560100029003840100032004130100038004450100030004830700
06800513083186700581085001002448085003102458085001902489085002602508085004802534
117000602582072000302588002001302591008008902604#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a11v37n1.htm#S#l#4#1#article#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#ilu
s#tab#11#IBJU010#nd#Int. braz j urol#37#1#20110200#^f87^l93#1677-5538#The implic
ation of initial 24-core transrectal prostate biopsy protocol on the detection o
f significant prostate cancer and high grade prostatic intraepithelial neoplasia
^len#^rND^1A01^nMichael^sNomikos#^rND^1A01^nIoannis^sKaryotis#^rND^1A01^nProdrom
os^sPhillipou#^rND^1A01^nCharalambos^sConstadinides#^rND^1A01^nDimitrios^sDelaka
s#^iA01^1Asklepion Voula Hospital^2Vasilleos Paulou 1^cAthens^pGreece#^len^aPURP
OSE: To assess the diagnostic value of an initial 24-sample transrectal ultrasou
nd guided (TRUS) prostate biopsy protocol compared to the 10-core technique. MAT
ERIALS AND METHODS: We retrospectively reviewed the prostate biopsy database of 
consecutive men undergoing prostate biopsies under local anesthesia by using the
 10 (Group A) and 24 (Group B) protocols. Men were stratified according to biops
y protocol and PSA levels. Exclusion criteria were age = 75 years and PSA &gt; 2
0 ng/mL. The Mann-Whitney U and Fisher's exact test were used for statistical an
alysis. RESULTS: Between April 2007 and August 2009, 869 men underwent TRUS pros
tate biopsies of which 379 were eligible for the study. Group A (10-cores) consi
sted of 243 (64.11 percent) men and group B (24-cores) included 139 (35.89 perce
nt) men. The overall prostate cancer detection rate was 39.09 percent and 34.55 
percent in Group A and B, respectively (p = 0.43). An overall 9.8 percent increa
se in Gleason 7 detection rate was found in Group B (p = 0.24). The high-grade p
rostatic intraepithelial neoplasia (HGPIN) detection rate in men with negative i
nitial biopsies was 15.54 percent and 35.55 percent in Group A and B, respective
ly (p < 0.001). In patients with PSA < 10 ng/mL, the 24-core technique increased
 Gleason 7 detection rate by 13.4  percent (p = 0.16) and HGPIN by 23.4 percent 
(p = 0.0008), compared to the 10 core technique. The 24-core technique increased
 the concordance between needle biopsy and prostatectomy specimen compared to 10
-core technique (p < 0.002). CONCLUSIONS: The initial 24-core prostate biopsy pr
otocol did not show any benefit in the detection of prostate cancer compared to 
the 10-core technique. However, it improved the HGPIN detection and the correlat
ion between biopsy results and radical prostatectomy Gleason score in men with l
ower PSA levels.#^ddecs^i1#^tm^len^kprostatic neoplasm^i1#^tm^len^kbiopsy^i1#^tm
^len^kGleason score^i1#^tm^len^kprostatic intraepithelial neoplasia^i1#other#23#
a11v37n1.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1
677-55382011000100011##
00356000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012300074002001300197#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#5#1#article#125#<p align="right"><fon
t face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>CLINICAL    UROLOGY</
b></font></p>     ^cY#a11v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#6#2#article#125#<p>&nbsp;</p>     ^cY
#a11v37n1.htm##
00517000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704028400074002001300358#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#7#3#article#125#<p><a name="top"></a>
<font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>The    implicatio
n of initial 24-core transrectal prostate biopsy protocol on the detection    of
 significant prostate cancer and high grade prostatic intraepithelial neoplasia<
/b></font></p>     ^cY#a11v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#8#4#article#125#<p>&nbsp;</p>     ^cY
#a11v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#9#5#article#125#<p>&nbsp;</p>     ^cY
#a11v37n1.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704019600075002001300271#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#10#6#article#125#<p><font face="Verda
na, Arial, Helvetica, sans-serif" size="2"><b>Michael    Nomikos; Ioannis Karyot
is; Prodromos Phillipou; Charalambos Constadinides; Dimitrios    Delakas</b></fo
nt></p>     ^cY#a11v37n1.htm##
00380000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704014600075002001300221#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#11#7#article#125#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Asklepion Voula    Hospital, Vasilleo
s Paulou 1, Athens, Greece</font></p>     ^cY#a11v37n1.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011600075002001300191#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#12#8#article#125#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#end">Correspondence</a></fo
nt></p>     ^cY#a11v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#13#9#article#125#<p>&nbsp;</p>     ^c
Y#a11v37n1.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#14#10#article#125#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a11v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#15#11#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#a
11v37n1.htm##
00479000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024400076002001300320#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#16#12#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>PURPOSE:</b>    To assess the dia
gnostic value of an initial 24-sample transrectal ultrasound    guided (TRUS) pr
ostate biopsy protocol compared to the 10-core technique.    ^cY#a11v37n1.htm##
00682000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044700076002001300523#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#17#13#article#125#<br>   <b>MATERIALS
 AND METHODS:</b> We retrospectively reviewed the prostate biopsy    database of
 consecutive men undergoing prostate biopsies under local anesthesia    by using
 the 10 (Group A) and 24 (Group B) protocols. Men were stratified according    t
o biopsy protocol and PSA levels. Exclusion criteria were age = 75 years and    
PSA &gt; 20 ng/mL. The Mann-Whitney U and Fisher's exact test were used for    s
tatistical analysis.    ^cY#a11v37n1.htm##
01216000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704098100076002001301057#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#18#14#article#125#<br>   <b>RESULTS:<
/b> Between April 2007 and August 2009, 869 men underwent TRUS prostate    biops
ies of which 379 were eligible for the study. Group A (10-cores) consisted    of
 243 (64.11%) men and group B (24-cores) included 139 (35.89%) men. The overall 
   prostate cancer detection rate was 39.09% and 34.55% in Group A and B, respec
tively    (p = 0.43). An overall 9.8% increase in Gleason 7 detection rate was f
ound in    Group B (p = 0.24). The high-grade prostatic intraepithelial neoplasi
a (HGPIN)    detection rate in men with negative initial biopsies was 15.54% and
 35.55% in    Group A and B, respectively (p &lt; 0.001). In patients with PSA &
lt; 10 ng/mL,    the 24-core technique increased Gleason 7 detection rate by 13.
4 % (p = 0.16)    and HGPIN by 23.4% (p = 0.0008), compared to the 10 core techn
ique. The 24-core    technique increased the concordance between needle biopsy a
nd prostatectomy    specimen compared to 10-core technique (p &lt; 0.002).    ^c
Y#a11v37n1.htm##
00631000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039600076002001300472#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#19#15#article#125#<br>   <b>CONCLUSIO
NS:</b> The initial 24-core prostate biopsy protocol did not show    any benefit
 in the detection of prostate cancer compared to the 10-core technique.    Howev
er, it improved the HGPIN detection and the correlation between biopsy    result
s and radical prostatectomy Gleason score in men with lower PSA levels.</font><f
ont face="Verdana, Arial, Helvetica, sans-serif">    ^cY#a11v37n1.htm##
00262000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002700076002001300103#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#20#16#article#125#<br>   </font></p> 
    ^cY#a11v37n1.htm##
00439000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020400076002001300280#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#21#17#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Key words:</b>    prostatic neopl
asm; biopsy; Gleason score; prostatic intraepithelial neoplasia</font></p> <HR s
ize="1" noshade>     ^cY#a11v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#22#18#article#125#<p>&nbsp;</p>     ^
cY#a11v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#23#19#article#125#<p>&nbsp;</p>     ^
cY#a11v37n1.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#24#20#article#125#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODUCTION</b></font></p>     ^
cY#a11v37n1.htm##
01148000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704091300076002001300989#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#25#21#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">As recommended    by Hodge et al. (1
), systematic transrectal ultrasound guided (TRUS) prostate    biopsies is the p
rincipal method of diagnosing prostate cancer. Several studies    have demonstra
ted that the traditional sextant technique may miss 15% - 31%    of cancers and 
additional sampling from the peripheral zone increases the diagnostic    yield o
f prostate biopsies (2-5). Although there is still a matter of debate    regardi
ng the optimal number of cores taken at the initial prostate biopsy,    several 
reports have shown that extended biopsy protocols involving &gt; 10-cores    hav
e improved the diagnostic accuracy of clinically significant prostate cancer    
especially in patients with bigger glands (6,7) and also improved the concordanc
e    of Gleason scores of needle biopsies and prostatectomy specimens (8).</font
></p>     ^cY#a11v37n1.htm##
00902000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704066700076002001300743#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#26#22#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The aim of the    present study was 
to evaluate the incidence of prostate cancer, high-grade prostatic    intraepith
elial neoplasia (HGPIN) and perineural infiltration rates in men who    had init
ial 24-core biopsies. The results were then compared with a similar    group of 
men who had an initial 10-core prostate biopsy protocol. Men were categorized   
 in different subgroups according to PSA levels. We also evaluated the ability  
  of the initial saturation biopsy scheme to improve the prediction of the radic
al    prostatectomy Gleason score compared to the 10-core technique.</font></p> 
    ^cY#a11v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#27#23#article#125#<p>&nbsp;</p>     ^
cY#a11v37n1.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011400076002001300190#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#28#24#article#125#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>MATERIALS AND    METHODS</b></fon
t></p>     ^cY#a11v37n1.htm##
01380000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704114500076002001301221#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#29#25#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> We retrospectively    reviewed the 
concurrently maintained database of consecutive men who underwent    TRUS prosta
te biopsies at one referral center. Indications for biopsy were abnormal    digi
tal rectal examination (DRE) and elevated age specific PSA levels. The 10    cor
es and saturation (24 cores) biopsy protocols were used as initial techniques   
 by two staff members of the department. We used a biplane 10 MHz transrectal   
 probe (Pro-Focus 2202 TM, BO-Medical, Denmark) with the capability of real time
    three-dimensional imaging. A 20 cm 18-gauge Chiba biopsy needle was used thr
ough    a Pro-Mag&#8482; automated ultra biopsy gun (Angiotech Vancouver, BC, Ca
nada).    Prostate biopsies were done with periprostatic nerve block by using 5 
mL 0.5%    marcaine mixed with 5 mL 1% lidocaine administered at the prostate ba
se where    the prostate sensory nerves enter the gland. One dose of ciprofloxac
in as standard    antibiotic prophylaxis was given to all patients prior to biop
sy and written    informed consent was obtained from all patients.</font></p>   
  ^cY#a11v37n1.htm##
00708000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047300076002001300549#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#30#26#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Men were categorized    in two group
s according to biopsy protocol and PSA levels. For group B (24 cores),    the fi
ve sectors biopsied on each side were lateral base (2), lateral mid-zone    (3),
 apex (3), parasagittal mid-zone (2) and parasagittal base (2), as shown    in <
a href="#fig1">Figure-1</a>. Men in group A (10 cores), had one biopsy core    o
btained from each of same sectors.</font></p>     ^cY#a11v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#31#27#article#125#<p>&nbsp;</p>     ^
cY#a11v37n1.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011200076002001300188#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#32#28#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a name="fig1" id="fig1"></a></font>
</p>     ^cY#a11v37n1.htm##
00372000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013700076002001300213#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#33#29#article#125#<p align="center"><
font face="Verdana, Arial, Helvetica, sans-serif"><img src="/img/revistas/ibju/v
37n1/a11fig1.jpg"></font></p>     ^cY#a11v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#34#30#article#125#<p>&nbsp;</p>     ^
cY#a11v37n1.htm##
00997000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076200076002001300838#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#35#31#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Men = 75 years    old, with PSA &lt;
 2.5 ng/mL and/or &gt; 20 ng/mL and those who were previously    biopsied , were
 excluded from analysis. Biopsy findings from both groups were    compared regar
ding prostate cancer and HGPIN detection rates. Repeat saturation    prostate bi
opsies were performed in 55 men from both groups with HGPIN in the    initial bi
opsy. The concordance of Gleason score in the needle biopsy and prostatectomy   
 specimens from both groups was also compared. Complications in both groups were
    recorded and compared. Results were analyzed using either the Mann-Whitney U
    test for continuous variables or Fisher's exact test for categorical variabl
es.</font></p>     ^cY#a11v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#36#32#article#125#<p>&nbsp;</p>     ^
cY#a11v37n1.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#37#33#article#125#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESULTS</b></font></p>     ^cY#a1
1v37n1.htm##
00791000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055600076002001300632#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#38#34#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Between April    2007 and August 20
09, 869 men were referred for TRUS needle prostate biopsies    to one referral c
enter. Overall, 379 men (clinical stage T1c, T2), were suitable    for analysis.
 Group A (10-cores) consisted of 243 (64.11%) men and group B (24-cores)    incl
uded 136 (35.89%) men. Both groups were comparable in terms of age, PSA    and p
rostate volumes. Patient's demographics are summarized in <a href="/img/revistas
/ibju/v37n1/a11tab1.jpg">Table-1</a>.</font></p>     ^cY#a11v37n1.htm##
01113000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087800076002001300954#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#39#35#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The overall prostate    cancer detec
tion rate was 39.09% and 34.55% in Group A and B respectively (p    = 0.43). <a 
href="/img/revistas/ibju/v37n1/a11tab2.jpg">Table-2</a> shows prostate cancer de
tection    rates according to biopsy protocol and PSA levels. An overall 9.8% in
crease    in Gleason 7 score was found in Group B compared to Group A (p = 0.24)
. There    was no difference in perineural infiltration rate between both groups
 (p = 0.79).    At a PSA range between 2.6 - 9.9 ng/mL, the 24-core technique sh
owed a non-statistically    significant increase in Gleason 7 detection rate com
pared to the 10-core technique    (p = 0.16). <a href="/img/revistas/ibju/v37n1/
a11tab3.jpg">Table-3</a> shows Gleason score detection    rates stratified accor
ding to biopsy protocol and PSA values.</font></p>     ^cY#a11v37n1.htm##
01069000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704083400076002001300910#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#40#36#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The overall HGPIN    detection rate 
in men with negative initial prostate biopsies was 15.54% and    35.55% in Group
 A and B, respectively (p &lt; 0.001). In Group B and at a PSA    range between 
2.6 - 9.9 ng/mL the overall HGPIN detection rate was increased    by 23.4% (p = 
0.0008), compared to Group A. Multifocal HGPIN detection was 8.7%    and 25.4% i
n group A and B, respectively (p &lt; 0.001). After a follow-up of    6 to 13 mo
nths, prostate cancer was subsequently detected in 8% and 74% at repeat    satur
ation biopsies of patients with isolated and multifocal HGPIN, respectively.    
<a href="/img/revistas/ibju/v37n1/a11tab4.jpg">Table-4</a> shows HGPIN detection
 rates at different    PSA levels stratified according to biopsy protocols.</fon
t></p>     ^cY#a11v37n1.htm##
01287000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704105200076002001301128#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#41#37#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Of the subset of    62 patients from
 both groups who underwent radical prostatectomy and were available    for analy
sis, 13.7% had clinically insignificant cancer (maximal tumor dimension    of 1.
0 cm or less, Gleason sum 6 or less and organ confined disease at radical    pro
statectomy). In men who underwent 10 core biopsies, the overall rate of Gleason 
   score upgrading after radical prostatectomy was 42.9% compared to 26.5% if 24
    cores were taken (p &lt; 0.002). No patients in the saturation needle biopsy
    group had a discrepancy of more than one Gleason unit in grade in the biopsy
    and surgical specimens. There were no differences in complication rates betw
een    both groups. Febrile urinary tract infections were recorded in three men 
from    Group-B and in two men from Group A. While rectal bleeding necessitating
 admission    was recorded in two men from Group B, there was no significant dif
ference in    patient discomfort between both groups.</font></p>     ^cY#a11v37n
1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#42#38#article#125#<p>&nbsp;</p>     ^
cY#a11v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#43#39#article#125#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>COMMENTS</b></font></p>     ^cY#a
11v37n1.htm##
01272000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704103700076002001301113#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#44#40#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Prostate cancer    screening has cu
rrently increased the importance of prostate biopsy in urological    practice an
d the detection of prostate cancer. Systemic transrectal needle biopsy    of the
 prostate is the standard practice to detect the clinical stage and grade    of 
disease, but controversy still exists about the optimal number of cores and    t
he significance of HGPIN on first biopsy and how the biopsy results will improve
    the prediction of the prostatectomy Gleason score. In a review study, Epstei
n    and Herawi recommended no repeat biopsies within the first year following t
he    diagnosis of HGPIN, because the 24% median risk of prostate cancer diagnos
is    following detection of HGPIN was not higher than that of initial biopsy wi
th    benign disease (9). In our study, it was not the presence but the multifoc
ality    of HGPIN which was the strongest predisposing factor for detecting pros
tate    cancer in a subsequent biopsy.</font></p>     ^cY#a11v37n1.htm##
00804000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056900076002001300645#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#45#41#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Presti (10) reviewed    several stud
ies evaluating several biopsy schemes and suggested that 10-12 core    technique
 is optimal for most men undergoing initial prostate biopsy. Nesrallah    et al.
 concluded that extended biopsy, with 14 cores, could improve prostate    cancer
 detection rate compared to the sextant technique (11). Jones et al. noted,    a
lthough in a small number of patients, that the 24 core technique as an initial 
   strategy did not improve cancer detection (12).</font></p>     ^cY#a11v37n1.h
tm##
01073000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704083800076002001300914#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#46#42#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">While many studies    show that satu
ration biopsy improves prostate cancer detection in patients with    suspicious 
findings in a first negative biopsy, it does not seem to increase    the cancer 
detection rate as an initial technique. Our findings are in agreement    with th
ese reports, as the 24 core initial biopsy technique did not improve    the over
all prostate cancer detection rate compared to the 10-core technique.    In our 
study, men with PSA &lt; 10 ng/mL who received an initial 24-core biopsy    did 
not have a statistically significant increase in Gleason 7 detection rate    whe
n compared to 10 core protocol at the same PSA level. Furthermore, there    was 
no difference in Gleason 8 and 9 detection rates between both biopsy protocols.<
/font></p>     ^cY#a11v37n1.htm##
00846000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061100076002001300687#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#47#43#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Scattoni et al.    also showed that 
the 18 core technique as an initial strategy demonstrated a    higher cancer det
ection rate, although not statistically significant, than the    12 core protoco
l in men with PSA &lt; 10 ng/mL, but they did not find any difference    in the 
Gleason score (13). In a recent study, Scattoni et al. showed that both    the n
umber and site of cores have a great impact on prostate cancer detection    and 
concluded that cancer detection rates increased with the increasing number    of
 cores (14).</font></p>     ^cY#a11v37n1.htm##
00648000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041300076002001300489#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#48#44#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">There are only    few reports in the
 literature that address the influence of increased biopsy    sampling on the de
tection rate of HGPIN and the cancer risk associated with    it in subsequent bi
opsies. Epstein et al. report no relationship between the    number of cores sam
pled and the incidence of HGPIN in needle biopsy (15).</font></p>     ^cY#a11v37
n1.htm##
00306000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007100076002001300147#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#49#45#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">    ^cY#a11v37n1.htm##
00546000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031100076002001300387#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#50#46#article#125#<br>   However, Sch
oenfield et al. found an incidence of 22% in HGPIN on the first    saturation bi
opsy. This finding was confirmed in our study, where the HGPIN    detection rate
 of 35.55% in men who had initial saturation biopsies was one    of the highest 
reported in the literature (16).</font></p>     ^cY#a11v37n1.htm##
01077000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084200076002001300918#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#51#47#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Several studies    have reported var
ying results for the positive predictive value of HGPIN as    a single finding f
or prostate cancer detection in subsequent biopsies (17,18).    In the present s
tudy, the cancer detection rate was significantly higher in    patients with mul
tifocal HGPIN in the initial biopsy, than in those with unifocal    HGPIN (p = 0
.001). The majority of patients (78%) with multifocal HGPIN on initial    satura
tion biopsy were diagnosed with prostate cancer on repeat saturation biopsy,    
of which 11.8% had clinically insignificant cancer in prostatectomy specimens.  
  These findings have been confirmed by other studies where multifocality of HGP
IN    is an independent risk factor of prostate cancer in subsequent biopsies (1
9).</font></p>     ^cY#a11v37n1.htm##
01082000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084700076002001300923#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#52#48#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Recently, few reports    have proved
 that the extended prostate biopsy scheme when compared to the sextant    techni
que, significantly improves the correlation between needle biopsy and    prostat
ectomy Gleason score, and reduces the risk of upgrading to a worse Gleason    gr
oup at prostatectomy (20,21). In our study, Gleason score upgrading was signific
antly    higher in the 10-core protocol when compared to the saturation techniqu
e. This    finding is important since most prostate cancer cases are now detecte
d at an    early stage and at a low PSA level. Leite et al. also, showed that ex
tended    prostate biopsies in men with PSA &lt; 4 ng/mL increased the accuracy 
in tumor    volume, Gleason score and stage, when comparing with higher PSA valu
es (22).</font></p>     ^cY#a11v37n1.htm##
00906000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067100076002001300747#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#53#49#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">No difference in    the detection of
 clinically insignificant cancer in radical prostatectomy specimens    was obser
ved between both biopsy protocols. In addition to its interesting results,    th
e present study presents some limitations with the most obvious being that    we
 do not know how many cancers were missed with either the 24 or 10 core techniqu
e.    Thus, our study is influenced by verification bias because we cannot defin
e    the real diagnostic accuracy of our biopsy schemes. Another limitation is t
hat    this study is a retrospective audit with a non randomized design.</font><
/p>     ^cY#a11v37n1.htm##
00752000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051700076002001300593#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#54#50#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The present study    did not show a 
real benefit for the saturation biopsy protocol as an initial    technique for t
he detection of prostate cancer. However, it did show that an    initial 24-core
 technique increased the detection of multifocal HGPIN and improved    the conco
rdance of Gleason grading between needle biopsy and radical prostatectomy    spe
cimen, which is crucial in therapeutic decision-making based on needle biopsy.</
font></p>     ^cY#a11v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#55#51#article#125#<p>&nbsp;</p>     ^
cY#a11v37n1.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010100076002001300177#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#56#52#article#125#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUSIONS</b></font></p>     ^c
Y#a11v37n1.htm##
01307000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704107200076002001301148#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#57#53#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Our findings add    to the growing 
evidence in the literature that an initial saturation (24-core)    prostate biop
sy protocol does not improve the overall cancer detection rate    compared to th
e 10-core technique. Although 24-core prostate biopsy technique    improved the 
sensitivity of HGPIN detection especially in men with PSA levels    less than 10
 ng/mL, it cannot be justified as the standard initial biopsy technique.    Pati
ents with multifocal HGPIN on initial saturation biopsy certainly warrant    rep
eat saturation biopsy since the great majority of them will be later diagnosed  
  with prostate cancer. Given the fact of its safety profile, the 24-core prosta
te    biopsy protocol could probably be proposed as the initial technique for a 
selected    group of patients, such as younger men with lower PSA levels who are
 candidates    for curative treatment, or younger patients who have opted for ac
tive surveillance.    Further studies are certainly needed in this field.</font>
</p>     ^cY#a11v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#58#54#article#125#<p>&nbsp;</p>     ^
cY#a11v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#59#55#article#125#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONFLICT OF    INTEREST</b></font
></p>     ^cY#a11v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#60#56#article#125#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> None declared.</font></p>     ^cY#a
11v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#61#57#article#125#<p>&nbsp;</p>     ^
cY#a11v37n1.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#62#58#article#125#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFERENCES</b></font></p>     ^cY
#a11v37n1.htm##
00512000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026300078002001300341#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#63#59#article#125#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 1. Hodge KK, McNeal  
  JE, Terris MK, Stamey TA: Random systematic versus directed ultrasound guided 
   transrectal core biopsies of the prostate. J Urol. 1989; 142: 71-4; discussio
n    74-5.    ^cY#a11v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#64#60#article#125#</font> </p>     ^c
Y#a11v37n1.htm##
00470000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022100078002001300299#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#65#61#article#125#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Epstein JI,    Wals
h PC, Carter HB: Importance of posterolateral needle biopsies in the detection  
  of prostate cancer. Urology. 2001; 57: 1112-6.    ^cY#a11v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#66#62#article#125#</font></p>     ^cY
#a11v37n1.htm##
00521000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027200078002001300350#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#67#63#article#125#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Epstein JI,    Leck
sell K, Carter HB: Prostate cancer sampled on sextant needle biopsy: significanc
e    of cancer on multiple cores from different areas of the prostate. Urology. 
1999;    54: 291-4.    ^cY#a11v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#68#64#article#125#</font></p>     ^cY
#a11v37n1.htm##
00596000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704034700078002001300425#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#69#65#article#125#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Miyake H, Sakai    
I, Harada K, Hara I, Eto H: Increased detection of clinically significant prosta
te    cancer by additional sampling from the anterior lateral horns of the perip
heral    zone in combination with the standard sextant biopsy. Int J Urol. 2004;
 11:    402-6.    ^cY#a11v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#70#66#article#125#</font></p>     ^cY
#a11v37n1.htm##
00579000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704033000078002001300408#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#71#67#article#125#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Eskicorapci    SY, 
Baydar DE, Akbal C, Sofikerim M, G&uuml;nay M, Ekici S, et al.: An extended    1
0-core transrectal ultrasonography guided prostate biopsy protocol improves    t
he detection of prostate cancer. Eur Urol. 2004; 45: 444-8; discussion 448-9.   
 ^cY#a11v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#72#68#article#125#</font></p>     ^cY
#a11v37n1.htm##
00562000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704031300078002001300391#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#73#69#article#125#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Ficarra V, Novella 
   G, Novara G, Galfano A, Pea M, Martignoni G, et al.: The potential impact of 
   prostate volume in the planning of optimal number of cores in the systematic 
   transperineal prostate biopsy. Eur Urol. 2005; 48: 932-7.    ^cY#a11v37n1.htm
##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#74#70#article#125#</font></p>     ^cY
#a11v37n1.htm##
00571000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704032200078002001300400#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#75#71#article#125#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Inahara M, Suzuki  
  H, Kojima S, Komiya A, Fukasawa S, Imamoto T, et al.: Improved prostate cancer
    detection using systematic 14-core biopsy for large prostate glands with nor
mal    digital rectal examination findings. Urology. 2006; 68: 815-9.    ^cY#a11
v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#76#72#article#125#</font></p>     ^cY
#a11v37n1.htm##
00545000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029600078002001300374#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#77#73#article#125#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. San Francisco    IF
, DeWolf WC, Rosen S, Upton M, Olumi AF: Extended prostate needle biopsy improve
s    concordance of Gleason grading between prostate needle biopsy and radical p
rostatectomy.    J Urol. 2003; 169: 136-40.    ^cY#a11v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#78#74#article#125#</font></p>     ^cY
#a11v37n1.htm##
00526000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027700078002001300355#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#79#75#article#125#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Epstein JI,    Hera
wi M: Prostate needle biopsies containing prostatic intraepithelial neoplasia   
 or atypical foci suspicious for carcinoma: implications for patient care. J    
Urol. 2006; 175: 820-34.    ^cY#a11v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#80#76#article#125#</font></p>     ^cY
#a11v37n1.htm##
00407000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704015700079002001300236#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#81#77#article#125#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Presti JC Jr:    
Prostate biopsy strategies. Nat Clin Pract Urol. 2007; 4: 505-11.    ^cY#a11v37n
1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#82#78#article#125#</font></p>     ^cY
#a11v37n1.htm##
00548000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704029800079002001300377#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#83#79#article#125#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Nesrallah L,    N
esrallah A, Antunes AA, Leite KR, Srougi M: The role of extended prostate biopsy
    on prostate cancer detection rate: a study performed on the bench. Int Braz 
   J Urol. 2008; 34: 563-70; discussion 570-1.    ^cY#a11v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#84#80#article#125#</font></p>     ^cY
#a11v37n1.htm##
00526000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704027600079002001300355#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#85#81#article#125#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Jones JS, Patel  
  A, Schoenfield L, Rabets JC, Zippe CD, Magi-Galluzzi C: Saturation technique  
  does not improve cancer detection as an initial prostate biopsy strategy. J   
 Urol. 2006; 175: 485-8.    ^cY#a11v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#86#82#article#125#</font></p>     ^cY
#a11v37n1.htm##
00567000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704031700079002001300396#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#87#83#article#125#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Scattoni V,    Ro
scigno M, Raber M, Deh&ograve; F, Maga T, Zanoni M, et al.: Initial extended    
transrectal prostate biopsy--are more prostate cancers detected with 18 cores   
 than with 12 cores? J Urol. 2008; 179: 1327-31; discussion 1331.    ^cY#a11v37n
1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#88#84#article#125#</font></p>     ^cY
#a11v37n1.htm##
00549000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704029900079002001300378#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#89#85#article#125#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Scattoni V,    Ra
ber M, Abdollah F, Roscigno M, Deh&ograve; F, Angiolilli D, et al.: Biopsy    sc
hemes with the fewest cores for detecting 95% of the prostate cancers detected  
  by a 24-core biopsy. Eur Urol. 2010; 57: 1-8.    ^cY#a11v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#90#86#article#125#</font></p>     ^cY
#a11v37n1.htm##
00508000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704025800079002001300337#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#91#87#article#125#15#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Epstein JI,    Po
tter SR: The pathological interpretation and significance of prostate needle    
biopsy findings: implications and current controversies. J Urol. 2001; 166:    4
02-10.    ^cY#a11v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#92#88#article#125#</font></p>     ^cY
#a11v37n1.htm##
00567000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704031700079002001300396#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#93#89#article#125#16#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Moore CK, Karikeh
alli    S, Nazeer T, Fisher HA, Kaufman RP Jr, Mian BM: Prognostic significance 
of high    grade prostatic intraepithelial neoplasia and atypical small acinar p
roliferation    in the contemporary era. J Urol. 2005; 173: 70-2.    ^cY#a11v37n
1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#94#90#article#125#</font></p>     ^cY
#a11v37n1.htm##
00524000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704027400079002001300353#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#95#91#article#125#17#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Naya Y, Ayala    
AG, Tamboli P, Babaian RJ: Can the number of cores with high-grade prostate    i
ntraepithelial neoplasia predict cancer in men who undergo repeat biopsy? Urolog
y.    2004; 63: 503-8.    ^cY#a11v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#96#92#article#125#</font></p>     ^cY
#a11v37n1.htm##
00574000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704032400079002001300403#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#97#93#article#125#18#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Herawi M, Kahane 
   H, Cavallo C, Epstein JI: Risk of prostate cancer on first re-biopsy within  
  1 year following a diagnosis of high grade prostatic intraepithelial neoplasia
    is related to the number of cores sampled. J Urol. 2006; 175: 121-4.    ^cY#
a11v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#98#94#article#125#</font></p>     ^cY
#a11v37n1.htm##
00618000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704036800079002001300447#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#99#95#article#125#19#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Schoenfield    L,
 Jones JS, Zippe CD, Reuther AM, Klein E, Zhou M, et al.: The incidence of    hi
gh-grade prostatic intraepithelial neoplasia and atypical glands suspicious    f
or carcinoma on first-time saturation needle biopsy, and the subsequent risk    
of cancer. BJU Int. 2007; 99: 770-4.    ^cY#a11v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#100#96#article#125#</font></p>     ^c
Y#a11v37n1.htm##
00503000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704025200080002001300332#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#101#97#article#125#20#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Mian BM, Lehr   
 DJ, Moore CK, Fisher HA, Kaufman RP Jr, Ross JS, et al.: Role of prostate biops
y    schemes in accurate prediction of Gleason scores. Urology. 2006; 67: 379-83
.    ^cY#a11v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#102#98#article#125#</font></p>     ^c
Y#a11v37n1.htm##
00579000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704032800080002001300408#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#103#99#article#125#21#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Mallick S,    Co
moz F, Le Toquin S, Fouques Y, Jeanne-Pasquier C, Rousselot P, Bensadoun H:    C
an the prostate cancer detection rate be improved with a saturation technique   
 of prostate biopsy? Urology 2007; 70(Suppl 1): 300-01. # Abstract POS-03.91.   
 ^cY#a11v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#104#100#article#125#</font></p>     ^
cY#a11v37n1.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028100081002001300362#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#105#101#article#125#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Leite KR, Sroug
i    M, Dall'Oglio MF, Sanudo A, Camara-Lopes LH: Histopathological findings in 
extended    prostate biopsy with PSA &lt; or = 4 ng/mL. Int Braz J Urol. 2008; 3
4: 283-90;    discussion 290-2.    ^cY#a11v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#106#102#article#125#</font></p>     ^
cY#a11v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#107#103#article#125#<p>&nbsp;</p>    
 ^cY#a11v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#108#104#article#125#<p>&nbsp;</p>    
 ^cY#a11v37n1.htm##
00366000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012900078002001300207#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#109#105#article#125#<p><font face="Ve
rdana, Arial, Helvetica, sans-serif" size="2"><i>Accepted after    revision: May
 7, 2010</i></font></p>     ^cY#a11v37n1.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019300078002001300271#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#110#106#article#125#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><b><a name="end"></a><a href="#top
"><img src="/img/revistas/ibju/v37n1/seta.gif" border="0"></a>    Correspondence
 to</b>:    ^cY#a11v37n1.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#111#107#article#125#<br>   Dr. Michae
l Nomikos    ^cY#a11v37n1.htm##
00276000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003900078002001300117#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#112#108#article#125#<br>   Asklepion 
Voula Hospital    ^cY#a11v37n1.htm##
00274000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003700078002001300115#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#113#109#article#125#<br>   Knossou 27
5, Heraklion    ^cY#a11v37n1.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003500078002001300113#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#114#110#article#125#<br>   Crete, 714
09, Greece    ^cY#a11v37n1.htm##
00274000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003700078002001300115#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#115#111#article#125#<br>   Fax: + 30 
28 1036-8083    ^cY#a11v37n1.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009300078002001300171#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#116#112#article#125#<br>   E-mail: <a
 href="mailto:mnomikos@gmail.com">mnomikos@gmail.com</a></font></p>     ^cY#a11v
37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#117#113#article#125#<p>&nbsp;</p>    
 ^cY#a11v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#118#114#article#125#<p>&nbsp;</p>    
 ^cY#a11v37n1.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010700078002001300185#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#119#115#article#125#<p><font size="3"
 face="Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL COMMENT</b></font></p
>     ^cY#a11v37n1.htm##
01443000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704120600078002001301284#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#120#116#article#125#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> The search continues    for the o
ptimal number of prostate biopsies to maximize clinical utility while    minimiz
ing complications. The authors reported on a non-randomized group of    379 men 
who underwent transrectal prostate biopsy using either a 10 or 24-core    techni
que. No increased complications were reported with the saturation technique.    
The detection of prostate cancer (including Gleason grade 7) was not statistical
ly    different between the two groups while HGPIN was increased. A prior thorou
gh    review publication (1) reported a median risk recorded in the literature f
or    cancer following the diagnosis of HGPIN on needle biopsy is 24.1%, which i
s    not much higher than the general population and recommended against rebiops
y    based solely on HGPIN. The authors in the current study report improved con
cordance    between biopsy and prostatectomy specimens when more biopsies were t
aken. In    the face of no increased cancer detection, the urologist must balanc
e the impact    of potential increased complications, time, and patient discomfo
rt when deciding    on prostate biopsy technique.</font></p>     ^cY#a11v37n1.ht
m##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#121#117#article#125#<p>&nbsp;</p>    
 ^cY#a11v37n1.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009900078002001300177#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#122#118#article#125#<p><font size="3"
 face="Verdana, Arial, Helvetica, sans-serif"><b>REFERENCE</b></font></p>     ^c
Y#a11v37n1.htm##
00529000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027700081002001300358#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#123#119#article#125#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Epstein JI,    H
erawi M: Prostate needle biopsies containing prostatic intraepithelial neoplasia
    or atypical foci suspicious for carcinoma: implications for patient care. J 
   Urol. 2006; 175: 820-34.    ^cY#a11v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#124#120#article#125#</font></p>     ^
cY#a11v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#125#121#article#125#<p>&nbsp;</p>    
 ^cY#a11v37n1.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011600078002001300194#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#126#122#article#125#<p align="right">
<font size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Dr.    Kenneth
 Nepple</b>    ^cY#a11v37n1.htm##
00292000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005500078002001300133#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#127#123#article#125#<br>   University
 of Iowa Hospitals and Clinics    ^cY#a11v37n1.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003500078002001300113#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#128#124#article#125#<br>   Iowa City,
 Iowa, USA    ^cY#a11v37n1.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010900078002001300187#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a11v37n1.htm#S#p#129#125#article#125#<br>   E-mail: <a
 href="mailto:kenneth-nepple@uiowa.edu">kenneth-nepple@uiowa.edu</a></i></font><
/p>     ^cY#a11v37n1.htm##
00613000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100017000930100
01700110010001700127012009800144030000700242065000900249064000500258031000400263
014000500267865000900272002001300281035001000294801000700304#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a11v37n1.htm#S#c#130#1#article#23#1#^rND^sHodge^nKK#^rND^s
McNeal^nJE#^rND^sTerris^nMK#^rND^sStamey^nTA#Random systematic versus directed u
ltrasound guided transrectal core biopsies of the prostate^len#J Urol#19890000#1
989#142#71-4#20110200#a11v37n1.htm#0022-5347#J Urol##
00575000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100016000950100
01700111012008500128030000800213065000900221064000500230031000300235014000700238
865000900245002001300254035001000267801000800277#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a11v37n1.htm#S#c#131#2#article#23#2#^rND^sEpstein^nJI#^rND^sWalsh^nPC#
^rND^sCarter^nHB#Importance of posterolateral needle biopsies in the detection o
f prostate cancer^len#Urology#20010000#2001#57#1112-6#20110200#a11v37n1.htm#0090
-4295#Urology##
00623000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100018000950100
01700113012013200130030000800262065000900270064000500279031000300284014000600287
865000900293002001300302035001000315801000800325#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a11v37n1.htm#S#c#132#3#article#23#3#^rND^sEpstein^nJI#^rND^sLecksell^n
K#^rND^sCarter^nHB#Prostate cancer sampled on sextant needle biopsy: significanc
e of cancer on multiple cores from different areas of the prostate^len#Urology#1
9990000#1999#54#291-4#20110200#a11v37n1.htm#0090-4295#Urology##
00734000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100015000930100
01600108010001400124010001300138012019200151030001100343065000900354064000500363
031000300368014000600371865000900377002001300386035001000399801001100409#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#c#133#4#article#23#4#^rND^sMiya
ke^nH#^rND^sSakai^nI#^rND^sHarada^nK#^rND^sHara^nI#^rND^sEto^nH#Increased detect
ion of clinically significant prostate cancer by additional sampling from the an
terior lateral horns of the peripheral zone in combination with the standard sex
tant biopsy^len#Int J Urol#20040000#2004#11#402-6#20110200#a11v37n1.htm#0919-817
2#Int J Urol##
00723000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100022000770100017000990100
01500116010001900131010001500150010001500165810000600180012012600186030000900312
06500090032106400050033003100030033501400060033886500090034400200130035303500100
0366801000900376#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#c#134#5
#article#23#5#^rND^sEskicorapci^nSY#^rND^sBaydar^nDE#^rND^sAkbal^nC#^rND^sSofike
rim^nM#^rND^sGünay^nM#^rND^sEkici^nS#et al#An extended 10-core transrectal ultra
sonography guided prostate biopsy protocol improves the detection of prostate ca
ncer^len#Eur Urol#20040000#2004#45#444-8#20110200#a11v37n1.htm#0302-2838#Eur Uro
l##
00729000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100017000940100
01600111010001700127010001300144010002000157810000600177012013500183030000900318
06500090032706400050033603100030034101400060034486500090035000200130035903500100
0372801000900382#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#c#135#6
#article#23#6#^rND^sFicarra^nV#^rND^sNovella^nG#^rND^sNovara^nG#^rND^sGalfano^nA
#^rND^sPea^nM#^rND^sMartignoni^nG#et al#The potential impact of prostate volume 
in the planning of optimal number of cores in the systematic transperineal prost
ate biopsy^len#Eur Urol#20050000#2005#48#932-7#20110200#a11v37n1.htm#0302-2838#E
ur Urol##
00737000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100016000940100
01600110010001600126010001800142010001700160810000600177012014500183030000800328
06500090033606400050034503100030035001400060035386500090035900200130036803500100
0381801000800391#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#c#136#7
#article#23#7#^rND^sInahara^nM#^rND^sSuzuki^nH#^rND^sKojima^nS#^rND^sKomiya^nA#^
rND^sFukasawa^nS#^rND^sImamoto^nT#et al#Improved prostate cancer detection using
 systematic 14-core biopsy for large prostate glands with normal digital rectal 
examination findings^len#Urology#20060000#2006#68#815-9#20110200#a11v37n1.htm#00
90-4295#Urology##
00682000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100024000770100017001010100
01500118010001500133010001600148012013300164030000700297065000900304064000500313
031000400318014000700322865000900329002001300338035001000351801000700361#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#c#137#8#article#23#8#^rND^sSan 
Francisco^nIF#^rND^sDeWolf^nWC#^rND^sRosen^nS#^rND^sUpton^nM#^rND^sOlumi^nAF#Ext
ended prostate needle biopsy improves concordance of Gleason grading between pro
state needle biopsy and radical prostatectomy^len#J Urol#20030000#2003#169#136-4
0#20110200#a11v37n1.htm#0022-5347#J Urol##
00609000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100016000950120
14900111030000700260065000900267064000500276031000400281014000700285865000900292
002001300301035001000314801000700324#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a1
1v37n1.htm#S#c#138#9#article#23#9#^rND^sEpstein^nJI#^rND^sHerawi^nM#Prostate nee
dle biopsies containing prostatic intraepithelial neoplasia or atypical foci sus
picious for carcinoma: implications for patient care^len#J Urol#20060000#2006#17
5#820-34#20110200#a11v37n1.htm#0022-5347#J Urol##
00451000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790120031000990300
02000130710000200150065000900152064000500161031000200166014000700168865000900175
002001300184#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#c#139#10#ar
ticle#23#10#^rND^sPresti^nJC Jr#Prostate biopsy strategies^len#Nat Clin Pract Ur
ol#2#20070000#2007#4#505-11#20110200#a11v37n1.htm##
00640000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100019000980100
01800117010001600135010001600151012010700167030001600274710000200290065000900292
064000500301031000300306014000700309865000900316002001300325#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a11v37n1.htm#S#c#140#11#article#23#11#^rND^sNesrallah^nL#^
rND^sNesrallah^nA#^rND^sAntunes^nAA#^rND^sLeite^nKR#^rND^sSrougi^nM#The role of 
extended prostate biopsy on prostate cancer detection rate: a study performed on
 the bench^len#Int Braz J Urol#2#20080000#2008#34#563-70#20110200#a11v37n1.htm##
00681000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
02100110010001700131010001600148010002300164012009800187030000700285065000900292
06400050030103100040030601400060031086500090031600200130032503500100033880100070
0348#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#c#141#12#article#23
#12#^rND^sJones^nJS#^rND^sPatel^nA#^rND^sSchoenfield^nL#^rND^sRabets^nJC#^rND^sZ
ippe^nCD#^rND^sMagi-Galluzzi^nC#Saturation technique does not improve cancer det
ection as an initial prostate biopsy strategy^len#J Urol#20060000#2006#175#485-8
#20110200#a11v37n1.htm#0022-5347#J Urol##
00709000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970100
01500115010001400130010001400144010001600158810000600174012011900180030000700299
06500090030606400050031503100040032001400080032486500090033200200130034103500100
0354801000700364#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#c#142#1
3#article#23#13#^rND^sScattoni^nV#^rND^sRoscigno^nM#^rND^sRaber^nM#^rND^sDehò^nF
#^rND^sMaga^nT#^rND^sZanoni^nM#et al#Initial extended transrectal prostate biops
y--are more prostate cancers detected with 18 cores than with 12 cores?^len#J Ur
ol#20080000#2008#179#1327-31#20110200#a11v37n1.htm#0022-5347#J Urol##
00709000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100015000970100
01800112010001800130010001400148010002000162810000600182012011200188030000900300
06500090030906400050031803100030032301400040032686500090033000200130033903500100
0352801000900362#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#c#143#1
4#article#23#14#^rND^sScattoni^nV#^rND^sRaber^nM#^rND^sAbdollah^nF#^rND^sRoscign
o^nM#^rND^sDehò^nF#^rND^sAngiolilli^nD#et al#Biopsy schemes with the fewest core
s for detecting 95% of the prostate cancers detected by a 24-core biopsy^len#Eur
 Urol#20100000#2010#57#1-8#20110200#a11v37n1.htm#0302-2838#Eur Urol##
00591000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970120
12800114030000700242065000900249064000500258031000400263014000700267865000900274
002001300283035001000296801000700306#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a1
1v37n1.htm#S#c#144#15#article#23#15#^rND^sEpstein^nJI#^rND^sPotter^nSR#The patho
logical interpretation and significance of prostate needle biopsy findings: impl
ications and current controversies^len#J Urol#20010000#2001#166#402-10#20110200#
a11v37n1.htm#0022-5347#J Urol##
00722000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100021000950100
01600116010001700132010002100149010001500170012014200185030000700327065000900334
06400050034303100040034801400050035286500090035700200130036603500100037980100070
0389#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#c#145#16#article#23
#16#^rND^sMoore^nCK#^rND^sKarikehalli^nS#^rND^sNazeer^nT#^rND^sFisher^nHA#^rND^s
Kaufman^nRP Jr#^rND^sMian^nBM#Prognostic significance of high grade prostatic in
traepithelial neoplasia and atypical small acinar proliferation in the contempor
ary era^len#J Urol#20050000#2005#173#70-2#20110200#a11v37n1.htm#0022-5347#J Urol
##
00645000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100016000930100
01700109010001800126012012800144030000800272065000900280064000500289031000300294
014000600297865000900303002001300312035001000325801000800335#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a11v37n1.htm#S#c#146#17#article#23#17#^rND^sNaya^nY#^rND^s
Ayala^nAG#^rND^sTamboli^nP#^rND^sBabaian^nRJ#Can the number of cores with high-g
rade prostate intraepithelial neoplasia predict cancer in men who undergo repeat
 biopsy?^len#Urology#20040000#2004#63#503-8#20110200#a11v37n1.htm#0090-4295#Urol
ogy##
00693000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01700111010001800128012017500146030000700321065000900328064000500337031000400342
014000600346865000900352002001300361035001000374801000700384#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a11v37n1.htm#S#c#147#18#article#23#18#^rND^sHerawi^nM#^rND
^sKahane^nH#^rND^sCavallo^nC#^rND^sEpstein^nJI#Risk of prostate cancer on first 
re-biopsy within 1 year following a diagnosis of high grade prostatic intraepith
elial neoplasia is related to the number of cores sampled^len#J Urol#20060000#20
06#175#121-4#20110200#a11v37n1.htm#0022-5347#J Urol##
00753000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100016001000100
01600116010001800132010001500150010001400165810000600179012018700185030000800372
71000020038006500090038206400050039103100030039601400060039986500090040500200130
0414#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#c#148#19#article#23
#19#^rND^sSchoenfield^nL#^rND^sJones^nJS#^rND^sZippe^nCD#^rND^sReuther^nAM#^rND^
sKlein^nE#^rND^sZhou^nM#et al#The incidence of high-grade prostatic intraepithel
ial neoplasia and atypical glands suspicious for carcinoma on first-time saturat
ion needle biopsy, and the subsequent risk of cancer^len#BJU Int#2#20070000#2007
#99#770-4#20110200#a11v37n1.htm##
00671000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100015000940100
01600109010001700125010002100142010001500163810000600178012007700184030000800261
06500090026906400050027803100030028301400070028686500090029300200130030203500100
0315801000800325#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.htm#S#c#149#2
0#article#23#20#^rND^sMian^nBM#^rND^sLehr^nDJ#^rND^sMoore^nCK#^rND^sFisher^nHA#^
rND^sKaufman^nRP Jr#^rND^sRoss^nJS#et al#Role of prostate biopsy schemes in accu
rate prediction of Gleason scores^len#Urology#20060000#2006#67#379-83#20110200#a
11v37n1.htm#0090-4295#Urology##
00739000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960100
01900111010001700130010002500147010001900172010001900191012010300210030000800313
06500090032106400050033003100030033503200040033801400070034286500090034900200130
0358035001000371801000800381#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a11v37n1.h
tm#S#c#150#21#article#23#21#^rND^sMallick^nS#^rND^sComoz^nF#^rND^sLe Toquin^nS#^
rND^sFouques^nY#^rND^sJeanne-Pasquier^nC#^rND^sRousselot^nP#^rND^sBensadoun^nH#C
an the prostate cancer detection rate be improved with a saturation technique of
 prostate biopsy?^len#Urology#20070000#2007#70#^s1#300-01#20110200#a11v37n1.htm#
0090-4295#Urology##
00620000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
02100111010001600132010002300148012008300171030001600254710000200270065000900272
064000500281031000300286014000700289865000900296002001300305#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a11v37n1.htm#S#c#151#22#article#23#22#^rND^sLeite^nKR#^rND
^sSrougi^nM#^rND^sDall'Oglio^nMF#^rND^sSanudo^nA#^rND^sCamara-Lopes^nLH#Histopat
hological findings in extended prostate biopsy with PSA < or = 4 ng/mL^len#Int B
raz J Urol#2#20080000#2008#34#283-90#20110200#a11v37n1.htm##
00610000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100018000780100016000960120
14900112030000700261065000900268064000500277031000400282014000700286865000900293
002001300302035001000315801000700325#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a1
1v37n1.htm#S#c#152#23#article#23#1#^rND^sEpstein^nJI#^rND^sHerawi^nM#Prostate ne
edle biopsies containing prostatic intraepithelial neoplasia or atypical foci su
spicious for carcinoma: implications for patient care^len#J Urol#20060000#2006#1
75#820-34#20110200#a11v37n1.htm#0022-5347#J Urol##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#o#1#1#article#1
#20110330#144523#a12v37n1.htm#128##
02191000000000433000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030001800109
03100030012703200020013006500090013201400090014103500100015001200530016001000310
02130700094002440831277003380850010016150850033016250850030016580850047016881170
00601735072000301741002001301744#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37
n1.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#12#IBJU030#nd#Int. braz j urol.#
37#1#20110200#^f94^l99#1677-5538#Infrapubic approach for malleable penile implan
t^len#^rND^1A01^nOswaldo L. D.^sBerg#Hospital da Lagoa^iA01^1Department of Urolo
gy^2Sexual Medicine Clinic^cRio de Janeiro^pBrazil#^len^aPURPOSE: Today, we find
 that the implant of malleable prostheses still plays a leading role in the surg
ical treatment of erectile dysfunction. These may involve patients for which the
 cosmetic advantages of inflatable devices are not as important as low cost, the
 easier use and less incidence of mechanical complications in the malleable impl
ants. This paper demonstrates infrapubic approach as a technical option for this
 kind of implant. SURGICAL TECHNIQUE: It offers technical resources and emphasiz
es the facility in using the method, reducing cutaneous exposure, which diminish
es risks of contamination. COMMENTS: As occurs in inflatable implants, when impl
anting malleable prostheses through the infrapubic access, care must also be tak
en regarding the possibility of lesion to the vascular-nervous bundle. On the ot
her hand, the approach through the dorsal surface of the corpora cavernosa has a
 natural capacity for anatomical protection of the urethra, not requiring transu
rethral catheterization. This benefit is of the utmost importance when consideri
ng possible causes of per and postoperative morbidity. Accordingly, we can consi
der that the infrapubic approach is an effective method and prevails as a techni
cal option for implanting malleable prostheses.#^ddecs^i1#^tm^len^kerectile dysf
unction^i1#^tm^len^kpenile prosthesis^i1#^tm^len^kurologic surgical procedures^i
1^smale#other#18#a12v37n1.htm##
02219000000000433000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030001800109
03100030012703200020013006500090013201400090014103500100015001200600016001000310
02200700094002510831298003450850010016430850033016530850030016860850047017161170
00601763072000301769002001301772#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37
n1.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#12#IBJU030#nd#Int. braz j urol.#
37#1#20110200#^f94^l99#1677-5538#<b>Infrapubic approach for malleable penile imp
lant</b>^len#^rND^1A01^nOswaldo L. D.^sBerg#Hospital da Lagoa^iA01^1Department o
f Urology^2Sexual Medicine Clinic^cRio de Janeiro^pBrazil#^len^a<b>PURPOSE:</b> 
Today, we find that the implant of malleable prostheses still plays a leading ro
le in the surgical treatment of erectile dysfunction. These may involve patients
 for which the cosmetic advantages of inflatable devices are not as important as
 low cost, the easier use and less incidence of mechanical complications in the 
malleable implants. This paper demonstrates infrapubic approach as a technical o
ption for this kind of implant. <b>SURGICAL TECHNIQUE:</b> It offers technical r
esources and emphasizes the facility in using the method, reducing cutaneous exp
osure, which diminishes risks of contamination. <b>COMMENTS:</b> As occurs in in
flatable implants, when implanting malleable prostheses through the infrapubic a
ccess, care must also be taken regarding the possibility of lesion to the vascul
ar-nervous bundle. On the other hand, the approach through the dorsal surface of
 the corpora cavernosa has a natural capacity for anatomical protection of the u
rethra, not requiring transurethral catheterization. This benefit is of the utmo
st importance when considering possible causes of per and postoperative morbidit
y. Accordingly, we can consider that the infrapubic approach is an effective met
hod and prevails as a technical option for implanting malleable prostheses.#^dde
cs^i1#^tm^len^kerectile dysfunction^i1#^tm^len^kpenile prosthesis^i1#^tm^len^kur
ologic surgical procedures^i1^smale#other#18#a12v37n1.htm##
02322000000000457000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108121000300113049000800116158000300124
03000170012703100030014403200020014706500090014901400090015803500100016701200530
01770100030002300700096002600831277003560850010016330850033016430850030016760850
04701706117000601753072000301759002001301762008008901775#v37n1#V:\SciELO\serial\
ibju\v37n1\markup\a12v37n1.htm#S#l#4#1#article#1#^mJan./Feb.^a2011#oa#en#br1.1#1
#4.0#ilus#12#IBJU030#nd#Int. braz j urol#37#1#20110200#^f94^l99#1677-5538#Infrap
ubic approach for malleable penile implant^len#^rND^1A01^nOswaldo L. D^sBerg#^iA
01^1Hospital da Lagoa^2Department of Urology^3Sexual Medicine Clinic^cRio de Jan
eiro^pBrazil#^len^aPURPOSE: Today, we find that the implant of malleable prosthe
ses still plays a leading role in the surgical treatment of erectile dysfunction
. These may involve patients for which the cosmetic advantages of inflatable dev
ices are not as important as low cost, the easier use and less incidence of mech
anical complications in the malleable implants. This paper demonstrates infrapub
ic approach as a technical option for this kind of implant. SURGICAL TECHNIQUE: 
It offers technical resources and emphasizes the facility in using the method, r
educing cutaneous exposure, which diminishes risks of contamination. COMMENTS: A
s occurs in inflatable implants, when implanting malleable prostheses through th
e infrapubic access, care must also be taken regarding the possibility of lesion
 to the vascular-nervous bundle. On the other hand, the approach through the dor
sal surface of the corpora cavernosa has a natural capacity for anatomical prote
ction of the urethra, not requiring transurethral catheterization. This benefit 
is of the utmost importance when considering possible causes of per and postoper
ative morbidity. Accordingly, we can consider that the infrapubic approach is an
 effective method and prevails as a technical option for implanting malleable pr
ostheses.#^ddecs^i1#^tm^len^kerectile dysfunction^i1#^tm^len^kpenile prosthesis^
i1#^tm^len^kurologic surgical procedures^i1^smale#other#18#a12v37n1.htm#Internet
^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382011000100012
##
00358000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012500074002001300199#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#5#1#article#106#<p align="right"><fon
t face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>SURGICAL    TECHNIQUE
</b></font></p>     ^cY#a12v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#6#2#article#106#<p>&nbsp;</p>     ^cY
#a12v37n1.htm##
00392000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704015900074002001300233#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#7#3#article#106#<p><a name="top"></a>
<font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Infrapubic    app
roach for malleable penile implant</b></font></p>     ^cY#a12v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#8#4#article#106#<p>&nbsp;</p>     ^cY
#a12v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#9#5#article#106#<p>&nbsp;</p>     ^cY
#a12v37n1.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011200075002001300187#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#10#6#article#106#<p><font face="Verda
na, Arial, Helvetica, sans-serif" size="2"><b>Oswaldo    L. D. Berg</b> </font><
/p>     ^cY#a12v37n1.htm##
00408000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704017400075002001300249#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#11#7#article#106#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Sexual Medicine    Clinic, Department
 of Urology, Hospital da Lagoa, Rio de Janeiro, Brazil</font></p>     ^cY#a12v37
n1.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011600075002001300191#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#12#8#article#106#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#end">Correspondence</a></fo
nt></p>     ^cY#a12v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#13#9#article#106#<p>&nbsp;</p>     ^c
Y#a12v37n1.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#14#10#article#106#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a12v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#15#11#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#a
12v37n1.htm##
00771000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053600076002001300612#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#16#12#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>PURPOSE:</b>    Today, we find th
at the implant of malleable prostheses still plays a leading    role in the surg
ical treatment of erectile dysfunction. These may involve patients    for which 
the cosmetic advantages of inflatable devices are not as important    as low cos
t, the easier use and less incidence of mechanical complications in    the malle
able implants. This paper demonstrates infrapubic approach as a technical    opt
ion for this kind of implant.    ^cY#a12v37n1.htm##
00431000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019600076002001300272#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#17#13#article#106#<br>   <b>SURGICAL 
TECHNIQUE:</b> It offers technical resources and emphasizes the    facility in u
sing the method, reducing cutaneous exposure, which diminishes    risks of conta
mination.    ^cY#a12v37n1.htm##
00782000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054700076002001300623#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#18#14#article#106#<br>   <b>COMMENTS:
</b> As occurs in inflatable implants, when implanting malleable    prostheses t
hrough the infrapubic access, care must also be taken regarding    the possibili
ty of lesion to the vascular-nervous bundle. On the other hand,    the approach 
through the dorsal surface of the corpora cavernosa has a natural    capacity fo
r anatomical protection of the urethra, not requiring transurethral    catheteri
zation. This benefit is of the utmost importance when considering possible    ca
uses of per and postoperative morbidity.    ^cY#a12v37n1.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018200076002001300258#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#19#15#article#106#<br>   Accordingly,
 we can consider that the infrapubic approach is an effective method    and prev
ails as a technical option for implanting malleable prostheses.</font></p>     ^
cY#a12v37n1.htm##
00436000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020100076002001300277#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#20#16#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Key words:</b>    erectile dysfun
ction; penile prosthesis; urologic surgical procedures, male</font></p> <HR size
="1" noshade>     ^cY#a12v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#21#17#article#106#<p>&nbsp;</p>     ^
cY#a12v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#22#18#article#106#<p>&nbsp;</p>     ^
cY#a12v37n1.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#23#19#article#106#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODUCTION</b></font></p>     ^
cY#a12v37n1.htm##
00780000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054500076002001300621#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#24#20#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Since 1936 when    Nikolaj Bogaraz 
reconstructed an amputated penis using a tubular abdominal graft    in which he 
inserted a section of rib cartilage, the search for ideal materials    and techn
iques for penile implants has been continuous. Over the years, acrylic,    polye
thylene, silastic, silicon rubber and other prostheses have been used,    whethe
r for rigid, articulated, malleable and later inflatable of one, two or    three
-piece constitution (1,2).</font></p>     ^cY#a12v37n1.htm##
00644000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040900076002001300485#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#25#21#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Currently, malleable    prostheses a
vailable in the market are quite similar to each other, with a central    struct
ure consisting of steel or silver filaments covered by two or more layers    of 
silicon sheath. They all offer various modalities of size adjustment, by    cutt
ing or adding extensors to their proximal portion.</font></p>     ^cY#a12v37n1.h
tm##
00662000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042700076002001300503#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#26#22#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Although today patients and surgeons
 prefer inflatable prostheses, some circumstances    may require the malleable i
mplant. These may involve patients for which the    cosmetic advantages of infla
table devices are not as important as low cost,    the easier use and less incid
ence of mechanical complications in the malleable    implants (1-6).</font></p> 
    ^cY#a12v37n1.htm##
00906000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067100076002001300747#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#27#23#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">With regard to    the surgical techn
ique, various approaches have been described for implanting    penile prostheses
: the dorsal subcoronal, penile proximal, longitudinal penoscrotal,    transvers
e penoscrotal perineal and combined incisions (7). More recently, a    minimally
 invasive infrapubic approach was proposed for the implant of a three-piece    i
nflatable prosthesis (8). The name used comes from the fact of making a single  
  transverse incision below the pubis. The purpose of this paper is to demonstra
te    the ease of this approach for the implant of malleable prostheses.</font><
/p>     ^cY#a12v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#28#24#article#106#<p>&nbsp;</p>     ^
cY#a12v37n1.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010800076002001300184#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#29#25#article#106#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>SURGICAL TECHNIQUE</b></font></p>
     ^cY#a12v37n1.htm##
00530000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029500076002001300371#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#30#26#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The infrapubic    approach adopted 
in our hospital is characterized by a two to three centimeter    transverse inci
sion, approximately one centimeter from the base of the penis    (<a href="#fig1
">Figure-1</a>).</font></p>     ^cY#a12v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#31#27#article#106#<p>&nbsp;</p>     ^
cY#a12v37n1.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011200076002001300188#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#32#28#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a name="fig1" id="fig1"></a></font>
</p>     ^cY#a12v37n1.htm##
00372000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013700076002001300213#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#33#29#article#106#<p align="center"><
font face="Verdana, Arial, Helvetica, sans-serif"><img src="/img/revistas/ibju/v
37n1/a12fig1.jpg"></font></p>     ^cY#a12v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#34#30#article#106#<p>&nbsp;</p>     ^
cY#a12v37n1.htm##
00673000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043800076002001300514#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#35#31#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Skin and subcutaneous    tissue are 
incised using a conventional scalpel. Of course, care must be taken    to preven
t lesions both to the suspensory ligament of the penis and to the medial    neur
ovascular bundle. With this in mind, the dissection is deepened using scissors, 
   staying at each angle of the incision and thus keeping away from its center.<
/font></p>     ^cY#a12v37n1.htm##
00601000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036600076002001300442#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#36#32#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The corpora cavernosa    are easily 
visible by a simple thrust of the penile axis. This procedure causes    stretchi
ng and shrinkage of the corpora cavernosa, facilitating its identification    an
d subsequent dissection (<a href="/img/revistas/ibju/v37n1/a12fig2.jpg">Figure-2
A</a>).</font></p>     ^cY#a12v37n1.htm##
00629000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039400076002001300470#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#37#33#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A small longitudinal    incision on 
the dorsal surface of the corpus cavernous is made using a conventional    scalp
el between stay sutures. The erectile tissue is pushed down using Halsted    for
ceps and the incision is extended to its two angles (<a href="/img/revistas/ibju
/v37n1/a12fig2.jpg">Figure-2B</a>).</font></p>     ^cY#a12v37n1.htm##
00468000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023300076002001300309#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#38#34#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The progressive    dilation of the c
orpus cavernous is made using Heggar dilators in the proximal    and distal dire
ctions, as described for the other approaches.    ^cY#a12v37n1.htm##
00697000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046200076002001300538#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#39#35#article#106#<br>   In cases whe
re any adherences or fibrosis of the cavernous tissue hamper the    dilation of 
the corpora cavernosa, several technical resources have been proposed    (9-11).
 In such cases, in our Hospital, this dilation is mostly done by using    a cave
rnotome developed by the urological unit. This instrument is characterized    by
 a grip with a distal cylindrical end containing cutting spiral grooves (<a href
="#fig3">Figure-3</a>).</font></p>     ^cY#a12v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#40#36#article#106#<p>&nbsp;</p>     ^
cY#a12v37n1.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011200076002001300188#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#41#37#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a name="fig3" id="fig3"></a></font>
</p>     ^cY#a12v37n1.htm##
00381000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014600076002001300222#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#42#38#article#106#<p align="center"><
font size="2" face="Verdana, Arial, Helvetica, sans-serif"><img src="/img/revist
as/ibju/v37n1/a12fig3.jpg"></font></p>     ^cY#a12v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#43#39#article#106#<p>&nbsp;</p>     ^
cY#a12v37n1.htm##
00785000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055000076002001300626#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#44#40#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The grooved surface    is considerab
ly more effective than that of the dilators and file used previously.    Its use
 consists of small delicate rotational and longitudinal movements in    order to
 remove the portion of the cavernous tissue with fibrosis, pushing the    rest d
own. It should be mentioned that the purpose is to "file" and not "pull    out" 
the tissue. Extreme care must be taken when using the instrument, especially    
at the start of apprenticeship.</font></p>     ^cY#a12v37n1.htm##
01071000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704083600076002001300912#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#45#41#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">We used the following    procedure t
o adapt the size of the prosthesis: first, it is introduced inverted    in the p
roximal direction. Next, the maximum extension of the penis will determine    th
e size of the prosthesis. The section of the cylinder or adaptation with extenso
rs    is done by taking as reference the height corresponding to half the glans.
 The    cylinder is then removed and replaced in its normal position. In our exp
erience    with this measuring method, when the prosthesis is introduced into it
s final    position, the natural angulation of the corpus cavernous, at the base
 of the    penis, adjusts perfectly to the prosthesis without requiring further 
corrections    (<a href="/img/revistas/ibju/v37n1/a12fig4.jpg">Figure-4</a>).</f
ont></p>     ^cY#a12v37n1.htm##
00445000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021000076002001300286#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#46#42#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Before finally    inserting the pros
thesis, the entire process described herein above is repeated    on the contrala
teral side.</font></p>     ^cY#a12v37n1.htm##
00617000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038200076002001300458#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#47#43#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This approach also    involves the w
ell-known resource of the loop curvature of the cylinder that    especially faci
litates its distal insertion and prevents deformities caused    by angulations r
esulting from nudging the metal filament (<a href="/img/revistas/ibju/v37n1/a12f
ig5.jpg">Figure-5</a>).</font></p>     ^cY#a12v37n1.htm##
00788000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055300076002001300629#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#48#44#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The synthesis of    tunica albuginea
 is accomplished with a 3-0 continuous absorbable synthetic    suture. Hemostasi
s is reviewed using diathermo-coagulation and the other incision    planes are c
losed with a 3-0 absorbable synthetic suture. Skin incision is closed    in a co
ntinuous or subcuticular 5-0 absorbable synthetic suture, in order to    prevent
 the patient's discomfort when removing the suture (<a href="/img/revistas/ibju/
v37n1/a12fig6.jpg">Figure-6A</a>).</font></p>     ^cY#a12v37n1.htm##
00586000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035100076002001300427#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#49#45#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">We only use an    occlusive sterile 
surgical paper tape, since the careful review of hemostasia    does not require 
larger compressive dressings that are, in fact, in this approach,    of very lit
tle help (<a href="/img/revistas/ibju/v37n1/a12fig6.jpg">Figure-6B</a>).</font><
/p>     ^cY#a12v37n1.htm##
00874000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063900076002001300715#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#50#46#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The proposed approach    is being ad
opted in both primary surgery and reoperations. In such cases, it    is fully in
 accordance with the basic principles of surgical interventions that    recommen
d that the approach adopted in a region already previously manipulated    is, wh
enever possible, through a fibrosis-free area. Accordingly, in the cases    of r
evisions or reimplants of malleable prostheses, where the first operation    was
 done through a penoscrotal approach, we consider the infrapubic approach    to 
be first option in another intervention.</font></p>     ^cY#a12v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#51#47#article#106#<p>&nbsp;</p>     ^
cY#a12v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#52#48#article#106#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>COMMENTS</b></font></p>     ^cY#a
12v37n1.htm##
00725000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049000076002001300566#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#53#49#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The proposed approach    as a techn
ical option for the implant of malleable prostheses finds support    when we con
sider that despite the advances in the technology of inflatable implants,    the
 malleable prostheses are still used. This fact is due not only to the technical
    facility of its implantation and less risk of mechanical failure, but also m
ainly    due to the much lower surgical cost (1-6).</font></p>     ^cY#a12v37n1.
htm##
00609000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037400076002001300450#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#54#50#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The infrapubic    approach has there
fore been adopted in our hospital since 2007, also as a technical    option for 
malleable penile implants. Considering how simple this approach is,    it has pr
actically totally substituted the longitudinal penoscrotal approach    that we p
reviously used.</font></p>     ^cY#a12v37n1.htm##
00694000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045900076002001300535#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#55#51#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Taking the three-piece    inflatable
 prostheses as reference, today the penoscrotal approach is being    widely used
 by surgeons, tending to substitute the infrapubic incision used    previously i
n such procedures (2,12). However, in recent years, a minimally    invasive tech
nique retrieves the infrapubic approach as an option for the three-piece    infl
atable implants (8).</font></p>     ^cY#a12v37n1.htm##
00740000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050500076002001300581#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#56#52#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Similarly, with    regard to malleab
le prostheses, although a kind of infrapubic approach has been    mentioned sinc
e 1976 by Kel&acirc;mi, we can state that, at present, this type    of access is
 seldom addressed in medical literature, while the penoscrotal approach    is mo
re often mentioned by the surgeons (1,2,7). Nevertheless, the infrapubic    appr
oach is also an excellent technical option in these cases (13-16).</font></p>   
  ^cY#a12v37n1.htm##
01112000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087700076002001300953#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#57#53#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">When implanting    the inflatable pr
ostheses, the main benefit of the infrapubic approach is the    possibility of d
irect vision for implanting the liquid reservoir. Its disadvantages    include l
imited corpus cavernous exposure and difficulty in anchoring the pump    in the 
scrotum. Although lesions of the dorsal nerves of the penis seldom occur    duri
ng this procedure, it is a risk to be considered in the dissection to expose    
the corpora cavernosa. The benefits of the penoscrotal approach include better  
  exposure of the corpus cavernous, impossibility of damaging dorsal nerves of  
  the penis and more facility in anchoring the inflating pump. Its main disadvan
tages    are more possibility of urethral lesion and blindly implant of the rese
rvoir    in the retropubic space (17).</font></p>     ^cY#a12v37n1.htm##
00833000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704059800076002001300674#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#58#54#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">As occurs in inflatable    implants,
 when implanting malleable prostheses through the infrapubic access    care must
 also be taken regarding the possibility of lesion to the vascular-nervous    bu
ndle. On the other hand, the approach through the dorsal surface of the corpora 
   cavernosa has a natural capacity for anatomical protection of the urethra, no
t    requiring transurethral catheterism. This benefit is of the utmost importan
ce    when considering possible causes of per and postoperative morbidity (18).<
/font></p>     ^cY#a12v37n1.htm##
00476000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024100076002001300317#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#59#55#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Accordingly, we    can consider that
 the infrapubic approach is an effective method and prevails    as a technical o
ption for implanting malleable prostheses.</font></p>     ^cY#a12v37n1.htm##
00475000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024000076002001300316#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#60#56#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">For obvious reasons, the benefits an
d disadvantages must be carefully considered    in obese patients with extensive
 adipose panicle in the region to be cut.</font></p>     ^cY#a12v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#61#57#article#106#<p>&nbsp;</p>     ^
cY#a12v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#62#58#article#106#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONFLICT OF    INTEREST</b></font
></p>     ^cY#a12v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#63#59#article#106#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> None declared.</font></p>     ^cY#a
12v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#64#60#article#106#<p>&nbsp;</p>     ^
cY#a12v37n1.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#65#61#article#106#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFERENCES</b></font></p>     ^cY
#a12v37n1.htm##
00505000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025600078002001300334#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#66#62#article#106#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 1. Henry GD: Historic
al    review of penile prosthesis design and surgical techniques: part 1 of a th
ree-part    review series on penile prosthetic surgery. J Sex Med. 2009; 6: 675-
81.    ^cY#a12v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#67#63#article#106#</font>  </p>     ^
cY#a12v37n1.htm##
00503000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025400078002001300332#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#68#64#article#106#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Sadeghi-Nejad    H:
 Penile prosthesis surgery: a review of prosthetic devices and associated    com
plications. J Sex Med. 2007; 4: 296-309. Erratum in: J Sex Med. 2007; 4:    1520
.    ^cY#a12v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#69#65#article#106#</font></p>     ^cY
#a12v37n1.htm##
00538000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028900078002001300367#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#70#66#article#106#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Wilson SK, Delk    
JR, Salem EA, Cleves MA: Long-term survival of inflatable penile prostheses:    
single surgical group experience with 2,384 first-time implants spanning two    
decades. J Sex Med. 2007; 4: 1074-9.    ^cY#a12v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#71#67#article#106#</font></p>     ^cY
#a12v37n1.htm##
00492000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024300078002001300321#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#72#68#article#106#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Lotan Y, Roehrborn 
   CG, McConnell JD, Hendin BN: Factors influencing the outcomes of penile prost
hesis    surgery at a teaching institution. Urology. 2003; 62: 918-21.    ^cY#a1
2v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#73#69#article#106#</font></p>     ^cY
#a12v37n1.htm##
00412000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704016300078002001300241#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#74#70#article#106#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Dorflinger T,    Br
uskewitz R: AMS malleable penile prosthesis. Urology. 1986; 28: 480-5.    ^cY#a1
2v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#75#71#article#106#</font></p>     ^cY
#a12v37n1.htm##
00451000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020200078002001300280#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#76#72#article#106#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Choi HK, Cho    IR,
 Xin ZC: Ten years of experience with various penile prosthesis in Korean.    Yo
nsei Med J. 1994; 35: 209-17.    ^cY#a12v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#77#73#article#106#</font></p>     ^cY
#a12v37n1.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022400078002001300302#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#78#74#article#106#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Glina S, Martins   
 F: T&eacute;cnicas de implante. In: Disfun&ccedil;&atilde;o Sexual Masculina.  
  S&atilde;o Paulo, Inst H Hellis.2002; pp. 259-62.    ^cY#a12v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#79#75#article#106#</font></p>     ^cY
#a12v37n1.htm##
00420000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704017100078002001300249#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#80#76#article#106#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Perito PE: Minimall
y    invasive infrapubic inflatable penile implant. J Sex Med. 2008; 5: 27-30.  
  ^cY#a12v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#81#77#article#106#</font></p>     ^cY
#a12v37n1.htm##
00493000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024400078002001300322#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#82#78#article#106#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Montague DK,    Ang
ermeier KW: Corporeal excavation: new technique for penile prosthesis implantati
on    in men with severe corporeal fibrosis. Urology. 2006; 67: 1072-5.    ^cY#a
12v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#83#79#article#106#</font></p>     ^cY
#a12v37n1.htm##
00548000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704029800079002001300377#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#84#80#article#106#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Shaeer O, Shaeer 
   A: Corporoscopic excavation of the fibrosed corpora cavernosa for penile pros
ethesis    implantation: optical corporotomy and trans-corporeal resection, Shae
er's technique.    J Sex Med. 2007; 4: 218-25.    ^cY#a12v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#85#81#article#106#</font></p>     ^cY
#a12v37n1.htm##
00474000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704022400079002001300303#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#86#82#article#106#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Shaeer O: Implant
ation    of penile prosthesis in cases of corporeal fibrosis: modified Shaeer's 
excavation    technique. J Sex Med. 2008; 5: 2470-6.    ^cY#a12v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#87#83#article#106#</font></p>     ^cY
#a12v37n1.htm##
00522000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704027200079002001300351#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#88#84#article#106#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Candela JV,    He
llstrom WJ: Three-piece inflatable penile prosthesis implantation: a comparison 
   of the penoscrotal and infrapubic surgical approaches. J La State Med Soc. 19
96;    148: 296-301.    ^cY#a12v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#89#85#article#106#</font></p>     ^cY
#a12v37n1.htm##
00443000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704019300079002001300272#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#90#86#article#106#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Kel&acirc;mi    A
: "Infrapubic" approach for small-carrion prosthesis in erectile impotence.    U
rology. 1976; 8: 164.    ^cY#a12v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#91#87#article#106#</font></p>     ^cY
#a12v37n1.htm##
00495000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704024500079002001300324#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#92#88#article#106#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Kel&acirc;mi    A
: Implantation of Small-Carrion prosthesis in the treatment of erectile impotenc
e    after priapism: difficulties and effects. Urol Int. 1985; 40: 343-6.    ^cY
#a12v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#93#89#article#106#</font></p>     ^cY
#a12v37n1.htm##
00450000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704020000079002001300279#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#94#90#article#106#15#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Kel&acirc;mi    A
: Erictile impotence, small-carrion prosthesis and the 'infrapubic' approach.   
 Eur Urol. 1977; 3: 299-302.    ^cY#a12v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#95#91#article#106#</font></p>     ^cY
#a12v37n1.htm##
00486000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704023600079002001300315#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#96#92#article#106#16#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Berg O, Leite    
A: Comparative study penoscrotal and infrapubic access routes for implanting    
malleable penile prostheses. J Sex Med. 2010: 7(Suppl 2): 51-68.    ^cY#a12v37n1
.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#97#93#article#106#</font></p>     ^cY
#a12v37n1.htm##
00484000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704023400079002001300313#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#98#94#article#106#17#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Montague DK,    A
ngermeir KW: Surgical approaches for penile prosthesis implantation: penoscrotal
    vs infrapubic. Int J Impot Res. 2003; 15(Suppl 5): S134-5.    ^cY#a12v37n1.h
tm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#99#95#article#106#</font></p>     ^cY
#a12v37n1.htm##
00496000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704024500080002001300325#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#100#96#article#106#18#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Anafarta K,    S
afak M, Bed&uuml;k Y, Baltaci S, Aydos K: Clinical experience with inflatable   
 and malleable penile implants in 104 patients. Urol Int. 1996; 56: 100-4.    ^c
Y#a12v37n1.htm##
00318000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704008200077002001300159#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#101#97#article#106#</font><font face=
"Verdana, Arial, Helvetica, sans-serif">    </font></p>     ^cY#a12v37n1.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002200077002001300099#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#102#98#article#106#<p>&nbsp;</p>     
^cY#a12v37n1.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002200077002001300099#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#103#99#article#106#<p>&nbsp;</p>     
^cY#a12v37n1.htm##
00367000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704013000078002001300208#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#104#100#article#106#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><i>Accepted after    revision: Jul
y 5, 2010</i></font></p>     ^cY#a12v37n1.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019300078002001300271#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#105#101#article#106#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><b><a name="end"></a><a href="#top
"><img src="/img/revistas/ibju/v37n1/seta.gif" border="0"></a>    Correspondence
 to</b>:    ^cY#a12v37n1.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004100078002001300119#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#106#102#article#106#<br>   Dr. Oswald
o Luiz Dias Berg    ^cY#a12v37n1.htm##
00286000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004900078002001300127#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#107#103#article#106#<br>   Rua S&atil
de;o Clemente, 114 / 708    ^cY#a12v37n1.htm##
00289000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005200078002001300130#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#108#104#article#106#<br>   Rio de Jan
eiro, RJ, 22160-000, Brazil    ^cY#a12v37n1.htm##
00274000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003700078002001300115#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#109#105#article#106#<br>   Fax: + 55 
21 2235-2828    ^cY#a12v37n1.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009100078002001300169#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a12v37n1.htm#S#p#110#106#article#106#<br>   E-mail: <a
 href="mailto:berg@vetor.com.br">berg@vetor.com.br</a></font></p>     ^cY#a12v37
n1.htm##
00545000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770120141000930300
01000234710000200244065000900246064000500255031000200260014000700262865000900269
002001300278#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#c#111#1#art
icle#18#1#^rND^sHenry^nGD#Historical review of penile prosthesis design and surg
ical techniques: part 1 of a three-part review series on penile prosthetic surge
ry^len#J Sex Med#2#20090000#2009#6#675-81#20110200#a12v37n1.htm##
00503000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100023000770120091001000300
01000191710000200201065000900203064000500212031000200217014000800219865000900227
002001300236#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#c#112#2#art
icle#18#2#^rND^sSadeghi-Nejad^nH#Penile prosthesis surgery: a review of prosthet
ic devices and associated complications^len#J Sex Med#2#20070000#2007#4#296-309#
20110200#a12v37n1.htm##
00630000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100015000940100
01600109010001700125012014100142030001000283710000200293065000900295064000500304
031000200309014000700311865000900318002001300327#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a12v37n1.htm#S#c#113#3#article#18#3#^rND^sWilson^nSK#^rND^sDelk^nJR#^r
ND^sSalem^nEA#^rND^sCleves^nMA#Long-term survival of inflatable penile prosthese
s: single surgical group experience with 2,384 first-time implants spanning two 
decades^len#J Sex Med#2#20070000#2007#4#1074-9#20110200#a12v37n1.htm##
00615000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100020000920100
02000112010001700132012009200149030000800241065000900249064000500258031000300263
014000700266865000900273002001300282035001000295801000800305#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a12v37n1.htm#S#c#114#4#article#18#4#^rND^sLotan^nY#^rND^sR
oehrborn^nCG#^rND^sMcConnell^nJD#^rND^sHendin^nBN#Factors influencing the outcom
es of penile prosthesis surgery at a teaching institution^len#Urology#20030000#2
003#62#918-21#20110200#a12v37n1.htm#0090-4295#Urology##
00502000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100020000970120
03600117030000800153065000900161064000500170031000300175014000600178865000900184
002001300193035001000206801000800216#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a1
2v37n1.htm#S#c#115#5#article#18#5#^rND^sDorflinger^nT#^rND^sBruskewitz^nR#AMS ma
lleable penile prosthesis^len#Urology#19860000#1986#28#480-5#20110200#a12v37n1.h
tm#0090-4295#Urology##
00561000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100014000920100
01400106012006900120030001300189065000900202064000500211031000300216014000700219
865000900226002001300235035001000248801001300258#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a12v37n1.htm#S#c#116#6#article#18#6#^rND^sChoi^nHK#^rND^sCho^nIR#^rND^
sXin^nZC#Ten years of experience with various penile prosthesis in Korean^len#Yo
nsei Med J#19940000#1994#35#209-17#20110200#a12v37n1.htm#0513-5796#Yonsei Med J#
#
00498000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100017000920120
02500109018003100134066001000165062001400175065000900189064000500198014000700203
865000900210002001300219#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S
#c#117#7#article#18#7#^rND^sGlina^nS#^rND^sMartins^nF#Técnicas de implante^len#D
isfunção Sexual Masculina^len#São Paulo#Inst H Hellis#20020000#2002#259-62#20110
200#a12v37n1.htm##
00464000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770120060000940300
01000154710000200164065000900166064000500175031000200180014000600182865000900188
002001300197#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#c#118#8#art
icle#18#8#^rND^sPerito^nPE#Minimally invasive infrapubic inflatable penile impla
nt^len#J Sex Med#2#20080000#2008#5#27-30#20110200#a12v37n1.htm##
00580000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100021000960120
11300117030000800230065000900238064000500247031000300252014000700255865000900262
002001300271035001000284801000800294#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a1
2v37n1.htm#S#c#119#9#article#18#9#^rND^sMontague^nDK#^rND^sAngermeier^nKW#Corpor
eal excavation: new technique for penile prosthesis implantation in men with sev
ere corporeal fibrosis^len#Urology#20060000#2006#67#1072-5#20110200#a12v37n1.htm
#0090-4295#Urology##
00604000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950120
17000111030001000281710000200291065000900293064000500302031000200307014000700309
865000900316002001300325#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S
#c#120#10#article#18#10#^rND^sShaeer^nO#^rND^sShaeer^nA#Corporoscopic excavation
 of the fibrosed corpora cavernosa for penile prosethesis implantation: optical 
corporotomy and trans-corporeal resection, Shaeer's technique^len#J Sex Med#2#20
070000#2007#4#218-25#20110200#a12v37n1.htm##
00515000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120109000950300
01000204710000200214065000900216064000500225031000200230014000700232865000900239
002001300248#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#c#121#11#ar
ticle#18#11#^rND^sShaeer^nO#Implantation of penile prosthesis in cases of corpor
eal fibrosis: modified Shaeer's excavation technique^len#J Sex Med#2#20080000#20
08#5#2470-6#20110200#a12v37n1.htm##
00617000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100020000970120
12600117030001900243065000900262064000500271031000400276014000800280865000900288
002001300297035001000310801001900320#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a1
2v37n1.htm#S#c#122#12#article#18#12#^rND^sCandela^nJV#^rND^sHellstrom^nWJ#Three-
piece inflatable penile prosthesis implantation: a comparison of the penoscrotal
 and infrapubic surgical approaches^len#J La State Med Soc#19960000#1996#148#296
-301#20110200#a12v37n1.htm#0024-6921#J La State Med Soc##
00506000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120077000950300
00800172065000900180064000500189031000200194014000400196865000900200002001300209
035001000222801000800232#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S
#c#123#13#article#18#13#^rND^sKelâmi^nA#"Infrapubic" approach for small-carrion 
prosthesis in erectile impotence^len#Urology#19760000#1976#8#164#20110200#a12v37
n1.htm#0090-4295#Urology##
00559000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120125000950300
00900220065000900229064000500238031000300243014000600246865000900252002001300261
035001000274801000900284#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S
#c#124#14#article#18#14#^rND^sKelâmi^nA#Implantation of Small-Carrion prosthesis
 in the treatment of erectile impotence after priapism: difficulties and effects
^len#Urol Int#19850000#1985#40#343-6#20110200#a12v37n1.htm#0042-1138#Urol Int##
00514000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120079000950300
00900174065000900183064000500192031000200197014000800199865000900207002001300216
035001000229801000900239#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S
#c#125#15#article#18#15#^rND^sKelâmi^nA#Erictile impotence, small-carrion prosth
esis and the 'infrapubic' approach^len#Eur Urol#19770000#1977#3#299-302#20110200
#a12v37n1.htm#0302-2838#Eur Urol##
00552000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100015000930120
10600108030001000214710000200224065000900226064000500235031000200240032000400242
014000600246865000900252002001300261#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a1
2v37n1.htm#S#c#126#16#article#18#16#^rND^sBerg^nO#^rND^sLeite^nA#Comparative stu
dy penoscrotal and infrapubic access routes for implanting malleable penile pros
theses^len#J Sex Med#2#20100000#2010#7#^s2#51-68#20110200#a12v37n1.htm##
00586000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100020000980120
08600118030001600204065000900220064000500229031000300234032000400237014000700241
865000900248002001300257035001000270801001600280#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a12v37n1.htm#S#c#127#17#article#18#17#^rND^sMontague^nDK#^rND^sAngerme
ir^nKW#Surgical approaches for penile prosthesis implantation: penoscrotal vs in
frapubic^len#Int J Impot Res#20030000#2003#15#^s5#S134-5#20110200#a12v37n1.htm#0
955-9930#Int J Impot Res##
00632000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100015000970100
01500112010001700127010001500144012008600159030000900245065000900254064000500263
031000300268014000600271865000900277002001300286035001000299801000900309#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a12v37n1.htm#S#c#128#18#article#18#18#^rND^sAn
afarta^nK#^rND^sSafak^nM#^rND^sBedük^nY#^rND^sBaltaci^nS#^rND^sAydos^nK#Clinical
 experience with inflatable and malleable penile implants in 104 patients^len#Ur
ol Int#19960000#1996#56#100-4#20110200#a12v37n1.htm#0042-1138#Urol Int##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#o#1#1#article#1
#20110330#144526#a13v37n1.htm#162##
02920000000000481000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030001800108
03100030012603200020012906500090013101400110014003500100015101200840016101000390
02450100032002840100030003160700053003460700102003990831827005010850010023280850
01902338085001802357085001702375085002402392117000602416072000302422002001302425
#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#h#2#1#article#1#oa#en#b
r1.1#1#4.0#TAB#13#IBJU120#nd#Int. braz j urol.#37#1#20110200#^f100^l107#1677-553
8#Urodynamics in women from menopause to oldest age: what motive? what diagnosis
?^len#^rND^1A01 A02^nFrançoise A.^sValentini#^rND^1A01 A02^nGilberte^sRobain#^rN
D^1A02^nBrigitte G.^sMarti#Universite Pierre et Marie Curie^iA01^cParis^pFrance#
Hopital Charles Foix^iA02^1Department of Physical Medicine and Rehabilitation^cI
vry-sur-Seine^pFrance#^len^aPURPOSE: To analyze age-associated changes as a moti
ve for urodynamics and urodynamic diagnosis in community-dwelling menopausal wom
en and to discuss the role of menopause and ageing. MATERIALS AND METHODS: Four 
hundred and forty nine consecutive menopausal women referred for urodynamic eval
uation of lower urinary tract (LUT) symptoms, met the inclusion criteria and wer
e stratified into 3 age groups: 55-64 years (A), 65-74 years (B), and 75-93 year
s (C). Comprehensive assessment included previous medical history and clinical e
xamination. Studied items were motive for urodynamics, results of uroflows (free
 flow and intubated flow) and cystometry, urethral pressure profilometry, and fi
nal urodynamic diagnosis. RESULTS: The main motive was incontinence (66.3%) with
 significant increase of mixed incontinence in group C (p = 0.028). Detrusor fun
ction significantly deteriorated in the oldest group, mainly in absence of neuro
logical disease (overactivity p = 0.019; impaired contractility p = 0.028). In t
he entire population, underactivity predominated in group C (p = 0.0024). A prog
ressive decrease of maximum urethral closure pressure occurred with ageing. In s
ubjects with no detrusor overactivity there was a decrease with age of detrusor 
pressure at opening and at maximum flow, and of maximum flow while post void res
idual increased only in the C group. CONCLUSION: In our population of community-
dwelling menopausal women, incontinence was the main motive for urodynamics incr
easing with ageing. A brisk change in LUT function of women older than 75 years 
underlined deterioration in bladder function with a high incidence of detrusor h
yperactivity with or without impaired contractility while change in urethral fun
ction was progressive. Effect of ageing appears to be predominant compared to me
nopause.#^ddecs^i1#^tm^len^kageing^i1#^tm^len^kwomen^i1#^tm^len^kLUTS^i1#^tm^len
^kurodynamics^i1#other#17#a13v37n1.htm##
02962000000000481000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030001800108
03100030012603200020012906500090013101400110014003500100015101200980016101000390
02590100032002980100030003300700053003600700102004130831855005150850010023700850
01902380085001802399085001702417085002402434117000602458072000302464002001302467
#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#f#3#1#article#1#oa#en#b
r1.1#1#4.0#TAB#13#IBJU120#nd#Int. braz j urol.#37#1#20110200#^f100^l107#1677-553
8#<b>Urodynamics in women from menopause to oldest age</b>: <b>what motive? what
 diagnosis?</b>^len#^rND^1A01 A02^nFrançoise A.^sValentini#^rND^1A01 A02^nGilber
te^sRobain#^rND^1A02^nBrigitte G.^sMarti#Universite Pierre et Marie Curie^iA01^c
Paris^pFrance#Hopital Charles Foix^iA02^1Department of Physical Medicine and Reh
abilitation^cIvry-sur-Seine^pFrance#^len^a<b>PURPOSE:</b> To analyze age-associa
ted changes as a motive for urodynamics and urodynamic diagnosis in community-dw
elling menopausal women and to discuss the role of menopause and ageing. <b>MATE
RIALS AND METHODS:</b> Four hundred and forty nine consecutive menopausal women 
referred for urodynamic evaluation of lower urinary tract (LUT) symptoms, met th
e inclusion criteria and were stratified into 3 age groups: 55-64 years (A), 65-
74 years (B), and 75-93 years (C). Comprehensive assessment included previous me
dical history and clinical examination. Studied items were motive for urodynamic
s, results of uroflows (free flow and intubated flow) and cystometry, urethral p
ressure profilometry, and final urodynamic diagnosis. <b>RESULTS:</b> The main m
otive was incontinence (66.3%) with significant increase of mixed incontinence i
n group C (p = 0.028). Detrusor function significantly deteriorated in the oldes
t group, mainly in absence of neurological disease (overactivity p = 0.019; impa
ired contractility p = 0.028). In the entire population, underactivity predomina
ted in group C (p = 0.0024). A progressive decrease of maximum urethral closure 
pressure occurred with ageing. In subjects with no detrusor overactivity there w
as a decrease with age of detrusor pressure at opening and at maximum flow, and 
of maximum flow while post void residual increased only in the C group. <b>CONCL
USION:</b> In our population of community-dwelling menopausal women, incontinenc
e was the main motive for urodynamics increasing with ageing. A brisk change in 
LUT function of women older than 75 years underlined deterioration in bladder fu
nction with a high incidence of detrusor hyperactivity with or without impaired 
contractility while change in urethral function was progressive. Effect of agein
g appears to be predominant compared to menopause.#^ddecs^i1#^tm^len^kageing^i1#
^tm^len^kwomen^i1#^tm^len^kLUTS^i1#^tm^len^kurodynamics^i1#other#17#a13v37n1.htm
##
03059000000000505000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000400108121000300112049000800115158000300123
03000170012603100030014303200020014606500090014801400110015703500100016801200840
01780100038002620100032003000100029003320700055003610700104004160831834005200850
01002354085001902364085001802383085001702401085002402418117000602442072000302448
002001302451008008902464#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S
#l#4#1#article#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#tab#13#IBJU120#nd#Int. braz
 j urol#37#1#20110200#^f100^l107#1677-5538#Urodynamics in women from menopause t
o oldest age: what motive? what diagnosis?^len#^rND^1A01 A02^nFrançoise A^sValen
tini#^rND^1A01 A02^nGilberte^sRobain#^rND^1A02^nBrigitte G^sMarti#^iA01^1Univers
ite Pierre et Marie Curie^cParis^pFrance#^iA02^1Hopital Charles Foix^2Department
 of Physical Medicine and Rehabilitation^cIvry-sur-Seine^pFrance#^len^aPURPOSE: 
To analyze age-associated changes as a motive for urodynamics and urodynamic dia
gnosis in community-dwelling menopausal women and to discuss the role of menopau
se and ageing. MATERIALS AND METHODS: Four hundred and forty nine consecutive me
nopausal women referred for urodynamic evaluation of lower urinary tract (LUT) s
ymptoms, met the inclusion criteria and were stratified into 3 age groups: 55-64
 years (A), 65-74 years (B), and 75-93 years (C). Comprehensive assessment inclu
ded previous medical history and clinical examination. Studied items were motive
 for urodynamics, results of uroflows (free flow and intubated flow) and cystome
try, urethral pressure profilometry, and final urodynamic diagnosis. RESULTS: Th
e main motive was incontinence (66.3 percent) with significant increase of mixed
 incontinence in group C (p = 0.028). Detrusor function significantly deteriorat
ed in the oldest group, mainly in absence of neurological disease (overactivity 
p = 0.019; impaired contractility p = 0.028). In the entire population, underact
ivity predominated in group C (p = 0.0024). A progressive decrease of maximum ur
ethral closure pressure occurred with ageing. In subjects with no detrusor overa
ctivity there was a decrease with age of detrusor pressure at opening and at max
imum flow, and of maximum flow while post void residual increased only in the C 
group. CONCLUSION: In our population of community-dwelling menopausal women, inc
ontinence was the main motive for urodynamics increasing with ageing. A brisk ch
ange in LUT function of women older than 75 years underlined deterioration in bl
adder function with a high incidence of detrusor hyperactivity with or without i
mpaired contractility while change in urethral function was progressive. Effect 
of ageing appears to be predominant compared to menopause.#^ddecs^i1#^tm^len^kag
eing^i1#^tm^len^kwomen^i1#^tm^len^kLUTS^i1#^tm^len^kurodynamics^i1#other#17#a13v
37n1.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-
55382011000100013##
00349000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704011600074002001300190#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#5#1#article#141#<p align="right"><fon
t face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>NEUROUROLOGY</b></fon
t></p>     ^cY#a13v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#6#2#article#141#<p>&nbsp;</p>     ^cY
#a13v37n1.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704019000074002001300264#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#7#3#article#141#<p><a name="top"></a>
<font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Urodynamics    in
 women from menopause to oldest age: what motive? what diagnosis?</b></font></p>
     ^cY#a13v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#8#4#article#141#<p>&nbsp;</p>     ^cY
#a13v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#9#5#article#141#<p>&nbsp;</p>     ^cY
#a13v37n1.htm##
00437000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704020300075002001300278#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#10#6#article#141#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Fran&ccedil;oise    A. Valentini<s
up>I,II</sup>; Gilberte Robain<sup>I,II</sup>; Brigitte G. Marti<sup>II</sup></b
></font>  </p>     ^cY#a13v37n1.htm##
00373000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704013900075002001300214#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#11#7#article#141#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>ER6    - Universite Pierr
e et Marie Curie, Paris, France    ^cY#a13v37n1.htm##
00373000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704013900075002001300214#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#12#8#article#141#<br>   <sup>II</sup>
Department of Physical Medicine and Rehabilitation, Hopital Charles    Foix, Ivr
y-sur-Seine, France</font></p>     ^cY#a13v37n1.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011600075002001300191#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#13#9#article#141#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#end">Correspondence</a></fo
nt></p>     ^cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#14#10#article#141#<p>&nbsp;</p>     ^
cY#a13v37n1.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#15#11#article#141#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a13v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#16#12#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#a
13v37n1.htm##
00505000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027000076002001300346#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#17#13#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>PURPOSE:</b>    To analyze age-as
sociated changes as a motive for urodynamics and urodynamic    diagnosis in comm
unity-dwelling menopausal women and to discuss the role of    menopause and agei
ng.    ^cY#a13v37n1.htm##
00808000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057300076002001300649#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#18#14#article#141#<br>   <b>MATERIALS
 AND METHODS:</b> Four hundred and forty nine consecutive menopausal    women re
ferred for urodynamic evaluation of lower urinary tract (LUT) symptoms,    met t
he inclusion criteria and were stratified into 3 age groups: 55-64 years    (A),
 65-74 years (B), and 75-93 years (C). Comprehensive assessment included    prev
ious medical history and clinical examination. Studied items were motive    for 
urodynamics, results of uroflows (free flow and intubated flow) and cystometry, 
   urethral pressure profilometry, and final urodynamic diagnosis.    ^cY#a13v37
n1.htm##
00931000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069600076002001300772#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#19#15#article#141#<br>   <b>RESULTS:<
/b> The main motive was incontinence (66.3%) with significant increase    of mix
ed incontinence in group C (p = 0.028). Detrusor function significantly    deter
iorated in the oldest group, mainly in absence of neurological disease    (overa
ctivity p = 0.019; impaired contractility p = 0.028). In the entire population, 
   underactivity predominated in group C (p = 0.0024). A progressive decrease of
    maximum urethral closure pressure occurred with ageing. In subjects with no 
   detrusor overactivity there was a decrease with age of detrusor pressure at  
  opening and at maximum flow, and of maximum flow while post void residual incr
eased    only in the C group.    ^cY#a13v37n1.htm##
00735000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050000076002001300576#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#20#16#article#141#<br>   <b>CONCLUSIO
N:</b> In our population of community-dwelling menopausal women,    incontinence
 was the main motive for urodynamics increasing with ageing. A brisk    change i
n LUT function of women older than 75 years underlined deterioration    in bladd
er function with a high incidence of detrusor hyperactivity with or    without i
mpaired contractility while change in urethral function was progressive.    Effe
ct of ageing appears to be predominant compared to menopause.</font></p>     ^cY
#a13v37n1.htm##
00393000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704015800076002001300234#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#21#17#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Key words:</b>    ageing; women; 
LUTS; urodynamics</font></p> <HR size="1" noshade>     ^cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#22#18#article#141#<p>&nbsp;</p>     ^
cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#23#19#article#141#<p>&nbsp;</p>     ^
cY#a13v37n1.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#24#20#article#141#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODUCTION</b></font></p>     ^
cY#a13v37n1.htm##
01149000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704091400076002001300990#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#25#21#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Lower urinary tract    (LUT) dysfunc
tion is a major cause of reduced quality of life in the ageing    population. Fo
r women the postmenopausal period has significantly increased    and is now up t
o one third or more of the total lifespan. &nbsp;LUT function    is affected by 
estrogen withdrawal and ageing. A major consequence of estrogen    withdrawal is
 urogenital atrophy with possible contribution to urinary symptoms    such as fr
equency, urgency and incontinence (1). Ageing is associated with a    progressiv
e decrease in autonomic innervation and of detrusor contractility    (2,3). Some
 studies have focused on identifying the effects of menopause and    ageing (4-6
) on lifestyle. In spite of a reported significant trend for increased    preval
ence of symptoms with ageing, none of these studies have identified causes.</fon
t></p>     ^cY#a13v37n1.htm##
00602000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036700076002001300443#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#26#22#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Despite the fact    that many patien
ts avoid discussing their problems, postmenopausal women constitute    a large p
opulation who undergo urodynamics for lower urinary tract symptoms    (LUTS) and
 urodynamics is considered as the best tool for the evaluation of    patients wi
th LUTS.</font></p>     ^cY#a13v37n1.htm##
00729000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049400076002001300570#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#27#23#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Some authors (7)    have concluded t
hat female bladder and urethral function deteriorate throughout    adult life, w
hether or not detrusor overactivity (DO) is present. In a previous    study (8) 
we analyzed the motive for urodynamics and the urodynamic diagnosis    in a popu
lation of community-dwelling elderly females (80+ years); we showed    that inco
ntinence was the main motive and DO the main diagnosis.</font></p>     ^cY#a13v3
7n1.htm##
00623000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038800076002001300464#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#28#24#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Our objectives    in this study were
 to extend our analysis to a large population of postmenopausal    community-dwe
lling women referred as outpatients for evaluation of LUTS and    to consider th
e relationships between menopause and ageing on the changes in    the motive of 
referral and in LUT function.</font></p>     ^cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#29#25#article#141#<p>&nbsp;</p>     ^
cY#a13v37n1.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011400076002001300190#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#30#26#article#141#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>MATERIALS AND    METHODS</b></fon
t></p>     ^cY#a13v37n1.htm##
01059000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082400076002001300900#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#31#27#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The population    consisted of 449 
consecutive women, community-dwelling, aged = 55 years who    underwent urodynam
ics for LUTS in our outpatient urodynamics clinic between    January 2005 and Ma
rch 2008. Patients were stratified in 3 age groups: 55-64    years (A, short-ter
m menopause), 65-74 years (B, middle-term menopause), and    75-93 years (C, lon
g-term menopause). The lowest age group (55 years) was set    so that the women 
were all postmenopausal (in France, the mean age of menopause    is 50.1 years).
 This retrospective study was conducted in accordance with the    declaration of
 Helsinki. The local practice of our Ethics Committee does not    require a form
al institutional review board approval for retrospective studies.</font></p>    
 ^cY#a13v37n1.htm##
01037000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080200076002001300878#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#32#28#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Urodynamics investigations    were p
erformed according to Good Urodynamic Practices (GUP) (9) using the Laborie's   
 Dorado&reg; unit. Detailed urodynamic session included one initial free uroflow
    (FF1), cystometry and pressure-flow study (PFs) in a seated position, urethr
al    pressure profilometry (UPP) in supine position, bladder empty before cysto
metry    and bladder filled (according with the functional bladder capacity) aft
er PFs    and then a second FF.&nbsp;Cystometry was performed with a 7F triple-l
umen urethral    catheter. Bladder was filled with saline at room-temperature at
 a medium filling    rate of 50 mL/min. Abdominal pressure was recorded using a 
punctured intra-rectal    balloon catheter.</font></p>     ^cY#a13v37n1.htm##
00442000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020700076002001300283#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#33#29#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Pressures were    zeroed to atmosphe
re with the transducers placed at the level of the upper edge    of the symphisi
s pubis.</font></p>     ^cY#a13v37n1.htm##
00464000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022900076002001300305#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#34#30#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">No routine provocative    manoeuvres
 for DO were performed but according to GUP coughs were used as quality    contr
ol of pressure recordings (9).</font></p>     ^cY#a13v37n1.htm##
00557000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032200076002001300398#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#35#31#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">All patients had    an evaluation in
cluding medical history and usual medication, bladder diary    for at least 48 h
ours including voiding times and voided volumes during day    and night-time, ph
ysical examination and dipstick urinalysis.</font></p>     ^cY#a13v37n1.htm##
00861000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062600076002001300702#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#36#32#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Specific evaluation    comprised of 
a history of LUTS, previous history of neurological disease (stroke,    multiple
 sclerosis, lumbar injury, etc.) or dementia, pelvic floor status and    previou
s pelvic surgery. Patients with LUTS due to a specific physiopathology    (compl
ete spinal cord injury) were excluded, as well as those who were unable    to pe
rform the standardized protocol for complete retention (no FF and PFs were    po
ssible) or severe dementia (involving failure to understand simple orders    or 
Mini Mental State &lt; 20).</font></p>     ^cY#a13v37n1.htm##
01054000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704081900076002001300895#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#37#33#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Two physicians    independently asse
ssed urodynamics; good agreement occurred in up to 95% of    the files. In the r
emaining 5%, a third interpretation was carried out jointly    to agree on a sin
gle conclusion. Studied items were motive for urodynamics,    feasibility of uro
flows (FF and PFs), detrusor behavior during filling cystometry,    UPP and fina
l urodynamic diagnosis. Feasibility of uroflows was defined by a    voided volum
e higher than 100 mL. To analyze the detrusor behavior during filling    cystome
try, an additive stratification was used with the following parameters:    age (
A,B,C), without neurological disease (I) or with (II) (was verified that    prev
ious pelvic surgery did not lead to significant difference).</font></p>     ^cY#
a13v37n1.htm##
00472000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023700076002001300313#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#38#34#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Quality of life    was assessed usin
g the ICIQ-UI-SF questionnaire for incontinent patients (10)    and visual analo
g scale (VAS) for continent patients. </font></p>     ^cY#a13v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#39#35#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Statistical    Analysis</b></font
></p>     ^cY#a13v37n1.htm##
00691000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045600076002001300532#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#40#36#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Data are presented    as mean &plus
mn; SD and range. The Wilcoxon signed rank test was used for comparison    of re
lated samples, analysis of variance and the chi-square test to compare    unrela
ted samples. Statistical analysis was performed using SAS, version 5.0    (SAS I
nstitute, Inc., Cary, NC). All statistical results were considered significant  
  at p &lt; 0.05.</font></p>     ^cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#41#37#article#141#<p>&nbsp;</p>     ^
cY#a13v37n1.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#42#38#article#141#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESULTS</b></font></p>     ^cY#a1
3v37n1.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#43#39#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Population</b></font></p>     ^cY
#a13v37n1.htm##
00509000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027400076002001300350#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#44#40#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The 3 sub-groups    were homogeneous
 in terms of numbers of patients: A = 137, B = 155, C = 157.    Mean age was 59 
&plusmn; 3 years in A, 70 &plusmn; 3y in B and 81 &plusmn; 4    years in C.</fon
t></p>     ^cY#a13v37n1.htm##
00495000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026000076002001300336#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#45#41#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Oral or transdermal    hormone repl
acement therapy (HRT) was respectively taken by 11 (8.0%) women    in A and 29 (
18.8%) in B; in C, 15 women (9.6%) received estrogen locally.</font></p>     ^cY
#a13v37n1.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011200076002001300188#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#46#42#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Motive for Urodynamics</b></font>
</p>     ^cY#a13v37n1.htm##
00607000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037200076002001300448#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#47#43#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> <a href="/img/revistas/ibju/v37n1/a
13tab1.jpg">Table-1</a>    lists the motive for urodynamics by age-groups. Incon
tinence was the main motive,    evoked by 298 (66.3%) patients. Mixed incontinen
ce increased with ageing with    a significant difference between groups A and C
 (p = 0.028).</font></p>     ^cY#a13v37n1.htm##
00450000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021500076002001300291#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#48#44#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">ICIQ-SF score (maximum    21) and VA
S score (maximum 10) are detailed in <a href="/img/revistas/ibju/v37n1/a13tab2.j
pg">Table-2</a>.</font></p>     ^cY#a13v37n1.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010600076002001300182#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#49#45#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Previous History</b></font></p>  
   ^cY#a13v37n1.htm##
00496000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026100076002001300337#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#50#46#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Previous history    of medical disea
se or/and pelvic surgery was obtained by detailed questioning,    and is listed 
in <a href="/img/revistas/ibju/v37n1/a13tab3.jpg">Table-3</a>.</font></p>     ^c
Y#a13v37n1.htm##
00519000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028400076002001300360#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#51#47#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">One hundred and    sixteen (25.8%) p
atients had a previous history of neurological disease (A =    35; B = 36; C = 4
5) and 151 (33.6%) had undergone previous pelvic surgery (A    = 56; B = 54; C =
 41).</font></p>     ^cY#a13v37n1.htm##
00524000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028900076002001300365#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#52#48#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Eleven patients    were referred for
 pre-operative evaluation of pelvic organ prolapse (POP); POP    grade 2-3 was r
evealed during urogenital examination in 31 additional patients    (A = 9; B = 1
3; C = 9).</font></p>     ^cY#a13v37n1.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011700076002001300193#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#53#49#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Feasibility    of the Tests</b></
font></p>     ^cY#a13v37n1.htm##
00640000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040500076002001300481#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#54#50#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The percentage    of interpretable 
initial FF was significantly higher in age-group B (A = 57.8%;    B = 69.3%; C =
 47.5%) while there was not a significant difference between the    age groups f
or both interpretable PFs (A = 64.2%; B = 56.1%; C = 56.4%) and    FF at end of 
the session (A = 94.6%; B = 94.8%; C = 97.2%).</font></p>     ^cY#a13v37n1.htm##
00403000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016800076002001300244#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#55#51#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Cystometry (</b><a href="/img/rev
istas/ibju/v37n1/a13tab4.jpg">Table-4</a><b>)</b></font></p>     ^cY#a13v37n1.ht
m##
00908000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067300076002001300749#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#56#52#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Detrusor overactivity    (involunta
ry detrusor contraction during the filling phase, DO) (9-11) and its    subset d
etrusor hyperactivity with impaired contractility (DHIC) (12) were found    in a
 total of 142 patients (32%) with a significant increase in group C: 43%    vs. 
23% A &amp; 30% B (p = 0.0004); detrusor underactivity (impaired detrusor    con
traction leading to prolonged voiding time and high residual volume) (DUA)    (9
) was found in 62 patients (14%) with also a significant increase in C (p    = 0
.0024). Normal detrusor behavior significantly decreased in c (p = 0.005).</font
></p>     ^cY#a13v37n1.htm##
00646000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041100076002001300487#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#57#53#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In sub-group I    (333 patients with
out neurological disease) the detrusor behavior was normal    in 194 (58.2%) wit
h only a significant difference between subgroups I-B and    I-C (p = 0.044). DO
 and DHIC significantly increased in subgroup I-C (respectively    p = 0.019 and
 0.028) but the increase in DUA was not significant.</font></p>     ^cY#a13v37n1
.htm##
00685000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045000076002001300526#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#58#54#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In subgroup II    (116 patients with
 neurological disease) the detrusor behavior was normal in    33 (28.4%). DO was
 found in 46 (39.6%), DHIC in 15 (12.9%) and DUA in 20 (17.2%).    There was no 
significant difference between the 3 age groups regarding DO: II-A    (45.7%), I
I-B (36.1%) and II-C (37.7%). An increase in DHIC and DUA in subgroup    II-C wa
s observed.</font></p>     ^cY#a13v37n1.htm##
00756000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052100076002001300597#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#59#55#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Functional bladder    capacity (FBC)
 did not change significantly with age but depended on DO (<a href="/img/revista
s/ibju/v37n1/a13tab5.jpg">Table-5</a>).    Some other voiding parameters were mo
dified in DO patients: p<sub>det.op</sub>    and p<sub>det.Qmax</sub> increased,
 the voiding time decreased, except in group    A, and PVR was lower in group C.
 In the DO population, p<sub>det.op</sub> was    higher than p<sub>det.Qmax</sub
>.</font></p>     ^cY#a13v37n1.htm##
00414000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017900076002001300255#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#60#56#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Uroflow Parameters    (</b><a hre
f="/img/revistas/ibju/v37n1/a13tab6.jpg">Table-6</a><b>)</b></font></p>     ^cY#
a13v37n1.htm##
00542000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030700076002001300383#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#61#57#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Maximum flow rate    diminished wit
h age whether measured during FF or PFs, and was significantly    lower during P
Fs. The decrease was independent of DO. Post void residual (PVR)    significantl
y increased only in group C.</font></p>     ^cY#a13v37n1.htm##
00396000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016100076002001300237#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#62#58#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>UPP (</b><a href="/img/revistas/i
bju/v37n1/a13tab7.jpg">Table-7</a><b>)</b></font></p>     ^cY#a13v37n1.htm##
00510000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027500076002001300351#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#63#59#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Maximum urethral    closure pressure
 (MUCP) decreased steadily with age remaining in the range of    the "theoretica
l" value which is bladder filled (110 - age) &plusmn; 20% in    cm H2O (13).</fo
nt></p>     ^cY#a13v37n1.htm##
00548000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031300076002001300389#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#64#60#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">MUCP was non significantly    higher
 in continent patients either with bladder empty or bladder filled, but    was s
ignificantly lower bladder filled vs. bladder empty in incontinent whatever    t
he age and incontinent in group B.</font></p>     ^cY#a13v37n1.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011000076002001300186#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#65#61#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Urodynamic Diagnosis</b></font></
p>     ^cY#a13v37n1.htm##
00701000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046600076002001300542#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#66#62#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Detrusor hyperactivity    (DO or DH
IC) was the main urodynamic diagnosis increasing significantly in group    C: 68
/157 (43%) vs. 38/137 (27%) (A) and 36/155 (23%) (B) (p = 0.0004) whatever    th
e neurological status. DO was significantly more frequent (p = 0.007) in the    
age-group C (28%) vs. A (23%) and B (15%) and DHIC increased with ageing: 4%    
in A, 8% in B and 15% in C.</font></p>     ^cY#a13v37n1.htm##
00524000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028900076002001300365#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#67#63#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">DUA was predominant    in the oldest
 group 34/157 (22%) compared with 14/137 (10%) (A) and 14/155 (9%)    (B). That 
dysfunction was associated with an incompetent sphincter in 2 A patients,    5 B
 and 14 C.</font></p>     ^cY#a13v37n1.htm##
00432000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019700076002001300273#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#68#64#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Intrinsic sphincter    deficiency (I
SD) was predominant in B 56/155 (36%) vs. A 34/137 (25%) or C 38/157    (24%).</
font></p>     ^cY#a13v37n1.htm##
00446000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021100076002001300287#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#69#65#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Low bladder compliance    (= 20 mL/c
m H2O) was predominant in group B: 10 women of which 9 were without    neurologi
cal disease.</font></p>     ^cY#a13v37n1.htm##
00415000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018000076002001300256#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#70#66#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Normal urodynamic    tests were obse
rved in 31 (22%) A patients, 24 (15%) in B and 18 (11%) in C.</font></p>     ^cY
#a13v37n1.htm##
00397000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016200076002001300238#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#71#67#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Various or uncertain    diagnoses we
re more frequent in A (16%) and B (14%) than in C (6%).    ^cY#a13v37n1.htm##
00262000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002700076002001300103#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#72#68#article#141#<br>   </font></p> 
    ^cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#73#69#article#141#<p>&nbsp;</p>     ^
cY#a13v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#74#70#article#141#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>COMMENTS</b></font></p>     ^cY#a
13v37n1.htm##
00635000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040000076002001300476#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#75#71#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> This study was    retrospective and
 therefore has its own limitations. However, we used a standardized    protocol 
for urodynamics and all files contain the same items. The population    is repre
sentative of community-dwelling women with urinary disorders and age-groups    a
re homogeneous in the number of patients.</font></p>     ^cY#a13v37n1.htm##
01045000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704081000076002001300886#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#76#72#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In our postmenopausal    population,
 urinary incontinence (UI) was the main motive for urodynamics with    a percent
age variation between 61.3 and 68.8. These values, above the estimated    preval
ence of urinary incontinence in middle-aged and older women (4), resulted    fro
m our recruitment, i.e. women referred for evaluation of LUT dysfunction.    In 
the general population many patients avoid discussing problems related to    inc
ontinence, lowering the recorded percentages. Prevalence of urinary incontinence
    during the menopausal transition has been reported with a variation from 8% 
   to 56%; nevertheless, evidence that menopause is an independent factor in the
    prevalence of incontinence remains lacking (4).</font></p>     ^cY#a13v37n1.
htm##
00471000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023600076002001300312#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#77#73#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Mixed UI increases    with ageing, p
robably due to the association of a decreased urethral sphincter    function and
 occurrence of detrusor overactivity.</font></p>     ^cY#a13v37n1.htm##
00710000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047500076002001300551#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#78#74#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Urge incontinence does not vary sign
ificantly with age. On the other hand, stress    incontinence appears as slightl
y predominant in age-group B in patients who    take oral or transdermal HRT (or
 who have taken it five to ten years after menopause);    this is consistent wit
h the findings of Steinauer et al. (14) who report an    increased risk for stre
ss incontinence in women taking HRT.</font></p>     ^cY#a13v37n1.htm##
00408000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017300076002001300249#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#79#75#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Quality of life    scores show that 
the impact of LUT dysfunction remains stable with age.</font></p>     ^cY#a13v37
n1.htm##
00469000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023400076002001300310#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#80#76#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Achievement of    interpretable test
s, requiring a "comfortable" environment and some relaxation    is often difficu
lt at the beginning of the session.</font></p>     ^cY#a13v37n1.htm##
00441000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020600076002001300282#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#81#77#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">As previously reported    (7) FBC do
es not diminish with age and is smaller, with no variation with age,    in DO su
bjects.</font></p>     ^cY#a13v37n1.htm##
00582000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034700076002001300423#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#82#78#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">There are some    surprising results
 as the sub-group B differs from the others in terms of normal    detrusor behav
ior, low occurrence of DO and low bladder compliance. One plausible    explanati
on may by the higher incidence of stress incontinence in this group.</font></p> 
    ^cY#a13v37n1.htm##
00604000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036900076002001300445#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#83#79#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">DO increases with    age regardless 
of a history of neurological disease or previous pelvic surgery.    In the entir
e DO population, p<sub>det.op</sub> is higher than p<sub>det.Qmax</sub>    which
 may imply a common finding of an incomplete sphincter relaxation at the    onse
t of flow.</font></p>     ^cY#a13v37n1.htm##
00671000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043600076002001300512#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#84#80#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">DHIC, is a common    condition in fr
ail elderly individuals (12), and DUA increases in the same way;    these two la
tter behaviors lead respectively to UI with high PVR and to chronic    retention
. The decrease of detrusor contractility with ageing can be related    to the de
crease in caveolae, bladder weight and smooth muscle density with age    (3).</f
ont></p>     ^cY#a13v37n1.htm##
00856000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062100076002001300697#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#85#81#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">For a complaint    consistent with b
ladder overactivity (urge or mixed incontinence, frequency)    similar percentag
e (near 85%) in DO plus DHIC is found in the 3 age-groups.    Q<sub>max</sub>, p
<sub>det.op</sub> and p<sub>det.Qmax</sub> all decline with    age in women with
out DO. This observation is consistent with previous studies    which show age-a
ssociated deterioration of the detrusor contractility (15,16).    However, decre
ased contractility allows an effective emptying except in the    oldest age-grou
p where PVR increases.</font></p>     ^cY#a13v37n1.htm##
00640000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040500076002001300481#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#86#82#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">MUCP decreases    with age, a result
 consistent with previous studies (7); with the bladder filled,    the values ar
e in the range of the "theoretical values" (13). Perucchini et    al. (17) repor
ted that this decrease could be the reflect of the association    with age of a 
loss of striated muscle in the female urethra.</font></p>     ^cY#a13v37n1.htm##
00584000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034900076002001300425#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#87#83#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In incontinent    women, the decreas
e observed between bladder empty and bladder filled demonstrates    a lack of ad
aptation of the urethral sphincter to bladder filling. This behavior    could be
 the explained by both sphincter sarcopenia and impaired pelvic floor.</font></p
>     ^cY#a13v37n1.htm##
00456000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022100076002001300297#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#88#84#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">An unexpected and    unexplained fin
ding is the significant decrease of MUCP bladder filled in continent    women of
 the middle age-group.</font></p>     ^cY#a13v37n1.htm##
00531000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029600076002001300372#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#89#85#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">For a complaint    consistent with a
n impaired sphincter function (stress or mixed incontinence),    a lower urethra
l closure pressure than expected for age was found in only 52.6%    (A), 57.4% (
B) and 62.7% (C).</font></p>     ^cY#a13v37n1.htm##
00407000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017200076002001300248#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#90#86#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Urodynamic diagnosis    was found in
 a high percentage (90% or more) of the 3 age groups.</font></p>     ^cY#a13v37n
1.htm##
00746000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051100076002001300587#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#91#87#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Abnormal detrusor    behavior appear
s as the main final diagnosis with specific changes according    to ageing. In t
he oldest women without neurological disease, a significant increase    of DO, D
HIC was observed; the increase of DUA was not considered significant.    The inc
idence of DHIC and DUA in this age group is more likely related to decreased    
p<sub>det.op</sub> and p<sub>det.Qmax</sub> leading to an increased PVR.</font><
/p>     ^cY#a13v37n1.htm##
00564000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032900076002001300405#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#92#88#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In all groups,    complaint of stres
s and urge incontinence was respectively associated with ISD    and detrusor hyp
eractivity (DO or DHIC). Mixed incontinence was associated with    ISD in age-gr
oups B and C and with detrusor hyperactivity in C.</font></p>     ^cY#a13v37n1.h
tm##
00457000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022200076002001300298#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#93#89#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">One final question:    Can the respo
nsibility of the changes in LUT function be attributed to the normal    ageing p
rocess or to menopause?</font></p>     ^cY#a13v37n1.htm##
01138000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704090300076002001300979#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#94#90#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Although menopause    has been shown
 to be associated with urinary incontinence, evidence for it being    an indepen
dent factor in the prevalence of urinary incontinence and bladder    dysfunction
 remains lacking. In our population, menopause and ageing could be    considered
 as independent factors as the percentage of women taking HRT is insignificant. 
   Brisk changes in LUT function occurred in the oldest group while for the two 
   other age groups (A and B) changes were progressive. Note that the change in 
   urethral function is progressive with ageing. Therefore, if the role of menop
ause    can be considered in younger and middle age, we propose that the role of
 ageing    is predominant with a strenuous expression in advanced age as it main
ly implies    the detrusor which is less dependent on estrogens.</font></p>     
^cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#95#91#article#141#<p>&nbsp;</p>     ^
cY#a13v37n1.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#96#92#article#141#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUSION</b></font></p>     ^cY
#a13v37n1.htm##
01107000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087200076002001300948#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#97#93#article#141#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> In our community-dwelling    popula
tion of menopausal females urinary incontinence remains the main motive    for u
rodynamics and there is an increasing complaint of urgency with ageing.    The l
ack of adaptation of the sphincter to bladder filling could explain the    compl
aint of incontinence. The role of ageing clearly results from deterioration    i
n bladder function leading to DO, DHIC and DUA in the oldest group. Due to    th
e brisk changes in detrusor function between the middle and the oldest age    gr
oups the role of ageing appears to predominate. Further studies are needed    to
 search for a better understanding of the neural control of micturition in    ag
eing women and to better define the conditions leading to impaired detrusor    f
unction in the oldest age groups.</font></p>     ^cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#98#94#article#141#<p>&nbsp;</p>     ^
cY#a13v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#99#95#article#141#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONFLICT OF    INTEREST</b></font
></p>     ^cY#a13v37n1.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704009800077002001300175#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#100#96#article#141#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"> None declared.</font></p>     ^cY#
a13v37n1.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002200077002001300099#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#101#97#article#141#<p>&nbsp;</p>     
^cY#a13v37n1.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704010000077002001300177#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#102#98#article#141#<p><font size="3" 
face="Verdana, Arial, Helvetica, sans-serif"><b>REFERENCES</b></font></p>     ^c
Y#a13v37n1.htm##
00510000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704026000079002001300339#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#103#99#article#141#1#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 1. Cardozo L,    Rob
inson D: Special considerations in premenopausal and postmenopausal women    wit
h symptoms of overactive bladder. Urology. 2002; 60(5 Suppl 1): 64-71; discussio
n    71.    ^cY#a13v37n1.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#104#100#article#141#</font> </p>     
^cY#a13v37n1.htm##
00458000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704020700080002001300287#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#105#101#article#141#2#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Gosling JA:    Mo
dification of bladder structure in response to outflow obstruction and ageing.  
  Eur Urol. 1997; 32(Suppl 1) :9-14.    ^cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#106#102#article#141#</font></p>     ^
cY#a13v37n1.htm##
00501000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704025000080002001300330#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#107#103#article#141#3#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Elbadawi A,    Ya
lla SV, Resnick NM: Structural basis of geriatric voiding dysfunction. II.    Ag
ing detrusor: normal versus impaired contractility. J Urol. 1993; 150: 1657-67. 
   ^cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#108#104#article#141#</font></p>     ^
cY#a13v37n1.htm##
00471000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704022000080002001300300#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#109#105#article#141#4#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Sherburn M,    Gu
thrie JR, Dudley EC, O'Connell HE, Dennerstein L: Is incontinence associated    
with menopause? Obstet Gynecol. 2001; 98: 628-33.    ^cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#110#106#article#141#</font></p>     ^
cY#a13v37n1.htm##
00534000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704028300080002001300363#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#111#107#article#141#5#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Chen YC, Chen    
GD, Hu SW, Lin TL, Lin LY: Is the occurrence of storage and voiding dysfunction 
   affected by menopausal transition or associated with the normal aging process
?    Menopause. 2003; 10: 203-8.    ^cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#112#108#article#141#</font></p>     ^
cY#a13v37n1.htm##
00547000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704029600080002001300376#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#113#109#article#141#6#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Pfisterer MH,    
Griffiths DJ, Rosenberg L, Schaefer W, Resnick NM: Parameters of bladder functio
n    in pre-, peri-, and postmenopausal continent women without detrusor overact
ivity.    Neurourol Urodyn. 2007; 26: 356-61.    ^cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#114#110#article#141#</font></p>     ^
cY#a13v37n1.htm##
00487000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704023600080002001300316#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#115#111#article#141#7#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Pfisterer MH,    
Griffiths DJ, Schaefer W, Resnick NM: The effect of age on lower urinary tract  
  function: a study in women. J Am Geriatr Soc. 2006; 54: 405-12.    ^cY#a13v37n
1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#116#112#article#141#</font></p>     ^
cY#a13v37n1.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704023900080002001300319#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#117#113#article#141#8#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Valentini FA,    
Robain G, Marti BG, Nelson PP: Urodynamics in women from menopause to oldest    
age: what motive? what diagnosis? Int Braz J Urol. 2010; 36: 218-24.    ^cY#a13v
37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#118#114#article#141#</font></p>     ^
cY#a13v37n1.htm##
00535000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704028400080002001300364#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#119#115#article#141#9#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Sch&auml;fer    W
, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A, et al.: Good urodynamic 
   practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neuro
urol    Urodyn. 2002; 21: 261-74.    ^cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#120#116#article#141#</font></p>     ^
cY#a13v37n1.htm##
00526000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027400081002001300355#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#121#117#article#141#10#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Avery K, Donova
n    J, Peters TJ, Shaw C, Gotoh M, Abrams P: ICIQ: a brief and robust measure f
or    evaluating the symptoms and impact of urinary incontinence. Neurourol Urod
yn.    2004; 23: 322-30.    ^cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#122#118#article#141#</font></p>     ^
cY#a13v37n1.htm##
00600000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034800081002001300429#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#123#119#article#141#11#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Abrams P, Cardo
zo    L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al.: The standardisation o
f    terminology of lower urinary tract function: report from the Standardisatio
n    Sub-committee of the International Continence Society. Neurourol Urodyn. 20
02;    21: 167-78.    ^cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#124#120#article#141#</font></p>     ^
cY#a13v37n1.htm##
00509000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025700081002001300338#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#125#121#article#141#12#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Resnick NM,    
Yalla SV: Detrusor hyperactivity with impaired contractile function. An unrecogn
ized    but common cause of incontinence in elderly patients. JAMA. 1987; 257: 3
076-81.    ^cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#126#122#article#141#</font></p>     ^
cY#a13v37n1.htm##
00485000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023300081002001300314#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#127#123#article#141#13#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Constantinou   
 CE: Urethrometry: considerations of static, dynamic, and stability characterist
ics    of the female urethra. Neurourol Urodyn 1988; 7: 521-39.    ^cY#a13v37n1.
htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#128#124#article#141#</font></p>     ^
cY#a13v37n1.htm##
00505000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025300081002001300334#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#129#125#article#141#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Steinauer JE,  
  Waetjen LE, Vittinghoff E, Subak LL, Hulley SB, Grady D, et al.: Postmenopausa
l    hormone therapy: does it cause incontinence? Obstet Gynecol. 2005; 106: 940
-5.    ^cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#130#126#article#141#</font></p>     ^
cY#a13v37n1.htm##
00431000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017900081002001300260#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#131#127#article#141#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. van Mastrigt   
 R: Age dependence of urinary bladder contractility. Neurourol Urodyn 1992; 11: 
   315-7.    ^cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#132#128#article#141#</font></p>     ^
cY#a13v37n1.htm##
00451000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019900081002001300280#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#133#129#article#141#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Resnick NM,    
Elbadawi A, Yalla SV: Age and the lower urinary tract: what is normal? Neurourol
    Urodyn 1995; 14: 577-579.    ^cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#134#130#article#141#</font></p>     ^
cY#a13v37n1.htm##
00521000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026900081002001300350#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#135#131#article#141#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Perucchini    D
, DeLancey JO, Ashton-Miller JA, Galecki A, Schaer GN: Age effects on urethral  
  striated muscle. II. Anatomic location of muscle loss. Am J Obstet Gynecol.   
 2002; 186: 356-60.    ^cY#a13v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#136#132#article#141#</font></p>     ^
cY#a13v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#137#133#article#141#<p>&nbsp;</p>    
 ^cY#a13v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#138#134#article#141#<p>&nbsp;</p>    
 ^cY#a13v37n1.htm##
00368000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704013100078002001300209#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#139#135#article#141#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><i>Accepted after    revision: Jun
e 26, 2010</i></font></p>     ^cY#a13v37n1.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019300078002001300271#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#140#136#article#141#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><b><a name="end"></a><a href="#top
"><img src="/img/revistas/ibju/v37n1/seta.gif" border="0"></a>    Correspondence
 to:</b>    ^cY#a13v37n1.htm##
00285000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004800078002001300126#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#141#137#article#141#<br>   Dr. Fran&c
cedil;oise A. Valentini    ^cY#a13v37n1.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006400078002001300142#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#142#138#article#141#<br>   Universit&
eacute; Pierre et Marie Curie (Paris 6)    ^cY#a13v37n1.htm##
00288000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005100078002001300129#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#143#139#article#141#<br>   4 Place Ju
ssieu, 75005 Paris, France    ^cY#a13v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003600078002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#144#140#article#141#<br>   Fax: + 33 
1 4959-4697    ^cY#a13v37n1.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009900078002001300177#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a13v37n1.htm#S#p#145#141#article#141#<br>   E-mail: <a
 href="mailto:favalentini@gmail.com">favalentini@gmail.com</a></font></p>     ^c
Y#a13v37n1.htm##
00583000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100018000940120
10500112030000800217065000900225064000500234031000300239032000500242014000600247
865000900253002001300262035001000275801000800285#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a13v37n1.htm#S#c#146#1#article#17#1#^rND^sCardozo^nL#^rND^sRobinson^nD
#Special considerations in premenopausal and postmenopausal women with symptoms 
of overactive bladder^len#Urology#20020000#2002#60#5^s1#64-71#20110200#a13v37n1.
htm#0090-4295#Urology##
00533000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770120084000950300
00900179065000900188064000500197031000300202032000400205014000500209865000900214
002001300223035001000236801000900246#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a1
3v37n1.htm#S#c#147#2#article#17#2#^rND^sGosling^nJA#Modification of bladder stru
cture in response to outflow obstruction and ageing^len#Eur Urol#19970000#1997#3
2#^s1#9-14#20110200#a13v37n1.htm#0302-2838#Eur Urol##
00603000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100016000950100
01800111012011200129030000700241065000900248064000500257031000400262014000800266
865000900274002001300283035001000296801000700306#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a13v37n1.htm#S#c#148#3#article#17#3#^rND^sElbadawi^nA#^rND^sYalla^nSV#
^rND^sResnick^nNM#Structural basis of geriatric voiding dysfunction: II. Aging d
etrusor: normal versus impaired contractility^len#J Urol#19930000#1993#150#1657-
67#20110200#a13v37n1.htm#0022-5347#J Urol##
00618000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100018000950100
01700113010002000130010002100150012004700171030001500218065000900233064000500242
031000300247014000700250865000900257002001300266035001000279801001500289#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#c#149#4#article#17#4#^rND^sSher
burn^nM#^rND^sGuthrie^nJR#^rND^sDudley^nEC#^rND^sO'Connell^nHE#^rND^sDennerstein
^nL#Is incontinence associated with menopause?^len#Obstet Gynecol#20010000#2001#
98#628-33#20110200#a13v37n1.htm#0029-7844#Obstet Gynecol##
00673000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100015000920100
01300107010001400120010001400134012013600148030001000284065000900294064000500303
031000300308014000600311865000900317002001300326035001000339801001000349#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#c#150#5#article#17#5#^rND^sChen
^nYC#^rND^sChen^nGD#^rND^sHu^nSW#^rND^sLin^nTL#^rND^sLin^nLY#Is the occurrence o
f storage and voiding dysfunction affected by menopausal transition or associate
d with the normal aging process?^len#Menopause#20030000#2003#10#203-8#20110200#a
13v37n1.htm#1072-3714#MENOPAUSE##
00692000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100020000970100
01900117010001800136010001800154012011600172030001700288065000900305064000500314
031000300319014000700322865000900329002001300338035001000351801001700361#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#c#151#6#article#17#6#^rND^sPfis
terer^nMH#^rND^sGriffiths^nDJ#^rND^sRosenberg^nL#^rND^sSchaefer^nW#^rND^sResnick
^nNM#Parameters of bladder function in pre-, peri-, and postmenopausal continent
 women without detrusor overactivity^len#Neurourol Urodyn#20070000#2007#26#356-6
1#20110200#a13v37n1.htm#0733-2467#Neurourol Urodyn##
00617000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100020000970100
01800117010001800135012007200153030001700225065000900242064000500251031000300256
014000700259865000900266002001300275035001000288801001700298#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a13v37n1.htm#S#c#152#7#article#17#7#^rND^sPfisterer^nMH#^r
ND^sGriffiths^nDJ#^rND^sSchaefer^nW#^rND^sResnick^nNM#The effect of age on lower
 urinary tract function: a study in women^len#J Am Geriatr Soc#20060000#2006#54#
405-12#20110200#a13v37n1.htm#0002-8614#J Am Geriatr Soc##
00584000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100016000970100
01600113010001700129012008400146030001600230710000200246065000900248064000500257
031000300262014000700265865000900272002001300281#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a13v37n1.htm#S#c#153#8#article#17#8#^rND^sValentini^nFA#^rND^sRobain^n
G#^rND^sMarti^nBG#^rND^sNelson^nPP#Urodynamics in women from menopause to oldest
 age: what motive? what diagnosis?^len#Int Braz J Urol#2#20100000#2010#36#218-24
#20110200#a13v37n1.htm##
00703000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100016000940100
01400110010002000124010001500144010001900159810000600178012009100184030001700275
06500090029206400050030103100030030601400070030986500090031600200130032503500100
0338801001700348#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#c#154#9
#article#17#9#^rND^sSchäfer^nW#^rND^sAbrams^nP#^rND^sLiao^nL#^rND^sMattiasson^nA
#^rND^sPesce^nF#^rND^sSpangberg^nA#et al#Good urodynamic practices: uroflowmetry
, filling cystometry, and pressure-flow studies^len#Neurourol Urodyn#20020000#20
02#21#261-74#20110200#a13v37n1.htm#0733-2467#Neurourol Urodyn##
00687000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01700111010001400128010001500142010001600157012009800173030001700271065000900288
06400050029703100030030201400070030586500090031200200130032103500100033480100170
0344#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#c#155#10#article#17
#10#^rND^sAvery^nK#^rND^sDonovan^nJ#^rND^sPeters^nTJ#^rND^sShaw^nC#^rND^sGotoh^n
M#^rND^sAbrams^nP#ICIQ: brief and robust measure for evaluating the symptoms and
 impact of urinary incontinence^len#Neurourol Urodyn#20040000#2004#23#322-30#201
10200#a13v37n1.htm#0733-2467#Neurourol Urodyn##
00770000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01400112010001900126010001600145010001700161810000600178012015800184030001700342
06500090035906400050036803100030037301400070037686500090038300200130039203500100
0405801001700415#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#c#156#1
1#article#17#11#^rND^sAbrams^nP#^rND^sCardozo^nL#^rND^sFall^nM#^rND^sGriffiths^n
D#^rND^sRosier^nP#^rND^sUlmsten^nU#et al#The standardisation of terminology of l
ower urinary tract function: report from the Standardisation Sub-committee of th
e International Continence Society^len#Neurourol Urodyn#20020000#2002#21#167-78#
20110200#a13v37n1.htm#0733-2467#Neurourol Urodyn##
00591000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970120
13200113030000500245065000900250064000500259031000400264014000800268865000900276
002001300285035001000298801000500308#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a1
3v37n1.htm#S#c#157#12#article#17#12#^rND^sResnick^nNM#^rND^sYalla^nSV#Detrusor h
yperactivity with impaired contractile function. An unrecognized but common caus
e of incontinence in elderly patients^len#JAMA#19870000#1987#257#3076-81#2011020
0#a13v37n1.htm#0098-7484#JAMA##
00562000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100023000790120105001020300
01700207065000900224064000500233031000200238014000700240865000900247002001300256
035001000269801001700279#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S
#c#158#13#article#17#13#^rND^sConstantinou^nCE#Urethrometry: considerations of s
tatic, dynamic, and stability characteristics of the female urethra^len#Neurouro
l Urodyn#19880000#1988#7#521-39#20110200#a13v37n1.htm#0733-2467#Neurourol Urodyn
##
00680000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100018000990100
02100117010001600138010001700154010001500171810000600186012006400192030001500256
06500090027106400050028003100040028501400060028986500090029500200130030403500100
0317801001500327#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#c#159#1
4#article#17#14#^rND^sSteinauer^nJE#^rND^sWaetjen^nLE#^rND^sVittinghoff^nE#^rND^
sSubak^nLL#^rND^sHulley^nSB#^rND^sGrady^nD#et al#Postmenopausal hormone therapy:
 does it cause incontinence?^len#Obstet Gynecol#20050000#2005#106#940-5#20110200
#a13v37n1.htm#0029-7844#Obstet Gynecol##
00508000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790120052001010300
01700153065000900170064000500179031000300184014000600187865000900193002001300202
035001000215801001700225#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S
#c#160#15#article#17#15#^rND^svan Mastrigt^nR#Age dependence of urinary bladder 
contractility^len#Neurourol Urodyn#19920000#1992#11#315-7#20110200#a13v37n1.htm#
0733-2467#Neurourol Urodyn##
00565000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970100
01600115012005300131030001700184065000900201064000500210031000300215014000800218
865000900226002001300235035001000248801001700258#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a13v37n1.htm#S#c#161#16#article#17#16#^rND^sResnick^nNM#^rND^sElbadawi
^nA#^rND^sYalla^nSV#Age and the lower urinary tract: what is normal?^len#Neurour
ol Urodyn#19950000#1995#14#577-579#20110200#a13v37n1.htm#0733-2467#Neurourol Uro
dyn##
00670000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100019000990100
02400118010001700142010001700159012008300176030002000259065000900279064000500288
031000400293014000700297865000900304002001300313035001000326801002000336#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a13v37n1.htm#S#c#162#17#article#17#17#^rND^sPe
rucchini^nD#^rND^sDeLancey^nJO#^rND^sAshton-Miller^nJA#^rND^sGalecki^nA#^rND^sSc
haer^nGN#Age effects on urethral striated muscle.: II. Anatomic location of musc
le loss^len#Am J Obstet Gynecol#20020000#2002#186#356-60#20110200#a13v37n1.htm#0
002-9378#Am J Obstet Gynecol##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#o#1#1#article#1
#20110330#144529#a14v37n1.htm#128##
02834000000000493000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030001800109
03100030012703200020013006500090013201400110014103500100015201200970016201000350
02590100034002940100030003280100026003580700088003840831714004720850010021860850
02402196085002002220085002002240085002102260085003702281117000602318072000302324
002001302327#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#h#2#1#artic
le#1#oa#en#br1.1#1#4.0#ILUS#14#IBJU120#nd#Int. braz j urol.#37#1#20110200#^f108^
l112#1677-5538#Laparoscopic skill laboratory in urological surgery: tools and me
thods for resident training^len#^rND^1A01^nFabio C. M.^sTorricelli#^rND^1A01^nGi
uliano^sGuglielmetti#^rND^1A01^nRicardo J.^sDuarte#^rND^1A01^nMiguel^sSrougi#Uni
versity of Sao Paulo Medical School^iA01^1Hospital das Clinicas^2Division of Uro
logy#^len^aPURPOSE: Laparoscopy has certainly brought considerable benefits to p
atients, but laparoscopic surgery requires a set of skills different from open s
urgery, and learning in the operating room may increase surgical time, and even 
may be harmful to patients. Several training programs have been developed to dec
rease these potential prejudices. PURPOSES: to describe the laparoscopic trainin
g program for urological residents of the "Hospital das Clinicas" of the Sao Pau
lo Medical School, to report urological procedures that are feasible in dry and 
wet labs, and to perform a critical analysis of the cost-benefit relation of adv
anced laparoscopic skills laboratory. MATERIALS AND METHODS: The laparoscopic sk
ill lab has two virtual simulators, three manual simulators, and four laparoscop
ic sets for study with a porcine model. The urology residents during their first
 year attend classes in the virtual and manual simulator and helps the senior ur
ological resident in activities carried out with the laparoscopic sets. During t
he second year, the urological resident has six periods per week, each period la
sting four hours, to perform laparoscopic procedures with a porcine model. Resul
ts: In a training program of ten weeks, one urological resident performs an aver
age of 120 urological procedures. The most common procedures are total nephrecto
my (30%), bladder suture (30%), partial nephrectomy (10%), pyeloplasty (10%), ur
eteral replacement or transuretero anastomosis (10%), and others like adrenalect
omy, prostatectomy, and retroperitoneoscopy. These procedures are much quicker a
nd caused less morbidity. CONCLUSION: Laparoscopic skills laboratory is a good m
ethod for achieving technical ability.#^ddecs^i1#^tm^len^klaparoscopy^i1#^tm^len
^kurology^i1#^tm^len^ksurgery^i1#^tm^len^ktraining^i1#^tm^len^kinternship and re
sidency^i1#other#16#a14v37n1.htm##
02876000000000493000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030001800109
03100030012703200020013006500090013201400110014103500100015201201110016201000350
02730100034003080100030003420100026003720700088003980831742004860850010022280850
02402238085002002262085002002282085002102302085003702323117000602360072000302366
002001302369#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#f#3#1#artic
le#1#oa#en#br1.1#1#4.0#ILUS#14#IBJU120#nd#Int. braz j urol.#37#1#20110200#^f108^
l112#1677-5538#<b>Laparoscopic skill laboratory in urological surgery</b>: <b>to
ols and methods for resident training</b>^len#^rND^1A01^nFabio C. M.^sTorricelli
#^rND^1A01^nGiuliano^sGuglielmetti#^rND^1A01^nRicardo J.^sDuarte#^rND^1A01^nMigu
el^sSrougi#University of Sao Paulo Medical School^iA01^1Hospital das Clinicas^2D
ivision of Urology#^len^a<b>PURPOSE:</b> Laparoscopy has certainly brought consi
derable benefits to patients, but laparoscopic surgery requires a set of skills 
different from open surgery, and learning in the operating room may increase sur
gical time, and even may be harmful to patients. Several training programs have 
been developed to decrease these potential prejudices. <b>PURPOSES:</b> to descr
ibe the laparoscopic training program for urological residents of the "Hospital 
das Clinicas" of the Sao Paulo Medical School, to report urological procedures t
hat are feasible in dry and wet labs, and to perform a critical analysis of the 
cost-benefit relation of advanced laparoscopic skills laboratory. <b>MATERIALS A
ND METHODS:</b> The laparoscopic skill lab has two virtual simulators, three man
ual simulators, and four laparoscopic sets for study with a porcine model. The u
rology residents during their first year attend classes in the virtual and manua
l simulator and helps the senior urological resident in activities carried out w
ith the laparoscopic sets. During the second year, the urological resident has s
ix periods per week, each period lasting four hours, to perform laparoscopic pro
cedures with a porcine model. Results: In a training program of ten weeks, one u
rological resident performs an average of 120 urological procedures. The most co
mmon procedures are total nephrectomy (30%), bladder suture (30%), partial nephr
ectomy (10%), pyeloplasty (10%), ureteral replacement or transuretero anastomosi
s (10%), and others like adrenalectomy, prostatectomy, and retroperitoneoscopy. 
These procedures are much quicker and caused less morbidity. <b>CONCLUSION:</b> 
Laparoscopic skills laboratory is a good method for achieving technical ability.
#^ddecs^i1#^tm^len^klaparoscopy^i1#^tm^len^kurology^i1#^tm^len^ksurgery^i1#^tm^l
en^ktraining^i1#^tm^len^kinternship and residency^i1#other#16#a14v37n1.htm##
02999000000000517000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108121000300113049000800116158000300124
03000170012703100030014403200020014706500090014901400110015803500100016901200970
01790100034002760100034003100100029003440100026003730700090003990831749004890850
01002238085002402248085002002272085002002292085002102312085003702333117000602370
072000302376002001302379008008902392#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a1
4v37n1.htm#S#l#4#1#article#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#ilus#14#IBJU120
#nd#Int. braz j urol#37#1#20110200#^f108^l112#1677-5538#Laparoscopic skill labor
atory in urological surgery: tools and methods for resident training^len#^rND^1A
01^nFabio C. M^sTorricelli#^rND^1A01^nGiuliano^sGuglielmetti#^rND^1A01^nRicardo 
J^sDuarte#^rND^1A01^nMiguel^sSrougi#^iA01^1University of Sao Paulo Medical Schoo
l^2Hospital das Clinicas^3Division of Urology#^len^aPURPOSE: Laparoscopy has cer
tainly brought considerable benefits to patients, but laparoscopic surgery requi
res a set of skills different from open surgery, and learning in the operating r
oom may increase surgical time, and even may be harmful to patients. Several tra
ining programs have been developed to decrease these potential prejudices. PURPO
SES: to describe the laparoscopic training program for urological residents of t
he "Hospital das Clinicas" of the Sao Paulo Medical School, to report urological
 procedures that are feasible in dry and wet labs, and to perform a critical ana
lysis of the cost-benefit relation of advanced laparoscopic skills laboratory. M
ATERIALS AND METHODS: The laparoscopic skill lab has two virtual simulators, thr
ee manual simulators, and four laparoscopic sets for study with a porcine model.
 The urology residents during their first year attend classes in the virtual and
 manual simulator and helps the senior urological resident in activities carried
 out with the laparoscopic sets. During the second year, the urological resident
 has six periods per week, each period lasting four hours, to perform laparoscop
ic procedures with a porcine model. Results: In a training program of ten weeks,
 one urological resident performs an average of 120 urological procedures. The m
ost common procedures are total nephrectomy (30 percent), bladder suture (30 per
cent), partial nephrectomy (10 percent), pyeloplasty (10 percent), ureteral repl
acement or transuretero anastomosis (10 percent), and others like adrenalectomy,
 prostatectomy, and retroperitoneoscopy. These procedures are much quicker and c
aused less morbidity. CONCLUSION: Laparoscopic skills laboratory is a good metho
d for achieving technical ability.#^ddecs^i1#^tm^len^klaparoscopy^i1#^tm^len^kur
ology^i1#^tm^len^ksurgery^i1#^tm^len^ktraining^i1#^tm^len^kinternship and reside
ncy^i1#other#16#a14v37n1.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sc
i_arttext&pid=S1677-55382011000100014##
00371000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704013800074002001300212#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#5#1#article#108#<p align="right"><fon
t face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>BASIC    AND TRANSLAT
IONAL UROLOGY</b></font></p>     ^cY#a14v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#6#2#article#108#<p>&nbsp;</p>     ^cY
#a14v37n1.htm##
00436000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704020300074002001300277#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#7#3#article#108#<p><a name="top"></a>
<font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Laparoscopic    s
kill laboratory in urological surgery: tools and methods for resident training</
b></font></p>     ^cY#a14v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#8#4#article#108#<p>&nbsp;</p>     ^cY
#a14v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#9#5#article#108#<p>&nbsp;</p>     ^cY
#a14v37n1.htm##
00390000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704015600075002001300231#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#10#6#article#108#<p><font face="Verda
na, Arial, Helvetica, sans-serif" size="2"><b>Fabio    C. M. Torricelli; Giulian
o Guglielmetti; Ricardo J. Duarte; Miguel Srougi    ^cY#a14v37n1.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704003200075002001300107#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#11#7#article#108#<br>   </b> </font><
/p>     ^cY#a14v37n1.htm##
00414000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704018000075002001300255#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#12#8#article#108#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Division of Urology,    Hospital das 
Clinicas, University of Sao Paulo Medical School, SP, Brazil</font></p>     ^cY#
a14v37n1.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011600075002001300191#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#13#9#article#108#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#end">Correspondence</a></fo
nt></p>     ^cY#a14v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#14#10#article#108#<p>&nbsp;</p>     ^
cY#a14v37n1.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#15#11#article#108#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a14v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#16#12#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#a
14v37n1.htm##
00667000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043200076002001300508#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#17#13#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>PURPOSE:</b>    Laparoscopy has c
ertainly brought considerable benefits to patients, but laparoscopic    surgery 
requires a set of skills different from open surgery, and learning in    the ope
rating room may increase surgical time, and even may be harmful to patients.    
Several training programs have been developed to decrease these potential prejud
ices.    ^cY#a14v37n1.htm##
00592000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035700076002001300433#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#18#14#article#108#<br>   <b>PURPOSES:
</b> to describe the laparoscopic training program for urological    residents o
f the "Hospital das Clinicas" of the Sao Paulo Medical School, to    report urol
ogical procedures that are feasible in dry and wet labs, and to perform    a cri
tical analysis of the cost-benefit relation of advanced laparoscopic skills    l
aboratory.    ^cY#a14v37n1.htm##
00791000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055600076002001300632#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#19#15#article#108#<br>   <b>MATERIALS
 AND METHODS:</b> The laparoscopic skill lab has two virtual simulators,    thre
e manual simulators, and four laparoscopic sets for study with a porcine    mode
l. The urology residents during their first year attend classes in the virtual  
  and manual simulator and helps the senior urological resident in activities   
 carried out with the laparoscopic sets. During the second year, the urological 
   resident has six periods per week, each period lasting four hours, to perform
    laparoscopic procedures with a porcine model.    ^cY#a14v37n1.htm##
00695000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046000076002001300536#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#20#16#article#108#<br>   Results: In 
a training program of ten weeks, one urological resident performs    an average 
of 120 urological procedures. The most common procedures are total    nephrectom
y (30%), bladder suture (30%), partial nephrectomy (10%), pyeloplasty    (10%), 
ureteral replacement or transuretero anastomosis (10%), and others like    adren
alectomy, prostatectomy, and retroperitoneoscopy. These procedures are    much q
uicker and caused less morbidity.    ^cY#a14v37n1.htm##
00364000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012900076002001300205#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#21#17#article#108#<br>   <b>CONCLUSIO
N:</b> Laparoscopic skills laboratory is a good method for achieving    technica
l ability.</font></p>     ^cY#a14v37n1.htm##
00427000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019200076002001300268#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#22#18#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Key words:</b>    laparoscopy; ur
ology; surgery; training; internship and residency </font></p> <HR size="1" nosh
ade>     ^cY#a14v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#23#19#article#108#<p>&nbsp;</p>     ^
cY#a14v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#24#20#article#108#<p>&nbsp;</p>     ^
cY#a14v37n1.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#25#21#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODUCTION</b></font></p>     ^
cY#a14v37n1.htm##
01012000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077700076002001300853#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#26#22#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Today, there is    no doubt that mi
nimally invasive surgery is the method of choice by patients    and surgeons as 
an approach to most urological surgical pathologies. It has    brought considera
ble benefits to patients such as, smaller incision with better    cosmetic resul
ts, reduced morbidity, faster recovery, and shorter hospital length    of stay (
1). Laparoscopic procedures are certainly the most important technique    that f
ulfils these purposes. However, laparoscopic surgery requires a different    set
 of skills from open surgery, and learning in the operating room may increase   
 surgical time and even morbidity for patients, moreover, it may be against ethi
cal    principles.</font></p>     ^cY#a14v37n1.htm##
00938000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070300076002001300779#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#27#23#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The acquisition    of basic laparosc
opic skills may help beginners who are learning laparoscopic    procedures. Howe
ver, it demands considerable time and dedication from trainees    and also requi
res appropriate teaching facilities. Current training involves    the use of box
 trainers, virtual reality, and animal models. Box trainers with    either innat
e models or animal tissues lack objective assessment of skill acquisition.    Vi
rtual reality simulators have the ability to teach laparoscopic psychomotor    s
kills, and objective assessment is now possible using dexterity-based and video 
   analyses systems (2).</font></p>     ^cY#a14v37n1.htm##
00854000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061900076002001300695#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#28#24#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A recent survey    (3) of surgery re
sidency program directors revealed that 55% of surgery training    programs have
 used laparoscopic skills laboratories. Nowadays, a resident in    surgery is no
t allowed to end his/her training program without being able to    perform lapar
oscopic surgery. Numerous protocols for laparoscopic skills training    using vi
rtual simulators and animal models have been described in the literature.    How
ever, there is a lack of guidelines about the training of an urologist for    im
proving such skills.</font></p>     ^cY#a14v37n1.htm##
00740000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050500076002001300581#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#29#25#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The aims of this    study were: to d
escribe the laparoscopic training program of the urological    residents of the 
"Hospital das Clinicas" of the Sao Paulo Medical School, University    of Sao Pa
ulo, to report urological procedures that are feasible in manual and    virtual 
simulators and with porcine model, and to perform a critical analysis    of the 
cost-benefit relation of advanced laparoscopic skill laboratories.</font></p>   
  ^cY#a14v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#30#26#article#108#<p>&nbsp;</p>     ^
cY#a14v37n1.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011400076002001300190#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#31#27#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>MATERIALS AND    METHODS</b></fon
t></p>     ^cY#a14v37n1.htm##
01318000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704108300076002001301159#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#32#28#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The laparoscopic    skill laborator
y of the "Hospital das Clinicas" of the Sao Paulo Medical School,    University 
of Sao Paulo, has completed three years in the training of urological    residen
ts. The urology department has 15 residents (five residents are admitted    per 
year for a three years course). It has two virtual and three manual simulators  
  and four laparoscopic sets for studying with a porcine model (<a href="#fig1">
Figure-1</a>).    The materials (laparoscopic equipments and threads) are acquir
ed from donations    or are bought at low-cost from retail stores. The animals a
re donated by a private    group. A salaried laboratory manager is responsible f
or maintaining the laboratory    schedule, setting-up, and keeping records of la
boratories expenditures. It is    estimated that the total direct or indirect ex
penses funded both by the Government    or private sources amount about US$ 1.0 
M in the project and construction of    this advanced laparoscopic skill laborat
ory.</font></p>     ^cY#a14v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#33#29#article#108#<p>&nbsp;</p>     ^
cY#a14v37n1.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#34#30#article#108#<p><a name="fig1"><
/a></p>     ^cY#a14v37n1.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007900076002001300155#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#35#31#article#108#<p align="center"><
img src="/img/revistas/ibju/v37n1/a14fig1.jpg"></p>     ^cY#a14v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#36#32#article#108#<p>&nbsp;</p>     ^
cY#a14v37n1.htm##
01246000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704101100076002001301087#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#37#33#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The urological    resident, during h
is first year, attends classes in the virtual and manual simulator    once a wee
k (basic skills) and helps the senior urological residents twice a    week in ac
tivities with the laparoscopic sets. During the second year, the urological    r
esident has six periods per week, each period lasting four hours, for performing
    laparoscopic procedures with a porcine model. These procedures range from ne
phrectomy,    simple bladder suture or transuretero-anastomosis, pyeloplasty, an
d prostatectomy.    Six pigs are available per week and all activities are super
vised by one staff    surgeon of the laparoscopic group of the urology departmen
t. Once a week, this    resident also performs one laparoscopic surgery on a pat
ient in the operating    room of our service, always in the presence of a physic
ian supervisor. The period    for training each resident in our service lasts fo
r ten weeks.</font></p>     ^cY#a14v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#38#34#article#108#<p>&nbsp;</p>     ^
cY#a14v37n1.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#39#35#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>RESULTS</b></font></p>     ^cY#a1
4v37n1.htm##
00801000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056600076002001300642#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#40#36#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> By the end of    the ten week train
ing program one urological resident has carried out an average    of 120 urologi
cal procedures. The most common procedures are total nephrectomy    (30%), bladd
er suture (30%), partial nephrectomy (10%), pyeloplasty (10%), ureteral    repla
cement or transuretero anastomosis (10%) and others like adrenalectomy,    prost
atectomy, and retroperitoneoscopy. All procedures follow the stages of    surger
y done on human beings with a great similarity.</font></p>     ^cY#a14v37n1.htm#
#
00702000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046700076002001300543#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#41#37#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The first year    urology resident a
lso improves their skills. After helping the senior resident    for ten weeks, t
hey are familiarized with abdominal access and proper trocar    placement, is co
mpletely adapted to laparoscopic bi-dimensional vision, and    is capable of per
forming basic tasks such as sutures, points and even more complex    procedures 
such as total nephrectomies.</font></p>     ^cY#a14v37n1.htm##
00753000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051800076002001300594#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#42#38#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The benefits are    evident in the r
eal operating room. The residents become more familiarized with    the procedure
s, the mean time of procedures decreases and fewer complications    are observed
 in the last weeks of the training program. The results are procedures    that a
re quicker, safer, and with less morbidity. It also represents an economy,    si
nce less time is spent in the operating room and patients are released earlier.<
/font></p>     ^cY#a14v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#43#39#article#108#<p>&nbsp;</p>     ^
cY#a14v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#44#40#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>COMMENTS</b></font></p>     ^cY#a
14v37n1.htm##
01519000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704128400076002001301360#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#45#41#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Minimally invasive    techniques as
 laparoscopy are more and more responsible for higher proportion    of total sur
gical procedures performed in operating rooms. Issues such as quality    control
 and patient safety, combined with increasing financial constraints and    cost-
effective results in operating rooms have to be considered as a need for    more
 skills training laboratories (4). Computer-based virtual reality systems    hav
e recently been developed and incorporated into some surgery residents training 
   programs (5-9). A recent survey done in USA revealed that 85% of general surg
ery    program directors consider skills labs effective for improving operating 
room    performance, however, only 55% have skills labs. Ninety-nine percent of 
these    have video trainer equipment and 46% have virtual reality trainer equip
ment.    On average, residents train for 0.8 hours per week (range 0 to 6), and 
this    training is mandatory for 55% and supervised for 73%. The mean developme
nt cost    was US$ 133,000 (3). This period of training is shorter than the one 
proposed    in our laparoscopic skill lab, where one resident spent more than 20
 hours per    week for a period of ten weeks.</font></p>     ^cY#a14v37n1.htm##
00665000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043000076002001300506#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#46#42#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Surgical skills    laboratories prov
ide residents with the opportunity to acquire technical skills    in a low stres
sed and stimulated environment, while focusing on learning and    repeating key 
stages of procedures in a setting where they are able to reduce    their learnin
g curve with the goal of decreasing potential harm to patients    (10).</font></
p>     ^cY#a14v37n1.htm##
00976000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074100076002001300817#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#47#43#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Some authors have    reported the be
nefits of laparoscopic training program. Vlaovic et al. (11)    reported their e
xperience with 101 urologists submitted to a one-week laparoscopic    training p
rogram and concluded that it significantly improved laparoscopic skills.    Pare
ek et al. (12) reported the results of a 2-day course of laparoscopic training. 
   Of the participants that answered the survey, 97% reported that their laparos
copic    practice had expanded after taking course. Condous et al. (13) in a pro
spective    observational study with 24 surgeons concluded that laparoscopic ski
lls workshops    could improve both knowledge and motor skill.</font></p>     ^c
Y#a14v37n1.htm##
02187000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704195200076002001302028#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#48#44#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Several studies have tried to compar
e the tools now available for training and    development of laparoscopic skills
. Manda et al. (14) compared the combination    of virtual reality and box train
ing. Twenty-four students were grouped according    to four training methods: vi
rtual reality training, inanimate box training,    a combination of both and no 
training. Post hoc analyses showed statistically    significant differences betw
een the participants with both trainers and control    subjects. Combination of 
virtual reality training and inanimate box training    leads to a better laparos
copic skill acquisition than either training method    alone or no training at a
ll. Munz et al. (4) compared the virtual reality simulator    with the classical
 box trainer. Again twenty-four beginners were divided into    three groups: vir
tual reality simulator, box trainer and no training and the    authors found tha
t both trained groups made significant improvements in all    parameters measure
d, however there was no difference between the tools of training.    They conclu
ded that they are equally effective in teaching psychomotor skills,    but a lar
ge cohort may show different results. We were not able to compare the    develop
ment of our residents, since the training was basically performed in    laparosc
opic sets, where objective evaluation is very limited. Our impression    is that
 the benefits are real with a great increase in laparoscopic skills of    our re
sidents who become more prepared for surgery in the operating room. Moreover,   
 porcine models made it possible to perform a larger number of urological proced
ures.    Perhaps in a future study we may be able to compare mean surgical time,
 blood    loss, and other parameters before, during, and after our training prog
ram, in    surgeries performed in the lab and in the real operating room.</font>
</p>     ^cY#a14v37n1.htm##
00767000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053200076002001300608#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#49#45#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The studies available    today are v
ery limited as far as cost analysis is concerned. Berg et al. (10)    reported t
hat they are able to provide surgical skills training for about $1,000    per re
sident per year; however the costs of donated services, equipment, and    suppli
es were not estimated. We have a similar problem in our cost assessment,    beca
use our material was acquired from donations or was bought at low-cost from    r
etail stores.</font></p>     ^cY#a14v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#50#46#article#108#<p>&nbsp;</p>     ^
cY#a14v37n1.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#51#47#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONCLUSION</b></font></p>     ^cY
#a14v37n1.htm##
00491000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025600076002001300332#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#52#48#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Laparoscopic skills    laboratory a
re an effective way for achieving technical skills in an optimal    environment 
and with the potential of being less harmful to patients.</font></p>     ^cY#a14
v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#53#49#article#108#<p>&nbsp;</p>     ^
cY#a14v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#54#50#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>CONFLICT OF    INTEREST</b></font
></p>     ^cY#a14v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#55#51#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> None declared.</font></p>     ^cY#a
14v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#56#52#article#108#<p>&nbsp;</p>     ^
cY#a14v37n1.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#57#53#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFERENCES</b></font></p>     ^cY
#a14v37n1.htm##
00410000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704016100078002001300239#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#58#54#article#108#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> 1. Darzi A, Mackay   
 S: Recent advances in minimal access surgery. BMJ. 2002; 324: 31-4.    ^cY#a14v
37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#59#55#article#108#</font> </p>     ^c
Y#a14v37n1.htm##
00435000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704018600078002001300264#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#60#56#article#108#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Aggarwal R,    Moor
thy K, Darzi A: Laparoscopic skills training and assessment. Br J Surg.    2004;
 91: 1549-58.    ^cY#a14v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#61#57#article#108#</font></p>     ^cY
#a14v37n1.htm##
00497000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024800078002001300326#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#62#58#article#108#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Korndorffer    JR J
r, Stefanidis D, Scott DJ: Laparoscopic skills laboratories: current assessment 
   and a call for resident training standards. Am J Surg. 2006; 191: 17-22.    ^
cY#a14v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#63#59#article#108#</font></p>     ^cY
#a14v37n1.htm##
00482000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023300078002001300311#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#64#60#article#108#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Munz Y, Kumar    BD
, Moorthy K, Bann S, Darzi A: Laparoscopic virtual reality and box trainers:    
is one superior to the other? Surg Endosc. 2004; 18: 485-94.    ^cY#a14v37n1.htm
##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#65#61#article#108#</font></p>     ^cY
#a14v37n1.htm##
00592000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704034300078002001300421#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#66#62#article#108#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Lehmann KS,    Ritz
 JP, Maass H, Cakmak HK, Kuehnapfel UG, Germer CT, et al.: A prospective    rand
omized study to test the transfer of basic psychomotor skills from virtual    re
ality to physical reality in a comparable training setting. Ann Surg. 2005;    2
41: 442-9.    ^cY#a14v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#67#63#article#108#</font></p>     ^cY
#a14v37n1.htm##
00547000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029800078002001300376#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#68#64#article#108#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Youngblood PL,    S
rivastava S, Curet M, Heinrichs WL, Dev P, Wren SM: Comparison of training    on
 two laparoscopic simulators and assessment of skills transfer to surgical    pe
rformance. J Am Coll Surg. 2005; 200: 546-51.    ^cY#a14v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#69#65#article#108#</font></p>     ^cY
#a14v37n1.htm##
00527000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027800078002001300356#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#70#66#article#108#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Conn J: The    game
s doctors play. Physicians are turning to high-tech simulators to practice    th
eir clinical techniques. Even video-game skills prove valuable in the OR.    Mod
 Healthc. 2004; 34: 32-3.    ^cY#a14v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#71#67#article#108#</font></p>     ^cY
#a14v37n1.htm##
00532000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028300078002001300361#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#72#68#article#108#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Grantcharov    TP, 
Kristiansen VB, Bendix J, Bardram L, Rosenberg J, Funch-Jensen P: Randomized    
clinical trial of virtual reality simulation for laparoscopic skills training.  
  Br J Surg. 2004; 91: 146-50.    ^cY#a14v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#73#69#article#108#</font></p>     ^cY
#a14v37n1.htm##
00562000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704031300078002001300391#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#74#70#article#108#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Gallagher AG,    Ri
tter EM, Champion H, Higgins G, Fried MP, Moses G, et al.: Virtual reality    si
mulation for the operating room: proficiency-based training as a paradigm    shi
ft in surgical skills training. Ann Surg. 2005; 241: 364-72.    ^cY#a14v37n1.htm
##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#75#71#article#108#</font></p>     ^cY
#a14v37n1.htm##
00496000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704024600079002001300325#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#76#72#article#108#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Berg DA, Milner  
  RE, Fisher CA, Goldberg AJ, Dempsey DT, Grewal H: A cost-effective approach   
 to establishing a surgical skills laboratory. Surgery. 2007; 142: 712-21.    ^c
Y#a14v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#77#73#article#108#</font></p>     ^cY
#a14v37n1.htm##
00557000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704030700079002001300386#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#78#74#article#108#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Vlaovic PD,    Sa
rgent ER, Boker JR, Corica FA, Chou DS, Abdelshehid CS, et al.: Immediate    imp
act of an intensive one-week laparoscopy training program on laparoscopic    ski
lls among postgraduate urologists. JSLS. 2008; 12: 1-8.    ^cY#a14v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#79#75#article#108#</font></p>     ^cY
#a14v37n1.htm##
00552000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704030200079002001300381#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#80#76#article#108#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Pareek G, Hedican
    SP, Bishoff JT, Shichman SJ, Wolf JS Jr, Nakada SY: Skills-based laparoscopy
    training demonstrates long-term transfer of clinical laparoscopic practice: 
   additional follow-up. Urology. 2008; 72: 265-7.    ^cY#a14v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#81#77#article#108#</font></p>     ^cY
#a14v37n1.htm##
00505000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704025500079002001300334#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#82#78#article#108#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Condous G,    Alh
amdan D, Bignardi T, VAN Calster B, VAN Huffel S, Timmerman D, et al.: The    va
lue of laparoscopic skills courses. Aust N Z J Obstet Gynaecol. 2009; 49:    312
-5.    ^cY#a14v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#83#79#article#108#</font></p>     ^cY
#a14v37n1.htm##
00494000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704024400079002001300323#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#84#80#article#108#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Madan AK, Frantzi
des    CT: Prospective randomized controlled trial of laparoscopic trainers for 
basic    laparoscopic skills acquisition. Surg Endosc. 2007; 21: 209-13.    ^cY#
a14v37n1.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#85#81#article#108#</font></p>     ^cY
#a14v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#86#82#article#108#<p>&nbsp;</p>     ^
cY#a14v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#87#83#article#108#<p>&nbsp;</p>     ^
cY#a14v37n1.htm##
00367000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013200076002001300208#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#88#84#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>Accepted after    revision: March
 20, 2010</i></font></p>     ^cY#a14v37n1.htm##
00428000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019300076002001300269#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#89#85#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b><a name="end"></a><a href="#top">
<img src="/img/revistas/ibju/v37n1/seta.gif" border="0"></a>    Correspondence t
o</b>:    ^cY#a14v37n1.htm##
00298000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006300076002001300139#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#90#86#article#108#<br>   Dr. F&aacute
;bio C&eacute;sar Miranda Torricelli    ^cY#a14v37n1.htm##
00291000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704005600076002001300132#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#91#87#article#108#<br>   Av. Vereador
 Jos&eacute; Diniz, 3300/ 208    ^cY#a14v37n1.htm##
00282000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004700076002001300123#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#92#88#article#108#<br>   Sao Paulo, S
P, 04604-006, Brazil    ^cY#a14v37n1.htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011600076002001300192#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#93#89#article#108#<br>   E-mail: <a h
ref="mailto:fabio_torri@yahoo.com.br">fabio_torri@yahoo.com.br</a><i>    </i></f
ont></p>     ^cY#a14v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#94#90#article#108#<p>&nbsp;</p>     ^
cY#a14v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#95#91#article#108#<p>&nbsp;</p>     ^
cY#a14v37n1.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010800076002001300184#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#96#92#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"> <b>EDITORIAL COMMENT</b></font></p>
     ^cY#a14v37n1.htm##
02132000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704189700076002001301973#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#97#93#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Authors present    their experience
 with a resident laparoscopic skill laboratory and a formal    training program 
for urology residents. It is our belief as well that these    programs should be
 present in all urology residency programs. There is no discussion    about the 
important and definitive role of laparoscopic surgery, and formal    training pr
ograms are essential. Several randomized studies have evaluated the    role of t
hese training programs (1), and they help to make surgical procedures    faster 
and more precise. Additional measures, as preoperative warm-up also seems    to 
be of value (2). Expensive virtual reality simulators are interesting, but    fa
r from being necessary. The Hospital das Clinicas' center is interesting,    and
 an honored model. We believe that similar but cheaper models are possible    an
d as effective as expensive centers, and are important to make these structures 
   accessible throughout Brazil. A progressive approach to simulation with incre
asing    complexity and a well-designed training curriculum is definitively the 
best    model. We have adopted the initial step of the curriculum of our residen
ts-in-training    at a dry lab, through exercises that can be objectively evalua
ted (time and    perfection to perform each exercise). The second step is to per
formed specific    surgical procedures, such as ureteral, intestinal, urethro-ve
sical anastomoses,    pyeloplasty, nephrectomy, etc., either in the dry lab or i
n porcine models.    It is important to mention however, that animal training sh
ould be reduced to    the minimum necessary, for ethical reasons; and the third 
step is to observe,    participate and perform real surgical procedures. Additio
nally, these training    models can also help to maintain skills for surgeons al
ready in practice.</font></p>     ^cY#a14v37n1.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#98#94#article#108#<p>&nbsp;</p>     ^
cY#a14v37n1.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#99#95#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>REFERENCES</b></font></p>     ^cY
#a14v37n1.htm##
00444000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704019300080002001300273#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#100#96#article#108#15#<p>
<font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Lachapelle    K: 
Teaching technical skills using medical simulation: a new frontier. Mcgill    J 
Med. 2007; 10: 149-51.    ^cY#a14v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#101#97#article#108#</font></p>     ^c
Y#a14v37n1.htm##
00525000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704027400080002001300354#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#102#98#article#108#16#<p>
<font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Korkes    F., Wro
clawski ML., Tavares A. Castro-Neves Neto O, Tobias-Machado M, Pompeo    ACL, Wr
oclawski ER: Video game as a preoperative warm-up for laparoscopic surgery.    E
instein 2009; 7: 462-4.    ^cY#a14v37n1.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#103#99#article#108#</font></p>     ^c
Y#a14v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#104#100#article#108#<p>&nbsp;</p>    
 ^cY#a14v37n1.htm##
00360000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012300078002001300201#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#105#101#article#108#<p align="right">
<font size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Dr.    Marcos 
Tobias-Machado</b>    ^cY#a14v37n1.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003300078002001300111#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#106#102#article#108#<br>   ABC Medica
l School    ^cY#a14v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003600078002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#107#103#article#108#<br>   Sao Paulo,
 SP, Brazil    ^cY#a14v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011100078002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#108#104#article#108#<br>   E-mail: <a
 href="mailto:tobias-machado@uol.com.br">tobias-machado@uol.com.br</a></i></font
></p>     ^cY#a14v37n1.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#109#105#article#108#<p>&nbsp;</p>    
 ^cY#a14v37n1.htm##
00354000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011700078002001300195#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#110#106#article#108#<p align="right">
<font face="Verdana, Arial, Helvetica, sans-serif" size="2"><i><b>Dr.    Fernand
o Korkes</b>    ^cY#a14v37n1.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003300078002001300111#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#111#107#article#108#<br>   ABC Medica
l School    ^cY#a14v37n1.htm##
00289000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005200078002001300130#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a14v37n1.htm#S#p#112#108#article#108#<br>   Sao Paulo,
 SP, Brazil</i></font></p>     ^cY#a14v37n1.htm##
00495000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100016000920120
04600108030000400154065000900158064000500167031000400172014000500176865000900181
002001300190035001000203801000400213#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a1
4v37n1.htm#S#c#113#1#article#16#1#^rND^sDarzi^nA#^rND^sMackay^nS#Recent advances
 in minimal access surgery^len#BMJ#20020000#2002#324#31-4#20110200#a14v37n1.htm#
0959-8138#BMJ##
00542000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100017000950100
01500112012004800127030001000175065000900185064000500194031000300199014000800202
865000900210002001300219035001000232801001000242#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a14v37n1.htm#S#c#114#2#article#16#2#^rND^sAggarwal^nR#^rND^sMoorthy^nK
#^rND^sDarzi^nA#Laparoscopic skills training and assessment^len#Br J Surg#200400
00#2004#91#1549-58#20110200#a14v37n1.htm#0007-1323#Br J Surg##
00604000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100025000770100020001020100
01600122012010000138030001000238065000900248064000500257031000400262014000600266
865000900272002001300281035001000294801001000304#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a14v37n1.htm#S#c#115#3#article#16#3#^rND^sKorndorffer^nJR Jr#^rND^sSte
fanidis^nD#^rND^sScott^nDJ#Laparoscopic skills laboratories: current assessment 
and a call for resident training standards^len#Am J Surg#20060000#2006#191#17-22
#20110200#a14v37n1.htm#0002-9610#Am J Surg##
00628000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100016000910100
01700107010001400124010001500138012008100153030001200234065000900246064000500255
031000300260014000700263865000900270002001300279035001000292801001200302#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#c#116#4#article#16#4#^rND^sMunz
^nY#^rND^sKumar^nBD#^rND^sMoorthy^nK#^rND^sBann^nS#^rND^sDarzi^nA#Laparoscopic v
irtual reality and box trainers: is one superior to the other?^len#Surg Endosc#2
0040000#2004#18#485-94#20110200#a14v37n1.htm#0930-2794#Surg Endosc##
00756000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100015000950100
01500110010001700125010002100142010001700163810000600180012015800186030000900344
06500090035306400050036203100040036701400060037186500090037700200130038603500100
0399801000900409#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#c#117#5
#article#16#5#^rND^sLehmann^nKS#^rND^sRitz^nJP#^rND^sMaass^nH#^rND^sCakmak^nHK#^
rND^sKuehnapfel^nUG#^rND^sGermer^nCT#et al#A prospective randomized study to tes
t the transfer of basic psychomotor skills from virtual reality to physical real
ity in a comparable training setting^len#Ann Surg#20050000#2005#241#442-9#201102
00#a14v37n1.htm#0003-4932#Ann Surg##
00710000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100021000770100020000980100
01500118010002000133010001300153010001500166012011600181030001500297065000900312
06400050032103100040032601400070033086500090033700200130034603500100035980100150
0369#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#c#118#6#article#16#
6#^rND^sYoungblood^nPL#^rND^sSrivastava^nS#^rND^sCuret^nM#^rND^sHeinrichs^nWL#^r
ND^sDev^nP#^rND^sWren^nSM#Comparison of training on two laparoscopic simulators 
and assessment of skills transfer to surgical performance^len#J Am Coll Surg#200
50000#2005#200#546-51#20110200#a14v37n1.htm#1072-7515#J Am Coll Surg##
00597000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770120162000910300
01200253065000900265064000500274031000300279014000500282865000900287002001300296
035001000309801001200319#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S
#c#119#7#article#16#7#^rND^sConn^nJ#The games doctors play. Physicians are turni
ng to high-tech simulators to practice their clinical techniques: Even video-gam
e skills prove valuable in the OR^len#Mod Healthc#20040000#2004#34#32-3#20110200
#a14v37n1.htm#0160-7480#Mod Healthc##
00690000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100022000770100022000990100
01600121010001700137010001900154010002200173012009300195030001000288065000900298
06400050030703100030031201400070031586500090032200200130033103500100034480100100
0354#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#c#120#8#article#16#
8#^rND^sGrantcharov^nTP#^rND^sKristiansen^nVB#^rND^sBendix^nJ#^rND^sBardram^nL#^
rND^sRosenberg^nJ#^rND^sFunch-Jensen^nP#Randomized clinical trial of virtual rea
lity simulation for laparoscopic skills training^len#Br J Surg#20040000#2004#91#
146-50#20110200#a14v37n1.htm#0007-1323#Br J Surg##
00729000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100017000970100
01800114010001700132010001600149010001500165810000600180012013000186030000900316
06500090032506400050033403100040033901400070034386500090035000200130035903500100
0372801000900382#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#c#121#9
#article#16#9#^rND^sGallagher^nAG#^rND^sRitter^nEM#^rND^sChampion^nH#^rND^sHiggi
ns^nG#^rND^sFried^nMP#^rND^sMoses^nG#et al#Virtual reality simulation for the op
erating room: proficiency-based training as a paradigm shift in surgical skills 
training^len#Ann Surg#20050000#2005#241#364-72#20110200#a14v37n1.htm#0003-4932#A
nn Surg##
00655000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01700111010001900128010001800147010001600165012007500181030000800256065000900264
06400050027303100040027801400070028286500090028900200130029803500100031180100080
0321#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#c#122#10#article#16
#10#^rND^sBerg^nDA#^rND^sMilner^nRE#^rND^sFisher^nCA#^rND^sGoldberg^nAJ#^rND^sDe
mpsey^nDT#^rND^sGrewal^nH#A cost-effective approach to establishing a surgical s
kills laboratory^len#Surgery#20070000#2007#142#712-21#20110200#a14v37n1.htm#0039
-6060#Surgery##
00695000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970100
01600115010001700131010001500148010002200163810000600185012012800191030000500319
71000020032406500090032606400050033503100030034001400040034386500090034700200130
0356#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#c#123#11#article#16
#11#^rND^sVlaovic^nPD#^rND^sSargent^nER#^rND^sBoker^nJR#^rND^sCorica^nFA#^rND^sC
hou^nDS#^rND^sAbdelshehid^nCS#et al#Immediate impact of an intensive one-week la
paroscopy training program on laparoscopic skills among postgraduate urologists^
len#JSLS#2#20080000#2008#12#1-8#20110200#a14v37n1.htm##
00708000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01800113010001900131010001800150010001700168012012600185030000800311065000900319
06400050032803100030033301400060033686500090034200200130035103500100036480100080
0374#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#c#124#12#article#16
#12#^rND^sPareek^nG#^rND^sHedican^nSP#^rND^sBishoff^nJT#^rND^sShichman^nSJ#^rND^
sWolf^nJS Jr#^rND^sNakada^nSY#Skills-based laparoscopy training demonstrates lon
g-term transfer of clinical laparoscopic practice: additional follow-up^len#Urol
ogy#20080000#2008#72#265-7#20110200#a14v37n1.htm#0090-4295#Urology##
00672000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
01800114010002100132010002000153010001900173012004500192030002700237065000900264
06400050027303100030027801400060028186500090028700200130029603500100030980100270
0319#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#c#125#13#article#16
#13#^rND^sCondous^nG#^rND^sAlhamdan^nD#^rND^sBignardi^nT#^rND^sVAN^nCalster B#^r
ND^sVAN Huffel^nS#^rND^sTimmerman^nD#The value of laparoscopic skills courses^le
n#Aust N Z J Obstet Gynaecol#20090000#2009#49#312-5#20110200#a14v37n1.htm#0004-8
666#Aust N Z J Obstet Gynaecol##
00585000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100021000950120
11100116030001200227065000900239064000500248031000300253014000700256865000900263
002001300272035001000285801001200295#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a1
4v37n1.htm#S#c#126#14#article#16#14#^rND^sMadan^nAK#^rND^sFrantzides^nCT#Prospec
tive randomized controlled trial of laparoscopic trainers for basic laparoscopic
 skills acquisition^len#Surg Endosc#20070000#2007#21#209-13#20110200#a14v37n1.ht
m#0930-2794#Surg Endosc##
00484000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100020000780120071000980300
01300169710000200182065000900184064000500193031000300198014000700201865000900208
002001300217#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#c#127#15#ar
ticle#16#1#^rND^sLachapelle^nK#Teaching technical skills using medical simulatio
n: a new frontier^len#Mcgill J Med#2#20070000#2007#10#149-51#20110200#a14v37n1.h
tm##
00669000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180002000760100016000780100021000940100
01700115010002700132010002400159010001800183010002100201012006600222030000900288
71000020029706500090029906400050030803100020031301400060031586500090032100200130
0330#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a14v37n1.htm#S#c#128#16#article#16
#2#^rND^sKorkes^nF#^rND^sWroclawski^nML#^rND^sTavares^nA#^rND^sCastro-Neves Neto
^nO#^rND^sTobias-Machado^nM#^rND^sPompeo^nACL#^rND^sWroclawski^nER#Video game as
 a preoperative warm-up for laparoscopic surgery^len#Einstein#2#20090000#2009#7#
462-4#20110200#a14v37n1.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a15v37n1.htm#S#o#1#1#text#1#20
110330#144530#a15v37n1.htm#51##
00759000000000409000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000800095158000300103030001800106
03100030012403200020012706500090012901400110013803500100014912300020015901200840
01610100021002450100018002660100022002840100022003061170006003280720002003340020
01300336#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a15v37n1.htm#S#h#2#1#text#1#oa
#en#br1.1#1#4.0#ILUS#15#IBJU210#nd#Int. braz j urol.#37#1#20110200#^f113^l114#16
77-5538#1#Emphysematous cystitis as complication in chronic rejection of renal t
ransplant^len#^rND^nErich K.^sLang#^rND^nKarl^sZhang#^rND^nDaniel^sThorner#^rND^
nQuan D.^sNguyen#other#3#a15v37n1.htm##
00766000000000409000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000800095158000300103030001800106
03100030012403200020012706500090012901400110013803500100014912300020015901200910
01610100021002520100018002730100022002910100022003131170006003350720002003410020
01300343#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a15v37n1.htm#S#f#3#1#text#1#oa
#en#br1.1#1#4.0#ILUS#15#IBJU210#nd#Int. braz j urol.#37#1#20110200#^f113^l114#16
77-5538#1#<b>Emphysematous cystitis as complication in chronic rejection of rena
l transplant</b>^len#^rND^nErich K.^sLang#^rND^nKarl^sZhang#^rND^nDaniel^sThorne
r#^rND^nQuan D.^sNguyen#other#3#a15v37n1.htm##
00887000000000433000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101038000500105121000300110049000800113158000300121
03000170012403100030014103200020014406500090014601400110015503500100016612300020
01760120084001780100020002620100018002820100022003000100021003221170006003430720
00200349002001300351008008900364#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a15v37
n1.htm#S#l#4#1#text#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#ilus#15#IBJU210#nd#Int
. braz j urol#37#1#20110200#^f113^l114#1677-5538#1#Emphysematous cystitis as com
plication in chronic rejection of renal transplant^len#^rND^nErich K^sLang#^rND^
nKarl^sZhang#^rND^nDaniel^sThorner#^rND^nQuan D^sNguyen#other#3#a15v37n1.htm#Int
ernet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-553820110001
00015##
00350000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704012100070002001300191#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#5#1#text#44#<p align="right"><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RADIOLOGY    PAGE</b></fo
nt></p>     ^cY#a15v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#6#2#text#44#<p>&nbsp;</p>     ^cY#a15
v37n1.htm##
00419000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704019000070002001300260#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#7#3#text#44#<p><a name="top"></a><fon
t face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Emphysematous    cyst
itis as complication in chronic rejection of renal transplant</b></font></p>    
 ^cY#a15v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#8#4#text#44#<p>&nbsp;</p>     ^cY#a15
v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#9#5#text#44#<p>&nbsp;</p>     ^cY#a15
v37n1.htm##
00380000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704015000071002001300221#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#10#6#text#44#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Erich K. Lang;    Karl Zhang; Daniel T
horner; Quan D. Nguyen</b></font></p>     ^cY#a15v37n1.htm##
00384000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704015400071002001300225#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#11#7#text#44#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Department of Radiology,    SUNY, Downsta
te Medical School, Brooklyn, New York, USA    ^cY#a15v37n1.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704010300071002001300174#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#12#8#text#44#<br>   Johns Hopkins Med
ical Institutions, Bayview Center, Baltimore, Maryland, USA</font></p>     ^cY#a
15v37n1.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704011600071002001300187#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#13#9#text#44#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><a href="#end">Correspondence</a></font><
/p>     ^cY#a15v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#14#10#text#44#<p>&nbsp;</p>     ^cY#a
15v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#15#11#text#44#<p>&nbsp;</p>     ^cY#a
15v37n1.htm##
00794000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704056300072002001300635#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#16#12#text#44#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">This 43-year-old    Caucasian female pre
sented in a septic condition in the emergency room. At the    time of admission 
her temperature was 38.5 Celsius, white blood cells (WBC)    12800, red blood ce
lls 3.8 mill, hemoglobin 10.8, hematocrit 36, urea 28 mg/dl,    serum creatinine
 3.2 mg/dl, K 5.8 meq/l, Na 128 meq/l, alk ptsa 142 U/l. Urine    analysis 50 WB
C/hpf, innumerable bacteria/hpf, cellular debries, gas bubbles.    Both urine an
d later blood cultures revealed E. coli.</font></p>     ^cY#a15v37n1.htm##
01159000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704092800072002001301000#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#17#13#text#44#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> The lower abdomen    and pelvis were ex
quisitely tender to palpation. Patient had been hemodialyzed    2 days earlier. 
Patient had received a cadaver-transplant 3 years ago, which    functioned well 
until 4 months ago. At this time chronic rejection was diagnosed.    An antegrad
e pyelogram revealed a stricture at the implant site of the cadaver    ureter, d
ilatation and possible ulcerations of the mid &#8211; and upper ureter.    Bullo
us edema of the native bladder was seen, most prominent near the implant    site
. Immunosuppressive therapy was instituted and despite these efforts, function  
  of the transplant kidney continued to deteriorate and the patient was finally 
   put on hemodialysis 1 month ago. It was contemplated to perform a uretero-neo
-calicostomy    with the still present native ureter to hopefully salvage the ki
dney.</font></p>     ^cY#a15v37n1.htm##
00494000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704026300072002001300335#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#18#14#text#44#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A non-contrast    multi-detector compute
d tomography demonstrated gas in the submucosa and bladder,    and also extraves
ical anterior to the bladder (<a href="#fig1">Figure-1</a>).</font></p>     ^cY#
a15v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#19#15#text#44#<p>&nbsp;</p>     ^cY#a
15v37n1.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003500072002001300107#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#20#16#text#44#<p><a name="fig1"></a><
/p>     ^cY#a15v37n1.htm##
00310000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007900072002001300151#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#21#17#text#44#<p align="center"><img 
src="/img/revistas/ibju/v37n1/a15fig1.jpg"></p>     ^cY#a15v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#22#18#text#44#<p>&nbsp;</p>     ^cY#a
15v37n1.htm##
00686000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704045500072002001300527#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#23#19#text#44#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Strands of debries    and sloughed tissu
e surrounded by air are seen in the bladder lumen (arrow).    Gas has dissected 
along the anterior abdominal wall (<a href="#fig2">Figure-2</a>).    A coronal r
econstruction shows relatively little striation in the perirenal    space. There
 is edema in the peripelvic area and around the upper ureter (<a href="#fig3">Fi
gure-3</a>).</font></p>     ^cY#a15v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#24#20#text#44#<p>&nbsp;</p>     ^cY#a
15v37n1.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003500072002001300107#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#25#21#text#44#<p><a name="fig2"></a><
/p>     ^cY#a15v37n1.htm##
00310000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007900072002001300151#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#26#22#text#44#<p align="center"><img 
src="/img/revistas/ibju/v37n1/a15fig2.jpg"></p>     ^cY#a15v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#27#23#text#44#<p>&nbsp;</p>     ^cY#a
15v37n1.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003500072002001300107#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#28#24#text#44#<p><a name="fig3"></a><
/p>     ^cY#a15v37n1.htm##
00310000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007900072002001300151#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#29#25#text#44#<p align="center"><img 
src="/img/revistas/ibju/v37n1/a15fig3.jpg"></p>     ^cY#a15v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#30#26#text#44#<p>&nbsp;</p>     ^cY#a
15v37n1.htm##
00845000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704061400072002001300686#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#31#27#text#44#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">To control the    fulminating gas formin
g infection, bladder, transplant kidney and ureter were    removed, the space of
 Retzius drained. Depending on the severity of the infection    and underlying c
onditions such as diabetes mere control of the diabetes and    appropriate antib
iotic therapy may suffice while severe forms may mandate surgical    interventio
n to remove the necrotic debries (1-3). After prolonged antibiotic    therapy an
d hemodialysis the patient recovered and received a second successful    transpl
ant kidney.</font></p>     ^cY#a15v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#32#28#text#44#<p>&nbsp;</p>     ^cY#a
15v37n1.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010000072002001300172#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#33#29#text#44#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>     ^cY#a15
v37n1.htm##
00525000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704028000074002001300354#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#34#30#text#44#1#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"> 1. Dinckan R,    Tekin R,
 Turkyilmaz S, Kacak H, Gurkan A, Erdogen G, Tuncer M: Early and late    urologi
c complications corrected surgically following renal transplantation.    Transpl
. Int. 2007; 20: 702-7.    ^cY#a15v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#35#31#text#44#</font></p>     ^cY#a15
v37n1.htm##
00491000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704024600074002001300320#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#36#32#text#44#2#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Akalin    E, Hyde C, Sc
hmitt G, Kaufman J, Hamburger RJ: Emphysematous cystitis and pyelitis    in a di
abetic renal transplant recipient. Transplantation 1996; 62: 1024 -6.    ^cY#a15
v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#37#33#text#44#</font></p>     ^cY#a15
v37n1.htm##
00520000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704027500074002001300349#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#38#34#text#44#3#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"> 3. Davavri HR,    Yarmoha
mmadi H, Malekhosseini SA, Salahi H, Bahador A, Salchipoun S: Urologic    compli
cations in 980 consecutive patients with renal transplantation. Int. J.    Urol.
 2006; 13: 1271-5.    ^cY#a15v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#39#35#text#44#</font></p>     ^cY#a15
v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#40#36#text#44#<p>&nbsp;</p>     ^cY#a
15v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#41#37#text#44#<p>&nbsp;</p>     ^cY#a
15v37n1.htm##
00424000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704019300072002001300265#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#42#38#text#44#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b><a name="end"></a><a href="#top"><img
 src="/img/revistas/ibju/v37n1/seta.gif" border="0"></a>    Correspondence to</b
>:    ^cY#a15v37n1.htm##
00263000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003200072002001300104#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#43#39#text#44#<br>   Dr. Erich K. Lan
g    ^cY#a15v37n1.htm##
00282000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005100072002001300123#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#44#40#text#44#<br>   Departments of U
rology and Radiology    ^cY#a15v37n1.htm##
00284000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005300072002001300125#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#45#41#text#44#<br>   SUNY, Downstate 
Health Science Center     ^cY#a15v37n1.htm##
00261000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003000072002001300102#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#46#42#text#44#<br>   455 Lenox Road  
   ^cY#a15v37n1.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004000072002001300112#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#47#43#text#44#<br>   Brooklyn, NY, 11
203, USA     ^cY#a15v37n1.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010800072002001300180#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a15v37n1.htm#S#p#48#44#text#44#<br>   E-mail: <a href=
"mailto:erich.lang@downstate.edu%20">erich.lang@downstate.edu</a></font></p>    
 ^cY#a15v37n1.htm##
00669000000000325000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100017000720100015000890100
02000104010001500124010001600139010001700155010001600172012009500188030001300283
71000020029606500090029806400050030703100030031201400060031586500090032100200130
0330#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a15v37n1.htm#S#c#49#1#text#3#1#^rN
D^sDinckan^nR#^rND^sTekin^nR#^rND^sTurkyilmaz^nS#^rND^sKacak^nH#^rND^sGurkan^nA#
^rND^sErdogen^nG#^rND^sTuncer^nM#Early and late urologic complications corrected
 surgically following renal transplantation^len#Transpl. Int#2#20070000#2007#20#
702-7#20110200#a15v37n1.htm##
00640000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100016000720100014000880100
01700102010001700119010002000136012008100156030001600237065000900253064000500262
031000300267014000800270865000900278002001300287035001000300801001600310#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a15v37n1.htm#S#c#50#2#text#3#2#^rND^sAkalin^nE
#^rND^sHyde^nC#^rND^sSchmitt^nG#^rND^sKaufman^nJ#^rND^sHamburger^nRJ#Emphysemato
us cystitis and pyelitis in a diabetic renal transplant recipient^len#Transplant
ation#19960000#1996#62#1024 -6#20110200#a15v37n1.htm#0041-1337#Transplantation##
00646000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100018000720100022000900100
02400112010001600136010001700152010002000169012008200189030001300271710000200284
065000900286064000500295031000300300014000700303865000900310002001300319#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a15v37n1.htm#S#c#51#3#text#3#3#^rND^sDavavri^n
HR#^rND^sYarmohammadi^nH#^rND^sMalekhosseini^nSA#^rND^sSalahi^nH#^rND^sBahador^n
A#^rND^sSalchipoun^nS#Urologic complications in 980 consecutive patients with re
nal transplantation^len#Int. J. Urol#2#20060000#2006#13#1271-5#20110200#a15v37n1
.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a16v37n1.htm#S#o#1#1#text#1#20
110330#150140#a16v37n1.htm#30##
00648000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201070
0159010001900266002001300285#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a16v37n1.h
tm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ND#16#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f116^l116#1677-5538#1#The effect of fat and nonfat components of the skin-
to-stone distance on shockwave lithotripsy outcome^len#^rND^nManoj^sMonga#a16v37
n1.htm##
00655000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201140
0159010001900273002001300292#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a16v37n1.h
tm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ND#16#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f116^l116#1677-5538#1#<b>The effect of fat and nonfat components of the sk
in-to-stone distance on shockwave lithotripsy outcome</b>^len#^rND^nManoj^sMonga
#a16v37n1.htm##
00763000000000361000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000800108158000300116030001700119
03100030013603200020013906500090014101400110015003500100016112300020017101201070
0173010001900280002001300299008008900312#v37n1#V:\SciELO\serial\ibju\v37n1\marku
p\a16v37n1.htm#S#l#4#1#text#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#16#IBJU050#nd#
Int. braz j urol#37#1#20110200#^f116^l116#1677-5538#1#The effect of fat and nonf
at components of the skin-to-stone distance on shockwave lithotripsy outcome^len
#^rND^nManoj^sMonga#a16v37n1.htm#Internet^ihttp://www.scielo.br/scielo.php?scrip
t=sci_arttext&pid=S1677-55382011000100016##
00337000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704010800070002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#5#1#text#26#<p align="right"><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>UROLOGICAL    SURVEY    ^
cY#a16v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704004400070002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#6#2#text#26#<br>   STONE DISEASE</b><
/font></p>     ^cY#a16v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#7#3#text#26#<p>&nbsp;</p>     ^cY#a16
v37n1.htm##
00427000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704019800070002001300268#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#8#4#text#26#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><b>The effect of    fat and nonfat compone
nts of the skin-to-stone distance on shockwave lithotripsy    outcome</b></font>
</p>     ^cY#a16v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#9#5#text#26#<p>&nbsp;</p>     ^cY#a16
v37n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#10#6#text#26#<p>&nbsp;</p>     ^cY#a1
6v37n1.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704011900071002001300190#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#11#7#text#26#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Hammad FT; Balakrishnan    A.</b></fon
t></p>     ^cY#a16v37n1.htm##
00376000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704014600071002001300217#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#12#8#text#26#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Department of Surgery,    Faculty of Medi
cine, Al Ain, United Arab Emirates    ^cY#a16v37n1.htm##
00355000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704012500071002001300196#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#13#9#text#26#<br>   </font><font size
="2" face="Verdana, Arial, Helvetica, sans-serif">J Endourol.    2010; 24: 1825-
9</font></p>     ^cY#a16v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#14#10#text#26#<p>&nbsp;</p>     ^cY#a
16v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#15#11#text#26#<p>&nbsp;</p>     ^cY#a
16v37n1.htm##
00609000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704037800072002001300450#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#16#12#text#26#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">BACKGROUND: Few    studies have addresse
d the effect of skin-to-stone distance (SSD) on the success    of extracorporeal
 shockwave lithotripsy (SWL). Nevertheless, the effect of the    two components 
of SSD, that is, the fat SSD (FSSD) and nonfat SSD (NFSSD) components,    was no
t previously investigated.     ^cY#a16v37n1.htm##
00751000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704052000072002001300592#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#17#13#text#26#<br>   METHODS: In this
 prospective study, all patients (n = 113) who had single radio-opaque    kidney
 stones and underwent SWL for the first time between January 2006 and    June 20
07 were recruited. SSD, FSSD, and NFSSD were measured by noncontrast    CT scan 
at 0&deg;, 45&deg;, and 90&deg; and the average was calculated. The    outcome w
as defined as successful (completely stone free or residual fragments    = 3 mm)
 or unsuccessful (residual fragments &gt; 3 mm or complete failure of    fragmen
tation).     ^cY#a16v37n1.htm##
00978000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704074700072002001300819#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#18#14#text#26#<br>   RESULTS: Sixty-n
ine (61%) patients had successful treatment. On univariate analysis,    SSD, FSS
D, and NFSSD were significantly lower in the successful group compared    with t
hose with unsuccessful outcome (71.9 &plusmn; 13.3 vs. 86.2 &plusmn; 25.1    mm 
&#91;p = 0.001&#93;, 27.2 &plusmn; 10.3 vs. 36.1 &plusmn; 17.3 mm &#91;p    = 0.
011&#93;, and 44.7 &plusmn; 7.2 vs. 50.1 &plusmn; 13.9 mm &#91;p = 0.02&#93;,   
 respectively). The muscle component of the NFSSD was also lower in the successf
ul    group (21.5 &plusmn; 4.1 vs. 25.2 &plusmn; 10.0 mm &#91;p = 0.01&#93;). On
 multivariate    analysis, factors that independently predicted treatment succes
s were SSD, stone    attenuation, and stone size but not the FSSD or NFSSD.     
^cY#a16v37n1.htm##
00514000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704028300072002001300355#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#19#15#text#26#<br>   CONCLUSIONS: Alt
hough the total SSD appeared to be a significant predictor of    SWL success, it
s fat and nonfat components did not independently predict the    final outcome a
nd only appeared to be important through their contribution to    the total SSD.
</font></p>     ^cY#a16v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#20#16#text#26#<p>&nbsp;</p>     ^cY#a
16v37n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#21#17#text#26#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL COMMENT</b></font></p>     
^cY#a16v37n1.htm##
01589000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704135800072002001301430#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#22#18#text#26#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> It is important    to note that the ave
rage skin-to-stone distance (SSD) of 7.8 cm and average    BMI of 25 indicates t
hat the study population was relatively healthy, and it    may be worthwhile to 
extend this study to patients with morbid obesity to confirm    that the relativ
e contribution of fat vs. muscle to the SSD does not affect    efficacy. The art
icle has important implications. Despite the fact that disproportionate    amoun
ts of fat vs. non-fat in the retroperitoneum have been reported in child    vs. 
adult, athlete vs. obese, Asian vs. Caucasian; for ESWL, differences in    skin-
to-stone distance are more important than the type of tissue between the    shoc
k and the stone; specifically the main issue is the distance traveled. The    ot
her major contribution of this article relates to their stringent evaluation    
of success with CT scans at 6 weeks and well defined endpoints. Specifically,   
 with a mean stone size of about 12 mm, approximately 40% were stone-free, 20%  
  had residual fragments &lt; 3 mm, 30% had residual fragments &gt; 3 mm and 10%
    had no fragmentation. It is feasible that as 92% of patients were treated wi
th    sedation, higher success rates might have been noted with general anesthes
ia    as reported in other studies.</font></p>     ^cY#a16v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#23#19#text#26#<p>&nbsp;</p>     ^cY#a
16v37n1.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011300072002001300185#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#24#20#text#26#<p align="right"><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2"><i><b>Dr.    Manoj Monga</
b>    ^cY#a16v37n1.htm##
00284000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005300072002001300125#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#25#21#text#26#<br>   Director, Stevan
 B. Streem Center for     ^cY#a16v37n1.htm##
00277000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004600072002001300118#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#26#22#text#26#<br>   Endourology &amp
; Stone Disease    ^cY#a16v37n1.htm##
00288000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005700072002001300129#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#27#23#text#26#<br>   Glickman Urologi
cal &amp; Kidney Institute    ^cY#a16v37n1.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003500072002001300107#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#28#24#text#26#<br>   The Cleveland Cl
inic    ^cY#a16v37n1.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003500072002001300107#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#29#25#text#26#<br>   Cleveland, Ohio,
 USA    ^cY#a16v37n1.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009700072002001300169#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a16v37n1.htm#S#p#30#26#text#26#<br>   E-mail: <a href=
"mailto:endourol@yahoo.com">endourol@yahoo.com</a></i></font></p>     ^cY#a16v37
n1.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a17v37n1.htm#S#o#1#1#text#1#20
110330#144532#a17v37n1.htm#31##
00677000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201360
0159010001900295002001300314#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a17v37n1.h
tm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ND#17#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f117^l117#1677-5538#1#Emergency ureteroscopic treatment for upper urinary 
tract calculi obstruction associated with acute renal failure: feasible or not?^
len#^rND^nManoj^sMonga#a17v37n1.htm##
00691000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201500
0159010001900309002001300328#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a17v37n1.h
tm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ND#17#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f117^l117#1677-5538#1#<b>Emergency ureteroscopic treatment for upper urina
ry tract calculi obstruction associated with acute renal failure</b>: <b>feasibl
e or not?</b>^len#^rND^nManoj^sMonga#a17v37n1.htm##
00792000000000361000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000800108158000300116030001700119
03100030013603200020013906500090014101400110015003500100016112300020017101201360
0173010001900309002001300328008008900341#v37n1#V:\SciELO\serial\ibju\v37n1\marku
p\a17v37n1.htm#S#l#4#1#text#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#17#IBJU050#nd#
Int. braz j urol#37#1#20110200#^f117^l117#1677-5538#1#Emergency ureteroscopic tr
eatment for upper urinary tract calculi obstruction associated with acute renal 
failure: feasible or not?^len#^rND^nManoj^sMonga#a17v37n1.htm#Internet^ihttp://w
ww.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382011000100017##
00337000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704010800070002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#5#1#text#27#<p align="right"><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>UROLOGICAL    SURVEY    ^
cY#a17v37n1.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704012100070002001300191#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#6#2#text#27#<br>   </b></font><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>STONE    DISEASE</b></fo
nt></p>     ^cY#a17v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#7#3#text#27#<p>&nbsp;</p>     ^cY#a17
v37n1.htm##
00456000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704022700070002001300297#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#8#4#text#27#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><b>Emergency ureteroscopic    treatment fo
r upper urinary tract calculi obstruction associated with acute    renal failure
: feasible or not?</b></font></p>     ^cY#a17v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#9#5#text#27#<p>&nbsp;</p>     ^cY#a17
v37n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#10#6#text#27#<p>&nbsp;</p>     ^cY#a1
7v37n1.htm##
00370000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704014000071002001300211#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#11#7#text#27#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Yang S; Qian    H; Song C; Xia Y; Chen
g F; Zhang C</b></font></p>     ^cY#a17v37n1.htm##
00420000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704019000071002001300261#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#12#8#text#27#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Division of Urology,    Renming Hospital 
of Wuhan University, Wuhan City, Hubei Province, People's Republic    of China  
  ^cY#a17v37n1.htm##
00285000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704005500071002001300126#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#13#9#text#27#<br>   J Endourol. 2010;
 24: 1721-4</font></p>     ^cY#a17v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#14#10#text#27#<p>&nbsp;</p>     ^cY#a
17v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#15#11#text#27#<p>&nbsp;</p>     ^cY#a
17v37n1.htm##
00524000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704029300072002001300365#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#16#12#text#27#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">PURPOSE: To determine    the efficacy an
d safety of emergency ureteroscopy (URS) and holmium:yttrium-aluminum-garnet    
(Ho:YAG) laser lithotripsy for ureteral calculi that are associated with acute  
  renal failure (ARF).    ^cY#a17v37n1.htm##
01287000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704105600072002001301128#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#17#13#text#27#<br>   PATIENTS AND MET
HODS: We retrospectively evaluated a cohort of 49 patients who    underwent URS 
from November 2005 to November 2008 for ARF that was caused by    calculi obstru
ction of the upper urinary tract. The mean (maximal diameter)    stone size was 
1.48 cm. Acute renal failure was demonstrated by oliguria or    anuria and marke
d increase in serum creatinine and blood urea nitrogen levels.    All the patien
ts were treated with URS and Ho:YAG laser lithotripsy emergently.    Ureteral st
ent placement was performed in all cases after lithotripsy. A plain    film of t
he kidneys, ureters, and bladder and abdominal ultrasonography were    performed
 to evaluate efficacy of treatment on the first day postoperatively.    Serum cr
eatinine and blood urea nitrogen levels and urine volume were successively    mo
nitored until they returned to normal. All patients had postoperative imaging,  
  including ultrasonography and excretory urography, to confirm stone clearance 
   and exclude late obstructive complications 3 months after URS.    ^cY#a17v37n
1.htm##
00692000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704046100072002001300533#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#18#14#text#27#<br>   RESULTS: URS and
 laser lithotripsy were successfully performed in all patients.    There were no
 major intraoperative complications, and no procedure was converted    to open s
urgery. The mean operative time was 35 minutes. The successful fragmentation    
rate was 95.5%. The overall stone-free rate was 91.8%. Normal renal function    
returned in 46 (93.8%) patients within 7 days. No postoperative ureteral strictu
re    occurred after 3 months.    ^cY#a17v37n1.htm##
00479000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704024800072002001300320#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#19#15#text#27#<br>   CONCLUSIONS: URS
 and Ho:YAG laser lithotripsy represent an effective and safe    modality for tr
eating patients with ARF that is caused by calculi obstruction    of the upper u
rinary tract in strictly selected situations.</font></p>     ^cY#a17v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#20#16#text#27#<p>&nbsp;</p>     ^cY#a
17v37n1.htm##
00248000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704001700072002001300089#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#21#17#text#27#<p> </p>     ^cY#a17v37
n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#22#18#text#27#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL COMMENT</b></font></p>     
^cY#a17v37n1.htm##
01348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704111700072002001301189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#23#19#text#27#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> The authors report    remarkable result
s (92% stone-free rates, ability to reach all proximal ureteral    stones) despi
te using a relatively large semi-rigid ureteroscope and not utilizing    a flexi
ble ureteroscope for any cases. Indeed, they report treating stones larger    th
an 3 cm in size in less than 1 hour. They utilized higher energy settings    (1.
8 J), which may facilitate more rapid fragmentation, but have been reported    i
n "in vitro" studies to lead to larger stone fragments. It may be that the    lo
nger stenting times (4-12 weeks) helped facilitate stone passage without the    
development of recurrent obstruction. The authors provide important information 
   concerning the safety of ureteroscopy in the face of acute renal failure, and
    the course of resolution of the renal failure with alleviation of the obstru
ction.    Likely, the short operative time is critical in these patients to mini
mize the    risks of peri-operative complication related to irrigant fluid absor
ption and    length of anesthetic.</font></p>     ^cY#a17v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#24#20#text#27#<p>&nbsp;</p>     ^cY#a
17v37n1.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011300072002001300185#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#25#21#text#27#<p align="right"><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2"><i><b>Dr.    Manoj Monga</
b>    ^cY#a17v37n1.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005200072002001300124#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#26#22#text#27#<br>   Director, Stevan
 B. Streem Center for    ^cY#a17v37n1.htm##
00277000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004600072002001300118#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#27#23#text#27#<br>   Endourology &amp
; Stone Disease    ^cY#a17v37n1.htm##
00288000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005700072002001300129#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#28#24#text#27#<br>   Glickman Urologi
cal &amp; Kidney Institute    ^cY#a17v37n1.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003500072002001300107#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#29#25#text#27#<br>   The Cleveland Cl
inic    ^cY#a17v37n1.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003500072002001300107#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#30#26#text#27#<br>   Cleveland, Ohio,
 USA    ^cY#a17v37n1.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009700072002001300169#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a17v37n1.htm#S#p#31#27#text#27#<br>   E-mail: <a href=
"mailto:endourol@yahoo.com">endourol@yahoo.com</a></i></font></p>     ^cY#a17v37
n1.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a18v37n1.htm#S#o#1#1#text#1#20
110330#144532#a18v37n1.htm#34##
00663000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201180
0159010002300277002001300300#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a18v37n1.h
tm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ND#18#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f118^l119#1677-5538#1#Qualitay of life after open or robotic prostatectomy
, cryoablation or brachytherapy for localized prostate cancer^len#^rND^nFernando
 J.^sKim#a18v37n1.htm##
00670000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201250
0159010002300284002001300307#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a18v37n1.h
tm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ND#18#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f118^l119#1677-5538#1#<b>Qualitay of life after open or robotic prostatect
omy, cryoablation or brachytherapy for localized prostate cancer</b>^len#^rND^nF
ernando J.^sKim#a18v37n1.htm##
00777000000000361000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000800108158000300116030001700119
03100030013603200020013906500090014101400110015003500100016112300020017101201180
0173010002200291002001300313008008900326#v37n1#V:\SciELO\serial\ibju\v37n1\marku
p\a18v37n1.htm#S#l#4#1#text#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#18#IBJU050#nd#
Int. braz j urol#37#1#20110200#^f118^l119#1677-5538#1#Qualitay of life after ope
n or robotic prostatectomy, cryoablation or brachytherapy for localized prostate
 cancer^len#^rND^nFernando J^sKim#a18v37n1.htm#Internet^ihttp://www.scielo.br/sc
ielo.php?script=sci_arttext&pid=S1677-55382011000100018##
00337000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704010800070002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#5#1#text#30#<p align="right"><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>UROLOGICAL    SURVEY    ^
cY#a18v37n1.htm##
00366000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704013700070002001300207#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#6#2#text#30#<br>   </b></font><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ENDOUROLOGY    &amp; LAP
AROSCOPY</b></font></p>     ^cY#a18v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#7#3#text#30#<p>&nbsp;</p>     ^cY#a18
v37n1.htm##
00438000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704020900070002001300279#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#8#4#text#30#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><b>Qualitay    of life after open or robot
ic prostatectomy, cryoablation or brachytherapy for    localized prostate cancer
</b></font></p>     ^cY#a18v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#9#5#text#30#<p>&nbsp;</p>     ^cY#a18
v37n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#10#6#text#30#<p>&nbsp;</p>     ^cY#a1
8v37n1.htm##
00428000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704019800071002001300269#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#11#7#text#30#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Malcolm JB;    Fabrizio MD; Barone BB;
 Given RW; Lance RS; Lynch DF; Davis JW; Shaves ME; Schellhammer    PF</b></font
></p>     ^cY#a18v37n1.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704018700071002001300258#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#12#8#text#30#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Department of Urology,    The Virginia Pr
ostate Center at Eastern Virginia Medical School, Norfolk, Virginia,    USA    ^
cY#a18v37n1.htm##
00282000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704005200071002001300123#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#13#9#text#30#<br>   J Urol. 2010; 183
: 1822-8</font></p>     ^cY#a18v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#14#10#text#30#<p>&nbsp;</p>     ^cY#a
18v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#15#11#text#30#<p>&nbsp;</p>     ^cY#a
18v37n1.htm##
00552000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704032100072002001300393#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#16#12#text#30#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">PURPOSE: Health    related quality of li
fe concerns factor prominently in prostate cancer management.    We describe hea
lth related quality of life impact and recovery profiles of 4    commonly used o
perative treatments for localized prostate cancer.    ^cY#a18v37n1.htm##
00677000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704044600072002001300518#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#17#13#text#30#<br>   MATERIALS AND ME
THODS: Beginning in February 2000 all patients treated with    open radical pros
tatectomy, robot assisted laparoscopic prostatectomy, brachytherapy    or cryoth
erapy were asked to complete the UCLA-PCI questionnaire before treatment,    and
 at 3, 6, 12, 18, 24, 30 and 36 months after treatment. Outcomes were compared  
  across treatment types with statistical analysis using univariate and multivar
iate    models.    ^cY#a18v37n1.htm##
01319000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704108800072002001301160#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#18#14#text#30#<br>   RESULTS: A total
 of 785 patients treated between February 2000 and December    2008 were include
d in the analysis with a mean followup of 24 months. All health    related quali
ty of life domains were adversely affected by all treatments and    recovery pro
files varied significantly by treatment type. Overall urinary function    and bo
ther outcomes scored significantly higher after brachytherapy and cryotherapy   
 compared to open radical prostatectomy and robotic assisted laparoscopic radica
l    prostatectomy. Brachytherapy and cryotherapy had a 3-fold higher rate of re
turn    to baseline urinary function compared to open radical prostatectomy and 
robotic    assisted laparoscopic radical prostatectomy. Sexual function and both
er scores    were highest after brachytherapy, with a 5-fold higher rate of retu
rn to baseline    function compared to cryotherapy, open radical prostatectomy a
nd robotic assisted    laparoscopic radical prostatectomy. All 4 treatments were
 associated with relatively    transient and less pronounced impact on bowel fun
ction and bother.    ^cY#a18v37n1.htm##
00697000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704046600072002001300538#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#19#15#text#30#<br>   CONCLUSIONS: In 
a study of sequential health related quality of life assessments    brachytherap
y and cryotherapy were associated with higher urinary function and    bother sco
res compared to open radical prostatectomy and da Vinci prostatectomy.    Brachy
therapy was associated with higher sexual function and bother scores compared   
 to open radical prostatectomy, robotic assisted laparoscopic radical prostatect
omy    and cryotherapy.</font></p>     ^cY#a18v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#20#16#text#30#<p>&nbsp;</p>     ^cY#a
18v37n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#21#17#text#30#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL COMMENT</b></font></p>     
^cY#a18v37n1.htm##
00531000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704030000072002001300372#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#22#18#text#30#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> The authors compared    4 commonly used
 operative treatments for localized prostate cancer: open radical    prostatecto
my (ORP), robot assisted laparoscopic prostatectomy (RALP), brachytherapy    (BT
) or cryotherapy.</font></p>     ^cY#a18v37n1.htm##
00407000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704017600072002001300248#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#23#19#text#30#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> A total of 785    patients were include
d in the analysis with a mean follow-up of 24 months.</font></p>     ^cY#a18v37n
1.htm##
00565000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704033400072002001300406#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#24#20#text#30#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> BT and cryotherapy    were associated w
ith a 3-fold higher rate of return to baseline urinary function    compared to O
RP and RALP. Moreover, all treatments had a more adverse impact    on sexual fun
ction and bother than on urinary and bowel domains.</font></p>     ^cY#a18v37n1.
htm##
00626000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704039500072002001300467#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#25#21#text#30#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Although the advent    of RALP has impr
oved visualization and surgeons' ergonomics it has not demonstrated    a signifi
cant improvement of urinary continence or sexual function in this prospective,  
  longitudinal study of health-related quality of life outcomes using validated 
   self-reported questionnaires.</font></p>     ^cY#a18v37n1.htm##
00598000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704036700072002001300439#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#26#22#text#30#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> The authors have    shown the 8 years c
linical follow-up analyzing different treatment modalities    for localized pros
tate cancer. I believe this assessment should be followed    by health care prov
iders managing patients with prostate cancer so we can better    serve our patie
nts.</font></p>     ^cY#a18v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#27#23#text#30#<p>&nbsp;</p>     ^cY#a
18v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011700072002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#28#24#text#30#<p align="right"><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Dr.    Fernando J. K
im</b>    ^cY#a18v37n1.htm##
00287000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005600072002001300128#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#29#25#text#30#<br>   Chief of Urology
, Denver Health Med. Ctr.    ^cY#a18v37n1.htm##
00298000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704006700072002001300139#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#30#26#text#30#<br>   Associate Profes
sor, Univ. Colorado Health Sci. Ctr.    ^cY#a18v37n1.htm##
00298000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704006700072002001300139#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#31#27#text#30#<br>   Director of Mini
mally Invasive Urol. Oncology, UCHSC    ^cY#a18v37n1.htm##
00267000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003600072002001300108#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#32#28#text#30#<br>   Denver, Colorado
, USA    ^cY#a18v37n1.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010300072002001300175#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#33#29#text#30#<br>   E-mail: <a href=
"mailto:fernando.kim@dhha.org">fernando.kim@dhha.org</a></i></font></p>     ^cY#
a18v37n1.htm##
00261000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003000072002001300102#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a18v37n1.htm#S#p#34#30#text#30#<p align="right"></p>  
   ^cY#a18v37n1.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a19v37n1.htm#S#o#1#1#text#1#20
110330#144533#a19v37n1.htm#29##
00641000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701200970
0159010002200256002001300278#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a19v37n1.h
tm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ND#19#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f119^l120#1677-5538#1#Positive predictive value of CT urography in the eva
luation of upper tract urothelial cancer^len#^rND^nAdilson^sPrando#a19v37n1.htm#
#
00648000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201040
0159010002200263002001300285#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a19v37n1.h
tm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ND#19#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f119^l120#1677-5538#1#<b>Positive predictive value of CT urography in the 
evaluation of upper tract urothelial cancer</b>^len#^rND^nAdilson^sPrando#a19v37
n1.htm##
00756000000000361000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000800108158000300116030001700119
03100030013603200020013906500090014101400110015003500100016112300020017101200970
0173010002200270002001300292008008900305#v37n1#V:\SciELO\serial\ibju\v37n1\marku
p\a19v37n1.htm#S#l#4#1#text#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#19#IBJU050#nd#
Int. braz j urol#37#1#20110200#^f119^l120#1677-5538#1#Positive predictive value 
of CT urography in the evaluation of upper tract urothelial cancer^len#^rND^nAdi
lson^sPrando#a19v37n1.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_a
rttext&pid=S1677-55382011000100019##
00341000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704011200070002001300182#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#5#1#text#25#<p align="right"><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>UROLOGICAL    SURVEY</b> 
   ^cY#a19v37n1.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704010800070002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#6#2#text#25#<br>   </font><font size=
"2" face="Verdana, Arial, Helvetica, sans-serif"><b>IMAGING</b></font></p>     ^
cY#a19v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#7#3#text#25#<p>&nbsp;</p>     ^cY#a19
v37n1.htm##
00414000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704018500070002001300255#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#8#4#text#25#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><b>Positive predictive    value of CT urog
raphy in the evaluation of upper tract urothelial cancer</b></font></p>     ^cY#
a19v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#9#5#text#25#<p>&nbsp;</p>     ^cY#a19
v37n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#10#6#text#25#<p>&nbsp;</p>     ^cY#a1
9v37n1.htm##
00381000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704015100071002001300222#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#11#7#text#25#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"> <b>Sadow CA; Wheeler    SC; Kim J; Ohno-
Machado L; Silverman SG</b></font></p>     ^cY#a19v37n1.htm##
00380000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704015000071002001300221#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#12#8#text#25#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Department of Radiology,    Brigham and W
omen's Hospital, Boston, MA 02115, USA    ^cY#a19v37n1.htm##
00296000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704006600071002001300137#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#13#9#text#25#<br>   AJR Am J Roentgen
ol. 2010; 195: W337-43</font></p>     ^cY#a19v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#14#10#text#25#<p>&nbsp;</p>     ^cY#a
19v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#15#11#text#25#<p>&nbsp;</p>     ^cY#a
19v37n1.htm##
00464000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704023300072002001300305#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#16#12#text#25#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">OBJECTIVE: The    purpose of this study 
was to determine the positive predictive value of CT urography    in the diagnos
is of upper tract urothelial malignancies.    ^cY#a19v37n1.htm##
01240000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704100900072002001301081#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#17#13#text#25#<br>   MATERIALS AND ME
THODS: Retrospective review of the records of patients who underwent    2,602 CT
 urographic examinations revealed that 81 (3%) examinations of 77 patients    ha
d findings suggesting upper tract urothelial cancer. Two radiologists in consens
us    categorized the findings as large masses (&gt; 5 mm), small masses (= 5 mm
),    or urothelial thickening. The positive predictive value of CT urography wa
s    determined with the findings at pathologic examination (n = 42), followup i
maging    (n = 29), or clinical follow-up alone (n = 5). One patient with insuff
icient    follow-up information was excluded. The effects of age, sex, indicatio
n for    examination, imaging appearance, and urine cytology were analyzed with 
the Fisher's    exact test or Student's t test. Multivariate logistic regression
 analysis was    used to generate a model for predicting the probability of the 
presence of upper    tract urothelial cancer in patients with positive CT urogra
phic examinations.    ^cY#a19v37n1.htm##
00936000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704070500072002001300777#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#18#14#text#25#<br>   RESULTS: The pos
itive predictive value of CT urography for upper tract urothelial    cancer was 
53% (40/76) overall, 83% (29/35) for large masses, 0% (0/17) for    small masses
, and 46% (11/24) for urothelial thickening. Imaging appearance,    urine cytolo
gy, and age were significant univariate predictors (p &lt; 0.05)    of the prese
nce of upper tract urothelial cancer in patients with positive CT    urographic 
examinations. The independent variables most likely associated with    upper tra
ct urothelial cancer were urine cytology (odds ratio, 60.0; 95% CI,    5.5-653.7
) and imaging appearance (odds ratio, 24.4; 95% CI, 3.0-201.9) after    adjustin
g for age and clinical indication.    ^cY#a19v37n1.htm##
00536000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704030500072002001300377#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#19#15#text#25#<br>   CONCLUSION: The 
positive predictive value of CT urography for upper tract urothelial    cancer i
s moderate because benign findings mimic cancer. Positive findings on    a CT ur
ogram are more likely to indicate cancer in the setting of large masses    or po
sitive urine cytology.</font></p>     ^cY#a19v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#20#16#text#25#<p>&nbsp;</p>     ^cY#a
19v37n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#21#17#text#25#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL COMMENT</b></font></p>     
^cY#a19v37n1.htm##
02253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704202200072002001302094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#22#18#text#25#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Several studies    have been shown that
 multidetector computerized tomography urography (CT urography)    is more sensi
tive, specific and accurate than excretory urography in the diagnosis    of uppe
r urinary tract transitional cell carcinoma in patients with hematuria    and in
 patients with history of urothelial cancer. In this retrospective study    the 
authors shows that positive predictive value (PPV) of abnormal findings    suspi
cious for upper tract urothelial cancer on CT urography was only moderate,    th
at is 53% (of 76 patients with either minimally or highly suspicious findings,  
  only 40 had pathologically proved upper tract urothelial cancer). CT urography
    findings suspicious for urothelial carcinoma were classified in three main c
ategories:    large mass (lesions &gt; 5 mm in maximum diameter), small mass (le
sions 5 mm    in maximum diameter), or urothelial thickening. For findings class
ified as large    masses, the PPV was 83% and for small masses was 0%. We have t
o consider however,    the large number and the variety of false-positive findin
gs in this study. This    was probably related to the retrospective analysis of 
reported findings. False    positive findings were caused mainly by normal or hy
pertrophied papilla, blood    clot and inflammation. Usually nonenhancing blood 
clots may be differentiated    from enhancing urothelial tumor by comparing the 
findings between non-contrast    phase and nephrographic phase. Presence of mild
, homogeneously enhanced and    thickened pelviocalyceal urothelium is relativel
y frequent feature of patients    with symptomatic or asymptomatically urinary t
ract infection. Normal prominent    renal papillae may occasionally invaginate d
eeply into the calices and thus    simulate urothelial tumor. The awareness of s
uch anatomic variation and the    search for this finding in other papillae in t
he same patient, are helpful for    the adequate diagnosis.</font></p>     ^cY#a
19v37n1.htm##
00789000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704055800072002001300630#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#23#19#text#25#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> The authors of    this manuscript, howe
ver, offered important information regarding the value    of urine cytology stud
ies, which were available in 80% of patients. Urine cytology    was very importa
nt for the adequate characterization of pelviocalyceal abnormalities,    such as
 urothelial tumor. When urine cytology was suspicious or malignant and    an upp
er tract urothelial abnormality was found at CT urography, the PPV for    upper 
tract urothelial carcinoma was 92%.</font></p>     ^cY#a19v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#24#20#text#25#<p>&nbsp;</p>     ^cY#a
19v37n1.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011600072002001300188#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#25#21#text#25#<p align="right"><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Dr.    Adilson Prand
o</b>    ^cY#a19v37n1.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004800072002001300120#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#26#22#text#25#<br>   Head, Department
 of Radiology and    ^cY#a19v37n1.htm##
00284000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005300072002001300125#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#27#23#text#25#<br>   Diagnostic Imagi
ng, Vera Cruz Hospital    ^cY#a19v37n1.htm##
00280000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004900072002001300121#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#28#24#text#25#<br>   Campinas, S&atil
de;o Paulo, Brazil    ^cY#a19v37n1.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010900072002001300181#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a19v37n1.htm#S#p#29#25#text#25#<br>   E-mail: <a href=
"mailto:adilson.prando@gmail.com">adilson.prando@gmail.com</a></i></font></p>   
  ^cY#a19v37n1.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a20v37n1.htm#S#o#1#1#text#1#20
110330#144534#a20v37n1.htm#34##
00749000000000373000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201730
0159117000600332072000200338010002200340002001300362#v37n1#V:\SciELO\serial\ibju
\v37n1\markup\a20v37n1.htm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ND#20#IBJU050#nd#Int
. braz j urol.#37#1#20110200#^f120^l121#1677-5538#1#Urinary calculi composed of 
uric acid, cystine, and mineral salts: differentiation with dual-energy CT at a 
radiation dose comparable to that of intravenous pyelography^len#other#1#^rND^nA
dilson^sPrando#a20v37n1.htm##
00763000000000373000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201870
0159117000600346072000200352010002200354002001300376#v37n1#V:\SciELO\serial\ibju
\v37n1\markup\a20v37n1.htm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ND#20#IBJU050#nd#Int
. braz j urol.#37#1#20110200#^f120^l121#1677-5538#1#<b>Urinary calculi composed 
of uric acid, cystine, and mineral salts</b>: <b>differentiation with dual-energ
y CT at a radiation dose comparable to that of intravenous pyelography</b>^len#o
ther#1#^rND^nAdilson^sPrando#a20v37n1.htm##
00864000000000385000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000800108158000300116030001700119
03100030013603200020013906500090014101400110015003500100016112300020017101201730
0173117000600346072000200352010002200354002001300376008008900389#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#l#4#1#text#1#^mJan./Feb.^a2011#oa#en#br
1.1#1#4.0#20#IBJU050#nd#Int. braz j urol#37#1#20110200#^f120^l121#1677-5538#1#Ur
inary calculi composed of uric acid, cystine, and mineral salts: differentiation
 with dual-energy CT at a radiation dose comparable to that of intravenous pyelo
graphy^len#other#1#^rND^nAdilson^sPrando#a20v37n1.htm#Internet^ihttp://www.sciel
o.br/scielo.php?script=sci_arttext&pid=S1677-55382011000100020##
00341000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704011200070002001300182#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#5#1#text#29#<p align="right"><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>UROLOGICAL    SURVEY</b> 
   ^cY#a20v37n1.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704004100070002001300111#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#6#2#text#29#<br>   <b>IMAGING</b></fo
nt></p>     ^cY#a20v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#7#3#text#29#<p>&nbsp;</p>     ^cY#a20
v37n1.htm##
00493000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704026400070002001300334#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#8#4#text#29#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><b>Urinary calculi    composed of uric aci
d, cystine, and mineral salts: differentiation with dual-energy    CT at a radia
tion dose comparable to that of intravenous pyelography</b></font></p>     ^cY#a
20v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#9#5#text#29#<p>&nbsp;</p>     ^cY#a20
v37n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#10#6#text#29#<p>&nbsp;</p>     ^cY#a2
0v37n1.htm##
00419000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704018900071002001300260#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#11#7#text#29#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Thomas C; Heuschmid    M; Schilling D;
 Ketelsen D; Tsiflikas I; Stenzl A; Claussen CD; Schlemmer HP</b></font></p>    
 ^cY#a20v37n1.htm##
00410000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704018000071002001300251#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#12#8#text#29#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Department of Diagnostic    and Intervent
ional Radiology, University of T&uuml;bingen, T&uuml;bingen, Germany    ^cY#a20v
37n1.htm##
00284000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704005400071002001300125#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#13#9#text#29#<br>   Radiology. 2010; 
257: 402-9</font></p>     ^cY#a20v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#14#10#text#29#<p>&nbsp;</p>     ^cY#a
20v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#15#11#text#29#<p>&nbsp;</p>     ^cY#a
20v37n1.htm##
00509000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704027800072002001300350#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#16#12#text#29#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">PURPOSE: To retrospectively    evaluate 
radiation dose, image quality, and the ability to differentiate urinary    calcu
li of differing compositions by using low-dose dual-energy computed tomography  
  (CT).    ^cY#a20v37n1.htm##
01258000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704102700072002001301099#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#17#13#text#29#<br>   MATERIALS AND ME
THODS: The institutional review board approved this retrospective    study; info
rmed consent was waived. A low-dose dual-energy CT protocol (tube    voltage and
 reference effective tube current-time product, 140 kV and 23 mAs    and 80 kV a
nd 105 mAs; collimation, 64 &times; 0.6 mm; pitch, 0.7) for the detection    of 
urinary calculi was implemented into routine clinical care. All patients    (n =
 112) who were examined with this protocol from July 2008 to August 2009    were
 included. The composition of urinary calculi was assessed by using commercially
    available postprocessing software and was compared with results of the refer
ence    standard (ex vivo infrared spectroscopy) in 40 patients for whom the ref
erence    standard was available. Effective doses were calculated. Image quality
 was rated    subjectively and objectively and was correlated with patient size 
expressed    as body cross-sectional area at the level of acquisition by using S
pearman correlation    coefficients.    ^cY#a20v37n1.htm##
00707000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704047600072002001300548#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#18#14#text#29#<br>   RESULTS: One cal
cified concrement in the distal ureter of an obese patient was    mistakenly int
erpreted as mixed calcified and uric acid. One struvite calculus    was falsely 
interpreted as cystine. All other uric acid, cystine, and calcium-containing    
calculi were correctly identified by using dual-energy CT. The mean radiation   
 dose was 2.7 mSv. The average image quality was rated as acceptable, with a    
decrease in image quality in larger patients.    ^cY#a20v37n1.htm##
00597000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704036600072002001300438#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#19#15#text#29#<br>   CONCLUSION: Low-
dose unenhanced dual-source dual-energy CT can help differentiate    between cal
cified, uric acid, and cystine calculi at a radiation dose comparable    to that
 of conventional intravenous pyelography. Because of decreased image    quality 
in obese patients, only nonobese patients should be examined with this    protoc
ol.</font></p>     ^cY#a20v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#20#16#text#29#<p>&nbsp;</p>     ^cY#a
20v37n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#21#17#text#29#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL COMMENT</b></font></p>     
^cY#a20v37n1.htm##
01274000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704104300072002001301115#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#22#18#text#29#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Nowadays multi-detector    computed tom
ography (MDCT) is used in attempt to determine the chemical composition    of ur
inary tract stones. However, the attenuations values given in Hounsfield    unit
s of different types of calculi obtained with current technique overlap,    maki
ng reliable distinction of chemical composition of urinary calculi very    diffi
cult. With the advent of new dual-source CT systems, CT scans are simultaneously
    and quickly obtained using two orthogonally positioned x-ray tubes and detec
tor    sets (double source at 80 and 140 kV); both helical acquisitions run simu
ltaneously    and are not limited by changes between the two scans in contrast e
nhancement    or patient motion (1). Dual-energy CT may be used to distinguish p
ure uric acid,    mixed uric acid, and calcified stones. However, dual-source CT
 imaging delivery    a higher radiation dose to the patient than the currently r
ecommended lower-dose    MDCT protocols.</font></p>     ^cY#a20v37n1.htm##
00945000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704071400072002001300786#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#23#19#text#29#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> The authors of    this manuscript offer
 a great contribution to this subject by developing a low-dose    unenhanced dua
l-source dual-energy CT protocol that can help differentiate between    calcifie
d, uric acid, and cystine calculi at a radiation dose comparable to    that of c
onventional intravenous pyelography (mean 2.7 mSv). This protocol however    was
 useful only in nonobese patients. New variation in dual-source CT protocols,   
 are still in progress in an attempt to further decrease the radiation dose to  
  the patients while keeping the ability to differentiate chemical composition  
  of urinary tract calculi (1).</font></p>     ^cY#a20v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#24#20#text#29#<p>&nbsp;</p>     ^cY#a
20v37n1.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009900072002001300171#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#25#21#text#29#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="3"><b>Reference</b></font></p>     ^cY#a20v
37n1.htm##
00521000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704027600074002001300350#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#26#22#text#29#1#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Ascenti G, Siragusa    
C, Racchiusa S, Ielo I, Privitera G, Midili F, et al.: Stone-targeted dual-energ
y    CT: a new diagnostic approach to urinary calculosis. AJR Am J Roentgenol. 2
010;    195: 953-8.    ^cY#a20v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#27#23#text#29#</font></p>     ^cY#a20
v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#28#24#text#29#<p>&nbsp;</p>     ^cY#a
20v37n1.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011600072002001300188#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#29#25#text#29#<p align="right"><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2"><i><b>Dr.    Adilson Prand
o</b>    ^cY#a20v37n1.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004800072002001300120#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#30#26#text#29#<br>   Head, Department
 of Radiology and    ^cY#a20v37n1.htm##
00284000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005300072002001300125#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#31#27#text#29#<br>   Diagnostic Imagi
ng, Vera Cruz Hospital    ^cY#a20v37n1.htm##
00280000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004900072002001300121#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#32#28#text#29#<br>   Campinas, S&atil
de;o Paulo, Brazil    ^cY#a20v37n1.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010900072002001300181#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a20v37n1.htm#S#p#33#29#text#29#<br>   E-mail: <a href=
"mailto:adilson.prando@gmail.com">adilson.prando@gmail.com</a></i></font></p>   
  ^cY#a20v37n1.htm##
00698000000000337000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100017000720100018000890100
01900107010001400126010001900140010001600159810000600175012008300181030002000264
06500090028406400050029303100040029801400060030286500090030800200130031703500100
0330801002000340#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a20v37n1.htm#S#c#34#1#
text#1#1#^rND^sAscenti^nG#^rND^sSiragusa^nC#^rND^sRacchiusa^nS#^rND^sIelo^nI#^rN
D^sPrivitera^nG#^rND^sMidili^nF#et al#Stone-targeted dual-energy CT: a new diagn
ostic approach to urinary calculosis^len#AJR Am J Roentgenol#20100000#2010#195#9
53-8#20110200#a20v37n1.htm#0361-803X#AJR Am J Roentgenol##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a21v37n1.htm#S#o#1#1#text#1#20
110330#144534#a21v37n1.htm#39##
00690000000000373000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201130
0159117000600272072000200278010002300280002001300303#v37n1#V:\SciELO\serial\ibju
\v37n1\markup\a21v37n1.htm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ND#21#IBJU050#nd#Int
. braz j urol.#37#1#20110200#^f122^l123#1677-5538#1#Application of the Epstein c
riteria for prediction of clinically insignificant prostate cancer in Korean men
^len#other#2#^rND^nAthanase^sBillis#a21v37n1.htm##
00697000000000373000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201200
0159117000600279072000200285010002300287002001300310#v37n1#V:\SciELO\serial\ibju
\v37n1\markup\a21v37n1.htm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ND#21#IBJU050#nd#Int
. braz j urol.#37#1#20110200#^f122^l123#1677-5538#1#<b>Application of the Epstei
n criteria for prediction of clinically insignificant prostate cancer in Korean 
men</b>^len#other#2#^rND^nAthanase^sBillis#a21v37n1.htm##
00805000000000385000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000800108158000300116030001700119
03100030013603200020013906500090014101400110015003500100016112300020017101201130
0173117000600286072000200292010002300294002001300317008008900330#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#l#4#1#text#1#^mJan./Feb.^a2011#oa#en#br
1.1#1#4.0#21#IBJU050#nd#Int. braz j urol#37#1#20110200#^f122^l123#1677-5538#1#Ap
plication of the Epstein criteria for prediction of clinically insignificant pro
state cancer in Korean men^len#other#2#^rND^nAthanase^sBillis#a21v37n1.htm#Inter
net^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382011000100
021##
00337000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704010800070002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#5#1#text#33#<p align="right"><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>UROLOGICAL    SURVEY    ^
cY#a21v37n1.htm##
00267000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704003800070002001300108#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#6#2#text#33#<br> PATHOLOGY</b></font>
</p>     ^cY#a21v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#7#3#text#33#<p>&nbsp;</p>     ^cY#a21
v37n1.htm##
00433000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704020400070002001300274#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#8#4#text#33#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><b>Application    of the Epstein criteria 
for prediction of clinically insignificant prostate    cancer in Korean men</b><
/font></p>     ^cY#a21v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#9#5#text#33#<p>&nbsp;</p>     ^cY#a21
v37n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#10#6#text#33#<p>&nbsp;</p>     ^cY#a2
1v37n1.htm##
00436000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704020600071002001300277#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#11#7#text#33#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Lee SE; Kim    DS; Lee WK; Park HZ; Le
e CJ; Doo SH; Jeong SJ; Yoon CY; Byun SS; Choe G; Hwang    SI; Lee HJ; Hong SK</
b></font></p>     ^cY#a21v37n1.htm##
00375000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704014500071002001300216#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#12#8#text#33#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Department of Urology,    Seoul National 
Bundang Hospital, Seongnam, Korea    ^cY#a21v37n1.htm##
00284000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704005400071002001300125#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#13#9#text#33#<br>   BJU Int. 2010; 10
5: 1526-30</font></p>     ^cY#a21v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#14#10#text#33#<p>&nbsp;</p>     ^cY#a
21v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#15#11#text#33#<p>&nbsp;</p>     ^cY#a
21v37n1.htm##
00515000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704028400072002001300356#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#16#12#text#33#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> OBJECTIVE: To    investigate the rate o
f pathologically confirmed unfavourable prostate cancers    among Korean men who
 fulfilled the contemporary Epstein criteria for clinically    insignificant pro
state cancer.    ^cY#a21v37n1.htm##
00738000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704050700072002001300579#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#17#13#text#33#<br>   PATIENTS AND MET
HODS: This was a retrospective study of 131 Korean men who underwent    radical 
prostatectomy (RP) for clinically insignificant prostate cancer as defined    by
 contemporary Epstein criteria. We assessed the percentage of unfavourable    pr
ostate cancer (pathological Gleason sum &gt; or = 7 and/or extraprostatic    ext
ension &#91;EPE&#93;) among these men and tried to identify useful predictors   
 for such unfavourable tumour profiles using uni- and multivariate analyses.    
^cY#a21v37n1.htm##
00927000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704069600072002001300768#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#18#14#text#33#<br>   RESULTS: Among 1
31 men with clinically insignificant prostate cancer, 40 (30.5%)    had patholog
ical Gleason &gt; or = 7 tumours after RP. Of these 40 men, four    (3.1%) also 
had EPE on examination of RP specimen. All those who did not have    Gleason sco
re upgrading after RP had organ-confined disease from examination    of RP speci
men. Overall, 40 (30.5%) of the 131 men who fulfilled the contemporary    Epstei
n criteria for clinically insignificant prostate cancer before RP had    patholo
gically unfavourable disease. Among our patients, no significant preoperative   
 predictor of pathologically unfavourable disease was identified using uni- and 
   multivariate analyses.    ^cY#a21v37n1.htm##
00698000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704046700072002001300539#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#19#15#text#33#<br>   CONCLUSION: Our 
results showed that a significant proportion of contemporary    Korean patients 
who meet all the conditions of the contemporary Epstein criteria    for predicti
on of clinically insignificant prostate cancer might actually harbour    prostat
e cancer with unfavourable pathological features. Such findings should    be con
sidered when treatment options are contemplated based upon the Epstein    criter
ia among Asian patients.</font></p>     ^cY#a21v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#20#16#text#33#<p>&nbsp;</p>     ^cY#a
21v37n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#21#17#text#33#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="3"><b>EDITORIAL COMMENT</b></font></p>     
^cY#a21v37n1.htm##
00787000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704055600072002001300628#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#22#18#text#33#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Watchful waiting    (active surveillanc
e) has gaining popularity as a management strategy for newly    diagnosed low-gr
ade, limited cancer on needle biopsy based on the large discrepancy    between i
ncidence and mortality rate of prostate cancer. Data from the European    Random
ized Study of Screening for Prostate Cancer Trial showed that PSA screening    r
educed the rate of death from prostate cancer by 20% but was associated with    
a high risk of overdiagnosis (1).</font></p>     ^cY#a21v37n1.htm##
00832000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704060100072002001300673#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#23#19#text#33#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Epstein proposed    a set of criteria b
ased on PSA and preoperative biopsy features that identify    a high likelihood 
of organ-confined insignificant cancers at radical prostatectomy    (2). Insigni
ficant cancers are defined as cancers confined to the prostate (pT2),    Gleason
 low-grade (score = 6), and low-volume (= 0.5 cc). It is important to    be awar
e that insignificant cancer is not synonymous of latent (indolent) carcinoma.   
 So far, there is no single marker of biological behavior for prostate cancer.</
font></p>     ^cY#a21v37n1.htm##
00782000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704055100072002001300623#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#24#20#text#33#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> The preoperative    biopsy and clinical
 features of Epstein's criteria for insignificant cancer    are: clinical stage 
T1c, preoperative PSA density &lt; 0.15, no Gleason pattern    4 or 5, no more t
han 2 cores with cancer, and no more than 50% of involvement    of cancer in a s
ingle core. According to Bastian at Johns Hopkins, the predictive    value using
 the Epstein's criteria for organ-confined disease and insignificant    cancer i
s 92% and 84%, respectively.</font></p>     ^cY#a21v37n1.htm##
00755000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704052400072002001300596#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#25#21#text#33#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Several studies    have applied Epstein
's criteria for prediction of clinically insignificant prostate    cancer with d
iffering results. In all studies, the criteria are predictive of    a high frequ
ency of organ-confined disease but differ for insignificant cancer.    In the st
udy from Korea, the frequency of organ-confined disease was 97% (vs.    92% from
 Johns Hopkins) but 69% for insignificant cancer (vs. 84% from Johns    Hopkins)
.</font></p>     ^cY#a21v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#26#22#text#33#<p>&nbsp;</p>     ^cY#a
21v37n1.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010000072002001300172#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#27#23#text#33#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="3"><b>References</b></font></p>     ^cY#a21
v37n1.htm##
00512000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704026700074002001300341#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#28#24#text#33#1#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Schr&ouml;der    FH, Hu
gosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al.: Screening    and pro
state-cancer mortality in a randomized European study. N Engl J Med.    2009; 36
0: 1320-8.    ^cY#a21v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#29#25#text#33#</font></p>     ^cY#a21
v37n1.htm##
00486000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704024100074002001300315#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#30#26#text#33#2#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Bastian PJ,    Mangold 
LA, Epstein JI, Partin AW: Characteristics of insignificant clinical    T1c pros
tate tumors. A contemporary analysis. Cancer. 2004; 101: 2001-5.    ^cY#a21v37n1
.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#31#27#text#33#</font></p>     ^cY#a21
v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#32#28#text#33#<p>&nbsp;</p>     ^cY#a
21v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011700072002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#33#29#text#33#<p align="right"><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2"><i><b>Dr.    Athanase Bill
is</b>    ^cY#a21v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004200072002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#34#30#text#33#<br>   Full-Professor o
f Pathology    ^cY#a21v37n1.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005200072002001300124#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#35#31#text#33#<br>   State University
 of Campinas, Unicamp    ^cY#a21v37n1.htm##
00280000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004900072002001300121#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#36#32#text#33#<br>   Campinas, S&atil
de;o Paulo, Brazil    ^cY#a21v37n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a21v37n1.htm#S#p#37#33#text#33#<br>   E-mail: <a href=
"mailto:athanase@fcm.unicamp.br">athanase@fcm.unicamp.br</a></i></font></p>     
^cY#a21v37n1.htm##
00677000000000337000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100019000720100018000910100
01700109010001800126010001600144010001500160810000600175012007500181030001300256
06500090026906400050027803100040028301400070028786500090029400200130030303500100
0316801001300326#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a21v37n1.htm#S#c#38#1#
text#2#1#^rND^sSchröder^nFH#^rND^sHugosson^nJ#^rND^sRoobol^nMJ#^rND^sTammela^nTL
#^rND^sCiatto^nS#^rND^sNelen^nV#et al#Screening and prostate-cancer mortality in
 a randomized European study^len#N Engl J Med#20090000#2009#360#1320-8#20110200#
a21v37n1.htm#0028-4793#N Engl J Med##
00607000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100018000720100018000900100
01800108010001700126012009100143030000700234065000900241064000500250031000400255
014000700259865000900266002001300275035001000288801000700298#v37n1#V:\SciELO\ser
ial\ibju\v37n1\markup\a21v37n1.htm#S#c#39#2#text#2#2#^rND^sBastian^nPJ#^rND^sMan
gold^nLA#^rND^sEpstein^nJI#^rND^sPartin^nAW#Characteristics of insignificant cli
nical T1c prostate tumors: A contemporary analysis^len#Cancer#20040000#2004#101#
2001-5#20110200#a21v37n1.htm#0008-543X#Cancer##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a22v37n1.htm#S#o#1#1#text#1#20
110330#144535#a22v37n1.htm#44##
00714000000000373000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201370
0159117000600296072000200302010002300304002001300327#v37n1#V:\SciELO\serial\ibju
\v37n1\markup\a22v37n1.htm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ND#22#IBJU050#nd#Int
. braz j urol.#37#1#20110200#^f123^l124#1677-5538#1#The Epstein criteria predict
 for organ-confined but not insignificant disease and a high likelihood of cure 
at radical prostatectomy^len#other#3#^rND^nAthanase^sBillis#a22v37n1.htm##
00721000000000373000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201440
0159117000600303072000200309010002300311002001300334#v37n1#V:\SciELO\serial\ibju
\v37n1\markup\a22v37n1.htm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ND#22#IBJU050#nd#Int
. braz j urol.#37#1#20110200#^f123^l124#1677-5538#1#<b>The Epstein criteria pred
ict for organ-confined but not insignificant disease and a high likelihood of cu
re at radical prostatectomy</b>^len#other#3#^rND^nAthanase^sBillis#a22v37n1.htm#
#
00829000000000385000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000800108158000300116030001700119
03100030013603200020013906500090014101400110015003500100016112300020017101201370
0173117000600310072000200316010002300318002001300341008008900354#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#l#4#1#text#1#^mJan./Feb.^a2011#oa#en#br
1.1#1#4.0#22#IBJU050#nd#Int. braz j urol#37#1#20110200#^f123^l124#1677-5538#1#Th
e Epstein criteria predict for organ-confined but not insignificant disease and 
a high likelihood of cure at radical prostatectomy^len#other#3#^rND^nAthanase^sB
illis#a22v37n1.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&
pid=S1677-55382011000100022##
00337000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704010800070002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#5#1#text#37#<p align="right"><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>UROLOGICAL    SURVEY    ^
cY#a22v37n1.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704004000070002001300110#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#6#2#text#37#<br>   PATHOLOGY</b></fon
t></p>     ^cY#a22v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#7#3#text#37#<p>&nbsp;</p>     ^cY#a22
v37n1.htm##
00457000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704022800070002001300298#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#8#4#text#37#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><b>The Epstein    criteria predict for org
an-confined but not insignificant disease and a high    likelihood of cure at ra
dical prostatectomy</b></font></p>     ^cY#a22v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#9#5#text#37#<p>&nbsp;</p>     ^cY#a22
v37n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#10#6#text#37#<p>&nbsp;</p>     ^cY#a2
2v37n1.htm##
00389000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704015900071002001300230#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#11#7#text#37#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Lee MC; Dong    F; Stephenson AJ; Jone
s JS; Magi-Galluzzi C; Klein EA</b></font></p>     ^cY#a22v37n1.htm##
00382000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704015200071002001300223#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#12#8#text#37#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Glickman Urological    and Kidney Institu
te, Cleveland Clinic, Cleveland, OH, USA    ^cY#a22v37n1.htm##
00281000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704005100071002001300122#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#13#9#text#37#<br>   Eur Urol. 2010; 5
8: 90-5</font></p>     ^cY#a22v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#14#10#text#37#<p>&nbsp;</p>     ^cY#a
22v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#15#11#text#37#<p>&nbsp;</p>     ^cY#a
22v37n1.htm##
00439000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704020800072002001300280#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#16#12#text#37#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Background: Few    reports attempt to va
lidate the role of Epstein criteria in selecting patients    for an active surve
illance protocol.    ^cY#a22v37n1.htm##
00489000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704025800072002001300330#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#17#13#text#37#<br>   Objective: To de
termine the performance of the Epstein biopsy criteria for predicting    patholo
gic end points and biochemical relapse-free survival (bRFS) in men with    early
 stage prostate cancer (PCa) treated by radical prostatectomy (RP).    ^cY#a22v3
7n1.htm##
00561000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704033000072002001300402#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#18#14#text#37#<br>   Design, Setting 
and Participants: Between October 1999 and January 2007, 746    consecutive pati
ents were biopsied, and then underwent RP at our tertiary care    institution. T
wo hundred sixty-eight patients met the entry criteria of Gleason    6 disease o
nly on initial biopsy with complete pathologic information.    ^cY#a22v37n1.htm#
#
00586000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704035500072002001300427#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#19#15#text#37#<br>   Measurements: Pr
imary end point was insignificant disease. Insignificant disease    was defined 
using a classical (organ-confined, Gleason score &lt; 6, and tumor    volume &lt
; 0.5 cm(3)) and more liberal (organ-confined, Gleason &lt; 6 tumor    of any vo
lume) formulation. Secondary end points included organ-confined disease    and b
RFS.    ^cY#a22v37n1.htm##
01139000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704090800072002001300980#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#20#16#text#37#<br>   Results and Limi
tations: One hundred thirty-six men (51%) met the Epstein biopsy    criteria, an
d 167 (62%) had organ-confined cancer. Insignificant disease by    the classical
 and liberal definitions was present in 68 (25%) and 92 (34%) patients,    respe
ctively. Cases meeting Epstein biopsy criteria were more likely to have    insig
nificant disease by either definition (p &lt; 0.001) and more likely to    have 
organ-confined tumors (p &lt; 0.001). Sensitivity, specificity, positive    pred
ictive value (PPV), and negative predictive value (NPV) varied widely among    t
he end points, with sensitivity (74%) and NPV (86%) best for the classical    de
finition of insignificant disease and specificity (74%) and PPV (92%) best    fo
r organ-confined disease. The estimated 5-yr bRFS was 100% for those meeting    
Epstein biopsy criteria compared to 83% for those not meeting these criteria.   
 ^cY#a22v37n1.htm##
00530000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704029900072002001300371#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#21#17#text#37#<br>   Conclusions: The
 Epstein biopsy criteria predict for a high likelihood of organ-confined    dise
ase and the absence of biochemical failure up to 5 years after RP. These    crit
eria are insufficiently robust to predict the presence of biologically insignifi
cant    disease.</font></p>     ^cY#a22v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#22#18#text#37#<p>&nbsp;</p>     ^cY#a
22v37n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#23#19#text#37#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="3"><b>EDITORIAL COMMENT</b></font></p>     
^cY#a22v37n1.htm##
00629000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704039800072002001300470#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#24#20#text#37#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> The conclusion    of Lee's et al. study
 from Cleveland Clinic is that Epstein biopsy criteria    predict for a high lik
elihood of organ-confined disease but are insufficiently    robust to predict th
e presence of insignificant disease defined as organ-confined,    Gleason low-gr
ade, and minimal volume (= 0.5 cc).</font></p>     ^cY#a22v37n1.htm##
01055000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704082400072002001300896#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#25#21#text#37#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> The findings are    supported by other 
studies (1-3). Epstein's criteria are highly predictive for    organ-confined pr
ostate cancer. The frequency varies from 91% to 97%. However,    the predictive 
value for insignificant cancer varies from 37% to 84%. Jeldre's    et al. conclu
ded that Epstein's criteria might underestimate the true nature    of prostate c
ancer in as many as 24% of European patients (1). Approximately    31% Korean pa
tients who meet all the conditions of the contemporary Epstein's    criteria for
 prediction of clinically insignificant prostate cancer may actually    harbor p
rostate cancer with unfavorable pathological features (2). In the Middle    East
 (Egypt), 46% of patients may present unfavorable cancer (3).</font></p>     ^cY
#a22v37n1.htm##
00770000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704053900072002001300611#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#26#22#text#37#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> There are several    causes for the dis
crepancies. Prostate cancers diagnosed in Asian, American,    and European men m
ay have innate differences associated with racial and/or environmental    factor
s. However, methodological factors seem to be more important: among others,    n
umber of patients studied, number of cores of the biopsy, and criteria for    vo
lume evaluation. The last one was considered by Lee's et al. study from the    C
leveland Clinic.</font></p>     ^cY#a22v37n1.htm##
00789000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704055800072002001300630#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#27#23#text#37#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> According to volume,    the authors def
ined prostate cancer by two ways: classical and liberal. The    classical defini
tion considered a tumor volume &lt; 0.5 cc; and the liberal    definition any gr
ade of volume. Using the liberal definition, the predictive    value of Epstein'
s criteria for insignificant cancer was 58%; using the classical    definition w
as 37%. In a similar study at our Institution (data not published),    the frequ
ency was 55% and 46%, respectively.</font></p>     ^cY#a22v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#28#24#text#37#<p>&nbsp;</p>     ^cY#a
22v37n1.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010000072002001300172#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#29#25#text#37#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="3"><b>References</b></font></p>     ^cY#a22
v37n1.htm##
00526000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704028100074002001300355#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#30#26#text#37#1#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Jeldres C, Suardi    N,
 Walz J, Hutterer GC, Ahyai S, Lattouf JB, et al.: Validation of the contemporar
y    epstein criteria for insignificant prostate cancer in European men. Eur Uro
l.    2008; 54: 1306-13.    ^cY#a22v37n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002100072002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#31#27#text#37# </font></p>     ^cY#a2
2v37n1.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704027800074002001300352#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#32#28#text#37#2#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Lee SE, Kim    DS, Lee 
WK, Park HZ, Lee CJ, Doo SH, et al.: Application of the Epstein criteria    for 
prediction of clinically insignificant prostate cancer in Korean men. BJU    Int
. 2010; 105: 1526-30.    ^cY#a22v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#33#29#text#37#</font></p>     ^cY#a22
v37n1.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704028800074002001300362#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#34#30#text#37#3#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Hekal IA, El-Tabey    N
A, Nabeeh MA, El-Assmy A, Abd El-Hameed M, Nabeeh A, et al.: Validation of    Ep
stein criteria of insignificant prostate cancer in Middle East patients. Int    
Urol Nephrol. 2010; 42: 667-71.    ^cY#a22v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#35#31#text#37#</font></p>     ^cY#a22
v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#36#32#text#37#<p>&nbsp;</p>     ^cY#a
22v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011700072002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#37#33#text#37#<p align="right"><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Dr.    Athanase Bill
is</b>    ^cY#a22v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004200072002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#38#34#text#37#<br>   Full-Professor o
f Pathology    ^cY#a22v37n1.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005200072002001300124#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#39#35#text#37#<br>   State University
 of Campinas, Unicamp    ^cY#a22v37n1.htm##
00280000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004900072002001300121#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#40#36#text#37#<br>   Campinas, S&atil
de;o Paulo, Brazil    ^cY#a22v37n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a22v37n1.htm#S#p#41#37#text#37#<br>   E-mail: <a href=
"mailto:athanase@fcm.unicamp.br">athanase@fcm.unicamp.br</a></i></font></p>     
^cY#a22v37n1.htm##
00692000000000337000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100017000720100016000890100
01400105010001900119010001500138010001800153810000600171012010200177030000900279
06500090028806400050029703100030030201400080030586500090031300200130032203500100
0335801000900345#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a22v37n1.htm#S#c#42#1#
text#3#1#^rND^sJeldres^nC#^rND^sSuardi^nN#^rND^sWalz^nJ#^rND^sHutterer^nGC#^rND^
sAhyai^nS#^rND^sLattouf^nJB#et al#Validation of the contemporary epstein criteri
a for insignificant prostate cancer in European men^len#Eur Urol#20080000#2008#5
4#1306-13#20110200#a22v37n1.htm#0302-2838#Eur Urol##
00660000000000325000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100014000720100014000860100
01400100010001500114010001400129010001400143810000600157012011300163030000800276
71000020028406500090028606400050029503100040030001400080030486500090031200200130
0321#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a22v37n1.htm#S#c#43#2#text#3#2#^rN
D^sLee^nSE#^rND^sKim^nDS#^rND^sLee^nWK#^rND^sPark^nHZ#^rND^sLee^nCJ#^rND^sDoo^nS
H#et al#Application of the Epstein criteria for prediction of clinically insigni
ficant prostate cancer in Korean men^len#BJU Int#2#20100000#2010#105#1526-30#201
10200#a22v37n1.htm##
00707000000000337000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100016000720100019000880100
01700107010001800124010002300142010001600165810000600181012009200187030001700279
06500090029606400050030503100030031001400070031386500090032000200130032903500100
0342801001700352#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a22v37n1.htm#S#c#44#3#
text#3#3#^rND^sHekal^nIA#^rND^sEl-Tabey^nNA#^rND^sNabeeh^nMA#^rND^sEl-Assmy^nA#^
rND^sAbd El-Hameed^nM#^rND^sNabeeh^nA#et al#Validation of Epstein criteria of in
significant prostate cancer in Middle East patients^len#Int Urol Nephrol#2010000
0#2010#42#667-71#20110200#a22v37n1.htm#0301-1623#Int Urol Nephrol##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a23v37n1.htm#S#o#1#1#text#1#20
110330#144536#a23v37n1.htm#28##
00688000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201430
0159010002300302002001300325#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a23v37n1.h
tm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ND#23#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f124^l125#1677-5538#1#The use of penile skin graft versus penile skin flap
 in the repair of long bulbo-penile urethral stricture: a prospective randomized
 study^len#^rND^nSean P.^sElliott#a23v37n1.htm##
00702000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201570
0159010002300316002001300339#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a23v37n1.h
tm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ND#23#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f124^l125#1677-5538#1#<b>The use of penile skin graft versus penile skin f
lap in the repair of long bulbo-penile urethral stricture</b>: <b>a prospective 
randomized study</b>^len#^rND^nSean P.^sElliott#a23v37n1.htm##
00802000000000361000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000800108158000300116030001700119
03100030013603200020013906500090014101400110015003500100016112300020017101201430
0173010002200316002001300338008008900351#v37n1#V:\SciELO\serial\ibju\v37n1\marku
p\a23v37n1.htm#S#l#4#1#text#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#23#IBJU050#nd#
Int. braz j urol#37#1#20110200#^f124^l125#1677-5538#1#The use of penile skin gra
ft versus penile skin flap in the repair of long bulbo-penile urethral stricture
: a prospective randomized study^len#^rND^nSean P^sElliott#a23v37n1.htm#Internet
^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382011000100023
##
00337000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704010800070002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#5#1#text#24#<p align="right"><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>UROLOGICAL    SURVEY    ^
cY#a23v37n1.htm##
00282000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704005300070002001300123#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#6#2#text#24#<br>   RECONSTRUCTIVE URO
LOGY</b></font></p>     ^cY#a23v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#7#3#text#24#<p>&nbsp;</p>     ^cY#a23
v37n1.htm##
00463000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704023400070002001300304#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#8#4#text#24#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><b>The use of penile    skin graft versus 
penile skin flap in the repair of long bulbo-penile urethral    stricture: a pro
spective randomized study</b></font></p>     ^cY#a23v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#9#5#text#24#<p>&nbsp;</p>     ^cY#a23
v37n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#10#6#text#24#<p>&nbsp;</p>     ^cY#a2
3v37n1.htm##
00381000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704015100071002001300222#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#11#7#text#24#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Hussein MM;    Moursy E; Gamal W; Zaki
 M; Rashed A; Abozaid A</b></font></p>     ^cY#a23v37n1.htm##
00381000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704015100071002001300222#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#12#8#text#24#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Urology Department,    Sohag Faculty of M
edicine, Sohag University, Sohag, Egypt    ^cY#a23v37n1.htm##
00307000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704007700071002001300148#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#13#9#text#24#<br>   Urology. 2011 Jan
 3. &#91;Epub ahead of print&#93;</font></p>     ^cY#a23v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#14#10#text#24#<p>&nbsp;</p>     ^cY#a
23v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#15#11#text#24#<p>&nbsp;</p>     ^cY#a
23v37n1.htm##
00437000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704020600072002001300278#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#16#12#text#24#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> OBJECTIVES: To    evaluate the use of p
enile circular skin graft versus flap as a ventral onlay    for bulbo-penile str
icture urethra.    ^cY#a23v37n1.htm##
00803000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704057200072002001300644#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#17#13#text#24#<br>   MATERIAL AND MET
HODS: Between 2003 and 2009, 37 patients with bulbo-penile stricture    were ran
domized to penile methods circular skin graft (PCG = 18) or flap (PCF    = 19). 
Inclusion criteria included postinstrumentation or idiopathic stricture.    Excl
usion criteria were unhealthy skin and previous urethrotomy/urethroplasty.    Pa
tients had urethrogram at three weeks, three months, one year, and urethroscopy 
   when needed. Any subsequent urethrotomy/urethroplasty was considered a failur
e.    Chi-square and Student's t test were used for analysis.    ^cY#a23v37n1.ht
m##
01376000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704114500072002001301217#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#18#14#text#24#<br>   RESULTS: Patient
s' ages were 45.3 (range: 30-65) and 45.5 (35-60) yr in PCG&amp;PCF    respectiv
ely. Stricture length was 15.2 (10-22) &amp;14.1 (9-21) cm in PCG&amp;PCF    res
pectively. The stricture was postinstrumentation in 9 and 11 and idiopathic    i
n 9 and 8 patients in PCG&amp;PCF respectively. Mean follow up was 36.2 (12-60) 
   and 37.1 (range: 13-24) months in PCG and PCF respectively. Operative time wa
s    significantly shorter in PCG than in PCF (203.3 and 281.6 min, respectively
;    P = .000). Early postoperative complications were similar in both groups. S
uperficial    skin necrosis occurred only in the PCF group (3 cases). Late compl
ications of    mild postvoid dribbling occurred similarly in both groups. One pa
tient in PCF    had a urethro-cutaneaous fistula at the level of fossa navicular
is that was    repaired later. Stricture recurred in 5 (27.7%) and 4(21%) patien
ts in PCG and    PCF, respectively (P = .249). Four patients had visual internal
 urethrotomy    (2, 2), four needed anastmotic urethroplasty (2, 2) in PCG and P
CF, respectively,    and one needed buccal mucosal graft in the PCG group.    ^c
Y#a23v37n1.htm##
00463000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704023200072002001300304#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#19#15#text#24#<br>   CONCLUSIONS: At 
intermediate follow-up, both penile circular graft and flap    had similar and h
igh success as a ventral onlay for repair of long bulbo-penile    stricture with
 a low rate of complications.</font></p>     ^cY#a23v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#20#16#text#24#<p>&nbsp;</p>     ^cY#a
23v37n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#21#17#text#24#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="3"><b>EDITORIAL COMMENT</b></font></p>     
^cY#a23v37n1.htm##
02095000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704186400072002001301936#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#22#18#text#24#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Hussein et al.    raise the bar in reco
nstructive urology research by completing a randomized    clinical trial of dist
al penile fasciocutaneous skin flap urethroplasty vs.    distal penile skin graf
t urethroplasty for non- lichen sclerosus strictures    of the bulbo-penile uret
hra. They chose to compare two surgical techniques,    which were similar in man
y ways but distinct in one important way. Similarities    included the circumcis
ing incision, the distal penile skin and the ventral onlay    approach. The diff
erence was in whether a graft or flap was used. The similarities    in technique
 were likely helpful in recruiting patients. The similarities were    also impor
tant in helping isolate the treatment effect of interest &#8211; flap    vs. gra
ft. Indeed, they did not detect a difference between the two groups in    their 
primary outcome &#8211; a subsequent procedure to treat a stricture recurrence  
  (21% for flap vs. 28% for graft). Here is where some additional planning could
    have strengthened the study. In order to detect a 10% difference at a signif
icance    level of p = 0.05 at a power of 0.8 they would have needed to randomiz
e 353    patients to each arm of the study, rather than 19 patients as done here
. Indeed,    with only 19 patients in each arm they would have only been able to
 detect a    massive difference between the recurrence rates. Additionally, the 
primary outcome    of interest &#8211; need for additional procedures &#8211; in
troduces significant    subjectivity into the success rates. A more objective ou
tcome measure would    have been preferable. Still, this study represents a grea
t advance for the field    of reconstructive urology and hope it will stimulate 
others to contribute randomized    studies to the literature.</font></p>     ^cY
#a23v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#23#19#text#24#<p>&nbsp;</p>     ^cY#a
23v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011700072002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#24#20#text#24#<p align="right"><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2"><i><b>Dr.    Sean P. Ellio
tt</b>    ^cY#a23v37n1.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004400072002001300116#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#25#21#text#24#<br>   Department of Ur
ology Surgery    ^cY#a23v37n1.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003800072002001300110#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#26#22#text#24#<br>   University of Mi
nnesota    ^cY#a23v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004200072002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#27#23#text#24#<br>   Minneapolis, Min
nesota, USA    ^cY#a23v37n1.htm##
00324000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009300072002001300165#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a23v37n1.htm#S#p#28#24#text#24#<br>   E-mail: <a href=
"mailto:selliott@umn.edu">selliott@umn.edu</a></i></font></p>     ^cY#a23v37n1.h
tm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a24v37n1.htm#S#o#1#1#text#1#20
110330#144536#a24v37n1.htm#29##
00659000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201140
0159010002300273002001300296#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a24v37n1.h
tm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ND#24#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f126^l126#1677-5538#1#Halofuginone-coated urethral catheters prevent periu
rethral spongiofibrosis in a rat model of urethral injury^len#^rND^nSean P.^sEll
iott#a24v37n1.htm##
00666000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201210
0159010002300280002001300303#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a24v37n1.h
tm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ND#24#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f126^l126#1677-5538#1#<b>Halofuginone-coated urethral catheters prevent pe
riurethral spongiofibrosis in a rat model of urethral injury</b>^len#^rND^nSean 
P.^sElliott#a24v37n1.htm##
00773000000000361000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000800108158000300116030001700119
03100030013603200020013906500090014101400110015003500100016112300020017101201140
0173010002200287002001300309008008900322#v37n1#V:\SciELO\serial\ibju\v37n1\marku
p\a24v37n1.htm#S#l#4#1#text#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#24#IBJU050#nd#
Int. braz j urol#37#1#20110200#^f126^l126#1677-5538#1#Halofuginone-coated urethr
al catheters prevent periurethral spongiofibrosis in a rat model of urethral inj
ury^len#^rND^nSean P^sElliott#a24v37n1.htm#Internet^ihttp://www.scielo.br/scielo
.php?script=sci_arttext&pid=S1677-55382011000100024##
00337000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704010800070002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#5#1#text#25#<p align="right"><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>UROLOGICAL    SURVEY    ^
cY#a24v37n1.htm##
00282000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704005300070002001300123#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#6#2#text#25#<br>   RECONSTRUCTIVE URO
LOGY</b></font></p>     ^cY#a24v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#7#3#text#25#<p>&nbsp;</p>     ^cY#a24
v37n1.htm##
00434000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704020500070002001300275#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#8#4#text#25#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><b>Halofuginone-coated    urethral cathete
rs prevent periurethral spongiofibrosis in a rat model of urethral    injury</b>
</font></p>     ^cY#a24v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#9#5#text#25#<p>&nbsp;</p>     ^cY#a24
v37n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#10#6#text#25#<p>&nbsp;</p>     ^cY#a2
4v37n1.htm##
00390000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704016000071002001300231#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#11#7#text#25#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Krane LS; Gorbachinsky    I; Sirintrap
un J; Yoo JJ; Atala A; Hodges SJ</b></font></p>     ^cY#a24v37n1.htm##
00399000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704016900071002001300240#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#12#8#text#25#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Department of Urology,    Wake Forest Uni
versity School of Medicine, Winston-Salem, North Carolina    ^cY#a24v37n1.htm##
00310000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704008000071002001300151#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#13#9#text#25#<br>   J Endourol. 2011 
Jan 4. &#91;Epub ahead of print&#93;</font></p>     ^cY#a24v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#14#10#text#25#<p>&nbsp;</p>     ^cY#a
24v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#15#11#text#25#<p>&nbsp;</p>     ^cY#a
24v37n1.htm##
00799000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704056800072002001300640#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#16#12#text#25#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">BACKGROUND AND    PURPOSE: Urethral stri
ctures are from periurethral spongiofibrosis that develops    as a result of ure
thral trauma, disease, or iatrogenic injury. The spongy tissue    that surrounds
 the strictured urethra has an altered ratio of collagen, with    increased coll
agen type I relative to type III. We evaluated the ability of    a urethral cath
eter that was coated with halofuginone (HF), a potent type I    collagen inhibit
or, to prevent spongiofibrosis formation in a rat model.     ^cY#a24v37n1.htm##
01005000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704077400072002001300846#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#17#13#text#25#<br>   MATERIALS AND ME
THODS: HF was coated on silicone catheters and release kinetics    were measured
. Success of impregnation was evaluated with scanning electron    microscopy, se
rial weights, and drug elution data. Urethral strictures were    induced in rats
 using electrocautery. Half the animals had placement of an HF-coated    cathete
r while the others had uncoated silicone controls. Animals were sacrificed    at
 predetermined time points, and urethral tissue was either processed for stainin
g    with Masson trichrome and anti-alpha-1 collagen or digested to determine HF
    concentration. Serum drug levels were also determined in treated animals. Sl
ides    were graded by a pathologist who was blinded to treatment to determine c
ollagen    deposition.     ^cY#a24v37n1.htm##
00619000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704038800072002001300460#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#18#14#text#25#<br>   RESULTS: HF was 
coated successfully on silicone catheters. Local urethral concentration    of HF
 was tenfold higher than serum concentration in treated rats. Animals with    HF
-coated catheters had no new type I collagen deposition after urethral injury.  
  Control animals had increased periurethral collagen type I deposition, typical
    of urethral stricture formation.     ^cY#a24v37n1.htm##
00537000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704030600072002001300378#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#19#15#text#25#<br>   CONCLUSIONS: HF 
can be coated successfully on silicone catheters. HF successfully    inhibits pe
riurethral type I collagen deposition after urethral injury. This    may become 
an important therapy to prevent urethral stricture formation or recurrence    af
ter endoscopic therapy.</font></p>     ^cY#a24v37n1.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002300072002001300095#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#20#16#text#25#<p>&nbsp; </p>     ^cY#
a24v37n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#21#17#text#25#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL COMMENT</b></font></p>     
^cY#a24v37n1.htm##
01035000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704080400072002001300876#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#22#18#text#25#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> The authors present    preliminary work
 in an animal model of urethral injury in which an extract of    a Chinese herb 
is impregnated onto a urethral catheter to prevent build-up of    Type 1 collage
n. Urethral stricture is known to be associated with accumulation    of Type 1 r
ather than Type 3 collagen in the corpus spongiosum. Halofuginone    has been sh
own to prevent collagen accumulation in other urologic models; however,    this 
is the first study to deliver the compound locally rather than systemically.    
Indeed, urethral stricture is an attractive field for such a delivery system,   
 in that a urethral catheter provides convenient delivery device. We look forwar
d    to future developments in this area.</font></p>     ^cY#a24v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#23#19#text#25#<p>&nbsp;</p>     ^cY#a
24v37n1.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011700072002001300189#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#24#20#text#25#<p align="right"><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Dr.    Sean P. Ellio
tt</b>    ^cY#a24v37n1.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004400072002001300116#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#25#21#text#25#<br>   Department of Ur
ology Surgery    ^cY#a24v37n1.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003800072002001300110#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#26#22#text#25#<br>   University of Mi
nnesota    ^cY#a24v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004200072002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#27#23#text#25#<br>   Minneapolis, Min
nesota, USA    ^cY#a24v37n1.htm##
00324000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009300072002001300165#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#28#24#text#25#<br>   E-mail: <a href=
"mailto:selliott@umn.edu">selliott@umn.edu</a></i></font></p>     ^cY#a24v37n1.h
tm##
00261000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003000072002001300102#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a24v37n1.htm#S#p#29#25#text#25#<p align="right"></p>  
   ^cY#a24v37n1.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a25v37n1.htm#S#o#1#1#text#1#20
110330#144537#a25v37n1.htm#33##
00680000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201370
0159010002100296002001300317#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a25v37n1.h
tm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ND#25#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f127^l128#1677-5538#1#Do patients benefit from routine follow-up to detect
 recurrences after radical cystectomy and ileal orthotopic bladder substitution?
^len#^rND^nAndreas^sBohle#a25v37n1.htm##
00687000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201440
0159010002100303002001300324#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a25v37n1.h
tm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ND#25#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f127^l128#1677-5538#1#<b>Do patients benefit from routine follow-up to det
ect recurrences after radical cystectomy and ileal orthotopic bladder substituti
on?</b>^len#^rND^nAndreas^sBohle#a25v37n1.htm##
00795000000000361000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000800108158000300116030001700119
03100030013603200020013906500090014101400110015003500100016112300020017101201370
0173010002100310002001300331008008900344#v37n1#V:\SciELO\serial\ibju\v37n1\marku
p\a25v37n1.htm#S#l#4#1#text#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#25#IBJU050#nd#
Int. braz j urol#37#1#20110200#^f127^l128#1677-5538#1#Do patients benefit from r
outine follow-up to detect recurrences after radical cystectomy and ileal orthot
opic bladder substitution?^len#^rND^nAndreas^sBohle#a25v37n1.htm#Internet^ihttp:
//www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382011000100025##
00337000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704010800070002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#5#1#text#29#<p align="right"><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>UROLOGICAL    SURVEY    ^
cY#a25v37n1.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704005000070002001300120#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#6#2#text#29#<br>   UROLOGICAL ONCOLOG
Y</b></font></p>     ^cY#a25v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#7#3#text#29#<p>&nbsp;</p>     ^cY#a25
v37n1.htm##
00457000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704022800070002001300298#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#8#4#text#29#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><b>Do patients    benefit from routine fol
low-up to detect recurrences after radical cystectomy    and ileal orthotopic bl
adder substitution?</b></font></p>     ^cY#a25v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#9#5#text#29#<p>&nbsp;</p>     ^cY#a25
v37n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#10#6#text#29#<p>&nbsp;</p>     ^cY#a2
5v37n1.htm##
00392000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704016200071002001300233#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#11#7#text#29#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Giannarini G;    Kessler TM; Thoeny HC
; Nguyen DP; Meissner C; Studer UE</b></font></p>     ^cY#a25v37n1.htm##
00378000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704014800071002001300219#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#12#8#text#29#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Department of Urology    University of Be
rne, Inselspital, Berne, Switzerland    ^cY#a25v37n1.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704005300071002001300124#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#13#9#text#29#<br>   Eur Urol. 2010; 5
8: 486-94</font></p>     ^cY#a25v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#14#10#text#29#<p>&nbsp;</p>     ^cY#a
25v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#15#11#text#29#<p>&nbsp;</p>     ^cY#a
25v37n1.htm##
00485000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704025400072002001300326#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#16#12#text#29#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">BACKGROUND: The    need for and intensit
y of follow-up to detect disease recurrence after radical    cystectomy (RC) for
 transitional cell carcinoma (TCC) remains a matter for debate.    ^cY#a25v37n1.
htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704019200072002001300264#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#17#13#text#29#<br>   OBJECTIVE: To de
termine whether diagnosis of asymptomatic recurrence after RC    by routine foll
ow-up investigations confers a survival benefit versus symptomatic    recurrence
.    ^cY#a25v37n1.htm##
00559000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704032800072002001300400#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#18#14#text#29#<br>   DESIGN, SETTING,
 AND PARTICIPANTS: Retrospective analysis of 479 patients with    nonmetastatic 
bladder TCC receiving no neoadjuvant chemotherapy/radiation therapy    and prosp
ectively followed with a standardised protocol for a median 4.3 yr    (range: 0.
3-20.9) after RC at an academic tertiary referral centre.    ^cY#a25v37n1.htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704012000072002001300192#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#19#15#text#29#<br>   Intervention: RC
 and extended pelvic lymph node dissection with ileal orthotopic    bladder subs
titution.    ^cY#a25v37n1.htm##
00669000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704043800072002001300510#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#20#16#text#29#<br>   MEASUREMENTS: Ca
ncer-specific survival (CSS) and overall survival (OS) probability    for asympt
omatic and symptomatic recurrent patients were estimated using the    Kaplan-Mei
er method. The effects of age, nerve-sparing surgery, pathologic tumour    stage
, lymph node status, adjuvant chemotherapy, mode of recurrence diagnosis,    and
 recurrence site on survival were assessed with multivariable Cox regression    
models.    ^cY#a25v37n1.htm##
01404000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704117300072002001301245#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#21#17#text#29#<br>   RESULTS AND LIMI
TATIONS: Of the 174 of 479 patients (36.3%) with tumour recurrence,    87 were d
iagnosed by routine follow-up investigations and 87 by symptoms. Routine    foll
ow-up mostly detected lung metastases and urethral recurrences, while symptoms  
  were predominantly the result of bone metastases and concomitant pelvic/distan
t    recurrences. Of 24 patients with urethral recurrences, 13 had carcinoma in 
situ    (CIS). Of these, 12 were successfully managed with urethra-sparing treat
ment,    and 6 are still alive with no evidence of disease. Most other recurrent
 long-term    survivors had lung and extrapelvic lymph node metastases. Cumulati
ve 5-yr survival    rates of the entire cohort were 69.8% (95% confidence interv
al &#91;CI&#93;,    65.5-74.3%) for CSS and 61.9% (95% CI, 57.4-66.7%) for OS. I
n multivariable    analysis, mode of recurrence diagnosis and site of initial re
currence were the    only independent predictors of CSS and OS. Patients with re
currences detected    by routine follow-up investigations and with secondary uro
thelial tumours as    site of recurrence had a slightly but significantly higher
 survival probability.    ^cY#a25v37n1.htm##
00714000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704048300072002001300555#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#22#18#text#29#<br>   CONCLUSIONS: Pat
ients diagnosed with asymptomatic recurrences during our routine    follow-up af
ter RC had a slightly higher survival than patients with symptomatic    recurren
ces. Routine follow-up appears particularly effective in early detection    of u
rethral CIS, which can be treated conservatively. In addition, the predominance 
   of lung and extrapelvic lymph node metastases in survivors may justify the us
e    of routine cross-sectional imaging.</font></p>     ^cY#a25v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#23#19#text#29#<p>&nbsp;</p>     ^cY#a
25v37n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#24#20#text#29#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL COMMENT</b></font></p>     
^cY#a25v37n1.htm##
00542000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704031100072002001300383#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#25#21#text#29#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Why do patients    need follow-up after
 cystectomy? This retrospective analysis on 174 patients    with cystectomy and 
orthotopic neobladders shows the evidence behind current    recommendations of r
outine follow-up procedures.</font></p>     ^cY#a25v37n1.htm##
00717000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704048600072002001300558#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#26#22#text#29#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Interestingly,    only about 7% of pati
ents had isolated pelvic recurrences whereas about 61%    had distant recurrence
s only. Ten percent of patients had concomitant local    and distant recurrences
. Roughly, half of patients were detected without symptoms    by routine follow-
up procedures. Especially urethral recurrences, which are    easily detected by 
cytology/biopsy, had the potential of cure.</font></p>     ^cY#a25v37n1.htm##
00464000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704023300072002001300305#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#27#23#text#29#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Thus, routine    follow-up including ur
ethral barbotage cytology and routine x-ray analyses are    advocated in patient
s with orthotopic neobladders.</font></p>     ^cY#a25v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#28#24#text#29#<p>&nbsp;</p>     ^cY#a
25v37n1.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011500072002001300187#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#29#25#text#29#<p align="right"><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Dr.    Andreas Bohle
</b>    ^cY#a25v37n1.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003500072002001300107#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#30#26#text#29#<br>   Professor of Uro
logy    ^cY#a25v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004200072002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#31#27#text#29#<br>   HELIOS Agnes Kar
ll Hospital    ^cY#a25v37n1.htm##
00268000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003700072002001300109#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#32#28#text#29#<br>   Bad Schwartau, G
ermany    ^cY#a25v37n1.htm##
00356000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704012500072002001300197#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a25v37n1.htm#S#p#33#29#text#29#<br>   E-mail: <a href=
"mailto:boehle@urologie-bad-schwartau.de">boehle@urologie-bad-schwartau.de</a></
i></font></p>     ^cY#a25v37n1.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a26v37n1.htm#S#o#1#1#text#1#20
110330#144538#a26v37n1.htm#31##
00662000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201190
0159010002100278002001300299#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a26v37n1.h
tm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ND#26#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f128^l129#1677-5538#1#Multicentric oncologic outcomes of high-intensity fo
cused ultrasound for localized prostate cancer in 803 patients^len#^rND^nAndreas
^sBohle#a26v37n1.htm##
00669000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201260
0159010002100285002001300306#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a26v37n1.h
tm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ND#26#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f128^l129#1677-5538#1#<b>Multicentric oncologic outcomes of high-intensity
 focused ultrasound for localized prostate cancer in 803 patients</b>^len#^rND^n
Andreas^sBohle#a26v37n1.htm##
00777000000000361000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000800108158000300116030001700119
03100030013603200020013906500090014101400110015003500100016112300020017101201190
0173010002100292002001300313008008900326#v37n1#V:\SciELO\serial\ibju\v37n1\marku
p\a26v37n1.htm#S#l#4#1#text#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#26#IBJU050#nd#
Int. braz j urol#37#1#20110200#^f128^l129#1677-5538#1#Multicentric oncologic out
comes of high-intensity focused ultrasound for localized prostate cancer in 803 
patients^len#^rND^nAndreas^sBohle#a26v37n1.htm#Internet^ihttp://www.scielo.br/sc
ielo.php?script=sci_arttext&pid=S1677-55382011000100026##
00337000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704010800070002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#5#1#text#27#<p align="right"><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>UROLOGICAL    SURVEY    ^
cY#a26v37n1.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704005000070002001300120#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#6#2#text#27#<br>   UROLOGICAL ONCOLOG
Y</b></font></p>     ^cY#a26v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#7#3#text#27#<p>&nbsp;</p>     ^cY#a26
v37n1.htm##
00439000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704021000070002001300280#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#8#4#text#27#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><b>Multicentric    oncologic outcomes of h
igh-intensity focused ultrasound for localized prostate    cancer in 803 patient
s</b></font></p>     ^cY#a26v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#9#5#text#27#<p>&nbsp;</p>     ^cY#a26
v37n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#10#6#text#27#<p>&nbsp;</p>     ^cY#a2
6v37n1.htm##
00432000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704020200071002001300273#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#11#7#text#27#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Crouzet S; Rebillard    X; Chevallier 
D; Rischmann P; Pasticier G; Garcia G; Rouviere O; Chapelon JY;    Gelet A</b></
font></p>     ^cY#a26v37n1.htm##
00366000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704013600071002001300207#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#12#8#text#27#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Department of Urology,    Edouard Herriot
 Hospital, Lyon, France     ^cY#a26v37n1.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704005300071002001300124#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#13#9#text#27#<br>   Eur Urol. 2010; 5
8: 559-66</font></p>     ^cY#a26v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#14#10#text#27#<p>&nbsp;</p>     ^cY#a
26v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#15#11#text#27#<p>&nbsp;</p>     ^cY#a
26v37n1.htm##
00443000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704021200072002001300284#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#16#12#text#27#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">BACKGROUND: High-intensity    focused ul
trasound (HIFU) is an emerging treatment for select patients with    localized p
rostate cancer (PCa).    ^cY#a26v37n1.htm##
00384000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704015300072002001300225#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#17#13#text#27#<br>   OBJECTIVES: To r
eport the oncologic outcome of HIFU as a primary care option    for localized pr
ostate cancer from a multicenter database.    ^cY#a26v37n1.htm##
00690000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704045900072002001300531#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#18#14#text#27#<br>   DESIGN, SETTING,
 AND PARTICIPANTS: Patients with localized PCa treated with    curative intent a
nd presenting at least a 2-yr follow-up from February 1993    were considered in
 this study. Previously irradiated patients were excluded    from this analysis.
 In case of any residual or recurrent PCa, patients were    systematically offer
ed a second session. Kaplan-Meier analysis was performed    to determine disease
-free survival rates (DFSR).    ^cY#a26v37n1.htm##
00368000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704013700072002001300209#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#19#15#text#27#<br>   MEASUREMENTS: Pr
ostate-specific antigen (PSA), clinical stage, and pathologic    results were me
asured pre- and post-HIFU.    ^cY#a26v37n1.htm##
01283000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704105200072002001301124#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#20#16#text#27#<br>   RESULTS AND LIMI
TATIONS: A total of 803 patients from six urologic departments    met the inclus
ion criteria. Stratification according to d'Amico's risk group    was low, inter
mediate, and high in 40.2%, 46.3%, and 13.5% of patients, respectively.    Mean 
follow-up was 42+/-33 mo. Mean PSA nadir was 1.0+/-2.8 ng/ml with 54.3%    reach
ing a nadir of &lt; or =0.3 ng/ml. Control biopsies were negative in 85%    of c
ases. The overall and cancer-specific survival rates at 8 yr were 89% and    99%
, respectively. The metastasis-free survival rate at 8 yr was 97%. Initial    PS
A value and Gleason score value significantly influence the DFSR. The 5- and    
7-yr biochemical-free survival rates (Phoenix criteria) were 83-75%, 72-63%,    
and 68-62% (p=0.03) and the additional treatment-free survival rates were 84-79%
,    68-61%, and 52-54% (p&lt;0.001) for low-, intermediate-, and high-risk pati
ents,    respectively. PSA nadir was a major predictive factor for HIFU success:
 negative    biopsies, stable PSA, and no additional therapy.    ^cY#a26v37n1.ht
m##
00525000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704029400072002001300366#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#21#17#text#27#<br>   CONCLUSIONS: Loc
al control and DFSR achieved with HIFU were similar to those    expected with co
nformal external-beam radiation therapy (EBRT). The excellent    cancer-specific
 survival rate is also explained by the possibility to repeat    HIFU and use sa
lvage EBRT.</font></p>     ^cY#a26v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#22#18#text#27#<p>&nbsp;</p>     ^cY#a
26v37n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#23#19#text#27#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL COMMENT</b></font></p>     
^cY#a26v37n1.htm##
01425000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704119400072002001301266#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#24#20#text#27#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">High-intensity    focused ultrasound (HI
FU) is not regarded an established treatment in prostate    cancer patients as r
adical prostatectomy and radiation therapy are. Therefore,    reports on the lon
g-term outcomes of patients treated with HIFU are very interesting    and should
 be analyzed carefully. Here, the authors report on 803 patients treated    with
 HIFU against localized primary prostate cancer. Forty percent, 46% and    14% w
ere of low, intermediate and high-risk group according to Amico, respectively.  
  If only the outcomes of the most recently treated patients is regarded, only  
  57% had a nadir PSA &lt; 0.3, 19% had a nadir PSA between 0.3 and 1, and 19%  
  had a nadir PSA of &gt; 1. The biochemical-free survival rates of these groups
    are important for the assessment of the curative efficacy. After 7 years of 
   follow-up roughly 90% of patients with a PSA nadir of &lt; 0.3 remained bioch
emically    recurrence-free, whereas these figures were much lower for patients 
with a PSA    nadir of 0.3-1 (~ 50% recurrence-free) and with a PSA nadir of &gt
; 1 (~ 40%    recurrence-free).</font></p>     ^cY#a26v37n1.htm##
00542000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704031100072002001300383#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#25#21#text#27#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">These and other    figures show that the
 cure rate of patients with localized prostate cancer after    HIFU treatment to
 my opinion is not yet comparable to the outcome after radical    prostatectomy 
or modern radiation therapy.</font></p>     ^cY#a26v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#26#22#text#27#<p>&nbsp;</p>     ^cY#a
26v37n1.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011500072002001300187#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#27#23#text#27#<p align="right"><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Dr.    Andreas Bohle
</b>    ^cY#a26v37n1.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003500072002001300107#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#28#24#text#27#<br>   Professor of Uro
logy    ^cY#a26v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004200072002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#29#25#text#27#<br>   HELIOS Agnes Kar
ll Hospital    ^cY#a26v37n1.htm##
00268000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003700072002001300109#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#30#26#text#27#<br>   Bad Schwartau, G
ermany    ^cY#a26v37n1.htm##
00356000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704012500072002001300197#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a26v37n1.htm#S#p#31#27#text#27#<br>   E-mail: <a href=
"mailto:boehle@urologie-bad-schwartau.de">boehle@urologie-bad-schwartau.de</a></
i></font></p>     ^cY#a26v37n1.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a27v37n1.htm#S#o#1#1#text#1#20
110330#144539#a27v37n1.htm#33##
00690000000000373000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201120
0159117000600271072000200277010002400279002001300303#v37n1#V:\SciELO\serial\ibju
\v37n1\markup\a27v37n1.htm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ND#27#IBJU050#nd#Int
. braz j urol.#37#1#20110200#^f129^l130#1677-5538#1#Salvage spiral sling techniq
ues: alternatives to manage disabling recurrent urinary incontinence in females^
len#other#1#^rND^nSteven P.^sPetrou#a27v37n1.htm##
00704000000000373000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201260
0159117000600285072000200291010002400293002001300317#v37n1#V:\SciELO\serial\ibju
\v37n1\markup\a27v37n1.htm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ND#27#IBJU050#nd#Int
. braz j urol.#37#1#20110200#^f129^l130#1677-5538#1#<b>Salvage spiral sling tech
niques</b>: <b>alternatives to manage disabling recurrent urinary incontinence i
n females</b>^len#other#1#^rND^nSteven P.^sPetrou#a27v37n1.htm##
00804000000000385000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000800108158000300116030001700119
03100030013603200020013906500090014101400110015003500100016112300020017101201120
0173117000600285072000200291010002300293002001300316008008900329#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#l#4#1#text#1#^mJan./Feb.^a2011#oa#en#br
1.1#1#4.0#27#IBJU050#nd#Int. braz j urol#37#1#20110200#^f129^l130#1677-5538#1#Sa
lvage spiral sling techniques: alternatives to manage disabling recurrent urinar
y incontinence in females^len#other#1#^rND^nSteven P^sPetrou#a27v37n1.htm#Intern
et^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-553820110001000
27##
00337000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704010800070002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#5#1#text#28#<p align="right"><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>UROLOGICAL    SURVEY    ^
cY#a27v37n1.htm##
00290000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704006100070002001300131#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#6#2#text#28#<br>   NEUROLOGY &amp; FE
MALE UROLOGY</b></font></p>     ^cY#a27v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#7#3#text#28#<p>&nbsp;</p>     ^cY#a27
v37n1.htm##
00432000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704020300070002001300273#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#8#4#text#28#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="4"><b>Salvage spiral    sling techniques: alt
ernatives to manage disabling recurrent urinary incontinence    in females</b></
font></p>     ^cY#a27v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#9#5#text#28#<p>&nbsp;</p>     ^cY#a27
v37n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#10#6#text#28#<p>&nbsp;</p>     ^cY#a2
7v37n1.htm##
00379000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704014900071002001300220#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#11#7#text#28#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Rodriguez AR;    Hakky T; Hoffman M; O
rdorica R; Lockhart J</b></font></p>     ^cY#a27v37n1.htm##
00402000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704017200071002001300243#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#12#8#text#28#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Department of Urology,    University of S
outh Florida and Tampa General Hospital, Tampa, Florida, USA    ^cY#a27v37n1.htm
##
00283000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704005300071002001300124#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#13#9#text#28#<br>   J Urol. 2010; 184
: 2429-33</font></p>     ^cY#a27v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#14#10#text#28#<p>&nbsp;</p>     ^cY#a
27v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#15#11#text#28#<p>&nbsp;</p>     ^cY#a
27v37n1.htm##
00715000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704048400072002001300556#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#16#12#text#28#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">PURPOSE: Females    with recurrent stres
s urinary incontinence after anti-incontinence surgery represent    a therapeuti
c challenge. In our experience and that of others standard sling    procedures h
ave occasionally failed to correct these problems. We determined    the effectiv
eness of various spiral sling techniques used in these cases to    manage pipe s
tem urethras in which conventional slings had failed.    ^cY#a27v37n1.htm##
00591000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704036000072002001300432#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#17#13#text#28#<br>   MATERIALS AND ME
THODS: Between January 2007 and July 2008 we evaluated 30 female    patients wit
h persistent stress urinary incontinence after multiple failed anti-incontinence
    procedures. Preoperative and postoperative evaluation consisted of history, 
   physical examination, number of pads, Stamey score and quality of life questi
onnaires.    ^cY#a27v37n1.htm##
00988000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704075700072002001300829#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#18#14#text#28#<br>   RESULTS: We foll
owed 28 patients a minimum of 15 months (range 15 to 18). Mean    patient age wa
s 60 years (range 36 to 84). At presentation patients had undergone    a mean of
 3.5 prior vaginal procedures (range 1 to 6) and used a mean of 7 pads    daily 
(range 3 to 12). Of the patients 21 received a synthetic spiral sling,    5 rece
ived an autologous spiral sling (rectus fascia in 3 and fascia lata in    2) and
 3 received a lateral spiral sling. Mean pad use decreased to 0.9 daily    (rang
e 0 to 2, p&lt;0.05). Postoperative mean Stamey score decreased from 2.6    to 0
.3 (p&lt;0.05). Complications included unilateral vesical perforation in    3 pa
tients with a contralateral lateral spiral sling. The overall success rate    wa
s 72%.    ^cY#a27v37n1.htm##
00593000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704036200072002001300434#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#19#15#text#28#<br>   CONCLUSIONS: Sal
vage spiral sling techniques are a satisfactory alternative    treatment for ref
ractory stress urinary incontinence. When synthetic material    cannot be used, 
autologous tissue can provide similar results. When the bladder    is perforated
 unilaterally, a lateral spiral sling can be used on the contralateral    side.<
/font></p>     ^cY#a27v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#20#16#text#28#<p>&nbsp;</p>     ^cY#a
27v37n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#21#17#text#28#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL COMMENT</b></font></p>     
^cY#a27v37n1.htm##
01420000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704118900072002001301261#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#22#18#text#28#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> This paper discusses    the use of a sa
lvage spiral urethral sling in a very difficult to treat patient    population, 
that is, females who have failed multiple vaginal operations for    urinary inco
ntinence. The authors provide an excellent technical analysis and    state that 
when using this technique they are able to salvage approximately    three out of
 four. Of interest is that they describe the use of both autologous    fascia as
 well as synthetic graft. Operative tactics are described in the event    of a b
ladder injury at the time of dissection (laterally placed spiral sling);    this
 is very valuable in view of the potential for injury during the periurethral   
 dissection in this patient population with a history of multiple surgeries.    
In addition, the authors discuss the use of this operation as opposed to the    
use of artificial urinary sphincter. Given the success rate of this operation   
 mirrors that reported for artificial urinary sphincter in female patients, it  
  has a potential to achieve a great deal of popularity in this very difficult  
  to treat population (1).</font></p>     ^cY#a27v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#23#19#text#28#<p>&nbsp;</p>     ^cY#a
27v37n1.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009900072002001300171#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#24#20#text#28#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>Reference</b></font></p>     ^cY#a27v
37n1.htm##
00444000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704019900074002001300273#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#25#21#text#28#1#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Thomas K, Venn    SN, M
undy AR: Outcome of the artificial urinary sphincter in female patients.    J Ur
ol. 2002; 167: 1720-2.    ^cY#a27v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#26#22#text#28#</font></p>     ^cY#a27
v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#27#23#text#28#<p>&nbsp;</p>     ^cY#a
27v37n1.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011800072002001300190#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#28#24#text#28#<p align="right"><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Dr.    Steven P. Pet
rou</b>    ^cY#a27v37n1.htm##
00282000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005100072002001300123#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#29#25#text#28#<br>   Professor of Uro
logy, Associate Dean    ^cY#a27v37n1.htm##
00287000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005600072002001300128#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#30#26#text#28#<br>   Mayo School of G
raduate Medical Education    ^cY#a27v37n1.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004100072002001300113#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#31#27#text#28#<br>   Jacksonville, Fl
orida, USA    ^cY#a27v37n1.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010500072002001300177#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a27v37n1.htm#S#p#32#28#text#28#<br>   E-mail: <a href=
"mailto:petrou.steven@mayo.edu">petrou.steven@mayo.edu</a></i></font></p>     ^c
Y#a27v37n1.htm##
00547000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100016000720100015000880100
01600103012006700119030000700186065000900193064000500202031000400207014000700211
865000900218002001300227035001000240801000700250#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a27v37n1.htm#S#c#33#1#text#1#1#^rND^sThomas^nK#^rND^sVenn^nSN#^rND^sMu
ndy^nAR#Outcome of the artificial urinary sphincter in female patients^len#J Uro
l#20020000#2002#167#1720-2#20110200#a27v37n1.htm#0022-5347#J Urol##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a28v37n1.htm#S#o#1#1#text#1#20
110330#144539#a28v37n1.htm#29##
00652000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201060
0159010002400265002001300289#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a28v37n1.h
tm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ND#28#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f130^l131#1677-5538#1#Long-term durability of percutaneous tibial nerve st
imulation for the treatment of overactive bladder^len#^rND^nSteven P.^sPetrou#a2
8v37n1.htm##
00659000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201130
0159010002400272002001300296#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a28v37n1.h
tm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ND#28#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f130^l131#1677-5538#1#<b>Long-term durability of percutaneous tibial nerve
 stimulation for the treatment of overactive bladder</b>^len#^rND^nSteven P.^sPe
trou#a28v37n1.htm##
00766000000000361000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000800108158000300116030001700119
03100030013603200020013906500090014101400110015003500100016112300020017101201060
0173010002300279002001300302008008900315#v37n1#V:\SciELO\serial\ibju\v37n1\marku
p\a28v37n1.htm#S#l#4#1#text#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#28#IBJU050#nd#
Int. braz j urol#37#1#20110200#^f130^l131#1677-5538#1#Long-term durability of pe
rcutaneous tibial nerve stimulation for the treatment of overactive bladder^len#
^rND^nSteven P^sPetrou#a28v37n1.htm#Internet^ihttp://www.scielo.br/scielo.php?sc
ript=sci_arttext&pid=S1677-55382011000100028##
00337000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704010800070002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#5#1#text#25#<p align="right"><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>UROLOGICAL    SURVEY    ^
cY#a28v37n1.htm##
00290000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704006100070002001300131#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#6#2#text#25#<br>   NEUROLOGY &amp; FE
MALE UROLOGY</b></font></p>     ^cY#a28v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#7#3#text#25#<p>&nbsp;</p>     ^cY#a28
v37n1.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704019400070002001300264#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#8#4#text#25#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><b>Long-term durability    of percutaneous
 tibial nerve stimulation for the treatment of overactive bladder</b></font></p>
     ^cY#a28v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#9#5#text#25#<p>&nbsp;</p>     ^cY#a28
v37n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#10#6#text#25#<p>&nbsp;</p>     ^cY#a2
8v37n1.htm##
00431000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704020100071002001300272#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#11#7#text#25#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>MacDiarmid SA;    Peters KM; Shobeiri 
SA; Wooldridge LS; Rovner ES; Leong FC; Siegel SW; Tate    SB; Feagins BA</b></f
ont></p>     ^cY#a28v37n1.htm##
00365000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704013500071002001300206#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#12#8#text#25#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Alliance Urology    Specialists, Greensbo
ro, North Carolina, USA    ^cY#a28v37n1.htm##
00282000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704005200071002001300123#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#13#9#text#25#<br>   J Urol. 2010; 183
: 234-40</font></p>     ^cY#a28v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#14#10#text#25#<p>&nbsp;</p>     ^cY#a
28v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#15#11#text#25#<p>&nbsp;</p>     ^cY#a
28v37n1.htm##
00848000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704061700072002001300689#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#16#12#text#25#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">PURPOSE: The Overactive    Bladder Innov
ative Therapy Trial during phase 1 was a randomized trial demonstrating    compa
rable effectiveness of percutaneous tibial nerve stimulation and extended-releas
e    tolterodine during 12 weeks of therapy for frequency, nocturia, urgency, vo
ided    volume and urge incontinence episodes. In this second phase of the Overa
ctive    Bladder Innovative Therapy Trial we assessed the sustained therapeutic 
efficacy    of percutaneous tibial nerve stimulation in subjects with overactive
 bladder    during 1 year.    ^cY#a28v37n1.htm##
00616000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704038500072002001300457#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#17#13#text#25#<br>   MATERIALS AND ME
THODS: After 12 weeks subjects randomized to weekly percutaneous    tibial nerve
 stimulation with Urgent((R)) PC were offered an additional 9 months    of treat
ment with assessments at 6 and 12 months from baseline. Outcome measures    incl
uded voiding diary data, overactive bladder questionnaires, global response    a
ssessments and safety assessments.    ^cY#a28v37n1.htm##
01150000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704091900072002001300991#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#18#14#text#25#<br>   RESULTS: A total
 of 33 percutaneous tibial nerve stimulation responders continued    therapy wit
h 32 and 25 subjects completing 6 and 12 months of therapy, respectively.    Sub
jects received a mean of 12.1 treatments during an average of 263 days, with    
a mean of 21 days (median 17) between treatments. Subject global response assess
ments    showed sustained improvement from 12 weeks at 6 and 12 months, with 94%
 and    96% of responders, respectively. At 12 months mean improvements from bas
eline    included a frequency of 2.8 voids daily (p &lt;0.001), urge incontinenc
e of    1.6 episodes daily (p &lt;0.001), nocturia with 0.8 voids (p &lt;0.05) a
nd a    voided volume of 39 cc (p &lt;0.05). Overactive bladder questionnaire sy
mptom    severity was significantly improved from 12 weeks to 12 months (p &lt;0
.01)    as well as from 6 to 12 months (p &lt;0.01). No serious adverse events o
ccurred.    ^cY#a28v37n1.htm##
00627000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704039600072002001300468#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#19#15#text#25#<br>   CONCLUSIONS: Sta
tistically significant overactive bladder symptom improvement    achieved with 1
2 weekly percutaneous tibial nerve stimulation treatments demonstrates    excell
ent durability through 12 months. The durability of response demonstrates    the
 effectiveness of percutaneous tibial nerve stimulation as a viable, long-term  
  therapy for overactive bladder.</font></p>     ^cY#a28v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#20#16#text#25#<p>&nbsp;</p>     ^cY#a
28v37n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#21#17#text#25#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL COMMENT</b></font></p>     
^cY#a28v37n1.htm##
00913000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704068200072002001300754#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#22#18#text#25#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> In this study,    the authors reviewed 
the response of patients to percutaneous tibial nerve stimulation    (TTNS) over
 a one year time period. Of the 44 subjects enrolled in the trial,    35 respond
ed to the therapy and of those 35 patients, 33 chose to continue on    with the 
treatment. As noted by the authors, this trial identified that the    symptom im
provements obtained after the initial 12 treatments were able to be    continued
 with routine ongoing therapy. The authors identified that a longitudinal    30 
minutes session every 3 weeks would help keep the symptomatic response durable.<
/font></p>     ^cY#a28v37n1.htm##
01112000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704088100072002001300953#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#23#19#text#25#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> This is an important    paper to review
 especially in view of the increasing popularity of this technology    for the t
reatment of the overactive bladder. Its efficacy, when used with patients    who
 are refractory to medication, raises the consideration for use as a first    li
ne therapy. The fact that after the initial 12 weeks sessions, a treatment    ev
ery three weeks sustains the symptoms makes it an attractive alternative to    d
aily anti-cholinergic therapy. The economic comparisons of the two long term    
results will be very interesting. Also exciting is the potential use for patient
s    in the institutional setting in which the side effects of anti-cholinergics
    such as cognitive disorder, xerostomia, and constipation could be avoided by
    an every 3 week bedside treatment.</font></p>     ^cY#a28v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#24#20#text#25#<p>&nbsp;</p>     ^cY#a
28v37n1.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011800072002001300190#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#25#21#text#25#<p align="right"><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Dr.    Steven P. Pet
rou</b>    ^cY#a28v37n1.htm##
00282000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005100072002001300123#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#26#22#text#25#<br>   Professor of Uro
logy, Associate Dean    ^cY#a28v37n1.htm##
00287000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005600072002001300128#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#27#23#text#25#<br>   Mayo School of G
raduate Medical Education    ^cY#a28v37n1.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004100072002001300113#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#28#24#text#25#<br>   Jacksonville, Fl
orida, USA    ^cY#a28v37n1.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010500072002001300177#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a28v37n1.htm#S#p#29#25#text#25#<br>   E-mail: <a href=
"mailto:petrou.steven@mayo.edu">petrou.steven@mayo.edu</a></i></font></p>     ^c
Y#a28v37n1.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a29v37n1.htm#S#o#1#1#text#1#20
110330#144540#a29v37n1.htm#29##
00729000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201850
0159010002200344002001300366#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a29v37n1.h
tm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ND#29#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f131^l132#1677-5538#1#A multicenter, randomized, controlled trial of trans
ureteral and shock wave lithotripsy: which is the best minimally invasive modali
ty to treat distal ureteral calculi in children?^len#^rND^nM. Chad^sWallis#a29v3
7n1.htm##
00763000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701202190
0159010002200378002001300400#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a29v37n1.h
tm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ND#29#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f131^l132#1677-5538#1#<strong>A multicenter, randomized, controlled trial 
of transureteral and shock wave lithotripsy</strong>: <strong>which is the best 
minimally invasive modality to treat distal ureteral calculi in children?</stron
g>^len#^rND^nM. Chad^sWallis#a29v37n1.htm##
00844000000000361000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000800108158000300116030001700119
03100030013603200020013906500090014101400110015003500100016112300020017101201850
0173010002200358002001300380008008900393#v37n1#V:\SciELO\serial\ibju\v37n1\marku
p\a29v37n1.htm#S#l#4#1#text#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#29#IBJU050#nd#
Int. braz j urol#37#1#20110200#^f131^l132#1677-5538#1#A multicenter, randomized,
 controlled trial of transureteral and shock wave lithotripsy: which is the best
 minimally invasive modality to treat distal ureteral calculi in children?^len#^
rND^nM. Chad^sWallis#a29v37n1.htm#Internet^ihttp://www.scielo.br/scielo.php?scri
pt=sci_arttext&pid=S1677-55382011000100029##
00337000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704010800070002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#5#1#text#25#<p align="right"><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>UROLOGICAL    SURVEY    ^
cY#a29v37n1.htm##
00277000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704004800070002001300118#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#6#2#text#25#<br>   PEDIATRIC UROLOGY<
/b></font></p>     ^cY#a29v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#7#3#text#25#<p>&nbsp;</p>     ^cY#a29
v37n1.htm##
00509000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704028000070002001300350#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#8#4#text#25#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><b>A multicenter,    randomized, controlle
d trial of transureteral and shock wave lithotripsy - which    is the best minim
ally invasive modality to treat distal ureteral calculi in    children?</b></fon
t></p>     ^cY#a29v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#9#5#text#25#<p>&nbsp;</p>     ^cY#a29
v37n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#10#6#text#25#<p>&nbsp;</p>     ^cY#a2
9v37n1.htm##
00411000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704018100071002001300252#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#11#7#text#25#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Basiri A; Zare    S; Tabibi A; Sharifi
aghdas F; Aminsharifi A; Mousavi-Bahar SH; Ahmadnia H</b></font></p>     ^cY#a29
v37n1.htm##
00450000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704022000071002001300291#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#12#8#text#25#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Urology and Nephrology    Research Center
 (UNRC), Shahid Labbafinejad Medical Center, Shahid Beheshti    University, M. C
. (SBMU), Tehran, I. R. Iran    ^cY#a29v37n1.htm##
00282000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704005200071002001300123#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#13#9#text#25#<br>   J Urol. 2010; 184
: 1106-9</font></p>     ^cY#a29v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#14#10#text#25#<p>&nbsp;</p>     ^cY#a
29v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#15#11#text#25#<p>&nbsp;</p>     ^cY#a
29v37n1.htm##
00604000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704037300072002001300445#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#16#12#text#25#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">PURPOSE: Since    there is insufficient 
evidence to determine the best treatment modality in children    with distal ure
teral calculi, we designed a multicenter, randomized, controlled    trial to eva
luate the efficacy and complications of transureteral and shock    wave lithotri
psy in these patients.    ^cY#a29v37n1.htm##
00756000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704052500072002001300597#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#17#13#text#25#<br>   MATERIALS AND ME
THODS: A total of 100 children with distal ureteral calculi    were included in 
the study. Of the patients 50 were randomized consecutively    to undergo shock 
wave lithotripsy using a Compact Delta II lithotriptor (Dornier    MedTech, Kenn
esaw, Georgia), and 50 were randomized to undergo transureteral    lithotripsy w
ith holmium laser and pneumatic lithotriptor between February 2007    and Octobe
r 2009. Stone-free, complication and efficiency quotient rates were    assessed 
in each group.    ^cY#a29v37n1.htm##
00976000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704074500072002001300817#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#18#14#text#25#<br>   RESULTS: Mean +/
- SD patient age was 6.5 +/- 3.7 years (range 1 to 13). Mean    stone surface wa
s 35 mm(2) in the transureteral group and 37 mm(2) in the shock    wave lithotri
psy group. Stone-free rates at 2 weeks after transureteral lithotripsy    and si
ngle session shock wave lithotripsy differed significantly, at 78% and    56%, r
espectively (p = 0.004). With 2 sessions of shock wave lithotripsy the    stone-
free rate increased to 72%. Efficiency quotient was significantly higher    for 
transureteral vs shock wave lithotripsy (81% vs. 62%, p = 0.001). Minor    compl
ications were comparable and negligible between the groups. Two patients    (4%)
 who underwent transureteral lithotripsy sustained a ureteral perforation.    ^c
Y#a29v37n1.htm##
00578000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704034700072002001300419#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#19#15#text#25#<br>   CONCLUSIONS: In 
the short term it seems that transureteral and shock wave lithotripsy    are acc
eptable modalities for the treatment of distal ureteral calculi in children.    
However, transureteral lithotripsy has a higher efficacy rate when performed    
meticulously by experienced hands using appropriate instruments.</font></p>     
^cY#a29v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#20#16#text#25#<p>&nbsp;</p>     ^cY#a
29v37n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#21#17#text#25#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="3"><b>EDITORIAL COMMENT</b></font></p>     
^cY#a29v37n1.htm##
01566000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704133500072002001301407#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#22#18#text#25#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Citing a lack    of well-designed rando
mized controlled trials for the treatment of distal ureteral    stones, the auth
ors of this study created a multicenter, randomized, controlled    trial, which 
compared ureteroscopy with extracorporeal shock wave lithotripsy.    They enroll
ed 100 children and randomized 50 of them to ureteroscopy with lithotripsy    us
ing primarily a pneumatic lithotripter. The other 50 children underwent shock   
 wave lithotripsy. Success rates were significantly better for the patients who 
   underwent ureteroscopy both at two weeks and at three months. The authors did
    have two cases of ureteral perforation in the ureteroscopy group, one of whi
ch    required open surgery to correct. They cited some equipment problems as co
ntributing    to these two major complications and one also has to wonder if usi
ng a pneumatic    lithotripter as opposed to Holmium laser in these patients may
 have also been    a contributing factor. In terms of differences in minor compl
ications, 30 of    the patients in the lithotripsy group had some skin bruising 
and three patients    developed "steinstrasse". There was some mucosal tearing n
oted in two patients    in the ureteroscopy group, which required temporary sten
t placement.</font></p>     ^cY#a29v37n1.htm##
00945000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704071400072002001300786#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#23#19#text#25#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Although surgical    experience is not 
accounted for in this study, certainly this is a factor that    will have an imp
act on success rates and complications for these modalities.    The results of t
his randomized controlled trial favor a ureteroscopic approach    to distal ston
es despite the fact that it is a more invasive procedure by nature.    Improved 
instrumentation for pediatric patients as well as routine use of Holmium    lase
r lithotripsy over a pneumatic lithotripter will likely continue to make    this
 modality a safe and more effective option for distal ureteral stone management 
   in the pediatric population.</font></p>     ^cY#a29v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#24#20#text#25#<p>&nbsp;</p>     ^cY#a
29v37n1.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011600072002001300188#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#25#21#text#25#<p align="right"><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Dr.    M. Chad Walli
s</b>    ^cY#a29v37n1.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004400072002001300116#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#26#22#text#25#<br>   Division of Pedi
atric Urology    ^cY#a29v37n1.htm##
00264000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003300072002001300105#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#27#23#text#25#<br>   University of Ut
ah    ^cY#a29v37n1.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004000072002001300112#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#28#24#text#25#<br>   Salt Lake City, 
Utah, USA    ^cY#a29v37n1.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010900072002001300181#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a29v37n1.htm#S#p#29#25#text#25#<br>   E-mail: <a href=
"mailto:chad.wallis@hsc.utah.edu">chad.wallis@hsc.utah.edu</a></i></font></p>   
  ^cY#a29v37n1.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a30v37n1.htm#S#o#1#1#text#1#20
110330#144541#a30v37n1.htm#30##
00633000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701200890
0159010002200248002001300270#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a30v37n1.h
tm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ND#30#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f133^l133#1677-5538#1#Impact of epispadias repair on bladder growth in boy
s with classic bladder exstrophy^len#^rND^nM. Chad^sWallis#a30v37n1.htm##
00640000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701200960
0159010002200255002001300277#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a30v37n1.h
tm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ND#30#IBJU050#nd#Int. braz j urol.#37#1#2011
0200#^f133^l133#1677-5538#1#<b>Impact of epispadias repair on bladder growth in 
boys with classic bladder exstrophy</b>^len#^rND^nM. Chad^sWallis#a30v37n1.htm##
00748000000000361000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000800108158000300116030001700119
03100030013603200020013906500090014101400110015003500100016112300020017101200890
0173010002200262002001300284008008900297#v37n1#V:\SciELO\serial\ibju\v37n1\marku
p\a30v37n1.htm#S#l#4#1#text#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#30#IBJU050#nd#
Int. braz j urol#37#1#20110200#^f133^l133#1677-5538#1#Impact of epispadias repai
r on bladder growth in boys with classic bladder exstrophy^len#^rND^nM. Chad^sWa
llis#a30v37n1.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&p
id=S1677-55382011000100030##
00337000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704010800070002001300178#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#5#1#text#26#<p align="right"><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>UROLOGICAL    SURVEY    ^
cY#a30v37n1.htm##
00277000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704004800070002001300118#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#6#2#text#26#<br>   PEDIATRIC UROLOGY<
/b></font></p>     ^cY#a30v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#7#3#text#26#<p>&nbsp;</p>     ^cY#a30
v37n1.htm##
00406000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704017700070002001300247#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#8#4#text#26#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><b>Impact of epispadias    repair on bladd
er growth in boys with classic bladder exstrophy</b></font></p>     ^cY#a30v37n1
.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#9#5#text#26#<p>&nbsp;</p>     ^cY#a30
v37n1.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#10#6#text#26#<p>&nbsp;</p>     ^cY#a3
0v37n1.htm##
00355000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704012500071002001300196#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#11#7#text#26#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Kufner M; Gearhart    JP; Mathews R</b
></font></p>     ^cY#a30v37n1.htm##
00441000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704021100071002001300282#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#12#8#text#26#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Division of Pediatric    Urology, The Jam
es Buchanan Brady Urological Institute, The Johns Hopkins School    of Medicine,
 Baltimore, MD, USA    ^cY#a30v37n1.htm##
00288000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704005800071002001300129#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#13#9#text#26#<br>   J Pediatr Urol. 2
010; 6: 578-81</font></p>     ^cY#a30v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#14#10#text#26#<p>&nbsp;</p>     ^cY#a
30v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#15#11#text#26#<p>&nbsp;</p>     ^cY#a
30v37n1.htm##
00617000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704038600072002001300458#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#16#12#text#26#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">OBJECTIVE: Growth    of the bladder in c
hildren with bladder exstrophy is primarily responsible for    later ability to 
void continently. Improvement in bladder capacity has been    noted in some boys
 following epispadias repair. Does the timing of epispadias    repair influence 
the ability of the bladder to grow?    ^cY#a30v37n1.htm##
00746000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704051500072002001300587#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#17#13#text#26#<br>   METHODS: Data we
re collected regarding bladder volume measurements, obtained    under anesthesia
 using a standard technique, during yearly follow-up of boys    with classic bla
dder exstrophy. Volume prior to epispadias repair was compared    to the next vo
lume measure following repair. Timing of epispadias repair was    compared to ch
anges in bladder capacity in 30 boys. Monthly increases in bladder    capacity w
ere calculated in boys repaired at &lt; 12 (4), 13-24 (12) and 25-48    (14) mon
ths.    ^cY#a30v37n1.htm##
00524000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704029300072002001300365#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#18#14#text#26#<br>   RESULTS: Patient
s who had surgery prior to 12 months of age had the highest    rate of monthly i
ncrease in bladder capacity (2.40 cc/month). Monthly growth    rates were 1.91 c
c/month for patients repaired at 13-24 months and 1.18 cc/month    for those rep
aired at 25-48 months.    ^cY#a30v37n1.htm##
00557000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704032600072002001300398#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#19#15#text#26#<br>   CONCLUSIONS: Epi
spadias repair does lead to early increase in bladder capacity    in boys with c
lassic bladder exstrophy. The monthly increases in bladder capacity    are great
er in boys &lt; 12 months. Improvement in bladder volume is less likely    when 
epispadias is repaired after age 29 months.</font></p>     ^cY#a30v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#20#16#text#26#<p>&nbsp;</p>     ^cY#a
30v37n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#21#17#text#26#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL COMMENT</b></font></p>     
^cY#a30v37n1.htm##
01304000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704107300072002001301145#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#22#18#text#26#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> This study evaluated    the timing of e
pispadias repair in exstrophy patients with its impact on bladder    capacity. T
he authors retrospectively reviewed all boys undergoing reconstruction,    where
 adequate data were available. The infants underwent routine cystographic    eva
luation to measure changes in bladder capacity following the initial closure    
and again 8-16 months following epispadias repair. The authors divided their    
cohort into three groups: those who underwent epispadias repair prior to 12    m
onths of age; those who were repaired between 13-24 months; and those having    
reconstruction at 25-48 months of age. They found the greatest increase in capac
ity    over time in those who underwent epispadias repair prior to 12 months of 
age.    Unfortunately, there were only four patients in this cohort. They had la
rger    numbers in the other two groups and both of these showed a trend towards
 improved    bladder capacity with epispadias repair at a younger age.</font></p
>     ^cY#a30v37n1.htm##
00878000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704064700072002001300719#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#23#19#text#26#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> Although the small    number of patient
s in this study does not lend itself to achieving statistical    significance, t
he data would certainly argue in favor of performing epispadias    repair at a y
ounger age. Increasing bladder outlet resistance should improve    bladder cycli
ng and allow for improved capacity as the child gets older which    will in turn
 give them the best chance for continence following bladder neck    reconstructi
on. This is the same line of reasoning given by those who favor    a complete pr
imary repair at the time of bladder closure.</font></p>     ^cY#a30v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#24#20#text#26#<p>&nbsp;</p>     ^cY#a
30v37n1.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011600072002001300188#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#25#21#text#26#<p align="right"><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Dr.    M. Chad Walli
s</b>    ^cY#a30v37n1.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004400072002001300116#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#26#22#text#26#<br>   Division of Pedi
atric Urology    ^cY#a30v37n1.htm##
00264000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003300072002001300105#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#27#23#text#26#<br>   University of Ut
ah    ^cY#a30v37n1.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004000072002001300112#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#28#24#text#26#<br>   Salt Lake City, 
Utah, USA    ^cY#a30v37n1.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010900072002001300181#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#29#25#text#26#<br>   E-mail: <a href=
"mailto:chad.wallis@hsc.utah.edu">chad.wallis@hsc.utah.edu</a></i></font></p>   
  ^cY#a30v37n1.htm##
00261000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003000072002001300102#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a30v37n1.htm#S#p#30#26#text#26#<p align="right"></p>  
   ^cY#a30v37n1.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a31v37n1.htm#S#o#1#1#text#1#20
110407#120627#a31v37n1.htm#41##
00731000000000385000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701200780
0159010002300237010003000260010002200290010002000312002001300332#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ND#31#IB
JU160#nd#Int. braz j urol.#37#1#20110200#^f134^l135#1677-5538#1#Robotic assisted
 laparoscopic treatment of gonadal vein syndrome in a boy^len#^rND^nHubert S.^sS
wana#^rND^nAlejandro R.^sRodriguez#^rND^nTimothy A.^sKim#^rND^nMark A.^sRich#a31
v37n1.htm##
00738000000000385000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701200850
0159010002300244010003000267010002200297010002000319002001300339#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ND#31#IB
JU160#nd#Int. braz j urol.#37#1#20110200#^f134^l135#1677-5538#1#<b>Robotic assis
ted laparoscopic treatment of gonadal vein syndrome in a boy</b>^len#^rND^nHuber
t S.^sSwana#^rND^nAlejandro R.^sRodriguez#^rND^nTimothy A.^sKim#^rND^nMark A.^sR
ich#a31v37n1.htm##
00842000000000397000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000800108158000300116030001700119
03100030013603200020013906500090014101400110015003500100016112300020017101200780
0173010002200251010002900273010002100302010001900323002001300342008008900355#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a31v37n1.htm#S#l#4#1#text#1#^mJan./Feb.^a2
011#oa#en#br1.1#1#4.0#31#IBJU160#nd#Int. braz j urol#37#1#20110200#^f134^l135#16
77-5538#1#Robotic assisted laparoscopic treatment of gonadal vein syndrome in a 
boy^len#^rND^nHubert S^sSwana#^rND^nAlejandro R^sRodriguez#^rND^nTimothy A^sKim#
^rND^nMark A^sRich#a31v37n1.htm#Internet^ihttp://www.scielo.br/scielo.php?script
=sci_arttext&pid=S1677-55382011000100031##
00338000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704010900070002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#5#1#text#37#<p align="right"><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>VIDEO</b></font></p>     
^cY#a31v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#6#2#text#37#<p>&nbsp;</p>     ^cY#a31
v37n1.htm##
00413000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704018400070002001300254#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#7#3#text#37#<p><a name="top"></a><fon
t face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Robotic    assisted l
aparoscopic treatment of gonadal vein syndrome in a boy</b></font></p>     ^cY#a
31v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#8#4#text#37#<p>&nbsp;</p>     ^cY#a31
v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#9#5#text#37#<p>&nbsp;</p>     ^cY#a31
v37n1.htm##
00392000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704016200071002001300233#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#10#6#text#37#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Hubert S. Swana;    Alejandro R. Rodri
guez; Timothy A. Kim; Mark A. Rich</b></font></p>     ^cY#a31v37n1.htm##
00364000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704013400071002001300205#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#11#7#text#37#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Nemours Children's    Clinic Orlando, Flo
rida, USA </font></p>     ^cY#a31v37n1.htm##
00406000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704017600071002001300247#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#12#8#text#37#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Department of Urology,    University of S
outh Florida School of Medicine, Tampa, Florida, USA</font></p>     ^cY#a31v37n1
.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704011600071002001300187#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#13#9#text#37#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><a href="#end">Correspondence</a></font><
/p>     ^cY#a31v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#14#10#text#37#<p>&nbsp;</p>     ^cY#a
31v37n1.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004400072002001300116#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#15#11#text#37#<p>&nbsp;</p> <hr size=
"1" noshade>     ^cY#a31v37n1.htm##
00329000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009800072002001300170#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#16#12#text#37#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#a31v3
7n1.htm##
00677000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704044600072002001300518#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#17#13#text#37#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>PURPOSE:</b>    Gonadal vein syndrome
, with ureteral obstruction and compression by an overlying    testicular vein i
s a controversial and rare diagnosis. Open, laparoscopic, and    robot-assisted 
laparoscopic repairs have been described. We report the first    case of robot-a
ssisted gonadal vein ligation for treatment of gonadal vein syndrome    in a nin
e year-old boy.    ^cY#a31v37n1.htm##
00926000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704069500072002001300767#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#18#14#text#37#<br>   <b>MATERIALS AND
 METHODS:</b> A 9 years-old boy presented with a four to six    month history of
 worsening intermittent flank pain, nausea and vomiting. Ultrasound    revealed 
moderate hydronephrosis. Diuretic renography and intravenous pyelography    repr
oduced his pain and demonstrated left-sided hydronephrosis and obstruction.    T
he patient underwent left robot-assisted surgery via a four port approach.    Th
e colon was reflected medially. The gonadal vein was dissected off the underlyin
g    ureter and ligated using laparoscopic clips. Segmental vein excision and ur
eterolysis    was performed. Inspection of the renal hilum did not reveal any ot
her crossing    vessels.    ^cY#a31v37n1.htm##
00441000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704021000072002001300282#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#19#15#text#37#<br>   <b>RESULTS:</b> 
Operative time was 94 minutes. The patient was discharged 36    hours after surg
ery. His hydronephrosis has resolved completely. He remains    pain-free nine mo
nths after surgery.    ^cY#a31v37n1.htm##
00451000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704022000072002001300292#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#20#16#text#37#<br>   <b>CONCLUSION:</
b> Robot-assisted laparoscopic vein excision and ureterolysis    is a safe optio
n for the management of ureteral obstruction caused by the gonadal    vein.</fon
t></p> <hr size="1" noshade>     ^cY#a31v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#21#17#text#37#<p>&nbsp;</p>     ^cY#a
31v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#22#18#text#37#<p>&nbsp;</p>     ^cY#a
31v37n1.htm##
00355000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704012400072002001300196#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#23#19#text#37#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>Int Braz J Urol.    2011; 37 (Video #
1): 134_5</b>    ^cY#a31v37n1.htm##
00454000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704022300072002001300295#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#24#20#text#37#<br>   Available at: <a
 href="http://www.brazjurol.com.br/videos/january_february_2011/Swana_134_135vid
eo.htm" target="_blank">www.brazjurol.com.br/videos/january_february_2011/Swana_
134_135video.htm</a></font></p>     ^cY#a31v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#25#21#text#37#<p>&nbsp;</p>     ^cY#a
31v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#26#22#text#37#<p>&nbsp;</p>     ^cY#a
31v37n1.htm##
00424000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704019300072002001300265#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#27#23#text#37#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b><a name="end"></a><a href="#top"><img
 src="/img/revistas/ibju/v37n1/seta.gif" border="0"></a>    Correspondence to</b
>:    ^cY#a31v37n1.htm##
00265000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003400072002001300106#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#28#24#text#37#<br>   Dr. Hubert S. Sw
ana    ^cY#a31v37n1.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004800072002001300120#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#29#25#text#37#<br>   Nemours Children
's Clinic Orlando    ^cY#a31v37n1.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004400072002001300116#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#30#26#text#37#<br>   1717 S. Orange A
ve, Suite 100    ^cY#a31v37n1.htm##
00274000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004300072002001300115#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#31#27#text#37#<br>   Orlando, Florida
, 32806, USA    ^cY#a31v37n1.htm##
00324000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009300072002001300165#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#32#28#text#37#<br>   E-mail: <a href=
"mailto:hswana@nemours.org">hswana@nemours.org</a></font></p>     ^cY#a31v37n1.h
tm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#33#29#text#37#<p>&nbsp;</p>     ^cY#a
31v37n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#34#30#text#37#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL COMMENT</b></font></p>     
^cY#a31v37n1.htm##
01055000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704082400072002001300896#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#35#31#text#37#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">In this video by    Swana et al., a nove
l application of robotic assisted laparoscopic surgery to    pediatric urology i
s very well depicted. This case of gonadal vein syndrome    in a symptomatic 9 y
ear old boy highlights that the superior three-dimensional    vision and surgica
l dexterity/range of motion attributable to current robotic    surgical technolo
gy is in some ways ideally suited to the surgical management    of pediatric uro
logical conditions. As with all evolving surgical technologies,    patient / cas
e selection remains the one pivotal criterion best predicting treatment    relat
ed outcome. I once again applaud these authors on a very illustrative and    inn
ovative surgical approach to a case of gonadal vein syndrome.</font></p>     ^cY
#a31v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#36#32#text#37#<p>&nbsp;</p>     ^cY#a
31v37n1.htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704012000072002001300192#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#37#33#text#37#<p align="right"><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Dr.    Philippe E. S
piess</b>    ^cY#a31v37n1.htm##
00286000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005500072002001300127#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#38#34#text#37#<br>   Assistant Profes
sor of Urologic Oncology    ^cY#a31v37n1.htm##
00274000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004300072002001300115#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#39#35#text#37#<br>   H. Lee Moffitt C
ancer Center    ^cY#a31v37n1.htm##
00265000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003400072002001300106#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#40#36#text#37#<br>   Tampa, Florida, 
USA    ^cY#a31v37n1.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011500072002001300187#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a31v37n1.htm#S#p#41#37#text#37#<br>   E-mail: <a href=
"mailto:philippe.spiess@moffitt.org">philippe.spiess@moffitt.org</a></i></font><
/p>     ^cY#a31v37n1.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a32v37n1.htm#S#o#1#1#text#1#20
110330#144542#a32v37n1.htm#59##
00740000000000397000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701200870
0159010003000246010001900276010002600295117000600321072000200327002001300329#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a32v37n1.htm#S#h#2#1#text#1#oa#en#br1.1#1#
4.0#ND#32#IBJU160#nd#Int. braz j urol.#37#1#20110200#^f136^l137#1677-5538#1#Lapa
ro-endoscopic single site retroperitoneal partial nephrectomy: a novel concept^l
en#^rND^nAlejandro R.^sRodriguez#^rND^nTariq^sHakky#^rND^nPhilippe E.^sSpiess#ot
her#4#a32v37n1.htm##
00754000000000397000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030001800104
03100030012203200020012506500090012701400110013603500100014712300020015701201010
0159010003000260010001900290010002600309117000600335072000200341002001300343#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a32v37n1.htm#S#f#3#1#text#1#oa#en#br1.1#1#
4.0#ND#32#IBJU160#nd#Int. braz j urol.#37#1#20110200#^f136^l137#1677-5538#1#<b>L
aparo-endoscopic single site retroperitoneal partial nephrectomy</b>: <b>a novel
 concept</b>^len#^rND^nAlejandro R.^sRodriguez#^rND^nTariq^sHakky#^rND^nPhilippe
 E.^sSpiess#other#4#a32v37n1.htm##
00853000000000409000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000800108158000300116030001700119
03100030013603200020013906500090014101400110015003500100016112300020017101200870
01730100029002600100019002890100025003081170006003330720002003390020013003410080
08900354#v37n1#V:\SciELO\serial\ibju\v37n1\markup\a32v37n1.htm#S#l#4#1#text#1#^m
Jan./Feb.^a2011#oa#en#br1.1#1#4.0#32#IBJU160#nd#Int. braz j urol#37#1#20110200#^
f136^l137#1677-5538#1#Laparo-endoscopic single site retroperitoneal partial neph
rectomy: a novel concept^len#^rND^nAlejandro R^sRodriguez#^rND^nTariq^sHakky#^rN
D^nPhilippe E^sSpiess#other#4#a32v37n1.htm#Internet^ihttp://www.scielo.br/scielo
.php?script=sci_arttext&pid=S1677-55382011000100032##
00338000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704010900070002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#5#1#text#51#<p align="right"><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>VIDEO</b></font></p>     
^cY#a32v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#6#2#text#51#<p>&nbsp;</p>     ^cY#a32
v37n1.htm##
00422000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704019300070002001300263#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#7#3#text#51#<p><a name="top"></a><fon
t face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Laparo-endoscopic    
single site retroperitoneal partial nephrectomy: a novel concept</b></font></p> 
    ^cY#a32v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#8#4#text#51#<p>&nbsp;</p>     ^cY#a32
v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#9#5#text#51#<p>&nbsp;</p>     ^cY#a32
v37n1.htm##
00362000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704013200071002001300203#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#10#6#text#51#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><b>Alejandro    R. Rodriguez; Tariq Hakky
; Philippe E. Spiess    ^cY#a32v37n1.htm##
00261000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704003100071002001300102#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#11#7#text#51#<br>  </b> </font></p>  
   ^cY#a32v37n1.htm##
00434000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704020400071002001300275#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#12#8#text#51#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Department of Urology,    Moffitt Cancer 
Center and Research Institute and University of South Florida,    Tampa, Florida
</font></p>     ^cY#a32v37n1.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704011600071002001300187#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#13#9#text#51#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><a href="#end">Correspondence</a></font><
/p>     ^cY#a32v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#14#10#text#51#<p>&nbsp;</p>     ^cY#a
32v37n1.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004400072002001300116#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#15#11#text#51#<p>&nbsp;</p> <hr size=
"1" noshade>     ^cY#a32v37n1.htm##
00329000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009800072002001300170#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#16#12#text#51#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#a32v3
7n1.htm##
00882000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704065100072002001300723#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#17#13#text#51#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>PURPOSE:</b>    Various treatment opt
ions are available for small incidentally detected kidney    masses, including s
urveillance, partial nephrectomy and probe ablative therapies.    When partial n
ephrectomy is considered, the procedure can be safely approached    laparoscopic
ally, either pure or robot assisted, in experienced hands. Laparo-endoscopic    
single site (LESS) surgery is a novel approach for partial nephrectomies in    w
ell selected cases. In this video, we present our experience with the LESS    re
troperitoneal partial nephrectomy using the Gelpoint device.    ^cY#a32v37n1.htm
##
00954000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704072300072002001300795#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#18#14#text#51#<br>   <b>MATERIAL AND 
METHODS:</b> A 63 year old male patient with a BMI of 31, and    a history of a 
T1c prostate cancer, had a 1.5 cm right posterior lower pole    renal enhancing 
mass discovered incidentally on a three phase CT scan. With    the patient under
 general anesthesia, and in a full flank position, a LESS retroperitoneal    par
tial nephrectomy was performed using a 3 cm transverse incision below the    tip
 of the 12th rib. The following instruments and devices were used: A gelpoint   
 device for single incision port of entry, one 10 mm and two 5 mm trocars used  
  through the gelpoint, one 5 mm Olympus HD endoeye flexible tip camera, one rot
iculator    scissors, and one articulating graspers.    ^cY#a32v37n1.htm##
00730000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704049900072002001300571#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#19#15#text#51#<br>   <b>RESULTS:</b> 
Operative time, EBL, and hospital stay were 1 hour, 5 ml, and    23 hours, respe
ctively. The pathology result confirmed a benign hemorrhagic    cystic mass. The
 visual analog scale (0-10) for pain at recovery, 6 hours post    op, and 23 hou
rs post op was 5, 3, and 1 point, respectively. The patient tolerated    clear l
iquids and regular diet at 6 and 16 hours, after the procedure. At one    month 
of follow-up, the patient is asymptomatic and practically scarless.     ^cY#a32v
37n1.htm##
00908000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704067700072002001300749#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#20#16#text#51#<br>   <b>CONCLUSIONS:<
/b> LESS retroperitoneal partial nephrectomy is safe and feasible    in selected
 cases such as small exophytic posterior renal masses. The retroperitoneal    ap
proach avoids mobilization of the colon and kidney to access the posterior    su
rface. Instrument clashing, limited range of motion, and CO2 leakage, can    be 
some difficulties encountered during single port retroperitoneal surgery.    How
ever, the Gelpoint device gives a great seal in the flank position and allows   
 the relocation of trocars, without loss of CO2 pressure, to prevent instrument 
   clashing during different parts of the procedure.</font></p> <hr size="1" nos
hade>     ^cY#a32v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#21#17#text#51#<p>&nbsp;</p>     ^cY#a
32v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#22#18#text#51#<p>&nbsp;</p>     ^cY#a
32v37n1.htm##
00355000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704012400072002001300196#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#23#19#text#51#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>Int Braz J Urol.    2011; 37 (Video #
2): 136_7</b>    ^cY#a32v37n1.htm##
00446000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704021500072002001300287#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#24#20#text#51#<br>   Available at: <a
 href="http://www.brazjurol.com.br/videos/january_february_2011/Rodriguez_136_13
7video.htm">www.brazjurol.com.br/videos/january_february_2011/Rodriguez_136_137v
ideo.htm</a></font></p>     ^cY#a32v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#25#21#text#51#<p>&nbsp;</p>     ^cY#a
32v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#26#22#text#51#<p>&nbsp;</p>     ^cY#a
32v37n1.htm##
00424000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704019300072002001300265#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#27#23#text#51#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><b><a name="end"></a><a href="#top"><img
 src="/img/revistas/ibju/v37n1/seta.gif" border="0"></a>    Correspondence to</b
>:    ^cY#a32v37n1.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004100072002001300113#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#28#24#text#51#<br>   Dr. Alejandro R.
 Rodriguez    ^cY#a32v37n1.htm##
00267000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003600072002001300108#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#29#25#text#51#<br>   Department of Ur
ology    ^cY#a32v37n1.htm##
00267000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003600072002001300108#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#30#26#text#51#<br>   Moffitt Cancer C
enter    ^cY#a32v37n1.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003900072002001300111#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#31#27#text#51#<br>   8203 Whistling P
ine Way     ^cY#a32v37n1.htm##
00268000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003700072002001300109#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#32#28#text#51#<br>   Tampa, FL, 33647
, USA     ^cY#a32v37n1.htm##
00322000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009100072002001300163#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#33#29#text#51#<br>   E-mail: <a href=
"mailto:armbkdd@yahoo.com">armbkdd@yahoo.com</a></font></p>     ^cY#a32v37n1.htm
##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#34#30#text#51#<p>&nbsp;</p>     ^cY#a
32v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#35#31#text#51#<p>&nbsp;</p>     ^cY#a
32v37n1.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#36#32#text#51#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL COMMENT</b></font></p>     
^cY#a32v37n1.htm##
01471000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704124000072002001301312#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#37#33#text#51#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">In this novel video    by Rodriguez and 
colleagues, a novel approach for a small exophytic renal lesion    is presented.
 Since the first laparoscopic single site surgery (LESS) report    in the urolog
ical literature by Rane in 2007, different urological procedures    including py
eloplasty, renal cryotherapy, adrenalectomy, varicocelectomy, ureterolithotomy  
  have been described (1). This approach uses a single surgical access following
    the same general principles of pure laparoscopic surgery, with its inherent 
   benefit of minimal surgical trauma. Previously, White et al. described eight 
   LESS retroperitoneal procedures including one partial nephrectomy (2). Aaron 
   et al. reported 5 partial nephrectomy using a transperitoneal (trans-umbilica
l)    LESS approach using a 2 mm port in the axillary line (hybrid technique) (3
).    Recently, Cindolo et al. reported six LESS cases using a transperitoneal a
pproach,    all performed without hilar clamping, one of which required conversi
on to a    standard laparoscopic approach to control bleeding and two necessitat
ing an    extra port for renal parenchyma suturing and liver retraction (4). </f
ont></p>     ^cY#a32v37n1.htm##
00772000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704054100072002001300613#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#38#34#text#51#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Single port surgery    is considered min
imally invasive laparoscopy, and is an alternative to standard    laparoscopy in
 appropriately selected cases. It however remains a technically    challenging p
rocedure even for experienced laparoscopists. Instruments for LESS    are rapidl
y evolving in order to avoid clashing and compensate for their limited    range 
of motion. In this regard, robotic technology is trying to eliminate these    cu
rrent limitations.</font></p>     ^cY#a32v37n1.htm##
01022000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704079100072002001300863#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#39#35#text#51#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">It remains that    partial nephrectomy i
s a very challenging procedure when a minimally invasive    approach is chosen. 
In this regard, it is imperative to have careful patient    selection when a new
 technique such as this is employed. Carefully chosen cases    such as the one s
hown in the present video by Rodriguez et al. can translate    into excellent pe
ri- and postoperative outcomes. Future randomized trials comparing    pure lapar
oscopic and LESS surgery will help delineate the role and merit of    this techn
ique. At the present time, careful patient selection remains the key    factor p
redicting a favorable outcome with these novel new surgical techniques    to the
 small enhancing renal mass.</font></p>     ^cY#a32v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#40#36#text#51#<p>&nbsp;</p>     ^cY#a
32v37n1.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010000072002001300172#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#41#37#text#51#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>REFERENCES</b></font></p>     ^cY#a32
v37n1.htm##
00545000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704030000074002001300374#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#42#38#text#51#1#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Rane A, Rao    P, Bonad
io F, Rao P: Single port laparoscopic nephrectomy using a novel laparoscopic    
port (R-port) and evolution of single laparoscopic port procedure (SLIPP). J    
Endourol. 2007: 21 (Suppl 1): A287, V18-11.    ^cY#a32v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#43#39#text#51#</font></p>     ^cY#a32
v37n1.htm##
00485000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704024000074002001300314#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#44#40#text#51#2#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">2. White WM, Goel    RK, K
aouk JH: Single-port laparoscopic retroperitoneal surgery:initial operative    e
xperience and comparative outcomes. Urology. 2009; 73: 1279-82.    ^cY#a32v37n1.
htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#45#41#text#51#</font></p>     ^cY#a32
v37n1.htm##
00469000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704022400074002001300298#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#46#42#text#51#3#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Aron M, Canes    D, Des
ai MM, Haber GP, Kaouk JH, Gill IS: Transumbilical single-port laparoscopic    p
artial nephrectomy. BJU Int. 2009; 103: 516-21.    ^cY#a32v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#47#43#text#51#</font></p>     ^cY#a32
v37n1.htm##
00471000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704022600074002001300300#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#48#44#text#51#4#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Cindolo L, Berardinelli
    F, Gidaro S, Schips L: Laparoendoscopic single-site partial nephrectomy with
out    ischemia. J Endourol. 2010; 24: 1997-2002.    ^cY#a32v37n1.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#49#45#text#51#</font></p>     ^cY#a32
v37n1.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#50#46#text#51#<p>&nbsp;</p>     ^cY#a
32v37n1.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704012700072002001300199#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#51#47#text#51#<p align="right"><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2"><b><i>Dr.    Jose Jaime Co
rrea </i></b><i>    ^cY#a32v37n1.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004400072002001300116#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#52#48#text#51#<br>   Urologic Oncolog
y Department     ^cY#a32v37n1.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004200072002001300114#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#53#49#text#51#<br>   Hospital Pablo T
obon Uribe     ^cY#a32v37n1.htm##
00265000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003400072002001300106#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#54#50#text#51#<br>   Medellin, Colomb
ia     ^cY#a32v37n1.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010300072002001300175#v37n1#V:\SciELO
\serial\ibju\v37n1\markup\a32v37n1.htm#S#p#55#51#text#51#<br>   E-mail: <a href=
"mailto:jocorreao@uces.edu.co">jocorreao@uces.edu.co</a></i></font></p>     ^cY#
a32v37n1.htm##
00673000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100014000720100013000860100
01700099010001300116012014200129030001100271065000900282064000500291031000300296
032000400299014001300303865000900316002001300325035001000338801001100348#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a32v37n1.htm#S#c#56#1#text#4#1#^rND^sRane^nA#^
rND^sRao^nP#^rND^sBonadio^nF#^rND^sRao^nP#Single port laparoscopic nephrectomy u
sing a novel laparoscopic port (R-port) and evolution of single laparoscopic por
t procedure (SLIPP)^len#J Endourol#20070000#2007#21#^s1#A287, V18-11#20110200#a3
2v37n1.htm#0892-7790#J Endourol##
00590000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100016000720100015000880100
01600103012010800119030000800227065000900235064000500244031000300249014000800252
865000900260002001300269035001000282801000800292#v37n1#V:\SciELO\serial\ibju\v37
n1\markup\a32v37n1.htm#S#c#57#2#text#4#2#^rND^sWhite^nWM#^rND^sGoel^nRK#^rND^sKa
ouk^nJH#Single-port laparoscopic retroperitoneal surgery: initial operative expe
rience and comparative outcomes^len#Urology#20090000#2009#73#1279-82#20110200#a3
2v37n1.htm#0090-4295#Urology##
00599000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100014000720100015000860100
01600101010001600117010001600133010001500149012006400164030000800228710000200236
065000900238064000500247031000400252014000700256865000900263002001300272#v37n1#V
:\SciELO\serial\ibju\v37n1\markup\a32v37n1.htm#S#c#58#3#text#4#3#^rND^sAron^nM#^
rND^sCanes^nD#^rND^sDesai^nMM#^rND^sHaber^nGP#^rND^sKaouk^nJH#^rND^sGill^nIS#Tra
nsumbilical single-port laparoscopic partial nephrectomy^len#BJU Int#2#20090000#
2009#103#516-21#20110200#a32v37n1.htm##
00252000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000200068118000200070865000900072002001300081#v37
n1#V:\SciELO\serial\ibju\v37n1\markup\a32v37n1.htm#S#c#59#4#text#4#4#20110200#a3
2v37n1.htm##
